



50^o CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI MICROBIOLOGIA

NAPOLI, 18-21 SETTEMBRE 2022 | HOTEL ROYAL CONTINENTAL

14/10/2022

Abstract Book

CON IL CONTRIBUTO NON CONDIZIONANTE DI



SHIONOGI

Sommario

1 Interazione ospite-patogeno	52
5 - Formyl peptide receptors 1 and 2 are essential vita-PAMP sensors of bacterial pathogens	52
GERMANA LENTINI ⁽¹⁾ - GIUSEPPE VALERIO DE GAETANO ⁽¹⁾ - AGATA FAMA' ⁽¹⁾ - FRANCESCO COPPOLINO ⁽²⁾ - GIUSEPPE TETI ⁽³⁾ - CONCETTA BENINATI ⁽¹⁾	52
UNIVERSITA' DEGLI STUDI DI MESSINA, DIPARTIMENTO DI PATOLOGIA UMANA E DELL'ETA' EVOLUTIVA G. BARRESI, MESSINA, Italia ⁽¹⁾ - UNIVERSITA' DEGLI STUDI DI MESSINA, DIPARTIMENTO DI SCIENZE BIOMEDICHE, ODONTOIATRICHE E DELLE IMMAGINI MORFOLOGICHE E FUNZIONALI, MESSINA, Italia ⁽²⁾ - CHARYBDIS VACCINES SRL, UNIVERSITA' DEGLI STUDI DI MESSINA, MESSINA, Italia ⁽³⁾	52
7 - PAD-mediated citrullination provides a new biomarker and an effective target to counteract	53
human papillomavirus transformation	53
Camilla Albano ⁽¹⁾ - Matteo Biolatti ⁽¹⁾ - Jasenka Mazibrada ⁽²⁾ - Selina Pasquero ⁽¹⁾ - Francesca Gugliesi ⁽¹⁾ - Gloria Griffante ⁽³⁾ - Irene Lo Cigno ⁽³⁾ - Elena Cat Genova ⁽¹⁾ - Greta Bajetto ⁽³⁾ - Santo Landolfo ⁽¹⁾ - Marisa Gariglio ⁽³⁾ - Marco De Andrea ⁽¹⁾ - Valentina Dell'Oste ⁽¹⁾	53
Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Università degli Studi di Torino, Torino, Italia ⁽¹⁾ - Dipartimento di Patologia Cellulare, Università di Norfolk e Norwich, Norwich, Regno Unito ⁽²⁾ - Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Novara, Italia ⁽³⁾	53
13 - Effect of SARS-CoV-2 on the coagulation cascade in COVID-19 associated coagulopathies	54
Daria Bortolotti ⁽¹⁾ - Marcello Baroni ⁽²⁾ - Giulia Turrin ⁽¹⁾ - Giovanna Schiuma ⁽¹⁾ - Silvia Beltrami ⁽¹⁾ - Sabrina Rizzo ⁽¹⁾ - Claudio Trapella ⁽¹⁾ - Roberta Rizzo ⁽¹⁾	54
Università di Ferrara, Dipartimento di Scienze Chimiche, Farmaceutiche ed Agrarie, Ferrara, Italia ⁽¹⁾ - Università di Ferrara, Dipartimento di Scienze della Vita e Biotecnologie, Ferrara, Italia ⁽²⁾	54
15 - Vaginal immunization by the human microbiota bacterium Streptococcus gordonii expressing a Chlamydia trachomatis antigen efficiently primes the immune system in mice	55
Bar Filosof ⁽¹⁾ - Elena Pettini ⁽¹⁾ - Fabio Fiorino ⁽¹⁾ - Francesco Santoro ⁽¹⁾ - Iannelli Francesco ⁽¹⁾ - Gianni Pozzi ⁽¹⁾	55
University of Siena, Department of Medical Biotechnologies, Siena, Italia ⁽¹⁾	55
30 - The two-component SaeRS system controls the interactions of group B streptococci with host cells by modulating PbsP expression.....	56
Francesco Coppolino ⁽¹⁾ - Giuseppe Valerio De Gaetano ⁽²⁾ - Germana Lentini ⁽²⁾ - Agata Famà ⁽²⁾ - Arnaud Firon ⁽³⁾ - Giuseppe Teti ⁽⁴⁾ - Concetta Beninati ⁽⁵⁾	56
University of Messina, Department of Biomedical, Dental and Imaging Sciences, Messina, Italia ⁽¹⁾ - University of Messina, Department of Human Pathology and Medicine, Messina, Italia ⁽²⁾ - Institut Pasteur, Microbiology Department, Biology of Gram-positive pathogens, Parigi, Francia ⁽³⁾ - Charybdis Vaccines, Srl, Messina, Italia ⁽⁴⁾ - Scylla Biotech, Srl, Messina, Italia ⁽⁵⁾	56
31 - Prevalence of hepatitis B virus infection among pregnant women: results from a hospital-based survey in Northern Italy.....	57
Flora De Conto ⁽¹⁾ - Giulia Montanari ⁽¹⁾ - Sharon Di Stefano ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Adriana Calderaro ⁽¹⁾	57

Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾	57
34 - Classification of Clostridioides difficile strains using a MALDI-TOF MS typing method.....	58
Mirko Buttrini ⁽¹⁾ - Benedetta Farina ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Monica Martinelli ⁽¹⁾ - Silvia Covan ⁽¹⁾ - Alan Di Maio ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Flora De Conto ⁽¹⁾ - Adriana Calderaro ⁽¹⁾	58
Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾	58
37 - "Bacterial Outer Membrane Vesicles: from biology to vaccines and cancer immunity"	59
Guido Grandi ⁽¹⁾	59
Università di Trento, CIBIO, Trento, Italia ⁽¹⁾	59
43 - Insight into the apoptosis mediated by feline herpesvirus (FeHV-1) on permissive cells	60
Gianmarco Ferrara ⁽¹⁾ - Valentina Iovane ⁽²⁾ - Francesca Paola Nocera ⁽¹⁾ - Elvira Improda ⁽¹⁾ - Ugo Pagnini ⁽¹⁾ - Serena Montagnaro ⁽¹⁾	60
University of Naples "Federico II", Naples, Italy, Department of Veterinary Medicine and Animal Productions, Napoli, Italia ⁽¹⁾ - University of Naples "Federico II", Naples, Italy, Department of Agricultural Sciences, Napoli, Italia ⁽²⁾	60
46 - Time-restricted feeding induces Lactobacillus- and Akkermansia-specific functional changes in the rat fecal microbiota.....	61
Alessandro Tanca ⁽¹⁾ - Antonio Palomba ⁽²⁾ - Marcello Abbondio ⁽¹⁾ - Rosangela Sau ⁽¹⁾ - Monica Serra ⁽³⁾ - Fabio Marongiu ⁽³⁾ - Cristina Fraumene ⁽²⁾ - Daniela Pagnozzi ⁽²⁾ - Ezio Laconi ⁽³⁾ - Sergio Uzzau ⁽¹⁾	61
University of Sassari, Department of Biomedical Sciences, Sassari, Italia ⁽¹⁾ - Porto Conte Ricerche, Science and Technology Park of Sardinia, Alghero, Italia ⁽²⁾ - University of Cagliari, Department of Biomedical Sciences, Cagliari, Italia ⁽³⁾	61
57 - Interferon beta augments the in vitro and in vivo microbicidal responses	62
of neutrophils leading to clearance of staphylococcal infection.....	62
AGATA FAMA' ⁽¹⁾ - Germana Lentini ⁽¹⁾ - Giuseppe Valerio De Gaetano ⁽¹⁾ - Francesco Coppolino ⁽²⁾ - Giuseppe Teti ⁽³⁾ - Concetta Beninati ⁽¹⁾	62
University of Messina, Department of Human Pathology, Messina, Italia ⁽¹⁾ - University of Messina, Department of Biomedical, Dental and Imaging Sciences, Messina, Italia ⁽²⁾ - Charibdis Vaccines Srl, Charibdis Vaccines Srl, Messina, Italia ⁽³⁾	62
59 - Consumption of traditional Sardinian fresh cheese casu axedu promotes changes in the rat gut microbiota composition and functions	63
Marcello Abbondio ⁽¹⁾ - Antonio Palomba ⁽²⁾ - Alessandro Tanca ⁽¹⁾ - Cristina Fraumene ⁽²⁾ - Monica Serra ⁽³⁾ - Rosangela Sau ⁽¹⁾ - Fabio Marongiu ⁽³⁾ - Daniela Pagnozzi ⁽²⁾ - Ezio Laconi ⁽³⁾ - Sergio Uzzau ⁽¹⁾	63
University of Sassari, Department of Biomedical Sciences, Sassari, Italia ⁽¹⁾ - Porto Conte Ricerche, Science and Technology Park of Sardinia, Alghero (SS), Italia ⁽²⁾ - University of Cagliari, Department of Biomedical Sciences, Cagliari, Italia ⁽³⁾	63
61 - The immunological activity of Bacteroides thetaiotaomicron rough-type lipopolysaccharide	64
Giuseppe Mantova ⁽¹⁾ - Alessia Stornaiuolo ⁽²⁾ - Elena Scaglione ⁽³⁾ - Valeria Caturano ⁽⁴⁾ - Martina DI Rosario ⁽¹⁾ - Molly D. Pither ⁽⁵⁾ - Chiara Pagliuca ⁽¹⁾ - Flaviana DI Lorenzo ⁽⁶⁾ - Roberta Colicchio ⁽⁷⁾ - Alba Silipo ⁽⁵⁾ - Antonio Molinaro ⁽⁵⁾ - Paola Salvatore ⁽⁸⁾	64

<i>University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italia</i> ⁽¹⁾ - <i>University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., University of Naples Federico II, Dpt. of Chem., Mat. and Ind. Prod. Eng., University of Naples Federico II, Naples, Italia</i> ⁽²⁾ - <i>University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Chem., Mat. and Ind. Prod. Eng., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. FedericoII, Naples, Italia</i> ⁽³⁾ - <i>University Hospital Federico II, Dpt. of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital FedericoII, Naples, Italia</i> ⁽⁴⁾ - <i>University of Naples Federico II, Department of Chemical Sciences, University of Naples Federico II, Naples, Italia</i> ⁽⁵⁾ - <i>University of Naples Federico II, Department of Agriculture, University of Naples Federico II, Naples, Italia</i> ⁽⁶⁾ - <i>University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. FedericoII, Naples, Italia</i> ⁽⁷⁾ - <i>University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. FedericoII, CEINGE, Task Force on Microbiome Studies, Naples, Italia</i> ⁽⁸⁾	64
67 - The probiotic <i>Lactobacillus rhamnosus</i> LGG restrains the angiogenic potential of colorectal carcinoma cells by activating a pro-resolving program via Formyl Peptide Receptor 1	66
Elena Scaglione ⁽¹⁾ - Federica Liotti ⁽²⁾ - Chiara Pagliuca ⁽³⁾ - Valeria Caturano ⁽⁴⁾ - Giuseppe Mantova ⁽³⁾ - Maria Marotta ⁽³⁾ - Daniela Sorriento ⁽⁵⁾ - Rosa Marina Melillo ⁽⁶⁾ - Roberta Colicchio ⁽⁷⁾ - Nella Prevete ⁽⁸⁾ - Paola Salvatore ⁽⁹⁾	66
University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech.; Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. U.O.C.; Dpt. of Chem. Mat. and Ind. Prod. Eng., Naples, Italia ⁽¹⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech.; Inst. of Experimental Endocrinology and Oncology (IEOS), CNR, Naples, Italia ⁽²⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italia ⁽³⁾ - University of Naples Federico II, Dpt. of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital FedericoII, Naples, Italia ⁽⁴⁾ - University of Naples Federico II, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italia ⁽⁵⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Inst. of Experimental Endocrinology and Oncology (IEOS), CNR, Naples, Italia ⁽⁶⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. U.O.C. FedericoII, Naples, Italia ⁽⁷⁾ - University of Naples Federico II, Inst. of Exp. End. and Onc., CNR; Dpt. of Tran. Med. Scien.; Task Force on Microbiome Studies, Naples, Italia ⁽⁸⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech.; Dpt. of Integ. Activ. of Lab. Med. and Transf. U.O.C. FedericoII; Task Force on Microbiome Studies ; CEINGE, Naples, Italia ⁽⁹⁾	66
68 - The <i>Shigella flexneri</i> virulence factor apyrase is released inside eukaryotic cells to manipulate host cell fate	68
Lisa Perruzza ⁽¹⁾ - Meysam Sarshar ⁽²⁾ - Francesco Strati ⁽³⁾ - Carlo Zagaglia ⁽⁴⁾ - Fabio Grassi ⁽¹⁾ - Mauro Nicoletti ⁽⁴⁾ - Anna Teresa Palamara ⁽⁵⁾ - Cecilia Ambrosi ⁽⁶⁾ - Daniela Scribano ⁽⁴⁾	68
Università della Svizzera Italiana, Institute for Research in Biomedicine, Bellinzona, Svizzera ⁽¹⁾ - Bambino Gesù Children's Hospital, IRCCS, Research Laboratories, Roma, Italia ⁽²⁾ - University of Milano-Bicocca, Mucosal Immunology Lab, Department of Biotechnology and Biosciences, Milano, Italia ⁽³⁾ - Sapienza University of Rome, Department of Public Health and Infectious Diseases, Roma, Italia ⁽⁴⁾ - Sapienza University of Rome, Department of Public Health and Infectious Diseases, Laboratory Affiliated to Institute Pasteur Italia-Cenci Bolognetti, Roma, Italia ⁽⁵⁾ - San Raffaele Open University, IRCCS, Department of Human Sciences and Promotion of the Quality of Life, Roma, Italia ⁽⁶⁾	68
71 - Exploring the Nrf2-mediated antioxidant pathway and the potential use of redox-modulating compounds during respiratory virus infections	70

Marta De Angelis ⁽¹⁾ - Gianni Gori Savellini ⁽²⁾ - Donatella Amatore ⁽³⁾ - Riccardo De Santis ⁽³⁾ - Rita Crinelli ⁽⁴⁾ - Alessandra Fraternale ⁽⁴⁾ - Maria Grazia Cusi ⁽²⁾ - Florigio Romano Lista ⁽³⁾ - Mauro Magnani ⁽⁴⁾ - Anna Teresa Palamara ⁽⁵⁾ - Lucia Nencioni ⁽¹⁾	70
Università di Roma Sapienza, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽¹⁾ - Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽²⁾ - Ospedale Militare Celio, Dipartimento Scientifico, Roma, Italia ⁽³⁾ - Università di Urbino Carlo Bo, Dipartimento di Scienze Biomolecolari, Urbino, Italia ⁽⁴⁾ - Università di Roma Sapienza; Istituto Superiore di Sanità, Dipartimento di Sanità Pubblica e Malattie Infettive; Dipartimento di Malattie Infettive, Roma, Italia ⁽⁵⁾	70
80 - Drug-targeted activation of the RIG-I pathway to develop novel combinatorial therapeutic approaches against human papillomavirus-associated cancers	72
Irene Lo Cigno ⁽¹⁾ - Carlo Girone ⁽¹⁾ - Federica Calati ⁽¹⁾ - Daniela Bosio ⁽²⁾ - Valentina Salvi ⁽²⁾ - Tiziana Schioppa ⁽²⁾ - Valentina Tassinari ⁽³⁾ - Cristina Cerboni ⁽³⁾ - Alessandra Soriani ⁽³⁾ - Aldo Venuti ⁽⁴⁾ - John Hiscott ⁽⁵⁾ - Marisa Gariglio ⁽¹⁾	72
University of Piemonte Orientale, Department of Translational Medicine, Novara, Italia ⁽¹⁾ - University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italia ⁽²⁾ - La Sapienza University, Molecular Medicine Department, Roma, Italia ⁽³⁾ - IRCCS Regina Elena National Cancer Institute, HPV Unit, UOSD Tumor Immunology and Immunotherapy, Roma, Italia ⁽⁴⁾ - Pasteur Institute, Fondazione Cenci Bolognetti, Roma, Italia ⁽⁵⁾	72
87 - Pro inflammatory status and bacterial gut-vagina translocation in pregnant women affected by COVID-19	74
Carolina Cason ⁽¹⁾ - Giuseppina Campisciano ⁽¹⁾ - Nunzia Zanotta ⁽¹⁾ - Alice Sorz ⁽²⁾ - Francesco De Seta ⁽²⁾ - Gianpaolo Maso ⁽²⁾ - Manola Comar ⁽¹⁾	74
Institute for Maternal and Child Health – IRCCS "Burlo Garofolo", Department of Advanced Translational Microbiology, Trieste, Italia ⁽¹⁾ - Institute for Maternal and Child Health – IRCCS "Burlo Garofolo", Department of Obstetrics and Gynecology, Trieste, Italia ⁽²⁾	74
88 - The fetal environment can harbor bacterial DNA overlapping the microbiome of vaginal, rectal and oral maternal body sites	75
Giuseppina Campisciano ⁽¹⁾ - Nunzia Zanotta ⁽¹⁾ - Carolina Cason ⁽¹⁾ - Francesco De Seta ⁽²⁾ - Alessandra Torresani ⁽³⁾ - Tamara Stampalija ⁽³⁾ - Mariachiara Quadrifoglio ⁽³⁾ - Manola Comar ⁽¹⁾	75
Department of Advanced Microbiology Diagnosis and Translational Research, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italia ⁽¹⁾ - Department of Obstetrics and Gynecology, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italia ⁽²⁾ - Department of Fetal Medicine & Prenatal Diagnosis, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italia ⁽³⁾	75
90 - Specific microbiota compositions regulate humoral and cellular responses to vaccines in outbred mice	76
Giuseppe Stefanetti ⁽¹⁾ - Joon S. Park ⁽²⁾ - Ximei Sun ⁽²⁾ - Meng Wu ⁽²⁾ - Dennis L. Kasper ⁽²⁾	76
Universita' degli Studi di Urbino "Carlo Bo", Dipartimento di Scienze Biomolecolari (DISB), Urbino, Italia ⁽¹⁾ - Harvard Medical School, Immunology, Boston, Stati Uniti D'america ⁽²⁾	76
91 - Persistence of spike-specific memory B cells and antibodies nine months after two doses of BNT162b2 mRNA vaccine	77

Gabiria Pastore ⁽¹⁾ - Simone Lucchesi ⁽¹⁾ - Elena Pettini ⁽¹⁾ - Sara Zirpoli ⁽¹⁾ - fabio Fiorino ⁽¹⁾ - Jacopo Polvere ⁽¹⁾ - Massimiliano Fabbiani ⁽²⁾ - Francesca Montagnani ⁽²⁾ - Mario Tumbarello ⁽²⁾ - Donata Medagliani ⁽¹⁾ - Annalisa Ciabattini ⁽¹⁾	77
University of Siena, Dept of Medical Biotechnology, Siena, Italia ⁽¹⁾ - University Hospital of Siena, Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena, Italia ⁽²⁾	77
95 - Depletion of the MS-ring protein FlIF impacts motility, mucin-adhesion, and virulence in <i>Bacillus cereus</i>	78
Diletta Mazzantini ⁽¹⁾ - Marco Calvigioni ⁽¹⁾ - Adelaide Panattoni ⁽¹⁾ - Mariacristina Massimino ⁽¹⁾ - Francesco Celandroni ⁽¹⁾ - Emilia Ghelardi ⁽¹⁾	78
University of Pisa, Translational Research and New Technologies in Medicine and Surgery, Pisa, Italia ⁽¹⁾	78
97 - Role of gut and oral microbiota in pediatric autism spectrum disorder	79
Martina Vidmar ⁽¹⁾ - Carolina Cason ⁽²⁾ - Giuseppina Campisciano ⁽²⁾ - Nunzia Zanotta ⁽¹⁾ - Antonella Zadini ⁽³⁾ - Manola Comar ⁽⁴⁾	79
Department of Advanced Translational Microbiology, Institute for Maternal and Child Health – IRCCS Burlo Garofolo, Department of Life Sciences, University of Trieste, Trieste, Italia ⁽¹⁾ - Department of Advanced Translational Microbiology, Institute for Maternal and Child Health IRCCS Burlo Garofolo, IRCCS Burlo Garofolo, Trieste, Italia ⁽²⁾ - University of Trieste, Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italia ⁽³⁾ - Department of Advanced Translational Microbiology, Institute for Maternal and Child Health – IRCCS Burlo Garofolo, Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italia ⁽⁴⁾	79
102 - Influenza virus-induced APE1 downregulation: implications for NRF2 pathway and host immune response	80
Walter Toscanelli ⁽¹⁾ - Marta De Angelis ⁽¹⁾ - Anna Teresa Palamara ⁽²⁾ - Lucia Nencioni ⁽¹⁾	80
Sapienza Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽¹⁾ - Sapienza Università di Roma / Istituto Superiore di Sanità, Dipartimento di Sanità Pubblica e Malattie Infettive / Dipartimento di Malattie Infettive, Roma, Italia ⁽²⁾	80
103 - Results from a large cross-sectional Italian study assessing <i>Ureaplasma</i> spp. and <i>Mycoplasma</i> spp urogenital infections among STI clinic attendees and couples with primary infertility.....	81
Nunzia Zanotta ⁽¹⁾ - Elena Magni ⁽¹⁾ - Vincenzo Petix ⁽¹⁾ - Petra Carli ⁽¹⁾ - Karin Sossi ⁽¹⁾ - Francesca Uliana ⁽¹⁾ - Francesco De Seta ⁽¹⁾ - Claudia Colli ⁽²⁾ - Lorenzo Monasta ⁽¹⁾ - Maria Cristina Salfa ⁽³⁾ - Barbara Suligoi ⁽³⁾ - Manola Comar ⁽¹⁾	81
IRCCS, BURLO GAROFALO, Trieste, Italia ⁽¹⁾ - ASUGI, centro MST, Trieste, Italia ⁽²⁾ - Istituto Superiore Sanita, National AIDS Unit/dip malattie infettive, Roma, Italia ⁽³⁾	81

Results from a large cross-sectional Italian study assessing *Ureaplasma* spp. and *Mycoplasma* spp urogenital infections among STI clinic attendees and couples with primary infertility. 81

NUNZIA ZANOTTA¹, ELENA MAGNI², VINCENZO PETIX¹, PETRA CARLI¹, KARIN SOSSI¹, FRANCESCA ULIANA¹, FRANCESCO DE SETA¹⁻⁵, CLAUDIA COLLI³, LORENZO MONASTA², MARIA C. SALFA⁴, BARBARA SULIGOI⁴, MANOLA COMAR¹⁻⁵. 81

¹Department of Advanced Translational Microbiology, Institute for Maternal and Child Health IRCCS “Burlo Garofolo” Trieste, Italy; ²Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health-IRCCS “Burlo Garofolo”, Trieste, Italy; ³MST Centre, ASUGI, Trieste, Italy;

⁴ National AIDS Unit, National Health Institute, Rome, Italy; ⁵ Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy.	81
114 - Human cytomegalovirus infection drives a cellular senescence-like phenotype in kidney epithelial cells.....	82
Stefano Raviola ⁽¹⁾ - Gloria Griffante ⁽²⁾ - Andrea Iannucci ⁽³⁾ - Shikha Chandel ⁽²⁾ - Irene Lo Cigno ⁽²⁾ - Davide Lacarbonara ⁽³⁾ - Valeria Caneparo ⁽¹⁾ - Francesco Favero ⁽⁴⁾ - Davide Corà ⁽⁴⁾ - VINCENZO CANTALUPPI ⁽⁵⁾ - SANTO LANDOLFO ⁽⁶⁾ - MARISA GARIGLIO ⁽²⁾ - MARCO DE ANDREA ⁽⁶⁾	82
Università del Piemonte orientale, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, Intrinsic Immunity Unit, University of Piemonte Orientale, Novara, Italia ⁽¹⁾ - Università del Piemonte orientale, Department of Translational Medicine, Virology Unit, Novara, Italia ⁽²⁾ - Università del Piemonte orientale, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, Novara, Italia ⁽³⁾ - Università del Piemonte orientale, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, Bioinformatics Unit, Novara, Italia ⁽⁴⁾ - Università del Piemonte Orientale, Department of Translational Medicine, Nephrology and Transplantation Unit, University of Piemonte Orientale, Novara, Italia ⁽⁵⁾ - Università degli studi di Torino, Department of Public Health and Pediatric Sciences, Viral Pathogenesis Unit, University of Turin, Torino, Italia ⁽⁶⁾	82
115 - Three-label host-cell adhesion assay to assess the exclusion effect exerted by Lactobacillus acidophilus on adhesion of Pseudomonas aeruginosa to A549 alveolar epithelial cells	84
Semih Esin ⁽¹⁾ - Esingül Kaya ⁽¹⁾ - Elisa Catelli ⁽¹⁾ - Giuseppantonio Maisetta ⁽¹⁾ - Giovanna Batoni ⁽¹⁾	84
Università di Pisa, Ricerca traslazionale e delle nuove tecnologie in medicina e chirurgia, Pisa, Italia ⁽¹⁾	84
118 - Recall immune responses after murine respiratory pneumococcal infection are detected by in vitro restimulation of splenocytes with Streptococcus pneumoniae inactivated whole cells	85
Isabelle Moscardini ⁽¹⁾ - Francesco Santoro ⁽²⁾ - Monica Carraro ⁽²⁾ - Alice Gerlini ⁽¹⁾ - Fabio Fiorino ⁽²⁾ - Chiara Germoni ⁽²⁾ - Samaneh Gholami ⁽²⁾ - Elena Pettini ⁽²⁾ - Donata Medagliani ⁽²⁾ - Francesco Iannelli ⁽²⁾ - Gianni Pozzi ⁽²⁾	85
Microbiotec srl, -, Siena, Italia ⁽¹⁾ - Univesità di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽²⁾	85
119 - Antimicrobial peptide human beta-defensin-2 reduces the gut inflammation induced by enteroinvasive Escherichia coli by inhibiting invasion and virulence factors expression	86
Alessandra Fusco ⁽¹⁾ - Vittoria Savio ⁽¹⁾ - Giovanna Donnarumma ⁽¹⁾	86
Università della Campania Luigi Vanvitelli, Dipartimento di Medicina Sperimentale, Napoli, Italia ⁽¹⁾ ...	86
123 - Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis homologues peptides elicit a strong humoral response in patients with neuroinflammatory disorders, and exacerbate EAE.....	87
Davide Cossu ⁽¹⁾ - Leonardo Antonio Sechi ⁽¹⁾ - Nobutaka Hattori ⁽²⁾	87
Universita, Dipartimento Scienze Biomediche, Sassari, Italia ⁽¹⁾ - Universita, Juntendo University, Department of Neurology, Tokyo, Giappone ⁽²⁾	87
129 - Salmonella Infantis releases Outer Membrane Vesicles (OMVs) including beta-lactamases enzymes during their biogenesis.....	88
Valeria Toppi ⁽¹⁾ - Gabriele Scattini ⁽¹⁾ - Laura Musa ⁽¹⁾ - Luisa Pascucci ⁽¹⁾ - Elisabetta Chiaradia ⁽¹⁾ - Alessia Tognoloni ⁽¹⁾ - Maria Pia Franciosini ⁽¹⁾ - Patrizia Casagrande Proietti ⁽¹⁾	88
Università degli Studi di Perugia, Dipartimento di Medicina Veterinaria, Perugia, Italia ⁽¹⁾	88

133 - Creation of an in vitro model for the screening of different probiotic strains able to prevent to inflammatory diseases of the gastrointestinal system.....	89
Adriana Chiaromonte ⁽¹⁾ - Angela Cacace ⁽¹⁾ - Brunella Perfetto ⁽¹⁾ - Vittoria Savio ⁽¹⁾ - Alberto Alfano ⁽¹⁾ - Giovanna Donnarumma ⁽¹⁾	89
Università della Campania Luigi Vanvitelli, Dipartimento di Medicina Sperimentale, Napoli, Italia ⁽¹⁾ ...	89
135 - Limosilactobacillus fermentum from buffalo milk inhibits Helicobacter pylori in a gastric epithelial cell model	90
Angela Cacace ⁽¹⁾ - Adriana Chiaromonte ⁽¹⁾ - Brunella Perfetto ⁽¹⁾ - Donatella Cimini ⁽²⁾ - Sergio D'Ambrosio ⁽¹⁾ - Giovanna Donnarumma ⁽¹⁾	90
Università della Campania Luigi Vanvitelli, Dipartimento di Medicina Sperimentale, Napoli, Italia ⁽¹⁾ - Università della Campania Luigi Vanvitelli, Dipartimento di Scienze e Tecnologie Ambientali Biologiche e Farmaceutiche, Napoli, Italia ⁽²⁾	90
137 - Induction of robust humoral immunity against SARS-CoV-2 both at post-infection and post-vaccine administration in a cohort of haematological cancer patients	91
Cinzia Borgogna ⁽¹⁾ - Riccardo Bruna ⁽²⁾ - Gloria Griffante ⁽¹⁾ - Licia Martuscelli ⁽¹⁾ - Marco De Andrea ⁽³⁾ - Daniela Ferrante ⁽⁴⁾ - Andrea Patriarca ⁽²⁾ - Abdurraouf Mahmoud ⁽²⁾ - Maghalie Ucciero ⁽²⁾ - Valentina Gaidano ⁽⁵⁾ - Monia Marchetti ⁽⁵⁾ - Davide Rapezzi ⁽⁶⁾ - Michele Lai ⁽⁷⁾ - Mauro Pistello ⁽⁷⁾ - Marco Ladetto ⁽⁵⁾ - Massimo Massaia ⁽⁶⁾ - Gianluca Gaidano ⁽²⁾ - Marisa Gariglio ⁽¹⁾	91
University of Piemonte Orientale, Virology Unit, Department of Translational Medicine, Novara, Italia ⁽¹⁾ - University of Piemonte Orientale and "Maggiore della Carità" Hospital, Division of Hematology, Department of Translational Medicine, Novara, Italia ⁽²⁾ - University of Turin, Viral Pathogenesis Unit, Department of Public Health and Pediatric Sciences, Torino, Italia ⁽³⁾ - University of Piemonte Orientale, Medical Statistics Unit, Department of Translational Medicine, Novara, Italia ⁽⁴⁾ - University of Piemonte Orientale and "SS Antonio e Biagio e Cesare Arrigo" Hospital, Division of Hematology, Department of Translational Medicine, Alessandria, Italia ⁽⁵⁾ - "Santa Croce e Carle di Cuneo" Hospital, Division of Hematology, Cuneo, Italia ⁽⁶⁾ - University of Pisa, Retrovirus Centre, Department of Translational Medicine and New Technologies in Medicine and Surgery, Pisa, Italia ⁽⁷⁾	91
146 - THE VIRAL SENSOR IFI16 AT THE CROSSROADS BETWEEN DAMAGE AND TOLERANCE DURING HUMAN CORONAVIRUS INFECTION	93
Gloria Griffante ⁽¹⁾ - Shika Chandel ⁽¹⁾ - Cinzia Borgogna ⁽¹⁾ - Serena Delbue ⁽²⁾ - Lucia Signorini ⁽²⁾ - Marco De Andrea ⁽³⁾ - Marisa Gariglio ⁽¹⁾	93
Università del Piemonte Orientale, Dip. Medicina Translazionale, Virology Unit, Novara, Italia ⁽¹⁾ - Università degli Studi di Milano, Department of Biomedical, Surgical and Dental Sciences, Milan, Italia ⁽²⁾ - University of Turin, Department of Public Health and Pediatric Sciences, Turin, Italia ⁽³⁾	93
Author affiliations:	93
149 - Correlations between chronic intestinal pseudo-obstruction (CIPO), gut microbiota and intestinal serotonin-related genes expression.	94
Giulia Radocchia ⁽¹⁾ - Bruna Neroni ⁽¹⁾ - Massimiliano Marazzato ⁽¹⁾ - Fabrizio Pantanella ⁽¹⁾ - Letizia Zenzeri ⁽²⁾ - Francesca Vassallo ⁽²⁾ - Enrico Felici ⁽³⁾ - Giovanni Di Nardo ⁽²⁾ - Serena Schippa ⁽¹⁾	94
La Sapienza University of Rome, Department of Public Health and Infectious Diseases, Roma, Italia ⁽¹⁾ - Child Neurology, NESMOS Department, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italia ⁽²⁾ - Pediatric and Pediatric Emergency Unit, "Umberto Bosio" Center for Digestive Diseases,, The Children Hospital, AO SS Antonio e Biagio e Cesare Arrigo, Rome, Italia ⁽³⁾	94

150 - Characterization of citrullination during infection with DNA and RNA viruses: a new strategy for host-targeting antivirals drugs	95
Selina Pasquero ⁽¹⁾ - Gloria Griffante ⁽²⁾ - Francesca Gugliesi ⁽¹⁾ - Matteo Biolatti ⁽¹⁾ - Camilla Albano ⁽¹⁾ - Greta Bajetto ⁽¹⁾ - Valentina Dell'Oste ⁽¹⁾ - Paul R Thompson ⁽³⁾ - Sudeshna Sen ⁽³⁾ - Serena Delbue ⁽⁴⁾ - Silvia Parapini ⁽⁴⁾ - Maria Dolci ⁽⁴⁾ - Santo Landolfo ⁽¹⁾ - Marco De Andrea ⁽¹⁾	
University of Turin, Department of Public Health and Pediatric Sciences, Torino, Italia ⁽¹⁾ - University of Eastern Piedmont, Department of Translational Medicine, Novara, Italia ⁽²⁾ - UMass Medical School, Department of Biochemistry and Molecular Pharmacology, Worcester, - ⁽³⁾ - University of Milan, Department of Biomedical, Surgical and Dental Sciences, Milano, Italia ⁽⁴⁾	
151 - News Microbiological Marker in type 1 diabetes	97
<i>The possible role of MAP And HERVs in the type 1 diabetes onset.</i>	
<i>Marta Noli ⁽¹⁾ - Seyedesomaye Jasemi ⁽¹⁾ - Stefano Ruberto ⁽¹⁾ - Elena Rita Simula ⁽¹⁾ - Gian Franco Meloni ⁽²⁾ - Davide Cossu ⁽¹⁾ - Leonardo Antonio Sechi ⁽¹⁾</i>	
<i>Università degli studi di Sassari, Dipartimento di Scienze Biomediche, Sassari, Italia ⁽¹⁾ - Università degli studi di Sassari, Dipartimento di medicina clinica e sperimentale, Sassari, Italia ⁽²⁾</i>	
153 - Peptide L18R plays an antimicrobial modulating action against polymicrobial biofilm in LCWB model	98
Paola Di Fermo ⁽¹⁾ - Simonetta D'Ercole ⁽²⁾ - Tecla Ciociola ⁽³⁾ - Firas Diban ⁽¹⁾ - Morena Petrini ⁽²⁾ - Stefania Conti ⁽³⁾ - Mara Di Giulio ⁽¹⁾ - Luigina Cellini ⁽¹⁾	
University of "G. d'Annunzio", Chieti-Pescara, Department of Pharmacy, Chieti, Italia ⁽¹⁾ - University of "G. d'Annunzio", Chieti-Pescara, Department of Medical, Oral and Biotechnological Sciences, Chieti, Italia ⁽²⁾ - University of Parma, Department of Medicine and Surgery, Parma, Italia ⁽³⁾	
154 - Potential preventive role of probiotics against Pseudomonas aeruginosa corneal infection	99
Irene Paterniti ⁽¹⁾ - Sarah Adriana Scuderi ⁽¹⁾ - Jessica Molinari ⁽¹⁾ - Antonia Nostro ⁽¹⁾ - Emanuela Esposito ⁽¹⁾ - Andreana Marino ⁽¹⁾	
Università, Università di Messina/Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali, Messina, Italia ⁽¹⁾	
157 - Prospective monitoring of HIV-1 infected patients after SARS-CoV-2 mRNA vaccination: characterization of IFN gene expression signature and humoral immune response	100
Federica Frasca ⁽¹⁾ - Mirko Scordio ⁽¹⁾ - Letizia Santinelli ⁽²⁾ - Luca Maddaloni ⁽²⁾ - Leonardo Sorrentino ⁽¹⁾ - Matteo Fracella ⁽¹⁾ - Alessandra D'Auria ⁽¹⁾ - Carla Selvaggi ⁽²⁾ - Eugenio Nelson Cavallari ⁽²⁾ - Anna Napoli ⁽²⁾ - Lilia Cinti ⁽²⁾ - Piergiorgio Roberto ⁽²⁾ - Giancarlo Ceccarelli ⁽²⁾ - Aurelia Gaeta ⁽²⁾ - Guido Antonelli ⁽³⁾ - Claudio Maria Mastroianni ⁽²⁾ - Gabriella d'Ettore ⁽²⁾ - Carolina Scagnolari ⁽¹⁾	
La Sapienza, Università di Roma, Dipartimento di Medicina Molecolare, Roma, Italia ⁽¹⁾ - La Sapienza, Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽²⁾ - La Sapienza Università di Roma, Unità di Microbiologia e Virologia, Policlinico Umberto I, Roma, Italia ⁽³⁾	
158 - Characterization of mucosal immune response against SARS-CoV-2 in vaccinated children.	102
Leonardo Sorrentino ⁽¹⁾ - Maria Giulia Conti ⁽¹⁾ - Eva Piano Mortari ⁽²⁾ - Federica Frasca ⁽¹⁾ - Matteo Fracella ⁽¹⁾ - Giuseppe Oliveto ⁽¹⁾ - Mirko Scordio ⁽¹⁾ - Alessandra D'Auria ⁽¹⁾ - Raffaella Nenna ⁽¹⁾ - Laura Petrarca ⁽¹⁾ - Carolina Scagnolari ⁽¹⁾ - Rita Carsetti ⁽²⁾ - Fabio Midulla ⁽¹⁾ - Alessandra Pierangeli ⁽¹⁾	
Università, Sapienza Università di Roma, Roma, Italia ⁽¹⁾ - Ospedale, Ospedale Bambino Gesù, Roma, Italia ⁽²⁾	

160 - Evaluation of redox state alterations in influenza A virus-infected neuronal cells: involvement in neurotropism..... 103

Anna Maria Marinelli ⁽¹⁾ - Dolores Limongi ⁽¹⁾ - Carla Prezioso ⁽²⁾ - Marta De Angelis ⁽³⁾ - Lucia Nencioni ⁽³⁾ - Anna Teresa Palamara ⁽³⁾ - Paola Checconi ⁽¹⁾ 103

San Raffaele University, Department of Human Sciences and Quality of Life Promotion, Roma, Italia ⁽¹⁾ - IRCCS San Raffaele, Microbiology of Chronic Neuro-Degenerative Pathologies, Roma, Italia ⁽²⁾ - Sapienza University, Department of Public Health and Infectious Diseases, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Roma, Italia ⁽³⁾ 103

Evaluation of redox state alterations in influenza A virus-infected neuronal cells: involvement in neurotropism..... 103

ANNA M. MARINELLI^{1,2}, DOLORES LIMONGI^{1,2}, CARLA PREZIOSO², MARTA DE ANGELIS³, LUCIA NENCIONI³, ANNA T. PALAMARA^{3,4}, PAOLA CHECCONI^{1,2} 103

¹Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy; 103

²Microbiology of Chronic Neuro-Degenerative Pathologies, IRCCS San Raffaele Roma, Rome, Italy;

³Department of Public Health and Infectious Diseases, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, Rome, Italy; 103

⁴Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy. 103

163 - Fecal-associated Enterobacteriaceae isolates from Celiac disease patients: could dietary sugars drive changes in bacterial composition? 104

Meysam Sarshar ⁽¹⁾ - Cecilia Ambrosi ⁽²⁾ - Daniela Scribano ⁽³⁾ - Francesca Ferretti ⁽⁴⁾ - Anna Teresa Palamara ⁽⁵⁾ - Andrea Masotti ⁽¹⁾ 104

Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy ⁽¹⁾ - Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Open University, IRCCS, Rome, Italy ⁽²⁾ - Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy ⁽³⁾ - Hepato-Gastroenterology and Nutrition Department, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy ⁽⁴⁾ - Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy ⁽⁵⁾ 104

164 - Discovering the role of Mycoplasma girerdii in Trichomonas vaginalis pathobiology: just a parasite or a new friend for the protist? 105

Valentina Margarita ⁽¹⁾ - Nicholas P Bailey ⁽²⁾ - Nicia Diaz ⁽¹⁾ - Daniele Dessi' ⁽¹⁾ - Paola Rappelli ⁽¹⁾ - Jennifer FETTWAS ⁽³⁾ - Robert P Hirt ⁽²⁾ - Pier Luigi Fiori ⁽¹⁾ 105

Universita' di Sassari, Dipartimento di Scienze Biomediche, Sassari, Italia ⁽¹⁾ - Newcastle University, Biosciences Institute, Faculty of Medical Sciences, Newcastle upon Tyne, Regno Unito ⁽²⁾ - Virginia Commonwealth University, Department of Microbiology and Immunology, Richmond, Stati Uniti D'america ⁽³⁾ 105

165 - Study of immunological parameters associated with Long COVID in children/adolescents 106

Matteo Fracella ⁽¹⁾ - Leonardo Sorrentino ⁽¹⁾ - Federica Frasca ⁽¹⁾ - Mirko Scordio ⁽¹⁾ - Giuseppe Oliveto ⁽¹⁾ - Agnese Viscido ⁽¹⁾ - Camilla Bitossi ⁽¹⁾ - Alessandra D'Auria ⁽¹⁾ - Stefania Rossi ⁽²⁾ - Lucia Gabriele ⁽²⁾ - Anna R. Ciccaglione ⁽³⁾ - Roberto Bruni ⁽³⁾ - Laura Petrarca ⁽⁴⁾ - Enrica Mancino ⁽⁴⁾ - Raffaella Nenna ⁽⁴⁾ - Fabio Midulla ⁽⁴⁾ - Guido Antonelli ⁽¹⁾ - Alessandra Pierangeli ⁽¹⁾ - Carolina Scagnolari ⁽¹⁾ 106

"Sapienza" University, Department of Molecular Medicine, Virology Laboratory, Roma, Italia ⁽¹⁾ - Istituto Superiore di Sanità, Department of Oncology and Molecular Medicine, Roma, Italia ⁽²⁾ - Istituto Superiore di Sanità, Department of Infectious Diseases, Roma, Italia ⁽³⁾ - "Sapienza" University, Department of Pediatrics and Infantile Neuropsychiatry, Roma, Italia ⁽⁴⁾ 106

167 - Neutralization titers and Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2 in a Sardinian cohort group.....	108
Giuseppina Sanna ⁽¹⁾ - ALESSANDRA Marongiu ⁽¹⁾ - Davide Firinu ⁽²⁾ - Cristina Piras ⁽³⁾ - Vanessa Palmas ⁽¹⁾ - Valeria Manca ⁽¹⁾ - Marta Serreli ⁽⁴⁾ - Marcello Campagna ⁽²⁾ - Andrea Perra ⁽⁵⁾ - Stefano Del Giacco ⁽²⁾ - Maria C. Ruffi ⁽²⁾ - Luchino Chessa ⁽²⁾ - Aldo Manzin ⁽¹⁾	108
University of Cagliari, Department of Biomedical Sciences, Microbiology and Virology Unit, Cagliari, Italia ⁽¹⁾ - University of Cagliari, Department of Medical Sciences and Public Health, Cagliari, Italia ⁽²⁾ - University of Cagliari, Department of Biomedical Sciences, Clinical Metabolomics Unit, Cagliari, Italia ⁽³⁾ - University of Cagliari, Department of Biomedical Sciences, Cagliari, Italia ⁽⁴⁾ - University of Cagliari, Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology,, Cagliari, Italia ⁽⁵⁾ ...	108
168 - CD169 IN BLOOD & CIRCULATING MICROVESICLES AS AN EARLY BIOMARKER OF COVID-19 DISEASE PROGRESSION.....	109
Marialaura Fanelli ⁽¹⁾ - Vita Petrone ⁽¹⁾ - Christian Maracchioni ⁽¹⁾ - Martina Giudice ⁽¹⁾ - Rossella Chiricio ⁽¹⁾ - Marco Iannetta ⁽²⁾ - Ines Ait Belkacem ⁽³⁾ - Marta Zordan ⁽²⁾ - Pietro Vitale ⁽⁴⁾ - Massimo Andreoni ⁽²⁾ - Loredana Sarmati ⁽²⁾ - Fabrice Malergue ⁽⁵⁾ - Emanuela Balestrieri ⁽¹⁾ - Sandro Grelli ⁽¹⁾ - Claudia Matteucci ⁽¹⁾ - Antonella Minutolo ⁽¹⁾	109
Università degli studi di Roma "Tor Vergata", Dipartimento Medicina Sperimentale, Roma, Italia ⁽¹⁾ - Università degli studi di Roma "Tor Vergata", Dipartimento Medicina dei Sistemi, Roma, Italia ⁽²⁾ - Aix Marseille Université, CNR INSERM, Marsiglia, Francia ⁽³⁾ - Policlino Tor Vergata, Malattie Infettive, Roma, Italia ⁽⁴⁾ - Dipartimento Ricerca e Sviluppo, Beckman Coulter, Marsiglia, Francia ⁽⁵⁾	109
169 - Preliminary evaluation of genomic and transcriptomic changes in the evolution from a USA300 wild-type isolate to SCV, able to perform phagosomal escape.	110
Dalida Angela Bivona (1) - Carmelo Bonomo (1) - Paolo G Bonacci (1) - Grete Privitera (1) - Nicolò Musso (1) - Giuseppe Caruso (2) - Filippo Caraci (2) - Stefania Stefani (1) - Dafne Bongiorno (1).....	110
Università di Catania, Department of Biomedical and Biotechnological Science, Catania, Italia (1) - Università di Catania, Department of Drug and Health Sciences, Catania, Italia (2)	110
171 - In vitro analysis of epithelial tolerability and anti-Candida effect of a new lactic acid-based vaginal gel formulation	112
Luca Spaggiari ⁽¹⁾ - Gianfranco Squartini ⁽²⁾ - Andrea Ardizzoni ⁽²⁾ - Francesco De Seta ⁽³⁾ - Elisabetta Blasi ⁽²⁾ - Eva Pericolini ⁽²⁾	112
Università degli Studi di Modena e Reggio Emilia (UNIMORE), Corso di Dottorato in Medicina Clinica e Sperimentale (CEM), Modena, Italia ⁽¹⁾ - Università degli Studi di Modena e Reggio Emilia (UNIMORE), Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, Modena, Italia ⁽²⁾ - Università degli Studi di Trieste, Dipartimento Clinico di Scienze Mediche, Chirurgiche e della Salute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Burlo Garofolo, Trieste, Italia ⁽³⁾	112
174 - Human endogenous retroviruses as markers of disease and prognosis of chronic lymphocytic leukemia	114
Vita Petrone ⁽¹⁾ - Alessandro Giovinnazzo ⁽²⁾ - Roberta Laureana ⁽³⁾ - Chiara Cipriani ⁽¹⁾ - Marialaura Fanelli ⁽¹⁾ - Antonella Minutolo ⁽¹⁾ - Giovangiaco Paterno ⁽³⁾ - Elisa Buzzatti ⁽³⁾ - Sandro Grelli ⁽¹⁾ - Giovanni Del Poeta ⁽³⁾ - Maria Ilaria Del Principe ⁽¹⁾ - Emanuela Balestrieri ⁽¹⁾ - Claudia Matteucci ⁽¹⁾	114
Università degli studi di Roma "Tor Vergata", Dipartimento di Medicina Sperimentale, Roma, Italia ⁽¹⁾ - istituto di biochimica e biologia cellulare, CNR, Roma, Italia ⁽²⁾ - Università degli studi di Roma "Tor Vergata", Dipartimento di Medicina e Prevenzione, Roma, Italia ⁽³⁾	114

178 - Maternal immune activation induces abnormal expression of endogenous retroviruses and immune effectors in a sex-dependent manner in a mouse model of Autism Spectrum Disorders	115
Martina Giudice ⁽¹⁾ - Erica D'Avorio ⁽¹⁾ - Anna Maria Tartaglione ⁽²⁾ - Rossella Chirico ⁽¹⁾ - Vita Petrone ⁽¹⁾ - Marialaura Fanelli ⁽¹⁾ - Christian Marracchioni ⁽¹⁾ - Antonella Minutolo ⁽¹⁾ - Sandro Grelli ⁽¹⁾ - Laura Ricceri ⁽²⁾ - Claudia Matteucci ⁽¹⁾ - Paola Sinibaldi-Vallebona ⁽¹⁾ - Emanuela Balestrieri ⁽¹⁾ - Chiara Cipriani ⁽¹⁾ ..	
Università degli studi di Roma "Tor Vergata", Dipartimento di Medicina Sperimentale, ROMA, Italia ⁽¹⁾ - Istituto Superiore di Sanità, Centro di scienze comportamentali e salute mentale, Roma, Italia ⁽²⁾	
182 - Effects of dysbiosis on 6-OHDA mouse model of Parkinson's disease: insights from core microbiota and co-occurrence network analyses	116
Luigia Turco ⁽¹⁾ - Lorena Coretti ⁽²⁾ - Adriano Lama ⁽²⁾ - Carmen Avagliano ⁽²⁾ - Federica Comella ⁽²⁾ - Carmen De Caro ⁽³⁾ - Giuseppina Mattace Raso ⁽²⁾ - Francesca Lembo ⁽²⁾ - Elisabetta Buommino ⁽²⁾	
Università degli studi della Campania Luigi Vanvitelli, Dipartimento di Medicina di Precisione, Napoli, Italia ⁽¹⁾ - Università degli studi di Napoli Federico II, Dipartimento di Farmacia, Napoli, Italia ⁽²⁾ - Università degli Studi "Magna Graecia" di Catanzaro, Dipartimento di Scienze della Salute, Catanzaro, Italia ⁽³⁾	
187 - Effects of antimicrobial protocols for Helicobacter pylori eradication on structure and functions of the human gut microbiota.....	117
Laura De Diego ⁽¹⁾ - Alessandro Tanca ⁽¹⁾ - Marcello Abbondio ⁽¹⁾ - Rosangela Sau ⁽¹⁾ - Giovanni Mario Pes ⁽²⁾ - Maria Pina Dore ⁽²⁾ - Sergio Uzzau ⁽¹⁾	
University of Sassari, Department of Biomedical Sciences, Sassari, Italia ⁽¹⁾ - University of Sassari, Department of Medical, Surgical and Experimental Sciences, Sassari, Italia ⁽²⁾	
191 - HERVs IMPLICATION IN DEVELOPMENT, PROGRESSION AND LONG-TERM COMPLIANCE OF COVID-19	118
Antonella Minutolo ⁽¹⁾ - Marialaura Fanelli ⁽¹⁾ - Vita Petrone ⁽¹⁾ - Elisabetta Teti ⁽²⁾ - Christian Marracchioni ⁽¹⁾ - Martina Giudice ⁽¹⁾ - Rossella Chirico ⁽¹⁾ - Marco Iannetta ⁽²⁾ - Federica Caldara ⁽²⁾ - Chiara Sorace ⁽²⁾ - Massimo Andreoni ⁽²⁾ - Loredana Sarmati ⁽²⁾ - Branka Horvat ⁽³⁾ - Hervè Perron ⁽⁴⁾ - Enrico Garaci ⁽⁵⁾ - Emanuela Balestrieri ⁽¹⁾ - Sandro Grelli ⁽¹⁾ - Claudia Matteucci ⁽¹⁾	
Università degli studi di Roma, Dipartimento di Medicina Sperimentale, ROMA, Italia ⁽¹⁾ - Policlinico di Roma Tor Vergata, Reparto di Malattie Infettive, Roma, Italia ⁽²⁾ - Scuola Normale superiore di Lione, Centro nazionale di ricerca per le malattie infettive, Lione, Francia ⁽³⁾ - Geneuro - innovation, Geneuro Research and Development, Lione, Francia ⁽⁴⁾ - Università San Raffaele, IRCCS San Raffaele Pisana, Roma, Italia ⁽⁵⁾	
199 - Third Sars-CoV-2 vaccine dose: B cell and antibody responses following heterologous and homologous vaccination strategies.....	119
Gabiria Pastore ⁽¹⁾ - Annalisa Ciabattini ⁽¹⁾ - Fabio Fiorino ⁽¹⁾ - Jacopo Polvere ⁽¹⁾ - Simone Lucchesi ⁽¹⁾ - Ilaria Rancan ⁽²⁾ - Arianna Lippi ⁽²⁾ - Sara Zirpoli ⁽¹⁾ - Elena Pettini ⁽¹⁾ - Massimiliano Fabbiani ⁽³⁾ - Mario Tumbarello ⁽²⁾ - Francesca Montagnani ⁽²⁾ - Donata Medaglini ⁽¹⁾	
Laboratorio di Microbiologia Molecolare e Biotecnologia, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italia ⁽¹⁾ - Dipartimento di Biotecnologie Mediche, Università di Siena, Dipartimento di Scienze Mediche, Unità di Malattie Infettive e Tropicali, Ospedale Universitario di Siena, Siena, Italia ⁽²⁾ - Dipartimento di Scienze Mediche, Unità di Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria di Siena, Siena, Italia ⁽³⁾	

200 - Prediction of <i>Pneumocystis jirovecii</i> pneumonia in COVID-19 patients through quantitative PCR on oral washings	120
Luca Fanasca ⁽¹⁾ - Elena Scaglione ⁽²⁾ - Ciro Rauch ⁽¹⁾ - Anna Fioretti ⁽¹⁾ - Valeria Pedata ⁽¹⁾ - Federica Amodio ⁽¹⁾ - Saveria Alfè ⁽¹⁾ - Giuseppina Montanile ⁽¹⁾ - Mariateresa Vitiello ⁽³⁾ - Roberta Colicchio ⁽³⁾ - Giulio Viceconte ⁽⁴⁾ - Antonio R. Buonomo ⁽⁴⁾ - Ivan Gentile ⁽⁴⁾ - Paola Salvatore ⁽⁵⁾	120
University Hospital Federico II, DAI Lab Med and Transf. UOC Clin Micr, Napoli, Italia ⁽¹⁾ - University of Naples Federico II; University Hospital Federico II, DAI Lab Med and Transf UOC Clin Micr; Dpt Mol Med Med Biotech; Dpt Chem Mat and Prod Eng, Napoli, Italia ⁽²⁾ - University of Naples Federico II; University Hospital Federico II, DAI Lab Med and Transf UOC Clin Micr; Dpt Mol Med Med Biotech, Napoli, Italia ⁽³⁾ - University of Naples Federico II, Dpt Clin Med and Surg, Sect of Inf Dis, Napoli, Italia ⁽⁴⁾ - University Hospital Federico II; University of Naples Federico II; CEINGE, Advanced Biotechnologies s.c.ar.l., DAI Lab Med and Transf UOC Clin Micr; Dpt Mol Med Med Biotech; Task Force on Microbiome Studies, Napoli, Italia ⁽⁵⁾	120
202 - Human endogenous retroviruses as potential therapeutic targets for the treatment of head and neck squamous cell carcinoma resistant to radiotherapy.....	121
Vita Petrone ⁽¹⁾ - Rossella Chirico ⁽¹⁾ - Marialaura Fanelli ⁽¹⁾ - Christian Marracchioni ⁽¹⁾ - Martina Giudice ⁽¹⁾ - Sandro Grelli ⁽²⁾ - Antonella Minutolo ⁽¹⁾ - Emanuela Balestrieri ⁽¹⁾ - Ira-Ida Skvortsova ⁽³⁾ - Claudia Matteucci ⁽¹⁾	121
Università degli studi di Roma, Dipartimento di Medicina Sperimentale, Roma, Italia ⁽¹⁾ - Policlino di Tor Vergata, Unità di Virologia, Roma, Italia ⁽²⁾ - Università di Medicinad di Innsbruck, Dipartimento di radiologia terapeutica e oncologia, Innsbruck, Austria ⁽³⁾	121
205 - A specific anti-IFITM2 antibody bars the way to SARS-CoV-2 entry into host cells.	122
Anna Basile ⁽¹⁾ - Carla Zannella ⁽²⁾ - Gianluigi Franci ⁽¹⁾ - Margot De Marco ⁽¹⁾ - Maria Ctaerina Turco ⁽¹⁾ - Alessandra Rosati ⁽¹⁾ - Liberato Marzullo ⁽¹⁾	122
UNISA, DIPMED, Baronissi, Italia ⁽¹⁾ - University of Campania “Luigi Vanvitelli”, Department of Experimental Medicine, Naples, Italia ⁽²⁾	122
209 - HSV-1 INDUCED COMPLEMENT ACTIVATION IN BRAIN CELLS: POSSIBLE TRIGGER OF SYNAPTIC DEFICITS.....	123
Mariya Timotey Miteva ⁽¹⁾ - Virginia Protto ⁽¹⁾ - Filomena Iannuzzi ⁽²⁾ - Flavia Pasquali ⁽¹⁾ - Maria Elena Marcocci ⁽¹⁾ - Giovanna De Chiara ⁽²⁾ - Anna Teresa Palamara ⁽³⁾	123
Sapienza Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽¹⁾ - Consiglio Nazionale delle Ricerche, Istituto di Farmacologia Traslazionale, Roma, Italia ⁽²⁾ - Sapienza Università di Roma; Istituto Superiore di Sanità, Dipartimento di Sanità Pubblica e Malattie Infettive; Dipartimento di Malattie Infettive, Roma, Italia ⁽³⁾	123
211 - Antibacterial activity of Rhein against <i>Streptococcus mutans</i>	124
Francesco Foglia ⁽¹⁾ - Emanuela Roscetto ⁽²⁾ - ALESSANDRA Amato ⁽³⁾ - Umbero Galdiero ⁽⁴⁾ - ROBERTA Gasparro ⁽⁵⁾ - Carla Zannella ⁽⁶⁾ - Vincenzo Casolaro ⁽⁷⁾ - Anna De filippis ⁽⁸⁾ - Maria Rosaria Catania ⁽⁹⁾ - Gianluigi Franci ⁽¹⁰⁾ - Massimiliano Galdiero ⁽¹¹⁾	124
Università della Campania I. Vanvitelli, Dipartimento di Medicina Sperimentale, Napoli, Italia ⁽¹⁾ - Università degli studi Federico II, Department of Molecular Medicine and Medical Biotechnology, Napoli, Italia ⁽²⁾ - University of salerno, 3Department of Medicine, Surgery and Dentistry, Salerno, Italia ⁽³⁾ - Università Degli studi Federico II, Department of Molecular Medicine and Medical Biotechnology,, Napoli, Italia ⁽⁴⁾ - University of Salerno, Department of Neurosciences, Reproductive Sciences and dentistry, Salerno, Italia ⁽⁵⁾ - University of Camapania L. Vanvitelli, 1Department of Experimental	

Medicine, Naples, Italia ⁽⁶⁾ - University of Salerno, Department of Medicine, Surgery and Dentistry, Salerno, Italia ⁽⁷⁾ - University of Campania L vanvitelli, Department of Experimental Medicine, Naples, Italia ⁽⁸⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, Naples, Italia ⁽⁹⁾ - University of Salerno, 5Department of Medicine, Surgery and Dentistry, salerno, Italia ⁽¹⁰⁾ - University of Campania L. Vanvitelli, Department of experimental medicine, Naples, Italia ⁽¹¹⁾	124
213 - Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines	126
Fabio Fiorino ⁽¹⁾ - Annalisa Ciabattini ⁽¹⁾ - Anna Sicuranza ⁽²⁾ - Gabiria Pastore ⁽¹⁾ - Adele Santoni ⁽²⁾ - Martina Simoncelli ⁽²⁾ - Jacopo Polvere ⁽¹⁾ - Sara Galimberti ⁽³⁾ - Claudia Barate ⁽³⁾ - Francesca Montagnani ⁽⁴⁾ - Vincenzo Sammartano ⁽²⁾ - Monica Bocchia ⁽²⁾ - Donata Medaglini ⁽¹⁾	126
Laboratorio di Microbiologia Molecolare e Biotecnologia, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italia ⁽¹⁾ - Unità di Ematologia, Dipartimento Scienze mediche, chirurgiche e neuroscienze, Azienda Ospedaliero Universitaria, Siena, Italia ⁽²⁾ - Sezione di Ematologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italia ⁽³⁾ - Dipartimento di Scienze Mediche, Unità di Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria di Siena,, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italia ⁽⁴⁾	126
214 - Antimicrobial and Antibiofilm Activities of Carvacrol, Amoxicillin and Salicylhydroxamic acid Alone and in Combination versus Helicobacter pylori	127
VALENTINA PUCA ⁽¹⁾ - BEATRICE MARINACCI ⁽¹⁾ - SIMONE CARRADORI ⁽¹⁾ - CLAUDIU TRANDAFIR SUPURAN ⁽²⁾ - CLEMENTE CAPASSO ⁽³⁾ - PAMELA DI GIOVANNI ⁽¹⁾ - ILARIA D'AGOSTINO ⁽¹⁾ - ROSSELLA GRANDE ⁽¹⁾	127
Università G. d'Annunzio Chieti-Pescara, Dipartimento di Farmacia, Chieti, Italia ⁽¹⁾ - University of Florence, Neurofarba Department, Section of Pharmaceutical and Nutraceutical Sciences, Firenze, Italia ⁽²⁾ - National Research Council (CNR), Department of Biology, Agriculture and Food Sciences, Napoli, Italia ⁽³⁾	127
216 - Expression profile of Human Endogenous Retroviruses, their receptors, inflammatory and regulatory cytokines in children with Kawasaki disease and Multisystem inflammatory syndrome	128
emanuela balestrieri ⁽¹⁾	128
Università degli studi di Roma Tor Vergata, Dipartimento di Medicina Sperimentale, roma, Italia ⁽¹⁾ .	128
217 - HSV-1-induced tau spreading in the brain: neurodegenerative damage or protective effect?	129
Virginia Protto ⁽¹⁾ - Filomena Iannuzzi ⁽²⁾ - Mariya Timotey Miteva ⁽¹⁾ - Flavia Pasquali ⁽¹⁾ - Domenica Donatella Li Puma ⁽³⁾ - Luigi Sansone ⁽⁴⁾ - Maria Elena Marcocci ⁽¹⁾ - Matteo Antonio Russo ⁽⁴⁾ - Claudio Grassi ⁽³⁾ - Anna Teresa Palamara ⁽⁵⁾ - Giovanna De Chiara ⁽²⁾	129
Sapienza Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽¹⁾ - Consiglio Nazionale delle Ricerche (CNR), Istituto di Farmacologia Traslazionale, Roma, Italia ⁽²⁾ - Università Cattolica del Sacro Cuore; Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Neuroscienze, Roma, Italia ⁽³⁾ - IRCCS San Raffaele Pisana, Dipartimento di Patologia Cellulare e Molecolare, Roma, Italia ⁽⁴⁾ - Sapienza Università di Roma; Istituto Superiore di Sanità, Dipartimento di Sanità Pubblica e Malattie Infettive; Dipartimento di Malattie Infettive, Roma, Italia ⁽⁵⁾	129
218 - Antimicrobial and Antibiofilm Activities of Cell Free Supernatant of Limosilactobacillus reuteri DSM 17938	131

BEATRICE MARINACCI ⁽¹⁾ - IRENE VITALE ⁽¹⁾ - VALENTINA PUCA ⁽¹⁾ - SIMONE CARRADORI ⁽¹⁾ - ANTONELLA DI SOTTO ⁽²⁾ - ROSSELLA GRANDE ⁽¹⁾	131
University "G. d'Annunzio" Chieti-Pescara, Department of Pharmacy, Chieti, Italia ⁽¹⁾ - Sapienza University of Rome, Department of Physiology and Pharmacology "V. Erspamer", Roma, Italia ⁽²⁾	131
233 - Longitudinal profiling of spike-specific antibody and B cell responses following mRNA-1273 SARS-CoV-2 vaccination in hematopoietic cell transplantation recipients	132
Elena Pettini ⁽¹⁾ - Annalisa Ciabattini ⁽¹⁾ - Gabiria Pastore ⁽¹⁾ - Jacopo Polvere ⁽¹⁾ - Simone Lucchesi ⁽¹⁾ - Fabio Fiorino ⁽¹⁾ - Francesca Montagnani ⁽¹⁾ - Alessandro Bucalossi ⁽²⁾ - Monica Tozzi ⁽²⁾ - Giuseppe Marotta ⁽²⁾ - Donata Medaglini ⁽¹⁾	132
Università degli Studi di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽¹⁾ - Azienda Ospedaliera Universitaria Senese, Dipartimento di Innovazione, sperimentazione e ricerca clinica e traslazionale, Siena, Italia ⁽²⁾	132
243 - Aspergillus infection and differential expression of TLRs and type I-III IFNs in the respiratory tract of a large cohort of CF patients from the Italian (Lazio) Reference Center for Cystic Fibrosis	133
Camilla Bitossi ⁽¹⁾ - Agnese Viscido ⁽¹⁾ - Mirko Scordio ⁽¹⁾ - Federica Frasca ⁽¹⁾ - Giuseppe Oliveto ⁽¹⁾ - Leonardo Sorrentino ⁽¹⁾ - Matteo Fracella ⁽¹⁾ - Alessandra D'Auria ⁽¹⁾ - Giuseppe Cimino ⁽²⁾ - Valeria Pietropaolo ⁽³⁾ - Maria Trancassini ⁽³⁾ - Alessandra Pierangeli ⁽¹⁾ - Guido Antonelli ⁽¹⁾ - Carolina Scagnolari ⁽¹⁾	133
Laboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italia ⁽¹⁾ - Lazio Reference Center for Cystic Fibrosis, Policlinico Umberto I University Hospital, Rome, Italia ⁽²⁾ - Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italia ⁽³⁾	133
254 - Evaluation of amphibian antimicrobial peptides as new therapeutic treatments against infectious diseases	135
Annalisa Chianese ⁽¹⁾ - Carla Zannella ⁽¹⁾ - Alessandra Monti ⁽²⁾ - Maria Vittoria Morone ⁽¹⁾ - Anna De Filippis ⁽¹⁾ - Nunzianna Doti ⁽²⁾ - Gianluigi Franci ⁽³⁾ - Massimiliano Galdiero ⁽¹⁾	135
Università, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, napoli, Italia ⁽¹⁾ - 2 Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR),, 2 Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR),, napoli, Italia ⁽²⁾ - Università, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, salerno, Italia ⁽³⁾	135
264 - In vitro characterization of an mRNA vaccine model.....	136
Lara Mitia Castronovo ⁽¹⁾ - Anna Maria Cuppone ⁽¹⁾ - Emma Gennaioli ⁽¹⁾ - Alessia Masella ⁽¹⁾ - Francesco Iannelli ⁽¹⁾ - Gianni Pozzi ⁽¹⁾	136
Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽¹⁾	136
275 - SARS-CoV-2 vaccine immune response in adults with Down syndrome.....	137
<i>Gabriele Di Sante ⁽¹⁾ - Carfi Angelo ⁽²⁾ - Maria del Carmen Pereyra Boza ⁽³⁾ - Maria Tredicine ⁽⁴⁾ - Onder Graziano ⁽⁵⁾ - Maurizio Sanguinetti ⁽³⁾ - Giovanni Delogu ⁽⁶⁾ - Michela Sali ⁽³⁾</i>	137
<i>Dipartimento di Medicina e Chirurgia, Sezione di Anatomia Umana, Clinica e Forense,, Università degli studi di Perugia, Perugia, Italia ⁽¹⁾ - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy,, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy,, roma, Italia ⁽²⁾ - Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie- Istituto di Microbiologia, Istituto di Microbiologia, Università Cattolica del Sacro</i>	

<i>Cuore, Roma, roma, Italia</i> ⁽³⁾ - <i>Dipartimento di Medicina e Chirurgia Traslazionale, Sezione di Patologia Generale, Università Cattolica del Sacro Cuore, Roma, Italia, Roma, Italia</i> ⁽⁴⁾ - <i>Malattie cardiovascolari, endocrino-metaboliche e invecchiamento, . Istituto Superiore di Sanità, ROMA, Italia</i> ⁽⁵⁾ - <i>Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie- Istituto di Microbiologia/ Mater Olbia, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Roma /Mater Olbia, Olbia, Roma/Olbia, Italia</i> ⁽⁶⁾	137
277 - A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota	139
Valerio Iebba ⁽¹⁾ - Lisa Derosa ⁽²⁾ - Bertrand Routy ⁽³⁾ - Carolina A. Costa Silva ⁽²⁾ - Cassandra Thelemaque ⁽²⁾ - Meriem Messaoudene ⁽³⁾ - Andrew Thomas ⁽⁴⁾ - Gerard Zalcman ⁽⁵⁾ - Sylvie Friard ⁽⁶⁾ - Julien Mazieres ⁽⁷⁾ - Clarisse Audigier-Valette ⁽⁸⁾ - Denis Moro-Sibilot ⁽⁹⁾ - Francois Goldwasser ⁽¹⁰⁾ - Arnaud Scherpereel ⁽¹¹⁾ - Hervé Pegliasco ⁽¹²⁾ - Francois Ghiringhelli ⁽¹³⁾ - Nicole Bouchard ⁽¹⁴⁾ - Cissé Sow ⁽²⁾ - Ines Darik ⁽²⁾ - Silvia Zoppi ⁽²⁾ - Pierre Ly ⁽²⁾ - Anna Reni ⁽²⁾ - Leonardo Lordello ⁽²⁾ - Romain Daillère ⁽¹⁵⁾ - Fabrice Barlesi ⁽²⁾ - Damien Drubay ⁽²⁾ - Eric Deutsch ⁽²⁾ - Karla Lee ⁽¹⁶⁾ - Laura Bolte ⁽¹⁷⁾ - Johannes Bjork ⁽¹⁷⁾ - Rinse Weersma ⁽¹⁷⁾ - Morten Isaksen ⁽¹⁸⁾ - Lucas Barros ⁽¹⁸⁾ - Bernard Escudier ⁽²⁾ - Laurence Albiges ⁽²⁾ - David Planchard ⁽²⁾ - Fabrice André ⁽²⁾ - Stephanie Martines ⁽¹⁹⁾ - Benjamin Besse ⁽²⁾ - Nicola Segata ⁽⁴⁾ - Guido Kroemer ⁽²⁾ - Laurence Zitvogel ⁽²⁾	139
Università di Trieste, Dipartimento Universitario Clinico di Scienze Mediche Chirurgiche e della Salute, Trieste, Italia ⁽¹⁾ - Gustave Roussy Cancer Campus, Gustave Roussy Cancer Campus, Villejuif, Francia ⁽²⁾ - Centre Hospitalier de l'Université de Montréal (CHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Canada ⁽³⁾ - Department CIBIO, University of Trento, Department CIBIO, University of Trento, Trento, Italia ⁽⁴⁾ - Université Paris Cité, Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Université Paris Cité, Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Paris, Francia ⁽⁵⁾ - Pneumology Department, Foch Hospital, Pneumology Department, Foch Hospital, Suresnes, Francia ⁽⁶⁾ - Centre Hospitalier Universitaire de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, Francia ⁽⁷⁾ - Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, Francia ⁽⁸⁾ - Department of Thoracic Oncology, Centre Hospitalier Universitaire, Department of Thoracic Oncology, Centre Hospitalier Universitaire, Grenoble, Francia ⁽⁹⁾ - UPR 4466, Paris Descartes University, Sorbonne Paris Cité, UPR 4466, Paris Descartes University, Sorbonne Paris Cité, Paris, Francia ⁽¹⁰⁾ - Department of Pulmonary and Thoracic Oncology, University of Lille, Department of Pulmonary and Thoracic Oncology, University of Lille, Lille, Francia ⁽¹¹⁾ - Pulmonary Department, European Hospital, Pulmonary Department, European Hospital, Marseille, Francia ⁽¹²⁾ - Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, Francia ⁽¹³⁾ - Centre Hospitalier de Sherbrooke, Centre Hospitalier de Sherbrooke, Sherbrooke, Canada ⁽¹⁴⁾ - EverImmune, Gustave Roussy Cancer Campus, EverImmune, Gustave Roussy Cancer Campus, Paris, Francia ⁽¹⁵⁾ - Department of Twin Research and Genetic Epidemiology, King's College London, Department of Twin Research and Genetic Epidemiology, King's College London, London, Regno Unito ⁽¹⁶⁾ - Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, Paesi Bassi ⁽¹⁷⁾ - Bio-Me Microbiome Profiling, Bio-Me Microbiome Profiling, Oslo, Norvegia ⁽¹⁸⁾ - Service des Maladies Respiratoires, Centre Hospitalier d'Aix-en-Provence, Service des Maladies Respiratoires, Centre Hospitalier d'Aix-en-Provence, Aix-en-Provence, Francia ⁽¹⁹⁾	139
285 - Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis homologues peptides elicit a strong humoral response in patients with neuroinflammatory disorders, and exacerbate EAE.....	142
Davide Cossu ⁽¹⁾ - Marta Noli ⁽¹⁾ - Leonardo Antonio Sechi ⁽¹⁾ - Nobutaka Hattori ⁽²⁾	142

Universita, Dipartimento Scienze Biomediche, Sassari, Italia ⁽¹⁾ - Juntendo University, Dipartimento Neurologia, Tokyo, Giappone ⁽²⁾	142
02 Meccanismi di patogenicità	143
11 - Streptococcal Surface Repeat (SSURE) domains from Streptococcus pneumoniae	143
bind to different types of collagens.....	143
Giuseppe Valerio De Gaetano ⁽¹⁾ - Francesco Coppolino ⁽²⁾ - Germana Lentini ⁽¹⁾ - Agata Famà ⁽¹⁾ - Chiara Motta ⁽³⁾ - Giuseppe Teti ⁽⁴⁾ - Pietro Speciale ⁽³⁾ - Giampiero Pietrocola ⁽³⁾ - Concetta Beninati ⁽¹⁾	143
Università, Dipartimento di Patologia Umana, Messina, Italia ⁽¹⁾ - Università, Dipartimento di Scienze biomediche, odontoiatriche e delle immagini morfologiche e funzionali, Messina, Italia ⁽²⁾ - Università, Dipartimento di Medicina Molecolare, Pavia, Italia ⁽³⁾ - Charybdis Vaccines Srl, Charybdis Vaccines Srl, Messina, Italia ⁽⁴⁾	143
17 - Bio-guided approach in the search of novel antibacterial compounds from three Myrtaceae plants	144
Elisabetta Buommino ⁽¹⁾ - FRANCESCA GUZZO ⁽²⁾ - Francesca Lembo ⁽¹⁾ - Nicola Molfetta ⁽¹⁾ - LESLIE LANDRUM ⁽³⁾ - Antonio Fiorentino ⁽²⁾ - Brigida D'Abrasca ⁽²⁾	144
Dipartimento di Farmacia, Università degli Studi di Napoli, Federico II, Napoli, Italia ⁽¹⁾ - Department of Environmental, Biological and Pharmaceutical Sciences and Technologies-DiSTABIF,, University of Campania "Luigi Vanvitelli", Caserta, Italia ⁽²⁾ - School of Life Sciences, Arizona State University, Tempe, Stati Uniti D'america ⁽³⁾	144
33 - Life cycle peculiarities of enteric Adenovirus 41	145
Maria Cristina Arcangeletti ⁽¹⁾ - Clara Maccari ⁽¹⁾ - Flora De Conto ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Cecilia Carubbi ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Adriana Calderaro ⁽¹⁾	145
Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾	145
52 - Serratiopeptidase affects adhesive features of Pseudomonas aeruginosa isolates from cystic fibrosis patients on biotic and abiotic substrates	146
Gianluca Vrenna ⁽¹⁾ - Rosanna Papa ⁽¹⁾ - Oliwia Sara Rogala ⁽¹⁾ - Marco Artini ⁽¹⁾ - Laura Selan ⁽¹⁾	146
Sapienza Università, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽¹⁾	146
60 - Resveratrol Restores Susceptibility to Chlorhexidine and Benzalkonium in Microorganisms Causing Health-Care Associated Infection	147
Antonella Migliaccio ⁽¹⁾ - Maria Stabile ⁽¹⁾ - Maria Bagattini ⁽¹⁾ - Maria Triassi ⁽¹⁾ - Rita Berisio ⁽²⁾ - Raffaele Zarrilli ⁽¹⁾ - Eliana De Gregorio ⁽³⁾	147
Dipartimento di Sanità Pubblica, Università degli Studi di Napoli Federico II, Napoli, Italia ⁽¹⁾ - Institute of Biostructures and Bioimaging, National Research Council, Institute of Biostructures and Bioimaging, National Research Council, Napoli, Italia ⁽²⁾ - Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Napoli, Italia ⁽³⁾	147
63 - RiV4PoC: A high effective microbicidal coating for high-touch surfaces	148
Fabrizio Angius ⁽¹⁾ - Alessandra Scano ⁽²⁾ - Francesca Esposito ⁽³⁾ - Guido Ennas ⁽²⁾ - Aldo Manzin ⁽¹⁾	148
University of Cagliari, Department of Biomedical Sciences, Unit of Microbiology and Virology, Cagliari, Italia ⁽¹⁾ - University of Cagliari, Department of Chemical and Geological Sciences, Cagliari Research Unit of the National Consortium of Materials Science and Technology (INSTM),, Cagliari, Italia ⁽²⁾ - University of Cagliari, Department of Life and Environmental Sciences, Unit of Molecular Virology, Cagliari, Italia ⁽³⁾	148

70 - Characterization of stringent response phenotype in <i>Neisseria meningitidis</i>	149
Chiara Pagliuca ⁽¹⁾ - Elena Scaglione ⁽²⁾ - Giuseppe Mantova ⁽¹⁾ - Alessia Stornaiuolo ⁽³⁾ - Martina Di Rosario ⁽¹⁾ - Leonardo Continisio ⁽¹⁾ - Valeria Caturano ⁽⁴⁾ - Lucia Sorbo ⁽⁴⁾ - Mariagrazia La Campora ⁽⁴⁾ - Pietro Alifano ⁽⁵⁾ - Mariateresa Vitiello ⁽⁶⁾ - Roberta Colicchio ⁽⁶⁾ - Paola Salvatore ⁽⁷⁾	
Federico II University, Department of Molecular Medicine and Medical Biotechnology, Naples, Italia ⁽¹⁾ - University of Naples "Federico II"; University Hospital Federico II,, Dep. of Mol Med and Med Biotech; Dep. of Chem, Mat and Ind Prod Eng ;DAI of Lab Med and Trans, Naples, Italia ⁽²⁾ - University of Naples "Federico II"; University Hospital Federico II,, Dep. of Mol Med and Med Biotech; Dep. of Chem, Mat and Ind Prod Eng, Naples, Italia ⁽³⁾ - University Hospital Federico II, Dep. of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology,, Naples, Italia ⁽⁴⁾ - University of Salento, Department of Biological and Environmental Sciences and Technologies, Lecce, Italia ⁽⁵⁾ - Federico II University, University Hospital Federico II, Dep. of Mol. Med. and Med Biotech; D.A.I. of Lab Med and Transfusion, UOC Clinical Microbiology, Naples, Italia ⁽⁶⁾ - Federico II University, University Hospital Federico II; Ceinge Naples, Dep. Mol. Med. and Med Biotech; D.A.I. Lab Med and Trans, UOC Clinical Microbiology; CEINGE scarl, Naples, Italia ⁽⁷⁾	
86 - Novel Options to Counteract Oral Biofilm Formation: in Vitro Evidence.....	151
Alessandra Odorici ⁽¹⁾ - Bruna Colombari ⁽²⁾ - Pierantonio Bellini ⁽²⁾ - Samuele Peppoloni ⁽²⁾ - Aida Meto ⁽³⁾ - Irene Venturelli ⁽⁴⁾ - Elisabetta Blasi ⁽²⁾	
University of Modena and Reggio Emilia, School of Doctorate in Clinical and Experimental Medicine, Laboratory of Microbiology and Virology, Unimore, Modena, Italia ⁽¹⁾ - University of Modena and Reggio Emilia, Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplant, Oncology and Regenerative Medicine, Laboratory of M, Modena, Italia ⁽²⁾ - Department of Dentistry, Faculty of Dental Sciences, University of Aldent, 1007 Tirana, Albania, Department of Dentistry, Faculty of Dental Sciences, University of Aldent, 1007 Tirana, Albania, Tirana, Albania ⁽³⁾ - School of Specialization in Microbiology and Virology, University of Modena and Reggio Emilia,, School of Specialization in Microbiology and Virology, University of Modena and Reggio Emilia,, Modena, Italia ⁽⁴⁾	
143 - A novel phenolic derivative inhibits AHL-dependent Quorum Sensing signaling in <i>Pseudomonas aeruginosa</i>	152
Giulia Bernabè ⁽¹⁾ - Giovanni Marzaro ⁽²⁾ - Giuseppe Di Pietra ⁽³⁾ - Massimo Bellato ⁽⁴⁾ - Anthony Pauletto ⁽¹⁾ - Melania Scarpa ⁽⁵⁾ - Stefania Sut ⁽²⁾ - Adriana Chilin ⁽²⁾ - Stefano Dall'Acqua ⁽²⁾ - Paola Brun ⁽¹⁾ - Ignazio Castagliuolo ⁽¹⁾	
Università degli studi di Padova, Dipartimento di medicina molecolare, Padova, Italia ⁽¹⁾ - Università degli studi di Padova, Dipartimento di scienze del farmaco, Padova, Italia ⁽²⁾ - Azienda Ospedaliera di Padova, Microbiologia, Padova, Italia ⁽³⁾ - Università degli studi di Padova, Dipartimento di Ingegneria Informatica, Padova, Italia ⁽⁴⁾ - Istituto Oncologico del Veneto, IOV, Laboratorio di ricerca traslazionale, Padova, Italia ⁽⁵⁾	
170 - Role of the histone deacetylase Hst3p in <i>Candida albicans</i> biology	153
Daniela Eletto ⁽¹⁾ - Marisa Conte ⁽¹⁾ - Martina Pannetta ⁽¹⁾ - Alessandra Tosco ⁽¹⁾ - Amalia Porta ⁽¹⁾	
Università degli studi di Salerno, Dipartimento di Farmacia, Fisciano, Italia ⁽¹⁾	
176 - Skin dysbiosis in inflammatory acne lesions and the role of <i>Cutibacterium acnes</i> biofilm	154
Ilaria Cavallo ⁽¹⁾ - Francesca Sivori ⁽¹⁾ - Giorgia Fabrizio ⁽¹⁾ - Aldo Morroe ⁽²⁾ - Fulvia Pimpinelli ⁽¹⁾ - Enea Gino Di Domenico ⁽³⁾	

IRCCS San Gallicano Institute, Microbiology and Virology, Rome, Italia ⁽¹⁾ - IRCCS San Gallicano Institute, Scientific Direction, Rome, Italia ⁽²⁾ - Sapienza University of Rome, Department of Biology and Biotechnology Charles Darwin, Rome, Italia ⁽³⁾	154
Microbiology and Virology, IRCCS San Gallicano Institute, Rome, Italy ¹ ; Scientific Direction, IRCCS San Gallicano Institute, Rome, Italy ² ; Department of Biology and Biotechnology Charles Darwin, Sapienza University of Rome, Rome, Italy ³	154
179 - Genotypic and phenotypic characterization of Staphylococcus aureus strains isolated in patients with atopic dermatitis	155
Antionietta Lucia Conte ⁽¹⁾ - Massimiliano Marazzato ⁽¹⁾ - Francesca Brunetti ⁽¹⁾ - Linda Maurizi ⁽¹⁾ - Catia Longhi ⁽¹⁾ - Anna Teresa Palamara ⁽²⁾ - Sara Grassi ⁽³⁾ - Maria Pia Conte ⁽¹⁾	155
“Sapienza” University of Rome, Department of Public Health and Infectious Diseases, Rome, Italia ⁽¹⁾ - Istituto Superiore di Sanità, Department of Infectious Diseases, Rome, Italia ⁽²⁾ - “Sapienza” University of Rome, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Rome, Italia ⁽³⁾	155
197 - Molecular characterization of hypermucoviscous and hypervirulent strains of Klebsiella pneumoniae: an emergent health care threat.....	156
Anna Ventura ⁽¹⁾ - Anna Bertoncelli ⁽¹⁾ - Davide Gibellini ⁽¹⁾ - Annarita Mazzariol ⁽¹⁾	156
Università di Verona, Dipartimento di Diagnostica e Sanità Pubblica, Verona, Italia ⁽¹⁾	156
274 - PGRS domain structures: doomed to sail the mycomembrane	157
Rita Berisio ⁽¹⁾ - Giovanni Delogu ⁽²⁾	157
Institute of Biostructures and Bioimaging, Institute of Biostructures and Bioimaging, Napoli, Italia ⁽¹⁾ - Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie- Istituto di Microbiologia / Mater Olbia Hospital, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Roma / Mater Olbia Hospital, Olbia, Roma/ Olbia, Italia ⁽²⁾	157
03 Virologia.....	158
4 - Competition for dominance within replicating quasi-species during prolonged SARS-CoV-2 infection in an immunocompromised host	158
Francesca Caccuri ⁽¹⁾ - Serena Messali ⁽¹⁾ - Daria Bortolotti ⁽²⁾ - Dario Di Silvestre ⁽³⁾ - Antonella De Palma ⁽³⁾ - Chiara Cattaneo ⁽⁴⁾ - Anna Bertelli ⁽¹⁾ - Alberto Zani ⁽¹⁾ - Maria Milanese ⁽⁵⁾ - Marta Giovanetti ⁽⁶⁾ - Giovanni Campisi ⁽¹⁾ - Valentina Gentili ⁽²⁾ - Antonella Bugatti ⁽¹⁾ - Federica Filippini ⁽¹⁾ - Erika Scaltriti ⁽⁷⁾ - Stefano Pongolini ⁽⁷⁾ - Alessandra Tucci ⁽⁴⁾ - Simona Fiorentini ⁽¹⁾ - Pasqualina D'Ursi ⁽⁸⁾ - Massimo Ciccozzi ⁽⁹⁾ - Pierluigi Mauri ⁽³⁾ - Roberta Rizzo ⁽²⁾ - Arnaldo Caruso ⁽¹⁾	158
Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italia ⁽¹⁾ - Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italia ⁽²⁾ - Proteomic and Metabolomic Laboratory, Institute of Biomedical Technologies, National Research Council, Segrate, Italia ⁽³⁾ - Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italia ⁽⁴⁾ - Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, Brescia, Italia ⁽⁵⁾ - Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Laboratório de Flavivírus, Rio de Janeiro, Brasile ⁽⁶⁾ - Risk Analysis and Genomic Epidemiology Unit, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Parma, Italia ⁽⁷⁾ - Institute of Biomedical Technologies, National Research Council, Segrate, Italia ⁽⁸⁾ - Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Rome, Italia ⁽⁹⁾	158
6 - IFI16 impacts metabolic reprogramming during human cytomegalovirus infection.....	160

GLORIA GRIFFANTE ⁽¹⁾ - WERONIKA HEWELT-BELKA ⁽²⁾ - CAMILLA ALBANO ⁽¹⁾ - FRANCESCA GUGLIESI ⁽¹⁾ - SELINA PASQUERO ⁽¹⁾ - SERGIO F. CASTILLO PACHECO ⁽¹⁾ - GRETA BAJETTO ⁽¹⁾ - LINDA TRIFIRO' ⁽¹⁾ - PAOLO E. PORPORATO ⁽³⁾ - ERICA MINA ⁽³⁾ - MARTA VALLINO ⁽⁴⁾ - CHRISTIAN KRAPP ⁽⁵⁾ - MARTIN R. JAKOBSEN ⁽⁵⁾ - JOHN PURDY ⁽⁶⁾ - JENS VON EINEM ⁽⁷⁾ - SANTO LANDOLFO ⁽¹⁾ - VALENTINA DELL'OSTE ⁽¹⁾ - MATTEO BIOLATTI ⁽¹⁾ 160

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italia ⁽¹⁾ - Department of Analytical Chemistry, Gdańsk University of Technology, Gdańsk, Polonia ⁽²⁾ - Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italia ⁽³⁾ - Institute for Sustainable Plant Protection, CNR, Turin, Italia ⁽⁴⁾ - Department of Biomedicine, Aarhus University, Aarhus, Danimarca ⁽⁵⁾ - Department of Immunobiology, University of Arizona, Tucson, Stati Uniti D'america ⁽⁶⁾ - Institute of Virology, Ulm University Medical Center, Ulm, Germania ⁽⁷⁾ 160

IFI16 impacts metabolic reprogramming during human cytomegalovirus infection 160

GLORIA GRIFFANTE,¹ WERONIKA HEWELT-BELKA,² CAMILLA ALBANO,¹ FRANCESCA GUGLIESI,¹ SELINA PASQUERO,¹ SERGIO F. CASTILLO PACHECO,¹ GRETA BAJETTO,¹ LINDA TRIFIRO',¹ PAOLO E. PORPORATO,³ ERICA MINA,³ MARTA VALLINO,⁴ CHRISTIAN KRAPP,⁵ MARTIN R. JAKOBSEN,⁵ JOHN PURDY,⁶ JENS VON EINEM,⁷ SANTO LANDOLFO,¹ VALENTINA DELL'OSTE,¹ MATTEO BIOLATTI¹ 160

¹Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy; ²Department of Analytical Chemistry, Gdańsk University of Technology, Gdańsk, Poland; ³Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy; ⁴Institute for Sustainable Plant Protection, CNR, Turin, Italy; ⁵Department of Biomedicine, Aarhus University, Aarhus, Denmark; ⁶Department of Immunobiology, University of Arizona, Tucson, Arizona, USA; ⁷Institute of Virology, Ulm University Medical Center, Ulm, Germany. 160

19 - Mesenchymal stem cells are susceptible but non-permissive to B19V replication 161

erika fasano ⁽¹⁾ 161

dipartimento di farmacia e biotecnologie, università di Bologna, bologna, Italia ⁽¹⁾ 161

21 - Coinfection by Human Cytomegalovirus and Herpesvirus type 6 can trigger cell fibrosis: possible impact on scleroderma..... 162

Irene Soffritti ⁽¹⁾ - Maria D'Accolti ⁽¹⁾ - Clara Maccari ⁽²⁾ - Francesca Bini ⁽¹⁾ - Eleonora Mazziga ⁽¹⁾ - Cristina Arcangeletti ⁽²⁾ - Elisabetta Caselli ⁽¹⁾ 162

University of Ferrara, Department of Chemical, Pharmaceutical and Agricultural Sciences, Section of Microbiology, CIAS research Center and LTTA, Ferrara, Italia ⁽¹⁾ - University of Parma, Department of Medicine and Surgery, Parma, Italia ⁽²⁾ 162

27 - Prevalence analysis of urinary and plasma JCPyV, BKPyV, MCPyV, HPyV6, HPyV7 and QPyV in patients infected with HIV-1..... 163

Sara Passerini ⁽¹⁾ - Carla Prezioso ⁽¹⁾ - Annalisa Prota ⁽¹⁾ - Luigi Coppola ⁽²⁾ - Alessandra Lodi ⁽²⁾ - Anna Chiara Epifani ⁽²⁾ - Loredana Sarmati ⁽²⁾ - Massimo Andreoni ⁽²⁾ - Ugo Moens ⁽³⁾ - Marco Ciotti ⁽⁴⁾ - Valeria Pietropaolo ⁽¹⁾ 163

"Sapienza" University of Rome, Department of Public Health and Infectious Diseases, Roma, Italia ⁽¹⁾ - Tor Vergata University, Clinical Infectious Diseases, Department of System Medicine, Roma, Italia ⁽²⁾ - University of Tromsø - The Arctic University of Norway, Faculty of Health Sciences, Department of Medical Biology, Tromsø, Norvegia ⁽³⁾ - Polyclinic Tor Vergata Foundation, Virology Unit, Roma, Italia ⁽⁴⁾

..... 163

28 - CLINICAL AND PROGNOSTIC SIGNIFICANCE OF MERKEL CELL POLYOMAVIRUS (MCPyV) IN NON-SMALL CELL LUNG CANCER (NSCLC).....	164
Carla Prezioso ⁽¹⁾ - Sara Passerini ⁽¹⁾ - Angelina Pernazza ⁽²⁾ - Valeria Di Maio ⁽²⁾ - Ugo Moens ⁽³⁾ - Giulia D'Amati ⁽⁴⁾ - Valeria Pietropaolo ⁽¹⁾	164
Sapienza University, Department of Public Health and Infectious Diseases, Rome, Italia ⁽¹⁾ - Sapienza University-Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italia ⁽²⁾ - The Arctic University of Norway, Department of Medical Biology, Tromsø, Norvegia ⁽³⁾ - Sapienza University, Department of Radiological, Oncological, and Pathological Sciences, Rome, Italia ⁽⁴⁾	164
29 - Prevalence of Merkel cell polyomaviruses, human polyomaviruses 6, 7 and Trichodysplasia Spinulosa-associated polyomaviruses in Actinic Keratosis Biopsy Specimens.....	165
Carla Prezioso ⁽¹⁾ - Gabriele Brazzini ⁽²⁾ - Sara Passerini ⁽²⁾ - Carlotta Di Fabio ⁽³⁾ - Terenzio Cosio ⁽⁴⁾ - Sergio Bernardini ⁽⁴⁾ - Elena Campione ⁽³⁾ - Ugo Moens ⁽⁵⁾ - Valeria Pietropaolo ⁽²⁾ - Marco Ciotti ⁽⁶⁾	165
IRCSS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, 00163 Rome, Italy, IRCSS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, 00163 Rome, Italy;; Roma, Italia ⁽¹⁾ - Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy;; Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy;; Roma, Italia ⁽²⁾ - Department of Systems Medicine, Dermatology Unit, Tor Vergata University Hospital, 00133 Rome, Italy;; Department of Systems Medicine, Dermatology Unit, Tor Vergata University Hospital, 00133 Rome, Italy;; Roma, Italia ⁽³⁾ - Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Roma, Italia ⁽⁴⁾ - Department of Medical Biology, Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, 9037 Tromsø, Norway;; Department of Medical Biology, Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, 9037 Tromsø, Norway;; Tromsø, Norvegia ⁽⁵⁾ - Virology Unit, Polyclinic Tor Vergata Foundation, Viale Oxford 81, 00133 Rome, Italy., Virology Unit, Polyclinic Tor Vergata Foundation, Viale Oxford 81, 00133 Rome, Italy., Roma, Italia ⁽⁶⁾	165
32 - Epidemiology of viral agents causing acute gastroenteritis in children in Northern Italy (2019-2021): focus on Norovirus circulation.	167
Flora De Conto ⁽¹⁾ - Sharon Di Stefano ⁽¹⁾ - Giulia Montanari ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Adriana Calderaro ⁽¹⁾	167
Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾	167
39 - Genomic sequence analysis of 8 SARS-CoV-2 strains circulating in Parma (Northern Italy) during the first and the second wave of COVID-19 pandemic.....	168
Giovanna Piccolo ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Greta Romano ⁽¹⁾ - Benedetta Farina ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Flora De Conto ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Adriana Calderaro ⁽¹⁾	168
Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾	168
48 - Study of Parvovirus B19 translocation across the placenta using the BeWo model	169
Gloria Bua ⁽¹⁾ - Francesca Bonvicini ⁽¹⁾ - Erika Fasano ⁽¹⁾ - Elisabetta Manaresi ⁽¹⁾ - Giorgio Gallinella ⁽¹⁾	169
Università di Bologna, Dipartimento di Farmacia e Biotechnologie, Bologna, Italia ⁽¹⁾	169
53 - Transcriptional analysis of human bronchial epithelial cells with and without CFTR modification after SARS-CoV-2 infection.....	170

Anna Lagni ⁽¹⁾ - Virginia Lotti ⁽¹⁾ - Erica Diani ⁽¹⁾ - Chiara Cascianelli ⁽²⁾ - Claudio Sorio ⁽³⁾ - Pier Paolo Piccaluga ⁽²⁾ - Davide Gibellini ⁽¹⁾	170
Università di Verona, Dipartimento di Diagnostica e Sanità Pubblica, Verona, Italia ⁽¹⁾ - Università di Bologna, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Bologna, Italia ⁽²⁾ - Università di Verona, Dipartimento di Medicina, Verona, Italia ⁽³⁾	170
56 - Anti-HSV-1 Activity of natural raw and roasted unsalted pistachio kernels in human monocytic THP-1 and Vero cells.	171
Rosamaria Pennisi ⁽¹⁾ - Maria Pia Tamburello ⁽¹⁾ - Davide Barreca ⁽¹⁾ - Maria Teresa Sciortino ⁽¹⁾ - Giuseppina Mandalari ⁽¹⁾	171
Università degli Studi di Messina, Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Messina, Italia ⁽¹⁾	171
58 - Broad range antiviral properties of small molecules against enveloped viruses.....	172
Paola Quaranta ⁽¹⁾ - Carmen Rita Piazza ⁽¹⁾ - Anna Corotti ⁽¹⁾ - Annalaura Brai ⁽²⁾ - Giulia Lottini ⁽¹⁾ - Michele Lai ⁽¹⁾ - Pietro Giorgio Spezia ⁽¹⁾ - Elena Dreassi ⁽²⁾ - Giulia Freer ⁽¹⁾ - Mauro Pistello ⁽¹⁾	172
Università di Pisa, Dipartimento di Ricerca Traslationale e Nuove Tecnologie in Medicina, Pisa, Italia ⁽¹⁾ - Università di Siena, Dipartimento di Biotecnologia, Chimica e Farmacia, Siena, Italia ⁽²⁾	172
62 - The peptide A-3302-B isolated from a marine bacterium Micromonospora sp. inhibits HSV-2 infection by preventing the viral egress from host cells	173
Irene Arduino ⁽¹⁾ - Massimo Rittà ⁽¹⁾ - Rachele Francese ⁽¹⁾ - Reiko Ueoka ⁽²⁾ - Jorn Piel ⁽²⁾ - Prasat Kittakoop ⁽³⁾ - David Lembo ⁽¹⁾ - Manuela Donalisio ⁽¹⁾	173
Università di Torino, Dip. Scienze Cliniche e Biologiche, Orbassano, Italia ⁽¹⁾ - Institute of Microbiology, ETH Zurich, Zurich, Svizzera ⁽²⁾ - Center of Excellence on Environmental Health and Toxicology, Ministry of Higher Education, Science, Research and Innovation, Bangkok, Thailandia ⁽³⁾	173
73 - Evaluation of the effect of time of addition of several compounds against SARS-CoV-2 and other RNA viruses.....	174
Erika Plicanti ⁽¹⁾ - Giulia Lottini ⁽¹⁾ - Maria Sidoti ⁽¹⁾ - Rossella Fonnesu ⁽¹⁾ - Paola Quaranta ⁽¹⁾ - Michele Lai ⁽¹⁾ - Roberta Ibba ⁽²⁾ - Sandra Piras ⁽²⁾ - Antonio Carta ⁽²⁾ - Mauro Pistello ⁽¹⁾ - Giulia Freer ⁽¹⁾	174
Università di Pisa, Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Pisa, Italia ⁽¹⁾ - Università di Sassari, Dipartimento di medicina, chirurgia e farmacia, Sassari, Italia ⁽²⁾	174
75 - Evaluation of neutralizing antibodies against Sars-Cov-2 in patients with Inflammatory bowel disease	175
Giuseppa Sanfilippo ⁽¹⁾ - Emanuela Garlisi ⁽²⁾ - Federica Cacioppo ⁽¹⁾ - Floriana Bonura ⁽¹⁾ - Giovanni M. Giammanco ⁽¹⁾ - Simona De Grazia ⁽¹⁾ - Donatella Ferraro ⁽¹⁾	175
University of Palermo, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties "G. D'Alessandro", Palermo, Italia ⁽¹⁾ - University of Palermo, Internal Medicine and Medical Specialties "G. D'Alessandro", Palermo, Italia ⁽²⁾	175
76 - CHARACTERIZATION OF THE ANTI-RHINOVIRUS ACTIVITY OF 25-HYDROXYCHOLESTEROL AND 27-HYDROXYCHOLESTEROL, AND VALIDATION ON NASAL AND BRONCHIAL HISTOCULTURES.	176
Andrea Civra ⁽¹⁾ - Matteo Costantino ⁽¹⁾ - Roberta Cavalli ⁽²⁾ - Marco Volante ⁽³⁾ - Giuseppe Poli ⁽¹⁾ - David Lembo ⁽¹⁾	176

Università di Torino, Dipartimento di Scienze Cliniche e Biologiche, Orbassano, Italia ⁽¹⁾ - Università di Torino, Dipartimento di Scienza e Tecnologia del Farmaco, Torino, Italia ⁽²⁾ - Università di Torino, Dipartimento di Oncologia, Orbassano, Italia ⁽³⁾	176
81 - Characterization of Human Polyomavirus JC (JCPyV) infection in Human Neuroblastoma SH-SY5Y cells and evaluation of redox state during viral replication.	177
CARLA PREZIOSO ⁽¹⁾ - paola checonni ⁽²⁾ - SARA BALDELLI ⁽³⁾ - anna maria marinelli ⁽⁴⁾ - valeria pietropaolo ⁽⁵⁾ - maria rosa ciriolo ⁽⁶⁾ - anna teresa palamara ⁽⁷⁾ - dolores limongi ⁽²⁾	177
IRCCS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, Rome, Italy, ROMA, Italia ⁽¹⁾ - IRCCS San Raffaele Roma, Telematic University, Rome, Italy, ROMA, Italia ⁽²⁾ - IRCCS San Raffaele Roma, Telematic University, Rome, Italy, roma, Italia ⁽³⁾ - IRCCS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, Rome, Italy, roma, Italia ⁽⁴⁾ - "Sapienza" University of Rome, Rome, Italy, Department of Public Health and Infectious Diseases, roma, Italia ⁽⁵⁾ - University of Rome "Tor Vergata", Rome, Italy, Department of Biology, Roma, Italia ⁽⁶⁾ - Istituto Superiore di Sanità, Rome, Italy., Department of Infectious Diseases, Roma, Italia ⁽⁷⁾	177
Characterization of Human Polyomavirus JC (JCPyV) infection in Human Neuroblastoma SH-SY5Y cells and evaluation of redox state during viral replication.....	177
<i>CARLA PREZIOSO ¹, PAOLA CHECCONI², SARA BALDELLI², ANNA M. MARINELLI¹, VALERIA PIETROPAOLO³, MARIA R. CIRIOLO^{4,5}, ANNA T. PALAMARA^{6,7}, DOLORES LIMONGI²</i>	<i>177</i>
<i>¹IRCCS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, Rome, Italy; ²IRCCS San Raffaele Roma, Telematic University, Rome, Italy; ³Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy; ⁴Department of Biology, University of Rome "Tor Vergata", Rome, Italy; ⁵IRCCS San Raffaele Roma, Rome, Italy; ⁶Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognietti, Rome, Italy; ⁷Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.</i>	<i>177</i>
92 - B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy	178
Jacopo Polvere ⁽¹⁾ - Massimiliano Fabbiani ⁽²⁾ - Gabiria Pastore ⁽¹⁾ - Ilaria Rancan ⁽²⁾ - Barbara Rossetti ⁽²⁾ - Miriam Durante ⁽³⁾ - Sara Zirpoli ⁽¹⁾ - Enrico Morelli ⁽³⁾ - Elena Pettini ⁽¹⁾ - Simone Lucchesi ⁽¹⁾ - Fabio Fiorino ⁽¹⁾ - Mario Tumbarello ⁽²⁾ - Annalisa Ciabattini ⁽¹⁾ - Francesca Montagnani ⁽²⁾ - Donata Medaglini ⁽¹⁾	178
100 - Indomethacin inhibits human seasonal coronavirus replication at post-entry level.....	179
Caterina Tramontozzi ⁽¹⁾ - Silvia Pauciullo ⁽¹⁾ - Simone La Frazia ⁽¹⁾ - Sara Piacentini ⁽¹⁾ - Maria Gabriella Santoro ⁽¹⁾	179
Università degli studi di Roma "Tor Vergata", Dipartimento di Biologia, Roma, Italia ⁽¹⁾	179
Indomethacin inhibits human seasonal coronavirus replication at post-entry level.....	179
107 - Infection rate of respiratory viruses in the pandemic SARS-CoV-2 period considering symptomatic patients: comparison between 2020 and 2021.....	180
Gaetana Costanza ⁽¹⁾ - Pierpaolo Paba ⁽²⁾ - Marco Ciotti ⁽³⁾ - domenico Ombres ⁽⁴⁾ - Ada Bertoli ⁽⁵⁾ - Fabbio Marcuccilli ⁽⁶⁾ - eleonora Andreassi ⁽²⁾ - Marta Btugneti ⁽³⁾ - Oreste Cennamo ⁽³⁾ - Vita Petrone ⁽⁷⁾ - Marialaura Fanelli ⁽⁷⁾ - Antonella Minutolo ⁽⁷⁾ - Claudia Matteucci ⁽⁷⁾ - Sandro Grelli ⁽³⁾	180
Università, PoliclinicoTor Vergata/ Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽¹⁾ - Policlinico, PoliclinicoTor Vergata/ Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽²⁾ - Policlinico, Policlinico Tor Vergata/ Università degli studi di Tor	

vergata/DIP Medicina Sperimentale, Roma, Italia ⁽³⁾ - Policlinico, Policlinico Tor Vergata/Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽⁴⁾ - policlinico, Policlinico Tor Vergata/ Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽⁵⁾ - Policlinico, PoliclinicoTor Vergata/ Università degli studi di Tor <vergata/DIP Medicina Sperimentale, Roma, Italia ⁽⁶⁾ - Università, Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽⁷⁾	180
110 - ARE III-GENERATION ANTIGENIC TEST SENSITIVE AS MOLECULAR TEST FOR DETECTION OF SARS-CoV-2?	181
Gaetana Costanza ⁽¹⁾	181
Policlinico, PoliclinicoTor Vergata/ Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽¹⁾	181
111 - Wastewater-based surveillance for the monitoring of SARS-CoV-2 circulation in Sicily	182
Chiara Filizzolo ⁽¹⁾ - Giuseppa Luisa Sanfilippo ⁽¹⁾ - Emilia Palazzotto ⁽¹⁾ - Mariangela Pizzo ⁽¹⁾ - Massimo Giuseppe Chiarelli ⁽²⁾ - Gabriella Caruso ⁽³⁾ - Domenico Mirabile ⁽⁴⁾ - Giorgio Iacono ⁽⁵⁾ - Mario Palermo ⁽⁶⁾ - Giovanni Maurizio Giammanco ⁽¹⁾ - Simona De Grazia ⁽¹⁾	182
Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro", Università degli Studi di Palermo, Palermo, Italia ⁽¹⁾ - Local Water Plant Management (Acque di Caltanissetta S.p.A.), Caltacqua S.p.A., Caltanissetta, Italia ⁽²⁾ - Area Igiene Sanità Pubblica, ASP5, Messina, Italy, UOC Servizio di Igiene Ambienti di Vita (SIAV), Dipartimento Strutturale di Prevenzione -, Messina, Italia ⁽³⁾ - ASP6, Palermo, Italy, UOC Igiene degli Ambienti di Vita (SIAV), Dipartimento di Prevenzione Medico,, Palermo, Italia ⁽⁴⁾ - ASP7, Ragusa, Italy, Servizio Epidemiologia e Profilassi, Dipartimento di Prevenzione, Ragusa, Italia ⁽⁵⁾ - DASOE - Public Health and Environmental Risk, Sicilian Region, Department of Public Health, Palermo, Italy, Palermo, Italia ⁽⁶⁾ .	182
116 - Emergence of novel Rotavirus G1P[8] strains in Sicily in 2021	184
Floriana Bonura ⁽¹⁾ - Chiara Filizzolo ⁽¹⁾ - Leonardo Mangiaracina ⁽¹⁾ - Giuseppa Luisa Sanfilippo ⁽¹⁾ - Francesca Di Bernardo ⁽²⁾ - Antonina Collura ⁽²⁾ - Giovanni Maurizio Giammanco ⁽¹⁾ - Simona De Grazia ⁽¹⁾	184
Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro" (PROSAMI), Università degli Studi di Palermo, Palermo, Italia ⁽¹⁾ - ARNAS, Palermo, Italy, Unità Operativa di Microbiologia e Virologia, Ospedale Civico e Di Cristina,, Palermo, Italia ⁽²⁾	184
127 - PREVALENCE AND LOAD OF THE RECENTLY DISCOVERED REDONDOVIRUS IN SALIVA SAMPLES FROM HEALTHY AND COVID-19 SUBJECTS.....	185
Andreina Baj ⁽¹⁾ - Federica Novazzi ⁽¹⁾ - Pier Giorgio Spezia ⁽²⁾ - Angelo Paolo Genoni ⁽¹⁾ - SARA BOUTAHAR ⁽¹⁾ - Francesca Dragoferrante ⁽¹⁾ - Fabrizio Maggi ⁽¹⁾	185
Università dell'Insubria, Dipartimento Medicina e Chirurgia, Varese, Italia ⁽¹⁾ - UNiversità di Pisa, Department of Translational Research, University of Pisa, Italy., Pisa, Italia ⁽²⁾	185
128 - Prolonged viral shedding and monkeypox virus isolation from seminal fluid	186
Daniele Lapa ⁽¹⁾ - Fabrizio Carletti ⁽¹⁾ - Valentina Mazzotta ⁽²⁾ - Giulia Matusali ⁽¹⁾ - Carmela Pinnetti ⁽²⁾ - Silvia Meschi ⁽¹⁾ - Laura Scorzolini ⁽²⁾ - Francesca Colavita ⁽¹⁾ - Roberta Gagliardini ⁽²⁾ - Claudia Minosse ⁽¹⁾ - Gaetano Maffongelli ⁽²⁾ - Annalisa Mondì ⁽²⁾ - Stefania Cicalini ⁽²⁾ - Eliana Specchiarello ⁽¹⁾ - Marta Camici ⁽²⁾ - Aurora Bettini ⁽¹⁾ - Francesco Baldini ⁽²⁾ - Massimo Francalancia ⁽¹⁾ - Klizia Mizzoni ⁽¹⁾ - Anna Rosa Garbuglia ⁽¹⁾ - Emanuele Nicastrì ⁽²⁾ - Enrico Girardi ⁽³⁾ - Andrea Antinori ⁽²⁾ - Francesco Vaia ⁽⁴⁾ - Fabrizio Maggi ⁽¹⁾	186

National Institute for Infectious Diseases ‘Lazzaro Spallanzani’, Laboratory of Virology, Rome, Italia ⁽¹⁾ - National Institute for Infectious Diseases ‘Lazzaro Spallanzani’, Clinical and Research Department, Rome, Italia ⁽²⁾ - National Institute for Infectious Diseases ‘Lazzaro Spallanzani’, Scientific Direction, Rome, Italia ⁽³⁾ - National Institute for Infectious Diseases ‘Lazzaro Spallanzani’, General Direction, Rome, Italia ⁽⁴⁾	186
132 - Development of SARS-CoV-2 Mpro inhibitors retaining in vitro activity against circulating SARS-CoV-2 variants of concern	187
Ilaria Vicenti ⁽¹⁾ - Lia Fiaschi ⁽¹⁾ - Simone Brogi ⁽²⁾ - Emmanuele Crespan ⁽³⁾ - Graziano Deidda ⁽³⁾ - Camilla Biba ⁽¹⁾ - Ilenia Varasi ⁽¹⁾ - Laura Bavagnoli ⁽³⁾ - Maurizio Zazzi ⁽¹⁾ - Giovanni Maga ⁽³⁾ - Sandra Gemma ⁽⁴⁾	187
Università degli Studi di Siena/AOUS Siena, Dipartimento di Biotecnologie Mediche/UOC Microbiologia e Virologia, Siena, Italia ⁽¹⁾ - University of Pisa, Department of Pharmacy, Pisa, Italia ⁽²⁾ - CNR “Luigi Luca Cavalli-Sforza”, Institute of Molecular Genetics IGM, Pavia, Italia ⁽³⁾ - Università degli Studi di Siena, Department of Biotechnology, Chemistry and Pharmacy, Siena, Italia ⁽⁴⁾	187
Francesco Ricchi ⁽¹⁾ - Gloria Agliata ⁽¹⁾ - Isabella Marchesi ⁽¹⁾ - Stefania Paduano ⁽¹⁾ - Letizia Verdolotti ⁽²⁾ - Federica Recubito ⁽²⁾ - Giuseppe Lama ⁽²⁾ - Giovanna Buonocore ⁽²⁾ - Mariamelia Stanzione ⁽²⁾ - Antonella Mansi ⁽³⁾ - Claudio Cermelli ⁽¹⁾	188
Università degli Studi di Modena e Reggio Emilia, Facoltà di Medicina e Chirurgia, Modena, Italia ⁽¹⁾ - Consiglio Nazionale delle Ricerche, Istituto per i Polimeri, Compositi e Biomateriali, Napoli, Italia ⁽²⁾ - INAIL, Dipartimento di Medicina Epidemiologia, Igiene del Lavoro e Ambientale, Monte Porzio Catone, Italia ⁽³⁾	188
139 - Anti-SARS-CoV-2 Neutralizing activity of human breast milk from COVID-19 positive and negative lactating mothers	190
Lucia Signorini ⁽¹⁾ - Maria Dolci ⁽¹⁾ - Daniela Morniroli ⁽²⁾ - Elena Pariani ⁽³⁾ - Laura Pellegrinelli ⁽³⁾ - Federica Perego ⁽¹⁾ - Andrea Ronchi ⁽⁴⁾ - Carlo Pietrasanta ⁽²⁾ - Fabio Mosca ⁽²⁾ - Maria Lorella Gianni ⁽²⁾ - Pasquale Ferrante ⁽⁵⁾ - Serena Delbue ⁽¹⁾	190
Università degli Studi di Milano, Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Milano, Italia ⁽¹⁾ - University of Milan, Department of Clinical Sciences And Community Health, Milano, Italia ⁽²⁾ - University of Milan, Department of Biomedical Sciences for Health, Milano, Italia ⁽³⁾ - Ospedale Maggiore Policlinico, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italia ⁽⁴⁾ - Istituto Clinico Città Studi, ICCS, Milano, Italia ⁽⁵⁾	190
140 - Expression of Human Endogenous Retroviruses (HERVs) in clinical specimens of colon cancer patients.....	191
Maria Dolci ⁽¹⁾ - Lucia Signorini ⁽¹⁾ - Pietro Bagnoli ⁽²⁾ - Luca Denti ⁽¹⁾ - Federica Perego ⁽¹⁾ - Pasquale Ferrante ⁽³⁾ - Serena Delbue ⁽¹⁾	191
Università degli Studi di Milano, Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Milano, Italia ⁽¹⁾ - Istituto Clinico Città Studi (ICCS), Unità Chirurgia Generale, Milano, Italia ⁽²⁾ - Istituto Clinico Città Studi, ICCS, Milano, Italia ⁽³⁾	191
141 - Study of the effects of new small molecules as antiviral agents against SARS-CoV-2	192
Alice Cara ⁽¹⁾ - Carmen Piazza ⁽²⁾ - Annalaura Brai ⁽³⁾ - Elena Dreassi ⁽³⁾ - Paola Quaranta ⁽²⁾ - Mauro Pistello ⁽¹⁾	192
Unità operativa di Virologia, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italia ⁽¹⁾ - Centro Retrovirus, Dipartimento di Ricerca Traslationale, Pisa, Italia ⁽²⁾ - Università di Siena, Dipartimento di Biotecnologia, Chimica e Farmacia, Siena, Italia ⁽³⁾	192

155 - SEROPREVALENCE OF TORCH INFECTIONS IN WOMEN OF CHILDBEARING AGE OVER THE 2012-2022 DECADE IN SICILY.....	193
Emilia Palazzotto ⁽¹⁾ - Floriana Bonura ⁽¹⁾ - Cinzia Calà ⁽¹⁾ - Giuseppina Capra ⁽¹⁾ - Daniela Pistoia ⁽¹⁾ - Chiara Mascarella ⁽¹⁾ - Giuseppe Mini ⁽¹⁾ - Marco Enea ⁽¹⁾ - Donatella Ferraro ⁽¹⁾ - Giovanni M. Giammanco ⁽¹⁾ - Simona De Grazia ⁽¹⁾	193
AOUP Policlinico Paolo Giaccone Palermo, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Italy, Palermo, Italia ⁽¹⁾	193
162 - SARS-CoV-2 OMICRON recombinant epidemiology in Northwest of Italy.....	194
Federica Novazzi ⁽¹⁾ - Daniele Focosi ⁽²⁾ - Andreina Baj ⁽¹⁾ - Angelo Paolo Genoni ⁽¹⁾ - SARA BOUTAHAR ⁽¹⁾ - Francesca Dragoferante ⁽¹⁾ - Fabrizio Maggi ⁽¹⁾	194
Università dell'Insubria, Dipartimento Medicina e Chirurgia, Varese, Italia ⁽¹⁾ - Ospedale di Pisa, North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy, Pisa, Italia ⁽²⁾	194
175 - The role of human DDX3 helicase in HSV-2 infection.	195
Carmen Rita Piazza ⁽¹⁾ - Giulia Lottini ⁽¹⁾ - Cristina Di Primio ⁽²⁾ - Marianna Mignanelli ⁽³⁾ - Pietro Giorgio Spezia ⁽⁴⁾ - Michele Lai ⁽⁴⁾ - Giulia Freer ⁽⁴⁾ - Paola Quaranta ⁽⁴⁾ - Mauro Pistello ⁽⁴⁾	195
Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽¹⁾ - CNR di Pisa, Istituto di Neuroscienze, Pisa, Italia ⁽²⁾ - Scuola Normale Superiore, Laboratorio di Biologia Bio@SNS, Pisa, Italia ⁽³⁾ - Università di Pisa, Dipartimento di Medicina Traslazionale, Pisa, Italia ⁽⁴⁾	195
184 - Antiviral activity of natural compounds and composite polymeric matrix against SARS-CoV-2.	196
Rossella Fonnesu ⁽¹⁾ - Camilla Dolfa ⁽¹⁾ - Alfredo Rosellini ⁽¹⁾ - Alice Cara ⁽¹⁾ - Paola Losi ⁽²⁾ - Ilenia Foffa ⁽²⁾ - Mario D'Acunto ⁽³⁾ - Giorgio Soldani ⁽²⁾ - Paola Quaranta ⁽⁴⁾ - Mauro Pistello ⁽¹⁾ - Paola Mazzetti ⁽¹⁾	196
U.O. Virologia Universitaria, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italia ⁽¹⁾ - Istituto Fisiologia Clinica, Consiglio Nazionale delle Ricerche, Pisa, Italia ⁽²⁾ - Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Pisa, Italia ⁽³⁾ - Centro Retrovirus - Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia, Università degli studi di Pisa, Pisa, Italia ⁽⁴⁾	196
Title: Antiviral activity of natural compounds and composite polymeric matrix against SARS-CoV-2.	196
185 - Palmitoylethanolamide (PEA) inhibits SARS-CoV-2 entry by interacting with S protein and ACE-2 receptor.	197
Rossella Fonnesu ⁽¹⁾ - Veronica La Rocca ⁽¹⁾ - Carolina Filipponi ⁽¹⁾ - Elena Iacono ⁽¹⁾ - Erika Plicanti ⁽¹⁾ - Maria Sidoti ⁽¹⁾ - Giulia Freer ⁽¹⁾ - Mauro Pistello ⁽²⁾ - Michele Lai ⁽¹⁾	197
Centro Retrovirus - Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia, Università degli studi di Pisa, Pisa, Italia ⁽¹⁾ - U.O. Virologia Universitaria, Azienda Ospedaliero Universitaria Pisana, Pisa, Italia ⁽²⁾	197
193 - First identification of SARS-CoV-2 Omicron BA.4 sub-variant in Italy: genomic comparison with omicron sub-variants.....	198
CINZIA PERONACE ⁽¹⁾ - ROSSANA TALLERICO ⁽¹⁾ - MANUELA COLOSIMO ⁽¹⁾ - MARCO DE FAZIO ⁽¹⁾ - FEDERICA PASCERI ⁽¹⁾ - ILENIA TALOTTA ⁽¹⁾ - GIUSEPPINA PANDURI ⁽¹⁾ - LETIZIA PINTOMALLI ⁽²⁾ - ROSARIA OTERI ⁽²⁾ - VALERIA CALANTONI ⁽²⁾ - MARIA TERESA FIORILLO ⁽²⁾ - MARIA CRISTINA CAROLEO ⁽³⁾ - VINCENZA DOLCE ⁽⁴⁾ - ERIKA CIONE ⁽⁴⁾ - PASQUALE MINCHELLA ⁽¹⁾	198
MICROBIOLOGIA E VIROLOGIA, PUGLIESE-CIACCIO, CATANZARO, Italia ⁽¹⁾ - MICROBIOLOGIA E VIROLOGIA, ASP RC N.5, REGGIO CALABRIA, Italia ⁽²⁾ - DIPARTIMENTO SCIENZE DELLA SALUTE,	

UNIVERSITA' MAGNA GRAECIA, CATANZARO, Italia ⁽³⁾ - DIPARTIMENTO DI FARMACOLOGIA, UNIVERSITA' DELLA CALABRIA, COSENZA, Italia ⁽⁴⁾	198
195 - In vitro virucidal activity of active food packaging based on monoglycerides against a Human Coronavirus and other viruses.....	200
Francesco Ricchi ⁽¹⁾	200
Università degli Studi di Modena e Reggio Emilia, Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, Modena, Italia ⁽¹⁾	200
204 - Gold-Nanoparticle delivery of CRISPR/Cas13 as antiviral strategy against emerging RNA viruses .	201
Alessandro De Carli ⁽¹⁾ - Domenico Favaro ⁽²⁾ - Rossella Fonnesu ⁽²⁾ - Piotr Barski ⁽³⁾ - Vittoria Raffa ⁽⁴⁾ - Mauro Pistello ⁽⁵⁾ - Michele Lai ⁽²⁾	201
Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽¹⁾ - Università di Pisa, Dipartimento di Medicina Traslazionale, Pisa, Italia ⁽²⁾ - ProChimia Surfaces Sp. z o.o., Research and Development ProChimia Surfaces, Gdynia, Polonia ⁽³⁾ - Università di Pisa, Dipartimento di Biologia, Pisa, Italia ⁽⁴⁾ - U.O. Virologia Universitaria, Azienda Universitaria Ospedaliera Pisana, Pisa, Italia ⁽⁵⁾	201
207 - Humoral and cell-mediated immune response in COVID-19 vaccinees according to history of prior SARS-CoV-2 infection.....	202
Giorgio Fedele ⁽¹⁾ - Annapina Palmieri ⁽²⁾ - Ilaria Schiavoni ⁽¹⁾ - Pasqualina Leone ⁽¹⁾ - Eleonora Olivetta ⁽³⁾ - Cecilia Damiano ⁽²⁾ - Anna Di Lonardo ⁽²⁾ - Caterina Trevisan ⁽⁴⁾ - Angela Marie Abbatecola ⁽⁵⁾ - Carmine Cafariello ⁽⁶⁾ - Alba Malara ⁽⁷⁾ - Pasquale Minchella ⁽⁸⁾ - Raffaele Antonelli Incalzi ⁽⁹⁾ - Anna Teresa Palamara ⁽¹⁾ - Graziano Onder ⁽²⁾ - Paola Stefanelli ⁽¹⁾	202
Istituto Superiore di Sanità, Dipartimento Malattie Infettive, Roma, Italia ⁽¹⁾ - Istituto Superiore di Sanità, Dipartimento Malattie Cardiovascolari, Endocrino-Metaboliche e dell'Invecchiamento, Roma, Italia ⁽²⁾ - Istituto Superiore di Sanità, Centro Nazionale per la Salute Globale, Roma, Italia ⁽³⁾ - Università di Ferrara, Dipartimento Scienze Mediche, Ferrara, Italia ⁽⁴⁾ - Azienda Sanitaria Locale (ASL) Frosinone, Dipartimento Centri Diurni Alzheimer, Frosinone, Italia ⁽⁵⁾ - Italian Hospital Group, Direzione Scientifica, Roma, Italia ⁽⁶⁾ - ANASTE Humanitas Foundation, Presidenza, Roma, Italia ⁽⁷⁾ - Azienda Ospedaliera Pugliese Ciaccio, Dipartimento di Microbiologia e Virologia, Catanzaro, Italia ⁽⁸⁾ - Università Campus Bio-Medico, Dipartimento di Medicina, Roma, Italia ⁽⁹⁾	202
226 - Antiviral activity of fungal secondary metabolites against Canine coronavirus infection	204
Claudia Cerracchio ⁽¹⁾ - Maria Michela Salvatore ⁽²⁾ - Francesca Paola Nocera ⁽¹⁾ - Luisa De Martino ⁽¹⁾ - Rosario Nicoletti ⁽³⁾ - Anna Andolfi ⁽²⁾ - Filomena Fiorito ⁽¹⁾	204
Università degli Studi di Napoli, Federico II, Dipartimento di Medicina Veterinaria e Produzioni Animali, Napoli, Italia ⁽¹⁾ - Università degli Studi di Napoli, Federico II, Dipartimento Scienze Chimiche, Napoli, Italia ⁽²⁾ - Università degli Studi di Napoli, Federico II, Dipartimento di Agraria, Napoli, Italia ⁽³⁾	204
227 - Canine coronavirus activates the aryl hydrocarbon receptor during infection	205
Claudia Cerracchio ⁽¹⁾ - Maria Grazia Polverino ⁽²⁾ - Valentina Iovane ⁽³⁾ - Anna Rita Attili ⁽⁴⁾ - Maria Grazia Amoroso ⁽²⁾ - Filomena Fiorito ⁽¹⁾	205
Università degli Studi di Napoli Federico II, Medicina Veterinaria e Produzioni Animali, Napoli, Italia ⁽¹⁾ - Istituto Zooprofilattico Sperimentale del Mezzogiorno, UOS Diagnostica Virologica e Colture Cellulari, Portici (Napoli), Italia ⁽²⁾ - Università degli Studi di Napoli Federico II, Agraria, Portici (Napoli), Italia ⁽³⁾ - Università di Camerino, Scuola di Bioscienze e Medicina Veterinaria, Camerino, Italia ⁽⁴⁾	205

236 - In vitro study of the interaction of enoxaparin sodium or heparan sulfate with not SARS-CoV strains	206
Virginia Fuochi ⁽¹⁾ - Rosalia Emma ⁽¹⁾ - Massimo Caruso ⁽¹⁾ - Federica Ronchi ⁽²⁾ - Celestino Ronchi ⁽²⁾ - Filippo Drago ⁽¹⁾ - Pio Maria Furneri ⁽¹⁾	206
Università degli Studi di Catania, BIOMETEC, Catania, Italia ⁽¹⁾ - Delim Cosmetics & Pharma s.r.l, R&D, Vimidrone (MI), Italia ⁽²⁾	206
238 - Identification of interactions between human nuclear proteins and HPV16 genome	207
Maria Vittoria Morone ⁽¹⁾ - Annalisa Chianese ⁽¹⁾ - Giuliana Donadio ⁽²⁾ - Angela Nebbioso ⁽³⁾ - Veronica Sian ⁽³⁾ - Giuseppe Greco ⁽¹⁾ - Giuseppina Sanna ⁽⁴⁾ - Sergio Amitrano ⁽⁵⁾ - Lucia Altucci ⁽³⁾ - Massimiliano Galdiero ⁽¹⁾ - Fabrizio Dal Piaz ⁽²⁾ - Gianluigi Franci ⁽²⁾	207
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italia ⁽¹⁾ - Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Italia ⁽²⁾ - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italia ⁽³⁾ - Department of Biomedical Sciences, Università di Cagliari, Monserrato (CA), Italia ⁽⁴⁾ - Fondazione "Bartolo Longo III Millenio", Fondazione, Pompei, Italia ⁽⁵⁾	207
240 - Antiviral Activity of the Rhamnolipids from the Antarctic Bacterium Pseudomonas gessardii against Herpesviridae and Coronaviridae family	209
Rosa Glugliano ⁽¹⁾ - Carmine Buonocore ⁽²⁾ - Carla Zannella ⁽¹⁾ - Fortunato Palma Esposito ⁽²⁾ - Pietro Tedesco ⁽²⁾ - Anna De Filippis ⁽¹⁾ - Massimiliano Galdiero ⁽¹⁾ - Donatella de Pascale ⁽²⁾ - Gianluigi Franci ⁽³⁾	209
Università degli Studi della Campania "Luigi Vanvitelli", dipartimento medicina sperimentale, Napoli, Italia ⁽¹⁾ - Stazione Zoologica Anton Dohrn, 2.Department of Marine Biotechnology, Napoli, Italia ⁽²⁾ - Università di Salerno, dipartimento di medicina, Salerno, Italia ⁽³⁾	209
241 - Evaluation of HPV genotype-specific viral loads in clinician-collected cervical samples as compared to vaginal self-collected samples in women with cervical dysplasia.....	211
Chiara Giubbi ⁽¹⁾ - Ardashel Latsuzbaia ⁽²⁾ - Marianna Martinelli ⁽¹⁾ - Ivan Vallini ⁽³⁾ - Silvia Paganoni ⁽³⁾ - Clementina Elvezia Cocuzza ⁽¹⁾ - Marc Arbyn ⁽²⁾	211
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italia ⁽¹⁾ - Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Bruxelles, Belgio ⁽²⁾ - Hiantis srl, Hiantis srl, Milano, Italia ⁽³⁾	211
247 - Prion-like alpha-synuclein detection in ante-mortem intestinal biopsies from Parkinson's disease patients by RT-QuIC assay	213
Sarah Vascellari ⁽¹⁾ - Christina Orrù ⁽²⁾ - Fabrizio Angius ⁽¹⁾ - Pier Paolo Carreras ⁽³⁾ - Byron Caughey ⁽²⁾ - Giovanni Cossu ⁽⁴⁾ - Aldo Manzin ⁽¹⁾	213
University of Cagliari, Department of Biomedical Sciences, Cagliari, Italia ⁽¹⁾ - National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), Laboratory of Persistent Viral Diseases (LPVD), Rocky Mountain Laboratories, Hamilton MT, Stati Uniti D'america ⁽²⁾ - AOBrotzu, S. C. Digestive Endoscopy Unit, Cagliari, Italia ⁽³⁾ - AOBrotzu, S. C. Neurology and Stroke Unit, Cagliari, Italia ⁽⁴⁾	213
252 - Inhibition of viral entry by peptides designed on the glycoproteins Gn and Gc of Schmallenberg virus	215

Carla Zannella ⁽¹⁾ - Annalisa Chianese ⁽¹⁾ - Biagio Santella ⁽¹⁾ - Giuseppe Greco ⁽¹⁾ - Serena Montagnaro ⁽²⁾ - Giuseppe Iovane ⁽²⁾ - Ugo Pagnini ⁽²⁾ - Rinaldo Grazioso ⁽³⁾ - Carla Isernia ⁽³⁾ - Anna De Filippis ⁽¹⁾ - Gianluigi Franci ⁽⁴⁾ - Matteo Porotto ⁽⁵⁾ - Massimiliano Galdiero ⁽¹⁾	215
Università degli Studi della Campania "Luigi Vanvitelli", Dipartimento di Medicina Sperimentale-Sezione Microbiologia e Virologia, Napoli, Italia ⁽¹⁾ - University of Naples Federico II, Department of Veterinary Medicine and Animal Productions, Napoli, Italia ⁽²⁾ - University of Campania "Luigi Vanvitelli", Department of Environmental, Biological and Pharmaceutical Science and Technology, Caserta, Italia ⁽³⁾ - Università di Salerno, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Baronissi, Italia ⁽⁴⁾ - Columbia University Vagelos College of Physicians and Surgeons, Department of Pediatrics, New York, Stati Uniti D'america ⁽⁵⁾	215
256 - A Cluster of SARS-CoV-2 omicron variant of concern harbouring a rare	217
mutation in the spike gene.....	217
Pietro Giorgio Spezia ⁽¹⁾ - ANNA-LISA CAPRIA ⁽²⁾ - Paola Mazzetti ⁽²⁾ - Mauro Pistello ⁽¹⁾ - Alice Cara ⁽²⁾ - Pietro Villa ⁽²⁾ - Alfredo Rosellini ⁽²⁾ - Simone Meini ⁽³⁾	217
Università di Pisa, Centro retrovirus, Università di Pisa, Dipartimento di scienze cliniche e traslazionali, Pisa, Italia ⁽¹⁾ - AOUP, azienda ospedaliera universitaria Pisana UOC Virologia, PISA, Italia ⁽²⁾ - Azienda Unità Sanitaria Locale Toscana Nord-Ovest, Internal Medicine Unit, Felice Lotti Hospital of Pontedera,, Pontedera, Italia ⁽³⁾	217
257 - Distribution and prevalence of Human papillomavirus (HPV) in oral samples collected from 2001 to 2020 in Sicily	218
Michela Buttà ⁽¹⁾ - Giuseppina Campisi ⁽¹⁾ - Vera Panzarella ⁽¹⁾ - Daniela Pistoia ⁽²⁾	218
Università di Palermo, AOUP P. Giaccone, Palermo, Italia ⁽¹⁾ - AOUP P. Giaccone, AOUP P. Giaccone, Palermo, Italia ⁽²⁾	218
259 - Isolation of SARS-CoV-2 in viral cell culture and immunologic characterization in immunocompromised patients	219
paola mazzetti ⁽¹⁾ - alice cara ⁽¹⁾ - alfredo rosellini ⁽¹⁾ - maria sidoti ⁽²⁾ - giovanna moscato ⁽³⁾ - giulia freer ⁽²⁾ - iacopo franconi ⁽¹⁾ - arianna forniti ⁽³⁾ - lorenzo suardi ⁽³⁾ - entrico tagliaferri ⁽³⁾ - spartaco sani ⁽⁴⁾ - marco falcone ⁽¹⁾ - riccardo iapoce ⁽³⁾ - mauro pistello ⁽¹⁾	219
Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, pisa, Italia ⁽¹⁾ - Centro Retrovirus, Dpt.Ricerca Traslazionale, Università di Pisa, pisa, Italia ⁽²⁾ - Azienda ospedaliera-universitaria Pisana, AOUP, pisa, Italia ⁽³⁾ - Azienda Sanitaria USL 6, U.O. Malattie infettive, Ospedale di Livorno, livorno, Italia ⁽⁴⁾	219
262 - Genetic diversity of norovirus Genogroups I and II in untreated wastewater in Rome Italy: a five-year monitoring study	220
Giusy Bonanno Ferraro (1) - Pamela Mancini (1) - Carolina Veneri (1) - Marcello Iaconelli (1) - Elisabetta Suffredini (2) - David Brandtner (3) - Giuseppina La Rosa (1)	220
Istituto Superiore di Sanità, Ambiente e Salute, Roma, Italia (1) - Istituto Superiore di Sanità, Sicurezza alimentare, nutrizione e sanità pubblica veterinaria, Roma, Italia (2) - Independent researcher, Independent researcher, Roma, Italia (3)	220
263 - Hepatitis E in urban wastewater, pig slurry, food products, and wild boars: a One Health approach for the study of virus occurrence and diversity in the region of Abruzzo	221
Giuseppina La Rosa (1) - Pamela Mancini (1) - Carolina Veneri (1) - Giusy Bonanno Ferraro (1) - Lidia Orlandi (1) - Claudia Del Giudice (1) - Farzad Beikpour (2) - Teresa Vicenza (2) - Simona Di Pasquale (2) -	

Loredana Cozzi (2) - Giuseppe Aprea (3) - Nadia Barile (4) - Silvia Scattolini (3) - Eliana Nerone (4) - Daniela D'Angelantonio (3) - Ilaria Del Matto (3) - Marcello Iaconelli (1) - Massimo Brambilla (5) - Alex Filisetti (5) - Carlo Bisaglia (5) - Elisabetta Suffredini (2) 221

Istituto Superiore di Sanità, Dipartimento Ambiente e Salute, Roma, Italia (1) - Istituto Superiore di Sanità, Sicurezza alimentare, nutrizione e sanità pubblica veterinaria, Roma, Italia (2) - Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale", Reparto di Igiene delle tecnologie alimentari e dell'alimentazione animale, Teramo, Italia (3) - Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale", Centro Ricerche per gli Ecosistemi marini e Pesca, Termoli, Italia (4) - CREA Consiglio per la ricerca in agricoltura e l'analisi dell'economia agraria, Research Centre for Engineering and Agro-Food Processing, Treviglio, Italia (5)..... 221

265 - Antiviral effect of bombinin H2/H4 against enveloped and naked viruses..... 223

Aurora Salvemme (1) - Ida Curtovic (1) - Sara Passerini (1) - Carla Prezioso (1) - Mariya T. Miteva (1) - Virginia Protto (1) - Giovanna De Chiara (2) - Maria Luisa Mangoni (3) - Valeria Pietropaolo (1) - Lucia Nencioni (1) - Anna Teresa Palamara (4) - Maria Elena Marcocci (1) 223

Sapienza Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia (1) - CNR, Istituto di Farmacologia traslazionale, Roma, Italia (2) - Sapienza Università di Roma, Dipartimento di Scienze Biochimiche, Roma, Italia (3) - Istituto Superiore di Sanità, Dipartimento di Malattie Infettive, Roma, Italia (4) 223

273 - Comparative assessment of molecular methods for studying TTV-virome species composition and prevalence estimates 224

Pietro Giorgio Spezia (1) - Fabio Filippini (1) - Andreina Baj (2) - Federica Novazzi (2) - Angelo Genoni (2) - Francesca D. Ferrante (2) - Mauro Pistello (1) - Fabrizio Maggi (3) 224

University of Pisa, Department of Translational Research, Retrovirus Center and Virology Section, Pisa, Italia (1) - University of Insubria, Department of Medicine and Surgery, Varese, Italia (2) - Spallanzani National Institute for Infectious Diseases, Laboratory of Virology and High Containment Laboratories, Roma, Italia (3) 224

276 - Wastewater surveillance of SARS-CoV-2 in Italy: outcomes of nine months of nationwide monitoring 225

Giuseppina La Rosa (1) - Giusy Bonanno Ferraro (1) - Pamela Mancini (1) - Carolina Veneri (1) - Lidia Orlandi (1) - Claudia Del Giudice (1) - Marcello Iaconelli (1) - David Brandtner (2) - Luca Lucentini (1) - Lucia Bonadonna (1) - Mirko Rossi (2) - Mauro Grigioni (3) - Giuseppe D'Avenio (3) - Mario Cerroni (1) - Federica Simonetti (1) - SARI NETWORK (4) - Elisabetta Suffredini (5) 225

Istituto Superiore di Sanità, Department of Environment and Health, Roma, Italia (1) - Independent Researcher, ---, Roma, Italia (2) - Istituto Superiore di Sanità, National Center for Innovative Technologies in Public Health,, Roma, Italia (3) - the list can be found at the ISS website (Acque reflue - ISS), the list can be found at the ISS website (Acque reflue - ISS), --, Italia (4) - Istituto Superiore di Sanità, Department of Food Safety, Nutrition and Veterinary Public Health, Roma, Italia (5) 225

Wastewater surveillance of SARS-CoV-2 in Italy: outcomes of nine months of nationwide monitoring 225

278 - Utility of genotypic CMV-drug resistance testing in immunocompromised patients..... 226

Gabriele Turello (1) - Giulia Piccirilli (1) - Maria Cristina Morelli (2) - Francesca Bonifazi (3) - Giorgia Comai (4) - Luciano Potena (5) - Eva Caterina Borgatti (6) - Liliana Gabrielli (1) - Tiziana Lazzarotto (6) 226

UOC Microbiologia, IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia (1) - UOC Medicina interna per il trattamento delle gravi insufficienze d'organo, IRCCS Policlinico di S.Orsola,

Università di Bologna, Bologna, Italia ⁽²⁾ - Istituto di Ematologia "Seràgnoli", IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia ⁽³⁾ - UO Nefrologia, dialisi e trapianto, IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia ⁽⁴⁾ - UO Cardiologia, IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia ⁽⁵⁾ - DIMES, UOC Microbiologia, IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia ⁽⁶⁾	226
280 - Antiviral potential of <i>Galdieria sulphuraria</i> , an extremophilic red alga	228
Antiviral potential of <i>Galdieria sulphuraria</i> , an extremophilic red alga	228
ANNALISA AMBROSINO, PRAGATI A. MORE ¹ , FRANCESCA PALMA ¹ , BIANCA M. NASTRI ¹ , ADELE SANTANGELO ¹ , VALENTINA FIORE ¹ , ROBERTA MANENTE ¹ , GIORGIA FALCONE ¹ , SIMONA PICCOLELLA ² , SEVERINA PACIFICO ² , ANNA DE FILIPPIS ¹ , MASSIMILIANO GALDIERO ¹	228
¹ Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.	228
² Department of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania Luigi Vanvitelli, Via Vivaldi 43, 81100 Caserta, Italy.	228
04 Batteriologia, micologia e parassitologia	230
2 - Climatic zone and soil properties determine the biodiversity of the soil bacterial communities associated to native plants from desert areas of North-Central Algeria	230
Elisa Bona ⁽¹⁾ - Nadia Massa ⁽²⁾ - Omrane Toumatia ⁽³⁾ - Giorgia Novello ⁽²⁾ - Patrizia Cesaro ⁽²⁾ - Valeria Todeschini ⁽²⁾ - Lara Boatti ⁽⁴⁾ - Flavio Mignone ⁽²⁾ - Guido Lingua ⁽²⁾ - Francesco Vuolo ⁽⁵⁾ - Elisa Gamalero ⁽²⁾	230
Università del Piemonte Orientale, Dipartimento per lo Sviluppo Sostenibile e la Transizione Ecologica, Vercelli, Italia ⁽¹⁾ - Università del Piemonte Orientale, Dipartimento di Scienze e Innovazione Tecnologica, Alessandria, Italia ⁽²⁾ - Agro-Pastoralism Research Center, Agro-Pastoralism Research Center, Djelfa, Algeria ⁽³⁾ - SmartSeq s.r.l., Spin-Off of the Università del Piemonte Orientale, Novara, Italia ⁽⁴⁾ - Sacco s.r.l., Sacco s.r.l., Cadorago, Italia ⁽⁵⁾	230
3 - Sequencing of the whole genome of <i>Acinetobacter baumannii</i> : monitoring of antibiotic resistance in hospital during the Sars-CoV-2 pandemic	232
Alice Caramaschi ⁽¹⁾ - Marianna Farotto ⁽¹⁾ - Marta Mellai ⁽²⁾ - Francesco Favero ⁽²⁾ - Davide Corà ⁽³⁾ - Cristian Leli ⁽⁴⁾ - Lidia Ferrara ⁽⁴⁾ - Andrea Rocchetti ⁽⁴⁾ - Elisa Bona ⁽¹⁾	232
Università del Piemonte Orientale, Dipartimento per lo Sviluppo Sostenibile e la Transizione Ecologica, Vercelli, Italia ⁽¹⁾ - UPO-CAAD, Centro Universitario per la Ricerca Traslazionale sulle Malattie Autoimmuni ed Allergiche, Novara, Italia ⁽²⁾ - Università del Piemonte Orientale, Dipartimento di Medicina Traslazionale, Novara, Italia ⁽³⁾ - Azienda ospedaliera Santi Antonio e Biagio e Cesare Arrigo, S.C. di Microbiologia, Alessandria, Italia ⁽⁴⁾	232
9 - Monitoring of fungal biodiversity in sea beaches of Sicily: a one-year environmental study	234
Maddalena Calvo ⁽¹⁾ - Giuseppe Migliorisi ⁽¹⁾ - Salvatore Oliveri ⁽²⁾ - Laura Trovato ⁽²⁾	234
Azienda ospedaliera, Azienda ospedaliera universitaria Policlinico - San Marco, Catania, Italia ⁽¹⁾ - Università di Catania, Dipartimento di Scienze biomediche e biotecnologiche, CATANIA, Italia ⁽²⁾	234
10 - A case of rhino-pharyngeal myiasis from Eastern Sicily: rare infectious diseases have their time for revenge	235
GIUSEPPE MIGLIORISI ⁽¹⁾ - MADDALENA CALVO ⁽¹⁾ - FRANCESCO LOMBARDO ⁽²⁾ - ALICE NICOLOSI ⁽³⁾ - GAETANO MAUGERI ⁽³⁾ - ILDEBRANDO PATAMIA ⁽³⁾	235

AZIENDA OSPEDALIERA, POLICLINICO-SAN MARCO, CATANIA, Italia ⁽¹⁾ - UNIVERSITA' DI CATANIA, DIPARTIMENTO DI SCIENZE BIOLOGICHE, GEOLOGICHE E AMBIENTALI, CATANIA, Italia ⁽²⁾ - UNIVERSITA' DI CATANIA, DIPARTIMENTO DI SCIENZE BIOMEDICHE E BIOTECNOLOGICHE, CATANIA, Italia ⁽³⁾	235
12 - Increasing the odds of discovering novel metabolites from a large microbial library	236
Paolo Monciardini ⁽¹⁾ - Cristina Brunati ⁽¹⁾ - Andrea Gentile ⁽¹⁾ - Marianna Iorio ⁽²⁾ - Sonia I. Maffioli ⁽²⁾ - Margherita Sosio ⁽¹⁾ - Arianna Tocchetti ⁽¹⁾ - Kristiina Vind ⁽¹⁾ - Mitja M. Zdouc ⁽¹⁾ - Stefano Donadio ⁽¹⁾	236
Naicons, Microbiologia, Milano, Italia ⁽¹⁾ - Naicons, Chimica, Milano, Italia ⁽²⁾	236
14 - Changes in microbial aetiology of Prosthetic Joint Infections: a three years evaluation.	237
LAURA SESSA ⁽¹⁾ - Iolanda Giuffrida ⁽¹⁾ - Valentina Costanzo ⁽¹⁾ - Maddalena Calvo ⁽¹⁾ - ELISABETTA FRAGALA' ⁽¹⁾ - GRAZIELLA FERLITO ⁽¹⁾ - STEFANIA STEFANI ⁽²⁾	237
Azienda ospedaliera, Azienda ospedaliera universitaria Policlinico - San Marco, Catania, Italia ⁽¹⁾ - Università degli Studi di Catania, Dipartimento di Scienze biomediche e biotecnologiche, CATANIA, Italia ⁽²⁾	237
16 - Interference on uterine bacterial population in hypofertile mares of intrauterine infusion of equine fresh platelets-rich plasma.	238
Francesca Paola Nocera ⁽¹⁾ - Chiara Del Prete ⁽¹⁾ - Angelo Masullo ⁽¹⁾ - Roberto Mancini ⁽¹⁾ - Natascia Cocchia ⁽¹⁾ - Maria Pia Pasolini ⁽¹⁾ - Luisa De Martino ⁽¹⁾	238
18 - The spread of fluconazole-resistant Candida parapsilosis strains during the global COVID-19 pandemic in a Northern Italy hospital.....	239
DOMENICO CALECA ⁽¹⁾ - PAOLO GIGANTE ⁽¹⁾ - GABRIELLA TOCCI ⁽¹⁾ - VALENTINA LEPERA ⁽¹⁾ - ANDREA ZAPPAVIGNA ⁽¹⁾ - CHIARA GORRINI ⁽¹⁾ - ROBERTA SCHIAVO ⁽¹⁾ - IRENE PERONI ⁽¹⁾ - LORENA LAVERGATA ⁽¹⁾ - CLAUDIA CORDINE ⁽¹⁾ - GIULIANA LO CASCIO ⁽¹⁾	239
AUSL PIACENZA, OSPEDALE GUGLIELMO DA SALICETO, DIPARTIMENTO PATOLOGIA CLINICA, PIACENZA, Italia ⁽¹⁾	239
20 - Acinetobacter baumannii and cefiderocol between cidalit and adaptability	240
Stefano Stracquadanio ⁽¹⁾ - Carmelo Bonomo ⁽¹⁾ - Andrea Marino ⁽²⁾ - Dafne Bongiorno ⁽¹⁾ - Grete Privitera ⁽³⁾ - Dalida Bivona ⁽¹⁾ - Alessia Mirabile ⁽¹⁾ - Paolo Bonacci ⁽¹⁾ - Stefania Stefani ⁽¹⁾	240
Dipartimento di Scienze Biomediche e Biotecnologiche, Sezione di Microbiologia, Università degli Studi di Catania, Catania, Italia ⁽¹⁾ - Dipartimento di Medicina Clinica e Sperimentale, Unità di Malattie Infettive, ARNAS Garibaldi / Università degli Studi di Catania, Catania, Italia ⁽²⁾ - Dipartimento di Medicina Clinica e Sperimentale, Unità di Bioinformatica, Università degli Studi di Catania, Catania, Italia ⁽³⁾	240
Acinetobacter baumannii and cefiderocol between cidalit and adaptability	240
22 - Combination of essential oils to poly(ε-caprolactone)-based biomaterial to achieve anti-bacterial and osteoblast proliferative properties for regenerative medicine scaffolds.	241
Sara Comini ⁽¹⁾ - Rosaria Sparti ⁽¹⁾ - Sara Scutera ⁽¹⁾ - Bartolomeo Coppola ⁽²⁾ - Anna Maria Cuffini ⁽¹⁾ - Lorenza Cavallo ⁽¹⁾ - Francesca Menotti ⁽¹⁾ - Cinzia Margherita Berteà ⁽³⁾ - Paola Palmero ⁽²⁾ - Giuliana Banche ⁽¹⁾ - Valeria Allizond ⁽¹⁾	241
University of Torino, Department of Public Health and Pediatrics, Turin, Italia ⁽¹⁾ - Politecnico di Torino, Department of Applied Science and Technology, Turin, Italia ⁽²⁾ - University of Torino, Department of Life Sciences and Systems Biology, Turin, Italia ⁽³⁾	241

23 - New drugs, new diagnostic techniques and new algorithms in fast track workflow of Gram-negative bloodstream infections: a three-year single-centre study	242
Sara Comini ⁽¹⁾ - Gabriele Bianco ⁽²⁾ - Guido Ricciardelli ⁽¹⁾ - Matteo Boattini ⁽²⁾ - Roberto Casale ⁽¹⁾ - Valeria Allizond ⁽³⁾ - Rossana Cavallo ⁽¹⁾ - Cristina Costa ⁽¹⁾	242
Università di Torino, Dipartimento di Scienze della Sanità Pubblica e Pediatriche/ A.O.U. Città della Salute e della Scienza di Torino, Torino, Italia ⁽¹⁾ - Azienda Ospedaliero Universitaria, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italia ⁽²⁾ - Università di Torino, Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Torino, Italia ⁽³⁾	242
24 - Antimicrobial activity of Curcumin and Curcumin/Chitosan loaded nanobubbles with photodynamic light	243
Lorenza Cavallo ⁽¹⁾ - Zunaira Munir ⁽²⁾ - Janira Roana ⁽¹⁾ - Ilaria Stura ⁽²⁾ - Sara Comini ⁽¹⁾ - Francesca Menotti ⁽¹⁾ - Vivian Tullio ⁽¹⁾ - Raffaele Pertusio ⁽²⁾ - Matteo Biolatti ⁽¹⁾ - Roberta Cavalli ⁽³⁾ - Anna Maria Cuffini ⁽¹⁾ - Caterina Guiot ⁽²⁾ - Narcisa Mandras ⁽¹⁾ - Giuliana Banche ⁽¹⁾	243
Università di Torino, Dipartimento di Scienze della sanità pubblica e pediatriche, Torino, Italia ⁽¹⁾ - Università di Torino, Dipartimento di Neuroscienze, Torino, Italia ⁽²⁾ - Università di Torino, Dipartimento di Scienza e Tecnologia del Farmaco, Torino, Italia ⁽³⁾	243
Antimicrobial activity of Curcumin and Curcumin/Chitosan loaded nanobubbles with photodynamic light	243
25 - optrA-mediated linezolid resistance in an Enterococcus faecalis isolate recovered from a wild raptor (Falco peregrinus peregrinus), central Italy	244
Sonia Nina Coccitto ⁽¹⁾ - Elisa Albini ⁽²⁾ - Marzia Cinthi ⁽³⁾ - Marco Gobbi ⁽²⁾ - Francesca Romana Massacci ⁽²⁾ - Silvia Pavone ⁽²⁾ - Eleonora Giovanetti ⁽³⁾ - Chiara Francesca Magistrali ⁽²⁾ - Andrea Brenciani ⁽¹⁾	244
Università Politecnica delle Marche, Dip. Scienze Biomediche e Sanità Pubblica, Ancona, Italia ⁽¹⁾ - Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, IZSUM, Perugia, Italia ⁽²⁾ - Università Politecnica delle Marche, Dip. Scienze della Vita e dell'Ambiente, Ancona, Italia ⁽³⁾	244
26 - Detection of an Enterococcus faecium carrying the phenicol-oxazolidinone resistance gene poxtA recovered from a freshwater river, central Italy	245
Marzia Cinthi ⁽¹⁾ - Sonia Nina Coccitto ⁽²⁾ - Gloria D'Achille ⁽²⁾ - Andrea Brenciani ⁽²⁾ - Gianluca Morroni ⁽²⁾ - Eleonora Giovanetti ⁽¹⁾	245
Università Politecnica delle Marche, Dipartimento Di Scienze Della Vita E Dell'Ambiente, Ancona, Italia ⁽¹⁾ - Università Politecnica delle Marche, Dipartimento di Scienze Biomediche e Sanità Pubblica, Ancona, Italia ⁽²⁾	245
35 - Evaluation of the MALDI-TOF mass spectrometry workflow for the identification of microorganisms involved in monomicrobial and polymicrobial bloodstream infections.....	246
Mirko Buttrini ⁽¹⁾ - Benedetta Farina ⁽¹⁾ - Monica Martinelli ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Alan Di Maio ⁽¹⁾ - Silvia Covan ⁽¹⁾ - Tiziano Moro ⁽¹⁾ - Elizabeth Prandini ⁽¹⁾ - Federica Crocamo ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Flora De Conto ⁽¹⁾ - Adriana Calderaro ⁽¹⁾	246
Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾	246
36 - Schistosoma haematobium, an imported parasite: a 5-year epidemiological study.....	247
Sara Montecchini ⁽¹⁾ - Federica Crocamo ⁽¹⁾ - Sabina Rossi ⁽¹⁾ - Federica Motta ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Benedetta Farina ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Flora De Conto ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Adriana Calderaro ⁽¹⁾	247
Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾	247

38 - In vitro effect of innovative light with photodynamic microbicidal activity in bacteria	248
Monica Ambrosio ⁽¹⁾ - Francesca Paola Nocera ⁽¹⁾ - Claudia Cerracchio ⁽¹⁾ - Filomena Fiorito ⁽¹⁾ - Martin Hohenegger ⁽²⁾ - Luisa De Martino ⁽¹⁾	248
Università degli studi di Napoli Federico II, Dipartimento di Medicina Veterinaria e Produzioni Animali, Napoli, Italia ⁽¹⁾ - Medical University of Vienna, Institute of Pharmacology, Vienna, Austria ⁽²⁾	248
40 - Temporal correlation between SARS-CoV-2 infection and Candida parapsilosis bloodstream infections.	249
Paolo Gigante ⁽¹⁾ - Domenico Caleca ⁽¹⁾ - Gabriella Tocci ⁽¹⁾ - Valentina Lepera ⁽¹⁾ - Andrea Zappavigna ⁽¹⁾ - Chiara Gorrini ⁽¹⁾ - Roberta Schiavo ⁽¹⁾ - Irene Peroni ⁽¹⁾ - Lorena La Vergata ⁽¹⁾ - Claudia Cordini ⁽¹⁾ - Giuliana Lo Cascio ⁽¹⁾	249
AUSL PIACENZA, Ospedale Guglielmo da Saliceto, Piacenza, Italia ⁽¹⁾	249
41 - Sexually transmitted pathogens in a selected population: a preliminary study	250
Michele Mastria ⁽¹⁾ - Enrica M. Ranieri ⁽¹⁾ - Manuela Mandorino ⁽¹⁾ - Stefania Garzone ⁽¹⁾ - Luigi Ronga ⁽²⁾ - Raffaele Del Prete ⁽¹⁾ - Adriana Mosca ⁽¹⁾ - Luigi Santacroce ⁽¹⁾	250
DIM, sezione Microbiologia e Virologia, Università di Bari, Aldo Moro, Bari, Italia ⁽¹⁾ - UOC Microbiologia e Virologia, Azienda Ospedaliero-Universitaria Policlinico of Bari, Bari, Italia ⁽²⁾	250
42 - Nontyphoidal Salmonella gastroenteritis in children: a preliminary study on antibiotic resistance.	251
Sofia Denicolo' ⁽¹⁾ - Maria Elena Maggiore ⁽¹⁾ - Francesca Indraccolo ⁽¹⁾ - Michele Mastria ⁽¹⁾ - Luigi Ronga ⁽²⁾ - Raffaele Del Prete ⁽¹⁾ - Desiree Caselli ⁽³⁾ - Adriana Mosca ⁽¹⁾	251
Dipartimento DIM, Università degli studi di Bari, Bari, Italia ⁽¹⁾ - UOC Microbiologia e Virologia, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italia ⁽²⁾ - UOC Malattie Infettive e Tropicali Giovanni XXIII, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italia ⁽³⁾	251
44 - Pilocarpine interferes with sphingolipids metabolism in Candida albicans.	252
EMERENZIANA OTTAVIANO ⁽¹⁾	252
UNIVERSITA' DEGLI STUDI DI MILANO, DIP. SCIENZE DELLA SALUTE, MILANO, Italia ⁽¹⁾	252
45 - KPC-producing Klebsiella pneumoniae spread: genotypic and epidemiological characterization of clinical strains from Marche region	253
Gloria D'Achille ⁽¹⁾ - Lucia Brescini ⁽¹⁾ - Marina Mingoia ⁽¹⁾ - Antonella Pocognoli ⁽²⁾ - Guido Zeni ⁽¹⁾ - Andrea Brenciani ⁽¹⁾ - Francesco Barchiesi ⁽¹⁾ - Gianluca Morroni ⁽¹⁾	253
Università Politecnica delle Marche, Dipartimento di Scienze Biomediche e Sanità Pubblica, Ancona, Italia ⁽¹⁾ - Ospedali Riuniti, Laboratorio di Microbiologia, Ancona, Italia ⁽²⁾	253
47 - Re-sensitizing Methicillin-resistant Staphylococcus aureus to antimicrobials.....	254
Nader Abdelmalek ⁽¹⁾	254
Università degli studi di Sassari, Dipartimento Scienze biomediche, Sassari, Italia ⁽¹⁾	254
49 - Implementation of a selective Chromatic medium for active surveillance of ceftazidime-avibactam resistance during COVID-19 pandemic: outbreaks and diagnostic issues.....	255
Gabriele Bianco ⁽¹⁾ - Sara Comini ⁽¹⁾ - Matteo Boattini ⁽¹⁾ - Alessandro Bondi ⁽¹⁾ - Alessio Leone ⁽¹⁾ - Federica Zullo ⁽¹⁾ - Valeria Allizond ⁽²⁾ - Rossana Cavallo ⁽¹⁾ - Cristina Costa ⁽¹⁾	255

Laboratorio di Microbiologia e Virologia, Città della Salute e della Scienza di Torino, Torino, Italia ⁽¹⁾ - Laboratorio di Batteriologia e Micologia, Dipartimento di Scienze della Sanità Pubbliche e Pediatriche- UNIVERSITA' DI TORINO, Torino, Italia ⁽²⁾	255
51 - Cutaneous staphylococcal infection in immunocompromised site during nivolumab treatment for non-small cell lung cancer: a first case report.....	256
Terenzio Cosio ⁽¹⁾ - Elena Campione ⁽²⁾ - Gaetana Costanza ⁽³⁾ - Sandro Grelli ⁽³⁾ - Eleonora Andreassi ⁽³⁾ - Valeria Flammini ⁽⁴⁾ - Francesca Pica ⁽¹⁾ - Roberta Gaziano ⁽¹⁾	256
Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Roma, Italia ⁽¹⁾ - Department of Systems Medicine, Dermatology Unit, Tor Vergata University Hospital, 00133 Rome, Italy;; Department of Systems Medicine, Dermatology Unit, Tor Vergata University Hospital, 00133 Rome, Italy;; Roma, Italia ⁽²⁾ - Microbiology and Virology Lab, Tor Vergata University Hospital, V.le Oxford, 81 00133, Rome, Italy., Microbiology and Virology Lab, Tor Vergata University Hospital, V.le Oxford, 81 00133, Rome, Italy., Roma, Italia ⁽³⁾ - Department of Systems Medicine, Oncology Unit, Tor Vergata University Hospital Foundation, 00133 Rome, Italy, Department of Systems Medicine, Oncology Unit, Tor Vergata University Hospital Foundation, 00133 Rome, Italy, Roma, Italia ⁽⁴⁾	256
54 - Introduction of probiotic-based sanitation in the emergency ward of a children's hospital during the COVID-19 pandemic	258
Maria D'Accolti ⁽¹⁾ - Irene Soffritti ⁽¹⁾ - Carolina Cason ⁽²⁾ - Giuseppina Campisciano ⁽²⁾ - Sante Mazzacane ⁽³⁾ - Francesca Bini ⁽¹⁾ - Eleonora Mazziga ⁽¹⁾ - Manola Comar ⁽²⁾ - Elisabetta Caselli ⁽¹⁾	258
Università degli Studi di Ferrara, Dip. Scienze Chimiche, Farmaceutiche ed Agrarie, Ferrara, Italia ⁽¹⁾ - I.R.C.C.S materno infantile Burlo Garofolo, Microbiologia avanzata traslazionale, Trieste, Italia ⁽²⁾ - Università degli Studi di Ferrara-, CIAS Centro Ricerca, Ferrara, Italia ⁽³⁾	258
55 - Genomic fingerprinting of a Mycobacterium bovis BCG causing a severe vertebral osteomyelitis following BCG instillation in a bladder cancer patient	259
Giulia Codda ⁽¹⁾ - Edward Willison ⁽²⁾ - Giuliana Carrega ⁽³⁾ - Ramona Barbieri ⁽²⁾ - Anna Marchese ⁽²⁾ - Vincenzo Di Pilato ⁽¹⁾	259
Università di Genova, Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate, Genova, Italia ⁽¹⁾ - Ospedale Policlinico San Martino-IRCCS, UO Microbiologia, Genova, Italia ⁽²⁾ - ASL2 Pietra Ligure, UO Malattie infettive osteo-articolari, Albenga, Italia ⁽³⁾	259
64 - Antimicrobial activity of WMR-K against Neisseria meningitidis	260
Alessia Stornaiuolo ⁽¹⁾ - Chiara Pagliuca ⁽²⁾ - Elena Scaglione ⁽³⁾ - Giuseppe Mantova ⁽²⁾ - Valeria Caturano ⁽⁴⁾ - Martina Di Rosario ⁽²⁾ - Roberta Colicchio ⁽⁵⁾ - Annarita Falanga ⁽⁶⁾ - Mariateresa Vitiello ⁽⁵⁾ - Stefania Galdiero ⁽⁷⁾ - Paola Salvatore ⁽⁸⁾	260
University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., University of Naples Federico II, Dpt. of Chem., Mat. and Ind. Prod. Eng., University of Naples Federico II, Naples, Italia ⁽¹⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italia ⁽²⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Chem., Mat. and Ind. Prod. Eng., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. F edericoll, Naples, Italia ⁽³⁾ - University of Naples Federico II, Dpt. of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italia ⁽⁴⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federicoll, Naples, Italia ⁽⁵⁾ - University of Naples Federico II, Department of Agriculture, University of Naples Federico II, Naples,	

Italia ⁽⁶⁾ - University of Naples Federico II, Department of Pharmacy, University of Naples Federico II, Naples, Italia ⁽⁷⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. FedericoII, CEINGE, Task Force on Microbiome Studies, Naples, Italia ⁽⁸⁾	260
65 - Effect of pomegranate peel extracts against ESKAPE	262
Valeria Caturano ⁽¹⁾ - Alessia Stornaiuolo ⁽²⁾ - Giuseppe Mantova ⁽³⁾ - Elena Scaglione ⁽⁴⁾ - Chiara Pagliuca ⁽³⁾ - Denise D'Orio ⁽¹⁾ - Erika Zarrillo ⁽¹⁾ - Antonietta Massaro ⁽¹⁾ - Caterina Pagliarulo ⁽⁵⁾ - Daniela Sateriale ⁽⁵⁾ - Mariateresa Vitiello ⁽⁶⁾ - Roberta Colicchio ⁽⁶⁾ - Paola Salvatore ⁽⁷⁾	262
University of Naples Federico II, Dpt. of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italia ⁽¹⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., University of Naples Federico II, Dpt. of Chem., Mat. and Ind. Prod. Eng., University of Naples Federico II, Naples, Italia ⁽²⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italia ⁽³⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Chem., Mat. and Ind. Prod. Eng., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. F ederico II, Naples, Italia ⁽⁴⁾ - University of Sannio, Benevento, Department of Sciences and Technologies, University of Sannio, Benevento, Italia ⁽⁵⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federicoll, Naples, Italia ⁽⁶⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federicoll, CEINGE, Task Force on Microbiome Studies, Naples, Italia ⁽⁷⁾	262
66 - Quality assessment of surface and groundwaters in Lombardy, Italy: detection and characterization of ESBLs-producing Enterobacterales.....	264
Aurora Piazza ⁽¹⁾ - Aseel AbuAlshaar ⁽¹⁾ - Antonietta Grosso ⁽¹⁾ - Francesca Piscopiello ⁽¹⁾ - Melissa Spalla ⁽¹⁾ - Michela Sturini ⁽²⁾ - Federica Maraschi ⁽²⁾ - Giorgio Pilla ⁽³⁾ - Roberta Migliavacca ⁽¹⁾	264
Università di Pavia, Dipartimento di Scienze Clinico Chirurgiche Diagnostiche e Pediatriche, Pavia, Italia ⁽¹⁾ - Università di Pavia, Dipartimento di Chimica, Pavia, Italia ⁽²⁾ - Università di Pavia, Dipartimento di Scienze della Terra e dell'Ambiente, Pavia, Italia ⁽³⁾	264
69 - The protein HslJ boosts Acinetobacter baumannii survival against oxidative stress.....	265
Daniela Scribano ⁽¹⁾ - Meysam Sarshar ⁽²⁾ - Carlo Zagaglia ⁽¹⁾ - Anna Teresa Palamara ⁽³⁾ - Cecilia Ambrosi ⁽⁴⁾	265
Università Sapienza di Roma, Department of Public Health and Infectious Diseases, Roma, Italia ⁽¹⁾ - 2Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, Roma, Italia ⁽²⁾ - Sapienza University of Rome, Department of Public Health and Infectious Diseases, Laboratory Affiliated to Institute Pasteur Italia-Cenci Bolognetti, Roma, Italia ⁽³⁾ - San Raffaele Open University, IRCCS, Rome, Department of Human Sciences and Promotion of the Quality of Life, Roma, Italia ⁽⁴⁾	265
72 - Antimicrobial resistance during COVID-19 pandemic: microbial surveillance at "Cristo Re" Hospital during 2020-2021	266
Camilla Bitossi ⁽¹⁾ - Arcangelo Schiattarella ⁽¹⁾ - Letizia Luconi ⁽¹⁾ - Marco Crobeddu ⁽¹⁾ - Elvira Macale ⁽¹⁾ - Gabriella Nasi ⁽²⁾ - Ornella De Pità ⁽¹⁾	266
Clinical analysis laboratory, "Cristo Re" Hospital, Roma, Italia ⁽¹⁾ - Clinical Management Staff, "Cristo Re" Hospital, Roma, Italia ⁽²⁾	266
74 - Antibacterial and antibiofilm activity in artificial sputum medium of Lactobacilli against Pseudomonas aeruginosa strains isolated from CF patients	267

Giuseppantonio Maisetta ⁽¹⁾ - Elisa Catelli ⁽¹⁾ - Easingül Kaja ⁽¹⁾ - Semih Esin ⁽¹⁾ - Giovanna Batoni ⁽¹⁾	267
Università di Pisa, Dip. di Ricerca Traslationale e delle nuove Tecnologie in Medicina e Chirurgia, Pisa, Italia ⁽¹⁾	267
77 - The One-year Comparative study between molecular and cultural cutaneous swab tests during surveillance program of Candida auris in ICUs of San Martino Hospital (July 2021-July 2022)	268
Giulia Coddà ⁽¹⁾ - Edward Willison ⁽²⁾ - Paola Morici ⁽²⁾ - Vincenzo Di Pilato ⁽¹⁾ - Anna Marchese ⁽¹⁾	268
Università di Genova, Dipartimento di Scienze Chirurgiche Diagnostiche e Integrate (DISC), Genova, Italia ⁽¹⁾ - Policlinico San Martino, U.O. Microbiologia, Genova, Italia ⁽²⁾	268
78 - Development, characterization and antibacterial activity of polyether-co-amide matrix films incorporating choline-calixarene nanoassembly	269
Loredana Ferreri ⁽¹⁾ - Grazia M.L. Consoli ⁽¹⁾ - Paola Bernardo ⁽²⁾ - Gabriele Clarizia ⁽²⁾ - Giovanna Ginestra ⁽³⁾ - Maria L. Giuffrida ⁽⁴⁾ - Giuseppe Granata ⁽¹⁾ - Daniela Zampino ⁽⁵⁾ - Stefania Zimbone ⁽⁴⁾ - Antonia Nostro ⁽³⁾	269
CNR, Institute of Biomolecular Chemistry, Catania, Italia ⁽¹⁾ - CNR, Institute on Membrane Technology, Rende (CS), Italia ⁽²⁾ - University of Messina, Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, Messina, Italia ⁽³⁾ - CNR, Institute of Crystallography, Catania, Italia ⁽⁴⁾ - CNR, Institute of Polymers, Composites and Biomaterials, Catania, Italia ⁽⁵⁾	269
79 - Antimicrobial effectiveness of ozonated olive and sunflower seeds oils	270
Silvia Puxeddu ⁽¹⁾ - Sarah Vascellari ⁽¹⁾ - Ilenia Delogu ⁽¹⁾ - Giuseppe Pala ⁽²⁾ - Alessandra Scanu ⁽³⁾ - Guido Ennas ⁽³⁾ - Aldo Manzin ⁽¹⁾ - Fabrizio Angius ⁽¹⁾	270
Università degli studi di Cagliari, Dipartimento di Scienze Biomediche, Cagliari, Italia ⁽¹⁾ - AOU Policlinico "D. Casula", Applied Microbiology Lab, Monserrato, Italia ⁽²⁾ - Università degli studi di Cagliari, Dipartimento di scienze chimiche e geologiche, Cagliari, Italia ⁽³⁾	270
82 - Epidemiology of bloodstream infections and mortality rates in patients admitted to the Intensive Care Unit in the pandemic era	271
Nadia Marascio ⁽¹⁾ - Angela Quirino ⁽¹⁾ - Luigia Gallo ⁽¹⁾ - Giuseppe Guido Maria Scarlata ⁽¹⁾ - Claudia Cicino ⁽¹⁾ - Giorgio Settimo Barreca ⁽¹⁾ - Aida Giancotti ⁽¹⁾ - Giovanni Matera ⁽¹⁾	271
Università degli Studi Magna Graecia di Catanzaro, Dipartimento di Scienze della Salute, Catanzaro, Italia ⁽¹⁾	271
83 - Humoral Response to Microbial Biomarkers in Parkinson's disease Patients	272
Seyedesomaye Jasemi (1) - Kai Paulus (2) - Davide Cossu (1) - Elena Rita Simula (1) - Marta Noli (1) - Stefano Ruberto (1)	272
Dipartimento di Scienze Biomediche, Università di Sassari, Università di Sassari, Sassari, Italia (1) - ATS Sardegna, Departement, Sassari, Italia (2)	272
84 - Active surveillance for MDR bacteria and correlation with HCAI in patients attending to a University Hospital: a 5-year retrospective study	273
Angela Quirino ⁽¹⁾ - Nadia Marascio ⁽¹⁾ - Luigia Gallo ⁽¹⁾ - Claudia Cicino ⁽¹⁾ - Giuseppe Guido Maria Scarlata ⁽¹⁾ - Maria Giuseppina Stillitano ⁽¹⁾ - Elettra Mancuso ⁽¹⁾ - Neill James Adams ⁽¹⁾ - Giovanni Matera ⁽¹⁾	273
Università degli Studi Magna Graecia, Dipartimento di Scienze della Salute, Catanzaro, Italia ⁽¹⁾	273
85 - Class-IIc bacteriocins produced by S. salivarius 24SMBc involved in antibacterial activity	274

Gaia Vertillo Aluisio ⁽¹⁾ - Ambra Spitale ⁽¹⁾ - Luca Bonifacio ⁽¹⁾ - Aldo Stivala ⁽¹⁾ - Giuseppe Baglieri ⁽¹⁾ - Renata Scuderi ⁽¹⁾ - Stefania Stefani ⁽¹⁾ - Maria Santagati ⁽¹⁾	274
Università di Catania, Dipartimento di Scienze Biomediche e Biotecnologiche, Catania, Italia ⁽¹⁾	274
89 - Four-Year Environmental Surveillance Program of Legionella spp. in One of Palermo's Largest Hospitals	275
IGNAZIO ARRIGO ⁽¹⁾ - ELENA GALIA ⁽¹⁾ - TERESA FASCIANA ⁽²⁾ - MARIA RITA TRICOLI ⁽²⁾ - MARIO PALERMO ⁽³⁾ - ANNA GIAMMANCO ⁽²⁾	275
LABORATORIO DI RIFERIMENTO REGIONALE PER LA LEGIONELLOSI DI PALERMO, A.O.U.P. P.GIACCONE, PALERMO, Italia ⁽¹⁾ - DIPARTIMENTO PROMISE, A.O.U.P. PAOLO GIACCONE, PALERMO, Italia ⁽²⁾ - ASSESSORATO DELLA SALUTE, UNIVERSITÀ DEGLI STUDI DI PALERMO, PALERMO, Italia ⁽³⁾	275
94 - Occurrence of a KPC-3-producing Klebsiella michiganensis strain in clams	276
SERENA SIMONI ⁽¹⁾ - FRANCESCA LEONI ⁽²⁾ - LAURA VESCHETTI ⁽³⁾ - MARIA CARELLI ⁽⁴⁾ - GIOVANNI MALERBA ⁽³⁾ - MARIA DEL MAR FERNANDEZ LEO ⁽⁵⁾ - ANDREA BRENCIANI ⁽⁶⁾ - GIANLUCA MORRONI ⁽⁶⁾ - ELEONORA GIOVANETTI ⁽⁶⁾ - CARLA VIGNAROLI ⁽¹⁾	276
UNIVERSITÀ POLITECNICA DELLE MARCHE, Department of Life and Environmental Sciences, ANCONA, Italia ⁽¹⁾ - Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, Laboratorio Nazionale di Riferimento (LNR) per il Controllo delle Contaminazioni Batteriche dei Molluschi Bivalvi Vivi, ANCONA, Italia ⁽²⁾ - UNIVERSITÀ DI VERONA, Department of Neurosciences, Biomedicine and Movement Sciences, VERONA, Italia ⁽³⁾ - UNIVERSITÀ DI VERONA, Department of Diagnostics and Public Health, VERONA, Italia ⁽⁴⁾ - UNIVERSITÀ DI VERONA, Department of Diagnostics and Public Health, VERONA, Italia ⁽⁵⁾ - UNIVERSITÀ POLITECNICA DELLE MARCHE, Department of Biomedical Sciences and Public Health, ANCONA, Italia ⁽⁶⁾	276
96 - In silico identification of novel inhibitors targeting the superoxide dismutase from the dental pathogen Streptococcus mutans and counteracting the biofilm formation.....	277
Chiara Varriale ⁽¹⁾ - Umberto Galdiero ⁽¹⁾ - Emanuela Roscetto ⁽¹⁾ - Camilla Esposito ⁽¹⁾ - Maria Rosaria Catania ⁽¹⁾ - Carmen Cerchia ⁽²⁾ - Rosarita Nasso ⁽³⁾ - Rosario Rullo ⁽¹⁾ - Antonio Lavecchia ⁽²⁾	277
Università Federico II di Napoli, Dip. di Medicina Molecolare e Biotecnologie Mediche, Napoli, Italia ⁽¹⁾ - Università Federico II di Napoli, Dip di Farmacia, Napoli, Italia ⁽²⁾ - Università Parthenope di Napoli, Dip. di Scienze Motorie e del Benessere, Napoli, Italia ⁽³⁾	277
98 - HPLC-MS-MS quantification of short-chain fatty acids secreted by probiotic strains	278
Marco Calvigioni ⁽¹⁾ - Andrea Bertolini ⁽²⁾ - Simone Codini ⁽²⁾ - Diletta Mazzantini ⁽¹⁾ - Francesco Celandroni ⁽¹⁾ - Adelaide Panattoni ⁽¹⁾ - Alessandro Saba ⁽²⁾ - Emilia Ghelardi ⁽¹⁾	278
Università di Pisa, Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Pisa, Italia ⁽¹⁾ - Università di Pisa, Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Pisa, Italia ⁽²⁾	278
99 - IQOS vapours decrease Klebsiella pneumoniae growth without compromising lung cells compared to cigarette smoke	279
Virginia Fuochi ⁽¹⁾ - Rosalia Emma ⁽¹⁾ - Massimo Caruso ⁽¹⁾ - Pio Maria Furneri ⁽¹⁾	279
Università degli Studi di Catania, BIOMETEC, Catania, Italia ⁽¹⁾	279
101 - Transcriptomics of VISA Emerging in a genomic context of CA-MRSA Under Teicoplanin Therapy	280
rossella salemi ⁽¹⁾ - Elvira Aguglia ⁽¹⁾ - Alessandra Zega ⁽¹⁾ - Flavia Loverde ⁽¹⁾ - Stefania Stefani ⁽¹⁾ - Viviana Cafiso ⁽¹⁾	280

Università degli studi di Catania, BIOMETEC, Catania, Italia ⁽¹⁾	280
104 - Evaluation of the anti-biofilm activity of four different antibiotics against <i>Staphylococcus aureus</i> strains from ocular infections.....	281
Aseel AbuAlshaar ⁽¹⁾ - Aurora Piazza ⁽¹⁾ - Francesca Piscopiello ⁽¹⁾ - Marta Corbella ⁽²⁾ - Patrizia Cambieri ⁽²⁾ - Carola Mauri ⁽³⁾ - Alessandra Consonni ⁽³⁾ - Sara Rimoldi ⁽⁴⁾ - Chiara Motta ⁽⁵⁾ - Giampiero Pietrocola ⁽⁵⁾ - Roberta Migliavacca ⁽¹⁾	281
University of Pavia, Unit of Microbiology and Clinical Microbiology, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, Pavia, Italia ⁽¹⁾ - Fondazione IRCCS Policlinico San Matteo, U.O.C. Microbiology and Virology, Pavia, Italia ⁽²⁾ - A. Manzoni Hospital ASST Lecco, Microbiology and Virology Unit, Lecco, Italia ⁽³⁾ - ASST Fatebenefratelli Sacco, Laboratory of Clinical microbiology, Virology and Bioemergency diagnostics, Milano, Italia ⁽⁴⁾ - University of Pavia, Unit of Biochemistry, Department of Molecular Medicine, Pavia, Italia ⁽⁵⁾	281
105 - Prevalence and virulence potential of <i>Aeromonas</i> spp. isolated from patients suffering from diarrhea	282
Giulia Bernabè ⁽¹⁾ - Paola Brun ⁽¹⁾ - Giuseppe Di Pietra ⁽²⁾ - Silvia Meneghello ⁽²⁾ - Maria Antonello ⁽²⁾ - Elisabetta Valente ⁽²⁾ - Giampaolo Cordioli ⁽²⁾ - Valeria Besutti ⁽²⁾ - Ignazio Castagliuolo ⁽¹⁾	282
Università degli studi di Padova, Dipartimento di medicina molecolare, Padova, Italia ⁽¹⁾ - Azienda Ospedaliera di Padova, Microbiologia, Padova, Italia ⁽²⁾	282
106 - Spread of Metallo-Beta Lactamase genes: characteristics and diffusion of broad-host range and highly conjugative plasmids.....	283
Gaia Menichincheri ⁽¹⁾ - Valerio Capitani ⁽¹⁾ - Gabriele Arcari ⁽¹⁾ - Federica Sacco ⁽²⁾ - Riccardo Polani ⁽¹⁾ - Francesco Bruno ⁽¹⁾ - Maria Trancassini ⁽³⁾ - Monica Coletti ⁽⁴⁾ - Gianmarco Raponi ⁽³⁾ - Alessandra Carattoli ⁽¹⁾	283
Università La Sapienza, Medicina Molecolare, Roma, Italia ⁽¹⁾ - Università La Sapienza, Policlinico Umberto I (UOC di Microbiologia e Virologia), Roma, Italia ⁽²⁾ - Università La Sapienza, Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽³⁾ - Università La Sapienza, Policlinico Umberto I (laboratorio di microbiologia), Roma, Italia ⁽⁴⁾	283
Spread of Metallo-Beta Lactamase genes: characteristics and diffusion of broad-host range and highly conjugative plasmids	283
108 - Anatomy of pKpQIL, the blaKPC plasmid, and its role in ceftazidime-avibactam resistance.....	284
Gabriele Arcari ⁽¹⁾ - Riccardo Polani ⁽¹⁾ - Francesco Bruno ⁽¹⁾ - Valerio Capitani ⁽¹⁾ - Gaia Menichincheri ⁽¹⁾ - Alessandra Carattoli ⁽¹⁾	284
Sapienza Università di Roma, Dipartimento di Medicina Molecolare, Roma, Italia ⁽¹⁾	284
109 - A new core-genome based typing method for <i>Providencia stuartii</i> : characterization of New Delhi Metallo-Beta-Lactamase-producing strains causing an outbreak.....	285
Valerio capitani ⁽¹⁾ - gabriele arcari ⁽¹⁾ - federica sacco ⁽²⁾ - riccardo polani ⁽¹⁾ - francesco bruno ⁽¹⁾ - federico cecilia ⁽¹⁾ - gaia menichincheri ⁽¹⁾ - giammarco raponi ⁽³⁾ - alessandra carattoli ⁽¹⁾	285
la sapienza, dipartimento di medicina molecolare, roma, Italia ⁽¹⁾ - Complex Operating Unit of Microbiology and Virology, Policlinico Umberto I, roma, Italia ⁽²⁾ - Sapienza University of Rome, , Sapienza University of Rome, Rome, ItalyDept. of Public Health and Infectious Diseases, roma, Italia ⁽³⁾	285
A new core-genome based typing method for <i>Providencia stuartii</i>: characterization of New Delhi Metallo-Beta-Lactamase-producing strains causing an outbreak	285

112 - Study of Acinetobacter species resistance patterns and virulence	287
in a multidisciplinary hospital.....	287
Carmen-Sarah Costinas ⁽¹⁾ - Mihaela Elena Idomir ⁽¹⁾ - Orietta Massidda ⁽²⁾	287
Faculty of Medicine, Transilvania University of Brasov, Microbiology department, Brasov, Romania ⁽¹⁾ - University of Trento, Italy, Department of Cellular Computational and Integrative Biology, Center of Medical Sciences (CISMed), Trento, Italia ⁽²⁾	287
117 - Activity of cell-free supernatants from probiotic Lactobacillus strains against Pseudomonas aeruginosa from cystic fibrosis patients.....	288
Esingül Kaya ⁽¹⁾ - Arianna Pompilio ⁽²⁾ - Elisa Catelli ⁽¹⁾ - Giuseppantonio Maisetta ⁽¹⁾ - Veronica Lupetti ⁽²⁾ - Giovanni Di Bonaventura ⁽²⁾ - Semih Esin ⁽¹⁾ - Giovanna Batoni ⁽¹⁾	288
University of Pisa, Translational Research and New Technologies in Medicine and Surgery, Pisa, Italia ⁽¹⁾ - "G. d'Annunzio" University of Chieti-Pescara, Medical, Oral and Biotechnological Sciences, and Center of Advanced Studies and Technologies (CAST), Chieti, Italia ⁽²⁾	288
120 - Antibiofilm activity of Moringa oleifera Lam. leaf extracts by Scanned Electron Microscopy visualization against Xanthomonas campestris pv. campestris	289
Riccardo Fontana ⁽¹⁾ - Anna Caproni ⁽¹⁾ - Chiara Nordi ⁽¹⁾ - Marco Marzola ⁽¹⁾ - Mattia Buratto ⁽¹⁾ - Francesca Salvatori ⁽¹⁾ - Mariangela Pappadà ⁽¹⁾ - Mariaconcetta Sicurella ⁽²⁾ - Peggy Marconi ⁽¹⁾	289
Università degli Studi di Ferrara, Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie, Ferrara, Italia ⁽¹⁾ - Università degli Studi di Ferrara, Dipartimento di Scienze dell'Ambiente e della Prevenzione, Ferrara, Italia ⁽²⁾	289
121 - Effects on Xanthomonas campestris pv. campestris by Moringa oleifera Lam. leaf fermented extracts	290
Anna Caproni ⁽¹⁾ - Riccardo Fontana ⁽¹⁾ - Chiara Nordi ⁽¹⁾ - Marco Marzola ⁽¹⁾ - Mattia Buratto ⁽¹⁾ - Francesca Salvatori ⁽¹⁾ - Mariangela Pappadà ⁽¹⁾ - Anna Baldisserotto ⁽²⁾ - Stefano Manfredini ⁽²⁾ - Raissa Buzzi ⁽²⁾ - Peggy Marconi ⁽¹⁾	290
Università degli Studi di Ferrara, Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie, Ferrara, Italia ⁽¹⁾ - Università degli Studi di Ferrara, Dipartimento di Scienze della Vita e Biotecnologie, Ferrara, Italia ⁽²⁾	290
122 - A fast microbiology experience in a Southern Italy hospital: a diagnostic stewardship approach..	291
Maria Teresa Della Rocca ⁽¹⁾ - Vittorio Panetta ⁽¹⁾ - Adriana Durante ⁽¹⁾ - Stefano Labella ⁽¹⁾ - Giuseppe Carfora Lettieri ⁽¹⁾ - Filomena Merola ⁽¹⁾ - Rita Greco ⁽¹⁾	291
UOSD Microbiologia, AORN Sant'Anna e San Sebastiano, Caserta, Italia ⁽¹⁾	291
125 - A case report of oral candidiasis in an immunocompetent patient.....	292
Case report: Disseminated cryptococcus neoformans in an immunocompetent patient.	292
GIUSEPPE GRECO ^{1,2} , FRANCESCO FOGLIA ^{1,2} , ENRICA SERRETIELLO ^{1,2} , FRANCESCA BORRELLI ^{1,2} , ROSADEA ZIMBARDI ^{1,2} , RAFFAELE VISCARDI ^{1,2} , DANIELA FONTANELLA ^{1,2} , CONCETTA BENTIVOGLIO ¹ , MONTELLA FORTUNATO ¹ , VALERIA CRUDELE ¹ , EMILIANA FINAMORE ¹ , MASSIMILIANO GALDIERO ^{1,2}	292
126 - Comparison of Loop Mediated Amplification (LAMP) and quantitative Real Time PCR (qRT-PCR) methods for the routine detection of Pneumocystis jirovecii.	293
Neill Adams ⁽¹⁾ - Nadia Marascio ⁽¹⁾ - Aida Giancotti ⁽¹⁾ - Marta Pantanella ⁽¹⁾ - Giuseppe De Angelis ⁽¹⁾ - Mariangela Cassadonte ⁽¹⁾ - Michele Manno ⁽¹⁾ - Grazia Pavia ⁽¹⁾ - Francesca Divenuto ⁽¹⁾ - Angela Quirino ⁽¹⁾ - Giovanni Matera ⁽¹⁾	293

Università degli Studi Magna Graecia, Dip di Scienza della Salute, U.O.C. Microbiologia, Catanzaro, Italia ⁽¹⁾	293
130 - INCREASE OF KPC-PRODUCING KLEBSIELLA PNEUMONIAE IN A NEONATAL INTENSIVE CARE UNIT: A THREE- YEARS EVALUATION	294
VALENTINA COSTANZO ⁽¹⁾ - FEDERICA OCCHIPINTI ⁽¹⁾ - GIUSEPPE PEPE ⁽¹⁾ - FABRIZIO PUGLISI ⁽¹⁾ - NICOLETTA SEVERINO ⁽¹⁾ - CRISTIAN LEMBO ⁽¹⁾ - ADRIANA DI MAURO ⁽¹⁾	294
AZIENDA OSPEDALIERA, AZIENDA OSPEDALIERA POLICLINICO-SAN MARCO, CATANIA, Italia ⁽¹⁾	294
131 - Human infection by Trichostrongylus spp. in an immigrant patient living in an asylum seekers center in Southern Italy	295
Marianna Marangi ⁽¹⁾ - Fabio Arena ⁽¹⁾ - Maurizio Margaglione ⁽¹⁾ - Rossella De Nittis ⁽²⁾	295
Università di Foggia, Dipartimento di Medicina Clinica e Sperimentale, Foggia, Italia ⁽¹⁾ - Azienda Ospedaliero-Universitaria "Policlinico Riuniti", Foggia, SSVD Microbiologia e Virologia, Foggia, Italia ⁽²⁾	295
136 - Bacteria from the vaginal microbiota cause suppurative hysteritis/pelvic inflammation in mice treated with estrogens	296
Elisa Lazzeri ⁽¹⁾ - Elena Pettini ⁽¹⁾ - Lorenzo Leoncini ⁽¹⁾ - Francesco Iannelli ⁽¹⁾ - Gianni Pozzi ⁽¹⁾	296
Università degli Studi di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽¹⁾	296
138 - Antibiofilm activity of Ciprofloxacin-loaded niosomes.	297
Linda Maurizi ⁽¹⁾ - Maria Grazia Ammendolia ⁽²⁾ - Jacopo Forte ⁽³⁾ - Maria Gioia Fabiano ⁽³⁾ - Carlo Zagaglia ⁽¹⁾ - Maria Pia Conte ⁽¹⁾ - Antonietta Lucia Conte ⁽¹⁾ - Catia Longhi ⁽¹⁾	297
"Sapienza" Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽¹⁾ - Istituto Superiore di Sanità, Centro Nazionale Tecnologie Innovative in Sanità Pubblica, Roma, Italia ⁽²⁾ - "Sapienza" Università di Roma, Dipartimento di Chimica e Tecnologie del Farmaco, Roma, Italia ⁽³⁾ ..	297
144 - Cryptococcal Meningitis	298
ALESSIA FILOSA ⁽¹⁾ - DE ROSA PAOLA ⁽¹⁾ - IMMACOLATA ABAGNALE ⁽¹⁾ - ANTONIO PACIOLLA ⁽¹⁾ - ITALO GRIMALDI ⁽¹⁾ - FRANCESCA FEROCCE ⁽¹⁾ - ENRICO PUNZO ⁽¹⁾	298
ASL NAPOLI 3 SUD, U.O.C Patologia clinica OO.RR. Area Stabiese, CASTELLAMMARE DI STABIA, Italia ⁽¹⁾	298
147 - Effect of Vitamin C on dormant states of Helicobacter pylori	299
Paola Di Fermo ⁽¹⁾ - Silvia Di Lodovico ⁽¹⁾ - Emanuela Di Campi ⁽¹⁾ - Sara D'Arcangelo ⁽¹⁾ - Luigina Cellini ⁽¹⁾ - Mara Di Giulio ⁽¹⁾	299
Università "G.d'Annunzio" Chieti-Pescara, Dipartimento di Farmacia, Chieti, Italia ⁽¹⁾	299
148 - Mechanisms involved in the reversal of antimicrobial resistance in Acinetobacter baumannii by albumin nanoparticles	300
SARA SCUTERA ⁽¹⁾ - ROSARIA SPARTI ⁽¹⁾ - FRANCESCA MENOTTI ⁽¹⁾ - MONICA ARGENZIANO ⁽²⁾ - STEFANIA RAIMONDO ⁽³⁾ - ILARIO FERROCINO ⁽⁴⁾ - GABRIELE BIANCO ⁽⁵⁾ - ROBERTA CAVALLI ⁽²⁾ - TIZIANA MUSSO ⁽¹⁾	300
UNIVERSITA' DI TORINO, DIPARTIMENTO DI SCIENZE DELLA SANITA' PUBBLICA E PEDIATRICHE, TORINO, Italia ⁽¹⁾ - UNIVERSITA' DI TORINO, DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, TORINO, Italia ⁽²⁾ - UNIVERSITA' DI TORINO, DIPARTIMENTO DI SCIENZE CLINICHE E BIOLOGICHE, TORINO, Italia ⁽³⁾ - UNIVERSITA' DI TORINO, Dipartimento di Scienze Agrarie, Forestali e Alimentari,	

GRUGLIASCO (TO), Italia ⁽⁴⁾ - AUO CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO, UNITA' DI MICROBIOLOGIA E VIROLOGIA, TORINO, Italia ⁽⁵⁾	300
--	-----

Mechanisms involved in the reversal of antimicrobial resistance in *Acinetobacter baumannii* by albumin nanoparticles..... 300

152 - Complete Genome Sequence of <i>Lactobacillus crispatus</i> Type Strain ATCC 33820	302
---	-----

Elisa Lazzeri ⁽¹⁾ - Lucia Teodori ⁽¹⁾ - Lorenzo Colombini ⁽¹⁾ - AnnaMaria Cuppone ⁽¹⁾ - David Pinzauti ⁽¹⁾ - Francesco Santoro ⁽¹⁾ - Gianni Pozzi ⁽¹⁾ - Francesco Iannelli ⁽¹⁾	302
--	-----

Università degli Studi di Siena, Dipartimento di Biotechnologie Mediche, Siena, Italia ⁽¹⁾	302
---	-----

156 - Antimicrobial and antivirulence effects of Hop extract against multi-drug resistant <i>Staphylococci</i> strains and <i>Cutibacterium acnes</i>	303
---	-----

Silvia Di Lodovico ⁽¹⁾ - Simonetta D'Ercole ⁽²⁾ - Firas Diban ⁽¹⁾ - Sara D'Arcangelo ⁽¹⁾ - Emanuela Di Campli ⁽¹⁾ - Lucinda Bessa ⁽³⁾ - Luigina Cellini ⁽¹⁾ - Mara Di Giulio ⁽¹⁾	303
--	-----

University "G. d'Annunzio" Chieti-Pescara, Department of Pharmacy, Chieti, Italia ⁽¹⁾ - University "G. d'Annunzio" Chieti-Pescara, Department of Medical, Oral and Biotechnological Sciences, Chieti, Italia ⁽²⁾ - Centro de Investigação Interdisciplinar Egas Moniz, IUEM/CiEM, Almada, Portogallo ⁽³⁾	303
---	-----

159 - The administration of <i>Enterococcus faecium</i> SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice	304
--	-----

Adelaide Panattoni ⁽¹⁾ - Marco Calvigioni ⁽¹⁾ - Laura Benvenuti ⁽²⁾ - Vanessa D'Antongiovanni ⁽²⁾ - Carolina Pellegrini ⁽²⁾ - Clelia Di Salvo ⁽²⁾ - Diletta Mazzantini ⁽¹⁾ - Francesco Celandroni ⁽¹⁾ - Matteo Fornai ⁽²⁾ - Luca Antonioli ⁽²⁾ - Emilia Ghelardi ⁽¹⁾	304
---	-----

Università di Pisa, Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Pisa, Italia ⁽¹⁾ - Università di Pisa, Dipartimento di Medicina Clinica e Sperimentale, Pisa, Italia ⁽²⁾	304
--	-----

161 - <i>Klebsiella pneumoniae</i> ST37: a never-ending story	305
---	-----

Riccardo Polani ⁽¹⁾	305
--------------------------------------	-----

Università di Roma, "La Sapienza", Policlinico Umberto I, Università di Roma, "La Sapienza", Roma, Italia ⁽¹⁾	305
--	-----

<i>Klebsiella pneumoniae</i> ST37: a never-ending story	305
---	-----

166 - Antibacterial efficacy of glycine airflow and hyaluronic acid-vehicled antibiotic mixture on contaminated titanium surfaces of dental osseointegrated implants	306
--	-----

Janira Roana ⁽¹⁾ - Lorenza Cavallo ⁽¹⁾ - Mario Alovise ⁽²⁾ - Massimo Carossa ⁽²⁾ - Enrico Pira ⁽¹⁾ - Maria Grazia Putzu ⁽³⁾ - Davide Bosio ⁽³⁾ - Ilaria Roato ⁽²⁾ - Federico Mussano ⁽²⁾ - Nicola Scotti ⁽²⁾ - Narcisa Mandras ⁽¹⁾	306
---	-----

Università degli Studi di Torino, Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Torino, Italia ⁽¹⁾ - Università degli Studi di Torino, Dipartimento di Scienze Chirurgiche-CIR Dental School, Torino, Italia ⁽²⁾ - Unità di Medicina Occupazionale, A.O.U. Città della Salute e della Scienza, Torino, Italia ⁽³⁾	306
---	-----

172 - Comparative evaluation of antimicrobial, antiamebic, and antiviral efficacy of ophthalmic formulations	307
--	-----

Martina Pannetta ⁽¹⁾ - Daniela Eletto ⁽¹⁾ - Ciro Caruso ⁽²⁾ - Alessandra Tosco ⁽¹⁾ - Amalia Porta ⁽¹⁾	307
--	-----

Università degli studi di Salerno, Dipartimento di Farmacia, Fisciano, Italia ⁽¹⁾ - Ospedale, Ospedale "Pellegrini", Napoli, Italia ⁽²⁾	307
---	-----

173 - Nocardia infections in a University Hospital in NorthEast Italy	308
Giampaolo Cordioli ⁽¹⁾ - Giuseppe Di Pietra ⁽¹⁾ - Shirin Asa'ad ⁽¹⁾ - Silvia Meneghello ⁽¹⁾ - Ignazio Castagliuolo ⁽¹⁾ - Claudia Del Vecchio ⁽¹⁾ - Ettore De Canale ⁽²⁾ - Antonella Zorzi ⁽²⁾	
Università degli studi di Padova, Università degli studi di Padova, Dipartimento di Medicina Molecolare, Padova, Italia ⁽¹⁾ - Azienda Ospedale Università Padova, Azienda Ospedale Università Padova, UOC Microbiologia e Virologia, Padova, Italia ⁽²⁾	
177 - Characterization of multidrug-resistant <i>Escherichia coli</i> strains isolated from mares with fertility problems.....	310
Francesca Paola Nocera ⁽¹⁾ - Carlo Zagaglia ⁽²⁾ - Linda Maurizi ⁽²⁾ - Antonietta L. Conte ⁽²⁾ - Monica Ambrosio ⁽¹⁾ - Luisa De Martino ⁽³⁾ - Catia Longhi ⁽²⁾	
Università degli Studi di Napoli "Federico II", Dipartimento di Medicina Veterinaria e Produzioni Animali, Napoli, Italia ⁽¹⁾ - Università degli Studi di Roma "La Sapienza", Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽²⁾ - Università degli Studi di Napoli "Federico II", Dipartimento di Medicina Veterinaria e Produzioni Animali, Task Force on Microbiome Studies, Napoli, Italia ⁽³⁾	
Characterization of multidrug-resistant <i>Escherichia coli</i> strains isolated from mares with fertility problems	310
181 - Omic-insights of Ceftazidime-Avibactam resistant <i>Klebsiella pneumoniae</i> clinical isolates.....	312
Dalida A Bivona ⁽¹⁾ - Claudia Cicino ⁽²⁾ - Enrico M Trecarichi ⁽³⁾ - Alessandro Russo ⁽³⁾ - Dafne Bongiorno ⁽¹⁾ - Nadia Marascio ⁽²⁾ - Marilina Mezzatesta ⁽¹⁾ - Nicolò Musso ⁽¹⁾ - Grete Privitera ⁽¹⁾ - Angela Quirino ⁽²⁾ - Giuseppe G.M Scarlata ⁽²⁾ - Giovanni Matera ⁽²⁾ - Carlo Torti ⁽³⁾ - Stefania Stefani ⁽¹⁾	
Università di Catania, Department of Biomedical and Biotechnological Science, Catania, Italia ⁽¹⁾ - Unit of Clinical Microbiology, Department of Health Sciences, "Magna Graecia" University, Catanzaro, Italia ⁽²⁾ - Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italia ⁽³⁾	
183 - Oral hygiene, dietary habits, dental caries experience, and quantitative determination of microbial species with high cariogenic potential in children with autism spectrum disorder.....	314
Esingül Kaya ⁽¹⁾ - Semih Esin ⁽¹⁾ - Francesca Pardossi ⁽²⁾ - Irene Tonacci ⁽²⁾ - Giuseppantonio Maisetta ⁽¹⁾ - Maria Rita Giuca ⁽³⁾ - Giovanna Batoni ⁽¹⁾	
University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italia ⁽¹⁾ - University of Pisa, Unit of Dentistry and Oral Surgery, University Hospital of Pisa, Pisa, Italia ⁽²⁾ - University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, Pisa, Italia ⁽³⁾	
186 - Ceftobiprole non-susceptibility in <i>Enterococcus faecalis</i> is influenced by PBP4 alterations	315
LORENZO M. LAZZARO ⁽¹⁾ - Marta Cassisi ⁽²⁾ - Fabio Longo ⁽¹⁾ - Stefania Stefani ⁽¹⁾ - Floriana Campanile ⁽¹⁾	
Università di Catania, Dipartimento di Scienze Biomediche e Biotechnologiche, Catania, Italia ⁽¹⁾ - Casa di cura, Casa di cura Regina Pacis, Sto arrivando!n Cataldo (CL), Italia ⁽²⁾	
188 - Blastocystis sp. prevalence and subtypes in autochthonous and immigrant patients in a Southern Italy hospital	316
Marianna Marangi ⁽¹⁾ - Daniela Pisanelli ⁽²⁾ - Maurizio Margaglione ⁽¹⁾ - Rossella De Nittis ⁽³⁾	
Università di Foggia, Dipartimento di Medicina Clinica e Sperimentale, Foggia, Italia ⁽¹⁾ - Azienda Ospedaliero-Universitaria "Policlinico Riuniti", SSVD Microbiologia e Virologia, Foggia, Italia ⁽²⁾ -	

Azienda Ospedaliero-Universitaria "Policlinico Riuniti", Foggia, SSVD Microbiologia e Virologia, Foggia, Italia ⁽³⁾	316
MARIANNA MARANGI¹, DANIELA PISANELLI², MAURIZIO MARGAGLIONE¹, ROSSELLA DE NITTIS²	316
190 - In vivo antibacterial activity of disposable gauzes for periocular antisepsis	317
Mariacristina Massimino ⁽¹⁾ - Francesco Celandroni ⁽¹⁾ - Vincenzo Scorcio ⁽²⁾ - Marco Calvigioni ⁽¹⁾ - Diletta Mazzantini ⁽¹⁾ - Adelaide Panattoni ⁽¹⁾ - Sabrina Vaccaro ⁽²⁾ - Giuseppe Giannaccare ⁽²⁾ - Emilia Ghelardi ⁽¹⁾	317
Università di Pisa, Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia, Pisa, Italia ⁽¹⁾ - Università di Catanzaro, Dipartimento di Oftalmologia, Catanzaro, Italia ⁽²⁾	317
192 - Cyano-pyrimidines and enamines as promising scaffolds for antibacterial activity	318
Floriana Campanile ⁽¹⁾ - Fabio Longo ⁽¹⁾ - Lorenzo M. Lazzaro ⁽¹⁾ - Matteo Pappalardo ⁽²⁾ - Vincenzo G. Nicoletti ⁽¹⁾ - Salvatore Guccione ⁽²⁾	318
Università di Catania, Dipartimento di Scienze Biomediche e Biotecnologiche, Catania, Italia ⁽¹⁾ - Università di Catania, Dipartimento di Scienze del Farmaco, Catania, Italia ⁽²⁾	318
196 - Lytic activity of four bacteriophages against planktonic and biofilm <i>Staphylococcus aureus</i> clinical isolates	319
Claudia Campobasso ⁽¹⁾ - Jeroen Wagemans ⁽²⁾ - Daria Bottai ⁽¹⁾ - Arianna Tavanti ⁽¹⁾ - Rob Lavigne ⁽²⁾ - Mariagrazia Di Luca ⁽¹⁾	319
Università di Pisa, Dipartimento di Biologia, Pisa, Italia ⁽¹⁾ - KU Leuven, Department of Biosystems, Leuven, Belgio ⁽²⁾	319
201 - <i>Klebsiella pneumoniae</i> strains resistant to ceftazidime/avibactam and meropenem/vaborbactam: molecular characterization	320
Maddalena Calvo ⁽¹⁾ - Giuseppe Migliorisi ⁽¹⁾ - Dalida Angela Bivona ⁽²⁾ - Francesca Di Bernardo ⁽³⁾ - Alessia Mirabile ⁽¹⁾ - Nicolò Musso ⁽²⁾ - Grete Privitera ⁽²⁾ - Laura Saporito ⁽³⁾ - Laura Sessa ⁽¹⁾ - Dafne Bongiorno ⁽²⁾ - Stefania Stefani ⁽²⁾	320
Università di Catania, U.O.C. Laboratory Analysis, University Hospital Policlinico-San Marco,, Catania, Italia ⁽¹⁾ - Università di Catania, Dipartimento di Scienze Biomediche e Biotecnologiche, Catania, Italia ⁽²⁾ - ARNAS Civico-Di Cristina-Benfratelli, Unit of Clinical Microbiology, Palermo, Italy, Palermo, Italia ⁽³⁾	320
208 - <i>Pleurotus eryngii</i> var. <i>thapsiae</i> a new potential culinary-medicinal mushroom from Sicily with antibiofilm potentiality	322
Teresa Maria Fasciana ⁽¹⁾ - Valeria Ferraro ⁽²⁾ - Fortunato Cirlincione ⁽²⁾ - Gaetano Balenzano ⁽³⁾ - Maria R. Tricoli ⁽¹⁾ - Ignazio Arrigo ⁽¹⁾ - Elena Galia ⁽¹⁾ - Laura Di Paola ⁽¹⁾ - Giuseppe Venturella ⁽¹⁾ - Anna Giammanco ⁽¹⁾	322
University of Palermo, Department of Health Promotion, Maternal-Childhood, Internal Medicine of Excellence 'G. D'Ales-sandro", Palermo, Italia ⁽¹⁾ - University of Palermo, Department of Agricultural, Food and Forest Sciences, Palermo, Italia ⁽²⁾ - University of Bari, University of Bari, Bari, Italia ⁽³⁾	322
210 - Profile of antibacterial activity of <i>Moringa oleifera</i> Lam. single phenols against the phytopathogen <i>Xanthomonas campestris</i> pv. <i>campestris</i>	323
Anna Caproni ⁽¹⁾ - Riccardo Fontana ⁽¹⁾ - Chiara Nordi ⁽¹⁾ - Marco Marzola ⁽¹⁾ - Giulia Trioschi ⁽¹⁾ - Ottavia Bonucelli ⁽¹⁾ - Mariaconcetta Sicurella ⁽²⁾ - Stefano Manfredini ⁽³⁾ - Anna Baldisserotto ⁽³⁾ - Peggy Marconi ⁽¹⁾	323

Università degli Studi di Ferrara, Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie, Ferrara, Italia ⁽¹⁾ - Università degli Studi di Ferrara, Dipartimento di Scienze dell'Ambiente e della Prevenzione, Ferrara, Italia ⁽²⁾ - Università degli Studi di Ferrara, Dipartimento di Scienze della Vita e Biotecnologie, Ferrara, Italia ⁽³⁾	323
212 - Blastocystis sp. subtypes detected from 2016 to 2018 and correlation to intestinal disease.....	324
Adriana Calderaro ⁽¹⁾ - Maria Cristina Angelici ⁽²⁾ - Sara Montecchini ⁽¹⁾ - Giovanna Piccolo ⁽¹⁾ - Sabina Rossi ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Benedetta Farina ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Flora De Conto ⁽¹⁾	324
Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾ - Istituto Superiore di Sanità, Dipartimento Ambiente e Salute, Roma, Italia ⁽²⁾	324
215 - Characterization of fosfomycin-resistance mechanisms in clinical isolates of methicillin-resistant Staphylococcus aureus	325
Noemi Aiezza ⁽¹⁾ - Alberto Antonelli ⁽¹⁾ - Marco Coppi ⁽¹⁾ - Vincenzo Di Pilato ⁽²⁾ - Tommaso Giani ⁽¹⁾ - Gian Maria Rossolini ⁽¹⁾	325
University of Florence, Department of Experimental and Clinical Medicine, Florence, Italia ⁽¹⁾ - University of Genoa, Department of Surgical Sciences and Integrated Diagnostics, Genoa, Italia ⁽²⁾ ...	325
219 - Cupferron, a new promising metal chelator against Candida albicans.....	326
Francesca Palma ⁽¹⁾ - Veronica Folliero ⁽¹⁾ - Annalisa Ambrosino ⁽¹⁾ - Roberta Della Marca ⁽¹⁾ - Rosa Giugliano ⁽¹⁾ - Mariavittoria Morone ⁽¹⁾ - Sara Borrelli ⁽¹⁾ - Anna De Filippis ⁽¹⁾ - Gianluigi Franci ⁽²⁾ - Massimiliano Galdiero ⁽¹⁾	326
Università degli Studi della Campania "Luigi Vanvitelli", Dipartimento di Medicina Sperimentale, Napoli, Italia ⁽¹⁾ - Università degli Studi di Salerno, Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana", Salerno, Italia ⁽²⁾	326
220 - Fourier Transform Infrared (FT-IR) Spectroscopy as new approach to analyze the clonal relationship of Citrobacter koseri and real time outbreak tracing.....	327
Mattia Scarazzai ⁽¹⁾ - Anna Bertoncelli ⁽¹⁾ - Davide Gibellini ⁽¹⁾ - Annarita Mazzariol ⁽¹⁾	327
Università di Verona, Dipartimento di Diagnostica e Sanità Pubblica, Verona, Italia ⁽¹⁾	327
221 - Prevalence and antimicrobial profile of Pseudomonas aeruginosa in clinical isolates collected at Ruggi d'Aragona Hospital in 2015-2019 period.....	328
ENRICA SERRETIELLO ⁽¹⁾ - VERONICA FOLLIERO ⁽¹⁾ - DOMENICO IERVOLINO ⁽²⁾ - ADELE SANTANGELO ⁽¹⁾ - ALESSANDRO PERRELLA ⁽³⁾ - EMANUELA SANTORO ⁽⁴⁾ - VINCENZO CASOLARO ⁽⁴⁾ - MASSIMILIANO GALDIERO ⁽¹⁾ - MARIO CAPUNZO ⁽⁴⁾ - GIANLUIGI FRANCI ⁽⁴⁾ - GIOVANNI BOCCIA ⁽⁴⁾	328
Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", NAPOLI, Italia ⁽¹⁾ - Department of Public Health and Infectious Diseases, Sapienza University of Rome, ROMA, Italia ⁽²⁾ - Division Emerging Infectious Disease and High Contagiousness, OSPEDALE D. COTUGNO, NAPOLI, Italia ⁽³⁾ - Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, BARONISSI, SALERNO, Italia ⁽⁴⁾	328
222 - Biofilm formation, genetic signatures, and antimicrobial resistance profile of Neisseria gonorrhoeae strains	329
Anna Carannante ⁽¹⁾ - Enea Di Domenico ⁽²⁾ - Paola Vacca ⁽¹⁾ - Ilaria Cavallo ⁽³⁾ - Francesca Sivori ⁽³⁾ - Luigina Ambrosio ⁽¹⁾ - Paola Stefanelli ⁽¹⁾	329

Istituto Superiore di Sanità, Department Infectious Diseases, Rome, Italia ⁽¹⁾ - Sapienza University, Department of Biology and Biotechnology "C. Darwin", Rome, Italia ⁽²⁾ - IRCCS San Gallicano Institute, Microbiology and Virology, Rome, Italia ⁽³⁾	329
223 - In vivo evolution of ceftazidime-avibactam and meropenem-vaborbactam resistance in a KPC-producing <i>Klebsiella pneumoniae</i> from meningoencephalitis complicated with brain abscess	331
Marco Coppi ⁽¹⁾ - EMMA PRUNERI ⁽²⁾ - DILETTA BASAGNI ⁽²⁾ - ALBERTO ANTONELLI ⁽¹⁾ - VINCENZO DI PILATO ⁽³⁾ - TOMMASO GIANI ⁽¹⁾ - BRUNO VIAGGI ⁽⁴⁾ - GIAN MARIA ROSSOLINI ⁽¹⁾	331
University of Florence, Department of Experimental and Clinical Medicine, Florence, Italia ⁽¹⁾ - University of Florence, Department of Health Sciences, Florence, Italia ⁽²⁾ - University of Genoa, Department of Surgical Sciences and Integrated Diagnostics, Genoa, Italia ⁽³⁾ - Florence Careggi University Hospital, Department of Anaesthesiology, Neuro Intensive Care Unit, Florence, Italia ⁽⁴⁾ ..	331
228 - Niclosamide as a Repurposing Drug against <i>Corynebacterium striatum</i> Multidrug-Resistant Infections	332
Federica Dell'Annunziata ⁽¹⁾ - Veronica Folliero ⁽¹⁾ - Emanuela Roschetto ⁽²⁾ - Marcella Cammarota ⁽¹⁾ - Federica Carillo ⁽¹⁾ - Anna De Filippis ⁽¹⁾ - Chiara Schiraldi ⁽¹⁾ - Maria Rosaria Catania ⁽²⁾ - Vincenzo Casolaro ⁽³⁾ - Alessandro Perrella ⁽⁴⁾ - Massimiliano Galdiero ⁽¹⁾ - Gianluigi Franci ⁽³⁾	332
University of Campania "Luigi Vanvitelli", Department of Experimental Medicine, Napoli, Italia ⁽¹⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, Napoli, Italia ⁽²⁾ - University of Salerno, Baronissi, Department of Medicine Surgery and Dentistry, Salerno, Italia ⁽³⁾ - Hospital D Cotugno, Division Emerging Infectious Disease and High Contagiousnes, Napoli, Italia ⁽⁴⁾	332
229 - Giving drugs a second chance: identification of drugs active against <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients using a drug repurposing strategy	334
ARIANNA POMPILIO ⁽¹⁾ - VERONICA LUPETTI ⁽¹⁾ - LISA CARIANI ⁽²⁾ - GIOVANNI DI BONAVENTURA ⁽¹⁾ ...	334
Università, Università degli Studi "G. d'Annunzio" di Chieti-Pescara / Dipartimento di Scienze Mediche, Orali e Biotechnologiche, CHIETI, Italia ⁽¹⁾ - Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico/ Fondazione IRCCS Ca' Granda, MILANO, Italia ⁽²⁾	334
230 - T2Bacteria® Panel sensitivity in bone marrow transplanted neutropenic febrile patients	335
Fabio Buffoli ⁽¹⁾ - Pierfrancesco Rizzi ⁽¹⁾ - Enzo Scifo ⁽¹⁾ - Silvia Carletti ⁽²⁾ - Floriana Gona ⁽²⁾ - Davide Carcione ⁽²⁾ - Nicola Clementi ⁽¹⁾ - Nicasio Mancini ⁽¹⁾ - Andrea Acerbis ⁽³⁾ - Edoardo Campodonico ⁽³⁾ - Raffaella Greco ⁽⁴⁾ - Daniela Clerici ⁽⁴⁾ - Massimo Clementi ⁽²⁾ - Fabio Ciceri ⁽³⁾	335
Università Vita-Salute San Raffaele, Università Vita-Salute San Raffaele Laboratorio di Microbiologia e Virologia, Milano, Italia ⁽¹⁾ - IRCCS Ospedale San Raffaele, IRCCS Osepdale San Raffaele Laboratorio di Microbiologia e Virologia, Milano, Italia ⁽²⁾ - Università Vita Salute San Raffaele, Università Vita Salute San Raffaele Unità di Ematologia e Trapianto di Midollo Osseo, Milano, Italia ⁽³⁾ - IRCCS Ospedale San Raffaele, IRCCS Ospedale San Raffaele Unità di Ematologia e Trapianto di Midollo Osseo, Milano, Italia ⁽⁴⁾	335
231 - Preliminary data of the prevalence of <i>Capnocytophaga</i> spp in kennel dogs and feline colonies of North-East Italy: emergent zoonotic bacteria?	336
Elena Spagnolo ⁽¹⁾ - Michela Corrà ⁽¹⁾ - Mery Campalto ⁽¹⁾ - Flavio Sbardellati ⁽²⁾ - Marilena Carrino ⁽¹⁾ - Elisa Mazzotta ⁽¹⁾ - Alda Natale ⁽¹⁾	336
Istituto Zooprofilattico delle Venezie, SCT3 - Diagnostica in sanità animale, Legnaro (PD), Italia ⁽¹⁾ - Azienda Ulss 9 Scaligera, Azienda Ulss 9 Scaligera, Verona (VR), Italia ⁽²⁾	336

234 - Antimicrobial applications of bimetallic nanoparticles by heterogenous green synthesis.....	337
Pragati Rajendra More ⁽¹⁾ - BIANCA MARIA NASTRI ⁽¹⁾ - Annalisa Ambrosino ⁽¹⁾ - Rosa Giuglino ⁽¹⁾ - MARCO MANFREDINI ⁽¹⁾ - ANTONETTA SCHETTINO ⁽¹⁾ - MARIANNA ASCIERTO ⁽¹⁾ - FRANCESCO FOGLIA ⁽¹⁾ - ANNA DE FILIPPIS ⁽¹⁾ - Massimiliano Galderio ⁽¹⁾	
Department of experimental medicine, University of Campania Luigi Vanvitelli, Naples, Italia ⁽¹⁾	337
235 - Repurposing Selamectin as antimicrobial drug against Hospital-Acquired Staphylococcus aureus infections	338
Veronica Folliero ⁽¹⁾ - Federica Dell'Annunziata ⁽¹⁾ - Emanuela Roscetto ⁽²⁾ - Umberto Galdiero ⁽²⁾ - Anna De Filippis ⁽¹⁾ - Gianluigi Franci ⁽³⁾ - Mariarosaria Catania ⁽²⁾ - Massimiliano Galdiero ⁽¹⁾	
University of Campania "Luigi Vanvitelli", Department of Experimental Medicine, Napoli, Italia ⁽¹⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, Napoli, Italia ⁽²⁾ - University of Salerno, Department of Medicine Surgery and Dentistry, Napoli, Italia ⁽³⁾	
237 - In vitro antibacterial and anti-inflammatory activity of Arctostaphylos uva-ursi leaf extract against Propionibacterium acnes.....	339
Roberta Della Marca ⁽¹⁾ - Federica Dell'Annunziata ⁽¹⁾ - Serena A. Maiella ⁽¹⁾ - Stefania Cometa ⁽²⁾ - Francesco Busto ⁽²⁾ - Elvira De Giglio ⁽²⁾ - Gianluigi Franci ⁽³⁾ - Anna De Filippis ⁽¹⁾ - Massimiliano Galdiero ⁽¹⁾	
University of Campania "Luigi Vanvitelli", Department of Experimental Medicine, Napoli, Italia ⁽¹⁾ - University of Bari, Department of Chemistry, Bari, Italia ⁽²⁾ - University of Salerno, Baronissi, Department of Medicine Surgery and Dentistry, Salerno, Italia ⁽³⁾	
239 - Rapid identification of clinically relevant Candida spp. by Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopy.....	340
Roberta Fais ⁽¹⁾ - Cesira Giordano ⁽²⁾ - Maria Rita Calabrese ⁽¹⁾ - Arianna Tavanti ⁽³⁾ - Simona Barnini ⁽²⁾ - Antonella Lupetti ⁽¹⁾	
Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Università di Pisa, Pisa, Italia ⁽¹⁾ - SD Microbiologia Batteriologica, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italia ⁽²⁾ - Dipartimento di Biologia, Università di Pisa, Pisa, Italia ⁽³⁾	
242 - Molecular characterization of linezolid resistance determinants in Staphylococcus epidermidis from invasive infections	341
Ilaria Baccani ⁽¹⁾ - Marco Coppi ⁽¹⁾ - Lorenzo Paci ⁽²⁾ - Alberto Antonelli ⁽¹⁾ - Tommaso Giani ⁽¹⁾ - Orietta Massidda ⁽²⁾ - Gian Maria Rossolini ⁽¹⁾	
University of Florence, Department of Experimental and Clinical Medicine, Florence, Italia ⁽¹⁾ - University of Trento, Department of Cellular, Computational and Integrative Biology (CIBIO), Trento, Italia ⁽²⁾	
245 - Prevalence and Antimicrobial Resistance Profile of Enterococcus Species: A Retrospective Cohort Study in Italy	342
Biagio Santella ⁽¹⁾ - Mariarosaria Boccella ⁽²⁾ - Roberta Manente ⁽¹⁾ - Domenico Iervolino ⁽³⁾ - Andrea Cirino ⁽¹⁾ - Mariagrazia Di Cristo ⁽¹⁾ - Pasquale Pagliano ⁽⁴⁾ - Riccardo Giorgio ⁽⁴⁾ - Luigi Fortino ⁽⁴⁾ - Domenico Pecora ⁽⁴⁾ - Anna Borrelli ⁽⁵⁾ - Massimiliano Galdiero ⁽¹⁾ - Mario Capunzo ⁽⁴⁾ - Gianluigi Franci ⁽⁴⁾ - Giovanni Boccia ⁽⁴⁾	
University of Campania "Luigi Vanvitelli", Section of Microbiology and Virology, University Hospital "Luigi Vanvitelli", Napoli, Italia ⁽¹⁾ - Agostino Gemelli University Hospital IRCCS, Department of	

Laboratory and Infectious Disease Sciences, Agostino Gemelli University Hospital IRCCS, Rome, Italia ⁽²⁾ - Sapienza University of Rome, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italia ⁽³⁾ - University of Salerno, Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Salerno, Italia ⁽⁴⁾ - Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D’Aragona, Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D’Aragona, Salerno, Italia ⁽⁵⁾	342
246 - Bacterial Coinfection and Antibiotic Resistance Profiles among COVID-19 Patients.....	344
Biagio Santella ⁽¹⁾ - Domenico Iervolino ⁽²⁾ - Massimiliano Galdiero ⁽¹⁾ - Mario Capunzo ⁽³⁾ - Gianluigi Franci ⁽³⁾ - Giovanni Boccia ⁽³⁾	344
University of Campania "Luigi Vanvitelli", Section of Microbiology and Virology, University Hospital “Luigi Vanvitelli”, Napoli, Italia ⁽¹⁾ - Agostino Gemelli University Hospital IRCCS, Department of Laboratory and Infectious Disease Sciences, Agostino Gemelli University Hospital IRCCS, Rome, Italia ⁽²⁾ - Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Salerno, Italia ⁽³⁾	344
248 - Carbapenem-resistant and extended-spectrum β -lactamase producing <i>Klebsiella pneumoniae</i> : Prevalence and Antimicrobial Resistance trends in Strains Isolated from Hospital in Italy.....	346
Biagio Santella ⁽¹⁾ - Mariarosaria Boccella ⁽²⁾ - Roberta Manente ⁽¹⁾ - Massimiliano Galdiero ⁽¹⁾ - Mario Capunzo ⁽³⁾ - Gianluigi Franci ⁽³⁾ - Giovanni Boccia ⁽³⁾	346
University of Campania "Luigi Vanvitelli", Section of Microbiology and Virology, University Hospital “Luigi Vanvitelli”, Napoli, Italia ⁽¹⁾ - Agostino Gemelli University Hospital IRCCS, Department of Laboratory and Infectious Disease Sciences, Agostino Gemelli University Hospital IRCCS, Rome, Italia ⁽²⁾ - Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Salerno, Italia ⁽³⁾	346
249 - Identification of new antivirulence compounds active against cystic fibrosis <i>Pseudomonas</i> <i>aeruginosa</i>	348
Arianna Pompilio ⁽¹⁾ - Veronica Lupetti ⁽¹⁾ - Gabriele Carullo ⁽²⁾ - Giuseppe Campiani ⁽²⁾ - Sandra Gemma ⁽²⁾ - Giovanni Di Bonaventura ⁽¹⁾	348
University of Chieti-Pescara "G. d'Annunzio", Department of Medical, Oral and Biotechnological Sciences, Chieti, Italia ⁽¹⁾ - University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Siena, Italia ⁽²⁾	348
250 - Prevalence and Antimicrobial Profile of Causative Agents to Ocular Infections	349
Roberta Manente ⁽¹⁾ - Biagio Santella ⁽¹⁾ - Pasquale Pagliano ⁽²⁾ - Enrica Serrettiello ⁽¹⁾ - Valentina Volpicelli ⁽¹⁾ - Anna Borrelli ⁽³⁾ - Massimiliano Galdiero ⁽¹⁾ - Mario Capunzo ⁽²⁾ - Gianluigi Franci ⁽²⁾ - Giovanni Boccia ⁽²⁾	349
University of Campania "Luigi Vanvitelli", Section of Microbiology and Virology, University Hospital “Luigi Vanvitelli”, Napoli, Italia ⁽¹⁾ - Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Salerno, Italia ⁽²⁾ - Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D’Aragona, Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D’Aragona,, Salerno, Italia ⁽³⁾	349
253 - Antibiotic resistance profiles of microplastics associated microbial communities in the Adriatic Sea	351

255 - A high-resolution melting PCR assay for rapid detection of linezolid-resistance-associated new mutations in <i>Mycobacterium avium</i> complex.....	352
Rosario Musumeci ⁽¹⁾ - Stefania Torri ⁽²⁾ - Marianna Martinelli ⁽¹⁾ - Chiara Giubbi ⁽¹⁾ - Federica Perdoni ⁽¹⁾ - Chiara Vismara ⁽²⁾ - Francesco Scaglione ⁽²⁾ - Clementina E. Cocuzza ⁽¹⁾	352
University of Milano-Bicocca, Department of Medicine and Surgery, Monza (MB), Italia ⁽¹⁾ - ASST Grande Ospedale Metropolitano Niguarda, Unit of Microbiology, Department of Chemical-Clinical and Microbiology Analyses, Milan, Italia ⁽²⁾	352
258 - Biofilm formation, genetic signatures, and antimicrobial resistance profile of <i>Neisseria gonorrhoeae</i> strains	353
Anna Carannante ⁽¹⁾ - Enea Gino Di Domenico ⁽²⁾ - Paola Vacca ⁽¹⁾ - Ilaria Cavallo ⁽³⁾ - Francesca Sivori ⁽³⁾ - Luigina Ambrosio ⁽¹⁾ - Silvia Fillo ⁽⁴⁾ - Florio Lista ⁽⁴⁾ - Paola Stefanelli ⁽¹⁾	353
Istituto Superiore di Sanità, Department Infectious Diseases, Rome, Italia ⁽¹⁾ - Sapienza University, Department of Biology and Biotechnology "C. Darwin", Rome, Italia ⁽²⁾ - IRCCS San Gallicano Institute, Microbiology and Virology, Rome, Italia ⁽³⁾ - Army Medical Center, Scientific Department, Rome, Italia ⁽⁴⁾	353
260 - Dissection of the enigmatic role of Everolimus during <i>Mycobacterium tuberculosis</i> infections.	355
Flavio De Maio ⁽¹⁾ - Delia Mercedes Bianco ⁽²⁾ - Ivana Palucci ⁽²⁾ - Giada Bianchetti ⁽³⁾ - Alessandro Salustri ⁽²⁾ - Giulia Santarelli ⁽²⁾ - Enrica Tamburrini ⁽⁴⁾ - Giuseppe Maulucci ⁽³⁾ - Michela Sali ⁽²⁾ - Giovanni Delogu ⁽⁵⁾	355
Istituto di Microbiologia, Fondazione Policlinico Universitario "A. Gemelli", IRCCS/ Dipartimento di Scienze di Laboratorio e Infettivologiche, Roma, Italia ⁽¹⁾ - Istituto di Microbiologia, Università Cattolica del Sacro Cuore/Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie, Roma, Italia ⁽²⁾ - Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore/Dipartimento di Neuroscienze, Roma, Italia ⁽³⁾ - Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario "A. Gemelli", IRCCS/ Dipartimento di Scienze di Laboratorio e Infettivologiche, Roma, Italia ⁽⁴⁾ - Mater Olbia Hospital, Mater Olbia Hospital/ Istituto di Microbiologia, Olbia, Italia ⁽⁵⁾	355
266 - The mobilome of probiotic <i>Lactobacillus crispatus</i> M247 includes Tn7088 a novel integrative and mobilizable element (IME) carrying a biosynthetic gene cluster for a class I bacteriocin	357
Lorenzo Colombini ⁽¹⁾ - Francesco Santoro ⁽¹⁾ - Nagaia Ciacchi ⁽¹⁾ - Elisa Lazzeri ⁽¹⁾ - Lorenzo Morelli ⁽²⁾ - Francesco Iannelli ⁽¹⁾ - Gianni Pozzi ⁽¹⁾	357
Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽¹⁾ - Università Cattolica del Sacro Cuore, Dipartimento di Scienze e Tecnologie Alimentari per una filiera agro-alimentare Sostenibile, Piacenza, Italia ⁽²⁾	357
267 - Epidemiological trends in Nontuberculous <i>Mycobacteria</i> isolation in the period 2018-2021 in a large tertiary care hospital	358
IVANA PALUCCI ⁽¹⁾ - MARIA DEL CARMEN Pereyra Boza ⁽²⁾ - FRANCESCO PAGLIONE ⁽²⁾ - ENRICA INTINI ⁽³⁾ - ALESSANDRO SALUSTRI ⁽¹⁾ - FLAVIO DE MAIO ⁽¹⁾ - GIULIA SANTARELLI ⁽¹⁾ - MAURIZIO SANGUINETTI ⁽¹⁾ - GIOVANNI DELOGU ⁽¹⁾ - MICHELA SALI ⁽¹⁾	358
Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie- Istituto di Microbiologia, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Roma, ROMA, Italia ⁽¹⁾ - Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie- Istituto di Microbiologia, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Roma, roma, Italia ⁽²⁾ - IRCCS - Policlinico Universitario A. Gemelli, - Roma, UOC Pneumologia, ROMA, Italia ⁽³⁾	358

268 - Shaping the subway microbiome by a probiotic-based sanitation during the COVID-19 emergency	359
Maria D'Accolti ⁽¹⁾ - Irene Soffritti ⁽¹⁾ - Francesca Bini ⁽¹⁾ - Eleonora Mazziga ⁽¹⁾ - Antonella Volta ⁽²⁾ - Matteo Bisi ⁽³⁾ - Sante Mazzacane ⁽³⁾ - Elisabetta Caselli ⁽¹⁾	359
Università degli Studi di Ferrara, Dip. Scienze Chimiche, Farmaceutiche ed Agrarie e LTTA, Ferrara, Italia ⁽¹⁾ - Università degli Studi di Ferrara, CIAS Centro Ricerca, Ferrara, Italia ⁽²⁾ - Università degli Studi di Ferrara-, CIAS Centro Ricerca, Ferrara, Italia ⁽³⁾	359
269 - Peptidoglycan analysis of Streptococcus pneumoniae serotype 19A isolates belonging to the same clonal complex with different susceptibility to beta-lactams in the presence or absence of cefotaxime	360
Dalia Denapaita ⁽¹⁾ - Berenice Furlan ⁽¹⁾ - Jacob Biboy ⁽²⁾ - Joe Gray ⁽²⁾ - Waldemar Vollmer ⁽²⁾ - Orietta Massidda ⁽¹⁾	360
Dipartimento di Biologia Computazionale, Cellulare e Integrata, Università di Trento, Trento, Italia ⁽¹⁾ - Centre for Bacterial Cell Biology, Biosciences Institute, Newcastle University, Newcastle upon Tyne, Regno Unito ⁽²⁾	360
270 - Antibiotic resistance pattern of Staphylococcus spp isolated from blood culture of hospitalized patients during the first and second wave of SARS-Cov2 infection: a single center retrospective analysis	361
Elena Di Prima ⁽¹⁾ - Paola Di Carlo ⁽¹⁾ - Nicola Serra ⁽²⁾ - Maria Andriolo ⁽³⁾ - Vincenza Maria Carelli ⁽³⁾ - Giovanni Mazzola ⁽⁴⁾ - Teresa Rea ⁽²⁾ - Maria R. Tricoli ⁽¹⁾ - Ignazio Arrigo ⁽¹⁾ - Anna Giammanco ⁽¹⁾	361
University of Palermo, Department of Health Promotion, Maternal-Childhood, Internal Medicine of Excellence "G. D'Ales-sandro", Palermo, Italia ⁽¹⁾ - University Federico II of Naples, Department of Public Health, Napoli, Italia ⁽²⁾ - Microbiology Unit, Sant'Elia Hospital, Caltanissetta, Italia ⁽³⁾ - Infectious diseases Unit, Sant'Elia Hospital, Caltanissetta, Italia ⁽⁴⁾	361
271 - Novel strategy against Chlamydiae: EVOO-based extracts.	362
Simone Filardo ⁽¹⁾ - Marisa Di Pietro ⁽¹⁾ - Roberto Mattioli ⁽²⁾ - Luciana Mosca ⁽²⁾ - Rosa Sessa ⁽¹⁾	362
Dipartimento di Sanità Pubblica e Malattie Infettive, Università di Roma "Sapienza", Roma, Italia ⁽¹⁾ - Dipartimento di Scienze Biochimiche, Università di Roma "Sapienza", Roma, Italia ⁽²⁾	362
272 - A new indole derivative dry powder for inhalation inhibits Staphylococcus aureus biofilm formation in vitro.....	363
Samuele Sabbatini ⁽¹⁾ - Styliani Xiroudaki ⁽²⁾ - Camilla Pecoraro ⁽³⁾ - Stella Cascioferro ⁽³⁾ - Patrizia Diana ⁽³⁾ - Nathalie Wauthoz ⁽⁴⁾ - Cinzia Antognelli ⁽⁵⁾ - Stefano Giovagnoli ⁽²⁾ - Aurélie Schoubben ⁽²⁾ - Claudia Monari ⁽¹⁾	363
Università degli Studi di Perugia, Dipartimento di Medicina e Chirurgia, Sezione di Microbiologia Medica, Perugia, Italia ⁽¹⁾ - Università degli Studi di Perugia, Dipartimento di Scienze Farmaceutiche, Perugia, Italia ⁽²⁾ - Università degli Studi di Palermo, Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Palermo, Italia ⁽³⁾ - Université libre de Bruxelles, Unit of Pharmaceutics and Biopharmaceutics, Brussels, Belgio ⁽⁴⁾ - Università degli Studi di Perugia, Dipartimento di Medicina e Chirurgia, Sezione di Bioscienze ed Embriologia Medica, Perugia, Italia ⁽⁵⁾	363
279 - Uncomplicated UTIs and old antimicrobials: a retrospective study on southern Sardinian population	365
giuseppe pala ⁽¹⁾ - Silvia Puxeddu ⁽¹⁾ - Fabrizio Angius ⁽²⁾ - Aldo Manzin ⁽¹⁾	365

Università degli Studi di Cagliari, AOU "D.Casula", Monserrato, Cagliari/Università degli studi di Cagliari/Dipartimento di scienze biomediche, Cagliari, Italia ⁽¹⁾ - Università degli studi di Cagliari, Università degli studi di Cagliari/Dipartimento di scienze biomediche, Cagliari, Italia ⁽²⁾	365
281 - Case report: Disseminated <i>Cryptococcus neoformans</i> in an immunocompetent patient.	366
Giuseppe Greco ⁽¹⁾ - FRANCESCO FOGLIA ⁽¹⁾ - ENRICA SERRETIELLO ⁽¹⁾ - FRANCESCA BORRELLI ⁽¹⁾ - ROSADEA ZIMBARDI ⁽¹⁾ - RAFFAELE VISCARDI ⁽¹⁾ - DANIELA FONTANELLA ⁽¹⁾ - CONCETTA BENTIVOGLIO ⁽¹⁾ - MONTELLA FORTUNATO ⁽¹⁾ - VALERIA CRUDELE ⁽¹⁾ - EMILIANA FINAMORE ⁽¹⁾ - MASSIMILIANO GALDIERO ⁽¹⁾	366
Department of Experimental Medicine, University of Campania, Department of Experimental Medicine, University of Campania, Napoli, Italia ⁽¹⁾	366
283 - Co-infection of <i>Pseudomonas aeruginosa</i> and <i>Achromobacter xylosoxidans</i> in green nail syndrome treated with ozenoxacin: a case report.....	367
Terenzio Cosio ⁽¹⁾ - Rosalba Petruccelli ⁽²⁾ - Roberta Gaziano ⁽¹⁾ - Carla Fontana ⁽³⁾ - Marco Favaro ⁽¹⁾ - Paola Zampini ⁽¹⁾ - Enrico Salvatore Pistoia ⁽¹⁾ - Flavia Lozzi ⁽⁴⁾ - Luca Bianchi ⁽⁴⁾ - Elena Campione ⁽⁴⁾ ...	367
Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Roma, Italia ⁽¹⁾ - Microbiology and Virology Lab, Tor Vergata University Hospital, V.le Oxford, 81 00133, Rome, Italy., Microbiology and Virology Lab, Tor Vergata University Hospital, V.le Oxford, 81 00133, Rome, Italy., Roma, Italia ⁽²⁾ - National Institute for Infectious Diseases (INMI) L. Spallanzani, IRCCS, Rome, Italy, National Institute for Infectious Diseases (INMI) L. Spallanzani, IRCCS, Rome, Italy, Roma, Italia ⁽³⁾ - Department of Systems Medicine, Dermatologic Unit, University of Rome Tor Vergata, Viale Oxford, Rome, Italy;; Department of Systems Medicine, Dermatologic Unit, University of Rome Tor Vergata, Viale Oxford, Rome, Italy;; Roma, Italia ⁽⁴⁾	367
284 - Molecular characterization of <i>Listeria monocytogenes</i> strains isolated from food and human sources.....	369
ANTONELLA COSTA ⁽¹⁾ - ANTONIETTA GATTUSO ⁽²⁾ - TERESA FASCIANA ⁽³⁾ - MARINA TORRESI ⁽⁴⁾ - VINCENZINA ALIO ⁽¹⁾ - MARIA RITA TRICOLI ⁽³⁾ - GASPARE BUTERA ⁽¹⁾ - ANNAMARIA CASTELLO ⁽¹⁾ - FRANCESCO POMILIO ⁽⁴⁾ - ANNA GIAMMANCO ⁽³⁾	369
Istituto Zooprofilattico Sperimentale della Sicilia, Istituto Zooprofilattico Sperimentale della Sicilia, Palermo, Italia ⁽¹⁾ - Istituto Superiore di Sanità, Dipartimento di Sicurezza Alimentare, Nutrizione, Sanità Veterinaria, Istituto Superiore di Sanità, Roma, Roma, Italia ⁽²⁾ - Pro.Mi.Se/Azienda Ospedaliera Universitaria Policlinico P.Giaccone, Palermo, Pro.Mi.Se/Azienda Ospedaliera Universitaria Policlinico P.Giaccone, Palermo, Palermo, Italia ⁽³⁾ - Istituto Zooprofilattico Sperimentale Abruzzo e Molise, LNR per <i>Listeria monocytogenes</i> Istituto Zooprofilattico Sperimentale Abruzzo e Molise, Teramo, Italia ⁽⁴⁾	369

1 Interazione ospite-patogeno

5 - Formyl peptide receptors 1 and 2 are essential vita-PAMP sensors of bacterial pathogens

GERMANA LENTINI⁽¹⁾ - GIUSEPPE VALERIO DE GAETANO⁽¹⁾ - AGATA FAMA⁽¹⁾ - FRANCESCO COPPOLINO⁽²⁾ - GIUSEPPE TETI⁽³⁾ - CONCETTA BENINATI⁽¹⁾

UNIVERSITA' DEGLI STUDI DI MESSINA, DIPARTIMENTO DI PATOLOGIA UMANA E DELL'ETA' EVOLUTIVA G. BARRESI, MESSINA, Italia⁽¹⁾ - UNIVERSITA' DEGLI STUDI DI MESSINA, DIPARTIMENTO DI SCIENZE BIOMEDICHE, ODONTOIATRICHE E DELLE IMMAGINI MORFOLOGICHE E FUNZIONALI, MESSINA, Italia⁽²⁾ - CHARYBDIS VACCINES SRL, UNIVERSITA' DEGLI STUDI DI MESSINA, MESSINA, Italia⁽³⁾

¹*Department of Human Pathology, University of Messina, Messina, Italy;* ²*Department of Biomedical, Dental and Imaging Sciences, University of Messina, Messina, Italy;* ³*Charybdis Vaccines Srl, Messina, Italy;* ⁴*Scylla Biotech Srl, Messina, Italy*

Introduction: Host defense systems are differentially activated by the presence of live versus dead organisms during infection. *Therefore, previous studies have postulated* the existence of a class of Pathogen-Associated Molecular Patterns (PAMPs), called *vita*-PAMPs, that are specifically associated with viable bacteria and are capable of triggering distinctive responses in macrophages and dendritic cells. However, the molecular mechanisms underlying live-dead discrimination in neutrophils, the primary mediators of antibacterial host defenses, are still unknown.

Materials and Methods: We examined the role of Formyl peptide receptor 1 (Fpr1) and 2 (Fpr2), which sense the presence of bacterial *N*-formyl peptides, using mice lacking these receptors in both *in vitro* and *in vivo* models of Group B Streptococcus (GBS) infection.

Results: *In vivo*, Fpr1- and Fpr2-defective mice were more susceptible to GBS infection relative to wild type mice, concomitantly with decreased production of the chemokine (CXC motif) ligand 2 (Cxcl2), impaired neutrophil influx and increased bacterial burden to infection sites. This phenotype was rescued by the exogenous administration of recombinant Cxcl2, but not Cxcl1, indicating that Fpr1/2 signaling is crucially required for robust Cxcl2 responses. *In vitro*, high-level production of Cxcl2 and reactive oxygen species (ROS) in neutrophils was elicited only by live, but not dead bacteria, and required both Fpr1 and Fpr2. Moreover, by systematically testing signal peptide sequences present in databases, we identified two distinctive sets of GBS signal peptides that could recapitulate the induction of high-level Cxcl2 responses when used in combination with toll-like receptor agonists.

Discussion and Conclusions: The simultaneous presence of agonists for Fpr1, Fpr2, and TLRs represents a unique signature associated with viable bacteria, which is sensed by neutrophils and induces high-level Cxcl2 production, Cxcl2-dependent autocrine cell activation and robust bactericidal activity. These results may be relevant to devise new alternative therapeutic strategies aimed at stimulating host defenses against antibiotic-resistant pathogens.

7 - PAD-mediated citrullination provides a new biomarker and an effective target to counteract human papillomavirus transformation

Camilla Albano⁽¹⁾ - Matteo Biolatti⁽¹⁾ - Jasenka Mazibrada⁽²⁾ - Selina Pasquero⁽¹⁾ - Francesca Gugliesi⁽¹⁾ - Gloria Griffante⁽³⁾ - Irene Lo Cigno⁽³⁾ - Elena Cat Genova⁽¹⁾ - Greta Bajetto⁽³⁾ - Santo Landolfo⁽¹⁾ - Marisa Gariglio⁽³⁾ - Marco De Andrea⁽¹⁾ - Valentina Dell'Oste⁽¹⁾

Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Università degli Studi di Torino, Torino, Italia⁽¹⁾ - Dipartimento di Patologia Cellulare, Università di Norfolk e Norwich, Norwich, Regno Unito⁽²⁾ - Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Novara, Italia⁽³⁾

PAD-mediated citrullination provides a new biomarker and an effective target to counteract human papillomavirus transformation

CAMILLA ALBANO¹, MATTEO BIOLATTI¹, JASENKA MAZIBRADA², SELINA PASQUERO¹, FRANCESCA GUGLIESI¹, GLORIA GRIFFANTE³, IRENE LO CIGNO³, ELENA CAT GENOVA¹, GRETA BAJETTO⁴, SANTO LANDOLFO¹, MARISA GARIGLIO³, MARCO DE ANDREA^{1,4}, AND VALENTINA DELL'OSTE¹.

¹Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy

²Department of Cellular Pathology, The Cotman Centre Norfolk and Norwich University Hospital, Colney Lane, Norwich, UK

³Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy

⁴Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Novara, Italy

INTRODUCTION: Citrullination is an emerging post-translational modification catalyzed by peptidyl arginine deiminases (PADs) that convert peptidylarginine into peptidylcitrulline. In humans, the PAD family is composed of five isozymes (PADs 1-4, 6), ubiquitously expressed, and relevant to human diseases, including cancer.

MATERIALS AND METHODS: To characterize protein citrullination in the context of human papillomavirus (HPV) transformation, we took advantage of different *in-vitro* models of persistent high-risk HPV transformation *i.e.*, CaSki and HeLa cells, harboring integrated HPV-16 and HPV-18 DNA, respectively.

RESULTS: We demonstrated that the expression of E6 and E7 HPV oncoproteins is strongly impaired in the presence of the pan-PAD inhibitor BB-CI-Amidine. Consistently, p53 and p21, the main targets of HPV oncoproteins, are upregulated by the PAD inhibitor, indicating that citrullination can be targeted to subvert HPV transformation. The overall citrullination nor the PADs profile are strongly affected by E6 and E7 expression *in-vitro*, but *in-vivo* analyses revealed a significant association between the presence of citrullinated proteins and cervical cancer progression. Interestingly, a higher PAD4, but not PAD2, score has been obtained in high-grade lesions, indicating that PADs could represent new suitable biomarkers for the disease.

DISCUSSION AND CONCLUSIONS: These findings could provide new insights into novel pathways beyond HPV-mediated cervical cancer progression.

13 - Effect of SARS-CoV-2 on the coagulation cascade in COVID-19 associated coagulopathies

Daria Bortolotti⁽¹⁾ - Marcello Baroni⁽²⁾ - Giulia Turrin⁽¹⁾ - Giovanna Schiuma⁽¹⁾ - Silvia Beltrami⁽¹⁾ - Sabrina Rizzo⁽¹⁾ - Claudio Trapella⁽¹⁾ - Roberta Rizzo⁽¹⁾

Università di Ferrara, Dipartimento di Scienze Chimiche, Farmaceutiche ed Agrarie, Ferrara, Italia⁽¹⁾
- Università di Ferrara, Dipartimento di Scienze della Vita e Biotecnologie, Ferrara, Italia⁽²⁾

Effect of SARS-CoV-2 on the coagulation cascade in COVID-19 associated coagulopathies

D. Bortolotti¹, M. Baroni², G. Turrin¹, G. Schiuma¹, S. Beltrami¹, S. Rizzo¹, C. Trapella¹, R. Rizzo¹

¹ Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy - Via Luigi Borsari, 46 - 44121 Ferrara

² Department of Life Sciences and Biotechnology (SVEB), University of Ferrara, Italy, via Fossato di Mortara, 74 - 44121 Ferrara

Background: Coagulation decompensation is one of the most frequent complications encountered in COVID-19 patients. In particular, the onset of thrombi and ischemia are often associated with a poor prognosis. Although the evidence for an association between SARS-CoV2 infection and coagulopathies has been already reported (Levi et al, 2020), to date the mechanism underlying the alteration of the coagulation cascade in some COVID-19 patients remains misunderstood. Recently, protein S (PROS1), an anticoagulant plasma protein involved in the correct homeostasis of the coagulation cascade, has been described as a potential risk factor for complications related to COVID19 (Lemke et al, 2020) and represents a potential target for PLpro SARS-CoV-2 enzyme proteolysis (Ruzika, 2020).

Aim: This study aims to investigate expression patterns in COVID19-associated coagulopathies, to identify possible pharmacological targets, focusing on PROS1 protein alteration.

Methods: Thrombotic, arteriosclerotic plaques, venous \ arterial, perivascular fat samples and blood samples were collected from COVID-positive and COVID-negative subject, and from COVID-positive subjects with no coagulopathies. SARS-CoV-2 presence will be evaluated by Real time PCR and by IHC and gene expression, and ELISA analysis will be performed to identify specific expression profiles associated with coagulation imbalances, with particular attention to protein S (PROS1).

Results and Conclusions: We found substantial differences in the activation of the coagulative cascade, and particularly a significant decrease of PROS1, in the COVID-19 cohort experiencing coagulative disorders, in association with SARS-CoV-2 positivity by IHC and real time PCR. These data suggested that, possibly, SARS-CoV-2 associated thrombotic/ischemic events might involve PROS-1 cleavage by viral PLpro, leading to the loss of its anticoagulant function. Basing on this evidence, the use of PLpro inhibitors might be suggest as a therapeutical tool for COVID-19 coagulopathies.

15 - Vaginal immunization by the human microbiota bacterium *Streptococcus gordonii* expressing a *Chlamydia trachomatis* antigen efficiently primes the immune system in mice

Bar Philosof⁽¹⁾ - Elena Pettini⁽¹⁾ - Fabio Fiorino⁽¹⁾ - Francesco Santoro⁽¹⁾ - Iannelli Francesco⁽¹⁾ - Gianni Pozzi⁽¹⁾

University of Siena, Department of Medical Biotechnologies, Siena, Italia⁽¹⁾

Vaginal immunization by the human microbiota bacterium *Streptococcus gordonii* expressing a *Chlamydia trachomatis* antigen efficiently primes the immune system in mice

Bar Philosof¹, Elena Pettini¹, Fabio Fiorino¹, Francesco Santoro¹, Francesco Iannelli¹, Gianni Pozzi¹

¹Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Introduction: Mucosal surfaces are active immunological interfaces, and as such are promising avenues for vaccines delivery. However, their unique characteristics and the nature of immune system activation in these tissues require the utilization of appropriate adjuvants or delivery systems. Recombinant *Streptococcus gordonii* expressing a heterologous antigen can activate the immune system when delivered mucosally in mice, owing to its colonization capabilities.

Materials and methods: In the present study, we examined whether intravaginal administration of a recombinant *S. gordonii* vector, named FR368, genetically engineered to express the *Chlamydia trachomatis* multivalent MOMP antigen, CTH522, could prime the immune system in a heterologous prime-boost scheme. Antibodies were quantified using ELISA. Presence and number of Antigen-specific Antibody Secreting Cells was quantified using B-cell ELISPOT. Plasma cells were quantified using Flow cytometry, staining for CD138 and TACI. Cytokines were assessed using *in vitro* stimulation of splenocytes, and intracellular cytokines staining using flow cytometry. **Results:** We show that the vaginal colonization itself triggered a systemic antigen-specific IgG response. Heterologous subcutaneous boosting with unadjuvanted CTH522 antigen at either three or six months after vaginal immunization resulted in a marked increase in serum CTH522-specific IgG levels in FR368-immunized mice, compared to WT-immunized ones. Concomitantly, a significant increase in the levels of CTH522-specific antibody secreting cells, alongside a rise in the percentage of plasma cells in the spleen and lymph nodes, respectively, were observed in the FR368-immunized mice. Vaginal colonization with FR368 also induced a shift in cytokines expression profile in antigen-specific T cells upon restimulation, dominated by an IL-17 increased expression, suggesting a mucosal association of antigen first encounter context. **Discussion and conclusions:** Our results highlight the potential of immunization with recombinant *S. gordonii* as a potent mucosal delivery system able to stimulate a systemic immune response in a heterologous prime-boost scheme, which is currently the focus of many vaccines' development.

30 - The two-component SaeRS system controls the interactions of group B streptococci with host cells by modulating PbsP expression

Francesco Coppolino⁽¹⁾ - Giuseppe Valerio De Gaetano⁽²⁾ - Germana Lentini⁽²⁾ - Agata Famà⁽²⁾ - Arnaud Firon⁽³⁾ - Giuseppe Teti⁽⁴⁾ - Concetta Beninati⁽⁵⁾

University of Messina, Department of Biomedical, Dental and Imaging Sciences, Messina, Italia⁽¹⁾ - University of Messina, Department of Human Pathology and Medicine, Messina, Italia⁽²⁾ - Institut Pasteur, Microbiology Department, Biology of Gram-positive pathogens, Parigi, Francia⁽³⁾ - Charybdis Vaccines, Srl, Messina, Italia⁽⁴⁾ - Scylla Biotech, Srl, Messina, Italia⁽⁵⁾

The two-component SaeRS system controls the interactions of group B streptococci with host cells by modulating PbsP expression

Francesco Coppolino¹, Giuseppe Valerio De Gaetano², Germana Lentini², Agata Famà², Arnaud Firon³, Giuseppe Teti⁴, Concetta Beninati^{2,5}

¹Department of Biomedical, Dental and Imaging Sciences, University of Messina, Messina, Italy²Department of Human Pathology and Medicine, University of Messina, Messina, Italy; ³Microbiology Department, Biology of Gram-positive pathogens, Institut Pasteur, Paris, France; ⁴Charybdis Vaccines Srl, Messina, Italy; ⁵Scylla Biotech Srl, Messina, Italy.

Introduction: *Streptococcus agalactiae*, also named Group B *Streptococcus* (GBS), is a commensal Gram-positive bacterium that colonizes the human gastro-intestinal tract and causes invasive infections in neonates, in the elderly and in patients with underlying chronic disease. Two-component signal transduction systems (TCSs), consisting of a sensor (S) histidine kinase and a response regulator (R), enable bacteria to adapt to a wide range of microenvironments. PbsP (Plasminogen binding surface Protein) is an important, highly conserved virulence factor of GBS that is markedly upregulated *in vivo*. This work was undertaken to study the functional role of SaeRS in PbsP regulation and virulence.

Materials and Methods: We introduced a single amino acid mutation in the *saeS* gene (T133A) and a full deletion of the *saeR* gene (Δ *saeR*) to obtain, respectively, constitutionally activated (phosphomimetic) and constitutionally deactivated systems in the background of the representative CC23 serotype III NEM316 strain. In these mutant strains, we have additionally deleted the *pbsP* gene to evaluate its role in these contexts. *In vivo* and *in vitro* gene expression was assessed in the mutants using RT-qPCR.

Results: The SaeS T133A mutant displayed a 100-1000 overexpression of *pbsP*, both at mRNA and protein levels, when grown under laboratory conditions compared to the parental strain. This mutant also displayed markedly increased adhesion to and invasion of human epithelial and endothelial cells, while parental adhesion levels were restored by *pbsP* deletion in the T133A background. Deletion of *saeR* markedly impaired the ability of GBS to persist *in vivo* and produce disease in mouse models of experimental infections, indicating a major role of the SaeRS system in virulence factor regulation.

Discussion and Conclusions: Collectively these data indicate that PbsP expression is markedly upregulated by SaeS activation, allowing GBS to adhere to and invade host barriers. Besides, *saeR* deletion results in complete loss of the ability of GBS to cause disease in different mouse infection models, indicating a major role of SaeR in virulence. These data suggest that the SaeRS TCS may represent a suitable target in alternative strategies to control GBS disease.

31 - Prevalence of hepatitis B virus infection among pregnant women: results from a hospital-based survey in Northern Italy.

Flora De Conto ⁽¹⁾ - [Giulia Montanari](#) ⁽¹⁾ - Sharon Di Stefano ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Adriana Calderaro ⁽¹⁾

Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾

Prevalence of hepatitis B virus infection among pregnant women: results from a hospital-based survey in Northern Italy.

FLORA DE CONTO, [GIULIA MONTANARI](#), SHARON DI STEFANO, MARIA CRISTINA ARCANGELETTI, MIRKO BUTTRINI, SARA MONTECCHINI, CARLO CHEZZI, ADRIANA CALDERARO

Department of Medicine and Surgery - University of Parma - Parma - Italy

Introduction. Although there is a safe and effective vaccine, hepatitis B virus (HBV) infection constitutes a global challenge, involving about one-third of the world's population with current or previous infection and possible progression to cirrhosis, liver failure, and hepatocellular carcinoma. Maternal-to-child transmission (MTCT) is the main HBV transmission route in many parts of the world, with a high risk to progression to chronicity. Screening programs aimed at identifying HBV surface antigen (HBsAg) positive mothers are part of routine examinations in most countries. In this study, the prevalence of HBV infection among pregnant women (PW) was evaluated in Parma (Northern Italy) from January 2021 to May 2022.

Materials and Methods. A total of 1,464 PW (771/1,464, 52.7%, Italian; 693/1,464, 47.3%, foreigners; 592/1,464, 40.4% inpatients; 872/1,464, 59.6%, outpatients) were examined. The median age of PW was 31.5 years \pm 4.2 for Italian and 30 years \pm 4.9 for foreigners. Laboratory diagnosis was carried out upon medical order. The diagnostic algorithm was aimed at assessing first anti-HBsAg antibodies (HBsAbs) (except in full-term or high-risk pregnancy, where only HBsAg was determined), and then HBsAg in case of a negative result for HBsAbs. Additional HBV serological markers were examined in case of HBsAg positivity. ARCHITECT chemiluminescent microparticle immunoassays (Abbott) were carried out, according to the manufacturer's instructions.

Results. Positive HBsAbs PW were 280 (280/1,464, 19.1%); 79.3% (222/280) were Italian and 20.7% (58/280) foreigners (79.3% vs 20.7% $P < 0.0001$). Vaccinated Italian PW were 28.8% (222/771), while foreigners 8.4% (58/693) (28.8% vs 8.4%, $P < 0.0001$). Unvaccinated and full-term/high-risk PW with negative HBsAg were 1,165 (1,165/1,464, 79.6%). PW positive for HBsAg were 19 (19/1,464, 1.3%); 18 were foreigners (18/19, 94.7%; median age 30.2 years \pm 5.4) and one Italian (1/19, 5.3%, aged 37 years) (94.7% vs 5.3%, $P < 0.0001$). PW positive for HBsAg had chronic infection with a negative result for HBeAg.

Discussion and Conclusions. This study found both a low prevalence (1.3%) of HBV infection among PW and a large part of the study population lacking protective HBsAbs. PW either unvaccinated or not responding to HBV vaccine imply periodical serological monitoring, with major impact on the national health system. Among HBsAg positive PW, foreigners prevailed (94.7%). Also considering the increasing migratory flows from HBV high endemic countries, continuous HBV monitoring and intensive vaccination campaigns are needed in order to reduce the risk of MTCT.

34 - Classification of *Clostridioides difficile* strains using a MALDI-TOF MS typing method.

Mirko Buttrini ⁽¹⁾ - Benedetta Farina ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Monica Martinelli ⁽¹⁾ - Silvia Covan ⁽¹⁾ - Alan Di Maio ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Flora De Conto ⁽¹⁾ - Adriana Calderaro ⁽¹⁾

Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾

Classification of *Clostridioides difficile* strains using a MALDI-TOF MS typing method.

MIRKO BUTTRINI, BENEDETTA FARINA, SARA MONTECCHINI, MONICA MARTINELLI, SILVIA COVAN, ALAN DI MAIO, MARIA CRISTINA ARCANGELETTI, CARLO CHEZZI, FLORA DE CONTO, ADRIANA CALDERARO

Department of Medicine and Surgery, University of Parma, Parma, Italy

Introduction. The epidemiology of *Clostridioides difficile* infection (CDI) changed over the last two decades since the emergence of *C. difficile* virulent strains, such as BI/NAP1/027 and BK/NAP7/078. In order to enhance the global surveillance system of this phenomenon, molecular typing methods are needed for epidemiological monitoring of CDI and for the identification and tracking of new emergent hypervirulent strains. This study evaluated the possibility to differentiate and classify by MALDI-TOF MS the different *C. difficile* strains circulating in our area using a statistical classifying algorithm model (CAM), in comparison with the PCR-ribotyping method. In addition, the MALDI-TOF MS approach was applied for typing of *C. difficile* strains isolated from an outbreak.

Materials and Methods. A total of 122 strains were used: 95 strains were submitted to PCR-ribotyping and used to create and validate the CAM and 27 strains, involved in a suspected outbreak and isolated after its creation, used to evaluate the performance of such CAM. For each strain, 400 µL of a 2.5 McFarland bacterial suspension were treated by heat shock and 15 µL of *C. difficile* DNA were added to a 35-µL reaction mixture for PCR-ribotyping by using two specific primers; 300 µL of the same suspension were subjected to protein extraction for MALDI-TOF MS typing (T-MALDI).

Results. The 95 *C. difficile* strains used during the first step were grouped in 10 ribotypes (PR1–PR10) by PCR-ribotyping. In particular, 93.7% of the isolates (89/95) were grouped in 5 ribotypes (PR1–PR5). For T-MALDI, two CAMs were tested: the first involved all 10 ribotypes whereas the second one only the PR1–PR5 ribotypes. A better performance was obtained using the second CAM: recognition capability of 100%, cross-validation of 96.6% and agreement of 98.4% with PCR-ribotyping results. During the second step, the 27 *C. difficile* isolates were grouped by T-MALDI in 3 different clusters, accounting for 21, 4 and 2 strains, respectively. The previously created CAM classified the 4-strains cluster as Ribotype 126, according to PCR-Ribotyping results. For the remaining 23 strains, the classification obtained by CAM was discordant with that obtained by PCR-Ribotyping, which identified ribotypes not included in the CAM.

Discussion and Conclusions. A validated CAM represents a useful epidemiological tool for the classification of the most frequently circulating ribotypes and for the clusterization of epidemiologically-linked *C. difficile* strains involved in outbreaks, even if related to ribotypes not included in CAM. A correct performance of the CAM requires its continuous updating on the basis of epidemiological data, in order to include new unknown circulating ribotypes.

37 - "Bacterial Outer Membrane Vesicles: from biology to vaccines and cancer immunity".

Guido Grandi ⁽¹⁾

Università di Trento, CIBIO, Trento, Italia ⁽¹⁾

"Bacterial Outer Membrane Vesicles: from biology to vaccines and cancer immunity".

(Guido Grandi - Prof. Microbiology and Clinical Microbiology, University of Trento, Trento, Italy)

Abstract

OMVs are closed spheroid particles of 20-300 nm in diameter, released from all Gram-negative bacteria generated through a “budding out” of the outer membrane. In addition of having a multitude of fascinating biological functions, OMVs are emerging as a promising vaccine platform for three main reasons: (i) are readily phagocytosed by antigen-presenting cells which present OMV-derived peptides on MHC class II and MHC class I; (ii) carry many Microbe-Associated-Molecular Patterns (MAMPs), which stimulate innate and adaptive immunity; (iii) can be engineered with foreign antigens and can be easily and rapidly purified from culture supernatant.

Over the last few years our laboratory has been involved in the development of OMV-based vaccines against infectious diseases and cancer. First, we have applied novel strategies to engineer OMVs with heterologous antigens. Second, by using Synthetic Biology, we have created novel *E. coli* strains which release OMVs deprived of a large number of endogenous proteins. Such strains feature interesting properties which make them particularly attractive for vaccine design. Taking advantage of the availability such OMV-platform, a multi-component vaccine against *Staphylococcus aureus* is now ready to move to development. In addition, an anti-COVID-19 vaccine candidate which elicits robust protection against the original Coronavirus strain as well as the new emerging variants has been developed.

More recently, we accumulated sufficient experimental evidences supporting the notion that OMVs can play an important role in cancer immunity. In studying the mechanisms through which intestinal microbiome affects cancer development and immunotherapy, we demonstrated that the presence of microbial species expressing proteins with amino acid sequences homologous to cancer neoepitopes can inhibit tumor development in experimental mouse models. Such anti-tumor activity appears to correlate with the presence of neoepitope-specific T cells which accumulate in the lamina propria and in the tumor microenvironment. The existence of T cells with identical TCRs at both sites suggests that such T cells originate at the mucosal level and subsequently reach the tumor. Interestingly enough, if homologous epitopes are expressed in Gram-negative intestinal species, the anti-tumor activity can be at least partially mediated by the release of OMVs carrying such homologous sequences. We demonstrated that by artificially administered neoepitope-decorated OMVs to mice, epitope-specific T cells are elicited and animals are protected from tumor challenge. These data provide evidence of a broader OMVs biological function, which extends to cancer immunity via molecular mimicry. Such immunological role of OMVs would underline how inseparable evolution has made mammals and their microbiota; humans may be viewed as a single unit of evolutionary selection comprised of a host and its associated microbes. From a translation viewpoint, our data leads to the attractive hypothesis that OMVs engineered with cancer neo-epitopes could be exploited, in combination with other therapies such as checkpoint inhibitors, to potentiate the elicitation of cancer-specific T cell responses.

43 - Insight into the apoptosis mediated by feline herpesvirus (FeHV-1) on permissive cells

Gianmarco Ferrara⁽¹⁾ - Valentina Iovane⁽²⁾ - Francesca Paola Nocera⁽¹⁾ - Elvira Improda⁽¹⁾ - Ugo Pagnini⁽¹⁾ - Serena Montagnaro⁽¹⁾

University of Naples “Federico II”, Naples, Italy, Department of Veterinary Medicine and Animal Productions, Napoli, Italia⁽¹⁾ - University of Naples “Federico II”, Naples, Italy, Department of Agricultural Sciences, Napoli, Italia⁽²⁾

Insight into the apoptosis mediated by feline herpesvirus (FeHV-1) on permissive cells

Gianmarco Ferrara¹, Valentina Iovane², Francesca P. Nocera¹, Elvira Improda¹, Ugo Pagnini¹, Serena Montagnaro¹.

¹Department of Veterinary Medicine and Animal Productions, University of Naples “Federico II”, Naples, Italy;

²Department of Agricultural Sciences, University of Naples “Federico II”, Naples, Italy.

1.Introduction:

Apoptosis, also known as programmed cell death, is a critical component of host defense mechanisms against viral infection, limiting viral replication and transmission. Multiple signaling pathways, both intrinsic and extrinsic, form a complex network to modulate apoptosis, even though viruses have distinct mechanisms for mediating or inhibiting apoptosis to avoid this process. In comparison to other herpesvirus members, little is known about the relationship between FeHV-1, the etiological agent of feline rhinotracheitis, and apoptosis. This study aimed to learn more about this connection by evaluating the impact of apoptosis on FeHV-1 infection of permissive cells.

2.Materials and methods:

Confluent monolayers of Crandell-Rees Feline Kidney Cell (CRFK) were infected using a MOI 1 at different time points. The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was used to determine cell viability. Moreover, the apoptotic pathway was investigated using two different approaches: a flow cytometry analysis using an Annexin V-FITC detection kit and a western blot assay targeting specific markers of apoptosis (Caspase 8, Caspase 9, Caspase 3, Bcl-XL, Bcl-2).

3.Results:

Our results suggested that FeHV-1 triggers apoptosis process starting with 12 hours post infection. A larger percentage of early apoptotic cells were detected by the flow cytometry analysis, starting at 12 hours after infection, while late apoptotic cells increased at 24 hours after infection. The western blot analysis showed the cleavage of caspase 9 after 24 hours and a time-dependent cleavage of caspase 3 after 48 and 72 hours. We also observed a reduction of the expression of the anti-apoptotic proteins Bcl-XL and Bcl-2, beginning from 24 hours, also in this case.

4.Discussion and conclusions:

In this work we investigated on apoptosis modulation made by FeHV-1. Similar to other herpesviruses, such as Herpes simplex virus (HSV-1), Bovine herpesvirus (BoHV-1), Pseudorabies virus (PRV), Anatid alphaherpesvirus-1 (DEV), and Caprine Herpesvirus 1, infection on permissive cells results in the activation of the apoptotic process, which reduces cell viability. The induction of the intrinsic pathway and the caspase 9 cleavage suggested a dysfunction of the mitochondrial membrane, and the downregulation of Bcl-2 and Bcl-XL expression supported this hypothesis.

Even though additional research is needed to fully understand the viral mechanism and the viral genes/proteins involved in this process, this study provides new knowledge on the host-FeHV-1 interaction. The potential proviral effect may be examined since it has been shown that some viruses manipulate the cellular apoptotic mechanism to enhance their own dissemination within apoptotic bodies.

46 - Time-restricted feeding induces *Lactobacillus*- and *Akkermansia*-specific functional changes in the rat fecal microbiota

Alessandro Tanca⁽¹⁾ - Antonio Palomba⁽²⁾ - Marcello Abbondio⁽¹⁾ - Rosangela Sau⁽¹⁾ - Monica Serra⁽³⁾ - Fabio Marongiu⁽³⁾ - Cristina Fraumene⁽²⁾ - Daniela Pagnozzi⁽²⁾ - Ezio Laconi⁽³⁾ - Sergio Uzzau⁽¹⁾

University of Sassari, Department of Biomedical Sciences, Sassari, Italia⁽¹⁾ - Porto Conte Ricerche, Science and Technology Park of Sardinia, Alghero, Italia⁽²⁾ - University of Cagliari, Department of Biomedical Sciences, Cagliari, Italia⁽³⁾

Time-restricted feeding induces *Lactobacillus*- and *Akkermansia*-specific functional changes in the rat fecal microbiota

ALESSANDRO TANCA^{1,2}, ANTONIO PALOMBA², MARCELLO ABBONDIO¹, ROSANGELA SAU¹, MONICA SERRA³, FABIO MARONGIU³, CRISTINA FRAUMENE², DANIELA PAGNOZZI², EZIO LACONI³, SERGIO UZZAU^{1,2}

¹Department of Biomedical Sciences, University of Sassari, Sassari, Italy; ²Porto Conte Ricerche, Science and Technology Park of Sardinia, Alghero, Italy; ³Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy

1. Introduction

Diet is known to strongly influence composition and functions of the gut microbiota (GM), with key effects on host health. Time-restricted (TR) feeding is receiving growing attention, having been associated to numerous health benefits. The impact of TR feeding on the GM structure has been quite largely explored by metagenomics, but little is known about how this dietary regimen modulates GM protein functions. The aim of this study was thus to analyze the effects of TR feeding on GM functionality in a rat model, by measuring protein expression changes through a metaproteomic approach.

2. Materials and methods

Two groups of rats (8 rats each) were fed ad libitum or received TR feeding, respectively. After 48 weeks, stool samples were collected and divided into two fractions, then subjected, respectively, to DNA extraction, 16S rRNA gene amplification and DNA sequencing, and to protein extraction, filter-aided sample preparation (FASP) and liquid chromatography-high-resolution mass spectrometry analysis.

3. Results

The integrated metaproteogenomic approach used in this study allowed us to carry out both a taxonomic and a functional characterization of the GM. We observed that TR feeding has a relevant impact on numerous GM protein functions, involved in different biological processes and metabolic pathways. Specifically, the TR feeding regimen appeared to specifically boost *Akkermansia muciniphila* and to enhance proteolytic and galactose metabolism enzymes expressed by *Lactobacillus* spp.

4. Discussion and Conclusions

These data can help improve our understanding of relationships between diet, GM, and health, through a mechanism involving protein functions expressed by the potential probiotics *A. muciniphila* and *Lactobacillus*. Further studies integrating different levels of meta-omic investigations and functional analyses will be needed to further deepen our knowledge about molecular aspects of diet-induced changes in the human GM.

57 - Interferon beta augments the *in vitro* and *in vivo* microbicidal responses of neutrophils leading to clearance of staphylococcal infection.

AGATA FAMA¹ - Germana Lentini⁽¹⁾ - Giuseppe Valerio De Gaetano⁽¹⁾ - Francesco Coppolino⁽²⁾ - Giuseppe Teti⁽³⁾ - Concetta Beninati⁽¹⁾

University of Messina, Department of Human Pathology, Messina, Italia⁽¹⁾ - University of Messina, Department of Biomedical, Dental and Imaging Sciences, Messina, Italia⁽²⁾ - Charibdis Vaccines Srl, Charibdis Vaccines Srl, Messina, Italia⁽³⁾

Interferon beta augments the *in vitro* and *in vivo* microbicidal responses of neutrophils leading to clearance of staphylococcal infection

AGATA FAMA¹, GERMANA LENTINI¹, GIUSEPPE V. DE GAETANO¹, FRANCESCO COPPOLINO², GIUSEPPE TETI³ AND CONCETTA BENINATI^{1,4}

¹Department of Human Pathology, University of Messina, Messina, Italy; ²Department of Biomedical, Dental and Imaging Sciences, University of Messina, Messina, Italy; ³Charibdis Vaccines Srl, Messina, Italy; ⁴Scylla Biotech Srl, Messina, Italy

Introduction: We have previously found that gram positive and gram negative extracellular pathogens induce robust interferon-beta (IFN-beta) responses after sensing bacterial nucleic acids *via* endosomal toll-like receptors. The role of this cytokine and other type I IFNs in bacterial infection is complex and context dependent. We investigate here the role of endogenous and exogenous IFN-beta on the outcome of infection by *Staphylococcus aureus*, an antibiotic-resistant pathogen responsible for a high percentage of skin, soft-tissue and pulmonary infections.

Materials and Methods: We examined the role of endogenous IFN-beta by observing infection outcome in mice lacking IFN-beta in comparison with wild type animals, using a previously characterized dermatitis model. In addition, the effects of treatment with recombinant IFN-beta (rIFN-beta) were analyzed *in vivo* and in phagocyte cultures. Cytokine responses were evaluated by measuring protein concentrations by ELISA.

Results: The absence of IFN-beta significantly decreased host resistance to *S. aureus*, as evidenced -in skin lesions- by increased ulceration and bacterial numbers as well as decreased neutrophil infiltration and pro-inflammatory cytokine production. All these defects were rescued to wild type levels by local administration of rIFN. Moreover, rIFN increased resistance to infection also in wild type animals. The addition of the cytokine to bone marrow-derived macrophages and neutrophils and to whole blood increased *in vitro* killing of *S. aureus*. The effects on neutrophils were marked and were associated with an increased intracellular content and release of proteins with potent anti-bacterial activity.

Discussion and Conclusions: Our data reveal a protective role of endogenous and exogenous IFN-beta in the context of *S. aureus* skin infections. Notably, neutrophils were identified as the main target of the beneficial effects of this cytokine, which were linked here to increased production of anti-microbial proteins. Studies are underway to identify the neutrophil products predominantly responsible for IFN-beta-induced antibacterial activities. These data may be useful to devise alternative strategies to treat antibiotic-resistant infections.

59 - Consumption of traditional Sardinian fresh cheese casu axedu promotes changes in the rat gut microbiota composition and functions

Marcello Abbondio⁽¹⁾ - Antonio Palomba⁽²⁾ - Alessandro Tanca⁽¹⁾ - Cristina Fraumene⁽²⁾ - Monica Serra⁽³⁾ - Rosangela Sau⁽¹⁾ - Fabio Marongiu⁽³⁾ - Daniela Pagnozzi⁽²⁾ - Ezio Laconi⁽³⁾ - Sergio Uzzau⁽¹⁾

University of Sassari, Department of Biomedical Sciences, Sassari, Italia⁽¹⁾ - Porto Conte Ricerche, Science and Technology Park of Sardinia, Alghero (SS), Italia⁽²⁾ - University of Cagliari, Department of Biomedical Sciences, Cagliari, Italia⁽³⁾

Consumption of traditional Sardinian fresh cheese *casu axedu* promotes changes in the rat gut microbiota composition and functions.

MARCELLO ABBONDIO¹, ANTONIO PALOMBA², ALESSANDRO TANCA¹, CRISTINA FRAUMENE², MONICA SERRA³, ROSANGELA SAU¹, FABIO MARONGIU³, DANIELA PAGNOZZI², EZIO LACONI³, SERGIO UZZAU¹

¹Dipartimento di Scienze Biomediche, Università degli Studi di Sassari, Sassari, Italy;

²Porto Conte Ricerche, Parco Scientifico e Tecnologico della Sardegna, Tramariglio, Alghero, Italy;

³Dipartimento di Scienze Biomediche, Università degli Studi di Cagliari, Cagliari, Italy.

1. Introduction

Fermented dairy foods are acknowledged for their health-promoting benefits, including obesity prevention and reduction of metabolic disorders risk, possible due to their production of bioactive metabolites and enrichment in beneficial microorganisms. Here, we aimed to investigate the effects of the consumption of *casu axedu*, a traditional Sardinian fresh cheese (FC), on the rat gut microbiota composition and functions.

2. Materials and Methods

We subjected rats to a diet supplemented with *casu axedu* (FC group, N=6) or unsupplemented (control group, N=6) for 8 weeks. Stools were collected at the beginning of the experiment and after 2, 4, and 6 weeks of treatment. Colonic luminal contents were also collected at the end of the experiment. 16S rRNA gene sequencing was performed on stool and colonic luminal samples to inspect the gut and FC microbiota structure. *Casu axedu* aliquots were also sequenced to evaluate their bacterial composition. Moreover, shotgun metaproteomics analysis was carried out on colonic luminal contents to evaluate the gut microbiota functionalities.

3. Results

FC supplementation led to an increase of several microorganisms of the intestinal microbiota after 8 weeks, including *Prevotella* and *Phascolarctobacterium*, as well as of specific FC members, such as *Lactococcus lactis* and *Leuconostoc mesenteroides*, already after 2 weeks of treatment. Metaproteomics led us to find many functions with a statistically significant difference in abundance between the two groups. In particular, the *Prevotella* proteome behaved differently based on the two different dietary treatments. Focusing on the microbial metabolic pathways, several differentially abundant enzymes were involved in the carbon metabolism pathway; of these, glycolysis- and pentose phosphate pathway-related enzymes were found as more abundant in the controls, whereas those involved in citrate cycle and propanoyl-CoA metabolism showed a higher abundance in the FC-fed rats.

4. Discussion and Conclusions

Our data illustrate the dynamics of intestinal microbiota taxonomic changes related to *casu axedu* consumption. Further, our metaproteogenomic approach provides evidence of the interplay between the bacteria and metabolites deriving from *casu axedu* assumption and the intestinal microbiota metabolism in the rat model.

61 - The immunological activity of *Bacteroides thetaiotaomicron* rough-type lipopolysaccharide

Giuseppe Mantova⁽¹⁾ - Alessia Stornaiuolo⁽²⁾ - Elena Scaglione⁽³⁾ - Valeria Caturano⁽⁴⁾ - Martina Di Rosario⁽¹⁾ - Molly D. Pither⁽⁵⁾ - Chiara Pagliuca⁽¹⁾ - Flaviana Di Lorenzo⁽⁶⁾ - Roberta Colicchio⁽⁷⁾ - Alba Silipo⁽⁵⁾ - Antonio Molinaro⁽⁵⁾ - Paola Salvatore⁽⁸⁾

University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy⁽¹⁾ - *University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., University of Naples Federico II, Dpt. of Chem., Mat. and Ind. Prod. Eng., University of Naples Federico II, Naples, Italy*⁽²⁾ - *University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Chem., Mat. and Ind. Prod. Eng., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federico II, Naples, Italy*⁽³⁾ - *University Hospital Federico II, Dpt. of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italy*⁽⁴⁾ - *University of Naples Federico II, Department of Chemical Sciences, University of Naples Federico II, Naples, Italy*⁽⁵⁾ - *University of Naples Federico II, Department of Agriculture, University of Naples Federico II, Naples, Italy*⁽⁶⁾ - *University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federico II, Naples, Italy*⁽⁷⁾ - *University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federico II, CEINGE, Task Force on Microbiome Studies, Naples, Italy*⁽⁸⁾

The immunological activity of *Bacteroides thetaiotaomicron* rough-type lipopolysaccharide

GIUSEPPE MANTOVA¹, ALESSIA STORNAIUOLO^{1,2,3}, ELENA SCAGLIONE^{1,2,3}, VALERIA CATURANO³, MARTINA DI ROSARIO¹, MOLLY D. PITHER⁴, CHIARA PAGLIUCA¹, FLAVIANA DI LORENZO⁵, ROBERTA COLICCHIO^{1,3}, ALBA SILIPO⁴, ANTONIO MOLINARO⁴, PAOLA SALVATORE^{1,3,6,7}

¹Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy; ²Department of Chemical, Materials and Industrial Production Engineering, University of Naples Federico II, Naples, Italy; ³Department of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italy; ⁴Department of Chemical Sciences, University of Naples Federico II, Naples, Italy; ⁵Department of Agriculture, University of Naples Federico II, Naples, Italy; ⁶CEINGE, Advanced Biotechnologies s.c.ar.l., Naples, Italy; ⁷Task Force on Microbiome Studies, University of Naples Federico II, Naples, Italy

Introduction: *Bacteroides thetaiotaomicron* is one of the most extensively studied symbionts of the human gut and a long-time used model organism for functional microbiota research. Despite its widespread distribution among human populations, still very little is known about the role of bacterial cell envelope constituents in the crosstalk with the human immune system. Due to the extraordinary characteristic of this gut bacterium to produce multiple diverse capsular polysaccharides on its surface, most of research activities focused on defining how these complex polymers affect immune responses. This resulted in the drawback of neglecting another key cell surface glycoconjugate expressed by this Gram-negative, the lipopolysaccharide (LPS). LPS, in fact, is widely known to trigger a pro-inflammatory response in humans, whose potency is strongly dependent on the chemical structure of LPS itself. By taking advantage of an acapsular mutant of *B. thetaiotaomicron*, we evaluate the immunological activity of the rough-type LPS (R-LPS) produced by this gut mutualist using engineered human TLR4 and TLR2 reported cells model (HEK-BlueTM hTLR4; HEK-BlueTM hTLR2). **Materials and Methods:** HEK-BlueTM hTLR4 cells were seeded into 96-well plates (3×10^5 cells per well) and incubated with different concentrations of *B. thetaiotaomicron* R-LPS or *S. typhimurium* SH 2201 LPS (1, 10, 100 ng/mL) for 18 h to analyze Nuclear Factor kappa B (NF- κ B) activation by evaluating NF- κ B-dependent secreted alkaline phosphatase (SEAP) using QUANTI-BlueTM. Likewise, HEK-BlueTM hTLR2 and HEK-BlueTM Null2TM cell lines were exposed to *B. thetaiotaomicron* R-LPS or *S. typhimurium* SH 2201 LPS (1, 10, 100 ng/mL) for 18 h, and for HEK-BlueTM hTLR2 cells also to Pam3CSK4 (500 ng/mL) and analyzed as above. **Results:** *B. thetaiotaomicron* R-LPS induced a significantly lower NF- κ B activation compared to *S. typhimurium* LPS in HEK-BlueTM hTLR4 cells. Notably, the stimulation induced in HEK-BlueTM hTLR2 cells highlighted a potent dose-dependent activation by *B. thetaiotaomicron* R-LPS compared to

S. typhimurium LPS for which, as expected, no significant TLR2 activation was noticed. The lack of any NF- κ B activation in HEK-Blue Null2 cells, indicated that NF- κ B activation by *B. thetaiotaomicron* R-LPS were TLR-dependent.

Discussion and Conclusions: The evaluation of the impact of this R-LPS on the human innate immune system *in vitro* revealed a weaker ability to engage the TLR4/MD-2/CD14 pathway compared to the LPS of the gut pathogen *Salmonella typhimurium*, while it was able to potently promote TLR2-mediated response. It would be interesting to evaluate the release of mediators after the interaction of this R-LPS with TLR2.

67 - The probiotic *Lactobacillus rhamnosus* LGG restrains the angiogenic potential of colorectal carcinoma cells by activating a pro-resolving program via Formyl Peptide Receptor 1

Elena Scaglione⁽¹⁾ - Federica Liotti⁽²⁾ - Chiara Pagliuca⁽³⁾ - Valeria Caturano⁽⁴⁾ - Giuseppe Mantova⁽³⁾ - Maria Marotta⁽³⁾ - Daniela Sorriento⁽⁵⁾ - Rosa Marina Melillo⁽⁶⁾ - Roberta Colicchio⁽⁷⁾ - Nella Prevete⁽⁸⁾ - Paola Salvatore⁽⁹⁾

University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech.; Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. U.O.C.; Dpt. of Chem. Mat. and Ind. Prod. Eng., Naples, Italia⁽¹⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech.; Inst. of Experimental Endocrinology and Oncology (IEOS), CNR, Naples, Italia⁽²⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italia⁽³⁾ - University of Naples Federico II, Dpt. of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital FedericoII, Naples, Italia⁽⁴⁾ - University of Naples Federico II, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italia⁽⁵⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Inst. of Experimental Endocrinology and Oncology (IEOS), CNR, Naples, Italia⁽⁶⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. U.O.C. Federicoll, Naples, Italia⁽⁷⁾ - University of Naples Federico II, Inst. of Exp. End. and Onc., CNR; Dpt. of Tran. Med. Scien.; Task Force on Microbiome Studies, Naples, Italia⁽⁸⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech.; Dpt. of Integ. Activ. of Lab. Med. and Transf. U.O.C. Federicoll; Task Force on Microbiome Studies ; CEINGE, Naples, Italia⁽⁹⁾

The probiotic *Lactobacillus rhamnosus* LGG restrains the angiogenic potential of colorectal carcinoma cells by activating a pro-resolving program via Formyl Peptide Receptor 1

ELENA SCAGLIONE^{1,2,3}, FEDERICA LIOTTI^{1,4}, CHIARA PAGLIUCA¹, VALERIA CATURANO², GIUSEPPE MANTOVA¹, MARIA MAROTTA¹, DANIELA SORRIENTO⁵, ROSA MARINA MELILLO^{1,4}, ROBERTA COLICCHIO^{1,2}, NELLA PREVETE^{4,6,7}, PAOLA SALVATORE^{1,2,7,8}

¹ Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy; ²Department of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italy; ³Department of Chemical, Materials and Production Engineering, University of Naples Federico II, Naples, Italy; ⁴ Institute of Experimental Endocrinology and Oncology (IEOS), CNR, Naples, Italy;

⁵Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy; ⁶Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy; ⁷Task Force on Microbiome Studies, University of Naples Federico II, Naples, Italy; ⁸CEINGE, Biotechnologie Avanzate s.c.ar.l., Naples, Italy.

Introduction: Chronic inflammation is a risk factor for Colorectal Carcinoma (CRC) onset, as strongly suggested by the increased predisposition to colon carcinogenesis of Inflammatory Bowel Disease patients. Intestinal inflammatory conditions are strongly influenced, and in turn affect, microbiota composition. Several studies in CRC patients and experimental models demonstrated that colon tumorigenesis is associated to significant alterations of intestinal microbial composition termed as dysbiosis. It is note that, *Lactobacillus rhamnosus* GG (LGG) is a commensal bacterium used as probiotic in order to reverse intestinal dysbiosis. Formyl Peptide Receptors (FPR1, 2, 3) are innate immune sensors of pathogen and commensal bacteria exerting a homeostatic role in colonic mucosa. FPR1, controls the production of pro-resolving mediators functioning as a tumor suppressor due to its ability to sustain an inflammation resolution response

with anti-angiogenic potential in gastric and in CRC cells. In this study, it was analysed the role of commensal *LGG* to promote intestinal epithelial homeostasis. It was investigated the possibility that *LGG*, interacting with FPR1, could activate a pro-resolving and an anti-angiogenic response in CRC cells. **Materials and Methods:** Colorectal carcinoma cells (HT29 and HCT116) were alternatively treated with bacterial supernatant (SN) of *LGG*, *Bifidobacterium bifidum*, a lactic acid bacteria and *Escherichia coli*, a non-probiotic bacteria, in order to evaluate the pro-resolving and anti-angiogenic effects. To verify this hypothesis, the levels of gene expression and production of pro-resolving and pro-angiogenic markers were evaluated by real-time PCR and ELISA assay. In addition, it was evaluated the ability of *LGG* SN to modulate CRC cell functional angiogenic potential through the *in vitro* Matrigel angiogenesis assays. To confirm that the pro-resolving and anti-angiogenic effects of *LGG* in CRC cells is FPR1-mediated, HCT116 cells stably expressing FPR1-short hairpin RNAs were treated with *LGG* SN. **Results:** Our results demonstrated that *LGG* can promote intestinal epithelial homeostasis through FPR1. A pro-resolving, anti-angiogenic and homeostatic functions were observed upon treatment of CRC cells with SN *LGG*, but not with SN of other lactic acid or non-probiotic bacteria. **Discussion and Conclusion:** The demonstrated beneficial effects of *LGG* are dependent on FPR1 expression, that could be a regulator of the balance between microbiota, inflammation and cancer in CRC model. These data also support the evidence that the pro-resolving and anti-angiogenic response in CRC cells is not general and common to all the commensal or to all the lactic acid bacteria.

68 - The *Shigella flexneri* virulence factor apyrase is released inside eukaryotic cells to manipulate host cell fate

Lisa Perruzza⁽¹⁾ - Meysam Sarshar⁽²⁾ - Francesco Strati⁽³⁾ - Carlo Zagaglia⁽⁴⁾ - Fabio Grassi⁽¹⁾ - Mauro Nicoletti⁽⁴⁾ - Anna Teresa Palamara⁽⁵⁾ - Cecilia Ambrosi⁽⁶⁾ - Daniela Scribano⁽⁴⁾

Università della Svizzera Italiana, Institute for Research in Biomedicine, Bellinzona, Svizzera⁽¹⁾ - Bambino Gesù Children's Hospital, IRCCS, Research Laboratories, Roma, Italia⁽²⁾ - University of Milano-Bicocca, Mucosal Immunology Lab, Department of Biotechnology and Biosciences, Milano, Italia⁽³⁾ - Sapienza University of Rome, Department of Public Health and Infectious Diseases, Roma, Italia⁽⁴⁾ - Sapienza University of Rome, Department of Public Health and Infectious Diseases, Laboratory Affiliated to Institute Pasteur Italia-Cenci Bolognetti, Roma, Italia⁽⁵⁾ - San Raffaele Open University, IRCCS, Department of Human Sciences and Promotion of the Quality of Life, Roma, Italia⁽⁶⁾

The *Shigella flexneri* virulence factor apyrase is released inside eukaryotic cells to manipulate host cell fate

Lisa Perruzza^{1,2*}, Meysam Sarshar³, Francesco Strati⁴, Carlo Zagaglia⁵, Fabio Grassi¹, Mauro Nicoletti⁵, Anna Teresa Palamara⁶⁻⁷, Cecilia Ambrosi⁸ and Daniela Scribano⁵

¹Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland;

* present affiliation ²Humabs BioMed, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland;

³Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy;

⁴Mucosal Immunology Lab, Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy;

⁵Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy;

⁶Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory Affiliated to Institute Pasteur Italia-Cenci Bolognetti Foundation, 00185 Rome, Italy;

⁷Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy;

⁸Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Open University, IRCCS, 00166 Rome, Italy

Introduction. *Shigella flexneri* is the causative agent of bacillary dysentery in humans. Its pathogenicity relies on the expression of type III secretion system that injects effector proteins inside host cell mediating bacterial internalization and cell response subversion. Apyrase is a periplasmic ATP-diphosphohydrolase required for *Shigella* actin-based motility whose catalytic role is still unknown. Caspase-mediated programmed cell death plays an essential role in the elimination of infected cells; it is tightly regulated by the intracellular levels of ATP. Here we hypothesized that apyrase could affect host cell survival by degrading the intracellular ATP. **Materials and Methods.** *S. flexneri* M90T, the *apy* mutant HND115, and the complemented HND115(pHND10) strains were grown in Luria-Bertani broth. Surface apyrase localization was analyzed by an immunodot-blot and western blot analyses. The human cell line Caco-2 was used for infection experiments, at a multiplicity of infection of 100, using the gentamicin protection assay; intracellular and extracellular ATP (iATP and eATP) quantification (ATP determination Kit Molecular Probes), caspase activity (Vybrant FAM poly Caspase Assay Kit), and cell death rates (eBioscience™ Annexin V Apoptosis Detection Kits) were measured. **Results.** The amounts of eATP during bacterial growth was significantly higher in the HND115 strain compared to those obtained from M90T and HND115(pHND10) strains, indicating that apyrase degrades eATP. Localization of apyrase on the outer bacterial surface was observed both in cultivated bacteria as well as in bacteria retrieved from infected cells at 4 hour post-infection (HPI). The iATP levels were significantly higher in Caco-2 cells infected with HND115 strain compared to those infected with M90T and the complemented strains at 3 HPI. Interestingly, cells infected with M90T and the complemented strains displayed ATP levels similar to the non-infected control cells. In addition, in these latter infected cells, apyrase was found to accumulate in the cytoplasm. This result indicates that apyrase is necessary to maintain the physiological levels of iATP during *S. flexneri* infection. Moreover, cells infected with HND115 strain showed a prominent increase in caspase activation compared to those infected with M90T and the complemented strains, as well as the non-infected control cells. Finally, the significant rise in the

percentage of Annexin V positivity by single and double staining with propidium iodide in HND115-infected cells suggests a possible activation of pyroptosis-mediated cell death. Conclusions. Our results indicate that apyrase reduces iATP content to keep caspase activation to basal levels, thereby promoting cell survival.

71 - Exploring the Nrf2-mediated antioxidant pathway and the potential use of redox-modulating compounds during respiratory virus infections

Marta De Angelis ⁽¹⁾ - Gianni Gori Savellini ⁽²⁾ - Donatella Amatore ⁽³⁾ - Riccardo De Santis ⁽³⁾ - Rita Crinelli ⁽⁴⁾ - Alessandra Fraternale ⁽⁴⁾ - Maria Grazia Cusi ⁽²⁾ - Florigio Romano Lista ⁽³⁾ - Mauro Magnani ⁽⁴⁾ - Anna Teresa Palamara ⁽⁵⁾ - Lucia Nencioni ⁽¹⁾

Università di Roma Sapienza, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽¹⁾ - Università di Siena, Dipartimento di Biotechnologie Mediche, Siena, Italia ⁽²⁾ - Ospedale Militare Celio, Dipartimento Scientifico, Roma, Italia ⁽³⁾ - Università di Urbino Carlo Bo, Dipartimento di Scienze Biomolecolari, Urbino, Italia ⁽⁴⁾ - Università di Roma Sapienza; Istituto Superiore di Sanità, Dipartimento di Sanità Pubblica e Malattie Infettive; Dipartimento di Malattie Infettive, Roma, Italia ⁽⁵⁾

Exploring the Nrf2-mediated antioxidant pathway and the potential use of redox-modulating compounds during respiratory virus infections

MARTA DE ANGELIS ¹, GIANNI GORI SAVELLINI ², DONATELLA AMATORE ³, RICCARDO DE SANTIS ³, RITA CRINELLI ⁴, ALESSANDRA FRATERNALE ⁴, MARIA G. CUSI ², FLORIGIO R. LISTA ³, MAURO MAGNANI ⁴, ANNA T. PALAMARA ^{1,5}, LUCIA NENCIONI ¹

¹Dept. Public Health and Infectious Diseases, Sapienza University, Rome, Italy;

²Dept. Medical Biotechnologies, University of Siena, Italy;

³Scientific Department, Army Medical Center, Rome, Italy;

⁴Dept. Biomolecular Sciences, University Carlo Bo, Urbino (PU), Italy;

⁵Dept. Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Introduction: Changes in redox state homeostasis occur during respiratory virus infections and they can affect different steps of viral replication. The nuclear factor erythroid 2-related factor 2 (Nrf2)-pathway, involved in antioxidant genes transcription, is decreased during influenza virus infection and more recently, it was found downregulated upon SARS-CoV-2 infection. However, the mechanisms at the basis of this regulation are still not defined. At the same time, oxidative stress can also regulate the virus/host binding favoring viral entry. In this study we aimed at: i) exploring the mechanism and viral proteins involved in the regulation of Nrf2-mediated antioxidant response during influenza virus and SARS-CoV-2 infections; ii) evaluating the efficacy of redox-modulating compounds against both respiratory virus infections.

Materials and Methods: Permissive cell lines were infected with SARS-CoV-2, influenza A/PR/8/34 H1N1 virus (PR/8) or transfected with different PR/8 or SARS-CoV-2 plasmids encoding for selected respiratory virus proteins. The treatment was performed by using the n-butanoyl derivative of glutathione (GSH-C4) and I-152, a conjugate of N-acetylcysteine (NAC) or S-acetyl-cysteamine (SMEA), pre-incubating SARS-CoV-2 or PR/8 with the molecules for 1 h at 37° C or by adding the compounds after the viral adsorption for 24 h post-infection. Viral titration was performed by TCID50, hemagglutination and plaque assays. Viral proteins expression was analyzed by western blot and in cell western assay.

Results: The transfection with plasmids encoding for several influenza virus proteins, showed that the non-structural NS1 protein regulated the activation of antioxidant response element promoter and Nrf2 protein expression. A similar downregulation of Nrf2 pathway was found during SARS-CoV-2 infection, where ORF6 accessory protein modulated

the antioxidant pathway. Treatment with redox-modulating compounds added for 24 h post-infection, was able to rescue the Nrf2-mediated antioxidant response and to inhibit influenza virus replication. Interestingly, the same molecules inhibited the infectivity of SARS-CoV-2 by impairing both the binding of S protein to its cellular receptor during the early stage of viral infection, as well as the formation of new mature viral particles. The use of GSH precursors also interfered with PR/8 entry. Indeed, cells infected with a mixture of PR/8 and GSH-C4 showed a lower expression of viral proteins compared to untreated condition.

Discussion and Conclusions: These data contribute to clarify the mechanisms through which influenza virus and SARS-CoV-2 modulate the intracellular redox state to their advantage and to identify new possible cell-targeted strategies against respiratory virus infections.

80 - Drug-targeted activation of the RIG-I pathway to develop novel combinatorial therapeutic approaches against human papillomavirus-associated cancers

Irene Lo Cigno⁽¹⁾ - Carlo Girone⁽¹⁾ - Federica Calati⁽¹⁾ - Daniela Bosisio⁽²⁾ - Valentina Salvi⁽²⁾ - Tiziana Schioppa⁽²⁾ - Valentina Tassinari⁽³⁾ - Cristina Cerboni⁽³⁾ - Alessandra Soriani⁽³⁾ - Aldo Venuti⁽⁴⁾ - John Hiscott⁽⁵⁾ - Marisa Gariglio⁽¹⁾

University of Piemonte Orientale, Department of Translational Medicine, Novara, Italia⁽¹⁾ - University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italia⁽²⁾ - La Sapienza University, Molecular Medicine Department, Roma, Italia⁽³⁾ - IRCCS Regina Elena National Cancer Institute, HPV Unit, UOSD Tumor Immunology and Immunotherapy, Roma, Italia⁽⁴⁾ - Pasteur Institute, Fondazione Cenci Bolognetti, Roma, Italia⁽⁵⁾

Drug-targeted activation of the RIG-I pathway to develop novel combinatorial therapeutic approaches against human papillomavirus-associated cancers

Irene Lo Cigno¹, Carlo Girone¹, Federica Calati¹, Daniela Bosisio², Valentina Salvi², Tiziana Schioppa², Valentina Tassinari³, Cristina Cerboni³, Alessandra Soriani³, Aldo Venuti⁴, John Hiscott⁵, Marisa Gariglio¹

¹Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; ²Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; ³Molecular Medicine Department, La Sapienza University, Rome, Italy; ⁴HPV Unit, UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy; ⁵Pasteur Institute, Fondazione Cenci Bolognetti, Rome, Italy.

Currently, the treatment for (HPV)-associated cancers involves radiotherapy, chemotherapy or surgery, all with devastating effects on the targeted anatomical sites. Thus, alternative antiviral therapies with fewer side effects are urgently needed to improve patient outcomes. Restoring pathways capable of triggering immunogenic cell death (ICD) of HPV-associated tumors through production of type I interferons (IFNs) and lymphocyte-recruiting chemokines is of increasing interest. In this scenario, pattern recognition receptors (PRRs), which are proteins able to recognize conserved pathogen-associated molecular patterns (PAMPs) and initiate an antiviral response through NF- κ B and interferon regulatory factor (IRF) signaling, appear to be among the most promising therapeutic targets. We have recently shown that HPV-transformed cells display marked downregulation of several PRRs, namely cGAS, RIG-I, and the downstream adaptor STING. Specifically, we found that HPV18 persistence in keratinocytes inhibits both type I and type III IFN production in response to DNA ligands, and that this effect is mainly due to suppression of the cGAS-STING pathway, which seems to be irreversible even after treatment with exogenous DNA. By contrast, the RIG-I pathway mediates the residual IFN production triggered by poly(dA:dT) or the sequence-optimized 5'pppRNA RIG-I agonist M8. In this regard, we have investigated the potential of the powerful RIG-I agonist M8 as an anti-cancer agent by analyzing its ability to induce cell death and activate the immune response in HPV16-transformed CaSki cells. We have demonstrated that M8 exerts an antiproliferative effect in CaSki cells that was enhanced upon combined treatment with the genotoxic agent cisplatin. This effect was almost abolished in CaSki cells stably knocked out for the RIG-I gene. In addition, conditioned media from M8-treated CaSki, but not CaSki RIG-I KO cells, significantly enhanced NK cell proliferation and CaSki cell killing *in vitro*. The same combined treatment was assessed in the preclinical murine syngeneic model of HPV-driven cancer based on dorsal subcutaneous (s.c.) injection of C3 cells, which harbor an integrated HPV16 genome, in C57BL/6J mice. Intratumoral M8 treatment significantly reduced tumor growth when compared to vehicle-treated tumors. This inhibitory effect was strongly enhanced when mice were co-treated intraperitoneally with cisplatin, when compared to

cisplatin or M8 alone. The immune infiltrate in the tumors treated with the combined therapy was significantly enriched in inflammatory monocytes and activated NK cells when compared to the single treatments. Our findings provide good evidence that drug-targeted activation of the RIG-I pathway is an attractive and feasible option to enhance the effectiveness of existing anticancer therapies.

87 - Pro inflammatory status and bacterial gut-vagina translocation in pregnant women affected by COVID-19

Carolina Cason⁽¹⁾ - Giuseppina Campisciano⁽¹⁾ - Nunzia Zanotta⁽¹⁾ - Alice Sorz⁽²⁾ - Francesco De Seta⁽²⁾ - Gianpaolo Maso⁽²⁾ - Manola Comar⁽¹⁾

Institute for Maternal and Child Health – IRCCS "Burlo Garofolo", Department of Advanced Translational Microbiology, Trieste, Italia⁽¹⁾ - Institute for Maternal and Child Health – IRCCS "Burlo Garofolo", Department of Obstetrics and Gynecology, Trieste, Italia⁽²⁾

Pro inflammatory status and bacterial gut-vagina translocation in pregnant women affected by COVID-19

CAROLINA CASON¹, GIUSEPPINA CAMPISCIANO¹, NUNZIA ZANOTTA¹, ALICE SORZ², FRANCESCO DE SETA^{2,3}, GIANPAOLO MASO², MANOLA COMAR^{1,3}

¹Department of Advanced Translational Microbiology, Institute for Maternal and Child Health – IRCCS "Burlo Garofolo", Trieste, Italy; ²Department of Obstetrics and Gynecology, Institute for Maternal and Child Health – IRCCS "Burlo Garofolo", Trieste, Italy; ³Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italy.

Introduction. Pregnant women are at increased risk for severe maternal and neonatal morbidity and mortality from viral diseases. The immune system during pregnancy is subject to changes that can lead to an increased risk of serious sequelae. This study aims to investigate the immunological and microbiological consequences of SARS-CoV-2 infection during pregnancy. **Materials and Methods.** During 2021-2022, at the Institute for Maternal and Child Health – IRCCS "Burlo Garofolo", Trieste, Italy, women diagnosed with SARS-CoV-2 infection during pregnancy were characterized for the presence of anti-SARS-CoV-2 IgG and the dosage of 27 soluble immune markers in sera and funicular blood samples at the time of delivery. In addition, the vaginal and rectal maternal microbiomes were profiled. At birth, newborns were tested for SARS-CoV-2 infection. Women were divided in three groups, "Early-CoV" negative for SARS-CoV-2 infection at time of delivery, "Late-CoV" positive during delivery, "Spread-CoV" positive during delivery and with other positive samples including vaginal, rectal, placental swabs and urine. **Results.** IgG dosage resulted more likely positive in funicular blood of the Early-CoV group (Chi-square $p = 0.033$), while no significant differences were observed in the maternal blood from different groups. In maternal blood, IL-8, IP-10 and MCP-1 increased in the Spread-CoV group compared with others. The G-CSF growth factor increased in maternal and funicular blood samples from the Spread-CoV group ($p = 0.033$). As regard the microbial profile, vaginal swabs from the Late-CoV and Spread-CoV groups showed higher alpha diversity. In addition, several bacteria, including *E. faecalis*, *Escherichia spp.* and *Prevotella spp.*, were present both in vaginal and rectal swabs. Among newborns, a total of two positive nasopharyngeal swabs was identified in the Late-CoV and Spread-CoV groups. **Discussion and Conclusions.** The infrequent SARS-CoV-2 vertical transmission is likely due to the maternal antibodies transplacental passage. The vaginal dysbiosis observed at the time of delivery in Late-CoV and Spread-CoV groups could negatively affect newborns' health, while the shared bacteria between vaginal and rectal swabs suggested a gut-vagina translocation. To date, the emerging variants of the virus seem to be unrelated to the spread of SARS-CoV-2 to other tissues, though, this point needs further studies.

88 - The fetal environment can harbor bacterial DNA overlapping the microbiome of vaginal, rectal and oral maternal body sites

Giuseppina Campisciano⁽¹⁾ - Nunzia Zanotta⁽¹⁾ - Carolina Cason⁽¹⁾ - Francesco De Seta⁽²⁾ -
Alessandra Torresani⁽³⁾ - Tamara Stampalija⁽³⁾ - Mariachiara Quadrifoglio⁽³⁾ - Manola Comar⁽¹⁾

Department of Advanced Microbiology Diagnosis and Translational Research, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italia⁽¹⁾ - Department of Obstetrics and Gynecology, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italia⁽²⁾ - Department of Fetal Medicine & Prenatal Diagnosis, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italia⁽³⁾

The fetal environment can harbor bacterial DNA overlapping the microbiome of vaginal, rectal and oral maternal body sites

*GIUSEPPINA CAMPISCIANO¹, NUNZIA ZANOTTA¹, CAROLINA CASON¹, FRANCESCO DE SETA^{2,3},
ALESSANDRA TORRESANI⁴, TAMARA STAMPALIJA⁴, MARIACHIARA QUADRIFOGLIO⁴, MANOLA COMAR^{1,3}*

¹Department of Advanced Microbiology Diagnosis and Translational Research, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy; ²Department of Obstetrics and Gynecology, Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy; ³Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italy; ⁴Department of Fetal Medicine & Prenatal Diagnosis, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.

Introduction. A controversy exists over the *in utero* microbial colonization hypothesis that challenges the clinical paradigm of the sterile womb. The debate is focused on the need to assure aseptic sampling and discriminate legitimate signals from contaminations in the sequencing outputs. **Materials and methods.** We profiled the microbiome of chorionic villi (CVS) and amniotic fluids (AF) and the matched vaginal, rectal, and saliva samples from 60 women undergoing villocentesis (n=23) or amniocentesis (n=37) for genetic reasons, maternal age or high risk screening tests. In addition, in CVS/AF samples and vaginal swabs, we dosed 27 immune soluble factors. **Results.** By filtering out the kitome (the reagents contaminations) observed in the ‘no template controls’ (n=24) from the taxonomic assignment of the biological samples, we identified 10/23 (43%) CVS samples positive for bacterial DNA and 12/37 (32%) AF positive samples. The ANCOM test identified bacteria significantly different between the negative and the positive samples, including *Anaerococcus* (W=551), *Corynebacterium* (W=560), *Dialister* (W=561), *Gemella* (W=554), *Haemophilus* (W=556), *Lactobacillus* (W=561), *Mobiluncus* (W=520), *Peptoniphilus* (W=552), *Porphyromonas* (W=561), *Prevotella* (W=561), *Streptococcus* (W=560), *Staphylococcus* (W=543), and *Veillonella* (W=558). These bacteria were identified in the positive CVS and AF samples, overlapping mostly the microbiome of the vaginal and rectal samples and, to a lesser extent, the saliva samples. In the vaginal swabs matching the CVS/AF positive samples, we identified a decreased concentration of the antiinflammatory FGF-beta growth factor (8±3 pg/mL) compared with the vaginal negative samples (13±15 pg/mL) (Mann-Whitney U test p=0.04). We did not identify significantly modulated immune factors in CVS/AF samples positive for bacterial DNA compared with the negative ones.

Discussion and conclusions. Commensal and pathogenic bacteria can be identified in the placenta and amniotic fluid, deriving from several maternal body sites including the vagina, the oral cavity and the gut. The decrease of the antiinflammatory FGF-beta growth factor in the vaginal samples matching the colonized CVS/AF samples can facilitate the spread of these microbial constituents in the fetal environment. To identify potential new microbiome markers in the prenatal intrauterine environment can increase the knowledge of their putative role in human health.

90 - Specific microbiota compositions regulate humoral and cellular responses to vaccines in outbred mice

Giuseppe Stefanetti⁽¹⁾ - Joon S. Park⁽²⁾ - Ximei Sun⁽²⁾ - Meng Wu⁽²⁾ - Dennis L. Kasper⁽²⁾

Universita' degli Studi di Urbino "Carlo Bo", Dipartimento di Scienze Biomolecolari (DISB), Urbino, Italia⁽¹⁾ - Harvard Medical School, Immunology, Boston, Stati Uniti D'america⁽²⁾

Specific microbiota compositions regulate humoral and cellular responses to vaccines in outbred mice

Giuseppe Stefanetti¹, Joon S. Park², Ximei Sun², Meng W, Dennis L. Kasper²

¹ Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.

² Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA

Introduction: Vaccination shows high variability in the elicited immune responses among individuals and populations, for reasons still poorly understood. An increasing number of studies are supporting the evidence that gut microbiota, along with other inter-playing variables, is able to modulate both humoral and cellular responses to infection and vaccination. With the aim of better understanding this connection, we have analyzed the antibody and cellular responses of outbred and inbred mice to several vaccines using different microbiota models.

Materials and Methods: We vaccinated 6-week-old Swiss Webster (SW) (outbred) and C57BL/6 (inbred) specific pathogen-free (SPF), antibiotic-treated and germ-free mice with a panel of glycoconjugate or protein antigens two times at two weeks interval using alum as adjuvant. Antigen-specific antibody responses were monitored during the experiment by ELISA. Cellular immune responses were characterized by extracting draining and mesenteric lymph nodes, Peyer's patches and spleen to measure both frequencies of dendritic cells (DC), T and B cells populations and their immunophenotype by flow cytometry. To investigate the microbiota drivers related to the differential antibody response, we analyzed gut microbial-community structure by 16S rRNA amplicon sequencing.

Results: After vaccinating SW mice, antigen-specific IgG responses of SPF mice were significantly higher than GF or antibiotic-treated mice responses, for all antigens tested. In SW SPF mice, we observed an increased development of germinal center B cell and T cell activation as opposed to a higher regulatory/co-inhibitory environment in SW GF mice. By cohousing SW GF mice, we also found that the organisms responsible for an enhanced response to vaccination are both transmissible and ampicillin sensitive. Taxonomic analysis indicates that, at phyla level, high IgG responses in SW mice were associated with a marked increase of Firmicutes and a decrease in the Bacteroidetes. In agreement with the literature, we found less impact of the microbiota on the C57BL/6 mice vaccination response.

Conclusion: Overall, our data suggest that specific microbiota compositions can regulate humoral and cellular responses to vaccines in SW (outbred) mice, providing an important contribution to a better understanding of the microbiota-immune response crosstalk after vaccination.

91 - Persistence of spike-specific memory B cells and antibodies nine months after two doses of BNT162b2 mRNA vaccine

Gabiria Pastore ⁽¹⁾ - Simone Lucchesi ⁽¹⁾ - Elena Pettini ⁽¹⁾ - Sara Zirpoli ⁽¹⁾ - fabio Fiorino ⁽¹⁾ - Jacopo Polvere ⁽¹⁾ - Massimiliano Fabbiani ⁽²⁾ - Francesca Montagnani ⁽²⁾ - Mario Tumbarello ⁽²⁾ - Donata Medaglini ⁽¹⁾ - Annalisa Ciabattini ⁽¹⁾

University of Siena, Dept of Medical Biotechnology, Siena, Italia ⁽¹⁾ - University Hospital of Siena, Department of Medical Sciences, Infectious and Tropical Diseases Unit, Siena, Italia ⁽²⁾

Persistence of spike-specific memory B cells and antibodies nine months after two doses of BNT162b2 mRNA vaccine

GABIRIA PASTORE¹, SIMONE LUCCHESI¹, ELENA PETTINI¹, SARA ZIRPOLI¹, FABIO FIORINO¹, JACOPO POLVERE¹, MASSIMILIANO FABBIANI², FRANCESCA MONTAGNANI^{2,3}, MARIO TUMBARELLO^{2,3}, DONATA MEDAGLINI¹ AND ANNALISA CIABATTINI¹

¹Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena; Siena, Italy; ²Department of Medical Biotechnologies, University of Siena; Siena, Italy ; ³Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena; Siena, Italy

Abstract

Introduction. SARS-CoV-2 mRNA vaccines have demonstrated high efficacy and immunogenicity, but information on the durability of the humoral and memory B cell responses is needed. Here, we investigated RBD-specific memory B cells and humoral responses in healthy subjects, up to nine months after two doses of BNT162b2 vaccine (Comirnaty) administration.

Materials and Methods. Twenty healthy subjects, enrolled in the context of the IMMUNO_COV study (n. 18869, approved by local Ethical Committee), were follow up from day 0 up to 9 months after two doses of mRNA BNT162b2 vaccine (February-November 2021). Subjects infected with SARS-CoV-2 during this period were excluded from the present study. Spike-specific IgG were analysed by ELISA, while the ability of blocking the RBD-ACE2 binding was assessed using a surrogate of neutralization assay. RBD⁺ B cells were identified by multiparametric flow cytometry, and data analyzed employing dimensionality reduction computational algorithm.

Results. Spike-specific antibodies were still present 9 months after two vaccine doses, even though a physiological reduction of titre was observed, with a stronger drop occurring in the first two months after the second dose. The frequency of subjects with antibodies inhibiting the RBD-ACE2 binding, decreased from 92.5% at month 3 to 80% at month 9. About 54% of subjects had IgG capable of recognizing the RBD of the Delta variant, while none of the subjects had antibodies capable of binding the RBD of Omicron variant. Three and nine months after vaccination RBD⁺ B cells were still circulating, with a resting IgG⁺ phenotype (CD21⁺CD27⁺), even though a small subset of IgA⁺ was still detected. In most of the subjects, the in vitro restimulation, promoted the reactivation of B cells with differentiation into spike-specific antibody secreting cells.

Discussion and Conclusion. These data demonstrate vaccination with two doses of the RNA-based BNT162b2 vaccine elicits a strong B cell response with spike-specific memory resting B cells still persistent nine months after vaccination

95 - Depletion of the MS-ring protein FliF impacts motility, mucin-adhesion, and virulence in *Bacillus cereus*

Diletta Mazzantini⁽¹⁾ - Marco Calvigioni⁽¹⁾ - Adelaide Panattoni⁽¹⁾ - Mariacristina Massimino⁽¹⁾ - Francesco Celandroni⁽¹⁾ - Emilia Ghelardi⁽¹⁾

University of Pisa, Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy⁽¹⁾

Depletion of the MS-ring protein FliF impacts motility, mucin-adhesion, and virulence in *Bacillus cereus*

DILETTA MAZZANTINI¹, MARCO CALVIGIONI¹, ADELAIDE PANATTONI¹, MARIACRISTINA MASSIMINO¹, FRANCESCO CELANDRONI¹, EMILIA GHELARDI¹

¹Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

1. Introduction. In the last decades, the scientific scenario had pointed out the pivotal contribution of bacterial flagella to the virulence of some gastrointestinal pathogens. In previous studies, we showed that the deletion of genes encoding flagellar components and regulators in *Bacillus cereus* has a significant impact on motility, surface-adhesion, and secretion of virulence proteins. The aim of this study was to dissect the contribution of FliF, the unique constituent of the flagellar MS-ring, in *B. cereus* virulence.

2. Materials and Methods. In *silico* analysis of FliF in *B. cereus* ATCC 14579 (WT) was performed. RT-PCR experiments were conducted to verify the inclusion of *fliF* in an operon. A *deltafliF* mutant of *B. cereus* was constructed using an *in frame* markerless gene replacement method. Flagellation was evaluated by microscopy and SDS-PAGE of assembled flagellin. Swimming and swarming were analyzed in liquid media and on solid surfaces. The ability to form biofilms and to adhere to gastrointestinal mucins were verified by the crystal violet and mucin-adhesion assays, respectively. The secretion of hemolysin BL, proteases, and phosphatidylcholine-specific phospholipase C (PC-PLC) was tested by immunoblot and agar diffusion assays.

3. Results. In *silico* analysis of *B. cereus* FliF revealed that the protein shares conserved domains with FliF of other species that are required for its insertion in the plasma membrane and for the interaction with the C-ring. *fliF* was found to form a dicistronic operon with the upstream gene *fliE*. The *deltafliF* strain was found still able to assemble flagella, although in a reduced amount compared to the WT. However, motility was completely abolished by FliF depletion. While no differences in biofilm production were evidenced, FliF deprivation resulted in a reduced ability to adhere to mucins. Lastly, a significant reduction in the amount of secreted PC-PLC was detected in the supernatants of the *deltafliF* strain.

4. Discussion and Conclusions. Our results highlight a cardinal role of FliF in *B. cereus* virulence, emphasizing the linkage between flagella and pathogenicity in this organism. FliF is essential for motility and, therefore, for *B. cereus* ability to move toward suitable body sites and colonize host surfaces. The finding that FliF depletion reduces mucin-adhesion indicates an active role of flagella during gut colonization *in vivo*.

97 - Role of gut and oral microbiota in pediatric autism spectrum disorder

Martina Vidmar⁽¹⁾ - Carolina Cason⁽²⁾ - Giuseppina Campisciano⁽²⁾ - Nunzia Zanotta⁽¹⁾ - Antonella Zadini⁽³⁾ - Manola Comar⁽⁴⁾

Department of Advanced Translational Microbiology, Institute for Maternal and Child Health – IRCCS Burlo Garofolo, Department of Life Sciences, University of Trieste, Trieste, Italia⁽¹⁾ - Department of Advanced Translational Microbiology, Institute for Maternal and Child Health IRCCS Burlo Garofolo, IRCCS Burlo Garofolo, Trieste, Italia⁽²⁾ - University of Trieste, Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italia⁽³⁾ - Department of Advanced Translational Microbiology, Institute for Maternal and Child Health – IRCCS Burlo Garofolo, Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italia⁽⁴⁾

Role of gut and oral microbiota in pediatric Autism Spectrum Disorder

MARTINA VIDMAR^{1,3}, CAROLINA CASON¹, GIUSEPPINA CAMPISCIANO¹, NUNZIA ZANOTTA¹, ANTONELLA ZADINI² MANOLA COMAR^{1,2}

¹Department of Advanced Translational Microbiology, Institute for Maternal and Child Health – IRCCS "Burlo Garofolo", Trieste, Italy; ²Department of Medical, Surgical, and Health Sciences, University of Trieste, Trieste, Italy; ³Department of Life Sciences, University of Trieste, Trieste, Italy

Introduction. Autism Spectrum Disorder (ASD) is a neurodevelopment disorder characterized by impairment in social interaction as well as sensory challenges. The gut microbiota in ASD patients revealed a high percentage of bacteria which seem negatively associated with the gut eubiosis. Recent studies on Alzheimer suggest that gut/oral bacteria metabolites (short chain fatty acids – SCFAs) may invade the blood-brain barrier (BBB) triggering inflammatory response, upregulation of microglia and alteration of metabolic activity in the CNS. This study aims to profile gut/oral bacteria of ASD children investigating the role of metabolites and cytokines linked to key bacteria in order to characterize possible relation with patient's metadata as well as the severity of the ASD clinical diagnosis. **Materials and Methods.** 35 matched stool and oral samples, collected after a teeth cleaning session, from pediatric children including 13 ASD and 24 no-ADS controls (average age: 7 years old) have been sequenced with PGM Ion Torrent. Eating habits have been additionally collected. Data have been analyzed through R dada2 pipeline and Blastn and for statistical analysis specific scripts were set up using Python libraries. **Results.** The analysis of the ASD microbiota composition at genus level compared to no-ADS group showed a decreased level in *Bacteroides*, *Bifidobacterium* and *Dialister* while *Sutterella* and *Alistipes* genera incremented. At specie level, *S. wadsworthensis*, which has already been associated with CNS and GI diseases as well as inflammation, was at a higher level in ASD group, while *A. muciniphila* and *B. adolescentis*, which were associated to beneficial effects, decreased. The analysis of the oral ADS microbiota showed a lower level of *Porphyromonas*, *Fusobacterium* and *Leptotrichia*, while pathogen genera like *Haemophilus* and *Streptococcus* levels increased. **Discussion and Conclusions.** So far, these preliminary results showed a specific microbiome composition of the gut and the mouth of ASD children independently of diet, with higher levels of bacteria already linked with inflammatory conditions and described in adult neurological diseases. Further analyses are going to be performed focusing on the role of SCFAs on BBB permeability and the inflammation level of the CNS.

102 - Influenza virus-induced APE1 downregulation: implications for NRF2 pathway and host immune response

Walter Toscanelli⁽¹⁾ - Marta De Angelis⁽¹⁾ - Anna Teresa Palamara⁽²⁾ - Lucia Nencioni⁽¹⁾

Sapienza Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia⁽¹⁾ -
Sapienza Università di Roma / Istituto Superiore di Sanità, Dipartimento di Sanità Pubblica e
Malattie Infettive / Dipartimento di Malattie Infettive, Roma, Italia⁽²⁾

Influenza virus-induced APE1 downregulation: implications for NRF2 pathway and host immune response

WALTER TOSCANELLI¹, MARTA DE ANGELIS¹, ANNA T. PALAMARA^{1,2}, LUCIA NENCIONI¹

¹Department of Public Health and Infectious Diseases, Section of Microbiology, Sapienza University of Rome, Rome, Italy - Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti; ²Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

Introduction

The influenza virus infection causes intracellular redox imbalance important for the activation of specific pathways involved in the control of viral replication. As an example, the nuclear factor erythroid 2-related factor 2 (NRF2) pathway regulates the antioxidant response; its expression is downregulated during the infection, although the mechanisms of this modulation are still unknown. One of the NRF2 interactor is the apurinic/apyrimidinic endonuclease1 (APE1); it has been reported that APE1 is required for the maintenance of NRF2 stability. Interestingly, APE1 redox function has been also involved in the activation of inflammatory factors in lipopolysaccharide-induced inflammation models. On the basis of this evidence, the aims of the study were: i) to evaluate the expression of APE1 during influenza virus infection and to correlate its expression with that of NRF2; ii) to evaluate the virus-elicited inflammatory response in APE1-inhibited or silenced conditions.

Methods

Human Bronchial Epithelial cells (BEAS-2B) were infected with influenza virus A/Puerto Rico 8/34 H1N1. Protein and mRNA expression was evaluated by western blot and q-RTPCR. Silencing of APE1 was performed by small interfering RNA (siRNA) assay. Pro-inflammatory cytokine levels were quantified by Luminex assay.

Results

NRF2 protein levels were downregulated by 55% after 24 h infection with respect to the mock-infected control, while the mRNA levels were downregulated by the 25%. At the same conditions, APE1 protein expression was reduced by 45% and mRNA levels by 21%. To evaluate an eventual relationship between both the proteins, in APE1-silenced infected cells (46% downregulation) NRF2 was further inhibited (42% downregulation), thus suggesting that the downregulation of APE1 could be a mechanism by which NRF2 is modulated during influenza virus infection.

To study the role of APE1 in the inflammatory response, cells were infected for 1 h and then treated or not with a molecular inhibitor of the APE1 redox activity, E3330. Levels of Interferons alpha and beta, RANTES and Interleukin-6 were induced after 24 h infection (2.7, 60, 349 and 1807 pg/mL, respectively), but their amounts were strongly decreased in the E3330-treated samples (1.6, 29, 167 and 1247 pg/mL, respectively). A similar modulation of cytokines and chemokines was found in APE1-silenced cells with respect to the scrambled controls.

Conclusions

The results indicate a downmodulation of APE1 during influenza virus infection and suggest its relationship with the drop of NRF2 expression. Even though further studies are needed to evaluate an eventual role of APE1 in controlling viral replication, data show that APE1/REF-1 redox function is capable of regulating the influenza virus-elicited inflammatory response.

103 - Results from a large cross-sectional Italian study assessing *Ureaplasma* spp. and *Mycoplasma* spp urogenital infections among STI clinic attendees and couples with primary infertility.

Nunzia Zanotta ⁽¹⁾ - Elena Magni ⁽¹⁾ - Vincenzo Petix ⁽¹⁾ - Petra Carli ⁽¹⁾ - Karin Sossi ⁽¹⁾ - Francesca Uliana ⁽¹⁾ - Francesco De Seta ⁽¹⁾ - Claudia Colli ⁽²⁾ - Lorenzo Monasta ⁽¹⁾ - Maria Cristina Salfa ⁽³⁾ - Barbara Suligoi ⁽³⁾ - [Manola Comar](#) ⁽¹⁾

IRCCS, BURLO GAROFALO, Trieste, Italia ⁽¹⁾ - ASUGI, centro MST, Trieste, Italia ⁽²⁾ - Istituto Superiore Sanita, National AIDS Unit/dip malattie infettive, Roma, Italia ⁽³⁾

Results from a large cross-sectional Italian study assessing *Ureaplasma* spp. and *Mycoplasma* spp urogenital infections among STI clinic attendees and couples with primary infertility.

NUNZIA ZANOTTA¹, ELENA MAGNI², VINCENZO PETIX¹, PETRA CARLI¹, KARIN SOSSI¹, FRANCESCA ULIANA¹, FRANCESCO DE SETA¹⁻⁵, CLAUDIA COLLI³, LORENZO MONASTA², MARIA C. SALFA⁴, BARBARA SULIGOI⁴, [MANOLA COMAR](#)¹⁻⁵.

¹Department of Advanced Translational Microbiology, Institute for Maternal and Child Health IRCCS “Burlo Garofolo” Trieste, Italy; ²Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health-IRCCS “Burlo Garofolo”, Trieste, Italy; ³MST Centre, ASUGI, Trieste, Italy; ⁴National AIDS Unit, National Health Institute, Rome, Italy; ⁵Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy.

Introduction. Mycoplasmas are frequently isolated from the genital tract and the majority of individuals do not develop any disease. In STI (Sexual Transmitted Infections) patients, the routine testing and treatment of asymptomatic or symptomatic patients with *M. hominis*, or *U. urealyticum* or *U. parvum* is not recommended whereas detection of the other STI agents is suggested. Female and male infertility have been associated to *Ureaplasma* spp. and *M. hominis* urogenital infections. In Italy, evidence from large studies assessing their prevalence and putative associations with symptoms and demographic characteristics among STI and infertility patients belonging to the same geographic area is still scarce. **Material and Methods.** The study design was a retrospective cross-sectional study (from 2015 to 2021) including 4372 subjects (2647 female, m.a 36y and 1725 male, m.a. 35y), 2053 with a diagnosis of primary infertility (PMA-group) and 2319 STI clinic attendees, all tested for *M. hominis/genitalium*, *U. urealyticum/parvum*, *C.trachomatis*, *N.gonorrhoeae* and *T.vaginalis* by a multiplex molecular PCR. Quantitative bacterial vaginosis (BV) was performed in female subjects. Clinical and demographic data were collected for all subjects. **Results.** The overall prevalence of *Ureaplasma* spp. was higher in PMA-group. In this serie, *U. parvum* was detected at 23,77% vs 10,47% of STI (p<0.001) and *U. urealyticum* at 27% vs 19.5%. Conversely, *Mycoplasma* spp. was higher in STI patients. *M. hominis* was the most frequently detected (12% in STI vs 3% of the PMA-group) while *M. genitalium* was detected at 5.6% vs 0.35% respectively (p<0.001). Coinfection with other STI or BV was very low in both groups showing *C. trachomatis* the microorganism most frequently detected. In both series, the prevalence by sex showed that infections occurred more frequently in female (65%) and the age range of 25y-34y was the most affected (31%). Casual sexual intercourse was significantly identified as risk factor for *U. urealyticum*, *M. hominis* and *M. genitalium* (p<0.001) but not for *U. parvum*. Although the majority of subjects were asymptomatic (79%) the presence of symptoms not linked to other STI were significantly associated with *M. genitalium* in both sex. From 2020 to 2021 an increased trend of symptomatic STI patients has been observed for *M. hominis/U. parvum* in female (p<0.001) and for *U. Urealiticum* in male (p<0.001). **Discussion and Conclusion.** The overall data showed an increase of these microorganisms as single infections in both STI and PMA-group. These evidence indicate the need for further investigation on the role of these microorganisms in the different clinical setting.

114 - Human cytomegalovirus infection drives a cellular senescence-like phenotype in kidney epithelial cells

Stefano Raviola⁽¹⁾ - Gloria Griffante⁽²⁾ - Andrea Iannucci⁽³⁾ - Shikha Chandel⁽²⁾ - Irene Lo Cigno⁽²⁾ - Davide Lacarbonara⁽³⁾ - Valeria Caneparo⁽¹⁾ - Francesco Favero⁽⁴⁾ - Davide Corà⁽⁴⁾ - VINCENZO CANTALUPPI⁽⁵⁾ - SANTO LANDOLFO⁽⁶⁾ - MARISA GARIGLIO⁽²⁾ - MARCO DE ANDREA⁽⁶⁾

Università del Piemonte orientale, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, Intrinsic Immunity Unit, University of Piemonte Orientale, Novara, Italia⁽¹⁾ - Università del Piemonte orientale, Department of Translational Medicine, Virology Unit, Novara, Italia⁽²⁾ - Università del Piemonte orientale, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, Novara, Italia⁽³⁾ - Università del Piemonte orientale, CAAD - Center for Translational Research on Autoimmune and Allergic Disease, Bioinformatics Unit, Novara, Italia⁽⁴⁾ - Università del Piemonte Orientale, Department of Translational Medicine, Nephrology and Transplantation Unit, University of Piemonte Orientale, Novara, Italia⁽⁵⁾ - Università degli studi di Torino, Department of Public Health and Pediatric Sciences, Viral Pathogenesis Unit, University of Turin, Torino, Italia⁽⁶⁾

Human cytomegalovirus infection drives a cellular senescence-like phenotype in kidney epithelial cells

STEFANO RAVIOLA¹, GLORIA GRIFFANTE², ANDREA IANNUCCI¹, VALERIA CANEPARO¹, DAVIDE LACARBONARA¹, SHIKHA CHANDEL², IRENE LO CIGNO², FRANCESCO FAVERO⁴, DAVIDE CORÀ⁴, VINCENZO CANTALUPPI³, SANTO LANDOLFO⁵, MARISA GARIGLIO^{1,2} AND MARCO DE ANDREA^{1,5}

¹CAAD - Center for Translational Research on Autoimmune and Allergic Disease, Intrinsic Immunity Unit, University of Piemonte Orientale, Novara, Italy;

²Department of Translational Medicine, Virology Unit, University of Piemonte Orientale, Novara, Italy;

³Department of Translational Medicine, Nephrology and Transplantation Unit, University of Piemonte Orientale, Novara, Italy;

⁴CAAD - Center for Translational Research on Autoimmune and Allergic Disease, Bioinformatics Unit, University of Piemonte Orientale, Novara, Italy;

⁵Department of Public Health and Pediatric Sciences, Viral Pathogenesis Unit, University of Turin, Turin, Italy.

INTRODUCTION. Human cytomegalovirus (HCMV), a member of the Betaherpesvirinae subfamily, is one of the most frequent viral pathogens associated with acute kidney injury and kidney rejection. Although a small number of studies are available, mounting evidence suggests the activation of senescence responses upon viral infections. Cellular senescence is a state of stable cell cycle arrest associated with macromolecular alterations and secretion of pro-inflammatory cytokines and molecules. Senescence-associated phenotypes restrict damage propagation and activate immune responses, two essential processes involved in response to viral infections. Senescent cells accumulate in the kidney due to aging, any insult causing acute kidney injury, including post-transplantation, and chronic kidney disease. In each of these broad settings, higher levels of senescent cells associate with worsened kidney function and outcome. Our group previously reported that HCMV infection in human fibroblasts triggers cell senescence, and here we show primary kidney proximal tubular epithelial cells (RPTEC) undergo cellular senescence in order to support complete viral replication upon HCMV infection.

MATERIAL AND METHODS. RPTECs and the kidney adenocarcinoma 786-O cell line were infected with HCMV strain TR. Fate of infection was evaluated through time course morphological analysis, western blotting for viral protein expression and flow cytometry. A transcriptome analysis was performed in both cell lines at 2dpi upon infection, then the senescent profile was assessed in RPTECs and human foreskin fibroblast (HFF) *in vitro*. Using tissue sections derived from a full-blown HCMV infection in a preterm child, we show a large number of tubular epithelial cells in kidney expressing both HCMV proteins and the senescence marker lipofuscin.

RESULTS. We experimentally demonstrated that RPTECs, but not a renal cancer derived-cell line, fully supports HCMV replication and undergoes a senescence program upon infection that triggers a harmful secretory phenotype with the

ensuing induction of paracrine senescence in uninfected surrounding cells. Notably, the hallmarks of senescence-related inflammation found in both infected and uninfected RPTECs, that were not observed in HFFs, suggest that this virus-evoked senescence may contribute to disease pathogenesis at least when it comes to renal tubular cells that are a classical site of HCMV replication

DISCUSSION AND CONCLUSION. Altogether, we define novel pathogenetic mechanisms of renal injury upon HCMV infection that involve induction of a senescence program which in turn may pave the way for novel intervention strategy to counteract HCMV-related kidney disease.

115 - Three-label host-cell adhesion assay to assess the exclusion effect exerted by *Lactobacillus acidophilus* on adhesion of *Pseudomonas aeruginosa* to A549 alveolar epithelial cells

Semih Esin ⁽¹⁾ - Esingül Kaya ⁽¹⁾ - Elisa Catelli ⁽¹⁾ - Giuseppantonio Maisetta ⁽¹⁾ - Giovanna Batoni ⁽¹⁾

Università di Pisa, Ricerca traslazionale e delle nuove tecnologie in medicina e chirurgia, Pisa, Italia
(1)

Three-label host-cell adhesion assay to assess the exclusion effect exerted by *Lactobacillus acidophilus* on adhesion of *Pseudomonas aeruginosa* to A549 alveolar epithelial cells

Semih Esin, Esingül Kaya, Elisa Catelli, Giuseppantonio Maisetta, Giovanna Batoni

Department of Translational Research and New technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

Introduction: There is increasing evidence that *Lactobacillus* strains can exert protective effects outside their traditional field of application i.e. the gut. As part of a project aimed at evaluating the aerogenous administration of probiotics for the treatment/prevention of pulmonary infections in cystic fibrosis (CF), in this study, we assessed the ability of different *Lactobacillus* strains to prevent adhesion of clinical isolates of *Pseudomonas aeruginosa* to the human alveolar A549 epithelial cell-line.

Materials and Methods: A panel of 8 commercial *Lactobacillus* strains was investigated for their adhesion capacity to A549 cells at a MOI of 10:1 *Lactobacillus* per cell. For exclusion experiments A549 were incubated with *Lactobacillus* spp for 2h, washed 3 times to remove non-adherent bacteria, and incubated with *P. aeruginosa* at a 10:1 MOI for 1h. The wells were washed twice and CFU counts were assessed. Image analysis was performed via the Operetta CLS High Content Analysis System following single or triple labeling of cells/bacteria with long tracking fluorescent dyes.

Results: *L. acidophilus* and *L. plantarum* displayed the highest adhesion ability evaluated as percent of adhered bacterial cells as compared to the inoculum. Dose-response experiments identified the MOI of approximately 100:1 as the best compromise between *Lactobacillus* adherence to and cytotoxicity towards A549 cells. In agreement with the observed adhesion capacity, *L. acidophilus* was the most efficient in preventing adhesion of a *P. aeruginosa* strain isolated from CF sputum, followed by *L. paracasei*, *L. rhamnosus*, *L. fermentum* and *L. plantarum*. Three-color fluorescence labeling of A549 cells, *P. aeruginosa*, and *L. acidophilus*, and confocal image analysis by Operetta system revealed a clear ability of *L. acidophilus* to prevent adhesion of *P. aeruginosa* to A549 cells, in exclusion experiments. Such results were confirmed by CFU count.

Discussion and conclusions: Diversity was observed in the adhesion properties of various *Lactobacillus* strains to human lung epithelial cells. Based upon such adhesive properties, *L. acidophilus* was identified as an interesting candidate that will undergo further studies as potential probiotic for aerogenous administration. The triple-fluorescence staining and the computer-assisted quantitative analysis via the Operetta system revealed a feasible and high sensitive method that can simultaneously probe and localize the relative adhesion of *Lactobacillus* and pathogens onto host cells. Such method may represent an important tool for studying the complex interplay between bacterial pathogens and host. *The study received support from the Italian Cystic fibrosis research foundation, Project FFC#13/2021.*

118 - Recall immune responses after murine respiratory pneumococcal infection are detected by *in vitro* restimulation of splenocytes with *Streptococcus pneumoniae* inactivated whole cells

Isabelle Moscardini ⁽¹⁾ - Francesco Santoro ⁽²⁾ - Monica Carraro ⁽²⁾ - Alice Gerlini ⁽¹⁾ - Fabio Fiorino ⁽²⁾ - Chiara Germoni ⁽²⁾ - Samaneh Gholami ⁽²⁾ - Elena Pettini ⁽²⁾ - Donata Medaglini ⁽²⁾ - Francesco Iannelli ⁽²⁾ - Gianni Pozzi ⁽²⁾

Microbiotec srl, -, Siena, Italia ⁽¹⁾ - Univesità di Siena, Dipartimento di Biotechnologie Mediche, Siena, Italia ⁽²⁾

Recall immune responses after murine respiratory pneumococcal infection are detected by *in vitro* restimulation of splenocytes with *Streptococcus pneumoniae* inactivated whole cells

ISABELLE F. MOSCARDINI¹, FRANCESCO SANTORO², MONICA CARRARO², ALICE GERLINI, FABIO FIORINO², CHIARA GERMONI², SAMANEH GHOLAMI², ELENA PETTINI², DONATA MEDAGLINI², FRANCESCO IANNELLI², GIANNI POZZI²

¹Microbiotec srl, Siena, Italy

²Department of Medical Biotechnologies, University of Siena, Siena, Italy

Introduction

The *in vitro* stimulation of immune system cells with live or killed bacteria is essential for understanding the host response to pathogens. In the present study, we propose a model combining transcriptomic and cytokine assays on murine splenocytes to describe the immune recall in the days following pneumococcal lung infection.

Materials and Methods

Mice were sacrificed at days 1, 2, 4, and 7 after *Streptococcus pneumoniae* (TIGR4 serotype 4) intranasal infection and splenocytes were cultured in the presence or absence of the same inactivated bacterial strain to access the transcriptomic and cytokine profiles.

Results

The stimulation of splenocytes from infected mice led to a higher number of differentially expressed genes than the infection or stimulation alone, resulting in the enrichment of 40 unique blood transcription modules, including many pathways related to adaptive immunity and cytokines. Together with transcriptomic data, cytokines levels suggested the presence of a recall immune response involving both innate and adaptive immunity, stronger from the fourth day after infection. Dimensionality reduction and feature selection identified key variables of this recall response and the genes associated with the increase in cytokine concentrations.

Discussion and Conclusions

This model could study the immune responses involved in pneumococcal infection and monitor vaccine immune response and experimental therapies efficacy in future studies. A set of possible biomarkers of early and late infection was identified.

119 - Antimicrobial peptide human beta-defensin-2 reduces the gut inflammation induced by enteroinvasive *Escherichia coli* by inhibiting invasion and virulence factors expression

Alessandra Fusco ⁽¹⁾ - Vittoria Savio ⁽¹⁾ - Giovanna Donnarumma ⁽¹⁾

Università della Campania Luigi Vanvitelli, Dipartimento di Medicina Sperimentale, Napoli, Italia ⁽¹⁾

Antimicrobial peptide human beta-defensin-2 reduces the gut inflammation induced by enteroinvasive *Escherichia coli* by inhibiting invasion and virulence factors expression

ALESSANDRA FUSCO, VITTORIA SAVIO, GIOVANNA DONNARUMMA

Dipartimento di Medicina Sperimentale, Università della Campania “Luigi Vanvitelli, Napoli, Italia

Introduction: the intestinal microbiota consist of a community of about 100 trillion of mutualistic microorganisms that contributes to homeostasis and to development of the intestine by regulating various metabolic functions of the host, such as digestion and the supply of nutrients. One of the species most represented in the intestinal microbiota is *Escherichia coli*, a Gram-negative bacillus that, as commensal, colonizes especially the lower tract of the human intestine. However, some strains of *E. coli* can acquire, through the horizontal transfer of DNA, a virulence factors which making them able to adapt to new intestinal niches. Among these, enteroinvasive *E. coli* (*EIEC*) is responsible for the bacillary dysentery that causes diarrheal symptoms similar to shigellosis in both children and adults, particularly in low-income countries and in poor hygiene conditions. The indiscriminate use of antibiotics has led to the development of bacterial resistance which represents a danger to global public health. In this scenario, antimicrobial peptides (AMPs) have received widespread attention due to their broad antimicrobial spectrum and low incidence of resistance phenomena. Furthermore, AMPs modulate the immune defenses of the host and regulate the composition of microbiota and the renewal of the intestinal epithelium. Aim of this work was to create a line of intestinal epithelial cells able to express high concentrations of antimicrobial peptide human beta-defensin-2 (HBD-2), to test its ability to interfere with the pathogenicity mechanisms of *EIEC*. Materials and Methods: *Cell cultures*: gene coding HBD-2 was cloned and transfected into Caco-2 cells which were subcultured for 21 days to obtain their full differentiation. *Infection and Real-Time PCR*: the transfected and untransfected cells were infected with *EIEC* and the modulation of expression levels of pro- and anti-inflammatory cytokines, and of bacterial virulence factors was evaluated by Real-Time PCR. *Invasiveness assay*: transfected and untransfected cells were infected with 10⁸ CFU/ml of *EIEC* for 2 hours at 37°C, then were treated with gentamicin at bactericidal concentration for additional 2 h, and finally lysed, serially diluted and incubated overnight at 37 °C to identify the viable intracellular bacteria. Results: HBD-2 is able to significantly reduce the expression of the proinflammatory cytokines and the invasiveness ability of *EIEC*. The molecular analysis on the bacterial genes associated with invasive ability shows a constant reduction in the expression of all virulence factors in presence of HBD-2. Discussion and Conclusions: These findings set the stage for the search for alternative natural therapeutic solutions for the treatment of difficult-to-treat infections.

123 - Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis homologues peptides elicit a strong humoral response in patients with neuroinflammatory disorders, and exacerbate EAE

Davide Cossu ⁽¹⁾ - Leonardo Antonio Sechi ⁽¹⁾ - Nobutaka Hattori ⁽²⁾

Universita, Dipartimento Scienze Biomediche, Sassari, Italia ⁽¹⁾ - Universita, Juntendo University, Department of Neurology, Tokyo, Giappone ⁽²⁾

Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis homologues peptides elicit a strong humoral response in patients with neuroinflammatory disorders, and exacerbate EAE

DAVIDE COSSU ^{1,2}, SECHI LEONARDO ANTONIO ², NOBUTAKA HATTORI ¹

¹*Department of Neurology, Juntendo University, Tokyo, Japan*

²*Department of Biomedical Sciences, Sassari University, Sassari, Italy*

1. Introduction

Neuroinflammation can be induced by pathogens infection such as bacteria and virus, however, their pathological role still unclear. Here, we characterized antibodies against *Epstein-Barr* virus (EBV) nuclear antigen 1 (EBNA1), *Mycobacterium avium* subsp. *paratuberculosis* (MAP) heat shock protein (HSP) 70, and human central nervous system protein GlialCAM homologues peptides in blood samples of Japanese patients with different neurological disorders. Furthermore, we tested the effects of these peptides in active experimental autoimmune encephalomyelitis (EAE), a common animal model of neuroinflammatory disorders.

2. Material and Methods

Forty-seven patients with multiple sclerosis (MS), 32 with neuromyelitis optica spectrum disorder (NMOSD), 19 with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), 32 disease controls, and 70 healthy controls, were retrospectively tested using indirect and inhibition ELISAs. Group of female C57BL/6J mice received were immunized with the pathogen-derived peptides two weeks prior active EAE induction using myelin oligodendrocyte glycoprotein.

3. Results

A significantly strong antibody response against EBNA1₃₈₆₋₄₀₅, MAPHSP70₅₃₃₋₅₄₅ and GlialCAM₃₇₀₋₃₈₉ was detected in the serum of patients with MS and NMOSD in comparison to patient with MOGAD, and both control groups. A good direct correlation between antibody titers was evidenced in patients with MS and NMOSD. Moreover, competitive immunoassay demonstrated the presence of cross-reactive antibodies to EBV and MAP antigens. No significant correlation was found between antibody titers and clinical therapy, aquaporin-4 antibody titer.

Following immunization with EBNA1₃₈₆₋₄₀₅ and MAPHSP70₅₃₃₋₅₄₅ peptides, mice showed early onset and more severe disease in comparison to no treated mice.

4. Discussion and Conclusions

We demonstrated a strong humoral response and the significant presence of cross-reactive antibodies against EBV and MAP derived peptides in patients with MS and NMOSD, as well as the encephalitogenic potential of these peptides in EAE model, providing evidence for an association between these pathogens and different demyelinating disorders. Molecular mimicry could be the mechanism by which EBV and MAP can induce autoimmunity in genetically susceptible individuals.

129 - Salmonella Infantis releases Outer Membrane Vesicles (OMVs) including beta-lactamases enzymes during their biogenesis

Valeria Toppi⁽¹⁾ - Gabriele Scattini⁽¹⁾ - Laura Musa⁽¹⁾ - Luisa Pascucci⁽¹⁾ - Elisabetta Chiaradia⁽¹⁾ - Alessia Tognoloni⁽¹⁾ - Maria Pia Franciosini⁽¹⁾ - Patrizia Casagrande Proietti⁽¹⁾

Università degli Studi di Perugia, Dipartimento di Medicina Veterinaria, Perugia, Italia⁽¹⁾

Salmonella Infantis releases Outer Membrane Vesicles (OMVs) including beta-lactamase enzymes during their biogenesis.

VALERIA TOPPI¹, GABRIELE SCATTINI², LAURA MUSA¹, LUISA PASCUCCI², ELISABETTA CHIARADIA³, ALESSIA TOGNOLONI³, MARIA PIA FRANCIOSINI¹, PATRIZIA CASAGRANDE PROIETTI¹.

¹Dipartimento di Medicina Veterinaria, sezione di Microbiologia e Malattie Infettive, Università degli Studi di Perugia, Perugia (Italia); ²Dipartimento di Medicina Veterinaria, sezione di Anatomia, Università degli Studi di Perugia, Perugia (Italia); ³Dipartimento di Medicina Veterinaria, sezione di Biochimica, Università degli Studi di Perugia, Perugia (Italia).

Introduction: Outer membrane vesicles (OMVs) are spherically bilayered nanoparticles, released into extracellular milieu by Gram-negative bacteria. OMVs originate from the outer membrane, contain different cargo molecules and mediate several biological processes. Recent studies have shown that OMVs are involved in antibiotic resistance (AR) mechanisms by including beta-lactamase enzymes, which degrade beta-lactam antibiotics, in their lumen. Recently, multidrug resistant and extended-spectrum beta-lactamases (ESBLs) *Salmonella* Infantis strains have spread widely in Europe. Since no studies have been conducted on *S. Infantis*' OMVs yet, the aim of the work was to collect OMVs from *S. Infantis* beta-lactam resistant and susceptible strains and to investigate whether beta lactamase enzymes are included in OMVs during their biogenesis by measuring the beta-lactamase enzymes activity in the OMVs. **Materials and Methods:** OMVs were isolated through filtration and ultrafiltration of culture supernatants. To investigate the presence of beta-lactamase enzymes into OMVs, beta-lactamase activity was quantified by Nitrocefin assay in three different samples: the filtered supernatants, the eluted samples from ultrafiltration, and then OMVs concentrates. Transmission electron microscopy (TEM) was used to investigate OMVs morphology. To normalize beta-lactamase activity value proteins from all samples were quantified by Bradford assay. Anti-beta-lactamase antibody was used to confirm the presence of beta-lactamase enzymes into OMVs. Statistical analysis was applied. **Results:** in the study we found that both beta-lactam and susceptible strains release OMVs. TEM images showed round shaped vesicles, from 60 to 230 nm, mainly organized in clusters with an electrodense appearance. No beta-lactamase activity value was detected in OMVs from susceptible strains. A very low value due to free beta-lactamase and OMVs was measured in filtered supernatants. The eluted samples showed a low activity value for the presence of free beta-lactamase. A significantly higher value than in the filtered and eluted samples, was obtained in OMVs concentrates. Anti-beta-lactamase antibody confirmed the presence of beta-lactamase enzymes in the lumen of the OMVs. **Discussion and Conclusions:** these results suggest that beta-lactamase enzymes also get packaged into OMVs from bacterial periplasm during OMVs biogenesis. A possible explanation could be that enzymes are loaded into OMVs to be protect from proteases degradative action. The possibility of investigating and understanding whether OMVs play a role in the mechanisms of AR opens the way towards the chance of developing new therapeutic strategies to fight antibiotic resistance in the future.

133 - Creation of an *in vitro* model for the screening of different probiotic strains able to prevent inflammatory diseases of the gastrointestinal system

Adriana Chiaromonte ⁽¹⁾ - Angela Cacace ⁽¹⁾ - Brunella Perfetto ⁽¹⁾ - Vittoria Savio ⁽¹⁾ - Alberto Alfano ⁽¹⁾ - Giovanna Donnarumma ⁽¹⁾

Università della Campania Luigi Vanvitelli, Dipartimento di Medicina Sperimentale, Napoli, Italia ⁽¹⁾

Creation of an *in vitro* model for the screening of different probiotic strains able to prevent inflammatory diseases of the gastrointestinal system

ADRIANA CHIAROMONTE, ANGELA CACACE, BRUNELLA PERFETTO, VITTORIA SAVIO, ALBERTO ALFANO, GIOVANNA DONNARUMMA

Dipartimento di Medicina Sperimentale, Università della Campania “Luigi Vanvitelli”, Napoli, Italia

Introduction:the integrity of intestinal barrier is fundamental for gut health and homeostasis; this condition is maintained by a mucus layer of epithelial cells held together by a complex system of intercellular junctions including weak and apical protein complexes that called “tight junctions” (TJs); TJs are composed of several multiprotein complexes including transmembrane proteins such as Claudin and Occludin, Junctional Adhesion Molecules and others, which interact with each other and with intracellular scaffold proteins, including Zonula Occludens, which are anchored to the actin cytoskeleton. These interactions control the passage of solutes, water, large molecules, and ions through the extracellular space. Alterations to TJs are associated with changes in epithelial permeability, which can lead to several diseases, such as inflammatory bowel disease, irritable bowel syndrome, celiac disease, diabetes, diarrhea, atopic eczema, and altered sensitivity to food allergens. *Lactobacillus* spp. are naturally present in the human intestinal tract, and several species and strains have been evaluated for their probiotic activity. The enhancement of epithelial barrier function is one of the proposed mechanisms by which certain probiotic organisms may confer beneficial activities. In this study we performed an intestinal co-cultures model, which provides a mucus-coated epithelial monolayer able to reproduce the condition that occurs *in vivo*, treated with different strain of *lactobacilli*, to establish the strains most active in strengthening the integrity of the barrier. **Materials and methods:** adenocarcinoma colorectal Caco-2 and HT29-MTX mucus-secreting epithelial cells were plated in 12-well Transwell® with polycarbonate insert, in a 7: 3 ratio Caco-2: HT29-MTX and cultured in DMEM medium with 10% fetal bovine serum, 100 IU / ml penicillin, 100mg / ml streptomycin and 2mM glutamine, at 37 ° C in a 5% CO₂ for 21 days to obtain their differentiation. Co-cultures were then treated with the 0.5 O.D. suspensions of *Lactobacillus brevis*, *Lactobacillus fermentum*, *Bifidobacterium lactis*, *Lactobacillus rhamnosus*, *Lactobacillus reuteri* and *Lactobacillus paracasei*, cultivated at 37 ° C in microaerophilic conditions in MRS broth. The infection was carried out for 6 hours, then the expression of the tight junctions Zonulin-1, Claudin-1 and Occludin genes was evaluated by Real-Time PCR. **Results:** all strains tested are able to significantly induce the expression of all TJs genes. **Discussion and Conclusions:** these data suggest the possibility to use specific formulations based on selected probiotic strains for the treatment and prevention of the reduced epithelial barrier function found in many disorders.

135 - *Limosilactobacillus fermentum* from buffalo milk inhibits *Helicobacter pylori* in a gastric epithelial cell model

Angela Cacace⁽¹⁾ - Adriana Chiaromonte⁽¹⁾ - Brunella Perfetto⁽¹⁾ - Donatella Cimini⁽²⁾ - Sergio D'Ambrosio⁽¹⁾ - Giovanna Donnarumma⁽¹⁾

Università della Campania Luigi Vanvitelli, Dipartimento di Medicina Sperimentale, Napoli, Italia⁽¹⁾ -
Università della Campania Luigi Vanvitelli, Dipartimento di Scienze e Tecnologie Ambientali
Biologiche e Farmaceutiche, Napoli, Italia⁽²⁾

***Limosilactobacillus fermentum* from buffalo milk inhibits *Helicobacter pylori* in a gastric epithelial cell model.**

ANGELA CACACE¹, ADRIANA CHIAROMONTE¹, BRUNELLA PERFETTO¹, DONATELLA CIMINI², SERGIO D'AMBROSIO¹, GIOVANNA DONNARUMMA¹

¹Dipartimento di Medicina Sperimentale, Università della Campania "Luigi Vanvitelli", Napoli, Italia

²Dipartimento di Scienze e Tecnologie Ambientali Biologiche e Farmaceutiche, Università della Campania "Luigi Vanvitelli", Napoli, Italia

Introduction: *Helicobacter pylori*, a Gram-negative microorganism, is recognized as a major cause of most gastroduodenal diseases, including gastric adenocarcinoma and gastric cancer. Prevailing therapy as the primary treatment of *H. pylori* infection involves a proton pump inhibitor and antibiotics (amoxicillin and clarithromycin), but this treatment can cause serious side effects. Therefore, probiotics, defined as "live microorganisms which, when administered in adequate quantities, can exert a health benefit to the host", have been studied as an adjuvant therapy modality. The aim of this study was to evaluate the role of a strain of *Limosilactobacillus fermentum* isolated from buffalo milk during *H. pylori* infection in gastric epithelial cells. **Materials and methods:** human gastric adenocarcinoma cell line AGS cells were cultured in Ham's F-12 K medium supplemented with 1% Penstrep, 1% glutamine and 10% fetal calf serum at 37°C and 5% CO₂. The isolated strain of *L. fermentum* was identified by molecular analysis with amplification of specific sequences. Before the infection, the strain was grown anaerobically in MRS broth at 37°C for 24-48 h, centrifuged at 4.000 x g for 10 min, washed twice with saline solution, resuspended at the concentration of 0.5 OD₆₀₀ (10⁸ CFU/ml) and added to the cell cultures in absence of antibiotics. *H. Pylori* was cultivated on TSA plates in microaerophilic conditions at 37° for 48-72 h. The infection was carried out in three different ways: (i) Competitive assay, in which AGS cells were incubated simultaneously for with *L. fermentum* and *H. pylori* for 2 h; (ii) Inhibition assay, in which AGS cells were preincubated with *L. fermentum* for 1.5 h and then *H. pylori* was added and incubated for 2 h; (iii) Displacement assay in which AGS cells were pre-incubated with *H. pylori* for 2 h and then *L. fermentum* was added and further incubated for 1.5 h. Finally, Real Time PCR was carried out to evaluate the expression of pro- and anti-inflammatory cytokines IL-6, IL-8, TNF-alpha, IL-1alfa, IL-1beta, TGF-beta and antimicrobial peptide human beta defensin-2 (HBD-2) with the LightCycler software. **Results:** the data obtained show that *L. fermentum* can almost completely inhibit the inflammatory state strongly induced by *H. pylori* in the displacement assay, by downregulating IL-1alfa, IL-6 and IL-8. Therefore, the probiotic is also able to increase the antimicrobial defenses by upregulating the expression of HBD-2, improving the conditions of the gastric mucosa damaged by *H. pylori*. **Discussion and conclusions:** considering that the treatments against *H. pylori* infections may cause serious side effects and increased antibiotic resistance, the use of *Lactobacillus* spp. instead of antibiotics could allow one to avoid this disadvantage.

137 - Induction of robust humoral immunity against SARS-CoV-2 both at post-infection and post-vaccine administration in a cohort of haematological cancer patients

Cinzia Borgogna⁽¹⁾ - Riccardo Bruna⁽²⁾ - Gloria Griffante⁽¹⁾ - Licia Martuscelli⁽¹⁾ - Marco De Andrea⁽³⁾ - Daniela Ferrante⁽⁴⁾ - Andrea Patriarca⁽²⁾ - Abdurraouf Mahmoud⁽²⁾ - Maghalie Ucciero⁽²⁾ - Valentina Gaidano⁽⁵⁾ - Monia Marchetti⁽⁵⁾ - Davide Rapezzi⁽⁶⁾ - Michele Lai⁽⁷⁾ - Mauro Pistello⁽⁷⁾ - Marco Ladetto⁽⁵⁾ - Massimo Massaia⁽⁶⁾ - Gianluca Gaidano⁽²⁾ - Marisa Gariglio⁽¹⁾

University of Piemonte Orientale, Virology Unit, Department of Translational Medicine, Novara, Italia⁽¹⁾ - University of Piemonte Orientale and “Maggiore della Carità” Hospital, Division of Hematology, Department of Translational Medicine, Novara, Italia⁽²⁾ - University of Turin, Viral Pathogenesis Unit, Department of Public Health and Pediatric Sciences, Torino, Italia⁽³⁾ - University of Piemonte Orientale, Medical Statistics Unit, Department of Translational Medicine, Novara, Italia⁽⁴⁾ - University of Piemonte Orientale and “SS Antonio e Biagio e Cesare Arrigo” Hospital, Division of Hematology, Department of Translational Medicine, Alessandria, Italia⁽⁵⁾ - “Santa Croce e Carle di Cuneo” Hospital, Division of Hematology, Cuneo, Italia⁽⁶⁾ - University of Pisa, Retrovirus Centre, Department of Translational Medicine and New Technologies in Medicine and Surgery, Pisa, Italia⁽⁷⁾

Induction of robust humoral immunity against SARS-CoV-2 both at post-infection and post-vaccine administration in a cohort of haematological cancer patients

Cinzia BORGOGNA¹, Riccardo *BRUNA*², Gloria *GRIFFANTE*¹, Licia *MARTUSCELLI*¹, Marco *DE ANDREA*³, Daniela *FERRANTE*⁴, Andrea *PATRIARCA*², Abdurraouf M. *MAHMOUD*², Maghalie A. M. *UCCIERO*², Valentina *GAIDANO*⁵, Monia *MARCHETTI*⁵, Davide *RAPEZZI*⁶, Michele *LAI*⁷, Mauro *PISTELLO*⁷, Marco *LADETTO*⁵, Massimo *MASSAIA*⁶, Gianluca *GAIDANO*² and Marisa *GARIGLIO*¹.

¹ Virology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; ² Division of Hematology, Department of Translational Medicine, University of Piemonte Orientale and “Maggiore della Carità” Hospital, Novara, Italy; ³ Viral Pathogenesis Unit, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy; ⁴ Medical Statistics, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; ⁵ Division of Hematology, University of Piemonte Orientale and “SS Antonio e Biagio e Cesare Arrigo” Hospital, Alessandria, Italy; ⁶ Division of Hematology, “Santa Croce e Carle di Cuneo” Hospital, Cuneo Italy; ⁷ Retrovirus Centre, Department of Translational Medicine and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Impaired seroconversion upon SARS-CoV-2 infection has been repeatedly reported in “frail” patients, including patients with haematological malignancies (HM). To date, the effectiveness of the antibody response to SARS-CoV-2 following both infection and vaccination in patients with HM remains poorly understood. Here, we have analysed the humoral response to anti-SARS-CoV-2 in a disease-overarching cohort of 120 HM patients at two time points (post-infection and post-vaccination). In the study cohort the overall percentage of seroconversion, as judged by COVID-SeroIndex ELISA, at post-infection was 84.2% (101/120), which has increased to 94.2% (113/120) after vaccination. At both timings, the lowest values were found in patients with lymphoid malignancies or undergoing chemotherapy. Therapy-naïve patients in the “watch and wait” status were more likely to seroconvert and display increased anti-s IgG titers. Quantification of neutralising antibody (NAb) levels by testing the sera against rVSV-SARS-CoV-2-S_{Δ21} infection of Vero E6-TMPRSS2 cells revealed that, after infection, males, patients in the groups “watch and wait” or “complete/ partial response” during SARS-CoV-2 infection, and patients who experienced severe/critical COVID-19 all displayed enhanced neutralizing activity. Likewise, vaccinated patients included in the ‘watch and wait’ and ‘complete/partial response’ groups showed the highest neutralising titres. Furthermore, as observed also with anti-s IgG titres, no significant variations were found between single or double vaccine administrations. In both conditions, the proportion of patients with a neutralisation titre

sufficient to provide 50% protection from symptomatic COVID-19 always exceeded 50%, regardless of the HM type, but the percentage of protected individuals increased after vaccination, especially in patients with lymphoid malignancies. Although our findings confirm the reduced seroconversion in HM patients, especially those with lymphoid disorders or undergoing chemotherapy-based treatment during SARS-CoV-2 infection, the overall neutralizing humoral response upon natural SARS-CoV-2 infection seems to be quite efficient and sustained overtime. Moreover, the humoral response after vaccine administration, even at a single dose, is significantly boosted in HM patients who recovered from SARS-CoV-2 infection with a percentage of patients displaying protection against severe COVID-19 falling in the range of 69 to 82%. Therefore, additional vaccine administration might be avoided, at least in the short-term period in this group of patients.

146 - THE VIRAL SENSOR IFI16 AT THE CROSSROADS BETWEEN DAMAGE AND TOLERANCE DURING HUMAN CORONAVIRUS INFECTION

Gloria Griffante⁽¹⁾ - Shika Chandel⁽¹⁾ - Cinzia Borgogna⁽¹⁾ - Serena Delbue⁽²⁾ - Lucia Signorini⁽²⁾ - Marco De Andrea⁽³⁾ - Marisa Gariglio⁽¹⁾

Università del Piemonte Orientale, Dip. Medicina Translazionale, Virology Unit, Novara, Italia⁽¹⁾ - Università degli Studi di Milano, Department of Biomedical, Surgical and Dental Sciences, Milan, Italia⁽²⁾ - University of Turin, Department of Public Health and Pediatric Sciences, Turin, Italia⁽³⁾

THE VIRAL SENSOR IFI16 AT THE CROSSROADS BETWEEN DAMAGE AND TOLERANCE DURING HUMAN CORONAVIRUS INFECTION

GLORIA GRIFFANTE¹, SHIKHA CHANDEL¹, CINZIA BORGOGNA¹, SERENA DELBUE², LUCIA SIGNORINI², MARCO DE ANDREA^{3,4}, MARISA GARIGLIO^{1,3}

Author affiliations:

¹*University of Piemonte Orientale, Department of Translational Research, Novara, Italy;*

²*University of Milan, Department of Biomedical, Surgical and Dental Sciences, Milano, Italy;*

³*CAAD Center for Translational Research on Autoimmune and Allergic Disease, Novara, Italy;*

⁴*University of Turin, Department of Public Health and Pediatric Sciences, Medical School, Turin, Italy.*

Abstract

Unlike humans, bats can asymptotically harbour different types of zoonotic viruses, such as severe acute respiratory syndrome coronaviruses (SARS-CoVs), thanks to their unique ability to efficiently regulate host immune responses to viral infections. Intriguingly, bats harbour genetic or functional loss of a number of proteins involved in innate immunity, including the PHYN gene family that comprises the interferon (IFN)-inducible gene IFI16. In humans, besides acting as viral DNA sensor involved in innate signalling and viral restriction, IFI16 appears to play a crucial role also in RNA virus infection. For example, IFI16 can bind to both influenza *viral RNA* and RIG-I, a pathogen recognition receptor (PRR), thereby leading to enhanced RIG-I-dependent IFN production and inhibition of viral replication. Fittingly, RIG-I has been recently shown to act as restriction factor in the early phase of SARS-CoV-2 infection. Thus, even though the cross talk between IFI16 and RIG-I during SARS-CoV-2 infection has not been analysed yet, it is very likely that both cellular receptors may play an important role in controlling human coronavirus (HCoV) replication and host innate response. Against this background, we hypothesized that IFI16 is a key regulator of PRR-mediated host response to HCoV infection in human epithelial cells and that therapeutic modulation of this pathway may impact HCoV replication/infectivity. To test this hypothesis, we used wild-type (WT) and IFI16 knock-out (KO) spontaneously immortalized human keratinocytes (HaCat) cell lines that were infected with two bat-derived HCoV e.g. the low pathogenic NL63 (alpha-hCoV) and the highly pathogenic SARS-CoV-2 (beta-hCoV). We have observed that infection of IFI16-depleted epithelial cells with the low-pathogenic virus NL63 leads to aberrant IFN production, which in turn interferes with the late stages of viral replication and the infectivity of the released virions. Similarly, SARS-CoV-2 infection is also impaired in epithelial cells lacking IFI16. Upon characterization of NL63 infection in a monkey epithelial cell line named LLC-Mk2, we have found that IFI16 trafficks from the nucleus to the cytoplasm in infected cells, whereby it colocalizes with the viral Nucleoprotein (NP), suggesting a potential interaction between IFI16 and NP or even with the viral genome. We are currently characterizing this interaction. Overall, the results so far obtained indicate that the IFI16 protein may interfere with the sensing of the viral genome with ensuing impact on the innate immune response during hCoV infection

149 - Correlations between chronic intestinal pseudo-obstruction (CIPO), gut microbiota and intestinal serotonin-related genes expression.

Giulia Radocchia⁽¹⁾ - Bruna Neroni⁽¹⁾ - Massimiliano Marazzato⁽¹⁾ - Fabrizio Pantanella⁽¹⁾ - Letizia Zenzeri⁽²⁾ - Francesca Vassallo⁽²⁾ - Enrico Felici⁽³⁾ - Giovanni Di Nardo⁽²⁾ - Serena Schippa⁽¹⁾

La Sapienza University of Rome, Department of Public Health and Infectious Diseases, Roma, Italia⁽¹⁾ - Child Neurology, NESMOS Department, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italia⁽²⁾ - Pediatric and Pediatric Emergency Unit, "Umberto Bosio" Center for Digestive Diseases, The Children Hospital, AO SS Antonio e Biagio e Cesare Arrigo, Rome, Italia⁽³⁾

Correlations between chronic intestinal pseudo-obstruction (CIPO), gut microbiota and intestinal serotonin-related genes expression.

GIULIA RADOCCIA¹, BRUNA NERONI¹, MASSIMILIANO MARAZZATO¹, FABRIZIO PANTANELLA¹, LETIZIA ZENZERI², FRANCESCA VASSALLO², ENRICO FELICI³, GIOVANNI DI NARDO², SERENA SCHIPPA¹

¹ Department of Public Health and Infectious Diseases, La Sapienza University of Rome, Rome, Italy;

² Child Neurology, NESMOS Department, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy;

³ Pediatric and Pediatric Emergency Unit, "Umberto Bosio" Center for Digestive Diseases, The Children Hospital, AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.

Introduction: Chronic intestinal pseudo-obstruction (CIPO) is a rare disease characterized by symptoms and radiological signs suggestive of intestinal obstruction, in the absence of lumen-occluding lesions. It results from an extremely severe impairment of propulsive motility. Serotonin (5-HT, a local mediator and neurotransmitter) release is linked to intestinal peristaltic and secretory reflexes. The intestinal microbiota and the enteric nervous system (ENS) interact and this results in effects on the synthesis of 5-HT, its release and the subsequent serotonin receptors' activation. The interplay between ENS/5-HT and dysbiosis in CIPO remains largely unclear. The project aim was to assess correlations between gut microbiota, intestinal serotonin-related genes expression and the disease status in CIPO pediatric patients. For this purpose, mucosa-associated microbiota (MAM) has been characterized, and changes in gastrointestinal (GI) serotonin pathway have been evaluated. **Material and Methods:** We collected biopsies of the colon, the ileum and the duodenum from 7 pediatric CIPO patients and 7 age-/sex-matched healthy controls at Cesare Arrigo Childrens' Hospital (Alessandria, Italy). After DNA extraction, the MAM was assessed by next generation sequencing (NGS) of the V3-V4 region of the bacterial RNA 16s, on an Illumina Miseq platform. The expression of genes implicated in serotonergic pathway (*TPH1*, *SLC6A4*, *5-HTR3* and *5-HTR4*) was established by qPCR, after total RNA extraction from the same tissue samples. Correlation analyses were performed to highlight relationships between MAM and the expression of genes linked to the production (*TPH1*), transport (*SLC6A4*) and reception (*5-HTR3*, *5-HTR4*) of 5-HT, and clinical parameters of CIPO patients. **Results:** Our results revealed a MAM different in its composition and biodiversity with respect to controls. Network analysis evidenced, in CIPO patients, a microbial ecosystem with fewer species, less connected, and with a greater number of non-synergistic relationships compared to controls. qPCR analysis results revealed alterations, a general decrease, in the expression of serotonin-related genes for CIPO patients when compared to controls. **Discussion and conclusion:** Results showed, for the first time in CIPO patients, a specific MAM associated to CIPO and an altered expression of genes related to intestinal serotonin pathway. A possible malfunctioning in the 5-HT pathway, maybe linked to or triggered by an altered microbiota, could be a mechanism underlying the intestinal motility disorder in CIPO patients. Our results could also represent the first step to design a new therapy targeting the microbiota or targeting the serotonin pathways, improving treatment outcomes and quality of life for CIPO patients.

150 - Characterization of citrullination during infection with DNA and RNA viruses: a new strategy for host-targeting antivirals drugs

Selina Pasquero ⁽¹⁾ - Gloria Griffante ⁽²⁾ - Francesca Gugliesi ⁽¹⁾ - Matteo Biolatti ⁽¹⁾ - Camilla Albano ⁽¹⁾ - Greta Bajetto ⁽¹⁾ - Valentina Dell'Oste ⁽¹⁾ - Paul R Thompson ⁽³⁾ - Sudeshna Sen ⁽³⁾ - Serena Delbue ⁽⁴⁾ - Silvia Parapini ⁽⁴⁾ - Maria Dolci ⁽⁴⁾ - Santo Landolfo ⁽¹⁾ - Marco De Andrea ⁽¹⁾

University of Turin, Department of Public Health and Pediatric Sciences, Torino, Italia ⁽¹⁾ - University of Eastern Piedmont, Department of Translational Medicine, Novara, Italia ⁽²⁾ - UMass Medical School, Department of Biochemistry and Molecular Pharmacology, Worcester, - ⁽³⁾ - University of Milan, Department of Biomedical, Surgical and Dental Sciences, Milano, Italia ⁽⁴⁾

Characterization of citrullination during infection with DNA and RNA viruses: a new strategy for host-targeting antivirals drugs

SELINA PASQUERO (1), GLORIA GRIFFANTE (3), FRANCESCA GUGLIESI (1), MATTEO BIOLATTI (1), CAMILLA ALBANO (1), GRETA BAJETTO (1), VALENTINA DELL'OSTE (1), PAUL R. THOMPSON (5), SUDESHNA SEN (5), SERENA DELBUE (4), SILVIA PARAPINI (4), MARIA DOLCI (4), SANTO LANDOLFO (1, 3), MARCO DE ANDREA (1, 2).

(1) *Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy*

(2) *CAAD Center for Translational Research on Autoimmune and Allergic Disease, Novara Medical School, 28100 Novara, Italy.*

(3) *Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy*

(4) *Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy*

(5) *Department of Biochemistry and Molecular Pharmacology, UMass Medical School, Worcester, Massachusetts 01605, United States.*

INTRODUCTION. One of the strategies devised by a number of bacteria and viruses to favor its replication consists in modifying host cellular proteins at the post-translational level, thereby altering their localization, interaction, activation and/or turnover. A post-translational modification (PTM) that is increasingly recognized to play an essential role in this regard is citrullination, also called deimination, a process where the guanidinium group of an arginine is hydrolyzed to form citrulline, a non-genetically encoded amino acid. This PTM is catalyzed by the calcium-dependent protein arginine deiminase (PAD) family of enzymes, which in humans is composed of five isoforms (PADs 1-4 and 6), with different tissue-specific expression and substrate specificities. Although aberrant citrullination has been detected in several inflammatory conditions, suggesting that it may play a pathogenic role in inflammation-related diseases, a direct correlation between citrullination and viral infections has only recently emerged. In the last few years our laboratory has defined the citrullination profile, the expression of the enzymes PADs and the citrullinated substrates in the course of infection with DNA and RNA viruses, Herpesvirus and Coronavirus respectively. In addition, we evaluated a large panel of PAD inhibitors for their antiviral activity against these virus classes in a wide variety of cell lines.

MATERIAL AND METHODS. We used Human Cytomegalovirus (HCMV) and herpes simplex virus type 1 (HSV-1) as models of DNA viruses and HCoV-OC43 and SARS-CoV-2 as models of RNA viruses. We tested the antiviral activity of well characterized PAD inhibitors. We used real time quantitative PCR to quantify copies of the viral genomes, Western blot analysis to evaluate the expression of PADs and viral proteins, and plaque assay to evaluate the production of new virions. Furthermore, we assessed the pattern of citrullination upon infection by using a citrulline-specific rhodamine phenylglyoxal (RhPG)-based probe.

RESULTS. Citrullinome analysis of infected cells reveals significant changes in deimination levels of both cellular and viral proteins, with interferon (IFN)-inducible protein IFIT1 being the most heavily deiminated one. Moreover, we show that in vitro IFIT1 citrullination impairs its ability to bind to 5'-pppRNA.

DISCUSSION AND CONCLUSION. In the present study, we unveil a signature of human Herpesvirus infection based on PAD-mediated citrullination of multiple cellular proteins to disrupt host defense mechanisms. Moreover, the pharmacological inhibition of PAD enzymes led to a significant reduction of viral replication.

151 - News Microbiological Marker in type 1 diabetes

The possible role of MAP And HERVs in the type 1 diabetes onset.

Marta Noli⁽¹⁾ - Seyedesomaye Jasemi⁽¹⁾ - Stefano Ruberto⁽¹⁾ - Elena Rita Simula⁽¹⁾ - Gian Franco Meloni⁽²⁾ - Davide Cossu⁽¹⁾ - Leonardo Antonio Sechi⁽¹⁾

Università degli studi di Sassari, Dipartimento di Scienze Biomediche, Sassari, Italia⁽¹⁾ - *Università degli studi di Sassari, Dipartimento di medicina clinica e sperimentale, Sassari, Italia*⁽²⁾

News Microbiological Marker in type 1 diabetes The possible role of MAP And HERVs in the type 1 diabetes onset.

Authors: MARTA NOLI¹, SEYEDESOMAYE JASEMI¹, STEFANO RUBERTO¹, ELENA R. SIMULA¹, GIAN FRANCO MELONI², DAVIDE COSSU¹, AND LEONARDO A. SECHI^{1,3}

¹Department of Biomedical Sciences, University of Sassari, viale San Pietro 43/B, 07100 Sassari, Italy; ² Department of clinical and experimental medicine, University of Sassari, viale San Pietro 8 07100 Sassari, Italy; ³AOU Sassari, UC Microbiologia e Virologia, 07100 Sassari, Italy.

Introduction: Type 1 diabetes (T1D) is an autoimmune disorder, characterized by the production of autoantibodies to the pancreatic beta-cells. In previous studies, we indicated that *Mycobacterium avium subspecies paratuberculosis* (MAP) could be a potential risk factor for T1D, suggesting that MAP infection could induce immune imbalance. Emerging evidence has also indicated that Human endogenous retrovirus (HERVs) may play a role in etiopathogenesis of T1D. Indeed, the envelope proteins of HERV-W and HERV-K families have been detected in serum and pancreas of patients with T1D. In the present study, we investigated the role of MAP and HERVs in a Sardinian pediatric population with T1D by analyzing the humoral response and variation over time toward peptides derived from both pathogens. **Materials and methods:** Different immunogenic peptides were used to test sera reactivity: MAP3865c₁₂₅₋₁₃₃, MAP2404c₇₀₋₈₀ peptides homologous to host beta-cell antigens, HERV-W₉₃₋₁₀₈, HERV-W₂₄₈₋₂₆₂ and HERV-K₁₉₋₃₇. Plasma samples collected from 69 patients with T1D, of which 26 at T1D onset, 23 from T1D diagnosed 1-5years, 20 with T1D diagnosed 6-12years, and 45 HCs were analyzed by indirect ELISA. To investigate the potential differences among the different antibodies in T1D patients, HCs we performed a Mann–Whitney test. The potential change in humoral response related to disease duration, the results of the four groups (onset T1D, 1–5years, 6–12years and HCs) were analyzed by Kruskal–Wallis test. **Results:** Statistical significative different response was observed in antibody titre against all MAP and HERVs peptides between patients at T1D Onset vs. HCs ($p < 0.0001$). A statistically significative and progressive decline was observed in antibody level as early as the first year of the disease. On the other hand, this pattern occurred with all peptides but not for HERV-K which remains constant from the onset until the age of six years. **Discussion and Conclusions:** Our results support the hypothesis that both pathogens are linked to T1D etiology, and also that HERVs activation can be induced by certain infectious agent such as MAP. The results are in line with this hypothesis, given the high reactivity expressed in patients T1D Onset for all peptide fragments evaluated. The progressive decrease in antibody titre over the years could reflect the development of an active autoimmune process at the onset. A contribution of MAP in this process could result from molecular mimicry with homologous epitopes such as Zinc transporter 8 (ZnT8) and Proinsulin (PI), leading to autoimmune responses. Taken together, these findings support the hypothesis that MAP and HERV could act as risk factors for T1D, suggesting that they may serve as potential biomarkers.

153 - Peptide L18R plays an antimicrobial modulating action against polymicrobial biofilm in LCWB model

Paola Di Fermo⁽¹⁾ - Simonetta D'Ercole⁽²⁾ - Tecla Ciociola⁽³⁾ - Firas Diban⁽¹⁾ - Morena Petrini⁽²⁾ - Stefania Conti⁽³⁾ - Mara Di Giulio⁽¹⁾ - Luigina Cellini⁽¹⁾

University of "G. d'Annunzio", Chieti-Pescara, Department of Pharmacy, Chieti, Italia⁽¹⁾ - University of "G. d'Annunzio", Chieti-Pescara, Department of Medical, Oral and Biotechnological Sciences, Chieti, Italia⁽²⁾ - University of Parma, Department of Medicine and Surgery, Parma, Italia⁽³⁾

Peptide L18R plays an antimicrobial modulating action against polymicrobial biofilm in LCWB model

PAOLA DI FERMO¹, SIMONETTA D'ERCOLE², TECLA CIOCIOLA³, FIRAS DIBAN¹, MORENA PETRINI², STEFANIA CONTI³, MARA DI GIULIO¹, LUIGINA CELLINI¹

¹Department of Pharmacy, University of "G. d'Annunzio" Chieti-Pescara, 66100, Chieti, Italy. ²Department of Medical, Oral and Biotechnological Sciences, University of "G. d'Annunzio" Chieti-Pescara, 66100, Chieti, Italy.

³Department of Medicine and Surgery, University of Parma, 43125, Parma, Italy.

Abstract

Introduction: Chronic wound infections represent an important health problem for the reduced response to antimicrobial treatment of the pathogens organized in structured biofilms. Over the last few years, antimicrobial peptides (AMPs) of various origins have attracted great attention as potential anti-infective agents to face the spreading resistance to conventional antibiotics. This study evaluated the potential effects of the antifungal peptide L18R against the relevant chronic wound pathogens: *Staphylococcus aureus*, *Pseudomonas aeruginosa* and *Candida albicans*. **Materials and methods:** The antimicrobial activity of L18R was evaluated against the single planktonic microbial populations, on single, dual and triadic species biofilms both in early stage and mature biofilm and in polymicrobial Lubbock Chronic Wound Biofilm (LCWB) model mimicking the spatial microbial colonization in a chronic wound. The evaluation of CFU, biofilm biomass detection, confocal and scanning electron microscopy analysis were performed. **Results:** L18R showed a significant antimicrobial activity against planktonic microorganisms (EC₅₀ values ranging from 0.278 to 1.157 µM) and was able to differentially reduce the biomass of monomicrobial biofilms (it reduces early and mature biofilm biomasses of *C. albicans* of 97.19% ± 1.02 and 98.81% ± 1.68, respectively, and of *S. aureus* of 45.65% ± 1.53 and 57.37% ± 6.45, respectively. A slight reduction was observed on *P. aeruginosa*). No reduction of biomass was observed against polymicrobial biofilm. In mature LCWB, L18R caused a moderate reduction in total CFU number, with a variable effect on the different tested microorganisms. In particular, L18R expressed a modulate action against all detected microorganisms, in respect to the control (Amikacin) in which the reduction of bacteria growth was associated to a great increase of the yeast cells. These data were confirmed by live/dead confocal images. **Discussion and Conclusions:** The results obtained show a modulating action of L18R making it an ideal approach for skin wound healing and recommend further studies on its potential role as adjunctive therapeutic agent in chronic wound management also in association to conventional or alternative treatments.

154 - Potential preventive role of probiotics against *Pseudomonas aeruginosa* corneal infection

Irene Paterniti ⁽¹⁾ - Sarah Adriana Scuderi ⁽¹⁾ - Jessica Molinari ⁽¹⁾ - Antonia Nostro ⁽¹⁾ - Emanuela Esposito ⁽¹⁾ - Andreana Marino ⁽¹⁾

Università, Università di Messina/Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali, Messina, Italia ⁽¹⁾

Potential preventive role of probiotics against *Pseudomonas aeruginosa* corneal infection

IRENE PATERNITI, SARA A. SCUDERI, MOLINARI JESSICA, ANTONIA NOSTRO, EMANUELA ESPOSITO, ANDREANA MARINO

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences. University of Messina, Messina, Italy.

Introduction. The ocular microbiome plays an important role in the maintenance of physiologic homeostasis of ocular surface and in the prevention of ocular diseases. Alterations of the normal microbiome change microbial composition causing an imbalance in favor of pathogenic species. Among these, *Pseudomonas aeruginosa* represents a common cause of severe corneal ulceration. The development of new antibiotics for ocular diseases is very slow, highlighting the need for alternative non-antibiotic strategies. Among these strategies, the probiotic therapy could help restoring the homeostasis of ocular surface and preventing or reducing adverse ocular outcomes caused by infection. The aim of this study was to assess the preventive role of probiotics against *P. aeruginosa* infection on human corneal epithelial cells (HCE). **Materials and Methods.** The HCE were used to assess the extent of protection by probiotics against *P. aeruginosa* infection. Probiotics: *Lactobacillus reuteri* DSM20016, *Bifidobacterium longum* subsp. *infantis* DSM20088 and *Staphylococcus epidermidis* DSM1798. Pathogen: *P. aeruginosa* ATCC 9027. The following assays were performed: cytotoxicity and adhesion to HCE of probiotics after 24 and 48 h of contact. Antagonism, cytotoxicity, anti-inflammatory and antioxidant properties of probiotics against *P. aeruginosa* infection were evaluated as follow: pretreatment of HCE with each probiotic (5×10^7 UFC/ml) at 1 h and 24 h prior to *P. aeruginosa* inoculation (5×10^6 UFC/ml) followed by 1 h and 24 h of growth in combination. **Results.** *S. epidermidis* significantly increased HCE vitality and demonstrated a greater ability to adhere to them both after 24 h and 48 h of contact than other probiotics. None of the probiotics have been shown to have antagonistic activity against growth and adhesion of *P. aeruginosa* to HCE. Instead, they have been shown to restore significantly the HCE viability and to promote the anti-inflammatory and antioxidant activity when in combination with the pathogen. MTT assay revealed that the probiotic combination groups significantly increased cell viability compared to *P. aeruginosa* infection groups particularly when HCE were pretreated with each probiotic for 24 h and exposed to pathogen for the next 24 h. At the same conditions Elisa test showed that the pretreated HCE significantly reduced the levels of TNF-alpha and increased those of IL-10 whereas Griess assay significantly demonstrated reduction of nitrite/nitrate ratio. **Discussion and Conclusions.** These results show that pretreatment with probiotics has not a direct role player in contrasting growth and adhesion of *P. aeruginosa* to HCE but, is to be highlighted that it reduces key factors associated with *P. aeruginosa* infection.

157 - Prospective monitoring of HIV-1 infected patients after SARS-CoV-2 mRNA vaccination: characterization of IFN gene expression signature and humoral immune response

Federica Frasca⁽¹⁾ - Mirko Scordio⁽¹⁾ - Letizia Santinelli⁽²⁾ - Luca Maddaloni⁽²⁾ - Leonardo Sorrentino⁽¹⁾ - Matteo Fracella⁽¹⁾ - Alessandra D'Auria⁽¹⁾ - Carla Selvaggi⁽²⁾ - Eugenio Nelson Cavallari⁽²⁾ - Anna Napoli⁽²⁾ - Lilia Cinti⁽²⁾ - Piergiorgio Roberto⁽²⁾ - Giancarlo Ceccarelli⁽²⁾ - Aurelia Gaeta⁽²⁾ - Guido Antonelli⁽³⁾ - Claudio Maria Mastroianni⁽²⁾ - Gabriella d'Ettore⁽²⁾ - Carolina Scagnolari⁽¹⁾

La Sapienza, Università di Roma, Dipartimento di Medicina Molecolare, Roma, Italia⁽¹⁾ - La Sapienza, Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia⁽²⁾ - La Sapienza Università di Roma, Unità di Microbiologia e Virologia, Policlinico Umberto I, Roma, Italia⁽³⁾

Prospective monitoring of HIV-1 infected patients after SARS-CoV-2 mRNA vaccination: characterization of IFN gene expression signature and humoral immune response

FEDERICA FRASCA¹, MIRKO SCORDIO¹, LETIZIA SANTINELLI², LUCA MADDALONI², LEONARDO SORRENTINO¹, MATTEO FRACELLA¹, ALESSANDRA D'AURIA¹, CARLA SELVAGGI², EUGENIO NELSON CAVALLARI², ANNA NAPOLI², LILIA CINTI², PIERGIORGIO ROBERTO², GIANCARLO CECCARELLI², AURELIA GAETA², GUIDO ANTONELLI^{1,3}, CLAUDIO MARIA MASTROIANNI², GABRIELLA D'ETTORRE², CAROLINA SCAGNOLARI¹

¹Laboratory of Virology, Department of Molecular Medicine, Sapienza University, Rome, Italy;

²Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy;

³Microbiology and Virology Unit, Sapienza University Hospital "Policlinico Umberto I", Rome, Italy.

Background

COVID-19 vaccine has been reported to elicit humoral and T cell immune response in HIV-1 patients. Remarkably, some studies suggest that Interferon (IFN) signature might correlate with immunological and clinical efficacy of COVID-19 vaccines, as reported for Influenza vaccines. Understanding the early innate response to vaccine exposure and the humoral activation is needed to characterize mechanisms related to immunization in HIV-1 individuals. Therefore, the aim of this study was to evaluate the humoral response and IFN signature in HIV-1 positive individuals receiving COVID-19 vaccine.

Material and methods

Longitudinal effects of mRNA-based SARS-CoV-2 vaccine on humoral response in HIV-1 patients (n=82) were investigated measuring antibodies levels using LIAISON SARS-CoV-2 Trimerics IgG assay in serum samples collected before vaccination (T0), at the time of the second dose (T1), and 1 or 6 months following the second dose (T2). Expression level of mRNA encoding for distinct type I IFNs (i.e. IFN-Alpha2, IFN-Beta, IFN-Epsilon and IFN-Omega), and IFN-stimulated genes (ISGs), ISG15 and ISG56, were quantified by RT/Real time PCR assays in peripheral blood mononuclear cells (PBMCs) collected at T0, T1 and T2.

Results

Eighty-two HIV-1 patients (57 males (70%), 25 females (30%), mean age 56 years) on long-term ART were enrolled in this study. Results showed that humoral response following immunization increased significantly from T0 to T1 (p<0.001), and from T1 to T2 (p<0.001). Stratifying patients according to CD4 T cell count, no differences in antibody production were observed up to 1 month after the second dose. However, individuals with CD4 T cell count <400 cells/mm³ maintained a lower anti spike-antibody response 5 months after full vaccination compared to those with high

(>400 cells/mm³) CD4 T cell count ($p < 0.05$). Gene expression analysis performed in 55 HIV-1 infected patients before and after COVID-19 vaccination, indicated an overall increased of IFN response up to 1 month after the second dose. Also, transcript levels of IFN-Alpha2, IFN-Beta, IFN-Epsilon and IFN-Omega, and of ISG15 and ISG56 were positively correlated with antibody production. By contrast, IFNs and ISGs mRNA levels decreased ($p < 0.05$) at 5 months after the second dose, concomitantly with the reduction of antibody levels.

Conclusion

Our results confirmed that mRNA-based SARS-CoV-2 vaccine successfully promote antibody production in ART-treated HIV-1 patients and that the levels of CD4 T cells can impact on the rate of humoral immune response activation. Moreover, we demonstrated that transcript levels of IFN related genes changed in patients receiving COVID-19 vaccine according to the amount of anti-spike antibodies.

158 - Characterization of mucosal immune response against SARS-CoV-2 in vaccinated children.

Leonardo Sorrentino ⁽¹⁾ - Maria Giulia Conti ⁽¹⁾ - Eva Piano Mortari ⁽²⁾ - Federica Frasca ⁽¹⁾ - Matteo Fracella ⁽¹⁾ - Giuseppe Oliveto ⁽¹⁾ - Mirko Scordio ⁽¹⁾ - Alessandra D'Auria ⁽¹⁾ - Raffaella Nenna ⁽¹⁾ - Laura Petrarca ⁽¹⁾ - Carolina Scagnolari ⁽¹⁾ - Rita Carsetti ⁽²⁾ - Fabio Midulla ⁽¹⁾ - Alessandra Pierangeli ⁽¹⁾

Università, Sapienza Università di Roma, Roma, Italia ⁽¹⁾ - Ospedale, Ospedale Bambino Gesù, Roma, Italia ⁽²⁾

INTRODUCTION

Children generally develop mild or asymptomatic SARS-CoV-2 infection. Innate immunity has a key role limiting viral replication in the upper airway. However, the role of mucosal IgA in children protection is to be defined yet. For this reason, we measured salivary IgA in a group of SARS-CoV-2 infected children and compared with a group of vaccinated children.

METHODS

We enrolled 90 vaccinated children (VAX-C) consecutively admitted at the pediatric vaccine center of Umberto I hospital receiving BNT162b2 (Pfizer/BioNTech) from February to April 2022 and 41 children who had previous SARS-CoV-2 infection (INF-C) from October 2020 to March 2021 (age range 5-11 years). Serum and saliva of vaccinated children were collected on the day of 1st vaccine dose (T0) and 10 days after 2nd vaccine dose (T1) while samples from infected children were collected 20 days after first positive molecular test (T1). Anti-spike IgA and IgG in both serum and saliva were measured using ELISA assay (EUROIMMUN), saliva was diluted 1:20 and serum 1:100. Statistical analysis was performed with SPSS software v25.

RESULTS

About ten days after the second dose (T1), 59 children returned to follow up and we collected saliva samples and 21 serum samples. At T0, 28% of children already had either measurable or borderline values of anti-Spike IgA in the saliva. At T1 the rate of IgA positivity significantly increased ($p=0.023$) and the frequency of IgA positive samples increased to 49% whereas 51% of the saliva samples remained negative. Next, we stratified the results according to the children history of SARS-CoV-2 infection or close contact with infected family members. Eight children had experienced COVID 19 (8.8%), several months before vaccination (Infected-VAX) while 16.6% were considered exposed-VAX and 74.6% had no history of previous contact. Spike specific IgA significantly increased in response to vaccination in the naïve-VAX ($p=0.0019$), but not in exposed-VAX and infected-VAX. Salivary spike-specific IgG were not detectable before vaccination in all three groups, while at T1 34.8% were positive to IgG. Lastly, Serum IgA and IgG levels were significantly higher in vaccinated children compared to the INF-C group ($p=0.037$ and $p<10^{-8}$).

DISCUSSION

Our results showed detectable levels of salivary IgA and IgG in vaccinated children.

This finding is compatible with the transudation of vaccine-produced IgG from the plasma to the oral cavity. Measurement of secretory IgA levels in mucosa of vaccinated children in comparison with infected ones will further clarify mucosal response against SARS-CoV-2 induced by vaccination.

160 - Evaluation of redox state alterations in influenza A virus-infected neuronal cells: involvement in neurotropism.

Anna Maria Marinelli⁽¹⁾ - Dolores Limongi⁽¹⁾ - Carla Prezioso⁽²⁾ - Marta De Angelis⁽³⁾ - Lucia Nencioni⁽³⁾ - Anna Teresa Palamara⁽³⁾ - Paola Checconi⁽¹⁾

San Raffaele University, Department of Human Sciences and Quality of Life Promotion, Roma, Italia⁽¹⁾ - IRCCS San Raffaele, Microbiology of Chronic Neuro-Degenerative Pathologies, Roma, Italia⁽²⁾ - Sapienza University, Department of Public Health and Infectious Diseases, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Roma, Italia⁽³⁾

Evaluation of redox state alterations in influenza A virus-infected neuronal cells: involvement in neurotropism.

ANNA M. MARINELLI^{1,2}, DOLORES LIMONGI^{1,2}, CARLA PREZIOSO², MARTA DE ANGELIS³, LUCIA NENCIONI³, ANNA T. PALAMARA^{3,4}, PAOLA CHECCONI^{1,2}

¹Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy;

²Microbiology of Chronic Neuro-Degenerative Pathologies, IRCCS San Raffaele Roma, Rome, Italy; ³Department of Public Health and Infectious Diseases, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, Rome, Italy;

⁴Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Introduction: As viruses use cell machinery to replicate, multiple intracellular factors affect the outcome of viral infection; on the other hand, they induce considerable alterations in cellular homeostasis, as in the redox balance. Several redox modifications have been described during influenza A virus (IAV) infection in respiratory epithelial cells, but less is known about redox state in infected neuronal cells which, although not the main target, can be reached leading to nervous complications. Redox modifications in IAV-infected epithelial cells include: ROS production, glutathione (GSH) reduction, glutathionylated proteins formation, oxidoreductases (as glutaredoxins, Grxs) modulation and the up-regulation of matrix metalloproteases (MMPs), endopeptidases involved in the inflammatory process. Our hypothesis is that redox modifications could regulate neurotropism of some IAV strains, i.e. viral replication in neuronal cells and virus-induced inflammation. Therefore, the aim of this study was to analyse the role of the redox state in influenza virus replication and viral-induced inflammation in a neuronal model of infection.

Materials and Methods: Human neuroblastoma SH-SY5Y cells were infected with influenza A/NWS/33 H1N1 (NWS) at high or low m.o.i. of infection for 8-24 h. The supernatants were collected and analyzed for the viral titer by hemagglutinin assay and for the MMPs activity by gelatin zymography. Cell lysates were analyzed: for GSH content by GSH assay kit; for Grx1, MMPs expression by immunoblotting with specific antibodies. Proteins from infected and Glutathione ethyl ester biotin amide (BioGEE)-treated cells were run under non-reducing or reducing conditions and analyzed by western blot with streptavidin-peroxidase conjugated.

Results: NWS virus, that efficiently infects and replicates in SH-SY5Y cells, led to a reduction in free GSH intracellular level and an increase in glutathionylated proteins. Grx1 expression increased as well. In the supernatants of NWS-infected cells, we observed an increase in MMP2 activity. The treatment with a Grx1 inhibitor, 2-AAPA, that we already showed to reduce inflammatory cytokine IL-6 secretion from epithelial cells, reduced secreted MMP2 activity.

Discussion and Conclusions: The results describe redox alterations in NWS-infected neuronal cells, suggesting that redox-sensitive pathways could be involved in viral replication and virus induced inflammation in the nervous system.

163 - Fecal-associated *Enterobacteriaceae* isolates from Celiac disease patients: could dietary sugars drive changes in bacterial composition?

Meysam Sarshar⁽¹⁾ - Cecilia Ambrosi⁽²⁾ - Daniela Scribano⁽³⁾ - Francesca Ferretti⁽⁴⁾ - Anna Teresa Palamara⁽⁵⁾ - Andrea Masotti⁽¹⁾

Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy⁽¹⁾ - Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Open University, IRCCS, Rome, Italy⁽²⁾ - Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy⁽³⁾ - Hepato-Gastroenterology and Nutrition Department, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy⁽⁴⁾ - Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy⁽⁵⁾

Fecal-associated *Enterobacteriaceae* isolates from Celiac disease patients: could dietary sugars drive changes in bacterial composition?

Meysam Sarshar¹, Cecilia Ambrosi², Daniela Scribano³, Francesca Ferretti⁴, Anna Teresa Palamara^{5,6}, and Andrea Masotti¹

¹Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, 00146 Rome, Italy; ²Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Open University, IRCCS, 00166 Rome, Italy; ³Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy; ⁴Hepato-Gastroenterology and Nutrition Department, Bambino Gesù Children's Hospital-IRCCS, 00165 Rome, Italy; ⁵Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy; ⁶Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory Affiliated to Institute Pasteur Italia-Cenci Bolognetti Foundation, 00185 Rome, Italy

1. Introduction: Celiac disease (CD) is a multifactorial immune-mediated disorder of the small intestine triggered by ingestion of gluten in genetically predisposed individuals. Like several intestinal diseases (i.e., IBDs), CD could be associated with intestinal dysbiosis characterized by an increased abundance of pathobionts. Here, we aimed to characterize fecal-associated *Enterobacteriaceae* isolates from CD patients and assess possible effects of dietary sugars on bacterial community and pathogenicity. Active CD patients are treated with a strict gluten free diet (GFD); however, gluten-free foods are often high in carbohydrates content. Therefore, we wondered if sugars in GFD could increase the abundance of commensal/pathogenic gram-negative bacteria or decrease the abundance of beneficial bacteria. 2. Materials and Methods: Various *Enterobacteriaceae*-like colonies were isolated on selective and differential media (i.e., MacConkey and Chromogenic agar) from fecal samples of our cohort including active CD, CD patients under GFD and healthy individuals (n=25 for CD and GFD and n=18 for controls). Diverse colonies differing in size, shape, and colour were sequenced and identified at species level. The most abundant sugars found in the small intestine (i.e., mono, di- and polysaccharides) were used for a "sugar challenge" study. 3. Results: *Escherichia coli* was identified as the most abundant bacterium followed by non-*E. coli* *Enterobacteriales* (NECE), such as *Klebsiella* spp. (i, e., *K. oxytoca*, *K. michiganensis*), *Enterobacter* spp., *Hafnia alvei/paralvei*, *Citrobacter freundii/koseri*, and *Serratia marcescens*. The total count (CFU/gram of feces) of *E. coli* was between 10 to 10⁶ in CD and GFD vs 10³ to 10⁸ in controls), whereas NECE were enumerated between 0 to <10⁶ among all groups. In some fecal samples, NECE were not isolated, being outnumbered by *E. coli*. The growth kinetics of the two most abundant isolated species (*E. coli* and *K. oxytoca* strains) were monitored either singularly or in co-culture in minimal medium supplemented with selected saccharides at different concentrations. We found that galactose, fructose and glucose differently boosted the growth rates of both species. Interestingly, *E. coli* outcompeted *K. oxytoca* in galactose-containing medium (1.8 to 2.4 log CFU/mL reduction), whereas *K. oxytoca* outcompeted *E. coli* in fructose-containing medium (0.8 to 1.4 log CFU/mL reduction). Mannose did not change any bacterial growth ratio. Neither *E. coli* nor *K. oxytoca* strains were able to grow in medium supplemented with sucrose at all concentrations tested. 4. Discussion and Conclusions: Overall, our results revealed that *Enterobacteriaceae* strains in fecal samples are highly heterogeneous among CD and GFD patients with respect to controls. Moreover, bacterial strains exhibited different sugar preferences to support their metabolism and growth. Pathogenic properties of CD-associated *E. coli*, determination of sugars in the feces through high performance liquid chromatography followed by complementary analyses at both genomic and proteomic levels are under investigation.

164 - Discovering the role of *Mycoplasma girerdii* in *Trichomonas vaginalis* pathobiology: just a parasite or a new friend for the protist?

Valentina Margarita⁽¹⁾ - Nicholas P Bailey⁽²⁾ - Nicia Diaz⁽¹⁾ - Daniele Dessi⁽¹⁾ - Paola Rappelli⁽¹⁾ - Jennifer FETTWAIS⁽³⁾ - Robert P Hirt⁽²⁾ - Pier Luigi Fiori⁽¹⁾

Universita' di Sassari, Dipartimento di Scienze Biomediche, Sassari, Italia⁽¹⁾ - Newcastle University, Biosciences Institute, Faculty of Medical Sciences, Newcastle upon Tyne, Regno Unito⁽²⁾ - Virginia Commonwealth University, Department of Microbiology and Immunology, Richmond, Stati Uniti D'america⁽³⁾

Discovering the role of *Mycoplasma girerdii* in *Trichomonas vaginalis* pathobiology: just a parasite or a new friend for the protist?

VALENTINA MARGARITA¹, NICHOLAS P. BAILEY², NICIA DIAZ¹, DANIELE DESSI¹, PAOLA RAPPELLI¹, JENNIFER FETTWAIS^{4,5}, ROBERT.P. HIRT², PIER LUIGI FIORI¹

1. Department of Biomedical Sciences, University of Sassari, Italy

2. Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

4. Department of Microbiology and Immunology, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA

5. Centre for Microbiome Engineering and Data Analysis, Virginia Commonwealth University, Richmond, VA, USA

Introduction: *Trichomonas vaginalis* is a protozoan pathogen of human urogenital tract causing the most common non-viral sexually transmitted disease worldwide. A fascinating feature of the protist is its capability to act in concert with endosymbiotic bacteria and viruses. Endosymbiosis involves two *Mycoplasma* species, *Mycoplasma hominis* and *Mycoplasma girerdii*, and up to four species of dsRNA *Trichomonas vaginalis* viruses. The influence of *M. hominis* on parasite's pathobiology and on dynamics of the host-parasite-bacteria interaction has been well studied, while the influence of *M. girerdii* (a new non-cultivable *Mycoplasma* species) on *T. vaginalis* pathobiology is still largely unknown.

Materials & Methods: We developed an *in vitro* model system in which features of isogenic *T. vaginalis* strains with and without *Mycoplasma girerdii* were compared. The influence of bacterium on cytolytic and adhesive properties of the protozoon, and on its metronidazole sensitivity was evaluated. In addition, RNAseq experiments were set up to study the influence on *T. vaginalis* gene expression.

Results: *M. girerdii* increases the cytopathic activity of *T. vaginalis*, as well as previously demonstrated for the endosymbiont *M. hominis*. Moreover, its presence increases the *in vitro* capability of the protozoon to adhere to human cells. These results are further supported by transcriptomic data showing major shifts gene expression of metabolic enzymes and virulence genes in *T. vaginalis* infected by *M.girerdii* compared to the same protozoan strain lacking the bacterium. Interestingly, the presence of *M. girerdii* seems to have no effect on metronidazole resistance in *T. vaginalis*, while the presence of *M. hominis* significantly increases the sensitivity to metronidazole in trichomonad cells.

Discussion and Conclusions: Our data support the hypothesis that the presence of endosymbionts may modulate *T. vaginalis* virulence, reinforcing the idea to consider pathogenic entities as microbial ecosystems.

165 - Study of immunological parameters associated with Long COVID in children/adolescents

Matteo Fracella⁽¹⁾ - Leonardo Sorrentino⁽¹⁾ - Federica Frasca⁽¹⁾ - Mirko Scordio⁽¹⁾ - Giuseppe Oliveto⁽¹⁾ - Agnese Viscido⁽¹⁾ - Camilla Bitossi⁽¹⁾ - Alessandra D'Auria⁽¹⁾ - Stefania Rossi⁽²⁾ - Lucia Gabriele⁽²⁾ - Anna R. Ciccaglione⁽³⁾ - Roberto Bruni⁽³⁾ - Laura Petrarca⁽⁴⁾ - Enrica Mancino⁽⁴⁾ - Raffaella Nenna⁽⁴⁾ - Fabio Midulla⁽⁴⁾ - Guido Antonelli⁽¹⁾ - Alessandra Pierangeli⁽¹⁾ - Carolina Scagnolari⁽¹⁾

“Sapienza” University, Department of Molecular Medicine, Virology Laboratory, Roma, Italia⁽¹⁾ - Istituto Superiore di Sanità, Department of Oncology and Molecular Medicine, Roma, Italia⁽²⁾ - Istituto Superiore di Sanità, Department of Infectious Diseases, Roma, Italia⁽³⁾ - “Sapienza” University, Department of Pediatrics and Infantile Neuropsychiatry, Roma, Italia⁽⁴⁾

Study of immunological parameters associated with Long COVID in children/adolescents

MATTEO FRACELLA¹, LEONARDO SORRENTINO¹, FEDERICA FRASCA¹, MIRKO SCORDIO¹, GIUSEPPE OLIVETO¹, AGNESE VISCIDO¹, CAMILLA BITOSSI¹, ALESSANDRA D'AURIA¹, STEFANIA ROSSI², LUCIA GABRIELE², ANNA R. CICCAGLIONE³, ROBERTO BRUNI³, LAURA PETRARCA⁴, ENRICA MANCINO⁴, RAFFAELLA NENNA⁴, FABIO MIDULLA⁴, GUIDO ANTONELLI¹, ALESSANDRA PIERANGELI¹, CAROLINA SCAGNOLARI¹.

1Department of Molecular Medicine, Virology Laboratory, “Sapienza” University, Rome, Italy; 2Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy; 3Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; 4Department of Pediatrics and Infantile Neuropsychiatry, “Sapienza” University, Rome, Italy.

Introduction

SARS-CoV-2 infection generally causes mild or no symptoms in children. Nevertheless, increasing evidence show that several immune-pathological changes can remain weeks or months after the infection; this persistent condition is known as “Long COVID (LC)”, that in adults is associated to highly activated innate immune cells. In this context, interferon (IFN) response and inflammation-related miRNAs in peripheral blood mononuclear cells (PBMCs) could have an important role. Hence, we measured the expression in PBMCs of the type I IFNs (IFN-I) genes and of miR-141, miR-155 and miR-146a in children/adolescent with and without LC symptoms.

Materials and Methods

Blood samples from SARS-CoV2 (+) and (-) children attending Umberto I hospital of Rome, were collected within 3-6 months after SARS-CoV-2 tests. From PBMCs, RNA was extracted for determining cellular gene expression (IFN-I alpha2A, beta, epsilon and omega), and miRNAs expression by quantitative RealTime-PCR assays, normalized to housekeeping GUS gene and RNU6B, respectively.

Results

Ten SARS-CoV2(+) patients (mean age 8.5y SD 1.7) with LC symptoms, 10 SARS-CoV2(+) patients (mean age 9.1y SD 2.1) without LC symptoms and 10 SARS-CoV-2(-) children (mean age 10.8y SD 2.9) were enrolled. Comparing LC patients and patients that did not report LC symptoms, we found a downregulation of IFNalpha2A, IFNbeta and IFNepsilon (p=0.016, p=0.016, p=0.010, respectively) in LC group. Moreover, IFNalpha2A, IFNbeta and IFNomega (p=0.041, p=0.010, p=0.016, respectively) showed a lower expression level in LC subjects with respect to negative controls. We also observed an overactivation of miR-141 either in LC (p=0.019) or convalescents without LC (p=0.001) compared to negative ones. Contrastingly, miR-155 and miR-146a showed a tendency to be downregulated in LC as opposed to other groups.

Discussion and Conclusion

Overall, our findings reported a downregulation of IFN-I in LC subjects with respect to other groups analyzed. Conforming to several studies, IFN-I are activated during SARS-CoV-2 infection and diminish gradually after patient conditions improved. It is possibly to speculate that this waning trend could persist more during LC or, alternatively, that the lower levels we observed were due to a lower activation during the acute phase. Moreover, we observed an overexpression of miR-141 in SARS-CoV2 convalescents and LC children with respect to negative controls. According to recent investigations, miR-141 regulates NLRP3 expression and ultimately inflammasome. Taken together our findings would suggest that a dysregulation of the IFN response and a prolonged inflammatory state could lead to LC symptoms, in children; however, these preliminary data must be investigated further in larger cohort.

167 - Neutralization titers and Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2 in a Sardinian cohort group.

Giuseppina Sanna⁽¹⁾ - ALESSANDRA Marongiu⁽¹⁾ - Davide Firinu⁽²⁾ - Cristina Piras⁽³⁾ - Vanessa Palmas⁽¹⁾ - Valeria Manca⁽¹⁾ - Marta Serreli⁽⁴⁾ - Marcello Campagna⁽²⁾ - Andrea Perra⁽⁵⁾ - Stefano Del Giacco⁽²⁾ - Maria C. Ruffi⁽²⁾ - Luchino Chessa⁽²⁾ - Aldo Manzin⁽¹⁾

University of Cagliari, Department of Biomedical Sciences, Microbiology and Virology Unit, Cagliari, Italia⁽¹⁾ - University of Cagliari, Department of Medical Sciences and Public Health, Cagliari, Italia⁽²⁾ - University of Cagliari, Department of Biomedical Sciences, Clinical Metabolomics Unit, Cagliari, Italia⁽³⁾ - University of Cagliari, Department of Biomedical Sciences, Cagliari, Italia⁽⁴⁾ - University of Cagliari, Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, Cagliari, Italia⁽⁵⁾

Neutralization titers and Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2 in a Sardinian cohort group.

GIUSEPPINA SANNA¹, ALESSANDRA MARONGIU¹, DAVIDE FIRINU², CRISTINA PIRAS³, VANESSA PALMAS¹, VALERIA MANCA¹, MARTA SERRELI¹, MARCELLO CAMPAGNA², ANDREA PERRA⁴, STEFANO DEL GIACCO², MARIA C. RUFFI², LUCHINO CHESSA², ALDO MANZIN¹

¹ Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy; Giuseppina Sanna; email: g.sanna@unica.it;

² Department of Medical Sciences and Public Health, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy;

³ Department of Biomedical Sciences, Clinical Metabolomics Unit, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy;

⁴ Department of Biomedical Sciences, Unit of Oncology and Molecular Pathology, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Cagliari, Italy.

Abstract:Introduction: Following several ChAdOx1 vaccine-associated adverse vascular events and thrombocytopenia, some countries recommended that patients under the age of 60 who received the first dose of ChAdOx1 receive a booster of the Pfizer BNT162b2 vaccine.

Material and methods: Quantitative IgG anti-SARS-CoV-2 Spike antibody (anti-S-IgG) and neutralization assay were run to investigate, in the long term period, the responses to vaccine treatment in our cohort of Sardinian subjects with heterologous priming with ChAdOx1 (ChAd) vector vaccine, followed by boosting with BNT162b2 (ChAd/BNT/BNT) and ChAd/ChAd/BNT). Results: The results were compared with those of a cohorts of health-care workers (HCW) who received homologous BNT162b2 (BNT/BNT/BNT) nCoV-19 vaccination or homologous regimen as a control group. At T2, one month after the second dose, and T3 (five months after the second dose), before the third dose, anti-spike antibody or neutralizing titers in the subjects given ChAdOx1-S/BNT162b2 were significantly higher than those given ChAdOx1-S/ChAdOx1-S or those given BNT162b2/BNT162b2.

Discussion and Conclusions: These data indicate that a ChAdOx1-S/BNT162b2 heterologous regimen provided a more robust antibody response than either of the homologous regimens. However, the anti-spike antibodies or neutralizing titers after the third injection (mRNA vaccine) of those given ChAdOx1-S as a second dose and those given BNT162b2 were not statistically different. Homologous and heterologous vaccination provided strong antibody response. Although the exact correlation between this response and protection has not yet been defined, subjects with a high neutralizing antibody response could be better protected against infection.

168 - CD169 IN BLOOD & CIRCULATING MICROVESICLES AS AN EARLY BIOMARKER OF COVID-19 DISEASE PROGRESSION

Marialaura Fanelli⁽¹⁾ - Vita Petrone⁽¹⁾ - Christian Maracchioni⁽¹⁾ - Martina Giudice⁽¹⁾ - Rossella Chiricio⁽¹⁾ - Marco Iannetta⁽²⁾ - Ines Ait Belkacem⁽³⁾ - Marta Zordan⁽²⁾ - Pietro Vitale⁽⁴⁾ - Massimo Andreoni⁽²⁾ - Loredana Sarmati⁽²⁾ - Fabrice Malergue⁽⁵⁾ - Emanuela Balestrieri⁽¹⁾ - Sandro Grelli⁽¹⁾ - Claudia Matteucci⁽¹⁾ - Antonella Minutolo⁽¹⁾

Università degli studi di Roma "Tor Vergata", Dipartimento Medicina Sperimentale, Roma, Italia⁽¹⁾ - Università degli studi di Roma "Tor Vergata", Dipartimento Medicina dei Sistemi, Roma, Italia⁽²⁾ - Aix Marseille Université, CNR INSERM, Marsiglia, Francia⁽³⁾ - Policlino Tor Vergata, Malattie Infettive, Roma, Italia⁽⁴⁾ - Dipartimento Ricerca e Sviluppo, Beckman Coulter, Marsiglia, Francia⁽⁵⁾

Title: CD169 IN BLOOD & CIRCULATING MICROVESICLES AS AN EARLY BIOMARKER OF COVID-19 DISEASE PROGRESSION

MARIALAURA FANELLI¹, VITA PETRONE¹, CHRISTIAN MARACCHIONI¹, MARTINA GIUDICE¹, ROSSELLA CHIRICO¹, MARCO IANNETTA^{2,3}, INES AIT BELKACEM^{4,5}, MARTA ZORDAN^{2,3}, PIETRO VITALE³, MASSIMO ANDREONI^{2,3}, LOREDANA SARMATI^{2,3}, FABRICE MALERGUE⁵, EMANUELA BALESTRIERI¹, SANDRO GRELLI^{1,7}, CLAUDIA MATTEUCCI¹, ANTONELLA MINUTOLO¹.

1. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 2. Department of Systems Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 3. Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome, 00133, Italy; 4. Aix Marseille Université, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Marseille, France; 5. Department of Research and Development, Beckman Coulter Life Sciences-Immunotech, Marseille, 13009, France. 6. Institute of Translational Pharmacology, National Research Council, Rome, 00133, Italy; 7. Virology Unit, Policlinic of Tor Vergata, Rome, 00133, Italy.

Introduction: The identification of early biomarkers for predicting COVID-19 progression and new therapeutic intervention for patient management are needed. CD169+ macrophages play an important role in viral infections and recently has been demonstrated that CD169 was strongly overexpressed in the blood of acute COVID-19 patients (A-COV). To investigate the possible association of CD169 with features of COVID-19 disease, we analysed CD169 in blood cells of A-COV at the time of hospitalization and correlated its expression with clinical characteristics and disease progression. Furthermore, based on recent work demonstrating the potential involvement of microvesicles (MVs) during SARS-CoV-2 infection, we characterised plasmatic MVs and assessed their potential role as a vehicle for the CD169 molecule in A-COV patients also in association with severity and characteristics of disease. **Materials and methods:** Flow cytometry was used for the evaluation of the median fluorescence intensity ratio of CD169 between monocytes and lymphocytes (CD169 RMFI) in blood samples from 27 healthy donors (HD) and 31 A-COV, and for immunophenotype and plasmatic MVs characterisation. **Results:** CD169 RMFI was significantly higher expressed in the macrophages of A-COV but not in those of HD and the ROC curve analysis show a high sensitivity and specificity value. In CD8+ T cells of A-COV, CD169 RMFI was associated with the decrease of naive cells and increase in Effector Memory cells. Finally, CD169 RMFI positively correlated with the senescence marker CD57+. Moreover, the CD169 RMFI increased with disease severity and pneumonia involvement in A-COV at sampling and reflects the respiratory outcome of patients during hospitalization. Flow cytometry analysis showed an increased percentage of MVS with a larger size (160-250 nm) in A-COV compared to HD. Interestingly, a significant increase in the Mean Intensity of Fluorescence (MFI) of circulating MVs expressing CD169 was observed in COV respect to HD. **Discussion and Conclusions:** Our data showed an association between CD169 expression and clinical status and respiratory outcome; moreover, the characterisation of MVs highlighted their contribution as a vehicle for CD169. Considering the immunological role of CD169 and its involvement during infection and COVID-19 progression, it could be considered an early biomarker of disease progression.

169 - Preliminary evaluation of genomic and transcriptomic changes in the evolution from a USA300 wild-type isolate to SCV, able to perform phagosomal escape.

Dalida Angela Bivona (1) - Carmelo Bonomo (1) - Paolo G Bonacci (1) - Grete Privitera (1) - Nicolò Musso (1) - Giuseppe Caruso (2) - Filippo Caraci (2) - Stefania Stefani (1) - Dafne Bongiorno (1)

Università di Catania, Department of Biomedical and Biotechnological Science, Catania, Italia (1) -
Università di Catania, Department of Drug and Health Sciences, Catania, Italia (2)

Preliminary evaluation of genomic and transcriptomic changes in the evolution from a USA300 wild-type isolate to SCV, able to perform phagosomal escape.

DALIDA A. BIVONA¹, CARMELO BONOMO¹, PAOLO G. BONACCI¹, GRETE PRIVITERA¹, NICOLÒ MUSSO¹, GIUSEPPE CARUSO^{2,3}, FILIPPO CARACI^{2,3}, STEFANIA STEFANI¹ AND DAFNE BONGIORNO¹

¹ EHPI Lab, Microbiology section, Dept of Biomedical and Biotechnological Science, University of Catania, Catania, Italy;

²Department of Drug and Health Sciences, University of Catania, Catania, Italy.

³Department of Drug and Health Sciences, University of Catania, Catania, Italy; Oasi Research Institute - IRCCS, Troina, Italy.

Introduction

Small colony variants (SCV) of *Staphylococcus aureus* USA300 have been reported as implicated in chronic infections. We investigated through preliminary experiments that natural antioxidant carnosine is able to modulate the activity of macrophages infected with different *S. aureus* strains. In particular, by its well-known ability to ameliorate the energy state and the antioxidant machinery of macrophages, carnosine could be indirectly able to modulate the formation of SCVs by bacteria who have been able to perform phagosomal escape. Here, we investigated the genomic and transcriptomic changes involved in the evolution from a wild-type to a SCV form of USA300 strain in a Eukaryotic-Prokaryotic co-culture model.

Materials and Methods

The infection of RAW 264.7 cells was carried out with *S.aureus* USA300 with a multiplicity of infection (MOI) of 1:50. Extracellular bacteria were removed by lysostaphin for 1 hour at 37°C. After Carnosine treatment, macrophages were lysed, at different time points, and lysates were plated on Blood Agar in order to isolate internalized bacteria. RNA extraction was carried out for USA300 wild-type and SCVs. Quantitative real-time PCR RT-qPCR, was performed. GraphPad Prism 9 software was used for statistical analysis, p-values set up at > 0.05. NGS sequencing was performed by using Illumina DNA Prep and Illumina MiSeq. Data were analyzed using QIAGEN CLC Genomics Workbench software.


Results

Internalized bacteria, isolated after carnosine treatment condition, showed a SCV stable phenotype on Blood Agar. In particular, the SCVs, isolated 48 hours after the infection, were subcultured several times showing to be stable (no reversion to normal phenotype was reported). Preliminary Whole Genome Sequencing (WGS) analysis, revealed a mutation in SD-repeat containing protein D (*sdrD*), adhesin involved in interaction with host cells, belonging to the microbial surface components recognizing adhesive matrix molecules (MSCRAMMs). Furthermore, consistent up-regulation of *sdrE*, *agrA*, *psmA*, *hla*, *hld* and *uhpt* was observed, as shown in figure 1, in the shift between colonization and invasive mechanism, suggesting a prominent role for these genes in staphylococcal pathogenesis.

Discussion and Conclusion

Our stable, SCV USA300 isolate seems to be a non-classical SCV phenotype, independent from the previously described hemin, thymidine or menadione auxotrophisms and dependent from an activated stringent response. Transcriptomic analysis highlighted a specific signature in the SCV strain including a complex, multi-level strategy of survival and adaptation to chronicity within the host, including a protection from the inflammatory response, an evasion of the immune response, and finally a constitutively activated stringent response.

Figure 1. Graph of quantitative real-time PCR RT-qPCR



t-Test Normalized Vs <i>girB</i>	<i>sdrE</i>	<i>agrA</i>	<i>psmA</i>	<i>hla</i>	<i>hld</i>	<i>uhpt</i>
P-value	0,0139	0,0149	0,0025	0,0241	0,0072	0,0289
95% Confidence Interval	32,38 to 100,2	21,8 to 71,4	9,52 to 14,73	16,25 to 85,21	11,57 to 24,98	9,05 to 62,65
P-value Summary	*	*	**	*	*	*

171 - In vitro analysis of epithelial tolerability and anti-Candida effect of a new lactic acid-based vaginal gel formulation

Luca Spaggiari⁽¹⁾ - Gianfranco Squartini⁽²⁾ - Andrea Ardizzoni⁽²⁾ - Francesco De Seta⁽³⁾ - Elisabetta Blasi⁽²⁾ - Eva Pericolini⁽²⁾

Università degli Studi di Modena e Reggio Emilia (UNIMORE), Corso di Dottorato in Medicina Clinica e Sperimentale (CEM), Modena, Italia⁽¹⁾ - Università degli Studi di Modena e Reggio Emilia (UNIMORE), Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, Modena, Italia⁽²⁾ - Università degli Studi di Trieste, Dipartimento Clinico di Scienze Mediche, Chirurgiche e della Salute, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Burlo Garofolo, Trieste, Italia⁽³⁾

LUCA SPAGGIARI¹, GIANFRANCO R. SQUARTINI², ANDREA ARDIZZONI², FRANCESCO DE SETA³, ELISABETTA BLASI², EVA PERICOLINI²

***In vitro* analysis of epithelial tolerability and anti-Candida effect of a new lactic acid-based vaginal gel formulation**

¹*Clinical and Experimental Medicine Ph.D. Program, University of Modena and Reggio Emilia, Modena, Italy;*

²*Department of Surgical, Medical, Dental and Morphological Sciences with interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy;*

³*Department of Medical Sciences, University of Trieste, Institute for Maternal and Child Health- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Burlo Garofolo, Trieste, Italy.*

INTRODUCTION. Vulvovaginal candidiasis (VVC) is the most prevalent vaginal infection in adult women. It is mainly caused by *Candida albicans*, and it affects 75% of healthy women at least once during their reproductive age; 5-10% of such women have recurrent episodes (RVVC), with more of 4 episodes of acute VVC per year. Symptoms of VVC include itching, burning, swelling and redness of the vaginal mucosa with white vaginal discharge. The urinary system can also be affected, with pain and burning when urinating. This condition seriously damages the well-being and the life quality of the affected women. Since *Candida* is a commensal fungus of the vaginal mucosa of healthy women, the main question is how the fungus can switch from harmless component of the vaginal microbiota to virulent pathogen. In this work we analyzed the capacity of lactic acid-based vaginal gel formulation Respecta® Balance Gel (RBG) to counteract *C. albicans* virulence after epithelial cells infection *in vitro*.

MATERIALS AND METHODS. For the establishment of the *in vitro* infection model, we used a monolayer of the A-431 vaginal epithelial cell line and two different strains of *C. albicans* (strain SC5314 and the bioluminescent strain gLUC59). Dose-dependent experiments were performed to test the epithelial tolerability to RBG (IHS srl, Biofarma Group) by monitoring lactate-dehydrogenase (LDH) release from damaged cells. The capacity of RBG to counteract *Candida*-induced epithelial damage were analysed by monitoring LDH release from cells. Fungal growth and adhesion capacity during vaginal epithelial cells infection in the presence of RBG were evaluated by quantify the Relative Luminescent Units (RLU) and CFU counts, respectively.

RESULTS. Our results show that, at dilution 1:150, RBG is well tolerated by the vaginal epithelium and consequently we used this dose for the subsequent experiments. RBG was able to significantly reduce (by 65%) *C. albicans*-induced damage of vaginal epithelial cells. This effect was accompanied with the capacity of RBG to significantly reduce *Candida*

adhesion to the epithelium (adhesion reduction by 34%). Intriguingly, no inhibition of fungal growth was observed after 24h of infection in the presence of RGB in our experimental conditions.

DISCUSSION AND CONCLUSIONS. Our results show that RGB significantly reduces *C. albicans*-induced damage of vaginal epithelial cells. One of the mechanisms underlying this effect is the inhibition of *C. albicans* adhesion to the vaginal epithelial cells, which may prevent *Candida* from penetrating and damaging epithelial cells, hence counteract *Candida* virulence. Collectively our preliminary results suggest that RGB can strengthen the VVC therapy favoring the establishment of an ecosystem that prevent *Candida* virulence.

174 - Human endogenous retroviruses as markers of disease and prognosis of chronic lymphocytic leukemia

Vita Petrone⁽¹⁾ - Alessandro Giovinazzo⁽²⁾ - Roberta Laureana⁽³⁾ - Chiara Cipriani⁽¹⁾ - Marialaura Fanelli⁽¹⁾ - Antonella Minutolo⁽¹⁾ - Giovangiacinto Paterno⁽³⁾ - Elisa Buzzatti⁽³⁾ - Sandro Grelli⁽¹⁾ - Giovanni Del Poeta⁽³⁾ - Maria Ilaria Del Principe⁽¹⁾ - Emanuela Balestrieri⁽¹⁾ - Claudia Matteucci⁽¹⁾

Università degli studi di Roma "Tor Vergata", Dipartimento di Medicina Sperimentale, Roma, Italia⁽¹⁾ - istituto di biochimica e biologia cellulare, CNR, Roma, Italia⁽²⁾ - Università degli studi di Roma "Tor Vergata", Dipartimento di Medicina e Prevenzione, Roma, Italia⁽³⁾

Human endogenous retroviruses as markers of disease and prognosis of chronic lymphocytic leukemia

VITA PETRONE¹, ALESSANDRO GIOVINAZZO², ROBERTA LAUREANA³, CHIARA CIPRIANI¹, MARIALAURA FANELLI¹, ANTONELLA MINUTOLO¹, GIOVANGIACINTO PATERNO³, ELISA BUZZATTI³, SANDRO GRELLI¹, GIOVANNI DEL POETA³, MARIA I. DEL PRINCIPE³, EMANUELA BALESTRIERI¹, CLAUDIA MATTEUCCI¹

1. Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy; 2. Institute of Biochemistry and Cell Biology, CNR, Monterotondo, Rome, Italy; 3. Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.

Background: The dysregulated expression of human endogenous retrovirus K (HERV-K) at transcriptional and protein levels, as well as viral particle production, have been found in tissues, sera, and cell lines isolated from different types of tumors. In our previous studies, we have already demonstrated the concomitant expression of HERVs and embryonic genes in cancer cells with aggressiveness and stemness features. In the field of onco-hematology, some studies have identified alterations of HERV-K and others HERV families' expression in human lymphoid leukemic cells and the presence of anti HERV-K antibodies. Moreover, a few studies describe the potential involvement of embryonic genes in chronic lymphocytic leukemia (CLL). On this basis, the aim of the work was to evaluate the potential involvement of HERVs and embryonic genes in the etiopathogenesis of CLL and their use as biomarkers and prognostic markers of CLL. **Materials and methods:** Peripheral blood mononuclear cells were isolated from peripheral venous blood of 75 patients with CLL and 49 healthy donors (HDs). CLL patients were divided according to the treatment regimen they received. The expression of the ENV gene of HERV-K (HML-2), HERV-H, HERV-W, pathogenic HERV-W and HEMO, as well as the embryonic OCT4, KLF4 and NANOG genes and the stemness marker CD133 were analyzed by Real Time PCR. In addition, the percentage of HERV-K ENV-positive cells in B lymphocyte subpopulations (CD19+CD5+) was characterized by flow cytometry analysis. The genes expression profiles were defined by principal component analysis (PCA) in CLL patients, and their association with favorable prognostic factors of CLL was evaluated by multivariate analysis. **Results:** Expression profiles of HERVs and embryonic genes have been defined in CLL: the molecular analysis showed significantly higher expression of HERVs and embryonic genes in patients compared with HDs. Significant differences in all genes analyzed between untreated patients and those treated with chemotherapeutic or biological drugs patients were found. Moreover, a higher level of ENV HERV-K protein in CD19+CD5+ cells of CLL patients and its modulation in the presence of therapy were found. PCA revealed specific expression profiles of HERVs and embryonic genes in CLL patients, which were found to be associated with different treatment regimens and unfavorable prognostic factors. **Discussion and conclusion:** These results could help to clarify the CLL complexity, proposing HERVs and embryonic genes as potential new diagnostic and prognostic markers, suggesting their involvement in the etiopathogenesis of the disease. This scenario opens new avenues for investigating the use of HERVs and embryonic genes as potential therapeutics in combination with standard therapies.

178 - Maternal immune activation induces abnormal expression of endogenous retroviruses and immune effectors in a sex-dependent manner in a mouse model of Autism Spectrum Disorders

Martina Giudice⁽¹⁾ - Erica D'Avorio⁽¹⁾ - Anna Maria Tartaglione⁽²⁾ - Rossella Chirico⁽¹⁾ - Vita Petrone⁽¹⁾ - Marialaura Fanelli⁽¹⁾ - Christian Marracchioni⁽¹⁾ - Antonella Minutolo⁽¹⁾ - Sandro Grelli⁽¹⁾ - Laura Ricceri⁽²⁾ - Claudia Matteucci⁽¹⁾ - Paola Sinibaldi-Vallebona⁽¹⁾ - Emanuela Balestrieri⁽¹⁾ - Chiara Cipriani⁽¹⁾

Università degli studi di Roma "Tor Vergata", Dipartimento di Medicina Sperimentale, ROMA, Italia
⁽¹⁾ - Istituto Superiore di Sanità, Centro di scienze comportamentali e salute mentale, Roma, Italia ⁽²⁾

Maternal immune activation induces abnormal expression of endogenous retroviruses and immune effectors in a sex-dependent manner in a mouse model of Autism Spectrum Disorders

MARTINA GIUDICE¹, ERICA D'AVORIO¹, ANNA MARIA TARTAGLIONE², ROSSELLA CHIRICO¹, VITA PETRONE¹, MARIALAURA FANELLI¹, CHRISTIAN MARRACCHIONI¹, ANTONELLA MINUTOLO¹, SANDRO GRELLI¹, LAURA RICCERI², CLAUDIA MATTEUCCI¹, PAOLA SINIBALDI-VALLEBONA¹, EMANUELA BALESTRIERI¹, CHIARA CIPRIANI¹

1. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, 00133, Italy.

2. Centre for Behavioural Sciences and Mental Health, Istituto Superiore di Sanità, Rome, Italy.

Introduction: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder resulting from complex interactions among genetic, environmental, and epigenetic factors. Maternal immune activation (MIA) is one of the major environmental risk factors recognized as increasing the odds of ASD in the offspring. MIA is triggered by infections and autoimmune diseases in the mother resulting in increased levels of cytokines and chemokines that cross the placental and blood-brain barriers affecting foetal neural development. A study conducted on two preclinical models of ASD, an idiopathic mouse model, and a mouse model induced by prenatal exposure to valproic acid, showed an altered expression of several endogenous retroviruses (ERVs) and cytokines, in embryos, blood and brain samples at different post-natal ages, supporting the potential involvement of ERVs in the pathophysiology of ASD. ERVs are relics of ancestral germline infections by exogenous retroviruses, stably integrated into the host cellular DNA, which are involved in the pathogenesis and progression of many human complex diseases. This work aims to study the expression of several ERVs families, ERV-related genes, immune effectors, and marker of damage to the central system (CNS), in several tissues of a well-validated mouse model of MIA, obtained with a single injection of viral mimetic analogous to a double-stranded RNA (Poly I:C). **Materials and methods:** C57BL/6J pregnant female mice were treated with Poly I:C or saline solution at gestational day 12.5. Behavioural evaluation of the offspring and tissue collection (pre-frontal cortex, hippocampus, and blood samples) were performed on post-natal day 60. The expression of several ERVs, ERV-related genes, proinflammatory and regulatory cytokines, toll-like receptors, and markers of CNS damage was evaluated by quantitative Real-Time PCR analysis. **Results:** The results obtained demonstrate that Poly I:C exposure modulates the expression of ERVs, ERV-related genes and inflammatory and regulatory cytokines in the pre-frontal cortex and hippocampus samples in mice showing autistic-like phenotype. Notable, the effect of Poly I:C is more marked in the pre-frontal tissue of female mice compared with males, while no statistically significant sex-dependent differences were found in hippocampus and blood samples. **Discussion and conclusions:** These findings support the hypothesis of the possible involvement of ERVs, ERV-related genes and immune effectors in the pathogenesis of ASD and demonstrate that prenatal exposure to Poly I:C can induce molecular sex-dependent differences in C57BL/6J mice with autistic-like phenotype.

182 - Effects of dysbiosis on 6-OHDA mouse model of Parkinson's disease: insights from core microbiota and co-occurrence network analyses

Luigia Turco ⁽¹⁾ - Lorena Coretti ⁽²⁾ - Adriano Lama ⁽²⁾ - Carmen Avagliano ⁽²⁾ - Federica Comella ⁽²⁾ - Carmen De Caro ⁽³⁾ - Giuseppina Mattace Raso ⁽²⁾ - Francesca Lembo ⁽²⁾ - Elisabetta Buommino ⁽²⁾

Università degli studi della Campania Luigi Vanvitelli, Dipartimento di Medicina di Precisione, Napoli, Italia ⁽¹⁾ - Università degli studi di Napoli Federico II, Dipartimento di Farmacia, Napoli, Italia ⁽²⁾ - Università degli Studi "Magna Graecia" di Catanzaro, Dipartimento di Scienze della Salute, Catanzaro, Italia ⁽³⁾

Effects of dysbiosis on 6-OHDA mouse model of Parkinson's disease: insights from core microbiota and co-occurrence network analyses

LUIGIA TURCO^{1,2}, LORENA CORETTI^{1,3}, ELISABETTA BUOMMINO^{1,3}, ADRIANO LAMA^{1,3}, CARMEN AVAGLIANO¹, FEDERICA COMELLA¹, CARMEN DE CARO^{1,4}, GIUSEPPINA MATTACE RASO^{1,3}, FRANCESCA LEMBO^{1,3}

¹Dipartimento di Farmacia, Università degli Studi di Napoli Federico II, Napoli, Italia; ²Department of Precision Medicine, University of Campania Luigi Vanvitelli - 80138 Naples, Italy; ³Task Force on Microbiome Studies, Università degli studi di Napoli "Federico II", Napoli, Italia; ⁴Dipartimento di Scienze della Salute, Università degli Studi "Magna Graecia" di Catanzaro, Catanzaro, Italia

Introduction: In the last years, several studies highlighted the pivotal role of the gut microbiota as a key regulator of immunological and neuroendocrine mechanisms of the gut-brain axis in Parkinson's disease (PD). We propose a two-hit mouse model of PD in which ceftriaxone (CFX)-induced dysbiosis amplifies PD progression, worsening motor deficits induced by striatal 6-hydroxydopamine injection (6-OHDA) in mice. This effect is accompanied by a significant increase in neuronal dopaminergic loss, enhancement of systemic and colon inflammation, and worsening of colonic architecture. In this model we followed the dynamics of gut microbiota to infer a role for dysbiosis in exacerbation of PD symptoms.

Materials and Methods: Gut microbiota was studied by performing V3-V4 16S rDNA amplicon sequencing, then demultiplexed paired-end reads from MiSeq were processed and analyzed using the Quantitative Insights Into Microbial Ecology (QIIME2, version 2021.4). Structure, composition and network of interactions of gut microbiota were assessed by alpha and beta diversity, "qiime feature-table core-features" QIIME2 scripts, linear discriminant analysis effect size (LEfSe) method and Spearman co-occurrence network using the CoNet plugin for Cytoscape (3.9.0).

Results: Dual insulted mice showed a reduced gut microbiota richness with a core microbiota depleted of common gut colonizers, bacteria with probiotic activity, and butyrate producers, namely *Butyricicoccus pullicaecorum* and *Papillibacter cinnamivorans*. Microbial communities of 6-OHDA+CFX mice were also depleted in *Bifidobacterium breve* and *Alistipes finegoldii*, main acetate producers, suggesting the lack of cross-feeding interactions with the acetate-depending butyrate producers *B. pullicaecorum* and *P. cinnamivorans*. Network analysis built on LEfSe results indicated that the reduction of *A. furcosa*, *P. cinnamivorans* and *Defluviitalea saccharophila* drove the loss of the microbiota structure in 6-OHDA+CFX mice. Furthermore, *P. cinnamivorans*, *A. furcosa*, *B. breve*, and *A. finegoldii* were negatively correlated in the network analysis with *Ruminococcus lactaris*, a mucin-degrading commensal, strongly enriched in 6-OHDA+CFX mice.

Discussion and Conclusions: Our data suggest that the increase of *R. lactaris* in double insulted mice can compensate for the decrease of butyrate production bacterial networks by re-enforcing mucus glycoprotein degradation and that this activity could be detrimental to gut barrier integrity and promote pathophysiological traits of PD.

187 - Effects of antimicrobial protocols for *Helicobacter pylori* eradication on structure and functions of the human gut microbiota

Laura De Diego ⁽¹⁾ - Alessandro Tanca ⁽¹⁾ - Marcello Abbondio ⁽¹⁾ - Rosangela Sau ⁽¹⁾ - Giovanni Mario Pes ⁽²⁾ - Maria Pina Dore ⁽²⁾ - Sergio Uzzau ⁽¹⁾

University of Sassari, Department of Biomedical Sciences, Sassari, Italia ⁽¹⁾ - University of Sassari, Department of Medical, Surgical and Experimental Sciences, Sassari, Italia ⁽²⁾

Effects of antimicrobial protocols for *Helicobacter pylori* eradication on structure and functions of the human gut microbiota

LAURA DE DIEGO¹, ALESSANDRO TANCA¹, MARCELLO ABBONDIO¹, ROSANGELA SAU¹, GIOVANNI MARIO PES², MARIA PINA DORE², SERGIO UZZAU¹

¹Dipartimento di Scienze Biomediche, Università degli Studi di Sassari, Sassari, Italy

²Dipartimento di Medicina, Chirurgia e Farmacia, Università degli Studi di Sassari, Sassari, Italy

1. Introduction

Antibiotic therapies are commonly used to eradicate bacterial pathogens. Despite their irreplaceable value, antibiotics cause an imbalance in the taxonomic structure of the gut microbiota as assessed by a number of metagenomics studies. However, no studies have yet described functional variations occurring in the gut microbiota in the context of antibiotic treatments.

The aim of our study was to investigate how antimicrobial standard protocols against *Helicobacter pylori* influence the human gut microbiota in taxonomic and functional terms, by profiling the gut metaproteome subjected to *H. pylori* eradication protocols, compared to the baseline.

2. Materials and Methods

Patients with *H. pylori* infection were prospectively recruited. Stool samples were collected at the enrollment, at the end and 30 days after the treatment. Gut microbiota composition and functions were analyzed using a metaproteomic approach. Protein extracts from samples were processed according to a modified filter-aided sample preparation (FASP) protocol and the peptide mixtures were analyzed through liquid chromatography-tandem mass spectrometry.

3. Results

The alpha diversity and the richness were calculated using data about peptide abundances. They decreased at the end of therapy compared with baseline and increased 30 days after the treatment. Studies at the level of peptide abundances allow a focus on microbial functions by highlighting different types of trends. First, there was a significant decrease following antibiotic therapy of certain functions, as bacterial *omega-amidase* and *aspartate-ammonia ligase* involved in amino acid metabolism. A second trend regarded functions significantly more represented immediately after antibiotic therapy and undergoing a decrease after thirty days, as in the case of the enzymes *glucose-fructose oxidoreductase* and *glucose-6-phosphate 1-dehydrogenase*. Finally, few functions including *Fe-S cluster assembly protein SufD* and *2-oxoglutarate/2-oxoacid ferredoxin oxidoreductase subunit beta*, were significantly different comparing baseline and thirty days after withdraw of therapy. These data were in agreement with peptide-based analyses of gut microbiota members that showed a change of taxa relative abundance according to the above-described trends.

4. Discussion and conclusions

Our study provides for the first time insight into the effects of antibiotic therapies on the functions of the human gut microbiota at metaproteomic level, confirming the resilience of most - but not all - gut microbiota members and of their metabolic functions after antibiotic therapy.

191 - HERVs IMPLICATION IN DEVELOPMENT, PROGRESSION AND LONG-TERM COMPLIANCE OF COVID-19

Antonella Minutolo⁽¹⁾ - Marialaura Fanelli⁽¹⁾ - Vita Petrone⁽¹⁾ - Elisabetta Teti⁽²⁾ - Christian Marracchioni⁽¹⁾ - Martina Giudice⁽¹⁾ - Rossella Chirico⁽¹⁾ - Marco Iannetta⁽²⁾ - Federica Caldara⁽²⁾ - Chiara Sorace⁽²⁾ - Massimo Andreoni⁽²⁾ - Loredana Sarmati⁽²⁾ - Branka Horvat⁽³⁾ - Hervè Perron⁽⁴⁾ - Enrico Garaci⁽⁵⁾ - Emanuela Balestrieri⁽¹⁾ - Sandro Grelli⁽¹⁾ - Claudia Matteucci⁽¹⁾

Università degli studi di Roma, Dipartimento di Medicina Sperimentale, ROMA, Italia⁽¹⁾ - Policlinico di Roma Tor Vergata, Reparto di Malattie Infettive, Roma, Italia⁽²⁾ - Scuola Normale superiore di Lione, Centro nazionale di ricerca per le malattie infettive, Lione, Francia⁽³⁾ - Geneuro - innovation, Geneuro Research and Development, Lione, Francia⁽⁴⁾ - Università San Raffaele, IRCCS San Raffaele Pisana, Roma, Italia⁽⁵⁾

Title: HERVs IMPLICATION IN DEVELOPMENT, PROGRESSION AND LONG-TERM COMPLIANCE OF COVID-19

ANTONELLA MINUTOLO¹, MARIALURA FANELLI¹, VITA PETRONE¹, ELISABETTA TETI², CHRISTIAN MARACCHIONI¹, MARTINA GIUDICE¹, ROSSELLA CHIRICO¹, MARCO IANNETTA^{2,3}, FEDERICA CALDARA², CHIARA SORACE², MASSIMO ANDREONI^{2,3}, LOREDANA SARMATI^{2,3}, BRANKA HORVAT⁴, HERVE' PERRON^{5,6}, ENRICO GARACI⁷, EMANUELA BALESTRIERI¹, SANDRO GRELLI^{1,8}, CLAUDIA MATTEUCCI¹
1. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 2. Infectious Diseases Clinic, Policlinic of Tor Vergata, Rome, 00133, Italy; 3. Department of Systems Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 4. International Center for Infectiology Research (CIRI), INSERM U1111, CNRS UMR5308, Ecole Normale Supérieure de Lyon, University of Lyon, Lyon-France; 5. Geneuro – Innovation, Lyon-France 69008; 6. University of Lyon, Lyon, 69007, France; 7. University San Raffaele, Rome Italy; 8. Virology Unit, Policlinic of Tor Vergata, Rome, 00133, Italy.

Introduction: The human coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated not only with elevated morbidity and mortality, but with long-term complications. Recent evidences highlight how the Human Endogenous Retroviruses (HERVs) were activated in response to infectious agents leading to immune-pathological effects and the present study aims to evaluate HERVs in the immune-pathogenesis of COVID-19, for the identification of new biomarkers for the diagnosis, prognosis, and follow-up of COVID-19 patients and their prioritization for targeted therapy. **Methods:** Blood samples were collected at Tor Vergata University Hospital of Rome from Acute COVID-19 (A-COV) patients and Healthy Donors (HD). Blood from Post COVID-19 (P-COV) was also collected (range: 7-48 weeks post-infection). The expression of the envelope (ENV) of HERV-K and HERV-W have been analyzed by flow cytometry and correlated with clinical signs, immunophenotyping, inflammatory markers, and disease progression. The T cell differentiation markers were also analysed. **Results:** HERV-W and HERV-K ENV proteins have been found expressed in blood samples from A-COV but not in HDs. Despite the percentage of Lymphocytes recovery, even after several weeks' post-infection the expression of HERVs remained elevated in P-COV. Among leukocytes, A-COV lymphocytes displayed the highest percentage of HERV-W ENV positive cells, which correlated with T cell differentiation, exhaustion, and senescence markers. Instead, HERV-K ENV resulted in highly expressed in granulocytes and directly correlates with senescence markers CD57. HERV-W ENV positive CD4+ T cells significantly correlated with coagulopathy and biochemical parameters associated with COVID-19 severity. In P-COV patients, HERVs protein expression remained high, especially in granulocytes. Notably, despite a restore of the normal distribution of leukocytes subpopulation in P-COV, the percentage of CD4 naïve cells and CD8 terminal effector memory resulted altered suggesting a persistent immune dysfunction in P-COV. To date, long-term health problems, including neurological symptoms such as headache, fatigue, dizziness, memory loss, confusion, and difficulty focusing, are associated with post-COVID-19 infection. Notably, HERVs expression was found higher in patients with specific neurological symptoms such as paraesthesia and tremors, suggesting their involvement in neurological alterations related to COVID-19. **Discussion and Conclusion:** These data suggest HERVs as contributing factors in the development, progression, and long-term complications of COVID-19 describing disease evolution and opening avenues for novel therapeutic strategies.

199 - Third Sars-CoV-2 vaccine dose: B cell and antibody responses following heterologous and homologous vaccination strategies

Gabiria Pastore⁽¹⁾ - Annalisa Ciabattini⁽¹⁾ - Fabio Fiorino⁽¹⁾ - Jacopo Polvere⁽¹⁾ - Simone Lucchesi⁽¹⁾ - Ilaria Rancan⁽²⁾ - Arianna Lippi⁽²⁾ - Sara Zirpoli⁽¹⁾ - Elena Pettini⁽¹⁾ - Massimiliano Fabbiani⁽³⁾ - Mario Tumbarello⁽²⁾ - Francesca Montagnani⁽²⁾ - Donata Medaglini⁽¹⁾

Laboratorio di Microbiologia Molecolare e Biotecnologia, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italia⁽¹⁾ - Dipartimento di Biotecnologie Mediche, Università di Siena, Dipartimento di Scienze Mediche, Unità di Malattie Infettive e Tropicali, Ospedale Universitario di Siena, Siena, Italia⁽²⁾ - Dipartimento di Scienze Mediche, Unità di Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria di Siena, Siena, Italia⁽³⁾

Third Sars-CoV-2 vaccine dose: B cell and antibody responses following heterologous and homologous vaccination strategies

Gabiria Pastore¹, Annalisa Ciabattini¹, Fabio Fiorino¹, Jacopo Polvere¹, Simone Lucchesi¹, Ilaria Rancan^{2,3}, Arianna Lippi^{2,3}, Sara Zirpoli¹, Elena Pettini¹, Massimiliano Fabbiani³, Mario Tumbarello^{2,3}, Francesca Montagnani^{2,3}, Donata Medaglini¹

¹Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy; ²Department of Medical Biotechnologies, University of Siena, Siena, Italy; ³Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy.

Introduction: Since the end of 2021, many countries have implemented vaccination against Sars-CoV-2 with a third dose of the vaccine. Heterologous vaccine regimen has been a valid opportunity to make vaccination programs more flexible and reliable in the face of supply fluctuations and to improve immunogenicity and safety of COVID-19 vaccines. The available data on immunogenicity beyond one month following third doses are mostly related to antibody responses and T cell response while no information is available on the persistence of memory B cells that are expected to play a crucial role for a rapid response to SARS-CoV-2 infection. **Materials and Methods:** In this study, we profiled and compared the Spike-specific memory B cells, antibody responses and ACE-2/RBD binding inhibition activity following the administration of heterologous or homologous COVID-19 vaccines to 138 healthy volunteers without a laboratory confirmed history of SARS-CoV-2 infection. Subjects enrolled in the study were divided into three groups, vaccinated with different combinations of SARS-CoV-2 vaccines for the first vaccination cycle (first two doses) and for the booster (third dose), including the BNT162b2 (Pfizer-BioNTech; Comirnaty), mRNA-1273 (Spikevax, ModernaTX), and ChAdOx1 (AZD1222, AstraZeneca) vaccines. **Results.** The heterologous combination of ChAdOx1 (dose I and II) with mRNA (III dose) vaccines elicited Spike-specific IgG levels comparable with the ones induced by the three doses of mRNA vaccines. ACE-2/RBD binding inhibition activity was significantly increased in the heterologous and homologous vaccination schedule. A good antibody binding inhibition activity to SARS-CoV-2 Omicron variant was found in all groups. Ig switched S+RBD+ B cells were detected in all groups following third vaccine doses. The Ig switched S+RBD+ B cells significantly increased at +30 v3 compared to +7 v3 in heterologous vaccinations schedules while were maintained constant after homologous vaccination. A fraction of Ig switched S+RBD+ B cells showed a plasmablast phenotype (CD27+CD38high) at +7v3 and became almost undetectable at longer time points (+30v3). **Discussion and Conclusions** Heterologous prime-boost vaccination strategy elicits Spike-specific antibody and B cell responses comparable to the ones induced by homologous approach. These data indicate that heterologous prime-boost vaccination is an important strategy against SARS-CoV2 and other pathogens especially in state of emergency.

200 - Prediction of *Pneumocystis jirovecii* pneumonia in COVID-19 patients through quantitative PCR on oral washings

Luca Fanasca⁽¹⁾ - Elena Scaglione⁽²⁾ - Ciro Rauch⁽¹⁾ - Anna Fioretti⁽¹⁾ - Valeria Pedata⁽¹⁾ - Federica Amodio⁽¹⁾ - Saveria Alfè⁽¹⁾ - Giuseppina Montanile⁽¹⁾ - Mariateresa Vitiello⁽³⁾ - Roberta Colicchio⁽³⁾ - Giulio Viceconte⁽⁴⁾ - Antonio R. Buonomo⁽⁴⁾ - Ivan Gentile⁽⁴⁾ - Paola Salvatore⁽⁵⁾

University Hospital Federico II, DAI Lab Med and Transf. UOC Clin Micr, Napoli, Italia⁽¹⁾ - University of Naples Federico II; University Hospital Federico II, DAI Lab Med and Transf UOC Clin Micr; Dpt Mol Med Med Biotech; Dpt Chem Mat and Prod Eng, Napoli, Italia⁽²⁾ - University of Naples Federico II; University Hospital Federico II, DAI Lab Med and Transf UOC Clin Micr; Dpt Mol Med Med Biotech, Napoli, Italia⁽³⁾ - University of Naples Federico II, Dpt Clin Med and Surg, Sect of Inf Dis, Napoli, Italia⁽⁴⁾ - University Hospital Federico II; University of Naples Federico II; CEINGE, Advanced Biotechnologies s.c.ar.l., DAI Lab Med and Transf UOC Clin Micr; Dpt Mol Med Med Biotech; Task Force on Microbiome Studies, Napoli, Italia⁽⁵⁾

Prediction of *Pneumocystis jirovecii* pneumonia in COVID-19 patients through quantitative PCR on oral washings

LUCA FANASCA¹, ELENA SCAGLIONE^{1,2,3}, CIRO RAUCH¹, ANNA FIORETTI¹, VALERIA PEDATA¹, FEDERICA AMODIO¹, SAVERIA ALFÈ¹, GIUSEPPINA MONTANILE¹, MARIATERESA VITIELLO^{1,2}, ROBERTA COLICCHIO^{1,2}, GIULIO VICECONTE⁴, ANTONIO R. BUONOMO⁴, IVAN GENTILE⁴, PAOLA SALVATORE^{1,2,5,6}

¹Department of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italy; ²Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy; ³Department of Chemical, Materials and Production Engineering, University of Naples Federico II, Naples, Italy; ⁴Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy; ⁵Task Force on Microbiome Studies, University of Naples Federico II, Naples, Italy; ⁶CEINGE, Advanced Biotechnologies s.c.ar.l., Naples, Italy

INTRODUCTION. The impact of SARS-CoV-2 infection on the immune system, albeit not completely understood this far, has been widely described, and encompasses lymphopenia and functional exhaustion of immune cells. On the other hand, the use of corticosteroids for treating COVID-19 could have a similar effect, especially in the case of high doses or prolonged administration. This could constitute a substrate for the many different opportunistic infections reported in critically ill COVID-19 patients, which include *Pneumocystis jirovecii* pneumonia (PjP). However, the execution of bronchoalveolar lavages (BAL) to diagnose PjP is not always viable in these patients, suggesting the need for different strategies. The use of oral washings (OW) to assess *P. jirovecii* colonization has already been described on immune depressed patients. **MATERIALS AND METHODS.** Two different OWs were obtained from a COVID-19 inpatient: the first on the day of admission, the second twelve days later, when he also underwent a BAL for suspected PjP. DNA was extracted from OWs and subsequently underwent a real-time PCR targeting the mitochondrial large subunit ribosomal RNA gene of *P. jirovecii*, with a standard curve for quantitation purposes. The BAL was examined through a direct fluorescence assay (DFA) for *Pneumocystis* cysts and vegetative forms. **RESULTS.** The first OW was found positive for *P. jirovecii* DNA, at a concentration of about 25 copies/ml. The second was found negative. On the same day of the second OW, however, the BAL tested positive for PjP DFA. **DISCUSSION AND CONCLUSIONS.** This finding suggests that a diagnosis of *P. jirovecii* colonization in the oral cavity by the means of a real-time PCR on oral washings can anticipate by several days the detection of the same pathogen in profound respiratory samples in COVID-19 patients. Interestingly, *P. jirovecii* DNA could not be found in the oral cavity on the day it was found in the lower respiratory tract, suggesting the transition of the pathogen towards the lungs. Further expansions of this research could lead to a better understanding on the prevalence of *P. jirovecii* colonization and infection in COVID-19 patients and on the possible impact of preemptive therapy in selected cases.

202 - Human endogenous retroviruses as potential therapeutic targets for the treatment of head and neck squamous cell carcinoma resistant to radiotherapy

Vita Petrone ⁽¹⁾ - [Rossella Chirico](#) ⁽¹⁾ - Marialaura Fanelli ⁽¹⁾ - Christian Marracchioni ⁽¹⁾ - Martina Giudice ⁽¹⁾ - Sandro Grelli ⁽²⁾ - Antonella Minutolo ⁽¹⁾ - Emanuela Balestrieri ⁽¹⁾ - Ira-Ida Skvortsova ⁽³⁾ - Claudia Matteucci ⁽¹⁾

Università degli studi di Roma, Dipartimento di Medicina Sperimentale, Roma, Italia ⁽¹⁾ - Policlino di Tor Vergata, Unità di Virologia, Roma, Italia ⁽²⁾ - Università di Medicinad di Innsbruck, Dipartimento di radiologia terapeutica e oncologia, Innsbruck, Austria ⁽³⁾

Human endogenous retroviruses as potential therapeutic targets for the treatment of head and neck squamous cell carcinoma resistant to radiotherapy

VITA PETRONE¹, ROSSELLA CHIRICO¹, MARIALAURA FANELLI¹, CHRISTIAN MARACCHIONI¹, MARTINA GIUDICE¹, SANDRO GRELLI^{1,2}, ANTONELLA MINUTOLO¹, EMANUELA BALESTRIERI¹, IRA-IDA SKVORTSOVA³, CLAUDIA MATTEUCCI¹

1. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 2. Virology Unit, Policlinic of Tor Vergata, Rome, 00133, Italy; 3. Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Introduction Human endogenous retroviruses (HERVs) are retrotransposon elements that originated from retroviral infections of the germ cell line millions of years ago. Altered expression of HERVs has been associated with the onset and acquisition of aggressiveness features in tumour cells. This study aimed to investigate HERVs as potential therapeutic targets for the treatment of radiotherapy-resistant head and neck squamous cell carcinoma. For this purpose, the effect of two reverse transcriptase inhibitors, efavirenz (EFV) and zidovudine (AZT), on the modulation of HERVs expression, the aggressiveness and survival of radioresistant (RR) and non-radioresistant (PAR) head and neck cancer cells (FaDu) was analyzed. Moreover, the effect of the inhibitor of a small GTPase, Rac1, in combination with antiretroviral drugs has been evaluated. Indeed, Rac1 is already known to regulate many cellular processes involved in radioresistance. Since radiotherapy is one of the most widely used strategies for the treatment of carcinomas, the effect of combined treatments was also evaluated during the exposure to ionizing radiation. **Materials and methods** FaDu-PAR and FaDu-RR cell lines were treated with antiretroviral drugs AZT and EFV, alone and subsequently in combination with Rac1 inhibitor (iRAC1) at different times. The relative expression of HERV-K (HML-2), HERV-H, and embryonic genes (OCT4, NANOG) were evaluated by Real-Time PCR. The expression of HERV-K ENV protein was assessed by flow cytometry. Colony formation assay and wound healing were performed. Moreover, the cell lines were exposed to ionizing radiation (2Gy,6Gy) after treatments to evaluate cell growth and apoptosis. **Results** FaDu-RR cell line showed high transcriptional activity of HERV-K, HERV-H, and embryonic genes OCT4 and NANOG, compared to the parental cell line. Treatment with antiretroviral drugs in combination with iRAC1 affected the transcriptional activity of HERVs and embryonic genes in FaDu-RR. Moreover, the co-treatment influenced clonogenic activity and cell motility. Furthermore, the co-treatment followed by exposure to ionizing radiations has induced the inhibition of cell growth and the induction of apoptosis in FaDU-RR cells. **Discussion and Conclusions** Nowadays, standard cancer treatments are often ineffective in carcinoma and new combination approaches are needed. The combination of antiretroviral drugs and iRAC1 was able to restore sensitivity to radiotherapy in FaDU-RR cells expressing high levels of HERV-K, suggesting its role in radioresistance and as a new potential therapeutic target.

205 - A specific anti-IFITM2 antibody bars the way to SARS-CoV-2 entry into host cells.

Anna Basile ⁽¹⁾ - Carla Zannella ⁽²⁾ - Gianluigi Franci ⁽¹⁾ - Margot De Marco ⁽¹⁾ - Maria Ctaerina Turco ⁽¹⁾ - Alessandra Rosati ⁽¹⁾ - Liberato Marzullo ⁽¹⁾

UNISA, DIPMED, Baronissi, Italia ⁽¹⁾ - University of Campania "Luigi Vanvitelli", Department of Experimental Medicine, Naples, Italia ⁽²⁾

TITLE

A specific anti-IFITM2 antibody bars the way to SARS-CoV-2 entry into host cells.

AUTHORS

Anna Basile ^{1,2}, Carla Zannella ³, Gianluigi Franci ^{1,3}, Margot De Marco ^{1,3}, Maria Caterina Turco ^{1,2}, Alessandra Rosati ^{1,2}, Liberato Marzullo ^{1,2}.

AFFILIATIONS

1. Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Salerno, Italy; 2. FIBROSYS s.r.l., University of Salerno, Baronissi, Salerno, Italy; 3. Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy

ABSTRACT

Introduction

Viral proteins able to hook plasma membrane proteins/receptors give the start to complex cell processes leading to viral entry, replication and spreading. The early steps of viral infection involve protein complexes and structural lipid rearrangements, which mark the characteristic strategies of each virus on the way of its host cell. Innate immune response evolved first line defences aimed at restricting the viral entry and invasion, among them, human IFITM proteins are described as inhibitors of a broad range of viruses. Despite their homology and functional redundancy, recently, it has been surprisingly showed that SARS-CoV-2 is able to specifically hijack human IFITM2 in the infection mechanism of a wide range of host human cells. Here we report the synthesis and the characterization of the biological activity of a new and specific anti-IFITM2 mAb. Our study showed that the mAb is able to bind the extracellular N-terminus of the human IFITM2 and to prevent SARS-CoV-2 entry into the host cells.

Materials and methods:

A specific anti-IFITM2 mAb was obtained by immunizing mice with a specific antigen encompassing the IFITM2 extracellular N-terminal sequence. IFITM2 expression on SARS-CoV-2 permissive cells was detected by flow cytometry and the inhibitory activity of the anti-IFITM2 mAb on the SARS-CoV-2 Spike protein entry was analyzed by Proximity Ligation Assays. Finally, the antiviral activity of the anti-IFITM2 mAb was assessed by plaque assay and by monitoring viral gene expression in RT-PCR.

Results:

Data supported the evidence of a strong expression of human IFITM2, as well as its monkey ortholog IFITM2/3, respectively on the cell membrane of SARS-CoV-2 permissive human cell line Calu-3 and monkey Vero E6 cells. Moreover, the use of this specific anti-IFITM2 mAb was able to impair the molecular mechanism leading to the endocytosis of the Spike protein. This effect was in agreement with functional assays showing that the IFITM2-blocking mAb was able to reduce SARS-CoV-2 dependent cytotoxicity and viral replication yield. These pieces of evidence let us infer that the antibody efficacy in reducing the success of the viral infection could be explained by its ability to interfere with spike internalization process.

Discussion and Conclusions:

The use of mAb against IFITM proteins can pave the way to the synthesis of new antiviral molecules as well as to a novel therapeutic strategy for the prevention, or early treatment, of Sars-CoV-2 positive patients. Because most emergency medications do not provide optimal responses, more valuable SARS-CoV-2 entry inhibitors are expected in the upcoming post-pandemic era, as well as in the context of counteracting new emerging viruses that spread through the respiratory tract.

209 - HSV-1 INDUCED COMPLEMENT ACTIVATION IN BRAIN CELLS: POSSIBLE TRIGGER OF SYNAPTIC DEFICITS

Mariya Timotey Miteva⁽¹⁾ - Virginia Protto⁽¹⁾ - Filomena Iannuzzi⁽²⁾ - Flavia Pasquali⁽¹⁾ - Maria Elena Marcocci⁽¹⁾ - Giovanna De Chiara⁽²⁾ - Anna Teresa Palamara⁽³⁾

Sapienza Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia⁽¹⁾ - Consiglio Nazionale delle Ricerche, Istituto di Farmacologia Traslazionale, Roma, Italia⁽²⁾ - Sapienza Università di Roma; Istituto Superiore di Sanità, Dipartimento di Sanità Pubblica e Malattie Infettive; Dipartimento di Malattie Infettive, Roma, Italia⁽³⁾

HSV-1 INDUCED COMPLEMENT ACTIVATION IN BRAIN CELLS: POSSIBLE TRIGGER OF SYNAPTIC DEFICITS

MARIYA T. MITEVA¹, VIRGINIA PROTTO¹, FILOMENA IANNUZZI², FLAVIA PASQUALI¹, MARIA E. MARCOCCI¹, GIOVANNA DE CHIARA², ANNA T. PALAMARA^{1,3}

¹*Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Rome, Italy;*

²*Institute of Translational Pharmacology, National Research Council, Rome, Italy;*

³*Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.*

Introduction: Among the multiple factors that may contribute to the pathogenesis of Alzheimer's disease (AD), numerous experimental and epidemiological evidence suggests that recurrent herpes simplex virus-1 (HSV-1) infection reaching the brain is one of the risk factors for the disease onset and/or progression. However, the molecular mechanisms linking HSV-1 infection to neuronal dysfunctions have yet to be fully elucidated. Genetic, proteomic, and immunologic evidence suggests that dysregulation of the complement cascade, a key component of the innate immune system that is rapidly recruited to allow the clearance of pathogens and promote tissue repair, is involved in the pathogenesis of AD. It is also known that proteins of the classical complement pathway play a role in the process of synaptic elimination or neuronal pruning in the brain, an important event in neurodegeneration.

Materials and Methods: Primary neuronal cultures were isolated from the brain of rat embryos (E18). Neurons were mock- and HSV-1 infected at different multiplicity of infection and the efficacy of HSV-1 infection was evaluated by standard plaque assays (SPA). Cells were analysed for the expression of complement components and PSD95 (postsynaptic marker) at protein and mRNA levels with western blotting (WB) and RT-PCR, respectively. Immunofluorescence analyses (IF) were also carried to detect specifically C3 expression. Neutralization assay was performed with the aid of a specific antibody directed against the complement component C3.

Results: We found that HSV-1 infection in cultured rat brain cells induces an increase of C1q and C3 mRNA expression, detected by RT-PCR, and also a dose-dependent increase of C1q, C3, and C4 detected by WB. The C3 increase after HSV-1 infection was also confirmed by IF. Results from a neutralization assay showed that in HSV-1 infected neurons the inhibition of the C3 component rescued the HSV-1 induced decrease of PSD-95.

Discussion and Conclusions: The dose-dependent increase of complement proteins after HSV-1 infection in cultured rat brain cells indicates that complement may play a role in the immune response to HSV-1 infection in rat brain. The decrease of the synaptic marker PSD-95 expression after HSV-1 infection in cultured rat brain cells indicates a possible HSV-1 induced synaptic reduction. Finally, the preliminary results of C3 neutralization assay suggest that the complement protein C3 may be involved in the process of synaptic reduction that follows HSV-1 infection. Overall, these results suggest a possible complement-dependent synaptic damage triggered by HSV-1 brain infection, thus strengthening the causal link between HSV-1 and neurodegeneration.

211 - Antibacterial activity of Rhein against *Streptococcus mutans*

Francesco Foglia⁽¹⁾ - Emanuela Roscetto⁽²⁾ - ALESSANDRA Amato⁽³⁾ - Umbero Galdiero⁽⁴⁾ - ROBERTA Gasparro⁽⁵⁾ - Carla Zannella⁽⁶⁾ - Vincenzo Casolaro⁽⁷⁾ - Anna De filippis⁽⁸⁾ - Maria Rosaria Catania⁽⁹⁾ - Gianluigi Franci⁽¹⁰⁾ - Massimiliano Galdiero⁽¹¹⁾

Università della Campania I. Vanvitelli, Dipartimento di Medicina Sperimentale, Napoli, Italia⁽¹⁾ - Università degli studi Federico II, Department of Molecular Medicine and Medical Biotechnology, Napoli, Italia⁽²⁾ - University of salerno, 3Department of Medicine, Surgery and Dentistry, Salerno, Italia⁽³⁾ - Università Degli studi Federico II, Department of Molecular Medicine and Medical Biotechnology,, Napoli, Italia⁽⁴⁾ - University of Salerno, Department of Neurosciences, Reproductive Sciences and dentistry, Salerno, Italia⁽⁵⁾ - University of Camapania L. Vanvitelli, 1Department of Experimental Medicine, Naples, Italia⁽⁶⁾ - University of Salerno, Department of Medicine, Surgery and Dentistry, Salerno, Italia⁽⁷⁾ - University of Campania L vanvitelli, Department of Experimental Medicine, Naples, Italia⁽⁸⁾ - University of Naplese Federico II, Department of Molecular Medicine and Medical Biotechnology, Naples, Italia⁽⁹⁾ - University of Salerno, 5Department of Medicine, Surgery and Dentistry, salerno, Italia⁽¹⁰⁾ - University of Campania L. Vanvitelli, Department of experimental medicine, Naples, Italia⁽¹¹⁾

Antibacterial activity of Rhein against *Streptococcus mutans*

*FRANCESCO FOGLIA*¹, *EMANUELA ROSCETTO*², *ALESSANDRA AMATO*³, *UMBERTO GALDIERO*², *ROBERTA GASPARRO*⁴, *CARLA ZANNELLA*¹, *VINCENZO CASOLARO*⁵, *ANNA DE FILIPPIS*¹, *MARIA ROSARIA CATANIA*², *GIANLUIGI FRANCI*⁵, *MASSIMILIANO GALDIERO*¹

¹Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy; ²Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy; ³Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Salerno, Italy; ⁴Department of Neurosciences, Reproductive Sciences and Dentistry, University of Naples Federico II, Naples, Italy; ⁵Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Salerno, Italy

Introduction

Streptococcus mutans (*S. mutans*) is considered the major etiological agent of human dental caries and resides primarily in biofilms that form on the tooth surfaces, also known as dental plaque. The aim of our study was to evaluate the antimicrobial activity of a natural plant product, pure 4,5"-dihydroxy-anthraquinone-2-carboxylic acid (Rhein) against *S. mutans*.

Materials and Methods

Assay for antimicrobial activity and the time-killing test were performed to evaluate Rhein effects against planktonic *S. mutans*. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to determine the viability of immortalized human keratinocytes (HaCaT) following treatment with Rhein. The effect of different concentrations of Rhein on biofilm biomass and the metabolism of biofilm cells were evaluated through crystal violet and MTT assays. Further, Rhein-treated biofilms were viewed by confocal laser scanning microscopy. Rhein effects on acid production and acid environment tolerance were also assessed.

Results

The minimum inhibitory concentration (MIC) of Rhein, exerting bacteriostatic action on 90% of planktonic *S. mutans* (MIC₉₀), was 5.69 µg/mL. MIC and sub-MIC concentrations of Rhein affected the metabolism of biofilm cells and disrupted biofilm biomass with minimal biofilm eradication concentrations (MBEC) inducing 50% (MBEC₅₀) and 90% eradication (MBEC₉₀) of 6.31 and > 50 µg/mL, respectively.

Discussion and Conclusions

Confocal images displayed a significant reduction in biofilm biomass following treatment with increasing concentrations of the compound. Rhein also reduced the virulence of the biofilm by affecting acid production and acid tolerance.

Conversely, active concentrations of Rhein did not affect HaCaT cell viability. Together, these findings indicate that Rhein, a natural product that counteracts the virulence of *S. mutans*, may represent a novel therapeutic option for dental caries.

213 - Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines

Fabio Fiorino ⁽¹⁾ - Annalisa Ciabattini ⁽¹⁾ - Anna Sicuranza ⁽²⁾ - Gabiria Pastore ⁽¹⁾ - Adele Santoni ⁽²⁾ - Martina Simoncelli ⁽²⁾ - Jacopo Polvere ⁽¹⁾ - Sara Galimberti ⁽³⁾ - Claudia Baratè ⁽³⁾ - Francesca Montagnani ⁽⁴⁾ - Vincenzo Sammartano ⁽²⁾ - Monica Bocchia ⁽²⁾ - Donata Medagliani ⁽¹⁾

Laboratorio di Microbiologia Molecolare e Biotecnologia, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italia ⁽¹⁾ - Unità di Ematologia, Dipartimento Scienze mediche, chirurgiche e neuroscienze, Azienda Ospedaliero Universitaria, Siena, Italia ⁽²⁾ - Sezione di Ematologia, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italia ⁽³⁾ - Dipartimento di Scienze Mediche, Unità di Malattie Infettive e Tropicali, Azienda Ospedaliera Universitaria di Siena,, Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italia ⁽⁴⁾

Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines

FABIO FIORINO ¹, *ANNA SICURANZA* ², *ANNALISA CIABATTINI* ¹, *ADELE SANTONI* ², *GABIRIA PASTORE* ¹, *MARTINA SIMONCELLI* ², *JACOPO POLVERE* ¹, *SARA GALIMBERTI* ³, *CLAUDIA BARATÈ* ³, *FRANCESCA MONTAGNANI* ^{4,5}, *VINCENZO SAMMARTANO* ², *MONICA BOCCIA* ^{2,*} AND *DONATA MEDAGLINI* ^{1,*}

¹Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena; 53100 Siena, Italy; ²Hematology Unit, Department of Medical Science, Surgery and Neuroscience, Azienda Ospedaliero Universitaria Senese, University of Siena, 53100 Siena, Italy; ³ Section of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy; ⁴Department of Medical Sciences, Infectious and Tropical Diseases Unit, Azienda Ospedaliero Universitaria Senese, University of Siena; 53100 Siena, Italy; ⁵ Department of Medical Biotechnologies, University of Siena; 53100 Siena, Italy

Introduction. Vaccination against SARS-CoV-2 using mRNA-based vaccines has been highly recommended for fragile subjects, including myelofibrosis patients (MF). Available data on the immune response developed by MF patients after mRNA SARS-CoV-2 vaccination, and the impact of the therapy with ruxolitinib, are still fragmented. Here, we profile the spike-specific IgG and memory B-cell response in MF patients, treated or not with the JAK inhibitor ruxolitinib, after the second and the third dose of SARS-CoV-2 BNT162b2 (BioNTech) and mRNA-1273 (Moderna) vaccines. **Materials and Methods.** Plasma and peripheral blood mononuclear cells samples were collected at baseline (before vaccination), after the second (post v2) and third vaccine dose (post v3) and tested for spike-specific antibodies, ACE2/RBD antibody inhibition binding activity and Spike/RBD-specific B cells. The anti-spike IgG levels were assessed by ELISA. Memory Spike/RBD B cells were identified by multiparametric flow cytometry as Spike⁺, RBD⁺, CD19⁺, CD20⁺ and IgD⁺. **Results.** Seven days after two doses of mRNA SARS-CoV-2 vaccine, 76% of MF patients developed spike-specific IgG, but the response showed a slower kinetics compared to healthy subjects, suggesting a reduced capability of their immune system to promptly react to vaccination. A reduced ACE2/RBD binding inhibition activity of spike-specific antibodies was also observed, especially in ruxolitinib-treated patients. A two- and five-fold increase in spike-specific IgG was elicited by the third dose in patients with or without ruxolitinib treatment, respectively, while the percentage of subjects with antibodies capable of in vitro blocking ACE2/RBD interaction raised from 50% up to 80%, irrespective of the ruxolitinib treatment. A significant increase of spike/RBD-specific B cells was observed after the booster dose, especially in patients under ruxolitinib treatment, reaching values comparable with healthy controls. Overall, the third vaccine dose significantly enhanced the immune responsiveness in MF subjects except in three patients which were under immunosuppressive therapies at the time of vaccination. **Discussion and Conclusions.** Our results highlight a slow kinetic of the immune response in MF patients following the second vaccine dose of mRNA SARS-CoV-2 vaccines and show the capacity of the third vaccine dose of strongly boosting the spike-specific antibody and B-cell responses.

214 - Antimicrobial and Antibiofilm Activities of Carvacrol, Amoxicillin and Salicylhydroxamic acid Alone and in Combination versus *Helicobacter pylori*

VALENTINA PUCA⁽¹⁾ - BEATRICE MARINACCI⁽¹⁾ - SIMONE CARRADORI⁽¹⁾ - CLAUDIU TRANDAFIR SUPURAN⁽²⁾ - CLEMENTE CAPASSO⁽³⁾ - PAMELA DI GIOVANNI⁽¹⁾ - ILARIA D'AGOSTINO⁽¹⁾ - ROSSELLA GRANDE⁽¹⁾

Università G. d'Annunzio Chieti-Pescara, Dipartimento di Farmacia, Chieti, Italia⁽¹⁾ - University of Florence, Neurofarba Department, Section of Pharmaceutical and Nutraceutical Sciences, Firenze, Italia⁽²⁾ - National Research Council (CNR), Department of Biology, Agriculture and Food Sciences, Napoli, Italia⁽³⁾

Antimicrobial and Antibiofilm Activities of Carvacrol, Amoxicillin and Salicylhydroxamic acid Alone and in Combination versus *Helicobacter pylori*

VALENTINA PUCA¹, BEATRICE MARINACCI¹, SIMONE CARRADORI¹, CLAUDIU T. SUPURAN², CLEMENTE CAPASSO³, PAMELA DI GIOVANNI¹, ILARIA D'AGOSTINO¹, ROSSELLA GRANDE¹

¹Department of Pharmacy, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy;

²Neurofarba Department, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Sesto Fiorentino, Florence, Italy;

³Department of Biology, Agriculture and Food Sciences, National Research Council (CNR), Institute of Biosciences and Bioresources, Naples, Italy

Introduction. *H. pylori* eradication is difficult to be achieved because of its genetic variability, its capacity of forming biofilm and its ability of developing resistance against the commonly used antimicrobials. Antimicrobial resistance is a global health issue and the WHO specified *H. pylori* resistant to clarithromycin, as one of twelve high priority pathogens for which the antimicrobial research development is necessary. For these reasons, the identification of new strategies or adjuvants to standard antibiotic therapy, is required to counteract *H. pylori* infection. The inhibition of bacterial urease and carbonic anhydrases (CA) could represent a new mechanism of impairing the bacterial growth. The aim of this study was the evaluation of the antimicrobial and the antibiofilm activity of a CA inhibitor, such as carvacrol (CAR), amoxicillin (AMX) and a urease inhibitor, such as salicylhydroxamic acid (SHA), alone and in combination versus *H. pylori* ATCC 43504.

Materials and Methods. The Minimal Inhibitory Concentration (MIC) and the Minimal Bactericidal Concentration (MBC) of the combination of CAR-AMX, AMX-SHA and CAR-SHA were evaluated by the checkerboard method. The best MIC combinations of CAR, AMX and SHA were tested against *H. Pylori* mature biofilm. The ability of the combinations to eradicate *H. pylori* biofilm was evaluated through the AlamarBlue (AB) assay, the Colony Forming Unit (CFU) counting method and the Crystal violet assay.

Results. The compounds in combination were able to inhibit *H. pylori* planktonic growth, as demonstrated by the FIC index that is additive for the association of CAR-AMX and CAR-SHA but indifferent for the association of AMX-SHA. A preformed *H. pylori* biofilm was treated with double MIC concentrations of the compounds in combination and the results demonstrated that the most effective combinations are those with carvacrol. In particular CAR-AMX combination showed synergy in reducing the biofilm biomass already at 1xMIC concentration with complete eradication of the biofilm at 2xMIC. CAR-SHA association reduces *H. pylori* biofilm at 2xMIC concentration with a total eradication of the biofilm at 4xMIC. The association of AMX-SHA was the less effective in reducing *H. pylori* biofilm, in fact the complete eradication of the biofilm was reached at 4xMIC.

Discussion and Conclusions. The data obtained in this study showed that the combinations of CAR, AMX and SHA were able to eradicate a preformed biofilm developed by *H. pylori*, representing a potential innovative strategy against *H. pylori* infections. CA inhibitors and urease inhibitors may contribute, alone and in association with currently used antibiotics, to limit the spread of the antimicrobial resistance as well as the pathogenicity of this microorganism.

216 - Expression profile of Human Endogenous Retroviruses, their receptors, inflammatory and regulatory cytokines in children with Kawasaki disease and Multisystem inflammatory syndrome

emanuela balestrieri ⁽¹⁾

Università degli studi di Roma Tor Vergata, Dipartimento di Medicina Sperimentale, roma, Italia ⁽¹⁾

Expression profile of Human Endogenous Retroviruses, their receptors, inflammatory and regulatory cytokines in children with Kawasaki disease and Multisystem inflammatory syndrome

MARTINA GIUDICE¹, VITA PETRONE¹, MARIALAURA FANELLI¹, ELENA CORINALDESI², MARIANNA FABI³, LAURA ANDREOZZI³, ERICA D'AVORIO¹, ROSSELLA CHIRICO¹, CHRISTIAN MARRACCHIONI¹, CHIARA CIPRIANI¹, ANTONELLA MINUTOLO¹, SANDRO GRELLI¹, MARCELLO LANARF³, PAOLA SINIBALDI-VALLEBONA^{1,4}, CLAUDIA MATTEUCCI¹, EMANUELA BALESTRIERI¹

1. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.

2. Pediatric Department, Ramazzini Hospital, Carpi, Modena, Italy.

3. Emergency Unit, Medical and Surgical Sciences Departement, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

4. Institute of Translational Pharmacology, National Research Council, Rome, Italy.

Introduction: Kawasaki disease (KD) is a febrile systemic vasculitis which usually affects children younger than 5 years of age. The causative agent leading to the clinical manifestation in childhood remains unknown and the most widespread hypothesis is that an infectious factor triggers the excessive inflammatory response in genetically predisposed children. The recent Human Coronavirus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, highlighted the onset of a new post-infectious complication, called multisystem inflammatory syndrome in children (MIS-C), characterized by severe inflammation and clinical features overlapping Kawasaki disease. Human Endogenous Retroviruses (HERVs) are relics of ancestral germline infections by exogenous retroviruses, stably integrated into the host cellular DNA, which make up about 8% of the human genome. Dereglulation of HERVs has been associated with many complex diseases, and recently our research group has demonstrated its involvement in the pathogenesis and progression of SARS-CoV-2-related disease. This work aims to study the expression of HERVs, their potential receptors and cytokines in blood samples of children affected by KD and MIS-C. **Materials and Methods:** 56 blood samples from affected children [4 with acute and 6 with subacute KD, 11 with acute and 13 with subacute MIS-C and 22 healthy children] were collected and the expression of several HERVs families (pHERV-W, HERV-K, HERV-H, HEMO, Syn-1, Syn-2), HERVs receptors (ASCT-1, ASCT-2, MFSD2A) and inflammatory mediators (IL-1 α , IL-6, IL-10, IL-17, TNF- α , MCP-1, INF- γ) have been analyzed by RT-Real time PCR. **Results:** The expression of pHERV-W and HERV-K was higher in children with MIS-C than in those with KD, reaching higher values in children with acute MIS-C. Higher levels of Syn-2 and its receptor MFSD2A were found in MIS-C patients than in KD, while the expression of Syn-1 and its receptor ASCT-1 was higher in all patients compared to controls. In children with MIS-C, the expression of IL-6 and TNF- α was higher in the acute children group than in subacute, while the expression of IL-10 and IL-17 was higher in subacute children. IL-1 α expression was higher in all patients compared to controls. Finally, MCP-1 and INF- γ expression was higher in children with acute KD than in the subacute group. **Discussion and conclusions:** These findings suggest HERVs a contributing factor in pathogenetic mechanism underlying KD and MIS-C and as potential molecular biomarkers.

217 - HSV-1-induced tau spreading in the brain: neurodegenerative damage or protective effect?

Virginia Protto⁽¹⁾ - Filomena Iannuzzi⁽²⁾ - Mariya Timotey Miteva⁽¹⁾ - Flavia Pasquali⁽¹⁾ - Domenica Donatella Li Puma⁽³⁾ - Luigi Sansone⁽⁴⁾ - Maria Elena Marcocci⁽¹⁾ - Matteo Antonio Russo⁽⁴⁾ - Claudio Grassi⁽³⁾ - Anna Teresa Palamara⁽⁵⁾ - Giovanna De Chiara⁽²⁾

Sapienza Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia⁽¹⁾ - Consiglio Nazionale delle Ricerche (CNR), Istituto di Farmacologia Traslazionale, Roma, Italia⁽²⁾ - Università Cattolica del Sacro Cuore; Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Neuroscienze, Roma, Italia⁽³⁾ - IRCCS San Raffaele Pisana, Dipartimento di Patologia Cellulare e Molecolare, Roma, Italia⁽⁴⁾ - Sapienza Università di Roma; Istituto Superiore di Sanità, Dipartimento di Sanità Pubblica e Malattie Infettive; Dipartimento di Malattie Infettive, Roma, Italia⁽⁵⁾

HSV-1-induced tau spreading in the brain: neurodegenerative damage or protective effect?

Virginia Protto¹, Filomena Iannuzzi², Mariya T. Miteva¹, Flavia Pasquali¹, Domenica D. Li Puma³, Luigi Sansone⁴, Maria E. Marcocci¹, Matteo A. Russo⁴, Claudio Grassi³, Anna T. Palamara^{1,5}, Giovanna De Chiara²

1 Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Rome, Italy;

2 Institute of Translational Pharmacology, CNR, Rome, Italy;

3 Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;

4 Department of Cellular and Molecular Pathology, IRCCS San Raffaele Pisana, Rome, Italy;

5 Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

Introduction Growing evidence supports the role of Herpes Simplex Virus-1 (HSV-1) infection in the pathogenesis of Alzheimer's disease (AD). In particular, HSV-1 replication induces the accumulation of AD-related neurotoxic proteins in neuronal cells, such as phosphorylated tau protein (ptau) and amyloid beta peptides (Abeta) both in monomeric and aggregated forms. These proteins can be released outside the cell both in a vesicle-free manner and via extracellular vesicles (EVs), likely contributing to the spreading of their dependent damage in the brain. Interestingly, recent data proposed Abeta as an antimicrobial peptide, whose production, aggregation and secretion could be induced in the infected cells to counteract the infection. Based on these findings, the aim of our study was to evaluate whether intracellular and secreted tau may exert, similarly to Abeta, a double role during HSV-1 neuronal infection, acting as an antimicrobial peptide and/or promote virus-induced neuronal damage.

Methods Primary neurons were isolated from embryo brains of wild type (wt) or tau KO mice. EVs were purified from supernatants of neuronal cells following HSV-1 infection (HSV-EV), treated with UV and layered on cells. Brain EVs were isolated by ultracentrifugation from cerebral tissues of HSV-1- and mock-infected mice. Cell lysates and EVs were analysed in WB for protein content. Levels of tau released in the supernatant were evaluated by ELISA assay. The efficacy of HSV-1 infection was evaluated by standard plaque (SPA) or in-Cell western (ICW) assays.

Results We found that HSV-1 infection induced the release of tau in the supernatant of infected cells both vesicle-free and via EVs. In particular, HSV-EVs contained increased amount of high molecular weight ptau with respect to EVs isolated from mock-infected neurons (ctr-EV). Accordingly, cells layered with HSV-EVs, previously treated with UV to inactivate the virus, showed higher levels of ptau, compared with ctr-EVs-treated cells. These results indicate that HSV-EVs could delivery neurotoxic proteins in uninfected neurons. Moreover, we found that HSV-1 viral replication was higher in primary tau KO neurons compared to wt neurons, suggesting that tau protein could interfere with HSV-1 replication in neurons. Finally, EVs enriched fractions isolated from the brains of HSV-infected mice contains several forms of ptau whose levels are modulated in HSV-1-infected mice compared with matched controls.

Conclusions Our results indicate that HSV-1 can promote ptau propagation, supporting the hypothesis that repeated HSV-1 reactivations may concur to neurodegeneration, but also suggest a potential protective role for tau against HSV-1 infection in neurons, highlighting a potential dual role of this protein.

218 - Antimicrobial and Antibiofilm Activities of Cell Free Supernatant of *Limosilactobacillus reuteri* DSM 17938

BEATRICE MARINACCI⁽¹⁾ - IRENE VITALE⁽¹⁾ - VALENTINA PUCA⁽¹⁾ - SIMONE CARRADORI⁽¹⁾ -
ANTONELLA DI SOTTO⁽²⁾ - ROSSELLA GRANDE⁽¹⁾

University "G. d'Annunzio" Chieti-Pescara, Department of Pharmacy, Chieti, Italia⁽¹⁾ - Sapienza
University of Rome, Department of Physiology and Pharmacology "V. Erspamer", Roma, Italia⁽²⁾

Antimicrobial and Antibiofilm Activities of Cell Free Supernatant of *Limosilactobacillus reuteri* DSM 17938

BEATRICE MARINACCI¹, IRENE VITALE¹, VALENTINA PUCA¹, SIMONE CARRADORI¹, ANTONELLA DI
SOTTO², ROSSELLA GRANDE¹

¹Department of Pharmacy, University of Chieti-Pescara "G. d'Annunzio", Chieti, Italy. ²Department of Physiology
and Pharmacology "V. Erspamer", Sapienza University of Rome, Rome, Italy.

Introduction. The microbial biofilm has been defined as a "key virulence factor" for a multitude of microorganisms associated with chronic infections. Its multifactorial nature and variability as well as drug tolerance suggest the need to identify new compounds, alternatives to the commonly used antimicrobials. The Cell Free Supernatant (CFS) produced by many probiotic strains and containing many bioactive compounds such as biosurfactants, bacteriocines and antimicrobial peptides demonstrated the inhibition of the pathogens growth. However, each probiotic strain produces its own compounds.

The aim of the present study was to assess both the antimicrobial and subsequently the antibiofilm activities of Cell Free Supernatant (CFS) produced by *Limosilactobacillus reuteri* DSM 17938 versus biofilm-producer bacterial species of clinical relevance such as *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Fusobacterium nucleatum*, *Escherichia coli* and *Streptococcus mutans*.

Material and methods. The Minimum Inhibitory Concentration was determined through the broth microdilution method and cell proliferation assay; the Minimum Bactericidal Concentration by Colony Forming Units counts. The characteristics of the antimicrobial compounds were evaluated by pH adjustments, proteinase treatment and size fractionation of the CFS. The Minimum Inhibitory Biofilm Concentration (MBIC) and the Minimum Biofilm Eradication Concentration (MBEC) were determined through Colony Forming Units (CFU), Cristal Violet assay (CV) and a metabolic assay.

Results. The results showed (i) a greater efficacy of CFS towards Gram-negative compared to Gram-positive bacteria; (iii) a molecular weight <3 KDa as well as a non-proteinaceous nature of the antimicrobial compounds. The data obtained supported the hypothesis that the antimicrobial effect might be associated with a synergistic activity of several molecules or compounds contained in the CFS as previously hypothesized by other authors. In addition, the CFS showed a promising antibiofilm activity. In particular, among the tested bacterial species, the CFS showed a significant effect *versus P. aeruginosa* and *S. aureus* with a MBEC corresponding to 1xMIC. While, the MBEC values *versus E. coli* were 2-3xMIC. On the contrary, CFS was not capable of inhibiting biofilm formation in none of the microorganisms tested. The safety profile toward human cell lines showed promising sureness.

Discussion and Conclusion. The CFS of *L. reuteri* DSM 17938 might be useful for developing alternative therapeutic strategies against bacterial infections associated with biofilm-producer microorganisms. However, further studies should be performed to detect the CFS components responsible of the antimicrobial and antibiofilm activities.

233 - Longitudinal profiling of spike-specific antibody and B cell responses following mRNA-1273 SARS-CoV-2 vaccination in hematopoietic cell transplantation recipients

Elena Pettini⁽¹⁾ - Annalisa Ciabattini⁽¹⁾ - Gabiria Pastore⁽¹⁾ - Jacopo Polvere⁽¹⁾ - Simone Lucchesi⁽¹⁾ - Fabio Fiorino⁽¹⁾ - Francesca Montagnani⁽¹⁾ - Alessandro Bucalossi⁽²⁾ - Monica Tozzi⁽²⁾ - Giuseppe Marotta⁽²⁾ - Donata Medaglini⁽¹⁾

Università degli Studi di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia⁽¹⁾ - Azienda Ospedaliera Universitaria Senese, Dipartimento di Innovazione, sperimentazione e ricerca clinica e traslazionale, Siena, Italia⁽²⁾

Longitudinal profiling of spike-specific antibody and B cell responses following mRNA-1273 SARS-CoV-2 vaccination in hematopoietic cell transplantation recipients

Elena Pettini¹, Annalisa Ciabattini¹, Gabiria Pastore¹, Jacopo Polvere¹, Simone Lucchesi¹, Fabio Fiorino¹, Francesca Montagnani^{2,3}, Alessandro Bucalossi⁴, Monica Tozzi⁴, Giuseppe Marotta⁴, Donata Medaglini¹

¹ Department of Medical Biotechnologies, Laboratory of Molecular Microbiology and Biotechnology, University of Siena, Siena, Italy; ² Department of Medical Biotechnologies, University of Siena, Siena, Italy; ³ Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy; ⁴ Department of Innovation, Experimentation, Clinical and Translational Research, Cellular Therapy Unit, University Hospital of Siena, Siena, Italy.

Introduction. Patients with hematologic malignancies treated with autologous (auto) and allogeneic (allo) hematopoietic cell transplantation (HCT) are at high risk of developing adverse outcomes related to SARS-CoV-2 infection. In the present work, we longitudinally profiled spike-specific antibody production and their functionality, as well as spike-specific B cell response in 23 auto-HCT and 56 allo-HCT recipients until the fourth dose of mRNA1273 vaccine. **Materials and Methods.** Blood samples were collected and analysed from baseline up to one month after the fourth mRNA1273 vaccine administration in HCT recipients enrolled in the context of a clinical study at the University Siena hospital. IgG serum antibodies were measured by ELISA, while the ACE2/RBD binding inhibition assay was performed as SARS-CoV-2 surrogate virus neutralization test. Spike-specific memory B cells were analysed by multiparametric flow cytometry. **Results.** Spike-specific IgG antibody production was observed in 90% of HCT recipients after the primary series of SARS-CoV-2 vaccination. The third and the fourth doses induced a robust increase in spike-specific IgG and ACE2/RBD binding inhibition in all the HCT recipients, including the 10% of subjects that didn't respond to the primary series of SARS-CoV-2 vaccination. The booster doses also induced an increase in the spike-specific B cells that are crucial for a rapid response to SARS-CoV-2 virus encounter. **Discussion and Conclusions.** Our findings provide evidence that the mRNA1273 vaccine elicits strong spike-specific antibody and B cell responses in both allo- and auto-HCT recipients. The third and fourth booster mRNA1273 vaccine doses considerably enhance SARS-CoV-2 specific immune response highlighting the importance of additional vaccine doses in HCT recipients who may have achieved a limited response to the primary series of SARS-CoV-2 vaccination.

243 - *Aspergillus* infection and differential expression of TLRs and type I-III IFNs in the respiratory tract of a large cohort of CF patients from the Italian (Lazio) Reference Center for Cystic Fibrosis

Camilla Bitossi⁽¹⁾ - Agnese Viscido⁽¹⁾ - Mirko Scordio⁽¹⁾ - Federica Frasca⁽¹⁾ - Giuseppe Oliveto⁽¹⁾ - Leonardo Sorrentino⁽¹⁾ - Matteo Fracella⁽¹⁾ - Alessandra D'Auria⁽¹⁾ - Giuseppe Cimino⁽²⁾ - Valeria Pietropaolo⁽³⁾ - Maria Trancassini⁽³⁾ - Alessandra Pierangeli⁽¹⁾ - Guido Antonelli⁽¹⁾ - Carolina Scagnolari⁽¹⁾

Laboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy⁽¹⁾ - Lazio Reference Center for Cystic Fibrosis, Policlinico Umberto I University Hospital, Rome, Italy⁽²⁾ - Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy⁽³⁾

***Aspergillus* infection and differential expression of TLRs and type I-III IFNs in the respiratory tract of a large cohort of CF patients from the Italian (Lazio) Reference Center for Cystic Fibrosis**

Camilla Bitossi¹, Agnese Viscido¹, Mirko Scordio¹, Federica Frasca¹, Giuseppe Oliveto¹, Leonardo Sorrentino¹, Matteo Fracella¹, Alessandra D'Auria¹, Giuseppe Cimino², Valeria Pietropaolo³, Maria Trancassini³, Alessandra Pierangeli¹, Guido Antonelli¹, Carolina Scagnolari¹

¹Laboratory of Microbiology and Virology, Department of Molecular Medicine, Sapienza University of Rome, Italy; ²Lazio Reference Center for Cystic Fibrosis, Policlinico Umberto I University Hospital, Rome, Italy; ³Department of Public Health and Infectious Diseases, Policlinico Umberto I, Sapienza University of Rome, Italy; ⁴Department of Pediatric Emergency, Sapienza University of Rome, Italy.

Introduction

Although an exceptional variety of fungal pathogens could be found in cystic fibrosis (CF) airway secretions, *Aspergillus* spp. is the main filamentous fungus cultured from the respiratory tract of CF airways with a prevalence range in CF patients between 10 and 57%. Clinical manifestations of *Aspergillus* infection are closely dependent on the immunological status of the infected host. In this scenario, given the pervasive influence of interferon (IFN) responses in the respiratory tract infections, it is imperative to characterize the potential involvement of type I-III IFN in the activation of immunity against *Aspergillus*.

Material and Methods

A total of 3746 search requests for *Aspergillus* research were processed from January 1st 2018 to December 31st 2019 on the respiratory samples of 467 CF patients attending the Regional Reference Center for Cystic Fibrosis, "Policlinico Umberto I". *Aspergillus* detection from respiratory samples was based on macroscopic and microscopic examination through culture on Sabouraud Dextrose Agar (BD Sabouraud). Gene expression of the most active toll like receptors (TLR) in fungal infections (TLR 2, 3, 4, 6, 8 and 9), type I and III IFN (IFN α 2, IFN β 1, IFN ϵ , IFN λ 1, IFN λ 2, IFN λ 3), type III IFN receptor (IFNLR1) and the IFN stimulated genes 15 (ISG15) was performed by RT/Real Time-PCR assays on positive *Aspergillus* patients' samples (n=67) and on a matched group of *Aspergillus* negative CF patients (n=66).

Results

One hundred and thirty six samples (3.6%) of 83 patients (17.7%) were found positive to *Aspergillus* research request. A statistically significant increased expression of TLR3, TLR6 and TLR9-mRNAs was observed in the *Aspergillus* positive patients compared to the negative matched group (p=0.009, p=0.044, p=0.001). Moreover, higher IFN α , IFN β , IFN λ 2, IFN λ 3 and IFNLR1 transcript levels were recorded in *Aspergillus* positive patients in comparison to the free ones (p<0.001, p=0.006, p=0.048, p<0.001, p<0.001). The first group presented higher expression of ISG15, a consolidated marker of IFNs' activation (p=0.036). Considering *P. aeruginosa* colonized patients, we found increased levels of ISG15,

IFN α , IFN ϵ , IFN λ 2, IFN λ 3, IFNLR1, TLR3, TLR4, TLR8 and TLR9 genes (p=0.002, p<0.001, p=0.017, p<0.001, p<0.001, p=0.009, p<0.001, p=0.002, p=0.001, p<0.001) in *Aspergillus* positive CF samples compared to those negative for *Aspergillus* detection.

Conclusion

These findings suggest that *Aspergillus* colonization can increase the activation status of the IFN pathways in the airway tract of CF patients. Presence of both *Aspergillus* spp. and *P. aeruginosa* seems likely to determine a further increase of the IFN related immunity, suggesting that fungal-bacterial coinfection might contribute to alter airway innate immunity in CF patients.

254 - Evaluation of amphibian antimicrobial peptides as new therapeutic treatments against infectious diseases

Annalisa Chianese ⁽¹⁾ - Carla Zannella ⁽¹⁾ - Alessandra Monti ⁽²⁾ - Maria Vittoria Morone ⁽¹⁾ - Anna De Filippis ⁽¹⁾ - Nunzianna Doti ⁽²⁾ - Gianluigi Franci ⁽³⁾ - Massimiliano Galdiero ⁽¹⁾

Università, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, napoli, Italia ⁽¹⁾ - 2 Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR),, 2 Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR),, napoli, Italia ⁽²⁾ - Università, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, salerno, Italia ⁽³⁾

Introduction. In recent years, the resistance of pathogenic microorganisms to common antimicrobial agents is representing a severe public health problem. Moderate and wise use of antimicrobials and prevention of infections are the most effective methods for decreasing the spread and development of resistance. Therefore, also the COVID-19 pandemic has evidenced the urgent need for the discovery of broad-spectrum antiviral therapies that could be deployed in the case of future emergence of novel viral threats. Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), represent an emerging class of therapeutic agents in different fields. In the present study, the antimicrobial activity of peptides derived from the secretion of the *Rana* genus has been evaluated against different human viruses and several bacteria pathogens for humans. **Material and methods.** AMPs have been synthesized using the solid-phase Fmoc chemistry method, followed by purification by reversed-phase HPLC. The toxicity was determined via the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, identifying a 50% cytotoxic concentration (CC50) at 50 μ M. The antiviral activity was evaluated against different members of the *Herpesviridae*, *Paramyxoviridae*, *Coronaviridae*, and *Picornaviridae* (poliovirus, PV-1) families, through both plaque assays, molecular test, and Transmission electron microscopy (TEM) analysis. While antibacterial activity was investigated against several strains of gram-positive, gram-negative, and clinical isolates bacteria, identifying minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and time-killing assays. **Results.** AMPs did not show strong toxicity at the tested concentrations. When peptides were preincubated with viruses, significant antiviral activity was observed, demonstrating that they could disrupt the viral envelope, as also confirmed by TEM. The peptides influenced the extracellular phases of the viral lifecycle, probably by blocking the viral attachment and entry phases. They also showed a very strong antibacterial effect against all strains tested. **Conclusions.** Our results indicated possible novel applications of amphibian skin peptides in the field of antivirals and antibacterials. Further studies will focus on their specific mechanism of action to understand the antimicrobial target on which the peptides act.

264 - In vitro characterization of an mRNA vaccine model.

Lara Mitia Castronovo ⁽¹⁾ - Anna Maria Cuppone ⁽¹⁾ - Emma Gennaioli ⁽¹⁾ - Alessia Masella ⁽¹⁾ -
Francesco Iannelli ⁽¹⁾ - Gianni Pozzi ⁽¹⁾

Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽¹⁾

***In vitro* characterization of an mRNA vaccine model.**

LARA MITIA CASTRONOVO ¹, ANNA MARIA CUPPONE ¹, EMMA GENNAIOLI ¹, ALESSIA MASELLA ¹,
FRANCESCO IANNELLI ¹, GIANNI POZZI ¹.

¹ *Department of Medical Biotechnologies, Laboratory of Molecular Microbiology and Biotechnology (LA.M.M.B.), University of Siena, Siena, Italy.*

Introduction: In today's biotechnological landscape, mRNA vaccines represent a promising alternative to conventional approaches due to their versatility, safety, rapid production, and efficacy. In this project, a model mRNA vaccine was tested and characterized *in vitro* by transfecting it into different human cell lines.

Materials and Methods: The mRNA was obtained by an *in vitro* transcription reaction from a previously designed DNA template containing the gene of interest: Receptor Binding Domain (RBD) of Spike protein of SARS-CoV-2, with the ovalbumin epitope (OVA) and the influenza A hemagglutinin tag (HA) upstream and downstream, respectively. Transcribed mRNA was modified by enzymatic reactions, adding a 5' cap and a 3' poly(A) tail and then purified before transfection. Human epithelial cell lines were transfected with a complex of mRNA and lipofectamines as a delivery system and incubated for different time points. Transfected cells were analyzed by flow cytometric assay.

Results: Expression of heterologous protein was already detected after 6 hours and increased with time. After 24 hours of incubation, observations with an inverted microscope revealed the presence of detached cells in the wells containing transfected lipofectamine-RNA complexes. This phenomenon wasn't observed in control cells. Transfected cells stained with annexin V and propidium iodide confirmed apoptosis of the cells. Preliminary phagocytosis assays showed that apoptotic transfected cells were efficiently engulfed by THP-1 induced macrophage-like cells, compared with not transfected cells.

Discussion and Conclusions: An mRNA vaccine model was developed and characterized *in vitro*, and protein expression was detected by flow cytometry. In our model, detachment of transfected cells was observed after 24 hours, and apoptosis was studied. To get closer to *in vivo* conditions, phagocytosis assays were performed, which showed that only the transfected cells were engulfed. This suggested us to investigate the fate of the mRNA vaccines *in vitro* once they were injected into mammalian cells. The next step is to transfect the mouse myoblast cell line C2C12, followed by a phagocytosis assay using mouse macrophage J774A.1 cell line.

275 - SARS-CoV-2 vaccine immune response in adults with Down syndrome

Gabriele Di Sante ⁽¹⁾ - Carfi Angelo ⁽²⁾ - Maria del Carmen Pereyra Boza ⁽³⁾ - Maria Tredicine ⁽⁴⁾ - Onder Graziano ⁽⁵⁾ - Maurizio Sanguinetti ⁽³⁾ - Giovanni Delogu ⁽⁶⁾ - Michela Sali ⁽³⁾

Dipartimento di Medicina e Chirurgia, Sezione di Anatomia Umana, Clinica e Forense,, Università degli studi di Perugia, Perugia, Italia ⁽¹⁾ - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., roma, Italia ⁽²⁾ - Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie- Istituto di Microbiologia, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Roma, roma, Italia ⁽³⁾ - Dipartimento di Medicina e Chirurgia Traslazionale, Sezione di Patologia Generale, Università Cattolica del Sacro Cuore, Roma, Italia, Roma, Italia ⁽⁴⁾ - Malattie cardiovascolari, endocrino-metaboliche e invecchiamento, . Istituto Superiore di Sanità, ROMA, Italia ⁽⁵⁾ - Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie- Istituto di Microbiologia/ Mater Olbia, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Roma /Mater Olbia, Olbia, Roma/Olbia, Italia ⁽⁶⁾

SARS-CoV-2 vaccine immune response in adults with Down syndrome

Di Sante G.¹, Carfi A.², Pereyra Boza MdC³, Tredicine M.⁴, Onder G.⁵, Sanguinetti M.^{3,6}, Delogu G.^{6,7}, Sali M.^{3,6}

1 Dipartimento di Medicina e Chirurgia, Sezione di Anatomia Umana, Clinica e Forense, Università degli studi di Perugia

2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

3 Dipartimento di Scienze di laboratorio e infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

4 Dipartimento di Medicina e Chirurgia Traslazionale, Sezione di Patologia Generale, Università Cattolica del Sacro Cuore, Roma, Italia

5 Malattie cardiovascolari, endocrino-metaboliche e invecchiamento. Istituto Superiore di Sanità,

6 Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie – Sezione di Microbiologia, Università Cattolica del S. Cuore

7 Mater Olbia, Olbia, Italy

Objective: People with Down syndrome (DS) are particularly vulnerable to coronavirus disease 2019 (COVID-19) and show altered immune response to vaccination. We aimed to evaluate the humoral and cellular immune response of a group of adults with DS treated with standard regimens of SARS-CoV-2 vaccine as compared with an age- and sex-matched group of persons without DS.

Methods: We compared antibody responses and cellular immune response between 42 subjects with DS (41.6 ± 10.8 years, 57% male), and an age- and sex-matched comparison group of healthy health care workers (HCW) (41.4 ± 8.8 years, 54.8% male) after SARS-CoV-2 vaccination with the standard regimen of BNT162b2 mRNA COVID-19 at 4 time points (baseline, 21 days after the first dose, 21 days after the second dose, and 21 days after the third dose). Receptor binding domain (RBD) IgG antibodies were assessed with Siemens SARS-CoV-2 IgG (COV2G) antibody test. We evaluated the specific cellular immune response assessing effector-regulatory T cells, B lymphocytes and monocytes subpopulations and specific for Spike peptide(s) and for SARS-CoV-2 stimulation.

Results: We observed significantly different antibody responses at all time points after vaccination (HCW vs. DS: 7.9 ± 3.9 vs. 1.4 ± 3.6 IU/mL at 21 days after first dose; 358.5 ± 3.8 vs. 38.1 ± 3.0 IU/mL at 21 days after second dose; 91.7 vs. 25.1 IU/mL at 21 days after third vaccination) and a significantly different time course of decline in antibody titers between the two groups. *In vitro* stimulation of circulating PBMC at different timepoints revealed an interesting modulation of specific cell subsets. Spike peptide or infection of PBMC culture with SARS-CoV-2 were not able to impact on B cells, probably for the potential low representation of circulating B lymphocytes specific for spike, corroborating the results obtained about Ab levels. The percentage of peripheral specific Th1 cells (IFNγ secreting CD4⁺/Tbet⁺ T cells) was significantly reduced after second dose (p=0.004 T2 vs T0, and p=0.02 T3 vs T0). The vaccination did not impact on specific Th17 response in DS adults. Regulatory T cell compartment (CD4⁺/CD25^{high}/FoxP3⁺/CD127^{low}), although appeared significantly upregulated during the early phases after first dose

($p=0.02$, T2 vs T0) was not anymore modulated by the second dose. Similarly the percentage of circulating M2 monocytes ($CD14^+/CD282^-/CD284^-/CD206^+/cd80^-$) significantly increased ($p=0.04$, T2 vs T0) during the early phases after the doses, while was reduced by the time.

Discussion: Subjects with DS have a valid antibody response to SARS-CoV-2 vaccination. However, this response is lower than that of subjects in the HCW group. This finding could indicate a more rapid decline in the protective effects of the vaccination in subjects with DS and could suggest that people with DS may benefit from a booster dose of vaccine.

277 - A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota

Valerio Iebba ⁽¹⁾ - Lisa Derosa ⁽²⁾ - Bertrand Routy ⁽³⁾ - Carolina A. Costa Silva ⁽²⁾ - Cassandra Thelemaque ⁽²⁾ - Meriem Messaoudene ⁽³⁾ - Andrew Thomas ⁽⁴⁾ - Gerard Zalcman ⁽⁵⁾ - Sylvie Friard ⁽⁶⁾ - Julien Mazieres ⁽⁷⁾ - Clarisse Audigier-Valette ⁽⁸⁾ - Denis Moro-Sibilot ⁽⁹⁾ - Francois Goldwasser ⁽¹⁰⁾ - Arnaud Scherpereel ⁽¹¹⁾ - Hervé Pegliasco ⁽¹²⁾ - Francois Ghiringhelli ⁽¹³⁾ - Nicole Bouchard ⁽¹⁴⁾ - Cissé Sow ⁽²⁾ - Ines Darik ⁽²⁾ - Silvia Zoppi ⁽²⁾ - Pierre Ly ⁽²⁾ - Anna Reni ⁽²⁾ - Leonardo Lordello ⁽²⁾ - Romain Daillère ⁽¹⁵⁾ - Fabrice Barlesi ⁽²⁾ - Damien Drubay ⁽²⁾ - Eric Deutsch ⁽²⁾ - Karla Lee ⁽¹⁶⁾ - Laura Bolte ⁽¹⁷⁾ - Johannes Bjork ⁽¹⁷⁾ - Rinse Weersma ⁽¹⁷⁾ - Morten Isaksen ⁽¹⁸⁾ - Lucas Barros ⁽¹⁸⁾ - Bernard Escudier ⁽²⁾ - Laurence Albiges ⁽²⁾ - David Planchard ⁽²⁾ - Fabrice André ⁽²⁾ - Stephanie Martines ⁽¹⁹⁾ - Benjamin Besse ⁽²⁾ - Nicola Segata ⁽⁴⁾ - Guido Kroemer ⁽²⁾ - Laurence Zitvogel ⁽²⁾

Università di Trieste, Dipartimento Universitario Clinico di Scienze Mediche Chirurgiche e della Salute, Trieste, Italia ⁽¹⁾ - Gustave Roussy Cancer Campus, Gustave Roussy Cancer Campus, Villejuif, Francia ⁽²⁾ - Centre Hospitalier de l'Université de Montréal (CHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Canada ⁽³⁾ - Department CIBIO, University of Trento, Department CIBIO, University of Trento, Trento, Italia ⁽⁴⁾ - Université Paris Cité, Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Université Paris Cité, Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Paris, Francia ⁽⁵⁾ - Pneumology Department, Foch Hospital, Pneumology Department, Foch Hospital, Suresnes, Francia ⁽⁶⁾ - Centre Hospitalier Universitaire de Toulouse, Centre Hospitalier Universitaire de Toulouse, Toulouse, Francia ⁽⁷⁾ - Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, Francia ⁽⁸⁾ - Department of Thoracic Oncology, Centre Hospitalier Universitaire, Department of Thoracic Oncology, Centre Hospitalier Universitaire, Grenoble, Francia ⁽⁹⁾ - UPR 4466, Paris Descartes University, Sorbonne Paris Cité, UPR 4466, Paris Descartes University, Sorbonne Paris Cité, Paris, Francia ⁽¹⁰⁾ - Department of Pulmonary and Thoracic Oncology, University of Lille, Department of Pulmonary and Thoracic Oncology, University of Lille, Lille, Francia ⁽¹¹⁾ - Pulmonary Department, European Hospital, Pulmonary Department, European Hospital, Marseille, Francia ⁽¹²⁾ - Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, Francia ⁽¹³⁾ - Centre Hospitalier de Sherbrooke, Centre Hospitalier de Sherbrooke, Sherbrooke, Canada ⁽¹⁴⁾ - EverImmune, Gustave Roussy Cancer Campus, EverImmune, Gustave Roussy Cancer Campus, Paris, Francia ⁽¹⁵⁾ - Department of Twin Research and Genetic Epidemiology, King's College London, Department of Twin Research and Genetic Epidemiology, King's College London, London, Regno Unito ⁽¹⁶⁾ - Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, Paesi Bassi ⁽¹⁷⁾ - Bio-Me Microbiome Profiling, Bio-Me Microbiome Profiling, Oslo, Norvegia ⁽¹⁸⁾ - Service des Maladies Respiratoires, Centre Hospitalier d'Aix-en-Provence, Service des Maladies Respiratoires, Centre Hospitalier d'Aix-en-Provence, Aix-en-Provence, Francia ⁽¹⁹⁾

A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota

Valerio Iebba¹, Lisa Derosa^{2,5}, Bertrand Routy^{6,7}, Carolina A. Costa Silva^{2,4,5}, Cassandra Thelemaque^{2,4}, Meriem Messaoudene⁷, Andrew M. Thomas⁸, Gerard Zalcman⁹, Sylvie Friard¹⁰, Julien Mazieres¹¹, Clarisse Audigier-Valette¹², Denis Moro-Sibilot¹³, François Goldwasser^{14;15;16}, Arnaud Scherpereel¹⁷, Hervé Pegliasco¹⁸, François Ghiringhelli^{19;20;21}, Nicole Bouchard²², Cissé Sow^{2,4}, Ines Darik^{2,4}, Silvia Zoppi^{2,4;23}, Pierre Ly^{2,4}, Anna Reni^{2,4;24}, Leonardo Lordello^{2,4}, Romain Daillère²⁵, Fabrice Barlesi^{2,3}, Damien Drubay^{2,26}, Eric Deutsch^{2,5;27;28}, Karla A. Lee²⁹, Laura A Bolte³⁰, Johannes R. Björk³⁰, Rinse K. Weersma³⁰, Morten Isaksen³¹, Lucas Barros³¹, Bernard Escudier^{2,3}, Laurence Albiges^{2,3}, David Planchard^{2,3}, Fabrice André^{2,3}, Stéphanie Martinez³², Benjamin Besse^{2,3}, Nicola Segata^{8;33}, Guido Kroemer^{2,34;35;36}, Laurence Zitvogel^{2,4;5;37}.

AFFILIATIONS

1 Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.

2 Gustave Roussy Cancer Campus, Villejuif, France.

3 Cancer Medicine Department, Gustave Roussy, Villejuif, France.

4 Institut National de la Santé et de la Recherche Médicale (INSERM) U1015, ClinicObiome, Equipe Labellisée—28 Ligue Nationale contre le Cancer, Villejuif, France.

5 Université Paris-Saclay, Ile-de-France, France.

6 Centre Hospitalier de l'Université de Montréal (CHUM), Hematology-Oncology Division,
Department of Medicine, Montréal, QC, Canada

7 Centre de Recherche du CHUM (CRCHUM), Montréal, QC, Canada

8 Department CIBIO, University of Trento, Trento, Italy; Istituto Europeo di Oncologie, Milan, Italy

9 Université Paris Cité, Thoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, AP-HP, Paris, France

10 Pneumology Department, Foch Hospital, Suresnes, France.

11 Centre Hospitalier Universitaire de Toulouse, Toulouse, France

12 Pneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, France.

13 Department of Thoracic Oncology, Centre Hospitalier Universitaire, Grenoble, France.

14 UPR 4466, Paris Descartes University, Sorbonne Paris Cité, Paris, France.

15 Department of Medical Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

16 Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.

17 Department of Pulmonary and Thoracic Oncology, University of Lille, University Hospital (CHU), Lille, France.

18 Pulmonary Department, European Hospital, Marseille, France.

19 Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France.

20 Centre de Recherche INSERM LNC-UMR1231, Dijon, France.

21 Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

22 Centre Hospitalier de Sherbrooke, Sherbrooke, Quebec, Canada

23 Department of Medicine and Surgery, University of Parma, Parma, Italy.

24 Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.

25 EverImmune, Gustave Roussy Cancer Campus, Villejuif, France

26 Institut National de la Santé Et de la Recherche Médicale (INSERM) U1018, Oncostat, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif, France.

- 27 Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
- 28 INSERM U1030, Radiothérapie Moléculaire et Innovation Thérapeutique, Villejuif, France.
- 29 Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
- 30 Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands
- 31 Bio-Me Microbiome Profiling. Gaustadalléen 21 N-0349 Oslo, Norway.
- 32 Service des Maladies Respiratoires, Centre Hospitalier d'Aix-en-Provence, Aix-en-Provence, France.
- 33 IEO, European Institute of Oncology IRCCS, Milan, Italy
- 34 Centre de Recherche des Cordeliers, Equipe labellisée—Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Institut Universitaire de France, Inserm U1138, Paris, France
- 35 Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France
- 36 Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
- 37 Center of Clinical Investigations in Biotherapies of Cancer (BIOTHERIS) 1428, Villejuif, France.

Introduction: Over the past decade, accumulating evidence points to the clinical impact of the intestinal microbiota on therapeutic outcome of various cancer treatments. Although specific gut microbial species have been associated with beneficial responses in meta-analyses, no consensus exists on a gut fingerprint identifying intestinal dysbiosis on an individual basis. **Materials and Methods:** Exploiting shotgun metagenomics sequencing of fecal samples from two retrospective cohorts of patients with advanced non-small cell lung cancer (NSCLC) prior to immune checkpoint inhibitors (ICI) initiation (n=393), we reconstructed ecosystem networks in responders and non-responders to ICI and detected patterns of bacterial species leading to a diagnostic tool predicting the individual response to immunotherapy. **Results:** The score was computed from topological networks of species interacting groups (SIG), identifying two SIG highly enriched in harmful (SIG1) or beneficial (SIG2) bacteria. Combining the SIG1/SIG2 ratio with *Akkermansia muciniphila* (Akk) abundance led to the TOPOSCORE, allowing estimation of the probability of a given individual to respond to ICI in a prospective cohort of 50 ICI-treated NSCLC patients with a superior accuracy than the actual prediction marker. The TOPOSCORE also predicted the response of 77 patients with advanced renal cell carcinoma treated with ICI. The sensitivity, specificity, positive and negative predictive value were 80%, 47%, 67% and 63%, respectively. The Cox proportional analysis revealed that the TOPOSCORE acted independently of and outperformed the actual clinical prognostic factors. Then, we exploited the publicly available datasets of MGS (n=641; NSCLC, RCC and melanoma) to validate TOPOSCORE across different cancer populations. Finally, we developed a PCR-assay measuring the prevalence of 7 harmful (SIG1), 16 beneficial (SIG2), and 1 discriminating (Akk) bacterial species. **Discussion and Conclusions:** TOPOSCORE represents the first easy-to-use and cost-effective tool capable of detecting intestinal dysbiosis associated with ICI resistance across cancers on an individual basis, under the precision-medicine agenda. This TOPOSCORE has several implementations, to select donors and recipients of fecal microbiota transplantations and follow any microbiota-centered interventions.

285 - Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis homologues peptides elicit a strong humoral response in patients with neuroinflammatory disorders, and exacerbate EAE

Davide Cossu ⁽¹⁾ - Marta Noli ⁽¹⁾ - Leonardo Antonio Sechi ⁽¹⁾ - Nobutaka Hattori ⁽²⁾

Universita, Dipartimento Scienze Biomediche, Sassari, Italia ⁽¹⁾ - Juntendo University, Dipartimento Neurologia, Tokyo, Giappone ⁽²⁾

Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis homologues peptides elicit a strong humoral response in patients with neuroinflammatory disorders, and exacerbate EAE

DAVIDE COSSU ^{1,2}, MARTA NOLI ², SECHI LEONARDO ANTONIO ², NOBUTAKA HATTORI ¹

¹Department of Neurology, Juntendo University, Tokyo, Japan

²Department of Biomedical Sciences, Sassari University, Sassari, Italy

1. Introduction

Neuroinflammation can be induced by pathogens infection such as bacteria and virus, however, their pathological role still unclear. Here, we characterized antibodies against *Epstein-Barr* virus (EBV) nuclear antigen 1 (EBNA1), *Mycobacterium avium* subsp. *paratuberculosis* (MAP) heat shock protein (HSP) 70, and human central nervous system protein GlialCAM homologues peptides in blood samples of Japanese patients with different neurological disorders. Furthermore, we tested the effects of these peptides in active experimental autoimmune encephalomyelitis (EAE), a common animal model of neuroinflammatory disorders.

2. Material and Methods

Forty-seven patients with multiple sclerosis (MS), 32 with neuromyelitis optica spectrum disorder (NMOSD), 19 with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), 32 disease controls, and 70 healthy controls, were retrospectively tested using indirect and inhibition ELISAs. Group of female C57BL/6J mice received were immunized with the pathogen-derived peptides two weeks prior active EAE induction using myelin oligodendrocyte glycoprotein.

3. Results

A significantly strong antibody response against EBNA1₃₈₆₋₄₀₅, MAPHSP70₅₃₃₋₅₄₅ and GlialCAM₃₇₀₋₃₈₉ was detected in the serum of patients with MS and NMOSD in comparison to patient with MOGAD, and both control groups. A good direct correlation between antibody titers was evidenced in patients with MS and NMOSD. Moreover, competitive immunoassay demonstrated the presence of cross-reactive antibodies to EBV and MAP antigens. No significant correlation was found between antibody titers and clinical therapy, aquaporin-4 antibody titer.

Following immunization with EBNA1₃₈₆₋₄₀₅ and MAPHSP70₅₃₃₋₅₄₅ peptides, mice showed early onset and more severe disease in comparison to no treated mice.

4. Discussion and Conclusions

We demonstrated a strong humoral response and the significant presence of cross-reactive antibodies against EBV and MAP derived peptides in patients with MS and NMOSD, as well as the encephalitogenic potential of these peptides in EAE model, providing evidence for an association between these pathogens and different demyelinating disorders. Molecular mimicry could be the mechanism by which EBV, and MAP can induce autoimmunity in genetically susceptible individuals.

02 Meccanismi di patogenicità

11 - Streptococcal Surface Repeat (SSURE) domains from *Streptococcus pneumoniae* bind to different types of collagens

Giuseppe Valerio De Gaetano ⁽¹⁾ - Francesco Coppolino ⁽²⁾ - Germana Lentini ⁽¹⁾ - Agata Famà ⁽¹⁾ - Chiara Motta ⁽³⁾ - Giuseppe Teti ⁽⁴⁾ - Pietro Speciale ⁽³⁾ - Giampiero Pietrocola ⁽³⁾ - Concetta Beninati ⁽¹⁾

Università, Dipartimento di Patologia Umana, Messina, Italia ⁽¹⁾ - Università, Dipartimento di Scienze biomediche, odontoiatriche e delle immagini morfologiche e funzionali, Messina, Italia ⁽²⁾ - Università, Dipartimento di Medicina Molecolare, Pavia, Italia ⁽³⁾ - Charybdis Vaccines Srl, Charybdis Vaccines Srl, Messina, Italia ⁽⁴⁾

Streptococcal Surface Repeat (SSURE) domains from *Streptococcus pneumoniae* **bind to different types of collagens**

Giuseppe Valerio De Gaetano ¹, Francesco Coppolino ², Germana Lentini ¹, Agata Famà ¹, Chiara Motta ³, Giuseppe Teti ⁴, Pietro Speciale ³, Giampiero Pietrocola ³, Concetta Beninati ^{1,5}

¹Department of Human Pathology and Medicine, University of Messina, Messina, Italy; ²Department of Biomedical, Dental and Imaging Sciences, University of Messina, Messina, Italy; ³ Department of Molecular Medicine, Biochemistry Section, University of Pavia, Pavia, Italy; ⁴ Charybdis Vaccines Srl, Messina, Italy; ⁵ Scylla Biotech Srl, Messina, Italy.

Introduction: *Streptococcus pneumoniae* (Sp) is one of the main causes of community-acquired pneumonia. This pathogen is capable of efficiently adhering to host surfaces and invading respiratory epithelia by expressing specialized adhesins, including the Plasminogen and fibronectin binding protein B (PfbB). Here, we describe a PfbB-dependent mechanism whereby Sp promotes adherence to the extracellular matrix and invasion of host cells.

Materials and Methods: We examined encapsulated and unencapsulated Sp, including *pfbB* deletion mutants, for their ability to bind to different types of collagens (Coll) and to interact with cultured epithelial cells. We also used recombinantly expressed Streptococcal Surface Repeats (SSURE), that make up for ~80 of PfbB, and anti-SSURE antibodies.

Results: The absence of *pfbB* significantly decreased the capacity of Sp to adhere to collagens and C1q. Recombinant SSURE domains showed a remarkable degree of specificity in binding to different collagen types. For example, the C-terminal SSURE domain interacted with Coll I, II, III and the complement component C1q, while the N-terminal SSURE domain bound Coll IV and VI, but not C1q. Pretreatment of bacteria with C1q significantly increased bacterial adhesion to and invasion of epithelial and endothelial cells by acting as a bridge between PfbB and the $\alpha_2\beta_1$ integrin.

Discussion and Conclusions: Our data suggest that the SSURE domains of Sp play a significant role in the ability of this pathogen to interact with collagens, the most abundant constituents of the human body. These versatile domains also bind C1q that, as shown here, acts as bridge between the bacteria and the $\alpha_2\beta_1$ integrin expressed on host cells. Our results may be useful to develop new strategies to control Sp infections by preventing colonization and invasion of mucosal surfaces.

17 - Bio-guided approach in the search of novel antibacterial compounds from three Myrtaceae plants

Elisabetta Buommino⁽¹⁾ - FRANCESCA GUZZO⁽²⁾ - Francesca Lembo⁽¹⁾ - Nicola Molfetta⁽¹⁾ - LESLIE LANDRUM⁽³⁾ - Antonio Fiorentino⁽²⁾ - Brigida D'Abrosca⁽²⁾

Dipartimento di Farmacia, Università degli Studi di Napoli, Federico II, Napoli, Italia⁽¹⁾ - Department of Environmental, Biological and Pharmaceutical Sciences and Technologies-DiSTABiF,, University of Campania "Luigi Vanvitelli", Caserta, Italia⁽²⁾ - School of Life Sciences, Arizona State University, Tempe, Stati Uniti D'america⁽³⁾

Bio-guided approach in the search of novel antibacterial compounds from three Myrtaceae plants.

ELISABETTA BUOMMINO^A, FRANCESCA GUZZO^B, FRANCESCA LEMBO^A, NICOLA MOLFETTA^A, LESLIE LANDRUM^C, ANTONIO FIORENTINO^B AND BRIGIDA D'ABROSCA^B

^ADepartment of Pharmacy, University of Naples "Federico II", Via Domenico Montesano 49, 80131 Naples, Italy; elisabetta.buommino@unina.it

^BDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies-DiSTABiF, University of Campania "Luigi Vanvitelli", via Vivaldi 43, I-81100 Caserta, Italy

^C School of Life Sciences, Arizona State University

Introduction. Most current infectious diseases are almost untreatable by conventional antibiotic therapy given the rise in frequency of resistance among human pathogenic bacteria. *S. aureus* is a pathogen that can be part of normal human flora but can cause both community- and hospital-acquired infections. It can colonize almost every tissue and organs, as well implants and can manifest resistance to antibiotic therapy. The emergence of multi-drug resistant strains such as MRSA (Methicillin-Resistant *S. aureus*) is nullifying the efforts until now made virtually eliminating the use of B-lactams as therapeutic options against *S. aureus*. Myrtaceae (Juss, year 1789) is an invaluable source of bioactive metabolites, such as terpenes, polyphenols and phloroglucinol derivatives. These latter compounds have unique features and a wide range of biological and pharmacological properties especially antimicrobial activity, an attractive target for researchers. The current work aims to study *Myrcianthes cisplatensis*, *Psidium friedrichsthalianum* and *P. oligospermum* through antimicrobial assays and NMR analysis performed to identify new antimicrobial compounds.

Material and methods. Dried leaves of each plant, collected in Arizona, were extracted with solvents at increasing polarity: hexane, chloroform, and methanol. The obtained crude extracts were tested for their antimicrobial activity against two strains of *Staphylococcus aureus*: ATCC 29213 and 43300 (a methicillin-resistant *Staphylococcus aureus* strain, MRSA). NMR analysis was performed to characterize the bioactive fractions.

Results. Crude extracts in hexane and methanol of *M. cisplatensis* were the most promising, exhibiting a minimal inhibitory concentration (MIC) of 16 and 64 microg/mL against *S. aureus* ATCC 29213 and MRSA, respectively. Chloroform and methanol extracts of *P. friedrichsthalianum* showed MIC values of 64 and 128 microg/mL respectively against both the strains. On the contrary, *P. oligospermum* showed no activity. Starting from the methanol extracts, 1D- and 2D-NMR analysis allowed to investigate the bioactive fractions to have information about the metabolite composition. Three cinnamoylated alkylphloroglucinol glucosides besides coumarin derivatives, isolated from *M. cisplatensis*, and tetronic acid derivative from *P. friedrichsthalianum* were characterized by 2D NMR and tested for their antimicrobial potential.

Discussion and conclusions. The bio-guided approaches allowed the identification of new promising antimicrobial compounds from the bioactive crude extracts of *M. cisplatensis* and *P. friedrichsthalianum*. Deeper investigation will be focused to define the pure metabolite responsible for the antimicrobial activity and the identification of the molecular mechanism of action.

33 - Life cycle peculiarities of enteric Adenovirus 41

Maria Cristina Arcangeletti ⁽¹⁾ - Clara Maccari ⁽¹⁾ - Flora De Conto ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Cecilia Carubbi ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Adriana Calderaro ⁽¹⁾

Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾

Life cycle peculiarities of enteric Adenovirus 41

MARIA-CRISTINA ARCANGELETTI¹, CLARA MACCARI¹, FLORA DE CONTO¹, MIRKO BUTTRINI¹, SARA MONTECCHINI¹, CECILIA CARUBBI², CARLO CHEZZI¹ AND ADRIANA CALDERARO¹

¹ University of Parma, Department of Medicine and Surgery, Parma, Italy

² University of Parma, Department of Medicine and Surgery, Unit of Anatomy, Parma, Italy

Introduction: Adenovirus belonging to F species, 41 serotype (AdV41) represents one of the most important viral agents causing gastroenteritis in pediatric patients. Recently, the interest in AdV41 circulation and behaviour has intensified due to their postulated involvement in the sudden increase of hepatitis cases of unknown origin among children. The aim of this study was to evaluate the life cycle peculiarities of AdV41 by comparing it to AdV5, in order to investigate some of the possible mechanisms underlying their differential behaviour, focusing on cell cycle interference and apoptosis induction in connection with AdV E1 early gene functions.

Materials and Methods: Ten AdV41 strains were randomly selected among 118 AdV F identified from stool samples of paediatric patients admitted with acute gastroenteritis to the University-Hospital of Parma during the years 2010-2015. They had been analysed by conventional methods (electron microscopy and cell culture) for routine diagnosis purposes, identified by restriction endonuclease analysis as AdV41 and then stored at -80C°. AdV41 and AdV5 virus replication was evaluated by cell culture, immunofluorescence, electron microscopy and Real-Time PCR. Viral interference on cell cycle and apoptosis was studied by flow cytometry. E1 gene from both strains was sequenced.

Results: The results show that both serotypes were able to complete the lytic cycle, with lower effectiveness for AdV41. In contrast to AdV5, which has a typical cytotoxic infection cycle, AdV41 gives rise to a non-lytic infection, even though it is able to complete its replication, producing a viral progeny which is able, in turn, to perform multiple infection runs with quite stable infection performance parameters. Moreover, a significant lack of cell accumulation into the S phase of the cell cycle was observed in AdV41 vs AdV5 infected cells, while no substantial changes in apoptosis levels were noted. Analysis of E1 gene coding regions evidenced relevant differences among the considered viral serotypes, mainly concerning the E1A region whose products are involved in viral replication and in the deregulation of cellular metabolism.

Discussion and Conclusions: These data support the ability of AdV41 serotype to give rise to non-lytic infections, possibly predisposing to viral persistence. This is of potential relevance considering that AdVs have been shown to persist in the gastrointestinal tract after primary infection in the pediatric setting, and that AdV41 could also reside in the human gut without causing disease, suggesting that it likely represents a risk factor for further development of intestinal or extra-intestinal pathologies.

52 - Serratiopeptidase affects adhesive features of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients on biotic and abiotic substrates

Gianluca Vrenna ⁽¹⁾ - Rosanna Papa ⁽¹⁾ - Oliwia Sara Rogala ⁽¹⁾ - Marco Artini ⁽¹⁾ - Laura Selan ⁽¹⁾
Sapienza Università, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽¹⁾

Serratiopeptidase affects adhesive features of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients on biotic and abiotic substrates.

Gianluca Vrenna, Oliwia S. Rogala, Rosanna Papa, Marco Artini, and Laura Selan

Department of Public Health and Infectious Diseases, Sapienza University, p.le Aldo Moro 5, 00185 Rome, Italy

Pseudomonas aeruginosa is an opportunistic pathogen often involved in airway infections of cystic fibrosis (CF) patients. During CF infection, the lung environment is extremely hostile because of the very high concentrations of antibiotics, reduced nutrient availability, elevated osmotic stress and intermicrobial competition: conditions that force *P. aeruginosa* to adapt for survival. The virulence of *P. aeruginosa* isolate is strongly related to different factors such as the capability to form a biofilm, different types of cell/colonial motility, production of toxins and the invasion of pulmonary cells. The dynamic process of biofilm formation offers protection to bacterial cells and resistance to drugs and host immune attacks. The self-produced exopolysaccharide matrix (EPS) that can incorporate different bacterial communities ensures their survival and resistance to certain antibiotics, complicating bacterial eradication. Motility also contributes to biofilm formation and bacterial colonization of surfaces. Furthermore, the ability to adhere is the prelude for the internalization into lung cells, a common immune evasion mechanism used by most intracellular bacteria, such as *P. aeruginosa*.

The impairment of bacterial cell adhesion and biofilm formation could represent a major target for the development of new therapeutic treatments for chronic infection control.

Previously reports evaluated the anti-infective properties of serratiopeptidase (SPEP), an extracellular metalloprotease produced by *Serratia marcescens*, in impairing virulence-related properties in bacteria, such as *Staphylococci* and *Listeria monocytogenes*. We demonstrated that SPEP was able to impair the attachment to inert surfaces and adhesion/invasion on eukaryotic cells with a mechanism independent by proteolytic mechanism.

This work aims to investigate the effect of SPEP on some virulence factors produced by *P. aeruginosa* isolated from CF patients, such as biofilm formation and accumulation, pyocyanin and pyoverdine production, motility and invasion to alveolar basal epithelial cells (A549 cell lines).

60 - Resveratrol Restores Susceptibility to Chlorhexidine and Benzalkonium in Microorganisms Causing Health-Care Associated Infection

Antonella Migliaccio ⁽¹⁾ - Maria Stabile ⁽¹⁾ - Maria Bagattini ⁽¹⁾ - Maria Triassi ⁽¹⁾ - Rita Berisio ⁽²⁾ - Raffaele Zarrilli ⁽¹⁾ - Eliana De Gregorio ⁽³⁾

Dipartimento di Sanità Pubblica, Università degli Studi di Napoli Federico II, Napoli, Italia ⁽¹⁾ - Institute of Biostructures and Bioimaging, National Research Council, Institute of Biostructures and Bioimaging, National Research Council, Napoli, Italia ⁽²⁾ - Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Napoli, Italia ⁽³⁾

Resveratrol Restores Susceptibility to Chlorhexidine and Benzalkonium in Microorganisms Causing Health-Care Associated Infection

*ANTONELLA MIGLIACCIO*¹, *MARIA STABILE*¹, *MARIA BAGATTINI*¹, *MARIA TRIASSI*¹, *RITA BERISIO*², *RAFFAELE ZARRILLI*¹ AND *ELIANA DE GREGORIO*³.

¹Department of Public Health, University of Naples Federico II, Via S. Pansini 5, Naples, Italy; ²Institute of Biostructures and Bioimaging, National Research Council, Naples, Italy; ³Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, Naples, Italy;

1. Introduction

The spread of microorganisms causing health-care associated infection (HAI) is contributed by their intrinsic tolerance to a variety of biocides used as antiseptics or disinfectants. The natural monomeric stilbenoid resveratrol (RV) is able to modulate the susceptibility to chlorhexidine (CHX) and to benzalkonium (BZK) biocide in *Acinetobacter baumannii*. The aim of the study was to: (i) analyze the susceptibility to CHX and BZK biocides in a panel of reference strains and clinical isolates of Gram-negative bacteria, Gram-positive bacteria and yeasts; (ii) analyze whether RV may modulate and restore susceptibility to CHX and BZK in the above pathogens.

2. Materials and Methods

MIC (mg/L) and MBC (mg/L) values of CHX and BZK were determined by a broth microdilution method. In vitro combination studies were carried out using the checkerboard method. The combined effects were determined by calculating the fractional inhibitory concentration (FIC) index. Furthermore, the Pearson's correlation coefficient ($p < 0.01$) was calculated both on CHX treatment in presence of the carbonyl cyanide m-chlorophenylhydrazine protonophore (CCCP) or RV and BZK treatment in presence of CCCP or RV.

3. Results

The CCCP efflux pump inhibitor reduced dose-dependently minimum inhibitory concentration (MIC) and minimum bactericidal/fungicidal concentration (MBC/MFC) of CHX in 31 out 33 reference strains and reduced BZK MIC and MBC in 20 out 33 analyzed strains. RV from 32 to 256 mg/L decreased dose-dependently CHX MIC and MBC in 33 selected strains, while not restored CHX susceptibility in *Klebsiella pneumoniae* ATCC 700603, all *Pseudomonas aeruginosa* and *Candida* spp. strains. RV up to 128 mg/L decreased dose-dependently BZK MIC and MBC, but not restored BZK susceptibility in 3 *Burkholderia* spp., *Enterocobacter cloacae* ATCC 13047, *K. pneumoniae* ATCC 700603, *Stenotrophomonas maltophilia* K279 and all *P. aeruginosa* strains. Furthermore, CHX and BZK combination in the presence of 32 mg/L RV inhibited CHX and BZK MIC and MBC in all strains and restored CHX or BZK susceptibility in 16 out of 21 strains, resulting in a synergic or additive effect in 18 and 3 strains, respectively. However, CHX and BZK combination in the presence of RV at 64 mg/L restored CHX or BZK susceptibility in all strains and showed a synergic in 20 out 21 strains and additive effect in 1 out 21 strains.

4. Discussion and Conclusions

A synergic microbicidal effect was observed when the two biocides were combined with RV in a panel of Gram-negative bacteria, Gram-positive bacteria and yeasts.

RV reverts tolerance and restores susceptibility to CHX and BZK in the majority of microorganisms responsible for HAI. The combination of RV, CHX and BZK may represent a useful strategy to maintain susceptibility to biocides in several nosocomial pathogens.

63 - RiV4PoC: A high effective microbicidal coating for high-touch surfaces

Fabrizio Angius⁽¹⁾ - Alessandra Scano⁽²⁾ - Francesca Esposito⁽³⁾ - Guido Ennas⁽²⁾ - Aldo Manzin⁽¹⁾

University of Cagliari, Department of Biomedical Sciences, Unit of Microbiology and Virology, Cagliari, Italia⁽¹⁾ - University of Cagliari, Department of Chemical and Geological Sciences, Cagliari Research Unit of the National Consortium of Materials Science and Technology (INSTM),, Cagliari, Italia⁽²⁾ - University of Cagliari, Department of Life and Environmental Sciences, Unit of Molecular Virology, Cagliari, Italia⁽³⁾

RiV4PoC: A high effective microbicidal coating for high-touch surfaces

*FABRIZIO ANGIUS*¹, *ALESSANDRA SCANO*^{2,3}, *FRANCESCA ESPOSITO*⁴, *GUIDO ENNAS*^{2,3}, *ALDO MANZIN*¹

¹ *Department of Biomedical Sciences, Unit of Microbiology and Virology, University of Cagliari, Cagliari, Italy*

² *Department of Chemical and Geological Sciences, University of Cagliari, Cagliari, Italy*

³ *Cagliari Research Unit of the National Consortium of Materials Science and Technology (INSTM), Cagliari, Italy*

⁴ *Department of Life and Environmental Sciences, Unit of Molecular Virology, University of Cagliari, Cagliari, Italy*

Introduction

Although airborne is the most efficient transmission route of various pathogens, the contamination of surfaces and objects remains a particularly effective path of indirect transmission. Infrastructures such as schools, airports, shopping centers and hospitals are particularly at risk, and specific attention must be paid to all those surfaces or objects that can function as a reservoir with a high load of microbes, even pathogens which represent a serious issue in hospitals where patients with weakened immune systems are more at risk than the general population. Naturally, the environment disinfection as well as hand hygiene represents the main tool of prevention of fomites transmission. However, this aspect is time-limited and difficult to control in public places. Therefore, it is necessary to develop technologies that have the ability to reduce or eliminate the microbes load on high-touched surfaces. Based on our solid previous data (patent WO2021255496A1), we aim to extend and strengthen the applicability of an innovative approach to limit the infectious load on contaminated surfaces of different materials in order to use it in the near future for medical devices and high-touch objects.

Materials and methods

We firstly performed structural, morphological, thermal and tribological characterization of the experimental model of coated surfaces, and then we applied the results of fundamental research to determine and validate the microbicidal activity of the coating against common contaminating bacteria (i.e., *Escherichia coli*, *Staphylococcus aureus*, methicillin resistant *S. aureus* [MRSA]) and viruses (i.e., alphacoronavirus 229E).

Results

In our experimental surface model, the coating formulation proved to have a potent bactericidal efficacy equal to 100% against Gram negative (*E. coli*) and positive (*S. aureus* and MRSA) bacteria. Moreover, the coating showed to be not toxic as evaluated by cytotoxicity assay and highly effective in reducing the initial infectious load of 229E by about 90% after exposure to the coating.

Discussion and conclusion

The main innovation of RiV4PoC is the revolutionary technological idea at the base which consists of a biocompatible, economical and future-proof formulation of a coating that exceeds the limits of toxicity/aggressiveness of the disinfectants on the market and which boasts an action which lasts over time. It will improve the health system resources with a direct impact on people's lives by effectively limiting the transmission of pathogens in the most risky social contexts. Such a tool would be of fundamental use in sensitive infrastructures (e.g. seats, handles, handrails) and commonly used devices (e.g. smartphones, medical devices) with enormous attractive potential.

70 - Characterization of stringent response phenotype in *Neisseria meningitidis*

Chiara Pagliuca⁽¹⁾ - Elena Scaglione⁽²⁾ - Giuseppe Mantova⁽¹⁾ - Alessia Stornaiuolo⁽³⁾ - Martina Di Rosario⁽¹⁾ - Leonardo Continisio⁽¹⁾ - Valeria Caturano⁽⁴⁾ - Lucia Sorbo⁽⁴⁾ - Mariagrazia La Campora⁽⁴⁾ - Pietro Alifano⁽⁵⁾ - Mariateresa Vitiello⁽⁶⁾ - Roberta Colicchio⁽⁶⁾ - Paola Salvatore⁽⁷⁾

Federico II University, Department of Molecular Medicine and Medical Biotechnology, Naples, Italia⁽¹⁾ - University of Naples "Federico II"; University Hospital Federico II, Dep. of Mol Med and Med Biotech; Dep. of Chem, Mat and Ind Prod Eng ;DAI of Lab Med and Trans, Naples, Italia⁽²⁾ - University of Naples "Federico II"; University Hospital Federico II, Dep. of Mol Med and Med Biotech; Dep. of Chem, Mat and Ind Prod Eng, Naples, Italia⁽³⁾ - University Hospital Federico II, Dep. of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, Naples, Italia⁽⁴⁾ - University of Salento, Department of Biological and Environmental Sciences and Technologies, Lecce, Italia⁽⁵⁾ - Federico II University, University Hospital Federico II, Dep. of Mol. Med. and Med Biotech; D.A.I. of Lab Med and Transfusion, UOC Clinical Microbiology, Naples, Italia⁽⁶⁾ - Federico II University, University Hospital Federico II; Ceinge Naples, Dep. Mol. Med. and Med Biotech; D.A.I. Lab Med and Trans, UOC Clinical Microbiology; CEINGE scarl, Naples, Italia⁽⁷⁾

Characterization of stringent response phenotype in *Neisseria meningitidis*

CHIARA PAGLIUCA¹, ELENA SCAGLIONE^{1,2,3}, GIUSEPPE MANTOVA¹, ALESSIA STORNAIUOLO^{1,2}, MARTINA DI ROSARIO¹, LEONARDO CONTINISIO¹, VALERIA CATURANO³, LUCIA DEL SORBO³, MARIAGRAZIA LA CAMPORA³, PIETRO ALIFANO⁴, MARIATERESA VITIELLO^{1,3}, ROBERTA COLICCHIO^{1,3}, PAOLA SALVATORE^{1,3,5,6}.

¹Department of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy;²Department of Chemical, Materials and Industrial Production Engineering, Federico II University, Naples, Italy;³Department of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italy;⁴ Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy; ⁵Task Force on Microbiome Studies, University of Naples Federico II, Naples, Italy; ⁶CEINGE, Advanced Biotechnologies s.c.ar.l., Naples, Italy.

Introduction: Bacteria must sense and adapt to multiple changes that take place in their rapidly fluctuating environments. In response to starvation, the global regulators pppGpp/ppGpp (guanosine 5'-triphosphate or diphosphate 3'-diphosphate), collectively abbreviated as ppGpp, are the molecular effectors of the bacterial stringent response, an extensive reprogramming of transcription and metabolism. In detail, upon exposure to stresses (nutrient deprivation, antibiotics misuse) the increased concentration of ppGpp lead to the downregulation of proliferative processes (rRNA and tRNA synthesis, cell division) and the upregulation of stress response processes (amino acid biosynthesis and virulence gene expression) through the interaction of ppGpp with RNA polymerase (RNAP). Previously, through comparative transcriptomic analysis, we characterized a mutant rifampicin resistant (RifR) strain of *Neisseria meningitidis* serogroup C (93/4286 strain) with a substitution in 553 position (Men C H553Y) of *rpoB* gene cluster I for its ability to mimic stringent response associated to a peculiar downregulation of virulence genes. Here, we evaluated the stringent response phenotype in *N. meningitidis* serogroup C wild type strain (MenC) and its relative stringent-like mutant (MenC H553Y RifR) by the evaluation of kill curves against gentamicin, thiostrepton, ceftriaxone, ciprofloxacin and the assessment of main virulence genes expression, with and without an inducer of the stringent response. **Materials and Methods:** For the evaluation of killing curve, Men C and MenC H553Y RifR strains were incubated at 37°C with concentrations equal to the MBC of gentamicin, thyostreptone, ceftriaxone and ciprofloxacin and viable counts were assessed up to the sixth hour of contact. For Real time RT-PCR analysis, both strains, grown in minimal medium with and without DL-Serine hydroxamate (DL-Ser) a seryl tRNA synthetase inhibitor were evaluated for the expression of *opa*, *fhlbp* and *pilE* genes. **Results:** The MenC H553Y RifR mutant showed a greater tolerance to the antibiotics acting on ribosomes compared to MenC strain; moreover, in presence of stringent response inducer, the expression analyses

revealed a downregulation of *opa*, *fhbp*, *pilE* genes in the MenC H553Y Rif^R mutant compared to MenC strain.

Discussion and Conclusions: In line with the characterized stringent phenotype, the MenC H553Y-Rif^R mutant shown a greater tolerance to antibiotics acting on ribosomes and a downregulation of virulence genes probably mimicking the bacterial dormancy, a less obvious and perhaps even more widespread phenomenon that leads to antibiotic failure.

86 - Novel Options to Counteract Oral Biofilm Formation: in Vitro Evidence

Alessandra Odorici⁽¹⁾ - Bruna Colombari⁽²⁾ - Pierantonio Bellini⁽²⁾ - Samuele Peppoloni⁽²⁾ - Aida Meto⁽³⁾ - Irene Venturelli⁽⁴⁾ - Elisabetta Blasi⁽²⁾

University of Modena and Reggio Emilia, School of Doctorate in Clinical and Experimental Medicine, Laboratory of Microbiology and Virology, Unimore, Modena, Italia⁽¹⁾ - University of Modena and Reggio Emilia, Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplant, Oncology and Regenerative Medicine, Laboratory of M, Modena, Italia⁽²⁾ - Department of Dentistry, Faculty of Dental Sciences, University of Aldent, 1007 Tirana, Albania, Department of Dentistry, Faculty of Dental Sciences, University of Aldent, 1007 Tirana, Albania, Tirana, Albania⁽³⁾ - School of Specialization in Microbiology and Virology, University of Modena and Reggio Emilia,, School of Specialization in Microbiology and Virology, University of Modena and Reggio Emilia,, Modena, Italia⁽⁴⁾

Novel Options to Counteract Oral Biofilm Formation: *in Vitro* Evidence

ALESSANDRA ODORICI¹, BRUNA COLOMBARI², PIERANTONIO BELLINI², SAMUELE PEPPOLONI², AIDA METO³, IRENE VENTURELLI⁴ and ELISABETTA BLASI²

¹ School of Doctorate in Clinical and Experimental Medicine, Laboratory of Microbiology and Virology, University of Modena and Reggio Emilia, Via G. Campi 287, 41125 Modena, Italy;

² Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplant, Oncology and Regenerative Medicine, Laboratory of Microbiology and Virology, University of Modena and Reggio Emilia, Via G. Campi 287, 41125 Modena, Italy;

³ Department of Dentistry, Faculty of Dental Medicine, University of Western Balkans, 1051 Tirana, Albania

⁴ School of Specialization in Microbiology and Virology, University of Modena and Reggio Emilia, Via G. Campi 287, 41125 Modena, Italy; 165721@studenti.unimore.it

1.Introduction: the oral cavity is a highly complex habitat, involving resident microbial communities importantly involved in local homeostasis. The biofilm production on biotic and abiotic surfaces is crucial step in the pathogenesis of most infections, particularly those occurring in the oral cavity. Its prevention and/or control may promote oral health and facilitate the management of patients with oral diseases. In this study, the antibiofilm activity of a biomimetic hydroxyapatite and a natural compound, MicroRepair (MicroR) and pomegranate (PomeGr), respectively, was assessed.

2.Materials and Methods: By luminescence/fluorescence-based assays, *Pseudomonas aeruginosa* (*P. aeruginosa*), *Staphylococcus aureus* (*S. aureus*) and *Candida albicans* (*C. albicans*) were tested for their biofilm production in the presence of MicroR and/or PomeGr.

3.Results: we found that that microbial exposure to PomeGr resulted in a marked decrease in *P. aeruginosa* biofilm formation. A partial, but non-significant, reduction was observed with *S. aureus*, while a significant impairment occurred in *C. albicans* exposed to PomeGr. Differently, the MicroR treatment reduced biofilm formation in all the strains tested, especially in *C. albicans*, where the reduction was highly significant ($p < 0.0001$).

4.Discussion and Conclusions: by mean of *in vitro* models, the antibiofilm activity of a biomimetic hydroxyapatite, MicroRepair, and the natural compound, pomegranate, has been established. Given the crucial role of biofilm formation in the pathogenesis of many oral diseases, our results offer a basic rationale for the design of trials aimed at maintaining health conditions or recovering homeostatic imbalance in the oral cavity.

143 - A novel phenolic derivative inhibits AHL-dependent Quorum Sensing signaling in *Pseudomonas aeruginosa*

Giulia Bernabè⁽¹⁾ - Giovanni Marzaro⁽²⁾ - Giuseppe Di Pietra⁽³⁾ - Massimo Bellato⁽⁴⁾ - Anthony Pauletto⁽¹⁾ - Melania Scarpa⁽⁵⁾ - Stefania Sut⁽²⁾ - Adriana Chilin⁽²⁾ - Stefano Dall'Acqua⁽²⁾ - Paola Brun⁽¹⁾ - Ignazio Castagliuolo⁽¹⁾

Università degli studi di Padova, Dipartimento di medicina molecolare, Padova, Italia⁽¹⁾ - Università degli studi di Padova, Dipartimento di scienze del farmaco, Padova, Italia⁽²⁾ - Azienda Ospedaliera di Padova, Microbiologia, Padova, Italia⁽³⁾ - Università degli studi di Padova, Dipartimento di Ingegneria Informatica, Padova, Italia⁽⁴⁾ - Istituto Oncologico del Veneto, IOV, Laboratorio di ricerca traslazionale, Padova, Italia⁽⁵⁾

A novel phenolic derivative inhibits AHL-dependent Quorum Sensing signaling in *Pseudomonas aeruginosa*

*GIULIA BERNABE*¹, *GIOVANNI MARZARO*², *GIUSEPPE DI PIETRA*¹, *MASSIMO BELLATO*³, *ANTHONY PAULETTO*¹, *MELANIA SCARPA*⁴, *STEFANIA SUT*², *ADRIANA CHILIN*², *STEFANO DALL'ACQUA*², *PAOLA BRUN*¹, *IGNAZIO CASTAGLIUOLO*^{1*}

¹Department of Molecular Medicine, University of Padua, Padua, Italy

²Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy

³Department of Information Engineering, University of Padua, Padua, Italy

⁴Laboratory of Advanced Translational Research, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy

Introduction: Increasing antibiotic resistance and declining pharmaceutical industry's investments have amplified the need for novel treatments for multidrug-resistant microbes. Quorum sensing (QS) inhibitors reduce pathogens' virulence without selective pressure on microbes and provide an alternative to conventional antibiotic-based therapies. *P. aeruginosa* (PA) uses complex QS signaling to control virulence and biofilm formation. We aimed to identify inhibitors of *P. aeruginosa* QS acting on lactones-mediated circuits.

Methods: Bioluminescence and qRT-PCR assays were employed to screen a library of 81 small phenolic derivatives (used at 50-100 µg/ml) for the ability to reduce AHL-dependent signaling. Cytotoxicity was then evaluated on procaryotic and eucaryotic cells by growth curve and MTT respectively. On PAO1 culture, treated or not with the most active compound, we determined: 1) AHL production by liquid chromatography plus mass-spectrometry analysis; 2) the biofilm disruption by resazurin method; 3) the production of pyocyanins, elastase, and rhamnolipids release by colorimetric method 4) adhering bacteria on pulmonary epithelial cells A549 by CFU counting 5) inhibition of interleukin-8 release by A549. Moreover, we collected 20 PA clinical isolates from patients with respiratory tract infections; elastase and pyocyanins were evaluated in treated or not treated isolates. By *in-vivo* assay on *Galleria mellonella* larvae, we evaluated the compound's ability to protect from PAO1 infection. Finally, by molecular docking, we examined the interaction between phenolic derivatives and QS receptor LasR or RhlR.

Results: We identified GM-50 as the most active compound inhibiting the expression of AHL-regulated genes but devoid of cytotoxic activity in human epithelial cells and biocidal effects on microbes. GM-50 reduced virulence factors such as rhamnolipids, pyocyanin elastase secretion, and swarming motility in PAO1, a PA laboratory strain. By molecular docking, we provided evidence that GM-50 highly interacts with RhlR. GM-50 significantly improved aztreonam-mediated biofilm disruption. Moreover, GM-50 prevented adhesion of PAO1 and inflammatory damage in A549 cell line and protects *G. mellonella* from pathogen-mediated killing. Additionally, GM-50 significantly reduced virulence factors in the 20 PA clinical isolates.

Conclusions: GM-50 inhibits AHL-signaling, reduces the expression and production of virulence factors, and enhances the anti-biofilm activity of aztreonam. It protects *G. mellonella* larvae and human A549 cells from damage induced by PA. Since GM-50 is active on clinical strains, it represents a starting point for identifying and developing new phenolic derivatives acting as QS-inhibitors in PA infections.

170 - Role of the histone deacetylase Hst3p in *Candida albicans* biology

Daniela Eletto ⁽¹⁾ - Marisa Conte ⁽¹⁾ - Martina Pannetta ⁽¹⁾ - Alessandra Tosco ⁽¹⁾ - Amalia Porta ⁽¹⁾

Università degli studi di Salerno, Dipartimento di Farmacia, Fisciano, Italia ⁽¹⁾

Role of the histone deacetylase Hst3p in *Candida albicans* biology

Daniela Eletto ¹, Marisa Conte ¹⁻², Martina Pannetta ¹⁻², Alessandra Tosco ¹, Amalia Porta ¹

¹ Department of Pharmacy, University of Salerno, 84084 Fisciano (SA)-Italy; ² PhD Program in Drug Discovery and Development, University of Salerno, 84084 Fisciano (SA), Italy.

1. Introduction. Infections caused by the polymorphic fungus *Candida albicans* are considered a serious concern either for the emerging drug resistance but also for the limited therapeutic options, that often target human cells due to their affinities to fungal cells with undesirable outcomes. Alternative strategies are needed to overcome the limitations of the current therapeutic plan. Many studies revealed that among various chromatin modifications, histone acetylation-deacetylation takes a leading role in *C. albicans* pathogenicity and virulence. In yeast, histone H3 Lys56 acetylation (H3K56ac) is an important post-translational modification that contributes to fungal genome integrity and depends on the activity of two opposite enzymes, the histone acetyltransferase RTT109 and the histone deacetylase Hst3p, a sirtuin inhibited by nicotinamide (NAM). Considering that, *HST3* deletion leads to decreased cell viability, genomic instability and attenuated virulence, and that fungal Hst3p family members share sequence motifs that are uncommon in human sirtuins, inhibition of Hst3p could be an attractive potential target for antifungal therapy. **2. Material and Methods.** To assess the effect of Hst3p on cell morphology, *C. albicans* cells treated with 10 mM NAM were observed by optical microscopy. In order to identify H3K56ac enriched regions across *C. albicans* genome, yeast cells treated as above were used for Chromatin immunoprecipitation assays followed by sequencing (ChIP-seq). Furthermore, to identify which pathway is altered by Hst3p inhibition, *Candida* transcriptome was analyzed by RNA-sequencing under the aforementioned conditions. **3. Results.** Our data show that Hst3p inhibition promotes the accumulation of H3K56 acetylation, which leads to the formation of an abnormal and enlarged filamentous structures with a particular V conformation (V-shaped hyphae) associated to a dysregulation of genes involved in adhesion, hyphal growth and cell wall maintenance.

176 - Skin dysbiosis in inflammatory acne lesions and the role of *Cutibacterium acnes* biofilm

Ilaria Cavallo⁽¹⁾ - Francesca Sivori⁽¹⁾ - Giorgia Fabrizio⁽¹⁾ - Aldo Morroe⁽²⁾ - Fulvia Pimpinelli⁽¹⁾ - Enea Gino Di Domenico⁽³⁾

IRCCS San Gallicano Institute, Microbiology and Virology, Rome, Italia⁽¹⁾ - IRCCS San Gallicano Institute, Scientific Direction, Rome, Italia⁽²⁾ - Sapienza University of Rome, Department of Biology and Biotechnology Charles Darwin, Rome, Italia⁽³⁾

Skin dysbiosis in inflammatory acne lesions and the role of *Cutibacterium acnes* biofilm

ILARIA CAVALLO¹, FRANCESCA SIVORI¹, GIORGIA FABRIZIO¹, ALDO MORRONE², FULVIA PIMPINELLI¹, ENEA GINO DI DOMENICO³

Microbiology and Virology, IRCCS San Gallicano Institute, Rome, Italy¹; Scientific Direction, IRCCS San Gallicano Institute, Rome, Italy²; Department of Biology and Biotechnology Charles Darwin, Sapienza University of Rome, Rome, Italy³

ABSTRACT

Introduction. Acne vulgaris is a common inflammatory disorder affecting more than 80% of young adolescents. *Cutibacterium acnes* plays a role in the pathogenesis of acne lesions, although the mechanisms are poorly understood. **Materials and Methods.** The study aimed to explore the microbiome at different skin sites in acne patients and the role of biofilm production in promoting the growth and persistence of *C. acnes* isolates. Swabs from non-inflammatory (NI) and inflammatory lesions (LA) of 10 acne patients and the skin of 10 healthy subjects (HS) were analyzed using 16S rRNA sequencing. In addition, traditional culture methods were combined with whole-genome sequencing. **Results.** Microbiota analysis showed a significantly lower alpha diversity in LA than in NI and HS. Differences at the species level were driven primarily by the overabundance of *C. acnes* on LA than NI and HS. The phylotype IA1 was more represented in the skin of acne patients than HS. Genes involved in lipids transport and metabolism, as well as potential virulence factors associated with host-tissue colonization, were selectively detected in phylotype IA1 strains. Additionally, the IA1 isolates were more efficient in early adhesion and biomass production than other phylotypes showing a significant increase in antibiotic tolerance for ampicillin, benzylpenicillin, clindamycin, and doxycycline. **Discussion and Conclusions.** Our data indicate a site-specific dysbiosis in LA compared to HS. Dysbiosis in the LA microbiome and colonization by virulent and highly tolerant *C. acnes* phylotypes may explain the prevalence of acne in a part of the population, despite the universal carriage of the microorganism.

179 - Genotypic and phenotypic characterization of *Staphylococcus aureus* strains isolated in patients with atopic dermatitis

Antonietta Lucia Conte⁽¹⁾ - Massimiliano Marazzato⁽¹⁾ - Francesca Brunetti⁽¹⁾ - Linda Maurizi⁽¹⁾ - Catia Longhi⁽¹⁾ - Anna Teresa Palamara⁽²⁾ - Sara Grassi⁽³⁾ - Maria Pia Conte⁽¹⁾

“Sapienza” University of Rome, Department of Public Health and Infectious Diseases, Rome, Italia⁽¹⁾ - Istituto Superiore di Sanità, Department of Infectious Diseases, Rome, Italia⁽²⁾ - “Sapienza” University of Rome, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Rome, Italia⁽³⁾

Genotypic and phenotypic characterization of *Staphylococcus aureus* strains isolated in patients with atopic dermatitis

ANTONIETTA L. CONTE¹, MASSIMILIANO MARAZZATO¹, FRANCESCA BRUNETTI¹, LINDA MAURIZI¹, CATIA LONGHI¹, ANNA T. PALAMARA^{2,3}, SARA GRASSI⁴, MARIA P. CONTE¹

¹Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Rome, Italy; ²Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; ³Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Laboratory Affiliated to Institute Pasteur Italia-Cenci Bolognetti Foundation, Rome, Italy; ⁴Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, “Sapienza” University of Rome, Rome, Italy

Introduction: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease. The interplay between impaired barrier integrity, genetic disposition, immune system imbalance and microbial dysbiosis plays a key role in AD development. On the inflamed skin of AD patients, an alteration of the bacterial diversity with an increased *Staphylococcus aureus* proliferation has been observed. It has been evidenced that *S. aureus* produces several virulence factors, it can form biofilms in AD lesions and it is able to invade and survive in keratinocytes, contributing to the severity and progress of the disease. Furthermore, although specific *S. aureus* strains were most frequently identified in AD patients, no specific clone prevailed in this group of patients. So, the main purpose of this study is the identification of *S. aureus* lineage-specific features associated to AD.

Materials and Methods: *S. aureus* isolated from AD patients, sampled at flare (t0) and post-flare (t1) phases, and from healthy carriers were identified by MALDI-TOF and genotyped by RAPD-PCR. Whole genome sequencing analyses of *S. aureus* strains, including multilocus sequence typing (MLST), *spa* typing, Agr typing, detection of genes associated to virulence factors and antibiotic resistance, core genome MLST, were performed. The antimicrobial susceptibility test (AST) was determined using Vitek-2. Biofilm production was detected through crystal violet staining. The *S. aureus* invasion ability was evaluated by *in vitro* gentamicin protection assays on human keratinocytes (HaCat cells).

Results: At t0, *S. aureus* was recovered in 100% of lesional skin samples and at t1 in 35.7% of skin ones, with a higher degree of colonization at t0 than at t1. RAPD-PCR analysis revealed a clonal diffusion within the host during disease flare, with a same strain that can persist in the post-flare. Molecular typing evidenced a heterogeneity of strains, from both AD patients and healthy carriers, confirmed by the phylogenetic analysis in which all *S. aureus* strains tended to cluster regardless of the origin of isolation and of the disease. AST revealed a sensitiveness to a wide range of antibiotics in most strains, and no MRSA strains were detected. Moreover, *S. aureus* strains from AD patients were strong or moderate biofilm producers, while those from healthy carriers were moderate or weak biofilm producers. Finally, most *S. aureus* strains from AD patients were non-invasive.

Discussion and Conclusions: No specific genomic and functional features of *S. aureus* strains associated to AD were identified, suggesting that *S. aureus* strains shared a strong and similar pathogenic potential, that they express in a susceptible host and in particular environmental conditions.

197 - Molecular characterization of hypermucoviscous and hypervirulent strains of *Klebsiella pneumoniae*: an emergent health care threat

Anna Ventura ⁽¹⁾ - Anna Bertoncelli ⁽¹⁾ - Davide Gibellini ⁽¹⁾ - [Annarita Mazzariol](#) ⁽¹⁾

Università di Verona, Dipartimento di Diagnostica e Sanità Pubblica, Verona, Italia ⁽¹⁾

Molecular characterization of hypermucoviscous and hypervirulent strains of *Klebsiella pneumoniae*: an emergent health care threat

ANNA VENTURA, ANNA BERTONCELLI, ELENA ADDIS, [ANNARITA MAZZARIOL](#)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy

Introduction. In recent years, *Klebsiella pneumoniae* become a serious infections agent resulting from its increasing resistance to antibiotic therapy. Furthermore, recently, additional genetic traits associated with hypervirulence and antibiotic resistance have been identified that make *K. pneumoniae* infection an increasingly emergency problem. The aim of this study is to characterize 19 isolates of *K. pneumoniae* identify as hypermucosviscous phenotype, focusing on the clonal relationship and through various genes linked to virulence factors.

Materials and methods. In order to identify strains of *K. pneumoniae* hypermucoviscous is applied the string test considered positive with a length > 5 mm. All strains were subjected to MLST (Pasteur protocol). The production of biofilm was also analysed through the cristal violet test perform on microtiter plate. The identification of hypervirulent strains were performed searching the following genes: *iroB*, *iucA*, *rmpA* and *rmpA2* and *peg-344*, which correspond respectively to the loci of Salmochelin siderophore, Aerobactin siderophore, hypermucoidy and alleged transporter. The *magA*, a gene encoding a component of K1 capsule formation, was also detected through PCR. Carbapenem resistance was investigated through Carba test NP and positive strains has been subjected to specific PCRs for the *bla_{KPC}*, *bla_{VIM}*, *bla_{IMP}*, *bla_{NDM}* and *bla_{OXA-48}* genes.

Results. 19 *K. pneumoniae* strains with a positive string test were investigated for hypervirulence factors. All 19 strains resulted strong biofilm producer. 7 strains out of 19 showed the presence of at least four of the hypervirulence genes screened and according to the literature we considered as hypervirulent *K. pneumoniae* (hvKpn). Two more strains showed the presence of *rmpA2* gene and we considered as potential hvKp pathotype. *magA* gene related to hypermucoviscosity was found in 6 strains out of 19 and just in one case in the presence of other virulence factors. Regard to MLST 3 out of 7 hvKpn strains were ST65, two ST29. Other important ST found were ST383, ST307 and ST101. Carba test NP established that only 4 out of the 19 strains have the enzyme responsible for the hydrolysis of carbapenems and carbapenemases were detected in different combination: KPC alone, OXA-48 alone, KPC and OXA 48, and one strains (ST383) harboured VIM. NDM and OXA-48. The latter is considered also a potential pathotype since it harbours the *rmpA2* gene, while the other three strain harbouring carbapenemases did not showed the hvKpn pattern.

Conclusions. Positive string test could be used to select strains for further investigations on virulence factors related to hvKpn pathotype. We detected hypervirulent genes in almost 50% of the string test positive strains. This phenomenon must be monitored and further studies are necessary to understand better virulence factors related to hvKpn. ST already related to hypervirulence were found, like ST65 (3 strains out 7). Note of worthy is the report of a ST 383, characterized by the co-production of OXA-48, VIM and NDM-5. This could represent a new hypervirulent XDR *K. pneumoniae* clone, as recently reported in northern Italy.

274 - PGRS domain structures: doomed to sail the mycomembrane

Rita Berisio ⁽¹⁾ - [Giovanni Delogu](#) ⁽²⁾

Institute of Biostructures and Bioimaging, Institute of Biostructures and Bioimaging, Napoli, Italia ⁽¹⁾
- Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie-
Istituto di Microbiologia / Mater Olbia Hospital, Istituto di Microbiologia, Università Cattolica del
Sacro Cuore, Roma / Mater Olbia Hospital, Olbia, Roma/ Olbia, Italia ⁽²⁾

PGRS domain structures: doomed to sail the mycomembrane

Rita Berisio¹ and Giovanni Delogu^{2,3},

¹ Institute of Biostructures and Bioimaging, IBB, CNR, Naples, Italy,

²Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie – Sezione di
Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy,

³Mater Olbia Hospital, Olbia, Italy

*Correspondence: rita.berisio@cnr.it; giovanni.delogu@unicatt.it;

Abstract

The impact of artificial intelligence in understanding biological processes is potentially immense. AlphaFold predicted the structure of thousands of proteins, including the enigmatic PE_PGRS protein family of *Mycobacterium tuberculosis*. Structural elucidation of mycobacterial PE_PGRS obtained with AlphaFold offers a unique opportunity to discuss how the findings obtained on these structurally complex proteins can be illuminating to solve key questions in biology. Gathering previous experimental findings and hypothesis with the predicted structures, we propose a PGRS “sailing” model as a smart tool to quickly move across the mycomembrane, for shipping enzymes or for host interactions.

03 Virologia

4 - Competition for dominance within replicating quasi-species during prolonged SARS-CoV-2 infection in an immunocompromised host

Francesca Caccuri⁽¹⁾ - Serena Messali⁽¹⁾ - Daria Bortolotti⁽²⁾ - Dario Di Silvestre⁽³⁾ - Antonella De Palma⁽³⁾ - Chiara Cattaneo⁽⁴⁾ - Anna Bertelli⁽¹⁾ - Alberto Zani⁽¹⁾ - Maria Milanese⁽⁵⁾ - Marta Giovanetti⁽⁶⁾ - Giovanni Campisi⁽¹⁾ - Valentina Gentili⁽²⁾ - Antonella Bugatti⁽¹⁾ - Federica Filippini⁽¹⁾ - Erika Scaltriti⁽⁷⁾ - Stefano Pongolini⁽⁷⁾ - Alessandra Tucci⁽⁴⁾ - Simona Fiorentini⁽¹⁾ - Pasqualina D'Ursi⁽⁸⁾ - Massimo Ciccozzi⁽⁹⁾ - Pierluigi Mauri⁽³⁾ - Roberta Rizzo⁽²⁾ - Arnaldo Caruso⁽¹⁾

Section of Microbiology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italia⁽¹⁾ - Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italia⁽²⁾ - Proteomic and Metabolomic Laboratory, Institute of Biomedical Technologies, National Research Council, Segrate, Italia⁽³⁾ - Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italia⁽⁴⁾ - Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, Brescia, Italia⁽⁵⁾ - Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Laboratório de Flavivírus, Rio de Janeiro, Brasile⁽⁶⁾ - Risk Analysis and Genomic Epidemiology Unit, Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Parma, Italia⁽⁷⁾ - Institute of Biomedical Technologies, National Research Council, Segrate, Italia⁽⁸⁾ - Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Rome, Italia⁽⁹⁾

Competition for dominance within replicating quasi-species during prolonged SARS-CoV-2 infection in an immunocompromised host

FRANCESCA CACCURI¹, SERENA MESSALI¹, DARIA BORTOLOTTI², DARIO DI SILVESTRE³, ANTONELLA DE PALMA³, CHIARA CATTANEO⁴, ANNA BERTELLI¹, ALBERTO ZANI¹, MARIA MILANESI⁵, MARTA GIOVANETTI^{6,7}, GIOVANNI CAMPISI¹, VALENTINA GENTILI², ANTONELLA BUGATTI¹, FEDERICA FILIPPINI¹, ERIKA SCALTRITI⁸, STEFANO PONGOLINI⁸, ALESSANDRA TUCCI⁴, SIMONA FIORENTINI¹, PASQUALINA D'URSI⁹, MASSIMO CICCOZZI⁹, PIERLUIGI MAURI³, ROBERTA RIZZO², AND ARNALDO CARUSO¹

¹Department of Molecular and Translational Medicine, Section of Microbiology, *University of Brescia, Brescia, Italy*; ²Department of Chemical, Pharmaceutical and Agricultural Sciences, *University of Ferrara, Ferrara, Italy*; ³Proteomic and Metabolomic Laboratory, *Institute of Biomedical Technologies, National Research Council, Segrate, Italy*; ⁴Department of Hematology, *ASST Spedali Civili di Brescia, Brescia, Italy*; ⁵Department of Molecular and Translational Medicine, *Section of Experimental Oncology and Immunology, University of Brescia, Brescia, Italy*; ⁶Laboratório de Flavivírus, *Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil*; ⁷Laboratório de Genética Celular e Molecular, *Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil*; ⁸Risk Analysis and Genomic Epidemiology Unit, *Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia-Romagna, Parma, Italy*; ⁹Institute of Technologies in Biomedicine, *National Research Council, Segrate, Italy*; ¹⁰Unit of Medical Statistics and Molecular Epidemiology, *University Campus Bio-Medico of Rome, Rome, Italy*.

Introduction: Since the beginning of the pandemic, different Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, defined as a variant of concern (VOC), have arisen worldwide. It has been suggested that the emergence

of VOCs has possibly occurred in immunocompromised patients who allowed intra-host persistent infection and variations in viral population. The RNA virus population consists of an ensemble of replicating viruses characterized by closely related sequences termed quasi-species, allowing RNA viruses to have a greater possibility to find the best adapting quasi-species to the specific host. However, the underlying mechanism leading to the emergence of VOCs during viral persistence in the immunocompromised host is still unknown. Here, we describe the existence of an ensemble of minor mutants in the early biological samples obtained from an immunocompromised patient and their dynamic interplay with the master mutant during a persistent and productive long-term infection. **Materials and methods:** RNA was extracted from nasopharyngeal swabs (NPSs), libraries were generated and sequenced on Illumina MiSeq platform. Viruses were isolated from NPSs and used to perform *in vitro* assays. **Results:** We were able to follow the dynamics of the intra-host evolution during a SARS-CoV-2 prolonged infection in an immunocompromised patient. After 222 days of active viral replication the original master mutant, named MB61⁰, was replaced by a minor quasi-species (MB61²²²) expressing two critical mutations in spike, namely Q493K and N501T. Isolation of these two viruses allowed us to show that MB61²²² entry into target cells occurred mainly by the fusion at the plasma membrane (PM), whereas endocytosis characterized the entry mechanism used by MB61⁰. Co-infection of human cell lines with the SARS-CoV-2 isolates highlighted the predominance of MB61²²² over MB61⁰ replication. This finding may be explained by the capability of MB61²²² to induce peculiar viral RNA sensing mechanisms leading to an increased production of Interferons (IFNs) and, in particular, of IFN-induced transmembrane protein 1 (IFITM1) and IFITM2. **Discussion and Conclusion:** On the whole, our analysis points to a crucial role of SARS-CoV-2 quasi-species in intra-host evolution aimed at achieving the best fitness to adapt to the human host. Our results propose that during SARS-CoV-2 infection host innate immunity exerts a selective pressure on quasi-species, leading to the establishment of the SARS-CoV-2 master mutant able to escape host innate responses. This finding may explain the rapid worldwide turnover of VOCs that use the PM fusion pathway to enter into target cells over the original pandemic strain.

6 - IFI16 impacts metabolic reprogramming during human cytomegalovirus infection

GLORIA GRIFFANTE ⁽¹⁾ - WERONIKA HEWELT-BELKA ⁽²⁾ - CAMILLA ALBANO ⁽¹⁾ - FRANCESCA GUGLIESI ⁽¹⁾ - SELINA PASQUERO ⁽¹⁾ - SERGIO F. CASTILLO PACHECO ⁽¹⁾ - GRETA BAJETTO ⁽¹⁾ - LINDA TRIFIRO' ⁽¹⁾ - PAOLO E. PORPORATO ⁽³⁾ - ERICA MINA ⁽³⁾ - MARTA VALLINO ⁽⁴⁾ - CHRISTIAN KRAPP ⁽⁵⁾ - MARTIN R. JAKOBSEN ⁽⁵⁾ - JOHN PURDY ⁽⁶⁾ - JENS VON EINEM ⁽⁷⁾ - SANTO LANDOLFO ⁽¹⁾ - VALENTINA DELL'OSTE ⁽¹⁾ - MATTEO BIOLATTI ⁽¹⁾

Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italia ⁽¹⁾ - Department of Analytical Chemistry, Gdańsk University of Technology, Gdańsk, Polonia ⁽²⁾ - Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italia ⁽³⁾ - Institute for Sustainable Plant Protection, CNR, Turin, Italia ⁽⁴⁾ - Department of Biomedicine, Aarhus University, Aarhus, Danimarca ⁽⁵⁾ - Department of Immunobiology, University of Arizona, Tucson, Stati Uniti D'america ⁽⁶⁾ - Institute of Virology, Ulm University Medical Center, Ulm, Germania ⁽⁷⁾

IFI16 impacts metabolic reprogramming during human cytomegalovirus infection

GLORIA GRIFFANTE,¹ WERONIKA HEWELT-BELKA,² CAMILLA ALBANO,¹ FRANCESCA GUGLIESI,¹ SELINA PASQUERO,¹ SERGIO F. CASTILLO PACHECO,¹ GRETA BAJETTO,¹ LINDA TRIFIRO',¹ PAOLO E. PORPORATO,³ ERICA MINA,³ MARTA VALLINO,⁴ CHRISTIAN KRAPP,⁵ MARTIN R. JAKOBSEN,⁵ JOHN PURDY,⁶ JENS VON EINEM,⁷ SANTO LANDOLFO,¹ VALENTINA DELL'OSTE,¹ MATTEO BIOLATTI¹

¹Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy; ²Department of Analytical Chemistry, Gdańsk University of Technology, Gdańsk, Poland; ³Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy; ⁴Institute for Sustainable Plant Protection, CNR, Turin, Italy; ⁵Department of Biomedicine, Aarhus University, Aarhus, Denmark; ⁶Department of Immunobiology, University of Arizona, Tucson, Arizona, USA; ⁷Institute of Virology, Ulm University Medical Center, Ulm, Germany.

Cellular lipid metabolism plays a pivotal role in human cytomegalovirus (HCMV) infection, as increased lipogenesis in HCMV-infected cells favors the envelopment of newly synthesized viral particles. As all cells are equipped with restriction factors able to exert a protective effect against invading pathogens, we asked whether a similar defense mechanism would also be in place to preserve the metabolic compartment from HCMV infection.

Here, we show that gamma interferon (IFN-gamma)-inducible protein 16 (IFI16), an restriction factor able to block HCMV DNA synthesis, can also counteract HCMV-mediated metabolic reprogramming in infected primary human foreskin fibroblasts (HFFs), thereby limiting virion infectivity. Specifically, we find that IFI16 downregulates the transcriptional activation of the glucose transporter 4 (GLUT4) through cooperation with the carbohydrate-response element-binding protein (ChREBP), thereby reducing HCMV-induced transcription of lipogenic enzymes. The resulting decrease in glucose uptake and consumption leads to diminished lipid synthesis, which ultimately curbs the *de novo* formation of enveloped viral particles in infected HFFs. Consistently, untargeted lipidomic analysis shows enhanced cholesteryl ester levels in IFI16 KO versus wild-type (WT) HFFs.

Overall, our data unveil a new role of IFI16 in the regulation of glucose and lipid metabolism upon HCMV replication and uncover new potential targets for the development of novel antiviral therapies.

19 - Mesenchymal stem cells are susceptible but non-permissive to B19V replication

[erika fasano](#) ⁽¹⁾

dipartimento di farmacia e biotecnologie, università di Bologna, bologna, Italia ⁽¹⁾

Mesenchymal stem cells are susceptible but non-permissive to B19V replication

ERIKA FASANO¹, GLORIA BUA¹, PASQUALE MARRAZZO², FRANCESCO ALVIANO², LAURA BONSI², GIORGIO GALLINELLA¹

¹Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.

²Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Mesenchymal stromal cells (MSCs) are multipotent stem cells with high expansion potential and self-renewal capacity. Their main characteristic is the ability to differentiate in vitro into multiple lineages, including osteocytes, chondrocytes, adipocytes and endothelial-like cells. Due to these characteristics, MSCs are good candidates for regenerative medicine and cell therapy strategies. The risk of transmitting viruses from ex vivo expanded MSCs is of particular concern, especially in immunosuppressed patients. Parvovirus B19 (B19V) is a human pathogenic virus with a specific tropism for bone marrow erythroid progenitor cells and the property to persist in several tissue types, including bone marrow. The virus can also cross the placenta and infect fetal erythroid progenitors. Thus, we investigated the susceptibility and permissiveness of bone marrow and placenta-derived MSCs to B19V to understand their potential role in the risk of B19V transmission. Mononuclear cells were isolated by Ficoll-Paque centrifugation of bone marrow blood from healthy donors and grown in DMEM containing 20% FBS at 37°C in 5% CO₂. Non-adherent cells were removed after one week and medium regularly changed. Expression of surface antigens, specific for defining the identity of MSCs, was measured by flow cytometry, as well B19V receptor. For infection experiments, cells were inoculated with B19V viremic serum in order to obtain a moi of 10⁴ geq/cell. After the absorption period of 2 h at 37°C, infected cells were washed and seeded at an initial density of 10⁶ cell/ml. Aliquots of cells were collected at different time post infection and analyzed for the presence of viral DNA and RNA by qPCR and qRT-PCR assays. Cells expressed the standard MSC markers, such as CD29, CD44, CD73, CD90, and OCT-4 and expression was maintained after infection. The B19V receptor globoside was expressed in most cells. Viral DNA became associated to cells, but analysis of viral nucleic acids revealed that neither replicative nor transcriptional activity occurred. However, viral DNA persisted in late time post infection. Our results showed that MSCs are susceptible but not a permissive environment to B19V productive infection and the presence of B19V DNA did not alter the expression profile of surface antigens. Further investigations are needed to understand the possible consequences on the cell physiology, like an impaired differentiation ability, as well the capability of virus reactivation after cell differentiation.

21 - Coinfection by Human Cytomegalovirus and Herpesvirus type 6 can trigger cell fibrosis: possible impact on scleroderma.

Irene Soffritti⁽¹⁾ - Maria D'Accolti⁽¹⁾ - Clara Maccari⁽²⁾ - Francesca Bini⁽¹⁾ - Eleonora Mazziga⁽¹⁾ - Cristina Arcangeletti⁽²⁾ - Elisabetta Caselli⁽¹⁾

University of Ferrara, Department of Chemical, Pharmaceutical and Agricultural Sciences, Section of Microbiology, CIAS research Center and LTTA, Ferrara, Italia⁽¹⁾ - University of Parma, Department of Medicine and Surgery, Parma, Italia⁽²⁾

Coinfection by Human Cytomegalovirus and Herpesvirus type 6 can trigger cell fibrosis: possible impact on scleroderma.

IRENE SOFFRITTI¹, MARIA D'ACCOLTI¹, CLARA MACCARI², FRANCESCA BINI¹, ELEONORA MAZZIGA¹, CRISTINA ARCANGELETTI² AND ELISABETTA CASELLI¹

¹*Department of Chemical, Pharmaceutical and Agricultural Sciences, Section of Microbiology, CIAS research Center and LTTA, University of Ferrara, Ferrara, Italy*

²*Department of Medicine and Surgery, University of Parma, Parma, Italy*

Introduction: Human cytomegalovirus (HCMV) and Human herpesvirus type-6A (HHV-6A) have been reportedly suggested as triggers of the onset and/or progression of many autoimmune diseases, including systemic sclerosis (SSc), a severe autoimmune disease characterized by vasculopathy and multi-organ fibrosis. Both viruses have a tropism for endothelial and fibroblast cells, deeply involved in SSc disease; *in vitro* infection with HCMV and HHV-6 induced the expression of pro-fibrotic factors in primary human dermal fibroblasts and modulated the expression of miRNAs recognized for their key function in fibrosis. Although these two viruses are often simultaneously reactivating in the adult host, where they can enhance each other, no data are available on their joint effect. Thus, we wanted to assess whether the co-infection by HCMV and HHV-6 could trigger cell fibrosis more than either virus alone. To this purpose, primary human dermal fibroblasts, were individually infected or co-infected with HCMV and HHV-6A, and the expression of miRNAs and cell factors correlated to fibrosis/apoptosis was investigated.

Materials and Methods: Human primary dermal fibroblasts were infected *in vitro* with cell-free inocula of HCMV and HHV-6A, and at different times post infection (0, 1, 2, 4, 7 and 10 d.p.i.) were collected to extract nucleic acids. The analysis was carried out by specific qPCR microarrays, detecting and quantifying 84 human microRNAs associated with cell fibrosis, and 84 factors associated with fibrosis or apoptosis.

Results: Concurrent HCMV/HHV-6A infection significantly modulated the expression of up to 58 miRNAs, 57 fibrosis-associated and 42 apoptosis-associated factors, evidencing significant differences between double-infected and single-infected cells and showing for the first time that the two viruses can cooperate in inducing alterations potentially leading to cell fibrosis.

Discussion and Conclusions: HCMV/HHV-6A infection profoundly remodulate miRNAs and transcriptional factors in human dermal fibroblasts. The correlation between these *in vitro* results with *in vivo* observations support a role of HCMV and HHV-6 in the multistep pathogenesis of fibrosis in SSc. Further work is required to definitely answer the question of whether beta-herpesviruses are causally linked to the disease and to enable the possible use of targeted antiviral treatments to improve clinical outcome.

27 - Prevalence analysis of urinary and plasma JCPyV, BKPyV, MCPyV, HPyV6, HPyV7 and QPyV in patients infected with HIV-1.

Sara Passerini⁽¹⁾ - Carla Prezioso⁽¹⁾ - Annalisa Prota⁽¹⁾ - Luigi Coppola⁽²⁾ - Alessandra Lodi⁽²⁾ - Anna Chiara Epifani⁽²⁾ - Loredana Sarmati⁽²⁾ - Massimo Andreoni⁽²⁾ - Ugo Moens⁽³⁾ - Marco Ciotti⁽⁴⁾ - Valeria Pietropaolo⁽¹⁾

“Sapienza” University of Rome, Department of Public Health and Infectious Diseases, Roma, Italia⁽¹⁾
- Tor Vergata University, Clinical Infectious Diseases, Department of System Medicine, Roma, Italia⁽²⁾
- University of Tromsø - The Arctic University of Norway, Faculty of Health Sciences, Department of Medical Biology, Tromsø, Norvegia⁽³⁾ - Polyclinic Tor Vergata Foundation, Virology Unit, Roma, Italia⁽⁴⁾

Prevalence analysis of urinary and plasma JCPyV, BKPyV, MCPyV, HPyV6, HPyV7 and QPyV in patients infected with HIV-1.

SARA PASSERINI¹, CARLA PREZIOSO^{1,2}, ANNALISA PROTA¹, LUIGI COPPOLA³, ALESSANDRA LODI³, ANNA CHIARA EPIFANI³, LOREDANA SARMATI³, MASSIMO ANDREONI³, UGO MOENS⁴, MARCO CIOTTI⁵, VALERIA PIETROPAOLO²

¹Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Rome, Italy; ²IRCSS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, Rome, Italy; ³Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy; ⁴Faculty of Health Sciences, Department of Medical Biology, University of Tromsø - The Arctic University of Norway, Tromsø, Norway; ⁵Virology Unit, Polyclinic Tor Vergata Foundation, Rome, Italy.

Introduction: a direct link between immunosuppression and the development of opportunistic infections has been established and it is also known that Human polyomaviruses (HPyVs), that commonly infects healthy humans, have a clearly established potential for causing severe organ damage or malignant transformation, especially in individuals with weakened immunity. For this reason, since it is well defined that HIV/AIDS predisposes to viral infection, persistence, or reactivation, in this study the HPyVs prevalence among HIV-1 infected patients and a possible correlation between HPyVs and HIV sero-status, were investigated.

Materials and Methods: qualitative PCR were performed to amplify the Viral Capsid protein 1 (VP1) and the Large T antigen (LT) of JCPyV, BKPyV, MCPyV, HPyV6, HPyV7 and QPyV. Samples tested positive to HPyVs DNA detection were subjected to a quantitative real time PCR (qPCR) in order to quantify the DNA viral amount. The Non-Coding Control Regions (NCCRs) of samples tested positive, were also amplified by nested PCR.

Results: Forty-four urine (44/78, 56%) and 16/78 (20,5%) plasma samples resulted positive for JCPyV, while 19 out of 78 urine (24%) and 4/78 (5%) plasma samples were positive for BKPyV. MCPyV was detected in 22 out of 78 urine (28%) and in 8 out of 78 plasma sample (10%); HPyV6, HPyV7 and QPyV, were not detected in any sample. qPCR showed a JCPyV load mean value of 3×10^7 in urine and of 6×10^5 in plasma. For BKPyV the viral load mean value was of 1×10^5 in urine and of 2.5×10^3 in plasma. Finally, the MCPyV load mean value was of 5×10^3 in urine and of 1×10^3 in plasma. The Non-Coding Control Region (NCCR) of HPyVs positive samples was amplified by nested PCR and sequenced. As expected, results showed an archetype NCCR structure organization in all analyzed urine samples and in MCPyV plasma samples. An archetype NCCR organization with the occurrence of some points mutations was observed in all JCPyV and BKPyV plasma samples.

The detection of HPyVs shown a significant correlation with a low level of CD4+, around 200 CD4+/mm³, supporting a possible role of HIV in HPyVs infection. No significant association was found between the presence of HPyVs DNA and HPyVs viral loads versus age, gender and HIV-1 load at enrollment.

Discussion and Conclusions: further studies are warranted in order to define the clinical importance of JCPyV, BKPyV and MCPyV DNA detection in HIV-1 patients. HPyV6, HPyV7 and QPyV, instead, were not detected in any sample confirming, as previously described, that these HPyVs seems not to have a clinical relevance in these patients.

28 - CLINICAL AND PROGNOSTIC SIGNIFICANCE OF MERKEL CELL POLYOMAVIRUS (MCPyV) IN NON-SMALL CELL LUNG CANCER (NSCLC)

Carla Prezioso⁽¹⁾ - Sara Passerini⁽¹⁾ - Angelina Pernazza⁽²⁾ - Valeria Di Maio⁽²⁾ - Ugo Moens⁽³⁾ - Giulia D'Amati⁽⁴⁾ - Valeria Pietropaolo⁽¹⁾

Sapienza University, Department of Public Health and Infectious Diseases, Rome, Italia⁽¹⁾ - Sapienza University-Polo Pontino, Department of Medico-Surgical Sciences and Biotechnologies, Latina, Italia⁽²⁾ - The Arctic University of Norway, Department of Medical Biology, Tromsø, Norvegia⁽³⁾ - Sapienza University, Department of Radiological, Oncological, and Pathological Sciences, Rome, Italia⁽⁴⁾

CLINICAL AND PROGNOSTIC SIGNIFICANCE OF MERKEL CELL POLYOMAVIRUS (MCPyV) IN NON-SMALL CELL LUNG CANCER (NSCLC)

CARLA PREZIOSO^{1,2}, SARA PASSERINI¹, ANGELINA PERNAZZA³, VALERIA DI MAIO³, UGO MOENS⁴, GIULIA D'AMATI⁵, VALERIA PIETROPAOLO¹.

¹Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy; ²IRCSS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, Rome Italy; ³ Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino- Sapienza University, Latina, Italy; ⁴Faculty of Health Sciences, Department of Medical Biology, University of Tromsø - The Arctic University of Norway, Tromsø, Norway; ⁵Department of Radiological, Oncological, and Pathological Sciences, Sapienza University, Rome, Italy.

Background: Merkel cell polyomavirus (MCPyV) is a double-stranded DNA virus associated with Merkel cell carcinoma (MCC). Considering the widespread prevalence of the virus across the body, the involvement of MCPyV in tumours other than MCC, such as non-small-cell lung carcinoma (NSCLC), cannot be excluded. A potential association between MCPyV infection and EGFR expression it has also been suggested since BRAF gene, a downstream target of EGFR pathway, was found to be higher expressed in MCPyV+ samples than negative ones. Moreover, this correlation, it would seem associated with worse prognosis. Therefore, in this study the prevalence of MCPyV in NSCLC, and the prognosis through the screening of EGFR were investigated.

Materials and Methods: Formalin-fixed paraffin-embedded tissue (FFPE) and corresponding nonmalignant lung tissue were obtained from 90 NSCLC patients. After DNA and RNA extraction, to detect MCPyV DNA, a quantitative real-time PCR (qPCR) was performed. To study the expression of viral RNA transcripts and virally encoded protein, a qualitative PCR, employing three set of primers (LT1, LT3 and VP1), was used. EGFR mutation analysis was carried out. PCR products were sequenced in service.

Results: MCPyV DNA was detected in 14/90 FFPE and in 1/90 nonmalignant lung tissue. qPCR showed viral DNA loads ranging from 1×10^2 to 5.5×10^2 copies/ug. By qualitative PCR, MCPyV DNA were detected in 3 samples with LT1 primer, in 7 with LT3 primer, and in 4 with VP1 primer. Four of ten samples also expressed the LT gene transcript, whereas no VP1 gene transcript was found. Sequence analysis of the LT gene of these 4 samples, showed in 3 samples, amino-acid substitutions at the C terminus of LT. None of these mutations caused stop codons. In contrast, the LT gene of 1 tumor, presented a frameshift mutation which generated stop codons. These mutations occurred downstream from the Rb-binding domain causing a truncated exon 2 encoding LT helicase. Analysis of EGFR showed that the infection rate of MCPyV, was higher in NSCLCs with EGFR mutations than without EGFR mutations; however, this difference was not statistically significant (>0.05).

Discussion and Conclusions: Although the viral prevalence in NSCLCs was low, the tumor-specific molecular signatures support the possibility that MCPyV could be associated with the pathogenesis of NSCLCs. Moreover, since MCPyV infection is observed in occurrence of EGFR mutation, our results could indicate that MCPyV could be considered an EGFR mutagen and might spark interests to deepen the prognostic value of EGFR in NSCLCs.

29 - Prevalence of Merkel cell polyomaviruses, human polyomaviruses 6, 7 and Trichodysplasia Spinulosa-associated polyomaviruses in Actinic Keratosis Biopsy Specimens

Carla Prezioso ⁽¹⁾ - Gabriele Brazzini ⁽²⁾ - Sara Passerini ⁽²⁾ - Carlotta Di Fabio ⁽³⁾ - Terenzio Cosio ⁽⁴⁾ - Sergio Bernardini ⁽⁴⁾ - Elena Campione ⁽³⁾ - Ugo Moens ⁽⁵⁾ - Valeria Pietropaolo ⁽²⁾ - Marco Ciotti ⁽⁶⁾

IRCSS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, 00163 Rome, Italy, IRCSS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, 00163 Rome, Italy;; Roma, Italia ⁽¹⁾ - Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy;; Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy;; Roma, Italia ⁽²⁾ - Department of Systems Medicine, Dermatology Unit, Tor Vergata University Hospital, 00133 Rome, Italy;; Department of Systems Medicine, Dermatology Unit, Tor Vergata University Hospital, 00133 Rome, Italy;; Roma, Italia ⁽³⁾ - Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Roma, Italia ⁽⁴⁾ - Department of Medical Biology, Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, 9037 Tromsø, Norway;; Department of Medical Biology, Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, 9037 Tromsø, Norway;; Tromsø, Norvegia ⁽⁵⁾ - Virology Unit, Polyclinic Tor Vergata Foundation, Viale Oxford 81, 00133 Rome, Italy., Virology Unit, Polyclinic Tor Vergata Foundation, Viale Oxford 81, 00133 Rome, Italy., Roma, Italia ⁽⁶⁾

Prevalence of Merkel cell polyomaviruses, human polyomaviruses 6, 7 and Trichodysplasia Spinulosa-associated polyomaviruses in Actinic Keratosis Biopsy Specimens

Carla PREZIOSO^{1,2}, Gabriele BRAZZINI², Sara PASSERINI², Carlotta DI FABIO³, Terenzio COSIO^{3,4}, Sergio BERNARDINI⁴, Elena CAMPIONE³, Ugo MOENS⁵, Valeria PIETROPAOLO², Marco CIOTTI⁶

¹IRCSS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, 00163 Rome, Italy;

²Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, 00185 Rome, Italy;

³Department of Systems Medicine, Dermatology Unit, Tor Vergata University Hospital, 00133 Rome, Italy;

⁴Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;

⁵Department of Medical Biology, Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, 9037 Tromsø, Norway;

⁶Virology Unit, Polyclinic Tor Vergata Foundation, Viale Oxford 81, 00133 Rome, Italy.

Introduction: To date, 14 human polyomaviruses (HpyVs) have been identified using high-throughput technologies. Among them, Merkel cell polyomaviruses (MCPyV), human polyomaviruses (HpyV6, HpyV7) and Trichodysplasia Spinulosa-associated polyomaviruses (TSPyV) present a skin tropism, but a causal role in skin diseases has been established only for MCPyV as causative agent of Merkel cell carcinoma (MCC) and TSPyV as etiological agent of Trichodysplasia Spinulosa (TS). In this study, we investigated the prevalence of MCPyV, HpyV6, HpyV7 and TSPyV in actinic keratosis (AK).

Materials & Methods: Nine consecutive patients with clinical diagnosis of AK have been recruited in our center. A lesional and a non-lesional skin biopsy have been performed in each patient to confirm clinical diagnosis and to investigate the prevalence of MCPyV, HpyV6, HpyV7 and TSPyV in AK, a premalignant skin lesion that has the potential to progress towards a squamous cell carcinoma (SCC). Positive HpyVs DNA samples were subjected to qualitative PCR with different specific primer pairs mapping VP1 and LT regions of the genome and subsequently sequenced.

Results: Nine patients with a mean age of 78.56 years, all male, have been enrolled in this study. All the lesions were found on the scalp, the 78% of AK were grade I (according to Olsen 1991); 22% of the lesions was Bowenoid AK, while 78% was atrophic AK at histological analyze. The presence of MCPyV, HPyV6, HPyV7 and TSPyV DNA in lesion and non-lesion skin sections was determined by qualitative PCR. MCPyV DNA was analyzed using primers amplifying the VP1 region of the genome (307bp). MCPyV DNA was found in all lesion tissue samples (9/9; 100%), and in 6/8 (75%) non-lesion biopsy samples. This finding confirms that MCPyV is part of cutaneous microbiota and is commonly isolated from skin samples of adult subjects. A qualitative PCR analysis, using primers amplifying the LT region of the genome was performed to find HPyV6 and HPyV7. HPyV6 was found only in 1/8 (12.5%) healthy tissue samples, while HPyV7 was not found in any samples. In this study none of the biopsies tested were found positive for TSPyV. All biopsy samples found positive for MCPyV showed a wild type VP1 sequence. P1, found positive to HPyV6, showed a LT sequence with two-point mutation, compared to the reference one: the first is 73A>G and the second is 135A>G.

Discussion: These results seem to confirm that HPyV6 is, like MCPyV, part of the skin microbiota whereas, the absence of HPyV6 and HPyV7 in AK samples could confirm that these two HPyVs are not involved in cutaneous malignancies. Future research to establish a possible role of MCPyV, HPyV6, HPyV7, and TSPyV in AK should include investigation of the genome copy number, the state of the viral genome, and the expression of viral genes.

32 - Epidemiology of viral agents causing acute gastroenteritis in children in Northern Italy (2019-2021): focus on Norovirus circulation.

Flora De Conto ⁽¹⁾ - [Sharon Di Stefano](#) ⁽¹⁾ - Giulia Montanari ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Adriana Calderaro ⁽¹⁾

Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾

Epidemiology of viral agents causing acute gastroenteritis in children in Northern Italy (2019-2021): focus on Norovirus circulation.

FLORA DE CONTO, SHARON DI STEFANO, GIULIA MONTANARI, MARIA CRISTINA ARCANGELETTI, MIRKO BUTTRINI, SARA MONTECCHINI, CARLO CHEZZI, ADRIANA CALDERARO

Department of Medicine and Surgery - University of Parma - Parma - Italy

Introduction. Acute gastroenteritis (AGE) with viral aetiology are a leading cause of mortality and morbidity, especially among children. There are nearly 1.7 billion cases of childhood diarrheal disease worldwide every year. Rapid diagnosis optimizes patient treatment and reduces hospitalization. This survey carried out in Parma (Northern Italy) from 2019 to 2021 aimed to assess the viral epidemiology of AGE in children using a multiplex polymerase-chain reaction (PCR) platform, and focusing on Norovirus (NoV) genogroup GI/GII dynamics.

Materials and Methods. In this study, 2,026 stool samples from as many children aged 0-14 years with AGE symptoms (vomiting, diarrhoea, abdominal pain, dehydration, and fever) were analysed with FilmArray Gastrointestinal Panel (BioFire Diagnostics) and Enterovirus-targeting PCR (BioMérieux). Conventional diagnostic assays (culture isolation and microscopic examination) were also carried out. Laboratory diagnosis was performed upon medical order.

Results. Overall, 1,386 potential enteric pathogens (bacteria, viruses and parasites) were detected in 1,001 (1,001/2,026, 49.4%) samples, as single or mixed infections. Of these, 515 viruses (515/1,386, 37.1%) were detected in 450 samples (450/2,026, 22.2%; 49.4% *vs* 22.2%, $P < 0.0001$). NoV was most frequently detected (161/1,386, 11.6%), followed by Enterovirus (109/1,386, 7.9%) and Rotavirus (99/1,386, 7.1%). NoV single infections (92/161, 57.1%) prevailed on mixed infections (69/161, 42.9%). NoV prevalence was highest in reference to total viruses detected in each year (66/266, 24.8% in 2019, 35/94, 37.2% in 2020, and 60/155, 38.7% in 2021, respectively). The NoV rate decreased in 2020 when compared to 2019 and 2021 (- 46.9% *vs* 2019 and - 41.6% *vs* 2021). In 2021, NoV rate was similar to that of 2019 (60 *vs* 66 cases, respectively). Viral AGE mostly affected children aged 0-5 years (376/450, 83.5%), male (258/450, 57.3%) and inpatients (286/450, 63.5%). Similarly, NoV was more frequent in children aged 0-5 years (133/450, 29.5%), male (103/450, 22.8%) and inpatients (103/450, 22.8%). NoV showed seasonal prevalence in winter in 2019 and 2021, while it was not found from April to October 2020.

Discussion and Conclusions. A prompt molecular diagnosis improves the surveillance of the burden associated to AGE, increasing the sensitivity of pathogen detection. Using a multiplex PCR, we found a highest prevalence of NoV mainly in young inpatients, highlighting the occurrence of severe AGE requiring hospitalization. NoV rate decreased in 2020, probably as a consequence of the SARS-CoV-2 pandemic, imposing a strengthening of restriction measures and decreasing the number of samples received. This aspect deserves attention, since NoV may cause severe AGE and vaccines are still under study.

39 - Genomic sequence analysis of 8 SARS-CoV-2 strains circulating in Parma (Northern Italy) during the first and the second wave of COVID-19 pandemic.

Giovanna Piccolo ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Greta Romano ⁽¹⁾ - Benedetta Farina ⁽¹⁾
- Maria Cristina Arcangeletti ⁽¹⁾ - Flora De Conto ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Adriana Calderaro ⁽¹⁾

Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾

Genomic sequence analysis of 8 SARS-CoV-2 strains circulating in Parma (Northern Italy) during the first and the second wave of COVID-19 pandemic.

GIOVANNA PICCOLO, SARA MONTECCHINI, MIRKO BUTTRINI, GRETA ROMANO, BENEDETTA FARINA, MARIA CRISTINA ARCANGELETTI, FLORA DE CONTO, CARLO CHEZZI, ADRIANA CALDERARO.

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Introduction. A growing number of emerging SARS-CoV-2 variants is being identified worldwide, impacting on COVID-19 severity, transmission, diagnostics, therapeutics, and natural and vaccine-induced immunity. This study reports the genomic sequences of 8 SARS-CoV-2 strains from patients with respiratory disease admitted to the University Hospital of Parma (Italy) during the first (February-May 2020) and the second (October 2020-March 2021) wave of the pandemic.

Materials and Methods. The detection of SARS-CoV-2 RNA in 8 samples (and in 4 cases also after cell culture detection) was carried out by rRT-PCR of the Centers for Disease Control and Prevention (CDC, Atlanta, USA) after RNA extraction by “EASYMAG®/EMAG®” (Biomérieux, France) or “Nimbus IVD” (Seegene Inc, Seoul, Korea). The amount of extracted RNA was checked by “Nanodrop” (Thermo Fisher Scientific, Inc) and 3 were sent to the company “Biogem S.c.a.r.l.” (Ariano Irpino, Italy) and 5 to “IGA Technology Services” (Udine, Italy) for the sequence analysis.

Results. The most common mutation observed in 7/8 strains was the A-to-G mutation at position 23,403 of the Wuhan reference strains resulting in SARS-CoV-2 “D614G variant” that leads to the Spike protein amino acid change “D614G” (which alters infectivity and virulence and can increase the mortality). FASTA was available only for 5 strains: “PangoLEARN” software identified these strains as “SARS-CoV-2 variants” in comparison with the reference SARS-CoV-2 strain “MN908947.3” and the following lineages were assigned: 3 United Kingdom (variant α)-Lineage B.1.1.7, 1 Large European Lineage B.1.160 and 1 South Africa (variant β)-Lineage B.1.351. The genomic sequences of these strains were deposited in GISAID; the remaining 3 strains are under investigation for the lineage assignment.

Discussion and Conclusions. In the study, as expected with respect to the variants circulating in Europe during the study period, we found 3 “B.1.1.7-variant α United Kingdom” and one “B.1.351-variant β South Africa”. Moreover, one strain detected in a nasal swab of a one-year-old Indian infant, belonged to lineage B.1.160 named variant “Large European Lineage”. This variant represents an EU/EEA and UK multi-country cluster circulating in Belgium, France, Germany, the United Kingdom, and Italy and has recently been shown to be responsible for the first evidence of transmission from human to dog. Phylogenetic analysis and homology modelling have added knowledge to the fine details of SARS-CoV-2, as well as the studies exploring the genome of the virus and the structure of its proteins. The continuous search for viral variants with decreased or increased pathogenic potential would be a significant step and it should be routinely performed.

48 - Study of Parvovirus B19 translocation across the placenta using the BeWo model

Gloria Bua ⁽¹⁾ - Francesca Bonvicini ⁽¹⁾ - Erika Fasano ⁽¹⁾ - Elisabetta Manaresi ⁽¹⁾ - Giorgio Gallinella ⁽¹⁾

Università di Bologna, Dipartimento di Farmacia e Biotecnologie, Bologna, Italia ⁽¹⁾

Study of Parvovirus B19 translocation across the placenta using the BeWo model

GLORIA BUA, FRANCESCA BONVICINI, ERIKA FASANO, ELISABETTA MANARESI, GIORGIO GALLINELLA
Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy

Introduction

Parvovirus B19 (B19V) is a human pathogenic virus characterized by a selective but not exclusive tropism for erythroid progenitor cells. In pregnancy, B19V poses a potential risk to the fetus as it can spread transplacentally leading to serious fetal complications such as anemia and hydrops, cardiomegaly and pericardial effusion, spontaneous abortions and intrauterine death. Although the etiologic role of B19V in these adverse outcomes has been widely recognized, the interaction between B19V and the human trophoblasts cells within the placenta has not yet been comprehensively explained.

Materials and Methods

We have therefore established *in vitro* experimental models based on the BeWo human choriocarcinoma cell line. BeWo cells show trophoblast-like appearance and form a confluent, polarized monolayer resembling first trimester placenta in structure and function; they can also be induced to undergo terminal differentiation and syncytialization, thus mimicking a mature placenta, when cultured in the presence of forskolin. A BeWo polarized monolayer using a collagen-coated membrane as scaffold was established, where the integrity was validated by cell morphology, biophysical features, and immunostaining of specific membrane proteins. Once obtained, these experimental models were used to detail B19V infection of human trophoblasts, and its transport across the placental barrier.

Results

The presence of the globoside as a cellular receptor was confirmed by cytofluorimetric analysis both on the cytotrophoblasts and on the syncytiotrophoblasts and evaluated at similar levels ($25.7 \pm 10\%$ and $28.1 \pm 9.8\%$, respectively). No evidence of productive infection was observed in the undifferentiated and forskolin-treated BeWo cells ($50 \mu\text{M}$) since viral DNA amounts gradually decreased in cells and in the corresponding supernatants. In addition, no mRNAs and accumulation of capsid proteins were detected in the unpolarized BeWo cell monolayers along a time course of infection, up to 72h. In polarized trophoblasts, a transcytosis mechanism can occur as demonstrated by kinetics of viral DNA accumulation.

Discussion and Conclusions

Knowledge on how B19V interacts with maternal-fetal interface will help to establish a suitable system to evaluate the effectiveness of the protective mechanisms operated by maternal antibodies against intrauterine infection, to assess the inhibitory activity of antiviral drugs and other therapeutic options that are not currently present.

53 - Transcriptional analysis of human bronchial epithelial cells with and without CFTR modification after SARS-CoV-2 infection

Anna Lagni⁽¹⁾ - Virginia Lotti⁽¹⁾ - [Erica Diani](#)⁽¹⁾ - Chiara Cascianelli⁽²⁾ - Claudio Sorio⁽³⁾ - Pier Paolo Piccaluga⁽²⁾ - Davide Gibellini⁽¹⁾

Università di Verona, Dipartimento di Diagnostica e Sanità Pubblica, Verona, Italia⁽¹⁾ - Università di Bologna, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Bologna, Italia⁽²⁾ - Università di Verona, Dipartimento di Medicina, Verona, Italia⁽³⁾

Transcriptional analysis of human bronchial epithelial cells with and without CFTR modification after SARS-CoV-2 infection

Anna Lagni¹, Virginia Lotti¹, [Erica Diani](#)¹, Chiara Cascianelli², Claudio Sorio³, Pier Paolo Piccaluga^{2,4,5,6}, Davide Gibellini¹

¹ Department of Diagnostic and Public Health, Verona University, 37134 Verona, Italy; ² Department of Experimental, Diagnostic, and Specialty Medicine, Institute of Hematology and Medical Oncology “L. and A. Seràgnoli”, University of Bologna School of Medicine, 40126 Bologna, Italy; ³ Department of Medicine, Verona University, 37134 Verona, Italy; ⁴ SBT - Biomolecular Strategies, Genetics and Cutting-Edge Therapies, Istituto Euro-Mediterraneo di Scienza e Tecnologia (IEMEST), 90139 Palermo, Italy; ⁵ Department of Pathology, School of Medicine, Jomo Kenyatta University of Agriculture and Technology, Juja 01001, Kenya; ⁶ School of Medicine, Nanchang University, Nanchang 330047, China

Introduction: Some evidence showed reduced spread of SARS-CoV-2 in people with cystic fibrosis, suggesting a complex regulation of SARS-CoV-2 replication. **Lotti et al demonstrated, by in vitro molecular analysis of SARS-CoV-2 infection in CFBE41o- cells, a higher viral load in WT cells compared to CFTR-modified one. Since the possible mechanism was not clarified, we** tried to shed light on this difference in SARS-CoV-2 infection, investigating the transcriptional landscape of the human bronchial epithelial cells with and without CFTR modification, before and after viral infection.

Methods: To reach our goals, we performed a global RNA sequencing of wild-type and CFTR-modified human bronchial epithelial cell lines before and after SARS-CoV-2 infection. We used Illumina library preparation protocols and run sequencing on an Illumina HiSeq2000 platform. The obtained data were firstly analysed to identify differentially expressed genes in different conditions (mutated vs wild type) and time points. To better understand the functional differences and effects of mutation or SARS-CoV-2 expression, we applied a Gene Set Enrichment Analysis (GSEA); the identified molecular signatures were explored in terms of functionally relevant sets of genes according to gene ontology and other specific categories.

Results: As first, we were able to find 716 differentially expressed genes analysing WT and CFTR-modified cells before SARS-CoV-2 infection, emphasising the different gene expression of cells related to CFTR mutation. At different time points after SARS-CoV-2 infection, in both WT and CFTR-modified cells were expressed, time dependently, different SARS-CoV-2 related genes. With the analysis of samples 96 hours after SARS-CoV-2 infection, by highlighting the different transcriptional profile present between WT and CFTR-modified cells, we were able to demonstrate that more than 800 genes, related to SARS-CoV-2 infection, were differentially expressed.

Discussion and Conclusions: We can therefore conclude that the presence of the CFTR mutation gives a distinct specific transcriptional phenotype compared to WT cells. Moreover, we demonstrate that both cell types were infected by SARS-CoV-2, even though its genes are expressed in a different, time-dependent manner. Therefore, it is possible to state the presence of distinct and different SARS-CoV-2-induced transcriptional profiles. Taken together these results, other than confirming the different behaviour of SARS-CoV-2 when infecting WT or CFTR-modified cells as we previously reported, provide crucial information on its molecular basis.

56 - Anti-HSV-1 Activity of natural raw and roasted unsalted pistachio kernels in human monocytic THP-1 and Vero cells.

Rosamaria Pennisi ⁽¹⁾ - Maria Pia Tamburello ⁽¹⁾ - Davide Barreca ⁽¹⁾ - Maria Teresa Sciortino ⁽¹⁾ - Giuseppina Mandalari ⁽¹⁾

Universita' degli Studi di Messina, Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Messina, Italia ⁽¹⁾

Anti-HSV-1 Activity of natural raw and roasted unsalted pistachio kernels in human monocytic THP-1 and Vero cells.

Rosamaria Pennisi¹, Maria Pia Tamburello¹, Davide Barreca¹, Maria Teresa Sciortino¹, Giuseppina Mandalari¹

¹Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno Alcontres, 31, 98166 Messina, Italy

Introduction. A great interest is globally devoted to the search for alternative treatment for HSV infections. To date, acyclovir and related nucleoside analogues are effective viral DNA polymerase inhibitors, though their intensive use has led to the increase of drug-resistance. Plants are rich sources of pharmacologically active agents, which provide several advantages such as reduced side effects, less resistance, low toxicity and various mechanisms of action. The purpose of the current study was to investigate the effects of natural raw (NRRE) and roasted unsalted (RURE) pistachio polyphenols-rich extracts in both human monocytic cells THP-1 and epithelial VERO cells on HSV-1 replication. **Materials and Methods.** Pistachio polyphenolic extracts were prepared following two different extraction methods, with or without *n*-hexane. Cell viability was measured by monitoring the metabolic activity over time following NRRE and RURE dose-dependent (0.2, 0.4, 0.8 mg/mL) treatment. Cells and virus dilutions were pre-treated with both extracts for 1h and mixed to allow viral adsorption. After 1 h, any unabsorbed virus was aspirated and the monolayer covered with Dulbecco's Modified Eagle's Medium containing 0.8% methylcellulose in presence of both extracts, separately. **Results and Conclusions.** The identification and quantification of phenolic compounds showed that the NRRE extracts were generally richer in polyphenolic compounds compared with RURE extracts. A better profile of cellular tolerability was reported for both NRRE and RURE extracts obtained without using *n*-hexane in both cell lines. Non-toxic concentrations of NRRE and/or RURE (0.6, 0.4 and 0.3 mg/mL) were employed to verify the antiviral effect by plaque reduction assay. In Vero cells, NRRE and RURE exhibited a significant inhibitory activity at 0.6 mg/mL and in particular, treatment with the mixture extracted with *n*-hexane determined a significant reduction of plaque numbers and size, as reported by change of morphology and by detection of micro plaques. Based on this, NRRE and RURE *n*-hexane were used to treat cells and virus suspension and detect the viral DNA and genes. We report that NRRE significantly reduced viral DNA and genes, whereas RURE mildly affected the viral DNA but partially reduced viral transcripts and protein at 0.6 mg/mL. A strong reduction was also detected in the intracellular virus production in THP-1 cells pre-treated with NRRE and RURE *n*-hexane and infected with HSV-1 by plaque assay. These data support the potential use of pistachio extracts as antiherpetic agents.

Acknowledgements: The work was funded by American Pistachio Growers (CA, USA).

58 - Broad range antiviral properties of small molecules against enveloped viruses

Paola Quaranta ⁽¹⁾ - Carmen Rita Piazza ⁽¹⁾ - Anna Corotti ⁽¹⁾ - Annalaura Brai ⁽²⁾ - Giulia Lottini ⁽¹⁾ - Michele Lai ⁽¹⁾ - Pietro Giorgio Spezia ⁽¹⁾ - Elena Dreassi ⁽²⁾ - Giulia Freer ⁽¹⁾ - Mauro Pistello ⁽¹⁾

Università di Pisa, Dipartimento di Ricerca Traslazionale e Nuove Tecnologie in Medicina, Pisa, Italia
⁽¹⁾ - Università di Siena, Dipartimento di Biotecnologia, Chimica e Farmacia, Siena, Italia ⁽²⁾

Broad range antiviral properties of small molecules against enveloped viruses

^aPaola Quaranta, ^aCarmen R. Piazza, ^aAnna Corotti, ^bAnnalaura Brai, ^aGiulia Lottini, ^aMichele Lai, ^aPietro Giorgio Spezia, ^bElena Dreassi, ^aGiulia Freer and ^{a,c}Mauro Pistello

^aRetrovirus Centre, Department of Translational Research, University of Pisa, Pisa, Italy

^bDepartment of Biotechnology, Chemistry & Pharmacy, University of Siena, Siena, Italy

^cVirology Operative Unit, Pisa University Hospital, Pisa, Italy

Introduction The global health emergency caused by the SARS-COV2 pandemic in the last 3 years has highlighted the need for broad-spectrum antiviral drugs capable of fighting new unknown viruses (panviral agents). Some panviral agents, for instance, degrades the envelope of coated viruses and are a promising weapon to prevent new pandemic waves. In this context, we have tested the antiviral effect of new oxidating small molecules(MAS). MAS, in silico designed and synthesized by University of Siena, oxidizes the lipids present on the viral envelope and hinders viral entry .

Methods To evaluate their antiviral activity, these compounds were tested against the following three viruses: Herpes simplex type 2 (HSV-2), Chikungunya (CHIKV) and Coxsackie virus B5 (COX-B5). HSV-2 and CHIKV are both enveloped viruses but have different genomes, DNA and positive single strand RNA (+ssRNA), respectively. In contrast, COXB5 is a naked virus with +ssRNA genome and used as a negative control. Cytotoxicity assays were performed to establish the range of concentration without toxic effect on cell lines used: A549 and Huh-7. The antiviral activity was evaluated by limited dilution and plaque assays by incubating viruses directly with the compounds. Western blot (WB) and real time PCR were used to confirm reduction of viral proteins in infected cells and of genome production, respectively.

Results All compounds did not show cytotoxicity up to 50 micromolar. MAS 584, 589 e 600 strongly inhibited replication of HSV-2 and CHIKV in A549 and Huh-7 cell lines, respectively. Viral proteins were also drastically reduced as demonstrated by WB. All compounds did not prevent infection by COX-B5, a nude virus.

Conclusion Selective degradation by oxidation of the viral membrane confers to MAS compounds the ability to prevent cell infections against enveloped viruses belonging to different families. It is possible to develop treatments based on these compounds that may prevent a wide range of infections. In all, MAS are promising panviral agents.

62 - The peptide A-3302-B isolated from a marine bacterium *Micromonospora* sp. inhibits HSV-2 infection by preventing the viral egress from host cells

Irene Arduino ⁽¹⁾ - Massimo Rittà ⁽¹⁾ - Rachele Francese ⁽¹⁾ - Reiko Ueoka ⁽²⁾ - Jorn Piel ⁽²⁾ - Prasat Kittakoop ⁽³⁾ - David Lembo ⁽¹⁾ - Manuela Donalisio ⁽¹⁾

Università di Torino, Dip. Scienze Cliniche e Biologiche, Orbassano, Italia ⁽¹⁾ - Institute of Microbiology, ETH Zurich, Zurich, Svizzera ⁽²⁾ - Center of Excellence on Environmental Health and Toxicology, Ministry of Higher Education, Science, Research and Innovation, Bangkok, Thailandia ⁽³⁾

The peptide A-3302-B isolated from a marine bacterium *Micromonospora* sp. inhibits HSV-2 infection by preventing the viral egress from host cells

IRENE ARDUINO¹, MASSIMO RITTA¹, RACHELE FRANCESE¹, REIKO UEOKA², JORN PIEL², PRASAT KITTAKOOP³, DAVID LEMBO¹, MANUELA DONALISIO¹

¹Department of Clinical and Biological Sciences, Laboratory of Molecular Virology and Antiviral Research, University of Turin, Orbassano, Italy; ²Institute of Microbiology, ETH Zurich, Zurich, Switzerland; ³Center of Excellence on Environmental Health and Toxicology, Ministry of Higher Education, Science, Research and Innovation, Bangkok, Thailand

Introduction. Despite antiviral drugs against herpetic infections, the increasing appearance of drug-resistant viral strains and their adverse effects prompt the research of novel antiherpetic drugs for treating lesions. Peptides obtained from natural sources have recently been considered a promising class of bioactive molecules for various biomedical applications including antiviral therapy. In this work, we investigated the antiviral activity of the peptide A-3302-B, isolated from a marine bacterium, *Micromonospora* sp. MAG 9-7, a rare actinomycete, against HSV-1, HSV-2 and HCMV.

Materials and Methods. From the purified crude extract of the strain MAG 9-7, isolated from marine sediment in Thailand, A-3302-B was identified by NMR analysis. Plaque reduction assays and virus yield reduction assays were performed to evaluate the antiviral activity in vitro. Its mechanism of action was explored by specific assays to evaluate the inhibited step of the viral replicative cycle by immunoblotting analysis, time of addition assays and transmission electron microscopy (TEM) analysis.

Results. A-3302-B exerted antiviral activity against HSV-2 with EC50 value of 14.22 microM whereas no inhibitory activity was observed against HSV-1 and HCMV. Furthermore, it was active also against an HSV-2 strain resistant to acyclovir previously generated in our laboratory. The peptide did not exert intrinsic virucidal activity and did not affect the expression of viral proteins

(ICP4, ICP8, and gD) at 4 and 16 hours post infection. Early cell membrane-virus interactions were not affected by the peptide. By contrast, A-3302-B affected later steps of the HSV-2 replicative cycle: it reduced the cell-to-cell virus spread and the transmission of the extracellular free virus by preventing the egress of HSV-2 progeny from the infected cells as demonstrated by TEM analysis.

Discussion and Conclusions. We demonstrated a specific anti-HSV-2 activity of A-3302-B. The peptide turned out to be a late inhibitor of HSV-2 infection, preventing the egress of newly produced viruses from host cells. This putative mechanism of action is supported by the following experimental evidence: (i) A-3302-B is active when administered after the viral inoculum; (ii) The expression of viral proteins and the assembly of infectious viral particles are preserved; (iii) The cell-to-cell spread of virions is inhibited in treated cellular monolayers; (iv) The release of extracellular free virus in culture supernatant is strongly reduced. The dual antiviral and the known reported anti-inflammatory activities of A-3302-B, and its effect against an acyclovir-resistant HSV-2 strain are attractive features for developing a drug to reduce the transmission of HSV-2 infections.

73 - Evaluation of the effect of time of addition of several compounds against SARS-CoV-2 and other RNA viruses

Erika Plicanti⁽¹⁾ - Giulia Lottini⁽¹⁾ - Maria Sidoti⁽¹⁾ - Rossella Fonnesu⁽¹⁾ - Paola Quaranta⁽¹⁾ - Michele Lai⁽¹⁾ - Roberta Ibba⁽²⁾ - Sandra Piras⁽²⁾ - Antonio Carta⁽²⁾ - Mauro Pistello⁽¹⁾ - Giulia Freer⁽¹⁾

Università di Pisa, Dipartimento di Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia, Pisa, Italia⁽¹⁾ - Università di Sassari, Dipartimento di medicina, chirurgia e farmacia, Sassari, Italia⁽²⁾

Evaluation of the effect of time of addition of several compounds against SARS-CoV-2 and other RNA viruses

ERIKA PLICANTI^a, GIULIA LOTTINI^{a,c}, MARIA SIDOTI^a, ROSSELLA FONNESU^{a,b}, PAOLA QUARANTA^{a,b}, MICHELE LAI^a, ROBERTA IBBA^d, SANDRA PIRAS^d, ANTONIO CARTA^d, MAURO PISTELLO^{a,b}, GIULIA FREER^a

a: Retrovirus Centre, Department of Translational Research, University of Pisa, Pisa, Italy; b: Virology Operative Unit, Pisa University Hospital, Pisa, Italy; c: Department of Medical Biotechnologies, University of Siena, Siena, Italy; d: Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy

Introduction

SARS-CoV-2 is a positive sense, single stranded RNA coronavirus that causes COVID-19, the respiratory illness responsible for the present pandemic. This pandemic highlighted lack of broad-spectrum drugs against infection by emerging viruses. Many laboratories began the search for drugs effective at blocking the onset of infection, or at blocking virus replication. In collaboration with the Pharmaceutical Chemistry group of the University of Sassari, a series of molecules of different chemical nature were selected. The antiviral activity of the molecules had previously been demonstrated on specific viruses. The aim of the study was the study of the mechanism of the antiviral activity of these compounds against SARS-CoV-2.

Materials and Methods

To evaluate the activity and the mechanism of action of the compounds against virus replication, HuH7 and VERO-TMPRSS2 cells were infected with 0.1 multiplicity of infection of SARS-CoV-2 in the presence of various concentrations of drugs. Time of addition experiments were carried out for the selected drugs to try to understand how they work and by what mechanism. Supernatants of infected cells were analyzed using qRT-PCR 48 hours post infection, while the cell lysates were analyzed by Western Blotting. These compounds were also tested against Zika Virus (ZIKV) and Vesicular Stomatitis Virus (VSV) using plaque assay on A549 cells.

Results

qRT-PCR showed that some of the drugs tested effectively inhibit SARS-CoV-2 infection, but this efficacy was only observed for a specific time of addition, different for each drug. This was also confirmed by Western Blots, which showed a reduced amount of Spike protein in infected and drug-treated cells. Plaque inhibition assays carried out by infecting cells with ZIKV showed, for some drugs, the same infection-reducing effect displayed on SARS-CoV-2, while for other compounds it detected no antiviral effect. As regards VSV, none of the compounds we tested had significant antiviral activity against it.

Discussion and conclusion

Given the encouraging results obtained, we believe that these drugs may be considered good candidates for the treatment of COVID-19. To this purpose, further studies will be needed to determine the mechanism of action of the compounds found to be most effective in inhibiting SARS-CoV-2 infection.

75 - Evaluation of neutralizing antibodies against Sars-Cov-2 in patients with Inflammatory bowel disease

Giuseppa Sanfilippo⁽¹⁾ - Emanuela Garlisi⁽²⁾ - Federica Cacioppo⁽¹⁾ - Floriana Bonura⁽¹⁾ - Giovanni M. Giammanco⁽¹⁾ - Simona De Grazia⁽¹⁾ - Donatella Ferraro⁽¹⁾

University of Palermo, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties "G. D'Alessandro", Palermo, Italia⁽¹⁾ - University of Palermo, Internal Medicine and Medical Specialties "G. D'Alessandro", Palermo, Italia⁽²⁾

Evaluation of neutralizing antibodies against Sars-Cov-2 in patients with Inflammatory bowel disease

Sanfilippo Giuseppa L., Garlisi Emanuela, Cacioppo Federica, Floriana Bonura, Giovanni M. Giammanco, Simona De Grazia and Donatella Ferraro

Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve worldwide generating new variants that are of concern because of their potential altered transmissibility and pathogenicity. The aim of this study was to evaluate the protective humoral response after administration of the second dose of vaccine (Pfizer-BioNTech mRNA BNT162b2) in patients with Inflammatory bowel disease (IBD). The results were also compared to a control group of naturally infected and uninfected vaccinated subjects in order to determine the production of vaccine-induced and naturally produced neutralizing antibodies (NtAbs) against the SARS-CoV-2 variants circulating in Italy.

Materials and methods: A total of 116 patients with IBD were recruited and divided into three subgroups according to the drug therapy administered (non-biological anti-TNF α (TNB), biological anti-TNF α (TB), and conventional therapy (TP)). The control group included 39 subjects with SARS-CoV-2 (COVID-19+) and 63 vaccinated subjects with two-dose of BNT162b2. A single serum sample from each subject in the IBD and COVID-19+ groups, collected at 35-52 days after the positive swab, was analyzed by *in vitro* live virus-neutralization test. While for the uninfected subjects, blood samples were taken at one (V1) and three months (V3) after administration of the second dose of vaccine.

Results: In IBD patients, the highest Nt Ab titers were found for the Gamma variant (5.88% TNB; 11.11% TB; 10.90% TC) while the lowest were observed against the Omicron variant (47.05% TNB; 59.25% TB; 41.81% TC). On the other hand, significantly higher Nt Ab titers were found against B.1 and Alpha in COVID-19+ and vaccines, while lower were found against Delta, Gamma and Omicron variants.

Discussion and Conclusions: Results obtained and compared with the control groups showed that, despite being subjected to immunosuppressive therapies, IBD patients after vaccination showed a protective antibody titer against SARS-CoV2 variants, except for Omicron. In conclusion, this study shows that the vaccine is effective even in subjects considered frail.

76 - CHARACTERIZATION OF THE ANTI-RHINOVIRUS ACTIVITY OF 25-HYDROXYCHOLESTEROL AND 27-HYDROXYCHOLESTEROL, AND VALIDATION ON NASAL AND BRONCHIAL HISTOCULTURES.

Andrea Civra ⁽¹⁾ - Matteo Costantino ⁽¹⁾ - Roberta Cavalli ⁽²⁾ - Marco Volante ⁽³⁾ - Giuseppe Poli ⁽¹⁾ - David Lembo ⁽¹⁾

Università di Torino, Dipartimento di Scienze Cliniche e Biologiche, Orbassano, Italia ⁽¹⁾ - Università di Torino, Dipartimento di Scienza e Tecnologia del Farmaco, Torino, Italia ⁽²⁾ - Università di Torino, Dipartimento di Oncologia, Orbassano, Italia ⁽³⁾

CHARACTERIZATION OF THE ANTI-RHINOVIRUS ACTIVITY OF 25-HYDROXYCHOLESTEROL AND 27-HYDROXYCHOLESTEROL, AND VALIDATION ON NASAL AND BRONCHIAL HISTOCULTURES

A. Civra¹, M. Costantino¹, R. Cavalli², M. Volante³, G. Poli¹, D. Lembo¹

¹Department of Clinical and Biological Sciences, University of Turin, Orbassano (Turin), Italy

²Department of Drug Science and Technology, University of Turin, Turin, Italy

³Department of Oncology, University of Turin, Orbassano (Turin), Italy

Introduction: Human rhinovirus (HRV) is a quasispecies, a highly antigenically diverse virus population endowed with a high rate of mutations. The aim of this study is to provide an empirical proof of principle of the actual greater genetic barrier of 25-hydroxycholesterol (25OHC) and 27-hydroxycholesterol (27OHC), two physiologic oxysterols and host-targeting antivirals, using HRV as a quasispecies model. Moreover, we selected 27OHC for further studies aiming at exploring further its putative potential of preclinical development.

Materials and Methods: We first tested the antiviral efficacy of 25OHC and 27OHC by focus reduction assay. The toxicity profile of both oxysterols, along with their 50% cytotoxic concentration (CC₅₀), was assessed by MTS assays and LDH assays. The ability of 25OHC or 27OHC to generate resistant strains of HRV was explored by exploiting clonal or serial passages approaches, and compared with the one of pleconaril and rupintrivir. Moreover, both the efficacy and biocompatibility of 27OHC were further validated in a challenging and predictive model, i.e. 3D in vitro fully reconstituted human nasal and bronchial epithelia from cystic fibrosis patients.

Results: 25OHC and 27OHC can block the infectivity of two different HRV strains, belonging to group A and B, at 50% effective concentrations (EC₅₀) in the low micromolar range, and are characterized by selectivity indexes (SIs=CC₅₀/EC₅₀) above 100. Moreover, we demonstrate with two different approaches that 25OHC and 27OHC do not select HRV oxysterol-resistant variants. Moreover, we demonstrate the ability of 27OHC to inhibit HRV yield in both nasal and bronchial epithelia, preventing virus-induced cilia damage.

Discussion and Conclusions: The complex of these characteristics suggests that 27OHC antiviral potential should be considered further, and provide a rationale for further studies aiming at exploring its potential of preclinical development.

81 - Characterization of Human Polyomavirus JC (JCPyV) infection in Human Neuroblastoma SH-SY5Y cells and evaluation of redox state during viral replication.

CARLA PREZIOSO ⁽¹⁾ - paola checconi ⁽²⁾ - SARA BALDELLI ⁽³⁾ - anna maria marinelli ⁽⁴⁾ - valeria pietropaolo ⁽⁵⁾ - maria rosa ciriolo ⁽⁶⁾ - anna teresa palamara ⁽⁷⁾ - [dolores limongi](#) ⁽²⁾

IRCCS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, Rome, Italy, ROMA, Italia ⁽¹⁾ - IRCCS San Raffaele Roma, Telematic University, Rome, Italy, ROMA, Italia ⁽²⁾ - IRCCS San Raffaele Roma, Telematic University, Rome, Italy, roma, Italia ⁽³⁾ - IRCCS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, Rome, Italy, roma, Italia ⁽⁴⁾ - "Sapienza" University of Rome, Rome, Italy, Department of Public Health and Infectious Diseases, roma, Italia ⁽⁵⁾ - University of Rome "Tor Vergata", Rome, Italy, Department of Biology, Roma, Italia ⁽⁶⁾ - Istituto Superiore di Sanità, Rome, Italy., Department of Infectious Diseases, Roma, Italia ⁽⁷⁾

Characterization of Human Polyomavirus JC (JCPyV) infection in Human Neuroblastoma SH-SY5Y cells and evaluation of redox state during viral replication.

CARLA PREZIOSO ¹, PAOLA CHECCONI², SARA BALDELLI², ANNA M. MARINELLI¹, VALERIA PIETROPAOLO³, MARIA R. CIRIOLO^{4,5}, ANNA T. PALAMARA^{6,7}, [DOLORES LIMONGI](#)².

¹IRCCS San Raffaele Roma, Microbiology of Chronic Neuro-Degenerative Pathologies, Rome, Italy; ²IRCCS San Raffaele Roma, Telematic University, Rome, Italy; ³Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy; ⁴Department of Biology, University of Rome "Tor Vergata", Rome, Italy; ⁵IRCCS San Raffaele Roma, Rome, Italy; ⁶Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Rome, Italy; ⁷Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Background: Several intracellular factors, including the redox state, might affect the progression and outcome of viral infection. In physiological conditions, the redox balance is maintained by enzymatic and non-enzymatic systems, and it finely regulates several cell functions. While the role of some viruses in break this equilibrium and induce oxidative stress is well characterized, the role of redox state, during Human Polyomavirus JC (JCPyV) infection, is still poorly understood. JCPyV, a non-enveloped virus with a circular dsDNA genome, causes a lifelong asymptomatic and persistent infection in the reno-urinary tract of the adult population worldwide. In immunocompromised individuals, JCPyV can spread to the central nervous system (CNS) and cause a fatal demyelinating disease known as Progressive Multifocal Leukoencephalopathy (PML).

Understanding the mechanisms of the intracellular redox alteration, which occurs during viral infections and whether they could be associated with the progression of JC virus-induced diseases is of particular interest. Hence, the aim of this study was to unveiling role of redox state during JCPyV replication that govern the survival and death of cells infected by JCPyV.

Materials and Methods: SH-SY5Y cells were infected with the JCPyV archetype strain and collected 24hours post-infection. Viral DNA was extracted and quantified by quantitative RealTime PCR (Q-PCR). The expression of Viral Capsid protein 1 (VP1) and the activity of NADPH oxidase 2 and 4 (NOX2 and NOX4) were studied by Western blot (WB). The intracellular concentration of glutathione (GSH) was assayed upon formation of S-carboxymethyl derivatives of free thiol with iodoacetic acid, followed by the conversion of free amino groups to 2,4-dinitrophenyl derivatives by reaction with 1-fluoro-2,4-dinitrobenzene. ROS were detected by cytofluorimetric analysis.

Results: JCPyV efficiently infects and replicates in SH-SY5Y cells. A loss in intracellular level of GSH and a ROS increase were observed. ROS increase depends mainly on NOX4, which is upregulated at both mRNA and protein levels. On the contrary, the expression of NOX2, the primary source of ROS in inflammatory cells, is downregulated.

Discussion and Conclusions: These data show redox alteration during JCPyV infection and suggest that redox-sensitive pathways could represent novel cell-based targets for therapies aimed at blocking both viral replication and virus-induced persistence.

92 - B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy

Jacopo Polvere⁽¹⁾ - Massimiliano Fabbiani⁽²⁾ - Gabiria Pastore⁽¹⁾ - Ilaria Rancan⁽²⁾ - Barbara Rossetti⁽²⁾ - Miriam Durante⁽³⁾ - Sara Zirpoli⁽¹⁾ - Enrico Morelli⁽³⁾ - Elena Pettini⁽¹⁾ - Simone Lucchesi⁽¹⁾ - Fabio Fiorino⁽¹⁾ - Mario Tumbarello⁽²⁾ - Annalisa Ciabattini⁽¹⁾ - Francesca Montagnani⁽²⁾ - Donata Medaglini⁽¹⁾

Laboratorio di Microbiologia Molecolare e Biotecnologia, Dipartimento di Biotecnologie Mediche, Università degli studi di Siena, Siena, Italia⁽¹⁾ - *UOC Malattie infettive e tropicali, Dipartimento di Scienze mediche, chirurgiche e neuroscienze, Azienda Ospedaliera Universitaria Senese, Siena, Italia*⁽²⁾ - *Dipartimento di Biotecnologie Mediche, Università degli studi di Siena, Siena, Italia*⁽³⁾

B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy

JACOPO POLVERE¹, MASSIMILIANO FABBIANI³, GABIRIA PASTORE¹, ILARIA RANCAN^{2,3}, BARBARA ROSSETTI³, MIRIAM DURANTE², SARA ZIRPOLI¹, ENRICO MORELLI², ELENA PETTINI¹, SIMONE LUCCHESI¹, FABIO FIORINO¹, MARIO TUMBARELLO^{2,3}, ANNALISA CIABATTINI¹, FRANCESCA MONTAGNANI^{2,3} AND DONATA MEDAGLINI¹

1 Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena; Siena, Italy; 2 Department of Medical Biotechnologies, University of Siena; Siena, Italy; 3 Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena; Siena, Italy

Introduction. SARS-CoV-2 mRNA vaccines have demonstrated high immunogenicity in healthy subjects and preliminary results for people living with HIV (PLWHIV) are promising too. We have previously reported the persistence of spike-specific circulating IgG and memory B cells in healthy adults up to six months after mRNA SARS-CoV-2 vaccination. Unfortunately, limited longitudinal data are available for PLWHIV and no evidence of persistent spike-specific memory B cells have been reported yet. Whether the HIV chronic immune impairment affects spike-specific memory B cells remains a burning question.

Materials and Methods. We investigated the humoral response and the persistence of spike-specific memory B cells up to six months after vaccination with two doses of mRNA vaccines in 84 PLWHIV under antiretroviral therapy (ART) and compared them to healthy controls (HCs). Humoral response was analyzed with enzyme-linked immunosorbent assay and with a surrogate neutralization assay measuring angiotensin-converting enzyme 2 (ACE2) and receptor binding domain (RBD) binding inhibition. Spike-specific B cells were identified as S+/RBD+ and characterized for IgD and CD27 expression with a cytofluorimetric approach.

Results. Spike-specific IgG titers peaked 1 month after second dose and persisted up to six months after vaccination with no significant differences compared to HCs. The stratification of patients according to CD4+ T cell count showed a significantly lower IgG response in case of CD4<350/ μ l, remarking the relevance of immune reconstitution. The ACE2/RBD inhibition activity was detected in 58.4% of PLWHIV, compared to 86.2% in HCs. The amount of circulating spike-specific memory B cells detected in PLWHIV six months after vaccination was not significantly different from HCs, however there was prevalence of antigen-specific double negative (IgD-/CD27-) cells that are associated to precocious immune aging.

Discussion and Conclusions. In summary, our study provides real-world data on immunogenicity of SARS-CoV-2 mRNA vaccines in PLWHIV up to 6 months after vaccination. These results corroborate the opinion that PLWHIV with an adequate CD4+ T cells population (>350 cells/ μ l) and under ART can mount a significant humoral immune response after vaccination. Nevertheless, hints of altered immune responsiveness have been observed with ACE2/RBD binding inhibition assay and by spike-specific B cell phenotyping.

100 - Indomethacin inhibits human seasonal coronavirus replication at post-entry level

Caterina Tramontozzi⁽¹⁾ - Silvia Pauciullo⁽¹⁾ - Simone La Frazia⁽¹⁾ - Sara Piacentini⁽¹⁾ - Maria Gabriella Santoro⁽¹⁾

Università degli studi di Roma "Tor Vergata", Dipartimento di Biologia, Roma, Italia⁽¹⁾

Indomethacin inhibits human seasonal coronavirus replication at post-entry level

CATERINA TRAMONTOZZI¹, SILVIA PAUCIULLO¹, SIMONE LA FRAZIA¹, SARA PIACENTINI¹ and M. GABRIELLA SANTORO¹.

¹Department of Biology, University of Rome Tor Vergata, Rome, Italy.

Introduction: The non-steroidal anti-inflammatory drug (NSAID) indomethacin (INDO), a traditional cyclooxygenase-1 (COX-1) and -2 (COX-2) inhibitor with anti-inflammatory and analgesic properties, is known to possess antiviral activity against several viral pathogens, including the SARS-CoV coronavirus. INDO has been recently used successfully in the treatment of COVID-19 patients; however, very little is known on the mechanism of the antiviral activity. Herein we investigated the effect of INDO on human seasonal coronavirus (sHCoV) replication, using the alpha-coronavirus HCoV-229E and beta-coronavirus HCoV-OC43 as models. **Materials and methods:** Human lung MRC-5 fibroblasts were infected with HCoV-229E or HCoV-OC43 (0.1 TCID₅₀/cell) for 1h at 33°C. INDO, dissolved in ethanol, was diluted in culture medium at the time of use. Virus yield was determined by TCID₅₀ infectivity assay, and cell viability was determined by MTT assay. Viral and cellular proteins were evaluated by Western-blot analysis and HCoV genomic RNA (gRNA) levels were determined by qRT-PCR. For RNA transfection experiments, MRC-5 cells were transfected with HCoV-229E or HCoV-OC43 gRNA (1 µg/ml) at 33°C, and treated with INDO after transfection. **Results:** Indomethacin was found to have a remarkable cytoprotective and antiviral activity in both models, causing a dose-dependent decrease of infectious virus yield and extracellular HCoV gRNA levels. Treatment with INDO at different stages of the virus infection cycle resulted in significant virus titer reduction when treatment was started after virus adsorption (0-6h p.i.), whereas treatment of cells before infection or during the adsorption period did not affect virus replication. INDO was also effective in inhibiting virus replication in HCoV-229E or HCoV-OC43 gRNA transfection experiments, confirming that the NSAID does not interfere with virus entry. Analysis of viral proteins and RNA shows that INDO reduces HCoV nucleocapsid N and spike S protein levels, as well as intracellular viral RNA expression, an effect associated with drug-induced phosphorylation of the translation initiation factor eIF2α at Ser51. **Discussion and Conclusions:** Seasonal HCoVs generally cause mild upper respiratory tract diseases, although they may sometimes cause severe infections. Presently there is no specific treatment for sHCoV infections. The results described herein indicate that indomethacin is effective against HCoV-229E and HCoV-OC43 infection *in vitro*, acting at post-entry level and causing a block of viral RNA and protein expression in infected cells. These results suggest a possible beneficial effect of indomethacin in the treatment of human coronavirus infections.

107 - Infection rate of respiratory viruses in the pandemic SARS-CoV-2 period considering symptomatic patients: comparison between 2020 and 2021.

Gaetana Costanza ⁽¹⁾ - Pierpaolo Paba ⁽²⁾ - Marco Ciotti ⁽³⁾ - domenico Ombres ⁽⁴⁾ - Ada Bertoli ⁽⁵⁾ - Fabbio Marcuccilli ⁽⁶⁾ - eleonora Andreassi ⁽²⁾ - Marta Btugneti ⁽³⁾ - Oreste Cennamo ⁽³⁾ - Vita Petrone ⁽⁷⁾ - Marialaura Fanelli ⁽⁷⁾ - Antonella Minutolo ⁽⁷⁾ - Claudia Matteucci ⁽⁷⁾ - Sandro Grelli ⁽³⁾

Università, PoliclinicoTor Vergata/ Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽¹⁾ - Policlinico, PoliclinicoTor Vergata/ Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽²⁾ - Policlinico, Policlinico Tor Vergata/ Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽³⁾ - Policlinico, Policlinico Tor Vergat/a Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽⁴⁾ - policlinico, Policlinico Tor Vergat/ Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽⁵⁾ - Policlinico, PoliclinicoTor Vergat/ Università degli studi di Tor <vergata/DIP Medicina Sperimentale, Roma, Italia ⁽⁶⁾ - Università, Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽⁷⁾

Infection rate of respiratory viruses in the pandemic SARS-CoV-2 period considering symptomatic patients: comparison between 2020 and 2021.

GAETANA COSTANZA¹, PIERPAOLO PABA¹, MARCO CIOTTI¹, DOMENICO OMBRES¹, ADA BERTOLI^{1,2}, FABBIO MARCUCCILLI¹, ELEONORA ANDREASSI¹, MARTA BRUGNETI¹, ORESTE CENNAME¹ VITA PETRONE², MARIALAURA FANELLI²; ANTONELLA MINUTOLO², CLAUDIA MATTEUCCI², SANDRO GRELLI^{1,2}

1. Unit of Virology, Policlinic of Tor Vergata, Rome, Italy; 2. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, 00133, Italy.

Background: In last two years, the SARS-CoV-2 pandemic has determined radical changes in human behaviours and lifestyles, with a drastic reduction of socialization due to physical distancing and self-isolation (<https://www.governo.it/it/coronavirus-misure-del-governo>). These changes have also been reflected in the epidemiological patterns of common respiratory viruses. For this reason, early discrimination of respiratory viruses is important as new variants emerge. **Methods:** Nasopharyngeal swabs of 2554 patients, with clinically suspected Acute Respiratory Infections (ARIs) from October 2019 to November 2021, were collected to detect one or more of the 23 common respiratory pathogens, especially viruses, via BioFilmArray RP2.1*plus*, including SARS-CoV-2. Demographical characteristics and epidemiological analyses were performed as well as laboratory features profile of positive patients. **Results:** An observational study on 2300 patients (254 patients were excluded because of missing data) including 1560 men and 760 women, median age of 64,5 years, has been carried out. Considering the respiratory virus research request, most of the patients were admitted at the Emergency Medicine Department (41.2%, of patients), whereas 29.5% were admitted at the Infectious Diseases Department. The most frequently detected pathogens included SARS-CoV-2 (31.06%, 707/2300, from March 2020 to November 2021), InfA-B (1.86%, 43/2300). The significative decrease of positive rate of SARS-CoV-2 was associated with the massive vaccination, especially in eldest people. **Conclusion:** This study represents a dynamic picture of the epidemiological curve of common respiratory viruses during the two years of pandemic, with a disregarded trend for additional viruses. The possible causes were attributable either to the use of masks, social distancing, smart working, and closure of schools, as measures implemented by the national policy to contain the spread of SARS-CoV-2 has further influenced the changes in the positivity rates of most respiratory viruses.vaccination campaigns and emerging of new SARS-Cov-2 variants.

110 - ARE III-GENERATION ANTIGENIC TEST SENSITIVE AS MOLECULAR TEST FOR DETECTION OF SARS-CoV-2?

Gaetana Costanza ⁽¹⁾

Policlinico, Policlinico Tor Vergata/ Università degli studi di Tor vergata/DIP Medicina Sperimentale, Roma, Italia ⁽¹⁾

ARE III-GENERATION ANTIGENIC TEST SENSITIVE AS MOLECULAR TEST FOR DETECTION OF SARS-CoV-2?

GAETANA COSTANZA¹, MARCO CIOTTI¹, PIERPAOLO PABA¹, DOMENICO OMBRES¹, FABBIO MARCUCCILLI¹, ELEONORA ANDREASSI¹, CLAUDIO CARAPELLESE¹, NICOLA BOTTALICO¹, ANGELICA SACCO¹, CLAUDIA ROTONDO¹, VITA PETRONE², MARIALaura FANELLI²; TERENCE COSIO² ANTONELLA MINUTOLO², LUCIA PIREDDA³, SERGIO BERNARDINI^{1,3}, EMANUELA BALESTRIERI², CLAUDIA MATTEUCCI², SANDRO GRELLI^{1,2}

1. Unit of Virology, Policlinic of Tor Vergata, Rome, Italy; 2. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 3. Laboratory Medicine, Policlinic of Tor Vergata, Rome, Italy; 4. Department of Biology, University of Rome Tor Vergata, Rome, 00133, Italy

Background The pandemic due to SARS-CoV-2 infection has brought about enormous changes from every point of view, from social habits to certainties in the scientific world. The need to manage thousands of users daily and the need to quickly diagnose the presence of infection in patients for the containment of the spread, has led to the development of many different assays and methodologies, to couple to the gold standard PCR, reliable, but complex and long. Among these technologies are third generation antigenic assay, based on principle of microfluidic. **Methods:** The methods used and compared with each other were the Microlab Nimbus/Starlet technologies with Kit Allplex and LumiraDX Platform respectively for molecular and antigenic testing on nasopharyngeal swabs as starting material. The results of patients who had carried out both tests were analyzed and through the Cohen index the sensitivity of the antigen test compared to the molecular test was evaluated. **Results:** A total of 5040 patients were enrolled in this study in the period September-December 2021. All patients performed a nasopharyngeal swab for the search and identification of SARS-CoV-2 at the Emergency Unit of the Tor Vergata Policlinic, Rome. Of these 1603 patients underwent both tests analysed in this study showing a remarkable concordance in response (98.23%), but Cohen's index lowers this concordance to 64%. Only in 1.77% of cases the test result was discordant. **Conclusion:** The use of the gold standard PCR method represents the safety for the detection of nucleic acids specific to SARS-CoV-2. But the need for fast diagnosis and at low costs, makes the third generation technology, in the field of antigen tests, LumiraDX Platform an excellent system for referring patients also taking into account the symptoms and clinical history of the patient.

111 - Wastewater-based surveillance for the monitoring of SARS-CoV-2 circulation in Sicily

Chiara Filizzolo⁽¹⁾ - Giuseppa Luisa Sanfilippo⁽¹⁾ - Emilia Palazzotto⁽¹⁾ - Mariangela Pizzo⁽¹⁾ - Massimo Giuseppe Chiarelli⁽²⁾ - Gabriella Caruso⁽³⁾ - Domenico Mirabile⁽⁴⁾ - Giorgio Iacono⁽⁵⁾ - Mario Palermo⁽⁶⁾ - Giovanni Maurizio Giammanco⁽¹⁾ - Simona De Grazia⁽¹⁾

Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”, Università degli Studi di Palermo, Palermo, Italia⁽¹⁾ - Local Water Plant Management (Acque di Caltanissetta S.p.A.), Caltacqua S.p.A., Caltanissetta, Italia⁽²⁾ - Area Igiene Sanità Pubblica, ASP5, Messina, Italy, UOC Servizio di Igiene Ambienti di Vita (SIAV), Dipartimento Strutturale di Prevenzione –, Messina, Italia⁽³⁾ - ASP6, Palermo, Italy, UOC Igiene degli Ambienti di Vita (SIAV), Dipartimento di Prevenzione Medico,, Palermo, Italia⁽⁴⁾ - ASP7, Ragusa, Italy, Servizio Epidemiologia e Profilassi, Dipartimento di Prevenzione, Ragusa, Italia⁽⁵⁾ - DASOE - Public Health and Environmental Risk, Sicilian Region, Department of Public Health, Palermo, Italy, Palermo, Italia⁽⁶⁾

Wastewater-based surveillance for the monitoring of SARS-CoV-2 circulation in Sicily

CHIARA FILIZZOLO^a, GIUSEPPA L. SANFILIPPO^a, EMILIA PALAZZOTTO^a, MARIANGELA PIZZO^a, MASSIMO G. CHIARELLI^b, GABRIELLA CARUSO^c, DOMENICO MIRABILE^d, GIORGIO IACONO^e, MARIO PALERMO^f, GIOVANNI M. GIAMMANCO^a, SIMONA DE GRAZIA^a

^aDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo

^bLocal Water Plant Management (Acque di Caltanissetta S.p.A.), Caltanissetta, Italy;

^cUOC Servizio di Igiene Ambienti di Vita (SIAV), Dipartimento Strutturale di Prevenzione – Area Igiene Sanità Pubblica, ASP5, Messina, Italy;

^dUOC Igiene degli Ambienti di Vita (SIAV), Dipartimento di Prevenzione Medico, ASP6, Palermo, Italy;

^eServizio Epidemiologia e Profilassi, Dipartimento di Prevenzione, ASP7, Ragusa, Italy;

^fDASOE - Public Health and Environmental Risk, Sicilian Region, Department of Public Health, Palermo, Italy.

Introduction: Wastewater-based epidemiology has been recognized as a complement for clinical disease surveillance. Several studies had demonstrated the advantages of environmental surveillance through wastewater monitoring for the assessment of viral circulation in a given territory. To this aim, the National Surveillance Network SARI (Sorveglianza Acque Reflue in Italia) group was established by the Istituto Superiore di Sanità (ISS) to monitor the presence of the SARS-CoV-2 genome in wastewater as a predictive tool for the prevalence of COVID-19 in the population. The Regional Reference Laboratory (RRL) of the PROMISE Department of the University of Palermo was included in the SARI network since June 2020. As a result of revisions to the list of sampling sites, from October 2021, receiving once or twice a week wastewater samples for virological analysis from 5 municipal wastewater treatment plants in Sicily: Modica (RG), Vittoria (RG), Ragusa (RG), Gela (CL) and Messina (ME).

Materials and Methods: In this study, 150 wastewater samples collected from October 1 2021 to June 30 2022 for virological investigations according to standard protocols approved by ISS (SARS-CoV-2 Surveillance Protocol in urban wastewater, SARI - rev. 3). Nucleic acids extraction from 4 ml of concentrated wastewater sample was optimized using MagNa Pure automatic extractor (Roche), and quantitative determination of SARS-CoV-2 genome was evaluated by RT-qPCR assays with specific primer sets. To assess the concentration/extraction/amplification efficiency of the method a process control virus solution (Murine Norovirus; MNoV) was added to each wastewater sample prior to concentration.

Results: Out of 150 samples collected from October 1 2021 to June 30 2022, 141 (94%) were positive for SARS-CoV-2, five negative (3.3%), while two showed an insufficient yield (<10%) and two were invalid. RNA quantization (genomic copies/μL) for all positive samples ranged between 1.75E+02 and 1.25E+06. Process yields calculated based on MNoV, ranged between 10.5% and 100%. Trend of SARS-CoV-2 concentrations in wastewater showed a significant increase (>30%) in SARS-CoV-2 genome concentrations in mid-June 2022, compared to the previous months.

Discussion and Conclusions: The results of this study confirmed the utility of wastewater surveillance as an important instrument to evaluate SARS-CoV-2 circulation into human populations.

The observed significant increase of SARS-CoV-2 loads suggested a rise in the number of individuals excreting SARS-CoV-2, which is in agreement with the rise of COVID-19 cases, possibly linked to the spread of the Omicron sublineages BA.4, BA.5 and BA.2.12.1.

116 - Emergence of novel Rotavirus G1P[8] strains in Sicily in 2021

Floriana Bonura ⁽¹⁾ - Chiara Filizzolo ⁽¹⁾ - Leonardo Mangiaracina ⁽¹⁾ - Giuseppa Luisa Sanfilippo ⁽¹⁾ - Francesca Di Bernardo ⁽²⁾ - Antonina Collura ⁽²⁾ - Giovanni Maurizio Giammanco ⁽¹⁾ - Simona De Grazia ⁽¹⁾

Dipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro" (PROSAMI), Università degli Studi di Palermo, Palermo, Italia ⁽¹⁾ - ARNAS, Palermo, Italy, Unità Operativa di Microbiologia e Virologia, Ospedale Civico e Di Cristina,, Palermo, Italia ⁽²⁾

Emergence of novel Rotavirus G1P[8] strains in Sicily in 2021

FLORIANA BONURA^a, CHIARA FILIZZOLO^a, LEONARDO MANGIARACINA^a, GIUSEPPA L. SANFILIPPO^a, FRANCESCA DI BERNARDO^b, ANTONINA COLLURA^b, GIOVANNI M. GIAMMANCO^a, SIMONA DE GRAZIA^a

^aDipartimento di Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro" (PROSAMI), Università di Palermo, Palermo, Italy

^bUnità Operativa di Microbiologia e Virologia, Ospedale Civico e Di Cristina, ARNAS, Palermo, Italy

Introduction: Rotavirus (RVA) is a major etiologic cause of gastroenteritis in children. RVA are classified into G and P types on the basis of antigenic and genetic diversity of the capsid proteins VP7 and VP4, which elicit for neutralizing antibodies. Accumulation of point mutations, interspecies transmission and/or reassortment events result in the evolution of RVA. Recently, novel G1P[8] RVAs, phylogenetically different from the previously known lineages have emerged and spread in our territory. These novel strains are also distant from the strain of the monovalent Rotarix vaccine, recommended and offered in Sicily. This study describes the molecular investigations of G1P[8] strains detected in Palermo in 2021, aiming at better understanding their genetic evolution.

Materials and Methods: As part of the surveillance of viral gastroenteritis, a total of 268 stool samples, collected from children admitted to the Children's Hospital "G. Di Cristina" in Palermo, were analyzed in 2021. All RVA-positive strains were G/P typed by hemi-nested PCR and 21 G1P[8] strains were further analyzed by phylogenetic analysis of VP7 and VP4 regions, according to the genotyping recommendations of the Rotavirus Classification Working Group.

Results: In 2021, RVA accounted for 8.9% of gastroenteric infections, and G1P[8] genotype was detected in 87.5% of RVA-positive samples. The phylogenetic study conducted showed the presence of a novel cluster for both VP7 and VP4, clustered with a high percentage of nucleotide identity (>98%) and different from strains analyzed in previous years or vaccine-derived strains. Comparison of VP7 and VP4 sequences with Rotarix vaccine showed the presence of multiple nucleotide substitutions.

Discussion and conclusions: The local distribution of RVAs is affected by introduction of Rotavirus vaccine, leading to a radical reduction in the circulation of G1P[8] RVAs and hospitalizations for infections with it. Recently, emerging novel G1P[8] RVAs were introduced in Palermo, contributing to the seasonal epidemic in 2021. These new G1P[8] strains represent further evidence of the evolutionary capacity of RVAs. Molecular surveillance of circulating RVAs is important for the early detection of new mutants that might emerge under vaccine pressure and for the monitoring of the effectiveness of vaccine programs.

127 - PREVALENCE AND LOAD OF THE RECENTLY DISCOVERED REDONDOVIRUS IN SALIVA SAMPLES FROM HEALTHY AND COVID-19 SUBJECTS

Andreina Baj⁽¹⁾ - Federica Novazzi⁽¹⁾ - Pier Giorgio Spezia⁽²⁾ - Angelo Paolo Genoni⁽¹⁾ - SARA BOUTAHAR⁽¹⁾ - Francesca Dragoferrante⁽¹⁾ - Fabrizio Maggi⁽¹⁾

Università dell'Insubria, Dipartimento Medicina e Chirurgia, Varese, Italia⁽¹⁾ - UNiversità di Pisa, Department of Translational Research, University of Pisa, Italy., Pisa, Italia⁽²⁾

Prevalence and load of the recently discovered redondovirus in saliva samples from healthy and covid-19 subjects

Andreina Baj^{1,2}, Federica Novazzi^{1,2}, Pier Giorgio Spezia³, Angelo Paolo Genoni^{1,2}, Sara Bouthar^{1,2}, Francesca Dragoferrante^{1,2}, Fabrizio Maggi^{1,2}.

¹Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy; ²Department of medicine and surgery, University of Insubria, Varese, Italy, ³ Department of Translational Research, University of Pisa, Italy.

Introduction: Redondoviridae is a recently described family of viruses that appear restricted to the human oral and respiratory tract and have a prevalence of up to 15%. Redondovirus (ReDoVs) levels are higher in the airway of intubated patients and oral samples of periodontitis patients, suggesting that they could be used as a marker to define the severity of the pathological conditions. Several published studies suggest that ReDoV is not part of the normal oral and/or respiratory microflora of humans, differently from other circular single-stranded DNA viruses and that ReDoV infection might be involved in clinically relevant disorders.

Materials and Methods: A total of 358 saliva samples were investigated for ReDoV presence and loads by in-house developed PCR methods. 283 samples were from healthy individuals, and 99 from hospitalized SARS-COV-2 positive patients. The median age in healthy subjects was 51 years, with 180 (63,6%) males. The hospitalized patients had 56 years in the median, 32 (32,3%) were males. Concomitantly to ReDoV, the presence and loads of ubiquitous TTV were also evaluated.

Results: Overall, ReDoV was detected in 213 of 358 (59%) saliva samples. Of 283 samples from healthy individuals, 157 (55%) were positive for ReDoV at a medium viral load of 3,6 log copies of ml of saliva. 56 of 99 (57%) saliva samples from hospitalized SARS-COV-2 positive patients whose 56 (56,6%) were ReDoV positive with a medium load of 2,8 log copies/ml. TTV was found with a higher prevalence (65 and 77% in healthy and diseased subjects, respectively) and levels (3.7 and 3.6 log TTV copies/ml in healthy and diseased subjects, respectively).

Discussion and Conclusions: The study reveals that the novel ReDoV is prevalent in saliva samples of healthy and diseased individuals with DNA levels that are comparable with those measured for TTV. Further study will be needed for investigating the role of ReDoV in the respiratory tract and if its presence can be correlated to the severity of acute and chronic respiratory pathologies.

128 - Prolonged viral shedding and monkeypox virus isolation from seminal fluid

Daniele Lapa⁽¹⁾ - Fabrizio Carletti⁽¹⁾ - Valentina Mazzotta⁽²⁾ - Giulia Matusali⁽¹⁾ - Carmela Pinnetti⁽²⁾ - Silvia Meschi⁽¹⁾ - Laura Scorzolini⁽²⁾ - Francesca Colavita⁽¹⁾ - Roberta Gagliardini⁽²⁾ - Claudia Minosse⁽¹⁾ - Gaetano Maffongelli⁽²⁾ - Annalisa Mondì⁽²⁾ - Stefania Cicalini⁽²⁾ - Eliana Specchiarello⁽¹⁾ - Marta Camici⁽²⁾ - Aurora Bettini⁽¹⁾ - Francesco Baldini⁽²⁾ - Massimo Francalancia⁽¹⁾ - Klizia Mizzoni⁽¹⁾ - Anna Rosa Garbuglia⁽¹⁾ - Emanuele Nicastrì⁽²⁾ - Enrico Girardi⁽³⁾ - Andrea Antinori⁽²⁾ - Francesco Vaia⁽⁴⁾ - Fabrizio Maggi⁽¹⁾

National Institute for Infectious Diseases 'Lazzaro Spallanzani', Laboratory of Virology, Rome, Italia
⁽¹⁾ - National Institute for Infectious Diseases 'Lazzaro Spallanzani', Clinical and Research Department, Rome, Italia ⁽²⁾ - National Institute for Infectious Diseases 'Lazzaro Spallanzani', Scientific Direction, Rome, Italia ⁽³⁾ - National Institute for Infectious Diseases 'Lazzaro Spallanzani', General Direction, Rome, Italia ⁽⁴⁾

Prolonged viral shedding and monkeypox virus isolation from seminal fluid

Daniele Lapa¹, Fabrizio Carletti¹, Valentina Mazzotta², Giulia Matusali¹, Carmela Pinnetti², Silvia Meschi¹, Laura Scorzolini², Francesca Colavita¹, Roberta Gagliardini², Claudia Minosse¹, Gaetano Maffongelli², Annalisa Mondì², Stefania Cicalini², Eliana Specchiarello¹, Marta Camici², Aurora Bettini¹, Francesco Baldini², Massimo Francalancia¹, Klizia Mizzoni¹, Anna Rosa Garbuglia¹, Emanuele Nicastrì², Enrico Girardi³, Andrea Antinori², Francesco Vaia⁴, Fabrizio Maggi¹

¹ National Institute for Infectious Diseases 'Lazzaro Spallanzani', National Institute for Infectious Diseases 'Lazzaro Spallanzani' (IRCCS), Rome, Italy; ² Clinical and Research Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' (IRCCS), Rome, Italy; ³ Scientific Direction, National Institute for Infectious Diseases 'Lazzaro Spallanzani' (IRCCS), Rome, Italy; ⁴ General Direction, National Institute for Infectious Diseases 'Lazzaro Spallanzani' (IRCCS), Rome, Italy

Background: Monkeypox is a rare viral zoonotic disease that is transmitted from one person to another by close contact with infectious materials or large respiratory droplets. Since May 2022, a multi-country outbreak of monkeypox virus (MPXV) is ongoing, with increasing cases identified all across the world. The virus transmission properties may be one of the key aspects associated with this unprecedented event to be elucidated. **Methods:** We investigated the viral shedding in the first available semen sample collected after the diagnosis from 11 MPXV-positive patients diagnosed between 17 May and 12 June 2022, at the National Institute for Infectious Diseases "L. Spallanzani", Italy. MPXV-specific PCR assay targeting the viral tumor necrosis factor receptor gene was performed to evaluate viral DNA levels based on quantification cycles (Cq) values. For one of the patients, longitudinal semen and plasma samples collected from day 5 to day 19 from symptoms onset (fso) were investigated to monitor the persistence of the viral DNA shedding. In this case, virus isolation on Vero E6 cells was also performed in the first available semen sample to evaluate presence of infectious virus. **Results:** MPXV DNA was detected in semen samples collected after the diagnosis (mean time: 2 days, interquartile range (IQR): 1-2.5, range: 1-6) in 9 of 11 patients (82%) at Cq levels ranging from 22.7 to 41.2 (IQR: 25.1-30.8), with a mean value of 24.9. Monitoring the shedding in longitudinal samples, we showed that MPXV DNA was detected in the plasma sample collected on day 8 fso (Cq: 34.5), while the following samples resulted negative. MPXV DNA was detected in all semen samples tested during the period of observation, with Cq values ranging from 27.8 to 40.6. More importantly, live and replication-competent virus was isolated from the semen sample collected on day 6 fso (Cq: 29.3). **Discussion and Conclusions:** Our findings support the evidence that a prolonged shedding of MPXV can occur in the semen samples of infected patients for weeks after the onset of the symptoms (at least up to 19 days). But, more importantly, our results demonstrate that semen may contain a replication-competent virus and represent a potential source of infection. Further studies will establish whether infectious MPXV found in semen derives from local genital lesions, is associated with seminal cells, or if viral replication occurs in the genital tract. The understanding of the viral tropism for the genital tract and the origin of viral particles in the seminal fluid of infected men will shed light on the role of sexual transmission in the spread of MPXV infection.

132 - Development of SARS-CoV-2 Mpro inhibitors retaining in vitro activity against circulating SARS-CoV-2 variants of concern

Ilaria Vicenti⁽¹⁾ - Lia Fiaschi⁽¹⁾ - Simone Brogi⁽²⁾ - Emmanuele Crespan⁽³⁾ - Graziano Deidda⁽³⁾ - Camilla Biba⁽¹⁾ - Ilenia Varasi⁽¹⁾ - Laura Bavagnoli⁽³⁾ - Maurizio Zazzi⁽¹⁾ - Giovanni Maga⁽³⁾ - Sandra Gemma⁽⁴⁾

Università degli Studi di Siena/AOUS Siena, Dipartimento di Biotecnologie Mediche/UOC Microbiologia e Virologia, Siena, Italia⁽¹⁾ - University of Pisa, Department of Pharmacy, Pisa, Italia⁽²⁾ - CNR "Luigi Luca Cavalli-Sforza", Institute of Molecular Genetics IGM, Pavia, Italia⁽³⁾ - Università degli Studi di Siena, Department of Biotechnology, Chemistry and Pharmacy, Siena, Italia⁽⁴⁾

Development of SARS-CoV-2 Mpro inhibitors retaining in vitro activity against circulating SARS-CoV-2 variants of concern.

AUTHORS: *ILARIA VICENTI¹, LIA FIASCHI¹, SIMONE BROGI², EMMANUELE CRESPIAN³, GRAZIANO DEIDDA³, CAMILLA BIBA¹, ILENIA VARASI¹, LAURA BAVAGNOLI³, MAURIZIO ZAZZI¹, GIOVANNI MAGA³ and SANDRA GEMMA⁴*

¹ Department of Medical Biotechnologies, UOC Microbiology and Virology, University of Siena, Siena University Hospital, Siena, Italy

² Department of Pharmacy, University of Pisa, Pisa, Italy

³ Institute of Molecular Genetics IGM CNR "Luigi Luca Cavalli-Sforza", Pavia (Italy)

⁴ Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy

Introduction. The peculiar cleavage recognition site combined with its high degree of conservation makes the main protease (Mpro) of SARS-CoV-2 an attractive therapeutic target. The aim of this work was to evaluate in vitro the anti-SARS-CoV-2 activity of a library of newly synthesized compounds designed against Mpro.

Materials and Methods. Peptidomimetic Mpro candidate inhibitors were rationally designed based on the available structural information and applying molecular docking and dynamics techniques. The synthesized peptidomimetic compounds were tested in an enzyme inhibition assay in vitro. A set of 10 hit compounds was tested in a cell-based assay using live virus to determine their ability to halt virus replication. VERO E6 cells were treated with non-toxic doses of each compound with or without the addition of 0.5 μ M P-gp inhibitor (CP-100356) and subsequently challenged with the SARS-CoV-2 delta and omicron BA.2 variant at 0.001 MOI. Each experiment was performed at least in 2 independent runs and included a mock control, a virus back titration and the licensed Mpro inhibitor nirmatrelvir (NRM) as a reference compound. The inhibitory activity of each compound was determined by measuring the nucleocapsid expression by immunodetection and expressed as half-maximal inhibitory concentration (IC₅₀) using a non-linear fit normalization curve (GraphPad version 6.01).

Results. Among 46 compounds tested in vitro by enzymatic assay, four compounds were active in the sub-micromolar range (0.5 ± 0.2 μ M) against Mpro enzyme. Compounds displaying enzyme inhibitory activities lower than 10 mM IC₅₀ were further progressed to the cell-based antiviral assay. The CC₅₀ of the selected compounds was >100 μ M without CP-100356 but it decreased 4.4 ± 1.7 fold for 3 compounds in the presence of CP-100356. In the absence of CP-100356, none of the compounds was able to inhibit virus replication while in the presence of CP-100356, 3 compounds (NF3101, NF3156, NF3021) were active against the delta variant (ID₅₀ 1.6 ± 0.5 , 1.8 ± 0.1 , and 8.0 ± 1.4 μ M respectively) and against the omicron variant (ID₅₀ 5.8 ± 0.6 , 2.5 ± 0.2 and 9.5 ± 0.5 μ M respectively). A slight reduction in activity against the omicron variant (3.6-fold) was observed only for compound NF3101.

Discussion and Conclusions. We discovered novel SARS-CoV-2 Mpro candidate inhibitors inhibiting both delta and omicron variants of concern. The dependence by CP-100356 administration in VERO E6 cells was similar to those observed for the reference licensed drug NRM. The antiviral activity of the novel compounds currently remains around 50-fold lower than NRM but their less complex molecular scaffold will allow further structure-based optimization.

134 - In vitro evaluation of the virucide activity of nanostructured antimicrobial coatings for personal protective equipments

Francesco Ricchi⁽¹⁾ - Gloria Agliata⁽¹⁾ - Isabella Marchesi⁽¹⁾ - Stefania Paduano⁽¹⁾ - Letizia Verdolotti⁽²⁾ - Federica Recubito⁽²⁾ - Giuseppe Lama⁽²⁾ - Giovanna Buonocore⁽²⁾ - Mariamelia Stanzione⁽²⁾ - Antonella Mansi⁽³⁾ - Claudio Cermelli⁽¹⁾

Università degli Studi di Modena e Reggio Emilia, Facoltà di Medicina e Chirurgia, Modena, Italia⁽¹⁾ - Consiglio Nazionale delle Ricerche, Istituto per i Polimeri, Compositi e Biomateriali, Napoli, Italia⁽²⁾ - INAIL, Dipartimento di Medicina Epidemiologia, Igiene del Lavoro e Ambientale, Monte Porzio Catone, Italia⁽³⁾

***In vitro* evaluation of the virucide activity of nanostructured antimicrobial coatings for personal protective equipments**

Francesco Ricchi¹, Gloria Agliata¹, Isabella Marchesi², Stefania Paduano², Letizia Verdolotti³, Federica Recupido³, Giuseppe Lama³, Giovanna G. Buonocore³, Mariamelia Stanzione³, Antonella Mansi⁴, Claudio Cermelli¹

¹ Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, Università degli Studi di Modena e Reggio Emilia, Modena

² Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Sezione di Sanità Pubblica, Università degli Studi di Modena e Reggio Emilia, Modena

³ Istituto per i Polimeri, Compositi e Biomateriali – Consiglio Nazionale delle Ricerche, Napoli

⁴ Dipartimento di Medicina Epidemiologia, Igiene del Lavoro e Ambientale, INAIL Centro Ricerche Monte Porzio Catone, Roma

INTRODUCTION

One of the most effective personal equipments in preventing infection by respiratory viruses is wearing surgical masks for mouth and nose protection. The aim of this study is to evaluate *in vitro* whether different nanostructured coatings applied to surgical masks have a virucide activity.

MATERIALS AND METHODS

The tested coatings contained the following chemical principles: zeine solution (a vegetal protein) in

ethanol/H₂O and in ethanol/lactic acid, aqueous solutions of CuCl₂ and NaOH (precursor to obtain nanometric copper oxide), aqueous solution of Zn(NO₃)₂ and NaOH (precursor to obtain nanometric zinc), all at the same concentration (25 g/L). The coatings were obtained by soaking small coupons of TNT fabric in each solution for 30' followed by air drying. For copper and zinc based coatings, the samples were soaked in a NaOH solution and oxidated at 60°C for 24h.

The virucide activity was studied against HCov-OC43, as a SARS-CoV-2 surrogate, Herpes Simplex Virus type-1, Human Adenovirus type 5 and Monkeypox Virus. The coupons coated with the different solutions were contaminated with the viruses under study and after 2' the fabric samples were soaked in 1ml of cell growth medium and vortexed for 1' to eluate the survived virus. Viral loads of these suspensions were titrated by end point dilution on cell cultures.

RESULTS

Preliminary experiments on surgical masks demonstrate a remarkable virucide activity of some coatings, though with different extent depending on the virus tested: the most effective ones appear to be zeine with lactic acid and the two copper compounds (reduction ≥ 2 Log).

CONCLUSIONS

Some of these coatings applied to polypropylene surfaces were already tested and demonstrated a considerable virus inhibition (in some cases up to 3 Logs). Therefore, this strategy for virus transmission containment seems to be promising, providing some advantages in comparison with traditional systems, such as lower toxicity and/or ecocompatibility.

139 - Anti-SARS-CoV-2 Neutralizing activity of human breast milk from COVID-19 positive and negative lactating mothers

Lucia Signorini⁽¹⁾ - Maria Dolci⁽¹⁾ - Daniela Morniroli⁽²⁾ - Elena Pariani⁽³⁾ - Laura Pellegrinelli⁽³⁾ - Federica Perego⁽¹⁾ - Andrea Ronchi⁽⁴⁾ - Carlo Pietrasanta⁽²⁾ - Fabio Mosca⁽²⁾ - Maria Lorella Gianni⁽²⁾ - Pasquale Ferrante⁽⁵⁾ - Serena Delbue⁽¹⁾

Università degli Studi di Milano, Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Milano, Italia⁽¹⁾ - University of Milan, Department of Clinical Sciences And Community Health, Milano, Italia⁽²⁾ - University of Milan, Department of Biomedical Sciences for Health, Milano, Italia⁽³⁾ - Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italia⁽⁴⁾ - Istituto Clinico Città Studi, ICCS, Milano, Italia⁽⁵⁾

Anti-SARS-CoV-2 Neutralizing activity of human breast milk from COVID-19 positive and negative lactating mothers

LUCIA SIGNORINI¹, MARIA DOLCI¹, DANIELA MORNIROLI^{2,3}, ELENA PARIANI⁴, LAURA PELLEGRINELLI⁴, FEDERICA PEREGO¹, ANDREA RONCHI³, CARLO PIETRASANTA^{2,3}, FABIO MOSCA^{2,3}, MARIA LORELLA GIANNI^{2,3}, SERENA DELBUE¹

¹Department of Biomedical, Surgical And Dental Sciences, University of Milan, Milan, Italy

²Department of Clinical Sciences And Community Health, University of Milan, Milan, Italy

³Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

⁴Department of Biomedical Sciences for Health, University of Milan, Milan, Italy

Introduction: Immunity transfer through human milk is a key element in the infant's developing immunity. Recent studies have demonstrated the presence of antibodies against SARS-CoV-2 in human breast milk (HBM). Furthermore, it is known that aspecific antiviral activity not related to the presence of antibodies, is reasonably present in the HBM of all lactating women. The aim of the study was to detect the presence and magnitude of the neutralizing activity against SARS-CoV-2 of HBM from infected and previously infected lactating mothers (group A and B) and from mothers who never experienced SARS-CoV-2 infection (group C).

Materials and Methods: Forty-two women were enrolled, 11 in group A, 5 in group B and 26 in group C. Milk samples were collected 2 days (T0 - colostrum), 7 days (T1 - transition milk), 20 days (T2 - mature milk) and 30 days (T3) after the delivery. The SARS-CoV-2 50% neutralizing endpoint (NT₅₀) titers were determined at each time point, based on a microneutralization assay results. A semiquantitative enzyme-linked immunosorbent assay (ELISA) was performed to investigate the presence of anti-SARS-CoV-2 neutralizing antibodies.

Results: Milk samples from group A showed antiviral activity with median NT₅₀ titers of 1:32.0 (T0, range 1:16.0 - 1:512.0), 1:55.2 (T1, range 1:19.8 - 1:90.5), 1:2.6 (T2). No neutralizing activity was observed at T3. Median NT₅₀ titers in group B were 1:15.7 (T1, range 1:4.0 - 1:256.0) and 1:6.7 (T2, range 1:2.3 - 1:20.7). Milk samples from group C presented neutralizing activity with median NT₅₀ titers of 1:32.0 (T0, range 1:2.8 - 1:81.7), 1:4.0 and 1:3.6 (T1 and T2, range 1:2.3 - 1:6.3). NT₅₀ titers were confirmed by positivity in the ELISA assay.

Discussion and Conclusions: Persistency of anti-SARS-CoV-2 activity was observed up to twenty days after delivery in groups A and B, probably due to the presence of specific neutralizing antibodies in the milk. Interestingly, 63.6% of milk samples collected from group C showed neutralizing activity against the virus and a borderline positivity in the ELISA test, suggesting the possible presence of aspecific antiviral activity. Our study confirms that HBM from infected mothers favors specific immunity in breastfed infants and HBM from non-infected mothers might contain aspecific antiviral compounds, serving as initial protection against SARS-CoV-2 infection.

140 - Expression of Human Endogenous Retroviruses (HERVs) in clinical specimens of colon cancer patients

Maria Dolci⁽¹⁾ - Lucia Signorini⁽¹⁾ - Pietro Bagnoli⁽²⁾ - Luca Denti⁽¹⁾ - Federica Perego⁽¹⁾ - Pasquale Ferrante⁽³⁾ - Serena Delbue⁽¹⁾

Università degli Studi di Milano, Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Milano, Italia⁽¹⁾ - Istituto Clinico Città Studi (ICCS), Unità Chirurgia Generale, Milano, Italia⁽²⁾ - Istituto Clinico Città Studi, ICCS, Milano, Italia⁽³⁾

Expression of Human Endogenous Retroviruses (HERVs) in clinical specimens of colon cancer patients

MARIA DOLCI¹, LUCIA SIGNORINI¹, PIETRO BAGNOLI², LUCA DENTI¹, FEDERICA PEREGO¹, PASQUALE FERRANTE³, SERENA DELBUE¹

¹Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Carlo Pascal, 36, Milano, Italy;

²General Surgery Unit, Istituto Clinico Città Studi, Via Jommelli 19, Milan, Italy; ³Istituto Clinico Città Studi, Via Jommelli 19, Milan, Italy

Introduction: Human endogenous retroviruses (HERV) are relicts of exogenous retroviral infections, constituting 8% of the human genome. The genomic structure of HERVs is composed of four main genes: group-specific antigen (*gag*), protease (*pro*), polymerase (*pol*) and envelope (*env*). Alteration of HERVs expression has been related to several cancers, but researches regarding HERVs gene expression in colon cancer are currently sporadic. Very few reports investigated the presence of HERVs transcripts in plasmatic extracellular vesicles (EVs).

Materials and Methods: Fifty-seven Italian patients with advanced-stage colon cancer were enrolled. The expression of HERV-H, -K, -P *env* gene, and HERV-K *pol* gene was analysed in the tumor tissues and negative surgical margins and, when possible, in the peripheral blood mononuclear cells (PBMCs). HERVs presence was also evaluated in the plasmatic EVs, collected from 20 patients. Associations among clinical characteristics, such as tumor location, vascular invasion, perineural invasion, and HERVs gene expression levels were analysed.

Results: HERV-H, -K, -P *env*, and HERV-K *pol* expression levels in the tumor tissues, negative surgical margins and PBMCs were similar. HERVs gene were expressed, at low levels, in the plasmatic EVs of 10% (-H *env*), 40% (-K *env*), 15% (-K *pol*), and 25% (-P *env*) tested patients. Considering the tumor tissue samples, significant associations were found between HERV-P *env* expression, and vascular/perineural invasion ($p < 0.05$).

Discussion and Conclusions: In our cohort of advanced-stage colon cancer patients, no reactivation of HERVs expression was observed, confirming that HERVs gene overexpression may be associated only to the early phase of cancer pathogenesis, as suggested by previous studies.

As known, cancer-secreted microvesicles influence the tumor microenvironment and support cancer growth and metastasis: HERVs sequences present in the circulating plasma EVs might be transferred from one cell to another, favouring cellular transforming mechanisms. Investigations regarding the use of HERVs expression as markers of prognosis and as targets of adoptive immunotherapy are warranted.

141 - Study of the effects of new small molecules as antiviral agents against SARS-CoV-2

Alice Cara⁽¹⁾ - Carmen Piazza⁽²⁾ - Annalaura Brai⁽³⁾ - Elena Dreassi⁽³⁾ - Paola Quaranta⁽²⁾ - Mauro Pistello⁽¹⁾

Unità operativa di Virologia, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italia⁽¹⁾ - Centro Retrovirus, Dipartimento di Ricerca Traslazionale, Pisa, Italia⁽²⁾ - Università di Siena, Dipartimento di Biotecnologia, Chimica e Farmacia, Siena, Italia⁽³⁾

Study of the effects of new small molecules as antiviral agents against SARS-CoV-2

ALICE CARA¹, CARMEN PIAZZA², ANNALAURA BRAI⁴, ELENA DREASSI⁴, PAOLA QUARANTA^{2,3} and MAURO PISTELLO^{1,2}

¹Virology Operative Unit, Pisa University Hospital, Pisa, Italy; ²Retrovirus Centre, Department of Translational Research, University of Pisa, Pisa, Italy; ³Institute of Neuroscience - CNR, Pisa, Italy; ⁴Department of Biotechnology, Chemistry & Pharmacy, University of Siena, Siena, Italy

Introduction

This work has been carried out under Tuscavir, an interdisciplinary consortium aimed at performing research and providing qualified services for the development of novel broad spectrum antiviral therapies. Tuscavir is founded by Tuscany Region and includes the University of Siena (UNISI), Azienda Ospedaliera Universitaria Senese (AOUP), Azienda Ospedaliera Universitaria Pisana (AOUP), and the University of Florence (UNIFI) as team members. As part of the project, UNISI has developed different antiviral compounds capable of inhibit SARS-CoV-2 infection *in vitro*. These compounds named TUS (1-12) are small molecules that act against different targets of the viral mechanism of replication. Some of these TUS (1, 2, 3, 4, 5, 6, 7) are entry inhibitors, and others (TUS 11, 12, 13, 14) are Kinase inhibitors. Here we investigate the antiviral activity of single or combined compound against SARS-CoV-2

Materials and Methods

Measurement of the cytotoxicity of the molecules was performed by WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt], a cell-based assay used for screening a library of compounds to determine if the investigational molecules have effects on cell proliferation or show direct cytotoxic effects, eventually leading cell to death. For every compound the IC 50 was calculated. The antiviral activity against SARS-CoV-2 variants of selected molecules was evaluated by limiting dilution assay. The viral titer was calculated by applying the Reed and Muench formula. In this case, the ability of the molecules to inhibit the entry and /or replication of viral particle was revealed by measuring the cytopathic effect (CPE) on the cellular platform. Moreover, difference in the viral genome production were determined by Real time PCR measurements. Vero E6 cells were adopted for both antiviral activity and cytotoxicity assays.

Discussion and Conclusions

The molecules investigated are generally well-tolerated by Vero E6 cells up to a concentration of 50 µM. This concentration was the maximum used to assess antiviral activity. Inhibition of the levels of infection of SARS-CoV-2 variants on Vero E6 in the presence of drugs was evaluated by using different protocols of administration, according to the supposed mechanism of actions. The reduction of CPE and of the viral genome in the supernatants of infected cells demonstrated the ability of some of the compounds to reduce infection.

155 - SEROPREVALENCE OF TORCH INFECTIONS IN WOMEN OF CHILDBEARING AGE OVER THE 2012-2022 DECADE IN SICILY

Emilia Palazzotto⁽¹⁾ - Floriana Bonura⁽¹⁾ - Cinzia Calà⁽¹⁾ - Giuseppina Capra⁽¹⁾ - Daniela Pistoia⁽¹⁾ - Chiara Mascarella⁽¹⁾ - Giuseppe Mini⁽¹⁾ - Marco Enea⁽¹⁾ - Donatella Ferraro⁽¹⁾ - Giovanni M. Giammanco⁽¹⁾ - Simona De Grazia⁽¹⁾

AOUP Policlinico Paolo Giaccone Palermo, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, Italy, Palermo, Italia⁽¹⁾

SEROPREVALENCE OF TORCH INFECTIONS IN WOMEN OF CHILDBEARING AGE OVER THE 2012-2022 DECADE IN SICILY

Emilia Palazzotto¹, Floriana Bonura¹, Cinzia Calà¹, Giuseppina Capra¹, Daniela Pistoia², Chiara Mascarella¹, Giuseppe Mini¹, Marco Enea¹, Donatella Ferraro¹, Giovanni M. Giammanco¹, Simona De Grazia¹

¹Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, Italy

²Microbiology Unit, University Hospital AOUP Paolo Giaccone, Palermo, Italy

Introduction

TORCH acronym, classically, includes *Toxoplasma gondii* (TOX), Other, comprising *Treponema pallidum* (TP), Rubella Virus (RV), Cytomegalovirus (CMV), and Herpes simplex Virus (HSV). TORCH agents are recognized as major pathogens during pregnancy, being important cause of congenital diseases. The high rate of asymptomatic TORCH infections and the absence of effective vaccines, except for anti-RV live attenuate vaccine, kept high the possibility of pathogens vertical transmission to the fetus during pregnancy. Serological screening represents a key instrument to provide information about immunological status of women of reproductive age in order to identify women susceptible to primary infection and contribute to prevention and treatment of congenital infections. The aim of this study was to retrospectively evaluate the serological status (IgG and/or IgM) of childbearing age women attending to AOUP “P. Giaccone” of Palermo, Sicily over almost 10 years to estimate the adherence to TORCH serological screening program and to value the prevalence of women at risk of primary infections.

Materials and Methods

A total of 2359 sera were collected from women of childbearing age (16-46 years) who were referred to the Microbiology Unit of the AOUP “P. Giaccone” University Hospital of Palermo, Sicily, from 10 November 2012 to 1 April 2022, accessing through the ambulatory care services (National Health Care Surveys) or the Gynecology ward prescriptions.

Results

2359 sera were collected from childbearing age women, whose age ranged from 16 to 46 years, with a mean age of 29 ± 6 . Most of the samples had been screened for Abs against a single TORCH pathogen, but 20.9% had been concurrently tested for two pathogens (TOX and CMV), while 14% were screened for three agents (TOX, CMV and RV). Therefore 61.2% had been tested for TOX, 58.6% for CMV, 46.9% for TP, 45.1% for RV and 5% for HSV. The overall seroprevalence was 90.5% for HSV (of which 9.5% for HSV2), 81.2% for RV, 72.1% for CMV, 20.9% for TOX and 4.8% for TP. No noteworthy differences were found in seroprevalence among different age groups analyzed (16–25, 26–35, and 36–46 years) and over the study period. Almost 50% of the women were not aware of their global TORCH serological status and that is still high the proportion of women susceptible to primary infection, in our geographic area.

Discussion and Conclusions

The availability of serological data, collected over almost 10 years, allowed to evaluate the adherence to TORCH serological screening in our geographic area and to define the number of women susceptible to primary infection. The results of this study highlight a limited access to complete TORCH screening as almost 50% of the women of childbearing age while almost all subjects investigated their serological status for one or more of the main TORCH agents, underlining that women in Palermo may not be consistently advised to seek serological testing before and during their pregnancies. The results of this retrospective study clearly confirm the importance of seroepidemiological surveillance study to plan the most effective prevention strategies to reduce the risk of congenital infections.

162 - SARS-CoV-2 OMICRON recombinant epidemiology in Northwest of Italy.

Federica Novazzi ⁽¹⁾ - Daniele Focosi ⁽²⁾ - Andreina Baj ⁽¹⁾ - Angelo Paolo Genoni ⁽¹⁾ - SARA BOUTAHAR ⁽¹⁾ - Francesca Dragoferrante ⁽¹⁾ - Fabrizio Maggi ⁽¹⁾

Università dell'Insubria, Dipartimento Medicina e Chirurgia, Varese, Italia ⁽¹⁾ - Ospedale di Pisa, North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy, Pisa, Italia ⁽²⁾

SARS-CoV-2 OMICRON recombinant epidemiology in Northwest of Italy.

Federica Novazzi^{1,2}, Daniele Focosi³, Andreina Baj^{1,2}, Angelo Paolo Genoni^{1,2}, Sara Bouthar^{1,2}, Francesca Dragoferrante^{1,2}, Fabrizio Maggi^{1,2}.

¹Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy; ²Department of Medicine and Surgery, University of Insubria, Varese, Italy, ³ North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy

Introduction: As has happened in the past, RNA viruses can recombine. Recombination can be difficult to detect and requires whole-genome sequencing. The study aimed to investigate the molecular epidemiology of SARS-COV-2 strains in the Lombardy Region, to monitor more aggressive strains. The first recombinant SARS-COV-2 Omicron strains were discovered in January 2022 and the spread is constantly monitored globally. Most Omicron recombinants identified to date have BA.1 as acceptor and the breakpoint within ORF1ab and hence preserve Spike protein from BA.2 (e.g., XE, XG, XH, XJ, XK, XM, XN, XP, XQ, and XR): this is not surprising since BA.2 currently outcompetes BA.1. XP is the lone exception, having BA.1.1 (the BA.1 sublineage with R346K mutation) as an acceptor (including Spike) and BA.2 as a donor.

Materials and Methods: Several nasopharyngeal swabs samples tested positive for SARS-CoV-2 presence, and received in the Microbiology Laboratory of ASST Sette Laghi in the period between April to June 2022 were screened for viral typing. The presence of SARS-COV-2 RNA was determined with the SARS-COV-2 AMP Kit Alinity (Abbott) test and typing was achieved by NGS sequencing (Illumina). According to the current regulations, typing was carried out on samples of a) patients hospitalized and immunocompromised; b) travelers from geographical areas at risk; c) subjects positive to the virus after vaccination; d) contacts of subjects positive to known variants; e) subjects from epidemic outbreaks.

Results: A total of 1000 samples were examined for the presence of SARS-CoV-2 RNA, and 177 (0,2%) were subjected to molecular typing analysis. After PANGOLIN analysis, the recombinant results obtained with sequencing showed the following prevalence rates: 6 (3,4%) were recombinant strains in particular 2 XN (1 BA.2 and 1 B.1.1.529), 1 XQ (BA.2), 1 XT (B.1.1.529), 1 XF and 1 XP. The other most detected lineages were OMICRON 21L, 21K, 21L, 21M, 22A,22B, and 20A.

Discussion and Conclusions: Constant monitoring of the distribution and prevalence of SARS CoV-2 variants is of fundamental utility to trace the presence of mutations potentially involved in the pathogenesis and immune escape of the virus. Currently, recombinant strains of SARS-COV-2 are monitored to understand how they behave over time and continued surveillance for SARS-CoV-2 recombinants is needed.

175 - The role of human DDX3 helicase in HSV-2 infection.

Carmen Rita Piazza ⁽¹⁾ - Giulia Lottini ⁽¹⁾ - Cristina Di Primio ⁽²⁾ - Marianna Mignanelli ⁽³⁾ - Pietro Giorgio Spezia ⁽⁴⁾ - Michele Lai ⁽⁴⁾ - Giulia Freer ⁽⁴⁾ - Paola Quaranta ⁽⁴⁾ - Mauro Pistello ⁽⁴⁾

Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽¹⁾ - CNR di Pisa, Istituto di Neuroscienze, Pisa, Italia ⁽²⁾ - Scuola Normale Superiore, Laboratorio di Biologia Bio@SNS, Pisa, Italia ⁽³⁾ - Università di Pisa, Dipartimento di Medicina Traslazionale, Pisa, Italia ⁽⁴⁾

The role of human DDX3 helicase in HSV-2 infection.

Authors: CARMEN R. PIAZZA^{1,2}, GIULIA LOTTINI^{1,2}, CRISTINA DI PRIMIO³, MARIANNA MIGNANELLI⁴, PIETRO G. SPEZIA¹, MICHELE LAI¹, GIULIA FREER¹, PAOLA QUARANTA¹, MAURO PISTELLO^{1,5}

Affiliations: ¹Centro Retrovirus, University of Pisa, Pisa, Italy; ²Department of Medical Biotechnologies, University of Siena, Siena, Italy; ³Institute of Neuroscience, CNR of Pisa, Pisa, Italy; ⁴Laboratorio di Biologia Bio@SNS, Scuola Normale Superiore, Pisa, Italy; ⁵Virology Operative Unit, University Hospital of Pisa, Pisa, Italy.

Introduction: The human protein DDX3 is a DEAD box ATP-dependent RNA helicase that regulates transcription, mRNA maturation and translation. DDX3 is also involved in replication of several RNA viruses. Recently, we demonstrated that some DDX3 inhibitors are effective against several viruses with positive sense single-stranded RNA (ssRNA+) genome such as Coxsackie B (CV-B), while they are not effective against viruses with negative sense single-stranded RNA (ssRNA-) genome such as measles virus (MeV) and vesicular stomatitis virus (VSV). In addition, it seems that DDX3 inhibition also impacts on DNA virus replication. To further clarify the role of DDX3 protein in viral infection, we investigate the effect of DDX3 inhibitors during Herpes Simplex virus 2 (HSV-2) infection. HSV-2 is a double strand DNA (dsDNA) virus belonging to Herpesviridae family. HSV-2 is a human pathogen and it is primarily associated with genital lesions but is also responsible for severe infections in both immunocompetent and immunodeficient individuals. Replication of HSV-2 occurs in the cell nucleus, where the virus takes over the host gene expression machinery during active infection. The compounds we tested target specifically DDX3 RNA binding domain leaving the ATP-binding domain unchanged.

Materials and Methods: A549 cells were infected with 0.004 MOI of HSV-2 in the presence of DDX3 inhibitors and monitored up to 2 days post infection (DPI). Antiviral activities of these compounds were determined *in vitro* by plaque assay and the half maximal inhibitory concentration (IC₅₀) and Selectivity Index (SI) were calculated. To evaluate the production of DDX3 and viral proteins, western blotting was performed by infecting A549 cells with 0.1 MOI of HSV-2 and doing protein extraction at different hour PI. Furthermore, A549 cells were infected with 0.1 MOI of HSV-2 in presence of DDX3 inhibitors and another western blotting was carried out 2DPI. Moreover, molecular analyses were performed to evaluate DDX3 and viral gene expression. Lastly, distribution and localization of DDX3 during HSV-2 infection were visualized by immunofluorescence.

Results: During the infection of cells with HSV-2, the level of DDX3 protein is significantly reduced, its cytoplasmatic distribution is altered compared to uninfected cells and DDX3 protein may colocalize with gD 1/2 HSV-2 protein. As DDX3 inhibitors exert antiviral activities against HSV-2, they are able to restore DDX3 protein level and cellular localization.

Discussion and Conclusions: DDX3 seems to be involved in HSV-2 infection; for this reason, it may be an excellent target to develop antiviral agents clinically relevant against HSV-2 infection.

184 - Antiviral activity of natural compounds and composite polymeric matrix against SARS-CoV-2.

Rossella Fonnesu ⁽¹⁾ - Camilla Dolfa ⁽¹⁾ - Alfredo Rosellini ⁽¹⁾ - Alice Cara ⁽¹⁾ - Paola Losi ⁽²⁾ - Ilenia Foffa ⁽²⁾ - Mario D'Acunto ⁽³⁾ - Giorgio Soldani ⁽²⁾ - Paola Quaranta ⁽⁴⁾ - Mauro Pistello ⁽¹⁾ - Paola Mazzetti ⁽¹⁾

U.O. Virologia Universitaria, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italia ⁽¹⁾ - Istituto Fisiologia Clinica, Consiglio Nazionale delle Ricerche, Pisa, Italia ⁽²⁾ - Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Pisa, Italia ⁽³⁾ - Centro Retrovirus - Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Università degli studi di Pisa, Pisa, Italia ⁽⁴⁾

Title: Antiviral activity of natural compounds and composite polymeric matrix against SARS-CoV-2.

¹ROSSELLA FONNESU, ¹CAMILLA DOLFA, ¹ALFREDO ROSELLINI, ¹CARA ALICE ²PAOLA LOSI, ²ILENIA FOFFA, ³MARIO D'ACUNTO, ²GIORGIO SOLDANI, ⁴PAOLA QUARANTA, ¹MAURO PISTELLO, ¹PAOLA MAZZETTI.

¹Laboratory of Virology Unit, Pisa University Hospital, Pisa, Italy; ²Institute of Clinical Physiology of the National Research Council (IFN-CNR), Pisa, Italy; ³Institute of Biophysics of the National Research Council (IBF-CNR), Pisa, Italy; ⁴Department of Translational Research and New Technologies in Medicine and Surgery, Retrovirus Center and Virology Section, University of Pisa, Pisa, Italy.

Introduction: The ongoing SARS-CoV-2 pandemic is pushing for the development of better and more protective personal protective equipment (PPE) to ensure greater safety in use. Metallic nanoparticles (NP), particularly copper or silver, have shown antibacterial and antiviral potential but also noticeable cell toxicity. Combining metal NP with a composite polymeric matrix could maintain the antiviral capacity and reduce toxicity due to NP dispersion. A further increase in virucidal capacity could be obtained by combining NP and essential oils such as the flavonoids that are known for their antiviral properties. Here, specific composite matrices, some of which have already been tested against influenza virus, hepatitis virus and immunodeficiency virus, were probed against SARS-CoV-2.

Materials and Methods: The nanomaterial composites in study were produced by IFC-CNR and IBF-CNR. Antiviral activity was tested in Vero-E6 cells using a clinical strain of SARS-CoV-2. Various concentrations of different flavonoids were tested to assess cytotoxicity. The compounds were incubated at different concentrations and different times with a titrated amount of SARS-CoV-2 and then seeded on Vero-E6 cells. Similarly, nanomaterials layered on discs of a polyurethane matrix were left in contact with the virus at different time points and the viral suspension was then added to Vero-E6 cells. In both experimental settings, cytopathic effect and viral release in supernatant were measured after three days of incubation.

Results: Both Quercetin and Myricetin did not show a cytotoxic effect up to 100 microM. Both compounds exhibited a dose-dependent virucidal effect that reached 90% and 69% reduction with 50 microM of Quercetin and Myricetin respectively. Ag-NP composite nanomaterial exerted an antiviral effect of nearly 60% after one minute of incubation and up to 90% after 10 minutes. Cu-NP composite nanomaterial showed an even higher effect that reduced the viral titer by 80% and 99% after 1 and 10 minutes, respectively.

Discussion and Conclusions: Polyurethane composite nanomaterials have shown good virucidal properties, while flavonoids appear good candidates to develop natural antivirals. Developing PPE coatings composed of NP embedded in a polymeric matrix could improve their efficacy. These new materials could coat many different surfaces and be active against multiple microorganisms.

185 - Palmitoylethanolamide (PEA) inhibits SARS-CoV-2 entry by interacting with S protein and ACE-2 receptor.

Rossella Fonnesu⁽¹⁾ - Veronica La Rocca⁽¹⁾ - Carolina Filippini⁽¹⁾ - Elena Iacono⁽¹⁾ - Erika Plicanti⁽¹⁾ - Maria Sidoti⁽¹⁾ - Giulia Freer⁽¹⁾ - Mauro Pistello⁽²⁾ - Michele Lai⁽¹⁾

Centro Retrovirus - Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Università degli studi di Pisa, Pisa, Italia⁽¹⁾ - U.O. Virologia Universitaria, Azienda Ospedaliero Universitaria Pisana, Pisa, Italia⁽²⁾

Title: Palmitoylethanolamide (PEA) inhibits SARS-CoV-2 entry by interacting with S protein and ACE-2 receptor.

ROSSELLA FONNESU¹, VERONICA LA ROCCA¹, CAROLINA FILIPPINI¹, ELENA IACONO¹, ERIKA PLICANTI¹, MARIA SIDOTI¹, GIULIA FREER¹, MAURO PISTELLO¹⁻², MICHELE LAI¹.

¹Department of Translational Research and New Technologies in Medicine and Surgery, Retrovirus Center and Virology Section, University of Pisa, Pisa, Italy;

²Laboratory of Virology Unit, Pisa University Hospital, Pisa, Italy.

Introduction: The rearrangement of lipid membranes is a crucial step in the replication of several positive-strand RNA viruses such as Coronaviridae. Due to the close connection between lipids, inflammation and viral infection, lipid metabolism has become an area of intense research.

Our work investigates the antiviral potency of PEA, an endogenous lipid mediator with analgesic and anti-inflammatory activity mediated by the activation of peroxisome proliferator receptor alpha (PPAR- α). This lipid was selected among hundreds of compounds for its in-silico predicted ability to bind SARS-CoV-2 S protein. This work aims to validate the in-silico prediction and assess how PEA might act as antiviral and anti-inflammatory compound during COVID19 pathogenicity.

Materials and Methods: Infection of Huh-7 and Calu-3 cells was performed with 0.1 MOI of SARS-CoV-2 VR PV10734, B.1.617.2, and B.1.1.529. Micronized PEA was used at various concentrations to treat cells prior to the infection or in a solution with the viral strains. Neutralization assays were used to validate the entry inhibition, while qRT-PCR and immunocytochemistry were used to assess infection rates.

Results: Preliminary *in silico* analyses predicted the interaction of PEA with SARS-CoV-2 S protein. Our results confirmed this prediction, while PEA causes a reduction of viral infection by nearly 70% when administered to cells or incubated with SARS-CoV-2 virions prior to infection. Interestingly, PEA antiviral activity was maintained among all SARS-CoV-2 variants. Then, we demonstrated by Cell-based ELISA assay the interaction between PEA and the RBD domain of Spike protein.

Finally, we discovered that PEA administration drops Lipid Droplets content in treated cells by 40%. These vesicles are the very same used by SARS-CoV-2 to boost its replication and enhance inflammation.

Discussion and Conclusions: Two different mechanisms could explain the activity of PEA: the inhibition of viral entry caused by PEA binding on SARS-CoV-2 S protein and the activation of lipolysis that dismantles lipid droplets, a fundamental resource of energy and protection for the virus.

The present work demonstrates a novel mechanism of action for PEA as a direct and indirect antiviral agent against SARS-CoV-2.

Further preclinical and clinical tests will be needed to fully consider this lipid as a promising adjuvant therapy in the current COVID-19 pandemic or against emerging RNA viruses that share the same route of replication as Coronaviruses.

193 - First identification of SARS-CoV-2 Omicron BA.4 sub-variant in Italy: genomic comparison with omicron sub-variants

CINZIA PERONACE ⁽¹⁾ - ROSSANA TALLERICO ⁽¹⁾ - MANUELA COLOSIMO ⁽¹⁾ - MARCO DE FAZIO ⁽¹⁾ - FEDERICA PASCERI ⁽¹⁾ - ILENIA TALOTTA ⁽¹⁾ - GIUSEPPINA PANDURI ⁽¹⁾ - LETIZIA PINTOMALLI ⁽²⁾ - ROSARIA OTERI ⁽²⁾ - VALERIA CALANTONI ⁽²⁾ - MARIA TERESA FIORILLO ⁽²⁾ - MARIA CRISTINA CAROLEO ⁽³⁾ - VINCENZA DOLCE ⁽⁴⁾ - ERIKA CIONE ⁽⁴⁾ - PASQUALE MINCHELLA ⁽¹⁾

MICROBIOLOGIA E VIROLOGIA, PUGLIESE-CIACCIO, CATANZARO, Italia ⁽¹⁾ - MICROBIOLOGIA E VIROLOGIA, ASP RC N.5, REGGIO CALABRIA, Italia ⁽²⁾ - DIPARTIMENTO SCIENZE DELLA SALUTE, UNIVERSITA' MAGNA GRAECIA, CATANZARO, Italia ⁽³⁾ - DIPARTIMENTO DI FARMACOLOGIA, UNIVERSITA' DELLA CALABRIA, COSENZA, Italia ⁽⁴⁾

First identification of SARS-CoV-2 Omicron BA.4 sub-variant in Italy: genomic comparison with omicron sub-variants

Cinzia Peronace¹, Rossana Talerico¹, Manuela Colosimo¹, Marco De Fazio¹, Federica Pasceri¹, Ilenia Talotta¹, Giuseppina Panduri¹, Letizia Pintomalli², Rosaria Oteri², Valeria Calantoni², Maria Teresa Fiorillo², Maria Cristina Caroleo³, Vincenza Dolce⁴, Erika Cione⁴, and Pasquale Minchella¹.

1Microbiology and Virology Unit, Pugliese-Ciaccio Hospital, Catanzaro, Italy 2Unit of Microbiology and Virology, North Health Center ASP 5, Reggio Calabria, Italy 3Department of Health Science, University of Catanzaro, 87100 Catanzaro, Italy 4Department of Pharmacy, Health, and Nutritional Sciences, University of Calabria, 87036 Rende

Introduction

We reported the first case of SARS-CoV-2 omicron variant in our region (Calabria, Italy) on December 5, 2021. The Omicron variant of Concern (VOC), has rapidly replaced the delta variant as a dominating SARS-COV-2 variant because of natural selection, favouring the variant with higher infectivity and more strong vaccine breakthrough ability. BA.5 and BA.4 lineages are the currently prevailing sub-variant, herein described and first detected in Italy, on April, 25 by depositing it in ICOGEN Platform by Istituto Superiore di Sanità (ISS). The omicron lineage BA.4 is here studied in comparison with the other three lineages, together with the capability of five different type of Rapid Antigenic Tests (RATs) to recognize it.

Materials and methods

A positive nasopharyngeal and oropharyngeal swab was collected in UTM™ and extracted for viral nucleic acids purification. The Real Time (RT) PCR test was carried out with the TaqPath COVID-19 CE-IVD RT-PCR kit, which targets the following genes of SARS-CoV-2: i) open reading frame (ORF)1ab; ii) nucleocapsid (N) and iii) spike (S). RNA extracted by the specimen, underwent genomic characterization following two methodologies: the Sanger-based sequencing and whole-genome based on next-generation sequencing (NGS) by MiSeq System. CleanPlex SARS-CoV-2 FLEX Paragon Genomics Panel performed a reverse transcription of the whole-genome and library preparation. The SOPHIA Platform analyzed FASTQ reads. Clade analyses were obtained by ICOGEN Platform (ISS) and the GISAID database.

Alignment of FASTQ obtained by NGS data were performed SnapGene® software. SNAP gene finder has been developed so far to be easily adaptable to a variety of genomes.

Results

The NGS approach and subsequent analysis of FASTQ reads by SOPHIA DDM Platform, revealed BA.4 omicron variant. The sequences were deposited in the ICOGEN Platform on the April, 25 2022 and GISAID on the April, 26 2022. The bioinformatics comparison analysis with the other three sub-variants, pointed out a new mutation specifically a deletion in ORF 1 ab gene which correspond to KSF141_del in non-structural protein 1 (nsp1) a critical virulence

factor able to escape immune-response. This deletion was not present previously and therefore was never reported till now. Concerning the Rapid Antigenic Tests (RATs) assayed, we obtained a positive result for all five antigenic tests evaluated.

Discussion and Conclusions

Our data showed a new deletion in the ORF1 ab gene linked to nsp1 protein that was indicating as an interesting target for the development of live attenuated vaccines with deletions in key regions of nsp1. For this reason, is necessary to study the viral strain by NGS approach in order to discover novel mutations and develop more effective vaccines.

195 - In vitro virucidal activity of active food packaging based on monoglycerides against a Human Coronavirus and other viruses

Francesco Ricchi ⁽¹⁾

Università degli Studi di Modena e Reggio Emilia, Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, Modena, Italia ⁽¹⁾

In vitro virucidal activity of active food packaging based on monoglycerides against a Human Coronavirus and other viruses

Francesco Ricchi¹, Arianna Sala¹, Gloria Agliata¹, Riccardo Di Leo², Andrea Quartieri², Andrea Pulvirenti³, Claudio Cermelli¹

¹ Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, Università degli Studi di Modena e Reggio Emilia, Modena

² Pactin, Laboratorio Biopolimeri, Reggio Emilia

³ Dipartimento di Scienze della Vita, Università degli Studi di Modena e Reggio Emilia, Modena

INTRODUCTION

The ongoing pandemic by SARS-CoV-2 has generated an increased demand for materials with virucidal properties, also in the field of food packaging. A solid body of evidence documents the microbicidal activity of lipids, such as fatty acids and monoglycerides, on a large spectrum of microorganisms. In this work, virucidal activity of four different formulations based on monolaurin and monocaprine, were tested on betacoronavirus HCoV OC43, Herpesvirus HSV-1 and the Adenovirus AdV-5. The first aim was to assess the most active formulation against these viruses. In a next step, the best performing formulation was used as antimicrobial agent to develop a film as active food packaging.

MATERIALS AND METHODS

Each of the 4 lipid formulations was tested at different concentrations and times of contact by incubating the virus suspensions with each formulation for 10 and 20 minutes followed by titration with end point dilution. In a second phase the most active formulation was used to prepare a packaging film which was tested for its ability in inactivating HCoV OC43 and HSV-1 but not AdV which resulted not inactivated by any of the 4 formulations. The virucidal activity of this active packaging was tested at different concentrations and time of contact, up to 24 hour. Briefly, the films were contaminated with the viruses under study and at different time points the film samples were soaked in 1ml of cell growth medium and vortexed for 1' to eluate the survived virus. Viral loads of these suspensions were titrated by end point dilution on cell cultures.

RESULTS

All the four formulations tested were found active on HCoV OC43 and HSV-1 (in some cases with a reduction >4 Log) but not on AdV-5. The packaging film showed a remarkable reduction of the viral load of both virus (>2,5 Log).

DISCUSSION

These results confirm that natural compounds with antiviral properties for active food packaging may represent a new and promising strategy for virus transmission.

204 - Gold-Nanoparticle delivery of CRISPR/Cas13 as antiviral strategy against emerging RNA viruses

Alessandro De Carli⁽¹⁾ - Domenico Favaro⁽²⁾ - Rossella Fonnesu⁽²⁾ - Piotr Barski⁽³⁾ - Vittoria Raffa⁽⁴⁾ - Mauro Pistello⁽⁵⁾ - Michele Lai⁽²⁾

Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia⁽¹⁾ - Università di Pisa, Dipartimento di Medicina Traslazionale, Pisa, Italia⁽²⁾ - ProChimia Surfaces Sp. z o.o., Research and Development ProChimia Surfaces, Gdynia, Polonia⁽³⁾ - Università di Pisa, Dipartimento di Biologia, Pisa, Italia⁽⁴⁾ - U.O. Virologia Universitaria, Azienda Universitaria Ospedaliera Pisana, Pisa, Italia⁽⁵⁾

Gold-Nanoparticle delivery of CRISPR/Cas13 as antiviral strategy against emerging RNA viruses

ALESSANDRO DE CARLI^{1,5}, DOMENICO FAVARO¹, ROSSELLA FONNESU¹, PIOTR BARSKI⁴, VITTORIA RAFFA³, MAURO PISTELLO^{1,2}, MICHELE LAI¹

¹Department of Translational Research and New Technologies in Medicine and Surgery, Retrovirus Center and Virology Section, University of Pisa, Pisa, Italy;

²Laboratory of Virology Unit, Pisa University Hospital, Pisa, Italy;

³Department of Biology, Nanomedicine and Molecular Biology Section, University of Pisa, Pisa, Italy;

⁴ProChimia Surfaces, Gdynia, Poland.

⁵Department of Medical Biotechnologies, University of Siena, Siena, Italy

Introduction: The pandemic that started in 2019 due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlighted the urgency of novel therapeutic approaches that can easily be used against emerging viruses whereas no vaccines or therapies are available. Recent evidence show that the enzyme CRISPR Associated Protein (Cas) 13 is capable to destroy SARS-CoV-2 genomes in infected cells. Cas13 localizes in the very same organelles in which both SARS-CoV-2 and ZIKV replicate and is capable to abolish infection in transfected cells. Unfortunately, no effective delivery of this protein is available at the moment. The aim of the present work is to use nanoformulated nanoparticles (GNPs) to deliver Cas13 into infected cells without any kind of transfection protocol and evaluate its effectiveness of it as a new efficient antiviral approach.

Materials and methods: *Selection of gRNAs:* We obtained HuH-7 lines stably expressing Cas13 and one gRNA previously selected, targeting N/RdRP and NSP3/C genes in SARS-CoV-2 or ZIKV genomes, respectively. These cells were then infected. Then, intracellular and extracellular viral load was detected by q-RT-PCR. The antiviral potency of GNP-Cas13 was then validated by Western Blot and Immunocytochemistry assays.

Evaluation of localization and efficacy of nanoformulation: we functionalized GNPs with Cas13 enzyme. Then, GNP-Cas13 were used to evaluate the cellular localization by confocal live imaging assays. Finally, GNP-Cas13 directed against SARS-CoV-2 N and ZIKV C proteins were administered to Huh-7 and Calu-3 cells before or after viral infection.

Results: *Selection of gRNAs:* We observed a reduction of SARS-CoV-2 infection when targeting RNA-dependent RNA polymerase (RdRP) and Nucleocapsid (N) protein resulting as if they had not been infected. In agreement, we observed the same reduction when ZIKV NSP3/C protein was targeted.

Evaluation of localization and efficacy of nanoformulation: our nanoformulation spontaneously enter in cells and localize into cytoplasmatic vesicles (autophagosomes, endosomes). In agreement, we observed a 3-logarithm decreased number of infected cells when GNP-Cas13 are administered before infection.

Discussion and conclusions: The results confirm that the CRISPR/Cas13 system effectively degrades the genomes of ZIKV and SARS-CoV-2 and blocks the infection when proper genomic sites are targeted. At the same time, GNPs are an excellent delivery system, as they allow the Cas13 to enter cells spontaneously and localize in the very same organelles in which these viruses replicate.

207 - Humoral and cell-mediated immune response in COVID-19 vaccinees according to history of prior SARS-CoV-2 infection.

Giorgio Fedele⁽¹⁾ - Annapina Palmieri⁽²⁾ - Ilaria Schiavoni⁽¹⁾ - Pasqualina Leone⁽¹⁾ - Eleonora Olivetta⁽³⁾ - Cecilia Damiano⁽²⁾ - Anna Di Lonardo⁽²⁾ - Caterina Trevisan⁽⁴⁾ - Angela Marie Abbatecola⁽⁵⁾ - Carmine Cafariello⁽⁶⁾ - Alba Malara⁽⁷⁾ - Pasquale Minchella⁽⁸⁾ - Raffaele Antonelli Incalzi⁽⁹⁾ - Anna Teresa Palamara⁽¹⁾ - Graziano Onder⁽²⁾ - Paola Stefanelli⁽¹⁾

Istituto Superiore di Sanità, Dipartimento Malattie Infettive, Roma, Italia⁽¹⁾ - Istituto Superiore di Sanità, Dipartimento Malattie Cardiovascolari, Endocrino-Metaboliche e dell'Invecchiamento, Roma, Italia⁽²⁾ - Istituto Superiore di Sanità, Centro Nazionale per la Salute Globale, Roma, Italia⁽³⁾ - Università di Ferrara, Dipartimento Scienze Mediche, Ferrara, Italia⁽⁴⁾ - Azienda Sanitaria Locale (ASL) Frosinone, Dipartimento Centri Diurni Alzheimer, Frosinone, Italia⁽⁵⁾ - Italian Hospital Group, Direzione Scientifica, Roma, Italia⁽⁶⁾ - ANASTE Humanitas Foundation, Presidenza, Roma, Italia⁽⁷⁾ - Azienda Ospedaliera Pugliese Ciaccio, Dipartimento di Microbiologia e Virologia, Catanzaro, Italia⁽⁸⁾ - Università Campus Bio-Medico, Dipartimento di Medicina, Roma, Italia⁽⁹⁾

Humoral and cell-mediated immune response in COVID-19 vaccinees according to history of prior SARS-CoV-2 infection.

Giorgio Fedele¹, Annapina Palmieri², Ilaria Schiavoni¹, Pasqualina Leone¹, Eleonora Olivetta³, Cecilia Damiano², Anna Di Lonardo², Caterina Trevisan⁴, Angela Marie Abbatecola⁵, Carmine Cafariello⁶, Alba Malara⁷, Pasquale Minchella⁸, Raffaele Antonelli Incalzi⁹, Anna Teresa Palamara¹, Graziano Onder², Paola Stefanelli¹.

1. Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
2. Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome, Italy.
3. National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy
4. Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
5. Alzheimer's Disease Day Clinic Department, Azienda Sanitaria Locale (ASL) Frosinone, Italy.
6. Geriatrics Outpatient Clinic and Territorial Residences, Italian Hospital Group, Rome, Italy
7. ANASTE Humanitas Foundation, Rome, Italy
8. Department of Microbiology and Virology, Pugliese Ciaccio Hospital, 88100 Catanzaro, Italy.
9. Geriatrics Unit, Department of Medicine, Campus Bio-Medico University and Teaching Hospital, Rome, Italy

Introduction: The present study aimed to monitor humoral and cell-mediated immune response to COVID-19 vaccines according to history of prior SARS-CoV-2 infection. To this purpose healthy adults and frail nursing home (NH) residents were enrolled at time of their first vaccination.

Material and Methods: Anti-trimeric Spike (Anti-S) IgG antibody levels were assessed at study enrolment (prior to the first dose of vaccine, T0) and then after 2 (T1), 6 months (T2) and 12 months (T3). Between T2 and T3 subjects received a third booster vaccine dose.

T-cell responses were measured at T2 and T3 in NH residents, as the frequency of Spike-specific CD4⁺ and CD8⁺ T cells producing IFN-gamma, TNF-alfa and IL-2 assessed by flow cytometry.

Results: Anti-trimeric Spike IgG were induced by the vaccination and their levels decreased in the interval between T1 and T2. Superior humoral immunity was induced in healthy adults and NH residents with a previous SARS-CoV-2 infection. Twelve months after the first vaccination (T3) the levels of Anti-S IgG were substantially increased both in healthy adults and in NH residents, and the effect of previous SARS-CoV-2 infection was no longer apparent.

Superior cell-mediated immunity was evident at T2 in NH residents with a previous SARS-CoV-2 infection. Similar levels of T-cell responses were observed at T3 in residents with previous SARS-CoV2 infection, while an increase in Spike-specific T cells was observed between T2 and T3 in COVID-19 naïve subjects, especially increasing the CD8⁺ response.

Discussion and Conclusions: These preliminary results show that a previous SARS-CoV-2 infection significantly potentiates the immune response to vaccination up to six months after the infection. Overall, these findings might provide important information for future prevention strategies.

226 - Antiviral activity of fungal secondary metabolites against Canine coronavirus infection

Claudia Cerracchio⁽¹⁾ - Maria Michela Salvatore⁽²⁾ - Francesca Paola Nocera⁽¹⁾ - Luisa De Martino⁽¹⁾
- Rosario Nicoletti⁽³⁾ - Anna Andolfi⁽²⁾ - Filomena Fiorito⁽¹⁾

Università degli Studi di Napoli, Federico II, Dipartimento di Medicina Veterinaria e Produzioni Animali, Napoli, Italia⁽¹⁾ - Università degli Studi di Napoli, Federico II, Dipartimento Scienze Chimiche, Napoli, Italia⁽²⁾ - Università degli Studi di Napoli, Federico II, Dipartimento di Agraria, Napoli, Italia⁽³⁾

Antiviral activity of fungal secondary metabolites against Canine coronavirus infection

Claudia Cerracchio¹, Maria Michela Salvatore², Francesca Paola Nocera¹, Luisa De Martino¹, Rosario Nicoletti^{3,4}, Anna Andolfi^{2,5}, Filomena Fiorito^{1,5}

¹Department of Veterinary Medicine and Animal Production, University of Naples Federico II, 80137 Naples, Italy; ²Department of Chemical Sciences, University of Naples Federico II, 80026 Naples, Italy; ³Council for Agricultural Research and Economics, Research Centre for Olive, Fruit and Citrus Crops, Caserta, Italy; ⁴Department of Agricultural Sciences, University of Naples Federico II, 80055, Portici, Italy. ⁵BAT Center-Interuniversity Center for Studies on Bioinspired Agro-Environmental Technology, University of Naples Federico II, 80055 Portici, Italy

filomena.fiorito@unina.it

Introduction - Canine coronavirus (CCoV-II), an alphacoronavirus, may cause self-limiting enteric disease in dogs, especially in puppies. The noteworthy plasticity of CoVs occurs through mutation and recombination processes, which occasionally generate new dangerous variants. The current SARS-CoV-2 pandemic as well as the recent detection of a novel canine-feline recombinant alphacoronavirus isolated from a human patient emphasizes the cross-species transmission ability of CoVs. In this contest, studying antiviral compounds is considered essential to fight CoVs infections.

Fungi produce secondary metabolites (SMs), often developed as antibiotics, fungicides, hormones, and plant growth regulators. Screening performed on benzo- γ -pyrone 3-*O*-methylfunicone, a SM produced by *Talaromyces pinophilus*, showed that it reduces infectivity of hepatitis C virus and bovine herpesvirus 1. Based on this evidence, herein antiviral ability of OMF was evaluated against CCoV-II infection.

Materials and methods - OMF was obtained by extraction and chromatographic purification of culture filtrate of *T. pinophilus* (strain LT6). Following CCoV (378/strain) infection in canine fibrosarcoma (A72) cell line, bioscreen, immunofluorescence staining, cytomorphological and virus yield analyses were performed.

Results - During CCoV infection, the non-toxic concentration of 0.5 μ M OMF markedly increased signs of cell viability. Moreover, OMF induced a significant reduction in virus yield. These findings occurred in the presence of an intense downregulation in the expression of the viral nucleocapsid protein.

Discussion and Conclusions - Taken together, our results suggest that OMF shows a potential activity against CCoV infection. To date, very few antiviral compounds to fight CCoV infection have been described. The screening of hypothetical antivirals in *in vitro* animal model of CoVs avoids the manipulation of extremely dangerous human CoVs (SARS-CoVs, MERS-CoV).

227 - Canine coronavirus activates the aryl hydrocarbon receptor during infection

Claudia Cerracchio⁽¹⁾ - Maria Grazia Polverino⁽²⁾ - Valentina Iovane⁽³⁾ - Anna Rita Attili⁽⁴⁾ - Maria Grazia Amoroso⁽²⁾ - Filomena Fiorito⁽¹⁾

Università degli Studi di Napoli Federico II, Medicina Veterinaria e Produzioni Animali, Napoli, Italia

⁽¹⁾ - Istituto Zooprofilattico Sperimentale del Mezzogiorno, UOS Diagnostica Virologica e Colture

Cellulari, Portici (Napoli), Italia ⁽²⁾ - Università degli Studi di Napoli Federico II, Agraria, Portici

(Napoli), Italia ⁽³⁾ - Università di Camerino, Scuola di Bioscienze e Medicina Veterinaria, Camerino, Italia ⁽⁴⁾

Canine coronavirus activates the aryl hydrocarbon receptor during infection

Claudia Cerracchio¹, M.G. Polverino², V. Iovane³, A.R. Attili⁴, M.G. Amoroso², F. Fiorito^{1,5}

¹Department of Veterinary Medicine and Animal Production, University of Naples Federico II, 80137 Naples, Italy; ²Istituto Zooprofilattico Sperimentale del Mezzogiorno, 80055, Portici, Portici (Naples), Italy; ³Department of Agricultural Sciences, University of Naples Federico II, 80055, Portici, Italy; ⁴School of Biosciences and Veterinary Medicine, University of Camerino, Italy; ⁵BAT Center-Interuniversity Center for Studies on Bioinspired Agro-Environmental Technology, University of Naples Federico II, 80055 Portici, Italy

filomena.fiorito@unina.it

Introduction - The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that interacts with various endogenous and exogenous substrates such as bilirubin, biliverdin, tryptophan metabolites, environmental pollutants, as well as microbial metabolites. After the activation, AhR translocates into the nucleus where it controls the expression of target genes, including AhR repressor, detoxifying monooxygenases, and cytokines. Current findings establish that AhR signaling can influence intrinsic, innate and adaptive immune response to different microorganisms. Recently, it has been demonstrated a role for AhR as a controller of the host response to Coronaviruses (CoVs) (MCoV, SARS-CoV-2, HCoV 229E) infection. Genotype II of canine coronavirus (CCoV-II), an alphacoronavirus, can provoke moderate to severe enteric disease in dogs. Herein, we tested the involvement of AhR in CCoV infection.

Materials and methods - Infection of CCoV (378/strain) in canine fibrosarcoma (A72) cell line was carried out in the presence of CH22319149, an AhR antagonist. Bioscreen, immunofluorescence, and virus yield analyses were performed.

Results - During CCoV infection an upregulation of AhR was detected. The non-toxic concentration of 2 μ M CH22319149 markedly decreased cell death signs and increased cell viability. Furthermore, the AhR antagonist provoked a considerable decrease in virus yield. These results were accompanied by the inhibition of the expression of viral nuclear protein.

Discussion and Conclusions - Overall, our findings demonstrate that infection with CCoV activates AhR. In addition, pharmacologic AhR inhibition provokes a reduction in CoVs replication *in vitro*, identifying AhR as a conceivable candidate target for antiviral therapy.

236 - In vitro study of the interaction of enoxaparin sodium or heparan sulfate with not SARS-CoV strains

Virginia Fuochi ⁽¹⁾ - Rosalia Emma ⁽¹⁾ - Massimo Caruso ⁽¹⁾ - Federica Ronchi ⁽²⁾ - Celestino Ronchi ⁽²⁾ - Filippo Drago ⁽¹⁾ - Pio Maria Furneri ⁽¹⁾

Università degli Studi di Catania, BIOMETEC, Catania, Italia ⁽¹⁾ - Delim Cosmetics & Pharma s.r.l, R&D, Vimidrone (MI), Italia ⁽²⁾

***In vitro* study of the interaction of enoxaparin sodium or heparan sulfate with not SARS-CoV strains**

VIRGINIA FUOCHI^{1,2}, ROSALIA EMMA¹, MASSIMO CARUSO^{1,2}, FEDERICA RONCHI³, CELESTINO RONCHI³,
FILIPPO DRAGO¹, & PIO MARIA FURNERI^{1,2}

¹Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Catania, Italy; ²Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy; ³Delim Cosmetics & Pharma s.r.l., Vimodrone (MI), Italy

Introduction: As is now well known, the entry into human cells of the SARS-CoV and SARS-CoV-2 viruses is initiated by binding to angiotensin converting enzyme 2 (ACE2). In fact, the attachment of the virus to the host cell is initiated by the interactions between the protein S and its receptor. Anyhow, the site of receptor binding domains within the S1 region of a coronavirus protein S varies for each coronavirus. Additionally, the spike protein of other human coronaviruses can bind to a secondary receptor, or co-receptor, to facilitate such entry. (MERS)-CoV uses sialic acid as a co-receptor together with its main receptor dipeptidyl peptidase 4. Human CoV-NL63, which also uses ACE2 as a receptor, uses heparan sulfate (HS) as a coreceptor. The SARS-CoV pseudovirus also uses HS as a co-receptor for infectivity. Differently, HCoV-229E uses human aminopeptidase N while HCoV-OC43 uses 9-O-acetyl-sialic acid. The aim of this work was to investigate the possible interactions between enoxaparin sodium salts (EX) and heparan sulfate (HS) on Coronavirus strains that do not have ACE2 as the main interaction receptor (HCoV-229E and HCoV-OC43) in order to be able to highlight these molecules as inhibitors of viral adsorption. **Materials and Methods:** The cytotoxicity of these molecules on MRC5 or HCT-8 cells was evaluated at different times by MTT. Moreover, an air-liquid interface (ALI) exposure using a Borgwaldt LM4E vaping machine with an aerosol nebulizer attached for the vaporization of the solutions object of our study directly on the cellular monolayer, was also investigated. Finally, for the evaluation of the antiviral activity, experimental condition was performed by co-exposure of HCoV-229E and HCoV-OC43 with HS and EX. **Results:** Both EX and HS showed cytotoxicity in a dose depending manner both in normal treatment or ALI exposure. Both EX and HS showed a slight viral inhibition. In fact, a reduction in virus CPE of about 30% was observed with the tested dose equal to 2.5 mg/mL against 229e. All other doses tested showed no inhibition, as well as, no inhibition was observed for HCoV-OC43 strain at any of the doses tested. **Discussion:** It is known that, SARS-CoV-2 spike protein interacts with glycosaminoglycans such HS to enhance the attachment of viral particles to the cell surface by promoting their entry, conversely EX has been reported to negatively interact with virus adsorption (SARS-CoV-2). Our results demonstrated that they could also interact with other cellular receptors for coronavirus for this reason other *in vitro* experiment and molecular docking modeling are on-going.

238 - Identification of interactions between human nuclear proteins and HPV16 genome

Maria Vittoria Morone⁽¹⁾ - Annalisa Chianese⁽¹⁾ - Giuliana Donadio⁽²⁾ - Angela Nebbioso⁽³⁾ - Veronica Sian⁽³⁾ - Giuseppe Greco⁽¹⁾ - Giuseppina Sanna⁽⁴⁾ - Sergio Amitrano⁽⁵⁾ - Lucia Altucci⁽³⁾ - Massimiliano Galdiero⁽¹⁾ - Fabrizio Dal Piaz⁽²⁾ - Gianluigi Franci⁽²⁾

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italia⁽¹⁾ - Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Italia⁽²⁾ - Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Napoli, Italia⁽³⁾ - Department of Biomedical Sciences, Università of Cagliari, Monserrato (CA), Italia⁽⁴⁾ - Fondazione "Bartolo Longo III Millenio", Fondazione, Pompei, Italia⁽⁵⁾

Identification of interactions between human nuclear proteins and HPV16 genome

MARIAVITTORIA MORONE¹, ANNALISA CHIANESE¹, GIULIANA DONADIO², ANGELA NEBBIOSO³, VERONICA SIAN³, GIUSEPPE GRECO¹, GIUSEPPINA SANNA⁴, SERGIO AMITRANO⁵, LUCIA ALTUCCI³, MASSIMILIANO GALDIERO¹, FABRIZIO DAL PIAZ², GIANLUIGI FRANCI².

¹ Department of Experimental Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.

² Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy

³ Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.

⁴ Department of Biomedical Sciences, University of Cagliari, Cittadella Universitaria Monserrato (CA), 09042 Monserrato, Italy.

⁵ Fondazione "Bartolo Longo III millennio" Via Lepanto, 153, 80045 Pompei (NA), Italia.

Introduction: Human Papillomavirus (HPV) is a member of the *Papillomaviridae* family, characterized by infecting cells in active proliferation such as epithelial cells, and its replicative cycle is associated with the differentiation of the host cell. HPV infections are one of the most common causes of sexually transmitted diseases spread around the world; it is estimated that about 75% of people contract the virus at least once in their lives: the infection affects both women and men, especially in the juvenile age, which coincides with the beginning of sexual activity. HPV is present in 99.7% of cervical cancers and in a high percentage in anal carcinomas, but vaginal, vulva and oral carcinomas are not excluded. To date, over 200 different genotypes are known, each of which shows a narrow tissue specificity for infection. Globally, almost 70% of cervical carcinoma cases are caused by HPV 16 and 18, while the remaining 30% is caused by HPV 31, 33 and other genotypes.

To counter this viral spread, it is advisable to increase prevention through vaccination, in fact, to date there are 3 vaccines approved by the Food and Drug Administration (FDA) as there is no effective treatment for cancer caused by HPV. The aim of this project is to identify all human proteins that interact with the HPV 16 genome in order to find new therapeutic drugs, through the use of an innovative approach. To date, several techniques have been known to detect such interactions as the chromatin immunoprecipitation test (ChIP) and the DNA pull-down test, both presenting limitations. Then an evolution of DNA pull-down was carried out for long regions of DNA modified with biotinylated oligo, thus identifying a new method: Long Regions of DNA Pull-down (LDP). **Materials and Methods:** First, hybrid oligos were designed using Primer 3 software for the entire HPV 16 sequence genome. Plasmid phpv-16 in the bacterium E.coli (ATCC[®] 45113~) was amplified, extracted and used as a template for the first stage amplification by

PCR pull-down. The first PCR amplifies the region of interest with the use of hybrid primers that carry a specific region and a second unique region not present in the genome. The 500 bp amplified segments, thus obtained, were used as templates in the second phase of PCR, to obtain fragments with biotinylated ends in 5'. In the meantime, the nuclear extraction of SiHa cells (Elabscience EP-CL-0210), containing about 3 integrated copies of HPV 16 per cell, has been conducted. Subsequently, the DNA pull-down was carried out: the biotinylated dsDNA fragment interacted with the streptavidin sepharose beads and the nuclear cell extract was added to this complex, and, finally, the final product was analyzed using Liquid Chromatography Mass Spectrometry-Mass Spectrometry (LC/MS-MS). **Results:** About 4350 proteins were identified by mass spectrometry analysis and 310 of these were unique. Gene ontology (GO) was carried out by analyzing the biological processes, molecular functions and cellular components in which the identified interactors participate. An important part of them is involved in DNA replication, transcription and translation.

Discussion and Conclusions: This technique could offer new informations about HPV 16-host cell interaction, for example new interactions involved in the mechanism of integration of the virus in the host cell which are still unknown. Further studies need to be conducted to investigate new therapies to combat the infection, progression and pathogenicity of HPV 16.

240 - Antiviral Activity of the Rhamnolipids from the Antarctic Bacterium *Pseudomonas gessardii* against Herpesviridae and Coronaviridae family

Rosa Glugliano⁽¹⁾ - Carmine Buonocore⁽²⁾ - Carla Zannella⁽¹⁾ - Fortunato Palma Esposito⁽²⁾ - Pietro Tedesco⁽²⁾ - Anna De Filippis⁽¹⁾ - Massimiliano Galdiero⁽¹⁾ - Donatella de Pascale⁽²⁾ - Gianluigi Franci⁽³⁾

Università degli Studi della Campania "Luigi Vanvitelli", dipartimento medicina sperimentale, Napoli, Italia⁽¹⁾ - Stazione Zoologica Anton Dohrn, 2. Department of Marine Biotechnology, Napoli, Italia⁽²⁾ - Università di Salerno, dipartimento di medicina, Salerno, Italia⁽³⁾

Antiviral Activity of the Rhamnolipids from the Antarctic Bacterium *Pseudomonas gessardii* against Herpesviridae and Coronaviridae family

ROSA GIUGLIANO¹, CARMINE BUONOCORE^{2,3}, CARLA ZANNELLA¹, FORTUNATO PALMA ESPOSITO², PIETRO TEDESCO², ANNA DE FILIPPIS¹, MASSIMILIANO GALDIERO¹, GIANLUIGI FRANCI⁴, DONATELLA DE PASCALE^{2,3}

1. Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy;
2. Department of Marine Biotechnology, Stazione Zoologica Anton Dohrn, Naples, Italy;
3. Institute of Biochemistry and Cell Biology, National Research Council, Naples, Italy;
4. Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy.

Introduction: Emerging and re-emerging viruses pose a serious threat to human health, consequently, new strategies are required to counteract their development. In this context, rhamnolipids (RLs) are good candidates. RLs are a class of glycolipids produced by the genus *Pseudomonas*, consisting of one or two rhamnose linked to one of two fatty acid chains. RLs show several advantages compared to synthetic surfactants; they are ecological, non-toxic and biodegradable. The RLs studied in this work were produced by an Antarctic *Pseudomonas gessardii* bacterium and evaluated for their antiviral action against the *Coronaviridae* and *Herpesviridae* family.

Material and method: To evaluate the antiviral activity of RLs, plaque reduction assay was performed. RLs activity was assessed against the enveloped viruses Herpes simplex virus type 1 (HSV-1) and 2 (HSV-2), Human coronavirus strain 229E (HCoV-229E), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and against the naked Poliovirus Type 1 (PV-1). The action of the RLs on the viral envelope was observed with transmission electron microscope (TEM). Moreover, the ability of RLs to inactivate viruses from surfaces was demonstrated by preparing 12-well plates coated with RLs. Finally, the cytotoxicity was evaluated by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay on Vero and HaCaT cell lines.

Results: Our results show complete inactivation of HSV-1 and HSV-2 by RLs at 6 µg/mL, and of HCoV-229E and SARS-CoV-2 at 25 and 50 µg/mL, respectively. No activity against PV-1 was detected, suggesting that the antiviral action is mainly directed towards the envelope. TEM images validated this hypothesis, showing HSV-1 particles lacking both tegument and envelope when treated with RLs. On the other side, TEM images showed that the main results of RLs action on SARS-CoV-2 is the detachment of S proteins from the envelope. Finally, the MTT assay at 100 µg/mL, Vero and HaCaT cells showed 80% and 45% of viability, respectively. The RLs showed no toxicity for both cell lines used at the other tested concentrations.

Discussion and Conclusions: RLs represent one of the most promising compounds in the pharmaceutical industry because of their structural versatility, stability and low toxicity that are useful in the design of therapeutics. The high antiviral activity of RLs encourage the application of these biosurfactants to counteract the widespread of viral

pathogens. The results suggest the opportunity of using RLs as antiviral additives in formulations of hand sanitizers, anti-herpes lipsticks and intimate detergents, surface and household cleaners, and as antimicrobial agents.

241 - Evaluation of HPV genotype-specific viral loads in clinician-collected cervical samples as compared to vaginal self-collected samples in women with cervical dysplasia

Chiara Giubbi⁽¹⁾ - Ardashes Latsuzbaia⁽²⁾ - Marianna Martinelli⁽¹⁾ - Ivan Vallini⁽³⁾ - Silvia Paganoni⁽³⁾ - Clementina Elvezia Cocuzza⁽¹⁾ - Marc Arbyn⁽²⁾

Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italia⁽¹⁾ - Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Bruxelles, Belgio⁽²⁾ - Hiantis srl, Hiantis srl, Milano, Italia⁽³⁾

Evaluation of HPV genotype-specific viral loads in clinician-collected cervical samples as compared to vaginal self-collected samples in women with cervical dysplasia

CHIARA GIUBBI¹, ARDASHES LATSUZBAIA², MARIANNA MARTINELLI¹, IVAN VALLINI³, SILVIA PAGANONI³, CLEMENTINA E. COCUZZA¹, MARC ARBYN²

¹Department of Medicine and Surgery, University of Milano-Bicocca; Monza, Italy; ²Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium; ³Hiantis Srl, Milan, Italy.

Introduction

According to European Guidelines many countries, including Italy, are switching to Human Papillomavirus (HPV)-based primary cervical cancer screening. The introduction of HPV test offers the possibility to use self-sampling as a valid well-accepted alternative to improve screening participation. PCR-based HPV tests on self-samples provide similar accuracy as cervical samples in the detection of cervical pre-cancer lesions.

The aim of this study was to assess agreement and compare type-specific high-risk HPV (hrHPV) viral load in paired vaginal-self and clinician-collected cervical samples using a quantitative full-genotyping hrHPV assay.

Materials and Methods

As part of a prospective clinical study conducted according to the European VALHUDES protocol (ClinicalTrials.gov Identifier: NCT04312737), 600 women were enrolled in 4 colposcopy centers. Prior to gynecological examination, women were asked to collect a self-vaginal swab using FLOQSwab® (Copan), while the clinician collected a cervical scraping with Cervex-Brush (Rovers). Cervical samples were immediately suspended 20mL ThinPrep® (Hologic), while vaginal self-collected swabs were transported dry to the laboratory and there suspended in 5ml of ThinPrep® (Hologic) or eNat® (Copan). A totally automated platform (Fluent 480, Tecan) was used for nucleic acid extraction using *Quick* DNA/RNA viral MagBead (Zymo) and Real-Time PCR preparation with HPV OncoPredict QT assay. HPV OncoPredict QT is a quantitative assay that individually detects and quantifies 12 hrHPV and sample cellularity. Viral load was normalized to sample cellularity and expressed as viral copies/cells. Kappa values (k) and Mann-Whitney tests were used to assess test concordance and differences in median viral load between samples.

Results

Eighty-eight percent of cervical and vaginal-self samples had a concordant result in hrHPV detection (k=0.75, 95%CI: 0.69-0.81). Individual HPV genotype concordance was moderate and good (k ranging from 0.64 to 0.93).

Type-specific viral loads were significantly higher for all individual genotypes in cervical compared to vaginal samples (Table 1). Interestingly, HPV51 and HPV58 median number of viral copies/cells were higher compared to other genotypes in both sample types.

The median number of cells in vaginal specimens (36,456 [IQR 1,818-52,359]) was significantly higher than in cervical samples (3,410 [IQR 1,180-8,524]).

Discussion and conclusions

The agreement in hrHPV detection between clinician-collected cervical and vaginal-self samples was good. Cellularity was higher but viral loads were substantially lower in vaginal compared to cervical samples.

Table 1: Type-specific median viral load expressed as viral copies/cells [IQR] of 12 hrHPV in cervical and vaginal-self samples.

HPV genotypes	N°	Cervical samples Median viral load [IQR]	Vaginal-self samples Median viral load [IQR]	p-value ^a
HPV16	98	1.47 [0.15-15.39]	0.02 [0.00-0.19]	0.0000
HPV18	19	0.36 [0.02-17.63]	0.01[0.00-0.07]	0.0003
HPV31	67	4.14 [0.07-26.37]	0.05 [0.01-0.57]	0.0000
HPV33	25	2.53 [0.20-37.56]	0.01 [0.00-0.35]	0.0000
HPV35	13	0.42 [0.04-4.75]	0.004 [0.00-0.04]	0.0015
HPV39	31	0.59 [0.02-9.59]	0.02 [0.00-0.35]	0.0001
HPV45	19	0.02 [0.00-1.55]	0.001 [0.00-0.04]	0.0019
HPV51	43	47.87 [1.00-438.50]	1.51 [0.07-17.69]	0.0000
HPV52	44	0.67 [0.03-1.67]	0.02 [0.00-0.21]	0.0000
HPV56	44	1.44 [0.02-17.54]	0.06 [0.00-0.64]	0.0000
HPV58	29	31.64 [5.52-356.08]	0.38 [0.03- 6.45]	0.0000
HPV59	24	0.51 [0.02-13.72]	0.05 [0.00- 3.31]	0.0010

247 - Prion-like alpha-synuclein detection in ante-mortem intestinal biopsies from Parkinson's disease patients by RT-QuIC assay

Sarah Vascellari ⁽¹⁾ - Christina Orrù ⁽²⁾ - Fabrizio Angius ⁽¹⁾ - Pier Paolo Carreras ⁽³⁾ - Byron Caughey ⁽²⁾ - Giovanni Cossu ⁽⁴⁾ - Aldo Manzin ⁽¹⁾

University of Cagliari, Department of Biomedical Sciences, Cagliari, Italia ⁽¹⁾ - National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), Laboratory of Persistent Viral Diseases (LPVD), Rocky Mountain Laboratories, Hamilton MT, Stati Uniti D'america ⁽²⁾ - AOBrotzu, S. C. Digestive Endoscopy Unit, Cagliari, Italia ⁽³⁾ - AOBrotzu, S. C. Neurology and Stroke Unit, Cagliari, Italia ⁽⁴⁾

Prion-like alpha-synuclein detection in ante-mortem intestinal biopsies from Parkinson's disease patients by RT-QuIC assay

¹SARAH VASCELLARI, ²CHRISTINA ORRÙ, ¹FABRIZIO ANGIUS, ³PIER PAOLO CARRERAS, ²BYRON CAUGHEY, ⁴GIOVANNI COSSU, ¹ALDO MANZIN

¹*Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy;*

²*Laboratory of Persistent Viral Diseases (LPVD), Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), Hamilton, MT, United States;*

³*S. C. Digestive Endoscopy Unit, AOBrotzu, Cagliari, Italy;*

⁴*S. C. Neurology and Stroke Unit, AOBrotzu, Cagliari, Italy;*

Introduction: Aggregation of misfolded alpha-synuclein (alpha-Syn) has been described as one of the most promising biomarkers of Parkinson's disease (PD). In recent years, the concept that misfolded alpha-Syn can spread from cell-to-cell likewise to infectious prion agents has increasingly gained agreement in the field. In fact, several reports have established that PD can be experimentally transmitted by a prion-like mechanism in different cellular and animal models. These findings have relevant implications for the applicability of innovative diagnostic approaches based on the prion principle of spreading by seeding to amplify the pre-existing seeds in vitro. Real-time quaking-induced conversion (RT-QuIC) assay is a breakthrough approach based on prion-like seeding activities recently exploited for the detection of seeds of alpha-Syn in different specimens from PD patients. The gastrointestinal (GI) tract has been proposed as a possible site of origin of alpha-Syn aggregation suggesting that the detection of a-Syn in the GI has high potential as in vivo and predictive diagnostic biomarker of PD. Previous studies showed alpha-Syn seeding activity in colon samples from rodents and post mortem biopsies of PD by RT-QuIC assay. In the present study, we evaluated for the first time the suitability of RT-QuIC assay for the ante-mortem detection of alpha-Syn in intestinal mucosa biopsies from patients with a clinical stage of PD.

Methods: A total of 24 participants to this study, 20 PD patients diagnosed according to the UK Brain Bank criteria, and 4 non-neurodegenerative healthy controls subjects were recruited. All patients underwent upper GI endoscopy for placement of an administration jejunal extension tube (PEG-J) for continuous levodopa enteral infusion, contextually. Two GI biopsies were taken for each patient. Based on the rostrocaudal distribution of alpha-Syn in the GI tract, the proximal small intestine (duodenum) was chosen as the most appropriate part for the analysis. A mutant human recombinant of alpha-Syn was used as substrate for the RT-QuIC reactions.

Results: alpha-Syn RT-QuIC analysis showed positive reactions in 17/20 patients with PD and negative reactions in all other non-neurodegenerative healthy subjects. RT-QuIC assay achieved a diagnostic sensitivity of 85% and specificity of 100%.

Discussion and Conclusions: These findings highlight for the first time that RT-QuIC reaction allows a sensitive detection of alpha-Syn seeds in safely accessible ex vivo intestinal biopsies from PD patients. The potential use of ultrasensitive RT-QuIC technique for the detection of very small amounts of intestinal alpha-Syn from live PD patients open a way for improved *intra vitam* diagnosis of clinical and prodromal PD.

252 - Inhibition of viral entry by peptides designed on the glycoproteins Gn and Gc of Schmallenberg virus

Carla Zannella⁽¹⁾ - Annalisa Chianese⁽¹⁾ - Biagio Santella⁽¹⁾ - Giuseppe Greco⁽¹⁾ - Serena Montagnaro⁽²⁾ - Giuseppe Iovane⁽²⁾ - Ugo Pagnini⁽²⁾ - Rinaldo Grazioso⁽³⁾ - Carla Isernia⁽³⁾ - Anna De Filippis⁽¹⁾ - Gianluigi Franci⁽⁴⁾ - Matteo Porotto⁽⁵⁾ - Massimiliano Galdiero⁽¹⁾

Università degli Studi della Campania "Luigi Vanvitelli", Dipartimento di Medicina Sperimentale-Sezione Microbiologia e Virologia, Napoli, Italia⁽¹⁾ - University of Naples Federico II, Department of Veterinary Medicine and Animal Productions, Napoli, Italia⁽²⁾ - University of Campania "Luigi Vanvitelli", Department of Environmental, Biological and Pharmaceutical Science and Technology, Caserta, Italia⁽³⁾ - Università di Salerno, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Baronissi, Italia⁽⁴⁾ - Columbia University Vagelos College of Physicians and Surgeons, Department of Pediatrics, New York, Stati Uniti D'America⁽⁵⁾

Inhibition of viral entry by peptides designed on the glycoproteins Gn and Gc of Schmallenberg virus

CARLA ZANNELLA¹, ANNALISA CHIANESE¹, BIAGIO SANTELLA¹, GIUSEPPE GRECO¹, SERENA MONTAGNARO², GIUSEPPE IOVANE², UGO PAGNINI², RINALDO GRAZIOSO³, CARLA ISERNIA³, ANNA DE FILIPPIS¹, GIANLUIGI FRANCI⁴, MATTEO POROTTO^{1,5}, MASSIMILIANO GALDIERO¹

¹ Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy;

² Department of Veterinary Medicine and Animal Productions, University of Naples "Federico II", Napoli, Italy;

³ Department of Environmental, Biological and Pharmaceutical Science and Technology, University of Campania "Luigi Vanvitelli", Caserta, Italy;

⁴ Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy;

⁵ Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.

Introduction. In recent years arthropod-borne viruses are emerging as a serious threat to human and animal health worldwide. Among the Orthobunyaviruses, the Schmallenberg virus (SBV) represents a novel and major member, appeared in central Europe during the summer of 2011 and rapidly spread all over Europe. The virus affects mainly but not exclusively the domestic ruminants causing abortion and malformation in the offspring, as well as febrile episodes, decreased milk production and diarrhea in adults. The viral particle is enclosed in a membrane formed by the glycoproteins N (Gn) and C (Gc) able to mediate the viral entry by means of their fusogenic potential. The fusion peptide is located on Gc, a class II fusion protein, but cell fusion requires the expression also of Gn, a chaperone essential for the correct trafficking of Gc to the Golgi complex before viral budding. Therefore, both Gn and Gc glycoproteins may represent a target for antiviral development. In the present study, we investigated the inhibitory activity mediated by synthetic overlapping peptides designed on the amino acid sequences of the proteins. **Materials and Methods.** We have synthesized peptides by standard 9-fluorenylmethoxycarbonyl polyamine solid-phase synthesis. Peptides cytotoxicity were evaluated on hamster kidney cells (BHK-21) at different concentrations starting by 100 μ M via the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Then cells were simultaneously treated with each peptide at 100 μ M and infected by SBV (gently provided by University Federico II of Naples). To better understand how peptides could interfere with the SBV lifecycle, different time of addition and temperature shift assays were performed at scalar concentrations. Furthermore, the expression levels of the viral M gene were analyzed. Finally, the secondary structure of peptides was determined via circular dichroism (CD). **Results.** We have performed a brute analysis of both glycoproteins in order to explore the inhibitory activity of such peptides against SBV infection. Five out of the Gc peptides at a concentration of 100 μ M reached the 50% of inhibition arbitrary cut-off. None of the Gn peptides had a consistent inhibiting effect and no peptide toxicity was observed by the MTT assay at the concentrations used in our experimental conditions. Gc peptides were able to target the viral particles, by preventing the early stages of the infection, namely virus attachment and entry into the host cell. In addition, molecular tests indicated that the two most active peptides (Gc30 and Gc49) were also able to interfere with gene expression. Finally, we analyzed their secondary structure via CD, revealing that Gc30 had a prevalent α -helical structure, differently from Gc49, which adopted a prevalent β -structure. **Discussion and conclusions.** Our data indicate the possible direct involvement of Gc described domains in the process of virus penetration; therefore, these results are of relevance to the potential development of novel therapeutic

compounds to prevent SBV infections and could serve as a model for many human pathogens belonging to the same family.

256 - A Cluster of SARS-CoV-2 omicron variant of concern harbouring a rare mutation in the spike gene

Pietro Giorgio Spezia ⁽¹⁾ - ANNA-LISA CAPRIA ⁽²⁾ - Paola Mazzetti ⁽²⁾ - Mauro Pistello ⁽¹⁾ - Alice Cara ⁽²⁾ - Pietro Villa ⁽²⁾ - Alfredo Rosellini ⁽²⁾ - Simone Meini ⁽³⁾

Università di Pisa, Centro retrovirus, Università di Pisa, Dipartimento di scienze cliniche e traslazionali, Pisa, Italia ⁽¹⁾ - AOUP, azienda ospedaliera universitaria Pisana UOC Virologia, PISA, Italia ⁽²⁾ - Azienda Unità Sanitaria Locale Toscana Nord-Ovest, Internal Medicine Unit, Felice Lotti Hospital of Pontedera,, Pontedera, Italia ⁽³⁾

Title: A Cluster of SARS-CoV-2 omicron variant of concern harbouring a rare mutation in the spike gene

PIETRO G. SPEZIA ^{1,2}, ANNA-LISA CAPRIA ², PAOLA MAZZETTI ², ALICE CARA ², ALFREDO ROSELLINI ², PIETRO VILLA ², SIMONE MEINI ³, MAURO PISTELLO ^{1,2}.

1 Department of Translational Research, Retrovirus Center and Virology Section, University of Pisa, Pisa, Italy;

2 Virology Division, Pisa University Hospital, Pisa, Italy;

3 Internal Medicine Unit, Felice Lotti Hospital of Pontedera, Azienda Unità Sanitaria Locale Toscana Nord-Ovest, Pisa, Italy.

Introduction: Whole-genome sequencing (WGS) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) helps distinguishing hospital-acquired from community-acquired infection by identifying the presence of clusters with common mutation patterns. In April 2022, 4 patients admitted to the Internal Medicine Unit of the Pontedera Hospital contracted SARS-CoV-2 infection during their hospitalization. Their clinical outcome was characterized by dry cough, hypophonia, and low-grade fever. The nasopharyngeal swabs (NPS), collected during the acute phase of the disease, were sent to the Virology Unit of the Azienda Ospedaliera Universitaria Pisana to search for SARS-CoV-2 genome and, if present, characterize the viral variant.

Materials and methods: The extracted RNA from NPS was processed for WGS by using Illumina COVIDSeq Assay kit and sequenced on Miseq Dx. Consensus sequences were classified according to PANGO Lineage and additional sublineage mutations were determined. Phylogenetic analyses were performed with Usher and MEGAX. Viral isolation was carried out on Vero/TMPRSS2 cells that were observed daily for cytopathic effect (CPE) and viral release in culture supernatant. Viral stocks are being produced for serum neutralization assays.

Results: The four patients, three fully vaccinated and one unvaccinated, aged 56-90 years. The whole-genome sequence was achieved with a genome coverage of 99.7 to 99.9 %. All sequences belonged to the PANGO lineage BA.2.3.15 and showed a unique mutation signature in the spike gene, D215E. Despite the high nucleotide identity of all sequences, a mutation in the spike gene N440K was also detected in the unvaccinated patient. The virus was promptly isolated from all patients, although it showed moderate CPE and low yield in the supernatant compared to laboratory-adapted variants.

Conclusions and discussion: WGS analysis of a cluster of SARS-CoV-2 infection in hospitalized patients demonstrated common and specific genomic mutations, confirming the epidemiological link. The Spike D215E mutation was first identified in Europe, but it is unknown whether it favours immune escape or transmission. Studies on the impact of this mutation on neutralization by monoclonal antibodies or hyperimmune plasma are ongoing. In conclusion, routine screening of patients and healthcare workers are important to restrain hospital transmission and promptly identify the emergence of new variants.

257 - Distribution and prevalence of Human papillomavirus (HPV) in oral samples collected from 2001 to 2020 in Sicily

Michela Buttà ⁽¹⁾ - Giuseppina Campisi ⁽¹⁾ - Vera Panzarella ⁽¹⁾ - Daniela Pistoia ⁽²⁾

Università di Palermo, AOUP P. Giaccone, Palermo, Italia ⁽¹⁾ - AOUP P. Giaccone, AOUP P. Giaccone, Palermo, Italia ⁽²⁾

Distribution and prevalence of Human papillomavirus (HPV) in oral samples collected from 2001 to 2020 in Sicily

BUTTÀ M.^a, CAMPISI G.^b, PANZARELLA V.^b, PISTOIA D.^c, AND G. CAPRA^a

^aMicrobiology and Virology Unit. Polyclinic Hospital “P. Giaccone” - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) “G. D’Alessandro”, University of Palermo, Italy

^b Department of Surgical, Oncological, and Oral Sciences, University of Palermo,

^c Microbiology and Virology Unit. Polyclinic Hospital “P. Giaccone”.

Introduction. Human papillomaviruses (HPV) are the most common sexually transmitted pathogens. Frequently detected in the anogenital area, they can also be found in the head and neck district, where they can be associated with various conditions: from head and neck cancers (HNSCC), like oral (OSCC) and oropharyngeal squamous cell carcinomas (OPSCC) to potentially malignant oral lesions (OPMDs) such as leukoplakia (LO), oral lichen planus (LPO) and erythroplakia (EP) and benign oral papillary lesions, like condyloma acuminatum (CA) and squamous papilloma (SP). The prevalence of oral HPV positivity varies from 0% to 81% among asymptomatic individuals, and 32–36% among HNSCC patients. Data on the prevalence of oral HPV infection and its correlation with oral diseases in Italy are scarce, with the most recent study dating back to 2015 and no region-specific epidemiological analysis ever been made. Hence, the aim of this study was to depict the prevalence of Human papillomavirus infection in relation to the diagnosis of different oral ailments in Sicily.

Material and methods. The study involved a total of 1400 oral rinses consecutively received by the Virology laboratory at the Department of Hygiene and Microbiology (Policlinico University of Palermo, Italy) in the period between 2001 and 2020. The patients were referred for HPV testing after identifying oral mucosal alterations. During the twenty-year period considered, different laboratory methods were applied for the detection of HPV-DNA, depending on their availability, such as PGMY/nGP0 PCR followed by Sanger sequencing, INNO-LiPA® HPV Genotyping Extra II (Fujirebio), Roche Linear Array HPV genotyping test (Linear Array), Ampliquality HPV-Type Express v3.0 (AB analitica).

Results. HPV was detected in 11.2% of cases, of which 90.4% were single infections. HPV16 (23.3%) and HPV6 (24%) as the most common detected genotypes. Patients were mainly affected by papillomatosis (19.5%), and in 14,9% HPV was detected. OSCC represented 12.3% of diagnoses, of which 13.8% were HPV positive, while, among OPMDs leukoplakia was the most common (15,6%), with a positivity rate of 11.6%.

Discussion and conclusions. The sample cohort analyzed shows rates of HPV positivity and oral mucosal changes consistent with what has already been described in the literature. In particular, the percentage of HPV-positive OSCC, falls within the range of 1.2% to 36%, as reported in several studies carried out in Italy. The information gathered in this study will help to expand the knowledge regarding the prevalence of oral HPV in our country.

259 - Isolation of SARS-CoV-2 in viral cell culture and immunologic characterization in immunocompromised patients

paola mazzetti⁽¹⁾ - alice cara⁽¹⁾ - alfredo rosellini⁽¹⁾ - maria sidoti⁽²⁾ - giovanna moscato⁽³⁾ - giulia freer⁽²⁾ - iacopo franconi⁽¹⁾ - arianna forniti⁽³⁾ - lorenzo suardi⁽³⁾ - entrico tagliaferri⁽³⁾ - spartaco sani⁽⁴⁾ - marco falcone⁽¹⁾ - riccardo iapoce⁽³⁾ - mauro pistello⁽¹⁾

Università di Pisa, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italia⁽¹⁾ - Centro Retrovirus, Dpt.Ricerca Traslationale, Università di Pisa, Pisa, Italia⁽²⁾ - Azienda ospedaliera-universitaria Pisana, AOUP, Pisa, Italia⁽³⁾ - Azienda Sanitaria USL 6, U.O. Malattie infettive, Ospedale di Livorno, Livorno, Italia⁽⁴⁾

Isolation of SARS-CoV-2 in viral cell culture and immunologic characterization in immunocompromised patients

PAOLA MAZZETTI¹, ALICE CARA¹, ALFREDO ROSELLINI¹, MARIA SIDOTI², GIOVANNA MOSCATO¹, GIULIA FREER², IACOPO FRANCONI¹, ARIANNA FORNITI³, LORENZO SUARDI³, ENRICO TAGLIAFERRI³, SPARTACO SANI⁴, MARCO FALCONE³, RICCARDO IAPOCE³, MAURO PISTELLO^{1,2}.

¹Virology Unit, Pisa University Hospital, Pisa, Italy; ²Retrovirus Center, Department of Translational Research, University of Pisa, Pisa, Italy; ³Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Pisa University Hospital, Pisa, Italy; ⁴Infectious Diseases Unit, Livorno Hospital, Livorno, Italy.

Introduction

Immunocompromised subjects can have prolonged SARS-CoV-2 shedding, even after weeks from the initial diagnosis of COVID-19. A positive molecular test does not always imply the presence of infectious virus, because in immunocompetent individuals viral isolation declines rapidly after the first week of diagnosis. This does not appear to be the case for immunocompromised and elderly patients who shed the virus even after weeks from infection. This study aimed at determining if SARS-CoV-2 can be isolated from immunocompromised subjects with persistently positive molecular tests and finding possible correlations with their immunological status. Finally, viral sequencing was performed to identify the variant and mutations that may favor viral persistence.

Materials and methods

The enrolled patients had a positive molecular test result for at least 21 days after their first positive test. Nasopharyngeal swabs were inoculated in Vero/TMPRSS2 cells and cultures monitored daily for cytopathic effect (CPE). Virus release in supernatant was tested every three days by RT-PCR and antigenic assays. Neutralizing antibodies were titrated by serum neutralization test performed in microtiter plates on Vero/TMPRSS2 cells. T cell response against SARS-CoV-2 S and N proteins and CMV pp 65 proteins was evaluated by ELISPOT using Ficoll-purified peripheral blood mononuclear cells isolated from heparinized blood. Whole-genome sequencing (WGS) was performed with swabs extracted RNA and using Illumina COVIDSeq Assay kit.

Results

As expected from previous reports, the virus was isolated from some patients while others were negative. Humoral and cell-mediated responses were highly variable from individual to individual and mostly linked to their pathological conditions, drug treatment, and anti-COVID vaccine status. No clear correlation was found between SARS-CoV-2 isolation and respective immunological status.

Conclusions and discussion

Persistently positive molecular test results pose serious problems for clinical management of SARS-CoV-2 patients, particularly if immunocompromised. This study can provide useful information to assess the potential risk of transmission of SARS-CoV-2 by immunocompromised individuals as related to their immunological profile. Further data are needed to identify possible correlations and determine the best strategies for patient management and prevention of transmission.

262 - Genetic diversity of norovirus Genogroups I and II in untreated wastewater in Rome Italy: a five-year monitoring study

Giusy Bonanno Ferraro (1) - Pamela Mancini (1) - Carolina Veneri (1) - Marcello Iaconelli (1) - Elisabetta Suffredini (2) - David Brandtner (3) - Giuseppina La Rosa (1)

Istituto Superiore di Sanità, Ambiente e Salute, Roma, Italia (1) - Istituto Superiore di Sanità, Sicurezza alimentare, nutrizione e sanità pubblica veterinaria, Roma, Italia (2) - Independent researcher, Independent researcher, Roma, Italia (3)

Genetic diversity of norovirus Genogroups I and II in untreated wastewater in Rome Italy: a five-year monitoring study

Giusy Bonanno Ferraro¹, Pamela Mancini¹, Carolina Veneri¹, Marcello Iaconelli¹, Elisabetta Suffredini², David Brandtner³, Giuseppina La Rosa¹

¹Department of Environment and Health, Istituto Superiore di Sanità, Rome, Italy.

²Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, Rome, Italy.

³Independent researcher, Rome Italy.

Introduction: Wastewater-based epidemiology applied to virology is an epidemiological complementary tool in the field of infectious disease surveillance to reveal viral circulation in the population, whether in symptomatic, asymptomatic, or preclinical states of disease. Human viruses released into feces and urine make their way into the environment by excretion or secretion of bodily fluids or skin cells. Among them, Human Norovirus (HNoV), belonging to the *Caliciviridae* viral family, is the most common etiological agent responsible of acute gastroenteritis in humans of all age. It is the leading cause of non-bacterial acute gastroenteritis (AGE) worldwide, causing approximately 18% of AGE and 212,000 deaths every year. Currently, HNoVs are divided into 10 genogroups and 49 genotypes, of which GI, GII, and GIV are known to infect humans. The aim of this study was to provide data on the genetic diversity of GI and GII HNoVs over a five-years period, testing urban sewage samples.

Materials and Methods: Between 2017 and 2021 a total of 260 sewage samples were collected from four wastewater treatment plants in Rome. Sewage concentration was performed by the two-phase polyethylene glycol (PEG), dextran separation method. Viral nucleic acids were extracted using the NucliSENS MiniMag extraction system (bioMérieux). All samples were analyzed by nested RT-PCR targeting region C (capsid gene). The PCR amplicons were pooled per year and analyzed by NGS carried out on MiSeq II sequencer (Illumina). Subsequent bioinformatic analysis was carried on with a similarity-based approach.

Results: Seven different GI capsid genotypes (GI.1, GI.2, GI.3, GI.4, GI.5, GI.6 and GI.7) were detected, and the most abundant were GI.1, GI.2 and GI.4. Among GII, thirteen genotypes (GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII.9, GII.10, GII.12, GII.13, GII.16, GII.17 and GII.21) were reported. During the first two years, GII.2 and GII.4 were prevalent until decreasing, in 2019, for the appearance of GII.5, GII.6, GII.7 and GII.12. Across the years, GII.3, GII.13, and GII.17 were always present, and the GII.4 Sydney was the prevalent variant. This strain was first detected in Australia in 2012 and rapidly became the major epidemic strain in Europe, America and Asia in 2012–2013.

Discussion and Conclusion: Next-generation sequencing proved to be an effective strategy for HNoV genotyping in wastewater samples. A significant variety of major and minor norovirus GI and GII genotypes was reported in wastewater in Rome. Complementary data obtained from both clinical and environmental samples can be an effective strategy for understanding the diversity and evolutionary dynamics of HNoVs and infer the epidemiological status of the population.

263 - Hepatitis E in urban wastewater, pig slurry, food products, and wild boars: a One Health approach for the study of virus occurrence and diversity in the region of Abruzzo

Giuseppina La Rosa (1) - Pamela Mancini (1) - Carolina Veneri (1) - Giusy Bonanno Ferraro (1) - Lidia Orlandi (1) - Claudia Del Giudice (1) - Farzad Beikpour (2) - Teresa Vicenza (2) - Simona Di Pasquale (2) - Loredana Cozzi (2) - Giuseppe Aprea (3) - Nadia Barile (4) - Silvia Scattolini (3) - Eliana Nerone (4) - Daniela D'Angelantonio (3) - Ilaria Del Matto (3) - Marcello Iaconelli (1) - Massimo Brambilla (5) - Alex Filisetti (5) - Carlo Bisaglia (5) - Elisabetta Suffredini (2)

Istituto Superiore di Sanità, Dipartimento Ambiente e Salute, Roma, Italia (1) - Istituto Superiore di Sanità, Sicurezza alimentare, nutrizione e sanità pubblica veterinaria, Roma, Italia (2) - Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale", Reparto di Igiene delle tecnologie alimentari e dell'alimentazione animale, Teramo, Italia (3) - Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale", Centro Ricerche per gli Ecosistemi marini e Pesca, Termoli, Italia (4) - CREA Consiglio per la ricerca in agricoltura e l'analisi dell'economia agraria, Research Centre for Engineering and Agro-Food Processing, Treviglio, Italia (5)

Hepatitis E in urban wastewater, pig slurry, food products, and wild boars: a One Health approach for the study of virus occurrence and diversity in the region of Abruzzo

Giuseppina La Rosa¹, Pamela Mancini¹, Carolina Veneri¹, Giusy Bonanno Ferraro¹, Lidia Orlandi¹, Claudia Del Giudice¹, Farzad Beikpour², Teresa Vicenza², Simona Di Pasquale², Loredana Cozzi², Giuseppe Aprea³, Nadia Barile⁴, Silvia Scattolini³, Eliana Nerone⁴, Daniela D'Angelantonio³, Ilaria Del Matto³, Marcello Iaconelli¹, Massimo Brambilla⁵, Alex Filisetti⁵, Carlo Bisaglia⁵, Elisabetta Suffredini².

¹ *Department of Environment and Health, Istituto Superiore di Sanità, Rome, Italy.*

² *Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, Rome, Italy.*

³ *Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale", Teramo, Italy.*

⁴ *Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise "G. Caporale", Termoli (CB), Italy.* ⁵ *CREA Consiglio per la ricerca in agricoltura e l'analisi dell'economia agraria - Research Centre for Engineering and Agro-Food Processing, Treviglio (BG), Italy*

Introduction: Hepatitis E virus (HEV) infection represents an emerging public health concern worldwide. In industrialized countries, sporadic autochthonous cases are rising. Pigs and wild boars are the main animal reservoir for HEV. An ongoing project "Improving understanding of autochthonous Hepatitis E transmission routes: a focus on foodborne and waterborne pathways" focuses on the Abruzzo Region, a known hotspot for HEV circulation. Here we show the results obtained by analyzing untreated sewage samples, coastal marine water samples, raw slurry samples from swine farming activities, food samples (meat products, fruit/vegetables, bivalve shellfish), and wild boar liver samples.

Materials and Methods: Untreated sewage samples (n°= 83), coastal marine water samples (n°= 10) and raw slurry samples collected from swine farming activities (n°= 36) were collected in the Region during 2021. Moreover, 129 food samples (58 meat products, 45 fruit/vegetables and 26 bivalve shellfish) and 377 liver samples, taken within the control plan for wild boar population, were collected between 2020 and 2021. Environmental samples were concentrated using a PEG based protocol or an adsorption/elution method. Food and liver samples were prepared with different matrix-specific protocols. A RT-nested-PCR using broad range primers targeting ORF1, and a real-time RT-qPCR were used for the screening of water and food/liver samples, respectively. Partial sequencing of the ORF2 region was performed for typing purposes, followed by analysis with the RIVM HEV typing tool.

Results: HEV RNA was detected in 10 urban sewage samples (12%) from 5 WTPs; all the samples were characterized as genotype G3, type 3c. Marine water samples were all negative for HEV. As for the pig slurries, five samples (14%) from four different farms tested positive for HEV G3, characterized as 3f and putative subtype 3l; moreover, “unassigned” types were detected. HEV RNA was never detected in the tested food products, while it was detected in 65/377 (17.2%) wild boar livers. Molecular characterization was achieved for 22 wild boar samples characterized as 3c, 3e, 3f, and the putative subtype 3l.

Discussion and Conclusions: HEV RNA genotype 3 was found in 12% of urban wastewaters, reflecting a not negligible viral circulation in the Region. Pig slurry was also found positive for HEV. HEV occurrence in food products, even in a hotspot region, was very low. However, genotype 3 HEV is widely present in the wild boar population of Central Italy and, therefore, the use of wild boar meat and liver for food preparation should be carefully considered. An integrated Food-Animal-Environmental surveillance is fundamental for gathering data on HEV epidemiology and studying transmission routes for autochthonous hepatitis E.

265 - Antiviral effect of bombinin H2/H4 against enveloped and naked viruses

Aurora Salvemme⁽¹⁾ - Ida Curtovic⁽¹⁾ - Sara Passerini⁽¹⁾ - Carla Prezioso⁽¹⁾ - Mariya T. Miteva⁽¹⁾ - Virginia Protto⁽¹⁾ - Giovanna De Chiara⁽²⁾ - Maria Luisa Mangoni⁽³⁾ - Valeria Pietropaolo⁽¹⁾ - Lucia Nencioni⁽¹⁾ - Anna Teresa Palamara⁽⁴⁾ - Maria Elena Marcocci⁽¹⁾

Sapienza Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia⁽¹⁾ - CNR, Istituto di Farmacologia traslazionale, Roma, Italia⁽²⁾ - Sapienza Università di Roma, Dipartimento di Scienze Biochimiche, Roma, Italia⁽³⁾ - Istituto Superiore di Sanità, Dipartimento di Malattie Infettive, Roma, Italia⁽⁴⁾

Antiviral effect of bombinin H2/H4 against enveloped and naked viruses

Aurora Salvemme¹, Ida Curtovic^{1,2}, Sara Passerini¹, Carla Prezioso¹, Mariya T. Miteva¹, Virginia Protto¹, Giovanna De Chiara³, Maria L. Mangoni⁴, Valeria Pietropaolo¹, Lucia Nencioni¹, Anna T. Palamara^{1,5}, Maria E. Marcocci¹

1 Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognietti, Rome, Italy

2 Department of Microbiology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia

3 Institute of Translational Pharmacology, CNR, Rome, Italy

4 Department of Biochemical Sciences, Sapienza University of Rome, Rome, Italy

5 Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

Introduction

Bombinins H (H for hydrophobic and hemolytic properties) are 20-residues amphibian antimicrobial peptides (AMP) originated from *Bombina variegata* skin secretion. These peptides are rich in glycine (25%) and can assume different conformations in addition to the typical amphiphatic α -helical structure in a membrane-mimicking environment, as shown by their circular dichroism spectra. Their most striking feature is the presence of a D-amino acid in the second N-terminal position in some of them, representing the first example of natural AMPs with a single D-amino acid in their sequence; moreover, the isomers coexist in the same secretion. In our study we focussed on Bombinin H2 and its diastereomer H4, known to exhibit high membrane-perturbing activity against Gram-negative bacteria. The aim of this study was to investigate the antiviral activity of Bombinin H2 and H4 against enveloped viruses, such as herpes simplex virus type 1 (HSV-1) and Influenza A virus (IAV), and naked virus, John Cunningham polyomavirus (JCPyV).

Methods

Vero, A549 and SVGp12 cells were infected with HSV-1, IAV and JCPyV, respectively. The efficacy of infection was evaluated by standard plaque assays and In-Cell Western assays in supernatants. Cellular monolayers were analyzed by Western blot. MTT assay was used to test possible cytotoxicity of bombinin H2 and H4 as well as to choose appropriate concentrations for further experiments.

Results

Bombinin H2 and H4 were both used at doses 10 and 20 $\mu\text{g/mL}$ after testing by MTT assay. To test their antiviral effect against HSV-1, IAV and JCPyV, cells were infected and treated with H2 or H4 (10 and 20 $\mu\text{g/mL}$) at different times of infection: before (PRE), during (D) or after (P) the virus adsorption to the host cells or during and after (D+P, double dose) the adsorption phase and for the following 24/48 h. Moreover, to verify the potentially direct effect of bombinins on virions, viruses were preincubated with each peptide, and then the mixtures were used to infect the cells. We found that bombinin H2 and H4 exert virucidal effect on both enveloped viruses, but bombinin H2 is more effective than H4. No significant decrease of HSV-1 and IAV infection was observed when the peptides were used at different times of infection, nor when used to pre-treat the cells. We also found that H2 reduces JCPyV infection, probably affecting both the earliest phases of its life-cycle and the viral particle, likely through an interaction with the viral capsid proteins.

Conclusions

Overall, these data indicate that Bombinin H2 and H4 could be promising AMPs for the treatment of viral infections. This study paves the way for the potential development of short naturally occurring peptides as novel antiviral agents to enlarge the available drug portfolio.

273 - Comparative assessment of molecular methods for studying TTV-virome species composition and prevalence estimates

Pietro Giorgio Spezia ⁽¹⁾ - Fabio Filippini ⁽¹⁾ - Andreina Baj ⁽²⁾ - Federica Novazzi ⁽²⁾ - Angelo Genoni ⁽²⁾ - Francesca D. Ferrante ⁽²⁾ - Mauro Pistello ⁽¹⁾ - Fabrizio Maggi ⁽³⁾

University of Pisa, Department of Translational Research, Retrovirus Center and Virology Section, Pisa, Italia ⁽¹⁾ - University of Insubria, Department of Medicine and Surgery, Varese, Italia ⁽²⁾ - Spallanzani National Institute for Infectious Diseases, Laboratory of Virology and High Containment Laboratories, Roma, Italia ⁽³⁾

Title: Comparative assessment of molecular methods for studying TTV-virome species composition and prevalence estimates

PIETRO G. SPEZIA ^{1,2}, *FABIO FILIPPINI* ¹, *ANDREINA BAJ* ^{3,4}, *FEDERICA NOVAZZI* ^{3,4}, *ANGELO GENONI* ^{3,4}, *FRANCESCA D. FERRANTE* ^{3,4}, *MAURO PISTELLO* ^{1,2}, *FABRIZIO MAGGI* ⁵.

1 Department of Translational Research, Retrovirus Center and Virology Section, University of Pisa, Pisa, Italy;

2 Virology Division, Pisa University Hospital, Pisa, Italy;

3 Department of Medicine and Surgery, University of Insubria, Varese, Italy;

4 Laboratory of Microbiology, ASST dei Sette Laghi, Varese, Italy;

5 Laboratory of Virology, Spallanzani National Institute for Infectious Diseases, Rome, Italy

Introduction: In recent years, interest has grown in the use of Torquetenovirus (TTV), the main component of human virome, for the prediction of post-transplant complications such as severe infections or transplant rejection. Due to the high degree of diversity, the complete genetic TTV characterization over time is poorly understood and constantly evolving. To overcome this challenge, the present study aims to investigate the individual TTV profiles in transplanted and healthy subjects by using three different molecular approaches: metagenomic next-generation sequencing (mNGS), NGS-based on TTV-amplicons (TTV-NGS), and semi-quantitative TTV species-specific PCRs (ssPCR). The final objective is to assess the complexity and diversity of TTV-virome in the study population.

Materials and methods: A total of 30 plasma samples (9 liver transplanted, 10 kidney transplanted, 11 healthy) were analyzed using the three different molecular approaches. Bioinformatic analysis of the sequences was performed by setting up an in-house bioinformatics pipeline.

Results: A high degree of complexity was identified in TTV species in healthy and transplanted subjects. Both NGS methods resulted in a good performance in terms of accuracy and reproducibility, however, the TTV-NGS method showed higher sensitivity than mNGS, and was able to improve TTV classification, especially for samples with low viral load. The ssPCRs revealed a high degree of concordance with both NGS methods, although some TTV species were sub-optimally amplified. A not significant correlation was found between the number of reads associated with a TTV species and the threshold cycle expressed in the ssPCR. Finally, also the prevalence of other anelloviruses was assessed. TTMV (genus betatorquevirus) was present in the majority of patients, and TTMDV (genus gammatorquevirus) was found in a few cases only.

Conclusions and discussion: This study represents the first comparative study between different molecular approaches to characterize the TTV-virome present in solid organ transplant recipients and healthy subjects. The development of in-house methods based on real-time PCR, specific for the detection of TTV species, is an important and simple tool for investigating the dynamic viral composition of this virus, so widespread but still poorly understood in its enormous genetic variability.

276 - Wastewater surveillance of SARS-CoV-2 in Italy: outcomes of nine months of nationwide monitoring

Giuseppina La Rosa ⁽¹⁾ - [Giusy Bonanno Ferraro](#) ⁽¹⁾ - Pamela Mancini ⁽¹⁾ - Carolina Veneri ⁽¹⁾ - Lidia Orlandi ⁽¹⁾ - Claudia Del Giudice ⁽¹⁾ - Marcello Iaconelli ⁽¹⁾ - David Brandtner ⁽²⁾ - Luca Lucentini ⁽¹⁾ - Lucia Bonadonna ⁽¹⁾ - Mirko Rossi ⁽²⁾ - Mauro Grigioni ⁽³⁾ - Giuseppe D'Avenio ⁽³⁾ - Mario Cerroni ⁽¹⁾ - Federica Simonetti ⁽¹⁾ - SARI NETWORK ⁽⁴⁾ - Elisabetta Suffredini ⁽⁵⁾

Istituto Superiore di Sanità, Department of Environment and Health, Roma, Italia ⁽¹⁾ - Independent Researcher, ---, Roma, Italia ⁽²⁾ - Istituto Superiore di Sanità, National Center for Innovative Technologies in Public Health,, Roma, Italia ⁽³⁾ - the list can be found at the ISS website (Acque reflue - ISS), the list can be found at the ISS website (Acque reflue - ISS), --, Italia ⁽⁴⁾ - Istituto Superiore di Sanità, Department of Food Safety, Nutrition and Veterinary Public Health, Roma, Italia ⁽⁵⁾

Wastewater surveillance of SARS-CoV-2 in Italy: outcomes of nine months of nationwide monitoring

Giuseppina La Rosa¹, [Giusy Bonanno Ferraro](#)¹, Pamela Mancini¹, Carolina Veneri¹, Lidia Orlandi, Claudia Del Giudice, Marcello Iaconelli¹, David Brandtner², Luca Lucentini¹, Lucia Bonadonna¹, , Mirko Rossi², Mauro Grigioni³, Giuseppe D'Avenio³, Mario Cerroni¹, Federica Simonetti¹, SARI network⁵, Elisabetta Suffredini⁴.

¹ *Department of Environment and Health, Istituto Superiore di Sanità, Rome, Italy.*

² *Independent Researcher, Rome, Italy.*

³ *National Center for Innovative Technologies in Public Health, Istituto Superiore di Sanità, Rome, Italy.*

⁴ *Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, Rome, Italy.*

⁵ *the list can be found at the ISS website ([Acque reflue - ISS](#))*

Introduction: Wastewater Surveillance represents an additional public health tool to investigate COVID-19 spread in a community. Following the EU Commission Recommendation 2021/472 “on a common approach to establish a systematic surveillance of SARS-CoV-2 and its variants in wastewaters in the EU” existing research activities were transformed into a national surveillance system, coordinated by Istituto Superiore di Sanità (ISS). Here we report the results of the environmental surveillance obtained during the period October 2021-June 2022. Results focus on the trend analysis of SARS-CoV-2 in sewage over time, as a descriptor of the dynamic of excretion of the virus in human faeces, and on the study of SARS-CoV-2 variants by sequencing of wastewater samples, performed throughout the country by regular monthly “flash surveys”.

Materials and Methods: The SARI project (Surveillance of SARS-CoV-2 in urban sewage in Italy) for the environmental surveillance of SARS-CoV-2, implemented a national network with the participation of 20 Italian Regions and Autonomous Provinces (A.P.) as on June 2022, and 167 Wastewater Treatment Plants involved as sampling points. The laboratories for analytical activities include wastewater service providers, regional environmental protection agencies, local health authorities, zooprophyllactic institutes, universities, and research institutions. Viral concentration, RNA extraction and Real time quantitative PCR (ORF1b region, nsp14) are performed by the laboratories of the SARI network using a common protocol and quantitative data are included in a GIS database implemented by ISS. For the monthly “flash surveys” aimed at investigating SARS-CoV-2 variants, the RNAs extracted from samples collected within one week are sent to ISS for sequencing of the spike protein, performed by both Sanger and next-generation sequencing using a MinION platform.

Results: Between October 2021-June 2022, 6694 wastewater samples were collected, and SARS-CoV-2 RNA was detected in 88% of the samples. Trends of SARS-CoV-2 concentrations in sewage, illustrated by means of Quiver graphs, show three main “waves” during the study period, in agreement with the waves observed in clinical cases. Sequencing of wastewater allowed to describe the replacement of SARS-CoV-2 variants along time, with the Delta variant predominant up to the last quarter of 2021. Since December 2021, Omicron took over in the whole country, with lineages BA.1, BA.2 and BA.5 appearing one after the other.

Discussion and Conclusions: We described trends and genetic diversity of SARS-CoV-2 in the Italian population and territory during the official environmental surveillance, along a nine-months period, confirming the effectiveness of sewage monitoring as a surveillance tool for SARS-CoV-2.

278 - Utility of genotypic CMV-drug resistance testing in immunocompromised patients

Gabriele Turello⁽¹⁾ - Giulia Piccirilli⁽¹⁾ - Maria Cristina Morelli⁽²⁾ - Francesca Bonifazi⁽³⁾ - Giorgia Comai⁽⁴⁾ - Luciano Potena⁽⁵⁾ - Eva Caterina Borgatti⁽⁶⁾ - Liliana Gabrielli⁽¹⁾ - Tiziana Lazzarotto⁽⁶⁾

UOC Microbiologia, IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia⁽¹⁾ - UOC Medicina interna per il trattamento delle gravi insufficienze d'organo, IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia⁽²⁾ - Istituto di Ematologia "Seràgnoli", IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia⁽³⁾ - UO Nefrologia, dialisi e trapianto, IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia⁽⁴⁾ - UO Cardiologia, IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia⁽⁵⁾ - DIMES, UOC Microbiologia, IRCCS Policlinico di S.Orsola, Università di Bologna, Bologna, Italia⁽⁶⁾

Utility of genotypic CMV-drug resistance testing in immunocompromised patients

GABRIELE TURELLO¹, GIULIA PICCIRILLI¹, MARIA C. MORELLI², FRANCESCA BONIFAZI³, GIORGIA COMAI⁴, LUCIANO POTENA⁵, EVA C. BORGATTI⁶, LILIANA GABRIELLI¹, TIZIANA LAZZAROTTO^{1,6}

¹ UOC Microbiologia, IRCCS Policlinico di S.Orsola, Università di Bologna; ² UOC Medicina interna per il trattamento delle gravi insufficienze d'organo, IRCCS Policlinico di S.Orsola, Università di Bologna; ³ Istituto di Ematologia "Seràgnoli", IRCCS Policlinico di S.Orsola, Università di Bologna; ⁴ UO Nefrologia, dialisi e trapianto, IRCCS Policlinico di S.Orsola, Università di Bologna; ⁵ UO Cardiologia, IRCCS Policlinico di S.Orsola, Università di Bologna; ⁶ DIMES, UOC Microbiologia, IRCCS Policlinico di S.Orsola, Università di Bologna

Introduction

Prolonged exposure to antiviral drugs used to prevent/treat cytomegalovirus (CMV) infections in immunocompromised patients can lead to the onset of mutations in the viral genome associated to drug resistance (DR). The study evaluates the clinical utility of genotypic testing for CMV-DR in this population.

Materials and methods

Seventy-one samples from 53 patients (28 hematopoietic stem cell transplant [HSCT] recipients, 23 solid organ recipients, 2 with AIDS and 1 with autoimmune disease) with CMV-DNAemia increase/persistence after more than 2 weeks of standard-dose antiviral therapy were tested. UL97 and UL54 genes were sequenced by Sanger method to identify resistance-associated mutations (r) for ganciclovir (GCV), foscarnet (FOS), cidofovir (CDV) and maribavir (MBV); UL56, UL89 and UL51 genes to assess resistance to letermovir (LTV).

Results

CMV-DR mutations were identified in 20/53 patients (37.7%). Specifically, 13 patients (65%) treated with GCV, had single or multiple mutations in UL97 (n=6 L595S, n=5 A594V, n=2 M460V, n=1 C603R and n=1 M460I) associated with GCVr. Therapy was replaced with FOS administration in 12 cases and LTV in 1 case; only 1 patient developed CMV-related symptoms (CMV myocarditis). In 4 patients mutations on both UL97 and UL54 genes were identified and correlated with multi-DR: A594V (UL97) and P522S (UL54) associated with GCVr and CDVr, such as C603W (UL97) and P522S (UL54), A594P and H520Q (UL97) and V715M (UL54) associated with GCVr and FOSr, M460V (UL97) and Q578H and E756D (UL54) associated with GCVr, CDVr and FOSr. In these patients, immunosuppressive therapy was reduced, FOS was administered in 2 cases, MBV was administered in 1 case, and anti-CMV immunoglobulin (IgG) and leflunomide were administered in 1 case. One patient developed CMV retinitis. In 1 patient, mutations on UL97 and UL56 genes were identified in sequential samples after the exposure to each drug: first A594V (UL97) associated with GCVr, then C325Y and C325R (UL56) associated with LTVr and finally T409M and H411Y (UL97) associated with MBVr. The patient developed a CMV myocarditis. Single mutations on the UL56 gene (C325Y, R369S and C325F) associated with LTVr were detected for 3 HSCT recipients undergoing LTV treatment. For these, LTV treatment was

stopped and GCV standard dose and in one case FOS was administered. Finally, in the remaining 33/53 cases no CMV-DR mutations were detected. Among them, 2/33 (6.4%) patients developed CMV-related diseases (a chorioretinitis and renal dysfunction) and 1/33 patient died.

Discussion and conclusions

Genotypic testing for CMV-DR identifies specific mutations that guide the choice of the most appropriate antiviral therapy and limits inappropriate administration of second-line drugs.

280 - Antiviral potential of *Galdieria sulphuraria*, an extremophilic red alga

Antiviral potential of *Galdieria sulphuraria*, an extremophilic red alga

ANNALISA AMBROSINO, PRAGATI A. MORE¹, FRANCESCA PALMA¹, BIANCA M. NASTRI¹, ADELE SANTANGELO¹, VALENTINA FIORE¹, ROBERTA MANENTE¹, GIORGIA FALCONE¹, SIMONA PICCOLELLA², SEVERINA PACIFICO², ANNA DE FILIPPIS¹, MASSIMILIANO GALDIERO¹

¹ Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy.

² Department of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTaBiF), University of Campania Luigi Vanvitelli, Via Vivaldi 43, 81100 Caserta, Italy.

Aim of the study: The recent Covid19 pandemic has shown how a single microorganism could affect the entire world, causing millions of death and job losses, with a significant psychological, social, and economic impact. As a result, the interest in alternative active compounds has increased significantly. It is known that terrestrial and aquatic macro and microorganisms are a rich source of natural bioactive compounds such as antioxidants, anti-inflammatory and immunomodulant agents, and antimicrobials which they produce in particular conditions (i.e., high/low temperatures, high pressures, light intensity, competitions). In this scenario, our study focused on exploring the biological potential of the extremophilic red alga *Galdieria sulphuraria*.

Methods: The red alga was purchased from the ACUF collection and grown in Allen medium at the same condition of the isolation site. The algal culture was collected at the exponential phase to extract its secondary metabolites, and the pellet was subjected to an organic extraction with different solvents. Cytotoxicity of the extract was evaluated by the 2,5-diphenyl-2H-tetrazolium bromide (MTT) assay on Vero cells (ATCC CCL-81). The antiviral activity was determined by plaque assay against Herpes Simplex virus type 1 and 2 (HSV-1, HSV-2) as DNA viruses, and Human coronavirus 229E (HCoV-229E) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) as RNA viruses. The plaque assay was performed under four conditions: co-treatment, virus pre-treatment, cell pre-treatment, and post-treatment. The inhibitory effect of the algal extract was confirmed by the quantitative RT-PCR, in which we analyzed the relative expression of viral genes. We explored the potential immunomodulatory activity by stimulating macrophages with 2 µg/mL of lipopolysaccharide (LPS) and then treating them with different extract concentrations. The amount of pro-inflammatory mediators and cytokines in supernatants was assessed by enzyme-linked immunosorbent assay (ELISA) kit.

The extract was subjected to a chemical characterization by the UHPLC method, carried out on a NEXERA UHPLC system (Shimadzu, Tokyo, Japan). The mobile phase consisted of water (solvent A) and acetonitrile (solvent B), both acidified with 0.1% formic acid. HR-MS analyses were performed using the AB SCIEX TripleTOF® 4600 spectrometer (AB Sciex, Concord, ON, Canada), equipped with a DuoSpray™ ion source operating in both negative and positive electrospray (ESI) ion mode.

Results: The crude extract exhibited a huge antiviral activity at the non-toxic concentrations against all the tested viruses in virus pre-treatment, particularly against the members of the Coronaviridae family, i.e., HCoV-229E and SARS-CoV-2, with an IC₅₀ of 0.8 and 6.3 µg/mL respectively. The molecular test confirmed the data obtained in vitro. In particular, in the virus pre-treatment, no detectable levels of the genes were recorded at the highest concentrations, while reduced expression levels were found at a lower concentration. The HPLC Mass spectrometry analysis disclosed the presence of 12 compounds, mainly lipids, besides two chlorophyll derivatives. In particular, compounds eluting at 23.308 and 30.259 were tentatively identified as pheophorbide a and hydroxypheophytin a. Finally, the addition of the extract in stimulating macrophages results in a general reduction of the cytokines levels.

Discussion and Conclusions: The potent antiviral activity in virus pre-treatment against DNA and RNA viruses, whose common feature is the presence of the envelope, indicates the algal extract could act on the viral envelope inhibiting cell entry. As the UPLC analysis revealed, a possible explanation is the presence in the extract of polyunsaturated fatty acids, well-known for their antimicrobial activity due to their capability to induce the complete disruption of microbial cell

membranes and viral envelope. Moreover, it is reported that pheophorbide a disclosed a strong antiviral activity against a broad range of enveloped viruses, including SARS-CoV-2. The presence of hydroxypheophytin could explain the reported immunomodulation, an anti-inflammatory, gastroprotective, and ulcerogenic compound found in red algae. *G. sulphuraria* is considered a promising organism thanks to its extremophilic properties. Furthermore, it has been demonstrated that it has a good potential for biofuel production and bioremediation⁵. In the present study, we demonstrated its biological potential could be applied not only to the environmental fields but to the pharmacological too.

04 Batteriologia, micologia e parassitologia

2 - Climatic zone and soil properties determine the biodiversity of the soil bacterial communities associated to native plants from desert areas of North-Central Algeria

Elisa Bona ⁽¹⁾ - Nadia Massa ⁽²⁾ - Omrane Toumatia ⁽³⁾ - Giorgia Novello ⁽²⁾ - Patrizia Cesaro ⁽²⁾ - Valeria Todeschini ⁽²⁾ - Lara Boatti ⁽⁴⁾ - Flavio Mignone ⁽²⁾ - Guido Lingua ⁽²⁾ - Francesco Vuolo ⁽⁵⁾ - Elisa Gamalero ⁽²⁾

Università del Piemonte Orientale, Dipartimento per lo Sviluppo Sostenibile e la Transizione Ecologica, Vercelli, Italia ⁽¹⁾ - Università del Piemonte Orientale, Dipartimento di Scienze e Innovazione Tecnologica, Alessandria, Italia ⁽²⁾ - Agro-Pastoralism Research Center, Agro-Pastoralism Research Center, Djelfa, Algeria ⁽³⁾ - SmartSeq s.r.l., Spin-Off of the Università del Piemonte Orientale, Novara, Italia ⁽⁴⁾ - Sacco s.r.l., Sacco s.r.l., Cadorago, Italia ⁽⁵⁾

Climatic zone and soil properties determine the biodiversity of the soil bacterial communities associated to native plants from desert areas of North-Central Algeria

ELISA BONA ¹, *NADIA MASSA* ², *OMRANE TOUMATIA* ^{3,4}, *GIORGIA NOVELLO* ², *PATRIZIA CESARO* ², *VALERIA TODESCHINI* ¹, *LARA BOATTI* ^{2,5}, *FLAVIO MIGNONE* ^{2,5}, *GUIDO LINGUA* ², *FRANCESCO VUOLO* ⁶, *ELISA GAMALERO* ²

¹ Dipartimento per lo Sviluppo Sostenibile e la Transizione Ecologica, Università del Piemonte Orientale, Vercelli, Italy

² Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Alessandria, Italy

³ Agro-Pastoralism Research Center, 17018 Djelfa, Algeria

⁴ Laboratoire de Biologie des Systèmes Microbiens, Ecole Normale Supérieure de Kouba, Algiers, Algeria

⁵ SmartSeq s.r.l., Spin-Off of the Università del Piemonte Orientale, Novara, Italy

⁶ Sacco s.r.l., Cadorago, Italy

1. Introduction

Algeria is the largest Country in Africa characterized by semi-arid and arid sites, located in the North, and hypersaline zones in the Center and South of the Country. Several autochthonous plants are well known as medicinal plants, having in common tolerance to aridity, drought, and salinity. In their natural environment, they live with a great number of microbial species that altogether are indicated as plant microbiota, while the plants are now viewed as a “holobiont”. In this work, the microbiota of the soil associated to the roots of fourteen economically relevant autochthonous plants from Algeria have been characterized by an innovative metagenomic approach.

2. Materials and methods

Soil samples were collected during September 2018, in two different Algerian regions (Ghardaïa and Djelfa), in six different provinces in correspondence of 14 active plant species. Four species (*C. arabica*, *R. villosa*, *Z. spinosa*, *P. undulata*) were sampled in the arid region of Ghardaïa and ten species (*A. scoparium*, *A. armatus*, *R. raetam*, *S.*

tenacissima, *A. herba-alba*, *S. tetragona*, *A. halimus*, *P. harmala*, *S. fruticosa*, *T. microphylla*) were sampled in the semi-arid region of Djelfa.

DNA was extracted from soil using the DNeasy® PowerSoil® kit. The bacterial 16S DNA libraries were prepared using the Microbiota solution B kits. The amplicon pool was processed using the Nano Kit v2 kit using Miseq platform. Raw sequences were processed by MicrobAT software. Statistical analysis was performed using both MicrobiomeAnalyst and R softwares.

3. Results

The number of observed species differed significantly according to the plant species and sampling site while Shannon's diversity index differed significantly according to the plant species, the sampling site, and the climatic zone. Seventeen bacterial species recognized as component of the core microbiota were shared between arid and semi-arid zones. Specific signature highlighted that Actinobacteria, Bacteroidetes and Proteobacteria were more represented in semi-arid zone in respect to arid one, where Actinobacteria (different genera), Proteobacteria (different genera), Chloroflexi, Planctomycetes and Firmicutes were the most prevalent. Specific bacterial signature was outlined in the different climatic zones.

4. Discussion and conclusions

The results demonstrated that in highly stressful environmental conditions, such as in desert environments, the extreme climatic conditions and the composition of the substrate are the main variables affecting the selection and recruitment of bacterial populations. In fact, specific signatures associated with the different conditions were identified for the first time, filling a gap in the current literature.

3 - Sequencing of the whole genome of *Acinetobacter baumannii*: monitoring of antibiotic resistance in hospital during the Sars-CoV-2 pandemic.

Alice Caramaschi ⁽¹⁾ - Marianna Farotto ⁽¹⁾ - Marta Mellai ⁽²⁾ - Francesco Favero ⁽²⁾ - Davide Corà ⁽³⁾ - Cristian Leli ⁽⁴⁾ - Lidia Ferrara ⁽⁴⁾ - Andrea Rocchetti ⁽⁴⁾ - Elisa Bona ⁽¹⁾

Università del Piemonte Orientale, Dipartimento per lo Sviluppo Sostenibile e la Transizione Ecologica, Vercelli, Italia ⁽¹⁾ - UPO-CAAD, Centro Universitario per la Ricerca Traslazionale sulle Malattie Autoimmuni ed Allergiche, Novara, Italia ⁽²⁾ - Università del Piemonte Orientale, Dipartimento di Medicina Traslazionale, Novara, Italia ⁽³⁾ - Azienda ospedaliera Santi Antonio e Biagio e Cesare Arrigo, S.C. di Microbiologia, Alessandria, Italia ⁽⁴⁾

Sequencing of the whole genome of *Acinetobacter baumannii*: monitoring of antibiotic resistance in hospital during the Sars-CoV-2 pandemic

ALICE CARAMASCHI¹, MARIANNA FAROTTO¹, MARTA MELLAI², FRANCESCO FAVERO^{2,3}, DAVIDE CORÀ^{2,3}, CRISTIAN LELI⁴, LIDIA FERRARA⁴, ANDREA ROCCHETTI⁴, ELISA BONA^{1,2}

¹ *Dipartimento per lo Sviluppo Sostenibile e la transizione ecologica, Università del Piemonte Orientale, Vercelli, Italy*

² *UPO-CAAD- Centro Universitario per la Ricerca Traslazionale sulle Malattie Autoimmuni ed Allergiche, Novara, Italy*

³ *Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Novara, Italy*

⁴ *Azienda ospedaliera Santi Antonio e Biagio e Cesare Arrigo, S.C. di Microbiologia, Alessandria, Italy*

INTRODUCTION

The importance of antibiotic-resistance phenomenon and its worldwide spread have given rise to the activation of numerous surveillance systems. To make the data collected by these systems homogeneous and interpretable and to facilitate comparison between the various countries, a European surveillance network was created in 2000 which in 2010 assumed institutional characteristics becoming the European network European Antimicrobial Resistance Surveillance Network (EARS-Net) coordinated by the ECDC.

The aim of this work was to evaluate the antibiotic-resistance profile from set of 24 whole genomes of *A. baumannii* strains isolated from different departments of Alessandria (Italy) hospital, in the COVID-19 era.

MATERIALS AND METHODS

The isolation of *A. baumannii* strains took place in the period of the Sars-CoV-2 pandemic. Genomic DNA was extracted from over-night cultures in Mueller-Hinton Broth, using the DNeasy® UltraClean® Microbial kit. The DNA was then quantified, and shotgun libraries built using the Nextera XT DNA Library Prep kit. After product purification, the libraries were normalized and sequenced using an Illumina MiSeq sequencer. The obtained sequences were bioinformatically analysed using different softwares: FastQC, Trimmomatic, SPAdes, CheckM, Mash, Prodigal, EggNOG, PhyloPhlAn, and RGI.

RESULTS

Here, we propose a new experimental and computational workflow to map epidemic clusters at the hospital level using a phylogenetic analysis based on Mash Index and the Resistance Gene Identifier software to determine the genomic similarity/diversity among the isolated strains. The comparisons presented in this work highlighted the presence in our data of two strains, BAU-3 and BAU-6, different from all the others. Within this latter cluster there are further divisions, more circumscribed clusters. Specifically, the cluster containing the BAU-23, BAU-15, BAU-6, BAU-19, BAU-14, BAU-22 and BAU-11 was different from BAU-6 strain.

DISCUSSION AND CONCLUSIONS

We proposed the usage of the Mash Index, and the relative thresholds, as reliable tool in determining the similarity among strains and in monitoring their diffusion. In the framework of our data, we hypothesize that strains, except BAU-3 and BAU-6, may be the same strain because the differences between the reconstructed genomes are minimal. It should be emphasized, however, that the distance calculated with the Mash Index does not take into account the plasmid DNA, which is very important from the point of view of the mutations that are lost.

9 - Monitoring of fungal biodiversity in sea beaches of Sicily: a one-year environmental study

Maddalena Calvo⁽¹⁾ - Giuseppe Migliorisi⁽¹⁾ - Salvatore Oliveri⁽²⁾ - Laura Trovato⁽²⁾

Azienda ospedaliera, Azienda ospedaliera universitaria Policlinico - San Marco, Catania, Italia⁽¹⁾ -
Università di Catania, Dipartimento di Scienze biomediche e biotecnologiche, CATANIA, Italia⁽²⁾

Monitoring of fungal biodiversity in sea beaches of Sicily: a one-year environmental study

MADDALENA CALVO¹, GIUSEPPE MIGLIORISI¹, SALVATORE OLIVERI², LAURA TROVATO^{1,2}

¹ U.O.C. Laboratory Analysis, University Hospital Policlinico-San Marco, Catania, Italy

² Department of Biomedical and Biotechnical Sciences, University of Catania, Catania, Italy

INTRODUCTION

Recreational waters and tidally-wetted sands represent an eligible matrix for the development of pathogenic microorganisms. A high percentage of organic matter and relative humidity create an ideal substrate for pathogens deriving from exogenous sources closely related to human activities. Considering beach environments as a potential reservoir for pathogens, several studies showed the presence of different types of microorganisms through laboratory culture-based methods. Our study aims to demonstrate how fungal species should even be carefully monitored.

MATERIALS AND METHODS

A one-year study (2017) was performed on three recreational beaches in Sicily (Italy). Sand and water samples were collected during different seasons, registering humidity rates and weather conditions. A handful of sand was collected from three points of the same beach, while a 250 ml Schott flask was filled with water. 40 g from sand samples were diluted in 40 ml of sterile distilled water, agitated for 30 minutes (100 rpm) and plated (0.2 ml) onto Sabouraud Dextrose agar (2%) and Mycosel agar which were respectively stored at 37°C for 10 days and at 25°C for 20 days. Water samples were not diluted and directly plated under the same conditions. Identification was performed through macroscopic and microscopic observation of colonies.

RESULTS

Each beach presented equal rates of yeasts and non-dermatophytic moulds, while dermatophytes were rarely observed. The most detected fungal species were *Candida albicans*, *Geotrichum candidum*, *Aspergillus fumigatus*, *Aspergillus niger*, *Aspergillus terreus* and *Penicillium notatum*. *Fusarium oxysporum*, *Trichophyton tonsurans* and *Trichophyton mentagrophytes* were barely identified. Non-dermatophytic moulds were always detectable, without significant variations depending on humidity or weather conditions. Otherwise, yeast and dermatophytic isolates were mostly present during warm climate conditions (average humidity equal to 75% and temperature of approximately 26°C).

DISCUSSION AND CONCLUSION

According to our data, several fungal isolates potentially related to clinical conditions are highly represented in Southern Italy beach environments. Microbial contamination of water and sand is intimately connected, due to ordinary pollution sources and climate factors (tides, waves, wind) which promote contact between both matrices. Routinary monitoring of recreational waters is based on the presence and concentration of indicators of faecal contamination such as *Escherichia coli* and enterococci. Although these established procedures, we strongly recommend monitoring both waters and sands for fungal isolates, which could be involved in human infectious diseases.

10 - A case of rhino-pharyngeal myiasis from Eastern Sicily: rare infectious diseases have their time for revenge

GIUSEPPE MIGLIORISI⁽¹⁾ - MADDALENA CALVO⁽¹⁾ - FRANCESCO LOMBARDO⁽²⁾ - ALICE NICOLOSI⁽³⁾ - GAETANO MAUGERI⁽³⁾ - ILDEBRANDO PATAMIA⁽³⁾

AZIENDA OSPEDALIERA, POLICLINICO-SAN MARCO, CATANIA, Italia⁽¹⁾ - UNIVERSITA' DI CATANIA, DIPARTIMENTO DI SCIENZE BIOLOGICHE, GEOLOGICHE E AMBIENTALI, CATANIA, Italia⁽²⁾ - UNIVERSITA' DI CATANIA, DIPARTIMENTO DI SCIENZE BIOMEDICHE E BIOTECNOLOGICHE, CATANIA, Italia⁽³⁾

A case of rhino-pharyngeal myiasis from Eastern Sicily: rare infectious diseases have their time for revenge

GIUSEPPE MIGLIORISI¹, MADDALENA CALVO¹, FRANCESCO LOMBARDO³, ALICE NICOLOSI^{1,2}, GAETANO MAUGERI^{1,2}, ILDEBRANDO PATAMIA^{1,2}

¹ U.O.C. Laboratory Analysis, University Hospital Policlinico - San Marco, Catania, Italy

² Department of Biomedical and Biotechnical Sciences, University of Catania, Catania, Italy

³ Department of Biological, geological, and environmental Sciences, University of Catania, Italy

INTRODUCTION

Mucosal myiasis is defined as a vertebrate's infectious disease caused by dipterous larvae of the *Calliphoridae*, *Oestridae*, and *Sarcophagidae* families. Animals from rural areas represent its most eligible target, even if accidental human infestations have been reported. A sheep and goat livestock parasite called *Oestrus ovis* could cause nasal myiasis, characterized by nasopharyngeal symptoms. Here we describe a rare *Oestrus ovis* nasal myiasis in a patient with no history of rural stay. The case aims to demonstrate how uncommon diseases could have variable distribution rates, leading to difficulties in timely recognition.

MATERIALS AND METHODS

A healthy young man came to the Emergency Room of University Hospital Policlinico in Catania, suffering from prolonged nasal itch and feeling a foreign presence in the nasopharyngeal cavity. His frequent sneezing was followed by the expulsion of white cottony material from his nostrils and mouth. Anamnestic investigation revealed a previous close contact with a dipterous during an amateur photoshoot in a maritime area of Eastern Sicily. Physical and computerized exams were firstly required. A clinical sample spontaneously derived from the patients' nasopharyngeal cavity was analyzed at the Parasitology Unit. The University Entomology Department completed a definitive identification.

RESULTS

On physical exam, the patient's nasal mucosa was erythematous, thickened and bled easily from both nostrils. A computed tomography (CT) scan revealed mucosal oedema and sinuses free from clinical involvement. Parasitological macroscopic and microscopic analysis revealed the evidence of several larvae, that encouraged the suspicion of a myiasis. These results required further investigations through specific morphological methods performed by the University Entomology Department. Larvae were identified as *Oestrus ovis* species members. The patient spontaneously resolved the infestation by expelling all the larvae, due to the lack of sinus involvement.

DISCUSSION AND CONCLUSIONS

Nasal myiasis represent an uncommon and accidental event in humans. Literature reports a few cases, mostly related to stable stays in rural areas, precarious sanitary conditions, or close contact with livestock. Our case shows how rare infectious diseases could involve patients who temporally cross no rural areas due to the variable distribution of aetiological agents' habitats. Myiasis from healthy patients is often sceptically considered by clinicians. This trend leads to underestimated infections and diagnostics delays. It is essential to perform a prompt and definitive diagnosis, considering rare infections as an occurrence even if typical conditions are absent.

12 - Increasing the odds of discovering novel metabolites from a large microbial library

Paolo Monciardini ⁽¹⁾ - Cristina Brunati ⁽¹⁾ - Andrea Gentile ⁽¹⁾ - Marianna Iorio ⁽²⁾ - Sonia I. Maffioli ⁽²⁾ - Margherita Sosio ⁽¹⁾ - Arianna Tocchetti ⁽¹⁾ - Kristiina Vind ⁽¹⁾ - Mitja M. Zdouc ⁽¹⁾ - Stefano Donadio ⁽¹⁾

Naicons, Microbiologia, Milano, Italia ⁽¹⁾ - Naicons, Chimica, Milano, Italia ⁽²⁾

Increasing the odds of discovering novel metabolites from a large microbial library

*PAOLO MONCIARDINI**, *CRISTINA BRUNATI**, *ANDREA GENTILE**, *MARIANNA IORIO**, *SONIA I. MAFFIOLI**, *MARGHERITA SOSIO**, *ARIANNA TOCCHETTI**, *KRISTIINA VIND**, *MITJA M. ZDOUC**, *STEFANO DONADIO**

**Naicons srl, Milano, Italy*

Introduction

Microbial cultures are the source of many bioactive molecules. With tens of thousands of molecules reported in the literature over the past 80 years, one of the main issues in natural product screening is avoiding the re-discovery of known metabolites. Naicons strain collection, comprising ca 45000 actinomycete strains, is a valuable source of metabolic diversity. In our screening projects we applied the use of a metabolic fingerprint library based on LCMS analysis of >14000 extracts to rapidly identify uncommon metabolites. We report here some of the novel metabolites identified through this strategy.

Materials and Methods

Actinomycete strains from the NAICONS collection were cultured in different liquid media. Culture extracts were prepared from biomass by ethanol extraction and from spent medium by solid phase extraction. Metabolites were analysed by LC-MS followed by molecular networking through GNPS platform (Global Natural Product Social Molecular Networking). Antibiotic activity of purified metabolites was evaluated using CLSI procedures. Structural characterization of compounds was based on LC-MS and NMR analyses.

Results

Extracts obtained from actinomycete strains were analysed by LC-MS and compared with an internal library containing data from >14000 extracts deriving from >4000 strains. An untargeted approach was followed, focusing on rarity and/or novelty of the signal. This approach led to several novel and interesting molecules, some of which are described herein. Biarylittes are unusual cyclic tripeptides identified in extracts from *Planomonospora* strains. Genome analysis showed that the peptides derive from 5-amino acid, ribosomally synthesized precursors, and that the corresponding minimal gene cluster is actually widespread among actinomycetes. Allopeptimicins A, produced by a member of the *Actinoallomurus* genus, are acylated cyclodepsipeptides active against Gram-positive bacteria. Conversion of the amino group in the polyketide chain to a sulfamide abolished antibacterial activity. A *Streptomyces* strain produced *N*-acetyl-cysteinyllated streptophenazines, molecules that probably result from the addition of mycothiol on the streptophenazine core.

Discussion and Conclusions

Using a metabolomic approach, novel family of metabolites can be readily identified, some possessing interesting bioactivities, from unusual and common genera alike. Despite decades of intensive screening, microbial cultures continue to provide novel chemical entities when appropriate techniques are applied.

14 - Changes in microbial aetiology of Prosthetic Joint Infections: a three years evaluation.

LAURA SESSA⁽¹⁾ - Iolanda Giuffrida⁽¹⁾ - Valentina Costanzo⁽¹⁾ - Maddalena Calvo⁽¹⁾ - ELISABETTA FRAGALA⁽¹⁾ - GRAZIELLA FERLITO⁽¹⁾ - STEFANIA STEFANI⁽²⁾

Azienda ospedaliera, Azienda ospedaliera universitaria Policlinico - San Marco, Catania, Italia⁽¹⁾ -
Università degli Studi di Catania, Dipartimento di Scienze biomediche e biotecnologiche, CATANIA, Italia⁽²⁾

Changes in microbial aetiology of Prosthetic Joint Infections: a three years evaluation

LAURA SESSA¹, IOLANDA GIUFFRIDA¹, VALENTINA COSTANZO¹, MADDALENA CALVO¹, ELISABETTA FRAGALA¹, GRAZIELLA FERLITO¹, STEFANIA STEFANI^{1,2}

¹U.O.C. Laboratory Analysis, University Hospital Policlinico-San Marco, Catania, Italy

²Department of Biomedical and Biotechnical Sciences, University of Catania, Catania, Italy

INTRODUCTION:

Periprosthetic joint infections (PJI) are the most feared complications in orthopaedic surgery, although occurring in 1-2% of primary arthroplasties, and are mainly related to biofilm-forming bacteria. PJIs are mostly caused by Gram-positive cocci, but in the last years, literature highlighted PJI cases involving Gram-negatives, including multi-drug resistant strains (MDR). PJI etiological agents can be isolated from tissue biopsies and implants. The aim is to investigate PJI aetiology in 2019, 2020 and 2021 at the Orthopedic ward of Policlinico of Catania.

MATERIALS AND METHODS:

Data from 50 orthopaedic patients with infections that underwent surgery mostly for hip (45%) or knee (20%) revision arthroplasties (figure 1) were analyzed. Overall infection percentage in orthopaedic patients was 2.2%. Removed prostheses were treated with dithiothreitol to dislodge biofilm, which was confirmed by mucosal colonies, especially for *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Klebsiella pneumoniae*. Tissue biopsies were also analyzed.

RESULTS:

In 2019, 11 isolates were from prosthesis (including n.1 MRSA, 1 *Escherichia coli*, 1 *Proteus mirabilis*, 1 *Enterococcus faecium* strains) and 6 from tissue biopsies, among which *Pseudomonas aeruginosa*, (1) *Enterococcus faecalis* (2) and MRSA (2). In 2020, from 8 tissue biopsies, we isolated 1 MRSA, 1 *E. faecalis*, 2 *P. mirabilis*, 1 *Acinetobacter baumannii*, while from prosthesis cultures we obtained 3 *S. aureus*, 2 *A. baumannii*, 1 *E. faecium*, 4 *Enterobacterales*, 1 *P. aeruginosa*. In 2021, from 7 implants we isolated 1 *S. aureus*, 1 VRE, 1 KPC, 1 *A. baumannii* and from 5 tissue biopsies we isolated 1 *A. baumannii*, 2 *S. aureus*, 2 *P. aeruginosa*. Considering susceptibility, most of the Gram-negatives were resistant to carbapenems (KPC positive), 3dG cephalosporins and Fqs but susceptible to protected cephalosporins.

DISCUSSION AND CONCLUSIONS:

Data from this 3-year study in which a percentage of infection almost similar was observed, documented a relevant change occurred in bacteria involved in PJIs. In 2019, mostly Gram-positive cocci have been isolated, with an important prevalence of *S. aureus*. In 2020, Gram-positives (mostly *S. aureus*) and Gram-negatives, including MDR bacteria, were present equally. In 2021, Gram-negatives were more represented, with a significant prevalence of MDR microorganisms. Further analysis including biofilm formation and new antibiotic treatments are ongoing.

16 - Interference on uterine bacterial population in hypofertile mares of intrauterine infusion of equine fresh platelets-rich plasma.

Francesca Paola Nocera⁽¹⁾ - Chiara Del Prete⁽¹⁾ - Angelo Masullo⁽¹⁾ - Roberto Mancini⁽¹⁾ - Natascia Cocchia⁽¹⁾ - Maria Pia Pasolini⁽¹⁾ - Luisa De Martino⁽¹⁾

Università di Napoli Federico II, Medicina Veterinaria e Produzioni Animali, Napoli, Italia⁽¹⁾

Interference on uterine bacterial population in hypofertile mares of intrauterine infusion of equine fresh platelets-rich plasma.

FRANCESCA PAOLA NOCERA¹, CHIARA DEL PRETE¹, ANGELO MASULLO¹, ROBERTO MANCINI¹, NATASCIA COCCHIA¹, MARIA PIA PASOLINI¹, LUISA DE MARTINO^{1,2}

¹Department of Veterinary Medicine and Animal Production, University of Naples "Federico II", Naples, Italy; ²Task Force on Microbiome Studies, University of Naples "Federico II", Naples, Italy.

Introduction The clinical use of platelet-rich plasma (PRP) in equine is increasing. Several *in vivo* and *in vitro* experiments have shown beneficial effects of PRP in modulation of the inflammatory process and tissue healing. PRP is an emerging therapeutic application also for persistent breeding-induced endometritis, which is one of the major causes of infertility in mares. This study aims to investigate whether intrauterine PRP infusion interferes with the uterine microbial population of hypofertile mares. **Materials and Methods** In the year 2022, low-volume uterine flush (150 ml) was collected from 12 in estrus mares presenting fertility problems (barren in preceding season or repeated breeder), before and after about 12 h the PRP intrauterine infusion treatment. All mares were artificially inseminated 10 h before the first lavage. The samples were processed at the Microbiology Laboratory of the Department of Veterinary Medicine and Animal Production, University of Naples "Federico II" (Italy). They were inoculated in the broth-enrichment Brain Heart Infusion (BHI) and incubated aerobically at 37°C for 24 h. The day after, turbid BHI tubes were sub-cultured on different types of solid culture agar media and incubated aerobically at 37°C for 24-48 h. The isolates were identified by matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS). **Results** We observed that the uterine flush samples from three Italian trotter mares resulted to be negative for bacterial growth, whereas the same bacterial species were detected from four mares both before and after PRP treatment. Moreover, after PRP treatment an increase of the bacterial species in four mares was observed, while in a single mare we detected *E. coli* growth before treatment but no bacterial growth after PRP treatment. The most isolated bacterial species was *Streptococcus equi* subspecies *zooepidemicus*, which was detected both before and after PRP treatment except in a mare, which resulted to be negative before and positive to *Streptococcus equi* subspecies *zooepidemicus* and *Klebsiella pneumoniae* after the PRP treatment. **Discussion and Conclusions** Although PRP is found to have antimicrobial properties and has been widely used in veterinary medicine, no study is known so far on the interference of PRP intrauterine infusion treatment on uterine bacterial population in hypofertile mares. This preliminary study demonstrated that PRP intrauterine infusion treatment appeared not to interfere with the viable uterine microbial community composition.

18 - The spread of fluconazole-resistant *Candida parapsilosis* strains during the global COVID-19 pandemic in a Northern Italy hospital.

DOMENICO CALECA⁽¹⁾ - PAOLO GIGANTE⁽¹⁾ - GABRIELLA TOCCI⁽¹⁾ - VALENTINA LEPERA⁽¹⁾ - ANDREA ZAPPAVIGNA⁽¹⁾ - CHIARA GORRINI⁽¹⁾ - ROBERTA SCHIAVO⁽¹⁾ - IRENE PERONI⁽¹⁾ - LORENA LAVERGATA⁽¹⁾ - CLAUDIA CORDINE⁽¹⁾ - GIULIANA LO CASCIO⁽¹⁾

AUSL PIACENZA, OSPEDALE GUGLIELMO DA SALICETO, DIPARTIMENTO PATOLOGIA CLINICA,
PIACENZA, Italia⁽¹⁾

The spread of fluconazole-resistant *Candida parapsilosis* strains during the global COVID-19 pandemic in a Northern Italy hospital.

DOMENICO CALECA¹, PAOLO GIGANTE¹, GABRIELLA TOCCI¹, VALENTINA LEPERA¹, ANDREA ZAPPAVIGNA¹, CHIARA GORRINI¹, ROBERTA SCHIAVO¹, IRENE PERONI¹, LORENA LA VERGATA¹, CLAUDIA CORDINI¹, GIULIANA LO CASCIO¹.

¹Department of Clinical Pathology, Unit of Microbiology, Guglielmo da Saliceto Hospital, Piacenza, Italy.

Introduction: The global pandemic of COVID-19 has predisposed a relatively high number of patients to acute respiratory distress syndrome, which carries a risk to develop super-infections. *Candida parapsilosis* (CPA), the most common species of *Candida non albicans* isolated from bloodstream infections, although usually susceptible to azoles, is has increased significantly in recent years and it has been reported as an emerging multi-resistant yeast. The current SARS-CoV-2 pandemic has evidenced that COVID-19 patients are more susceptible to secondary infections. The aim of this work was to evaluate the prevalence of fluconazole resistant-CPA (CPA-R) in our hospital during SARS-CoV-2 pandemic period.

Materials and Methods: This study, conducted at the “Guglielmo da Saliceto” Hospital (Piacenza), refers to the period January 2019 - March 2022. CPA isolates from blood cultures were divided according to both isolation period and susceptibility/resistance to azole; period 1 (January 2019 - March 2020; control period) and period 2 (January 2021-March 2022; SARS-CoV-2 pandemic period). Yeast identification was performed by using MALDI-TOF MS (Vitek MS, bioMérieux, France) and antifungal susceptibility was evaluated by using the Vitek2 system (bioMérieux, France) and confirmed by Sensititre Yeast One YO10 (Thermofisher Scientific, USA) microdilution broth. ERG11 gene of 24/32 CPA fluconazole-resistant strains isolated from January 2021 to March 2022 was analyzed by sequencing according to Sanger method. Statistical analysis was performed according to Fisher Exact Test.

Results: As shown in Table 1, CPA isolates had a significant increase of +135,7 % ($p < 0.01$) in Period 2 compared to Period 1. Moreover, we observed increase of CPA-R strains in the same period, according to the data shown in Table 1. The evaluation of ERG11 gene sequences in 24 of 32 strains in Period 2 allowed to highlight the presence of Y132F mutation in almost all CPA-R strains (23/24). The detection of R398I mutation is detected in only one CPA-R (1/24).

	Period 1	Period 2
Total CPA	28	66
CPA-S (%)	22 (78,6%)	34 (51,5%)
CPA-R (%)	6 (21,4%)	32 (48,5%)

Table 1. Numbers and percentages of *Candida parapsilosis* in blood infections, and in particular, CPA fluconazole susceptible (CPA-S) strains and CPA-R strains in the two periods of the study.

Discussion and Conclusions: In this study we observed a substantial increase of CPA bloodstream infections during period 2, especially the ones caused by CPA-R strains. This could be explained by the reduction of infection control practices during a pandemic period and subsequent spreading of multi-resistant pathogens. The presence of the same mutation in the azole-resistant strains suggests the possible existence of a spreading cluster. Further investigations will be performed through NGS sequencing to confirm our suspicion.

20 - *Acinetobacter baumannii* and cefiderocol between cidalty and adaptability

Stefano Stracquadanio⁽¹⁾ - Carmelo Bonomo⁽¹⁾ - Andrea Marino⁽²⁾ - Dafne Bongiorno⁽¹⁾ - Grete Privitera⁽³⁾ - Dalida Bivona⁽¹⁾ - Alessia Mirabile⁽¹⁾ - Paolo Bonacci⁽¹⁾ - Stefania Stefani⁽¹⁾

Dipartimento di Scienze Biomediche e Biotecnologiche, Sezione di Microbiologia, Università degli Studi di Catania, Catania, Italia⁽¹⁾ - Dipartimento di Medicina Clinica e Sperimentale, Unità di Malattie Infettive, ARNAS Garibaldi / Università degli Studi di Catania, Catania, Italia⁽²⁾ - Dipartimento di Medicina Clinica e Sperimentale, Unità di Bioinformatica, Università degli Studi di Catania, Catania, Italia⁽³⁾

Acinetobacter baumannii and cefiderocol between cidalty and adaptability

STEFANO STRACQUADANIO¹, CARMELO BONOMO¹, ANDREA MARINO², DAFNE BONGIORNO¹, GRETE F. PRIVITERA³, DALIDA A. BIVONA¹, ALESSIA MIRABILE¹, PAOLO G. BONACCI¹, STEFANIA STEFANI¹

1. Dipartimento di Scienze Biomediche e Biotecnologiche, Sezione di Microbiologia, Università degli Studi di Catania – Catania, Italy; 2. Dipartimento di Medicina Clinica e Sperimentale, Unità di Malattie Infettive, ARNAS Garibaldi, Università degli Studi di Catania – Catania, Italy; 3. Dipartimento di Medicina Clinica e Sperimentale, Unità di Bioinformatica, Università degli Studi di Catania – Catania, Italy.

Introduction: Among the bacterial species included in the ESKAPE group, *Acinetobacter baumannii* is of great interest due to its intrinsic and acquired resistance to many antibiotics and its ability to infect different body districts. Cefiderocol (FDC) is a novel cephalosporin active against Gram-negative bacteria with promising efficacy on *A. baumannii* infections, but some studies have reported therapeutic failures even in the presence of susceptible strains.

Materials and Methods: This study aims to investigate the interactions between FDC and ten *A. baumannii* strains through determination of their susceptibility to FDC using both disk diffusion and broth microdilution as well as MBC/MIC evaluation to determine the bactericidal effect of FDC. Heteroresistance and adaptation of *A. baumannii* to FDC were evaluated by population analysis profile and induction assay respectively. Genomic analyses were performed to assess the presence of mutations related to the different FDC resistance profile. Eventually, the efficacy of beta-lactamase inhibitors (BLIs) in restoring the activity of FDC was evaluated.

Results: We confirmed diverse susceptibility profiles, with resistance values close to the EUCAST-proposed breakpoints in some strains. MBC/MIC demonstrated bactericidal activity of the drug with ratio values ≤ 4 for all the strains but ATCC 19606; on the other hand, bacterial regrowth was evident after exposition to FDC, as were changes in the shape of colonies and bacterial cells. A switch to a non-susceptible phenotype in the presence of high FDC concentrations was found in one strain as adaptation mechanism implemented to overcome the *cidal* activity of this antibiotic, also confirmed by the presence of heteroresistant, unstable subpopulations in 8/10 samples. Genomic analyses revealed the presence of mutations in PBP3 and TonB shared by all the strains regardless to their resistance phenotype. BLIs showed the ability to restore the antimicrobial activity of FDC despite the different non-susceptibility levels of the tested strains.

Discussion and Conclusions: By investigating the resistance profile of some clinical and laboratory-adapted *A. baumannii* strains to FDC, we found that these strains are not easily classified into the commonly used categories of susceptibility - especially strains with susceptibility levels very close to the proposed resistance breakpoints – due to a high prevalence of heteroresistant subpopulations. Heteroresistance in *A. baumannii* seems to be common as a stress response mechanism, but - luckily - it is apparently an unstable and transient trait. These *in vitro* results, can sustain the concept of using combination therapy to eliminate drug-adapted subpopulations and regain full FDC activity in this difficult-to-treat species.

22 - Combination of essential oils to poly(ϵ -caprolactone)-based biomaterial to achieve anti-bacterial and osteoblast proliferative properties for regenerative medicine scaffolds.

Sara Comini ⁽¹⁾ - Rosaria Sparti ⁽¹⁾ - Sara Scutera ⁽¹⁾ - Bartolomeo Coppola ⁽²⁾ - Anna Maria Cuffini ⁽¹⁾ - Lorenza Cavallo ⁽¹⁾ - Francesca Menotti ⁽¹⁾ - Cinzia Margherita Bertea ⁽³⁾ - Paola Palmero ⁽²⁾ - Giuliana Banche ⁽¹⁾ - [Valeria Allizond](#) ⁽¹⁾

University of Torino, Department of Public Health and Pediatrics, Turin, Italia ⁽¹⁾ - Politecnico di Torino, Department of Applied Science and Technology, Turin, Italia ⁽²⁾ - University of Torino, Department of Life Sciences and Systems Biology, Turin, Italia ⁽³⁾

Combination of essential oils to poly(ϵ -caprolactone)-based biomaterial to achieve anti-bacterial and osteoblast proliferative properties for regenerative medicine scaffolds.

SARA COMINI¹, ROSARIA SPARTI¹, SARA SCUTERA¹, BARTOLOMEO COPPOLA², ANNA MARIA CUFFINI¹, LORENZA CAVALLO¹, FRANCESCA MENOTTI¹, CINZIA MARGHERITA BERTEA³, PAOLA PALMERO², GIULIANA BANCHE¹, [VALERIA ALLIZOND](#)¹

¹Department of Public Health and Pediatrics, University of Torino, Turin, Italy. ²Department of Applied Science and Technology, Politecnico di Torino, Turin, Italy; ³Department of Life Sciences and Systems Biology, University of Torino, Turin, Italy.

Introduction: Biomedical implants, an essential part of the medical treatments, still suffer from bacterial infections that hamper patients' recovery and lives. Antibiotics are widely used to treat those infections but brought to antibiotic resistance. Essential oils (EOs), a complex mixture of different natural biomolecules, demonstrate excellent antimicrobial activity, being active against fungi and a wide range of gram-negative and gram-positive bacteria, and low resistance development risk. However, EOs application in medicine is still quite scarce and almost no research work considers its use in combination with bioresorbable biomaterials, such as poly (ϵ -caprolactone) (PCL) polymer. This work aimed to combine the antibacterial properties of EOs, particularly eugenol and cinnamon, with those of PCL for medical applications in which good tissue regeneration and antimicrobial effects are required.

Materials and methods: PCL porous samples were developed by solvent casting combined with a salt-leaching method, in which sodium chloride and sodium nitrate were used as pore former. Different concentrations of EOs (from 30% to 50%) with respect to the PCL mass were added to the polymer. Samples were further characterized from the morphological and microstructural point of view by Field Emission Scanning Electron Microscopy (FESEM). *In vitro* direct-contact tests on sarcoma osteogenic-2 (Saos-2) cells vitality/proliferation at different incubation times were performed. Antibacterial properties of different PCL samples against *Staphylococcus aureus* ATCC 29213, *S. epidermidis* ATCC 35984 and *Escherichia coli* ATCC 25922 were determined by both inhibition halo assay on agar and by adhesion tests that consisted in the count of adherent or planktonic bacteria.

Results: FESEM showed that the samples were characterized by square-shaped macropores, whose average dimension well matched that of the starting salt. Saos-2 cells cell vitality and proliferation was hampered by 40 and 50% EOs-enriched PCL, whereas no cytotoxic effect was recorded for both 30% EOs-added PCL and pure-PCL used as control, within 12 hours of incubation. The antibacterial tests revealed the presence of a small inhibition halo around the 30% eugenol and cinnamon-functionalized PCL scaffolds only for *S. aureus* and *S. epidermidis*, on the contrary no inhibition halo was observed for *E. coli*. A significant ($p < 0.001$) 2 log decrease on adherent bacteria was achieved for all the three bacteria: from 10^9 to 10^7 CFU/mL for *S. aureus* and *E. coli*, and from 10^7 to 10^5 CFU/mL for *S. epidermidis*, independently to the EO, eugenol or cinnamon, or the porous agent used. In addition, a 1 log reduction ($p < 0.05$) in the number of planktonic microorganisms was also obtained, thus proving that even if the EOs are only in part released by the EOs-added PCL scaffolds an antibacterial feature is anyway achieved.

Discussion and Conclusions: A biocompatible synthetic polymer scaffold for prosthetic implants that could enhance osteogenesis, and simultaneously prevent post-surgical infection and inflammation, is urgently needed. This research shows the great potential of EOs use for biomaterial functionalization with enhanced anti-bacterial properties without affecting osteoblasts vitality/proliferation.

23 - New drugs, new diagnostic techniques and new algorithms in fast track workflow of Gram-negative bloodstream infections: a three-year single-centre study

Sara Comini⁽¹⁾ - Gabriele Bianco⁽²⁾ - Guido Ricciardelli⁽¹⁾ - Matteo Boattini⁽²⁾ - Roberto Casale⁽¹⁾ - Valeria Allizond⁽³⁾ - Rossana Cavallo⁽¹⁾ - Cristina Costa⁽¹⁾

Università di Torino, Dipartimento di Scienze della Sanità Pubblica e Pediatriche/ A.O.U. Città della Salute e della Scienza di Torino, Torino, Italia⁽¹⁾ - Azienda Ospedaliero Universitaria, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italia⁽²⁾ - Università di Torino, Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Torino, Italia⁽³⁾

New drugs, new diagnostic techniques and new algorithms in fast track workflow of Gram-negative bloodstream infections: a three-year single-centre study

SARA COMINI^{1,2}, GABRIELE BIANCO¹, GUIDO RICCIARDELLI^{1,2}, MATTEO BOATTINI^{1,2}, ROBERTO CASALE^{1,2}, VALERIA ALLIZOND², ROSSANA CAVALLLO^{1,2}, CRISTINA COSTA^{1,2}

¹*Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy.*

²*Department of Public Health and Paediatrics, University of Torino, Turin, Italy.*

Introduction The contribution of rapid diagnostics in tackling antimicrobial resistance and improving the outcomes of patients with BSI is a matter of debate but might be enhanced by the availability of new approved drugs. In this study we evaluated a rapid diagnostic algorithm based on direct MALDI-TOF MS, lateral flow immunoassays (LFIs) and molecular testing performed directly from positive blood cultures (BCs) for Gram-negative species identification and detection of CTX-M extended-spectrum- β -lactamases and main carbapenemases. Secondly, we evaluated the association between detected resistance markers and antimicrobial susceptibility towards main antimicrobials including those newly approved such as ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam and cefiderocol.

Methods: Non-duplicate BCs positive to Gram-negative bacteria at microscope examination were subjected to species identification by direct MALDI-TOF MS following recovery of bacterial pellet by Rapid MBT Sepsityper[®] kit. Subsequently, NG-Test[®] CARBA 5 and NG-Test[®] CTX-M MULTI LFIs were performed according to identified microbial species. Eazyplex[®] SuperBug CRE molecular assay was performed in cases of NG-Test[®] CARBA 5 negative results in patients with documented carbapenemase-producers carriage. Results of rapid diagnostic workflow were compared with those obtained by conventional diagnostic routine. Associations between detected resistance markers and antimicrobial susceptibility to main antimicrobials were analysed using χ^2 test.

Results: Overall, the direct MALDI-TOF MS protocol allowed reliable identification to the species level of 92% of the 2398 monomicrobial BCs. Rate of matched identification was significantly higher for Enterobacterales (97%) in comparison to non-fermenting Gram-negative species (82%), obligate anaerobic bacteria (42%) and fastidious Gram-negative species (41%). The overall sensitivity of NG-Test[®] CARBA 5 and NG-Test[®] CTX-M MULTI was 92.2% and 91.6%, respectively. Integration of Eazyplex[®] SuperBug CRE allowed detecting *bla*_{KPC} mutants associated with ceftazidime/avibactam resistance, reaching 100% sensitivity in carbapenemase detection. Both LFIs and molecular testing showed no false positive results. Statistical significant associations between detected resistance markers and susceptibility to old e new antimicrobials were observed.

Conclusion: Algorithms based on MALDI-TOF MS, LFIs and molecular testing may represent a cost effective tool to timely identify Gram-negative species and detect resistance markers directly from BCs. According to local epidemiology, these results may allow antimicrobial stewardship interventions including prompt use of new approved drugs.

24 - Antimicrobial activity of Curcumin and Curcumin/Chitosan loaded nanobubbles with photodynamic light

Lorenza Cavallo⁽¹⁾ - Zunaira Munir⁽²⁾ - Janira Roana⁽¹⁾ - Ilaria Stura⁽²⁾ - Sara Comini⁽¹⁾ - Francesca Menotti⁽¹⁾ - Vivian Tullio⁽¹⁾ - Raffaele Pertusio⁽²⁾ - Matteo Biolatti⁽¹⁾ - Roberta Cavalli⁽³⁾ - Anna Maria Cuffini⁽¹⁾ - Caterina Guiot⁽²⁾ - Narcisa Mandras⁽¹⁾ - Giuliana Banche⁽¹⁾

Università di Torino, Dipartimento di Scienze della sanità pubblica e pediatriche, Torino, Italia⁽¹⁾ -
Università di Torino, Dipartimento di Neuroscienze, Torino, Italia⁽²⁾ - Università di Torino,
Dipartimento di Scienza e Tecnologia del Farmaco, Torino, Italia⁽³⁾

Antimicrobial activity of Curcumin and Curcumin/Chitosan loaded nanobubbles with photodynamic light

**LORENZA CAVALLO^a, ZUNAIRA MUNIR^b, JANIRA ROANA^a, ILARIA STURA^b, SARA COMINI^a,
FRANCESCA MENOTTI^a, VIVIAN TULLIO^a, RAFFAELE PERTUSIO^b, MATTEO BIOLATTI^a, ROBERTA
CAVALLI^c, ANNA MARIA CUFFINI^a, CATERINA GUIOT^b, NARCISA MANDRAS^a, GIULIANA BANCHE^a**

^a Department of Public Health and Pediatrics, Microbiology Division, University of Turin, 10126 Turin, Italy

^b Department of Neurosciences, University of Turin, 10124 Turin, Italy

^c Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy

Introduction: Curcumin is a natural substance extracted from turmeric that has *in vitro* antimicrobial properties against a wide variety of microorganisms. Moreover, due to its ability to emit fluorescence, its antimicrobial efficacy can be enhanced by photoactivation. However, the potential of this natural extract is limited by poor water solubility and instability at physiological pH, leading to poor absorption and rapid degradation by hydrolysis and molecular fragmentation. To overcome these issues, curcumin can be encapsulated in biocompatible nanosystems, which also have antibacterial properties, increasing its bioavailability and solubility. The present work aimed at investigating antimicrobial properties on both gram negative and gram positive bacteria (*Escherichia coli* ATCC 25922, *Staphylococcus aureus* ATCC 29213 and *Enterococcus faecalis* ATCC 29212) by using curcumin and curcumin/chitosan nanobubbles (NBs) with and without photodynamic treatment.

Materials and Methods: The effectiveness of curcumin alone, curcumin-chitosan loaded NBs and oxygen-curcumin-chitosan loaded NBs with and without irradiation (photodynamic blue light at 450nm) against above-mentioned bacterial strains were determined by using micro plate dilution assay for Minimum Inhibition Concentration (MIC) determination and colony counting method for Minimum Bactericidal Concentration (MBC) and time kill curves. In addition, the effect of curcumin and NBs on bacterial membrane integrity was assessed by measuring the release of lactate dehydrogenase (LDH) enzyme.

Results: We ascertained that curcumin (alone) with blue light have a robust effect against the mentioned bacterial strains. We find out MIC at a very low concentration of curcumin (0.125mg/ml, 0.0075mg/ml and 0.0037mg/ml) against *E. coli*, *S. aureus* and *E. faecalis* respectively, after three hours of LED irradiation. On the other hand, NBs showed a high antibacterial activity with MIC ranges of 0.011-0.46 mg/ml. Curcumin and NB MBC values were 1-2 times higher than MIC. Moreover, time kill kinetics confirmed that NBs were very effective to inhibit bacterial growth more than 72 hours. Bacterial membrane integrity was also checked and the results of LDH showed that NBs damaged microbial cell membranes.

Discussion and conclusions: In conclusion, it is interesting to speculate on a potential role of curcumin and curcumin loaded NBs, alone or together with photodynamic light, as to enhance antimicrobial activity. The findings of the proposed research will be helpful in fighting against harmful microorganisms.

25 - *optrA*-mediated linezolid resistance in an *Enterococcus faecalis* isolate recovered from a wild raptor (*Falco peregrinus peregrinus*), central Italy

Sonia Nina Coccitto⁽¹⁾ - Elisa Albini⁽²⁾ - Marzia Cinthi⁽³⁾ - Marco Gobbi⁽²⁾ - Francesca Romana Massacci⁽²⁾ - Silvia Pavone⁽²⁾ - Eleonora Giovanetti⁽³⁾ - Chiara Francesca Magistrali⁽²⁾ - Andrea Brenciani⁽¹⁾

Università Politecnica delle Marche, Dip. Scienze Biomediche e Sanità Pubblica, Ancona, Italia⁽¹⁾ - Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, IZSUM, Perugia, Italia⁽²⁾ - Università Politecnica delle Marche, Dip. Scienze della Vita e dell'Ambiente, Ancona, Italia⁽³⁾

***optrA*-mediated linezolid resistance in an *Enterococcus faecalis* isolate recovered from a wild raptor (*Falco peregrinus peregrinus*), central Italy**

***SONIA N. COCCITTO*¹, *ELISA ALBINI*², *MARZIA CINTHI*³, *MARCO GOBBI*², *FRANCESCA R. MASSACCI*², *SILVIA PAVONE*², *ELEONORA GIOVANETTI*³, *CHIARA F. MAGISTRALI*², *ANDREA BRENCIANI*¹**

¹Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy; ²Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche "Togo Rosati", Perugia, Italy; ³Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy

Introduction: *Enterococcus* species are commensal bacteria that colonized the intestinal tract of humans, mammals, and birds, and are commonly present in the environment. *Enterococcus faecalis* have been increasingly identified as important animal and human pathogens. The emergence of linezolid-resistant enterococci (LRE) has been described in several countries and LRE isolates harbouring a *cfr* (encoding a 23S rRNA methylase) and *optrA*- and *poxA* (encoding ABC-F ribosomal protection proteins)-containing plasmid were reported from animals, mostly from Asian countries and livestock animals. In this work, we studied an *E. faecalis* strain from a hawk and harbouring the *optrA* gene.

Materials and Methods: *E. faecalis* 30488 was isolated in June 2021 in Umbria region from an adult female Peregrine falcon (*Falco peregrinus* subspecies *peregrinus*) that died of septicemia, confirmed by culture and histopathological examination, as a probable consequence of a gunshot wound. The strain was screened for the presence of *cfr/cfr*-like, *optrA* and *poxA* genes by PCR assays. Antimicrobial susceptibility testing was carried out by broth microdilution. S1-PFGE, southern blotting and hybridization with *optrA*-specific probe have been used to determine gene location. Transferability was assessed by conjugation experiments using *E. faecalis* JH2-2 as recipient. The *optrA* genetic context and clonal lineage were analyzed by Whole Genome Sequencing (WGS).

Results: *E. faecalis* 30488 harbored the *optrA* gene and exhibited resistance to linezolid, chloramphenicol, florfenicol, tetracycline and erythromycin and susceptibility to tedizolid and vancomycin. Conjugation experiments failed to demonstrate the transferability of the *optrA* gene to *E. faecalis* JH2-2. S1-PFGE and hybridization assays displayed a chromosomal localization of the *optrA* gene. Further genome analysis showed that the *optrA* gene – linked to *fexA* and adjacent to a complete Tn554 element containing *erm(A)* and *spc* genes – was carried by a chromosomal Tn6674-like transposon inserted in *radC*. The Tn6674-like was 99% identical to the Tn6674 first reported in a porcine *E. faecalis* strain. WGS analysis showed that the strain belonged to the ST476, normally associated with human and animal enterococci. From phylogenetic analysis the *E. faecalis* 30488 isolate was closely related to the *E. faecalis* S338 strain previously isolated from swine farms in central Italy.

Discussion and Conclusions: This is the first report of a linezolid-resistant *E. faecalis* isolate of wild raptor origin carrying *optrA* gene. The identification of acquired mechanism of resistance to linezolid in wild animals, especially in birds, is highly worrisome for the potential role of wild animals as possible reservoir of LRE among different ecological niches.

26 - Detection of an *Enterococcus faecium* carrying the phenicol-oxazolidinone resistance gene *poxA* recovered from a freshwater river, central Italy

Marzia Cinthi⁽¹⁾ - Sonia Nina Coccitto⁽²⁾ - Gloria D'Achille⁽²⁾ - Andrea Brenciani⁽²⁾ - Gianluca Morroni⁽²⁾ - Eleonora Giovanetti⁽¹⁾

Università Politecnica delle Marche, Dipartimento Di Scienze Della Vita E Dell'Ambiente, Ancona, Italia⁽¹⁾ - Università Politecnica delle Marche, Dipartimento di Scienze Biomediche e Sanità Pubblica, Ancona, Italia⁽²⁾

Detection of an *Enterococcus faecium* carrying the phenicol-oxazolidinone resistance gene *poxA* recovered from a freshwater river, central Italy

MARZIA CINTHI¹, SONIA N. COCCITTO², GLORIA D'ACHILLE², ANDREA BRENCIANI², GIANLUCA MORRONI², ELEONORA GIOVANETTI¹.

¹Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy; ²Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy

Introduction: Enterococci are members of gut microbiota of human and animals. Although regarded as commensals, they are an increasing cause of nosocomial and antibiotic-resistant infections worldwide. The treatment of severe infections due to VRE and MDR enterococci is often limited to the last-resort antibiotics such as linezolid (LZD) and tedizolid (TDZ). Due to their abundance in animal feces and persistence in the environment, enterococci spread in many habitats including soil, water, food of animal origin, sewage and plants. Here we report the occurrence of an *E. faecium* isolate carrying the LZD resistance gene *poxA* from a freshwater river.

Materials and methods: Florfenicol-resistant enterococci from water samples from the Salinello river estuary, were tested by PCR for the presence of LZD resistance genes and for their susceptibility to several antibiotics by standard broth microdilution assay. S1-PFGE and southern blotting/hybridization assays were performed to determine the gene location. Conjugative transfer was assessed both *in vitro* filter mating experiment and in aquaria microcosm assays using *E. faecium* 64/3 and *E. faecium* Ef1 as recipients. WGS was carried out using the Illumina and Nanopore platforms. The presence of circular forms was examined by inverse PCR. Plasmid stability was also assessed.

Results: *E. faecium* M1, was positive for the presence of *poxA* gene that displayed both a chromosomal and plasmid localization. WGS analysis indicated that *poxA* was on a 30,877-bp plasmid (pEfM1) with high identity and synteny to the enterococcal 27-kb plasmid pEfM-Ef3. In both plasmids the *poxA* genetic context, flanked by two IS1216, was located in a Tn6657-like transposon also containing *fexB* gene; *tet*(L) and *tet*(M) genes in tandem, were located upstream of the transposon. The comparative analysis of the two plasmids showed that in pEfM1 a second copy of *poxA* genetic context was inserted within the Tn6657-like upstream of the *orf8*.

The *poxA* environment was proved to be unstable. In filter mating experiments, *poxA* was successfully transferred from *E. faecium* M1 to both enterococcal recipients, while in aquaria microcosm assays the gene was transferred only to *E. faecium* 64/3. To test the pEfM1 stability, *E. faecium* M1 and transconjugants were subjected to serial passages in antibiotic-free plates for 30 days at 37°C and 42°C. After only three passages, both at 37°C and 42°C, the transconjugants obtained in aquaria microcosm experiments had lost the *poxA*, but not pEfM1.

Discussion and conclusions: To our knowledge, this is the first report on the occurrence of a *poxA*-carrying enterococcus from freshwater, in Italy. Our findings suggest that also the freshwater ecosystem could represent an important reservoir of LZD resistance genes.

35 - Evaluation of the MALDI-TOF mass spectrometry workflow for the identification of microorganisms involved in monomicrobial and polymicrobial bloodstream infections.

Mirko Buttrini ⁽¹⁾ - Benedetta Farina ⁽¹⁾ - Monica Martinelli ⁽¹⁾ - Sara Montecchini ⁽¹⁾ - Alan Di Maio ⁽¹⁾ - Silvia Covan ⁽¹⁾ - Tiziano Moro ⁽¹⁾ - Elizabeth Prandini ⁽¹⁾ - Federica Crocamo ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Flora De Conto ⁽¹⁾ - Adriana Calderaro ⁽¹⁾

Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾

Evaluation of the MALDI-TOF mass spectrometry workflow for the identification of microorganisms involved in monomicrobial and polymicrobial bloodstream infections.

MIRKO BUTTRINI, BENEDETTA FARINA, MONICA MARTINELLI, SARA MONTECCHINI, ALAN DI MAIO, SILVIA COVAN, TIZIANO MORO, ELIZABETH PRANDINI, FEDERICA CROCAMO, MARIA CRISTINA ARCANGELETTI, CARLO CHEZZI, FLORA DE CONTO, ADRIANA CALDERARO

Department of Medicine and Surgery, University of Parma, Parma, Italy

Introduction. The rapid identification (ID) of microorganisms from blood samples is critical for a prompt and adequate patient's management. The diagnosis of bloodstream infections (BSIs) traditionally relies on blood cultures (BCs) but suffer from long time-to-result. Since MALDI-TOF mass spectrometry performant in timely identifying microorganisms cultured on solid media, several in-house-pre-treatment protocols have been developed for the direct ID of microorganisms in BCs. This study aims to evaluate the MALDI-TOF Sepsityper™ workflow (MSW), focusing on mixed BSIs.

Materials and Methods. A total of 361 positive BCs was selected to perform the Sepsityper™ sample preparation procedure according to the manufacturers' instructions (Bruker, Germany). One ml of each BC was purified to obtain a pellet by a quick-to-perform purification protocol. In parallel, further aliquots of each BC were used for both microscopic examination with Gram staining technique and subculture onto solid media (CC). The detection limit of the MSW was assessed by analysing experimentally seeded monomicrobial BCs using different microorganisms. To evaluate MSW's performance in identifying mixed BSIs, 10 experimentally seeded mixtures of two microorganisms (among 7 distinct bacteria) at different concentrations for a total of 50 combinations were used.

Results. As a result of microscopic examination, the 322 monomicrobial positive BCs contained Gram-positive (GP) and Gram-negative (GN) bacteria in 64.6% (208/322) and 35.4% (114/322), respectively. An ID at species level was obtained for 89.4% (186/208) of BCs-containing-GP bacteria and for 97.4% (111/114) BCs-containing-GN bacteria. The subculture results showed 92% (296/322) agreement with the MSW results. With regard to the 39 polymicrobial BCs, the MSW gave an ID at species level, in agreement with CC, for both microorganisms in 2.6% (1/39), an ID for only one of the microorganisms in 89.7% (35/39), and no ID in 7.7% (3/39). The detection limit was assessed to range from 2.5×10^6 to 6.8×10^6 cfu/ml. As concern the experimentally seeded mixed BCs, the ID of both microorganisms was obtained for all mixtures at least in one combination.

Discussion and Conclusions. The MSW demonstrated to be a helpful tool in identifying the microorganisms from BCs. This method showed a high identification capability for both GP and GN bacteria and no misidentification was observed. With regard to mixed BSIs, more often only one of the microorganisms involved was identified at species level. In addition to its significant performance, MSW relies on a cheap, easy- and rapid-to-perform protocol highly standardized and, therefore, it demonstrated to be dependent from pre-analytic and analytic variables.

36 - *Schistosoma haematobium*, an imported parasite: a 5-year epidemiological study.

Sara Montecchini ⁽¹⁾ - Federica Crocamo ⁽¹⁾ - Sabina Rossi ⁽¹⁾ - Federica Motta ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Benedetta Farina ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Flora De Conto ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Adriana Calderaro ⁽¹⁾

Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾

***Schistosoma haematobium*, an imported parasite: a 5-year epidemiological study.**

Autori: SARA MONTECCHINI, FEDERICA CROCAMO, SABINA ROSSI, FEDERICA MOTTA, MIRKO BUTTRINI, BENEDETTA FARINA, MARIA CRISTINA ARCANGELETTI, FLORA DE CONTO, CARLO CHEZZI, ADRIANA CALDERARO

Department of Medicine and Surgery, University of Parma, Parma, Italy

Introduction. Schistosomiasis is a parasitic disease caused by *Schistosoma* species pathogenic to humans. This parasitosis has long been considered a phenomenon confined to Tropics, however it is estimated that 220 million people in 78 countries are affected worldwide. The majority of the cases are associated to *S. haematobium*, the aetiological agent of urogenital schistosomiasis. Schistosomiasis is one of the most imported parasitoses in our area, therefore this study aims to evaluate the trend of the prevalence rates during a five-year period.

Materials and Methods. From 2017 to 2021, 883 cases of suspected urogenital schistosomiasis were investigated. Single and multiple urine and serum samples of the same patient were considered as a single case based on the following criteria: (i) all the samples of the same patient analysed for 1 month; (ii) the samples of a patient being always positive for *S. haematobium* continuously over a long period. In 381 and 209 cases, only serum or urine samples were analysed, respectively; for the remaining 293 cases both samples were tested. All serum samples were analysed by Schistosomiasis Serology Microwell ELISA (SCIMEDX, USA). All urine samples were submitted to microscopic examination to detect *S. haematobium* ova after concentration by using a Cellulose Nitrate Microporus membrane (Thermo Scientific, USA)

Results. A total of 115 positive cases (39.3%) were revealed among the 293 cases for which both urine and serum samples were tested: in 97 cases only serum and in 1 case only urine were positive, whereas in 17 cases both samples were positive. *S. haematobium* ova were detected in 15 cases (7.2%) of the 209 for which only urine samples were tested, while a positive result was obtained in 140 cases (36.7%) of the 381 for which only serum samples were tested. Among the overall 270 positive cases, for 12.3% (33/270) *S. haematobium* ova were detected, with a decreasing trend through the years (2017: 5.3%; 2018: 4.5%; 2019: 3.7%; 2020: 1.7%; 2021: 1.8%).

Discussion and Conclusions. During the last two years, a decreased number of samples for urogenital schistosomiasis suspicion has been observed as well as its prevalence, probably due to the reduced migratory flows all worldwide because of the COVID-19 pandemic. Although its prevalence rate is apparently reduced in 2020 as compared to the previous years, any reliable conclusion could be affected by the low number of cases reported during the pandemic period. Overall, 270 positive cases were observed, but only in 33 cases the outcome was referred to *S. haematobium*, since the ova were detected. The high number of positive serum samples without ova detection referred to an equally number of subjects exposed to the parasite, but not infested at the time of the investigation.

38 - In vitro effect of innovative light with photodynamic microbicidal activity in bacteria

Monica Ambrosio⁽¹⁾ - Francesca Paola Nocera⁽¹⁾ - Claudia Cerracchio⁽¹⁾ - Filomena Fiorito⁽¹⁾ - Martin Hohenegger⁽²⁾ - Luisa De Martino⁽¹⁾

Università degli studi di Napoli Federico II, Dipartimento di Medicina Veterinaria e Produzioni Animali, Napoli, Italia⁽¹⁾ - Medical University of Vienna, Institute of Pharmacology, Vienna, Austria⁽²⁾

***In vitro* effect of innovative light with photodynamic microbicidal activity in bacteria.**

MONICA AMBROSIO^{1,2}, FRANCESCA P. NOCERA¹, CLAUDIA CERRACCHIO¹, FILOMENA FIORITO¹, MARTIN HOHENEGGER² and LUISA DE MARTINO^{1,3}

¹Department of Veterinary Medicine and Animal Production, Infectious Diseases Unit, University of Naples "Federico II", Naples, Italy; ²Institute of Pharmacology, University of Medicine, Vienna, Austria; ³Task Force on Microbiome Studies, University of Naples "Federico II", Naples, Italy.

Introduction Light energy emitted in the visible light spectrum (VIS) is a non-harmful form of radiance and can result in photodynamic microbicidal effect in bacteria. Photosensitizing chromophores, like porphyrins, are present in bacteria and are sensitive to light in the visible spectrum, particularly in the visible blue-violet spectrum (400-420 nm). These wavelengths result in excitation of porphyrins and subsequent production of singlet oxygen (¹O₂) and other reactive species (RS). These products damage cytoplasmic and membrane structures, causing reduction of survival, even in multidrug-resistant microorganisms. The *Biovitae*® light, used in this study, emits white light from a light-emitting diode (LED) system but no UV spectrum. This technology has an microbicidal power on bacterial strains and viruses, without harming mammalian cells. **Materials and Methods** The tested light was provided by the *Nextense* company, and it uses a special combination of frequencies which cover the visible spectrum and create a multispectral interfering wave system for microbial eradication (MIME): 400-420 nm, 400-450 nm, 400-700 nm at an intensity of 3,51 mW/cm², 5,85 mW/cm², 12,53 mW/cm², respectively. The tests (n=16) were performed *in vitro* using 96-well plates and *Escherichia coli* (*E. coli*) and *Staphylococcus aureus* (*S. aureus*) strains, previously cultured in LB medium for 24 h at 37°C. We obtained an average optical density (OD_{595nm}) for *E. coli* of 0.140 A (1.1 x 10⁸ cells/ml) and for *S. aureus* of 0.150 A (1.2 x 10⁸ cells/ml) using Victor spectrophotometer (PerkinElmer). The absorbance of the empty culture medium was subtracted from the bacteria containing samples. The bacterial stock solutions were also diluted 1:2 and 1:4. Plates with bacteria were exposed to antimicrobial light for six hours, and bacterial growth monitored over 24 hours. **Results** During light exposure, a slight and steady increase in growth was observed for both *E. coli* and *S. aureus*. However, 18 hours after light exposure, bacterial growth significantly ($P \leq 0,005$) decreased compared to probes not exposed to the light. Comparison of the corresponding samples with Student's *t*-Test showed that growth reduction appears to be higher significant in the 1:2 dilution of both bacteria strains. **Discussion and conclusion** These results confirm the antimicrobial action of *Biovitae*® light both against Gram-negative and Gram-positive bacteria. Although during light exposure bacterial growth seems to be stimulated, the post light growth significantly ($P \leq 0,005$) decreased the bacterial survival.

40 - Temporal correlation between SARS-CoV-2 infection and Candida parapsilosis bloodstream infections.

Paolo Gigante⁽¹⁾ - Domenico Caleca⁽¹⁾ - Gabriella Tocci⁽¹⁾ - Valentina Lepera⁽¹⁾ - Andrea Zappavigna⁽¹⁾ - Chiara Gorrini⁽¹⁾ - Roberta Schiavo⁽¹⁾ - Irene Peroni⁽¹⁾ - Lorena La Vergata⁽¹⁾ - Claudia Cordini⁽¹⁾ - Giuliana Lo Cascio⁽¹⁾

AUSL PIACENZA, Ospedale Guglielmo da Saliceto, Piacenza, Italia⁽¹⁾

Temporal correlation between SARS-CoV-2 infection and Candida parapsilosis bloodstream infections.

PAOLO GIGANTE¹, DOMENICO CALECA¹, GABRIELLA TOCCI¹, VALENTINA LEPERA¹, ANDREA ZAPPAVIGNA¹, CHIARA GORRINI¹, ROBERTA SCHIAVO¹, IRENE PERONI¹, LORENA LA VERGATA¹, CLAUDIA CORDINI¹, GIULIANA LO CASCIO¹.

¹Department of Clinical Pathology, Unit of Microbiology, Guglielmo da Saliceto Hospital, Piacenza, Italy.

Introduction: Candida species are major constituents of the human mycobiome and the main cause of invasive fungal infections with a high mortality rate. Invasive yeast infections are increasingly recognized as complication of severe COVID-19. Candida parapsilosis (CPA), the most common species of Candida non albicans isolated from bloodstream infections, although usually susceptible to azoles, is recently reported as an emerging multi-resistant yeast. Current SARS-CoV-2 pandemic has evidenced COVID-19 patients' susceptible to secondary fungal infections, either mould and yeast infections. Aim of this study was to investigate whether SARS-CoV-2 infection predisposes to the onset of CPA-borne candidemia.

Material and methods: This study was conducted at the "Guglielmo da Saliceto" Hospital (Piacenza) from January 2021 to March 2022. CPAs isolated from blood cultures were analyzed. Virtuo (bioMerieux) automated blood culture system was used for monitoring blood culture bottles. Yeasts were identified at species level by using VitekMS (bioMerieux) device and MALDI-TOF MS method. For patients with CPA candidemia we investigated prior SARS-CoV-2 positivity. The diagnosis of COVID-19 was made with polymerase chain reaction (PCR) for SARS-CoV-2 with RT-qPCR Alinity m SARS-CoV-2 assay (Abbott Laboratories, Chicago, IL, USA).

Results: Over the period considered, 66 patients with candidemia by CPA have been identified. Thirty-two of them (48.5%) have never tested positive for SARS-CoV-2, while the remaining 34 (51.5%) were hospitalized for COVID-19. In the latter group, time of onset of candidemia was related to time of SARS CoV-2 diagnosis: 10 (29.4%) patients contracted SARS-CoV-2 within 15 days prior to the diagnosis of candidemia, 9 (26.5%) tested positive between the 16th and 30th day, and, eventually, 15 (44.1%) contracted COVID-19 more than one month before the CPA candidemia.

Discussion and Conclusions: The collected data did not show a significant difference between CPA candidemia in SARS-CoV-2 positive and negative patients. While, analysing the three different groups of patients with SARS-CoV-2 infection, 70% of patients presented candidemia after 15 days of COVID-19 infection, and 44% after more than 30 days. The monocentric evaluation of the study and the relatively low number of analysed patients does not allow to reach statistical significance of the data, but an evident correlation between length of stay and onset of candidemia is appreciable. Clinical features and risk factors such as ICU admission and use of corticosteroids could be investigated. Moreover, further multicentric studies on specific SARS-CoV-2 predisposing factors for candida systemic infections are advisable to clarify specific pathophysiological pathway of host/viral and yeast pathogen interaction.

41 - Sexually transmitted pathogens in a selected population: a preliminary study

Michele Mastria (1) - Enrica M. Ranieri (1) - Manuela Mandorino (1) - Stefania Garzone (1) - Luigi Ronga (2) - Raffaele Del Prete (1) - Adriana Mosca (1) - Luigi Santacroce (1)

DIM, sezione Microbiologia e Virologia, Università di Bari, Aldo Moro, Bari, Italia (1) - UOC Microbiologia e Virologia, Azienda Ospedaliero-Universitaria Policlinico of Bari, Bari, Italia (2)

Sexually transmitted pathogens in a selected population: a preliminary study

MICHELE MASTRIA¹, ENRICA M. RANIERI¹, MANUELA MANDORINO¹, STEFANIA GARZONE¹, LUIGI SANTACROCE^{1,2}, LUIGI RONGA², ADRIANA MOSCA^{1,2}, RAFFAELE DEL PRETE^{1,2}

¹ *Departement of Interdisciplinary Medicine (DIM), Sect. Microbiology and Virology, University "Aldo Moro", Bari, Italy;*

² *UOC Microbiology and Virology, Azienda Ospedaliero-Universitaria Policlinico of Bari, Bari, Italy.*

Background

Sexually transmitted infections (STIs) are frequently diagnosed among men who have sex with men (MSM), above all in HIV positive patients. The aim of the study was to evaluate pathogens etiologically related to STIs in MSM population attending the clinic dedicated to sexually transmitted diseases (STDs) at the Azienda Ospedaliero Universitaria Policlinico, Bari, Italy.

Materials and methods

From November 2021 to May 2022, 161 samples (50 anal and 53 buccal swabs, 58 urines) collected from 56 patients, in particular 28 HIV+, 19 HIV- and 9 HIV- in pre-exposure prophylaxis (PrEP). were analyzed. In order to detect the following pathogens: Chlamydia trachomatis (Ct), Mycoplasma genitalium (Mg) and Mycoplasma hominis (Mh), Ureaplasma urealyticum (Uu) and Ureaplasma parvum (Up), Neisseria gonorrhoeae (Ng) and Trichomonas vaginalis (Tv), a multiplex Real-Time PCR (mRT-PCR) (Anyplex™ II STI-7, Seegene, Inc., Seoul, Korea) assay was performed.

Results

34 of 56 patients (60%), were positive for at least one of the detected microorganisms. Positivity for STIs was revealed in 20/28 (71.43%) HIV+, 10/19 (52.53%) HIV- and 4/9 (44.44%) HIV- using PrEP. We also identified and compared the most frequent sexually transmitted pathogens between HIV+, HIV- and PrEP, respectively. The results were as: Uu (12.35% in HIV+, 14.81% in HIV- vs 11.32% in PrEP), Mh (9.88% in HIV+, 7.55% in HIV- vs 3.70% in PrEP), Mg (3.70% in HIV+, 3.77% in HIV- vs 7.41% in PrEP) and Ct (7.41% in HIV+, 7.41% in PrEP vs 1.89 % in HIV-).

Discussion and Conclusions

Sexually transmitted pathogens were detected in 34 of the 56 (60%) evaluated patients. Data highlighted that Uu, Mh, Mg and Ct were the most etiological agents responsible for STIs in MSM selected population attending STDs clinic. Positivity for Uu was observed in 15 of 56 (26.78%) of the patients studied. Furthermore, HIV+ patients were affected by Mh infections.

Moreover, Ct infection was revealed equally in both HIV+ and HIV- in PrEP subject as reported in the results seen above. The study is unaffected by a limitation due to a small amount of samples collected in the time considered.

42 - Nontyphoidal Salmonella gastroenteritis in children: a preliminary study on antibiotic resistance.

Sofia Denicolo¹ - Maria Elena Maggiore⁽¹⁾ - Francesca Indraccolo⁽¹⁾ - Michele Mastroia⁽¹⁾ - Luigi Ronga⁽²⁾ - Raffaele Del Prete⁽¹⁾ - Desiree Caselli⁽³⁾ - Adriana Mosca⁽¹⁾

Dipartimento DIM, Università degli studi di Bari, Bari, Italia⁽¹⁾ - UOC Microbiologia e Virologia, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italia⁽²⁾ - UOC Malattie Infettive e Tropicali Giovanni XXIII, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italia⁽³⁾

Nontyphoidal Salmonella gastroenteritis in children: a preliminary study on antibiotic resistance.

SOFIA DENICOLÒ¹, MARIA E. MAGGIORE¹, FRANCESCA INDRACCOLO¹, MICHELE MASTRIA¹, LUIGI RONGA², RAFFAELE DEL PRETE¹, DESIREE CASELLI³, ADRIANA MOSCA¹

¹Section Of Microbiology, Department of Interdisciplinary of Medicine, University of Bari, 70124 Bari, Italy.

²UOC Microbiology and Virology, University Hospital, Bari, Italy

³UOC Infectious Disease, Giovanni XXIII Children Hospital, Bari, Italy

Introduction

Nontyphoidal *Salmonella* (NTS) is one of the most common causes of acute bacterial gastroenteritis in children. Since multidrug-resistance NTS is an emerging health problem, the aim of this study was to evaluate the incidence and antimicrobial susceptibility of NTS isolated from diarrheic paediatric patients admitted to Giovanni XXIII Hospital, Bari, Italy.

Materials and methods

Stool samples were collected from 466 paediatric patients (range 0-23 years) from August 2021 to April 2022. *Salmonella enterica* was identified using MALDI-TOF mass spectrometry (Vitek® MS, BioMerieux), serotyped by slide micro-agglutination and tested for antimicrobial susceptibility to using Vitek® 2 system (BioMerieux).

Results

Thirty-nine (8%) stool samples were positive for NTS and *Salmonella* serovar Typhimurium was the most dominant serotype (75,67%). Other isolated serotypes were: *Salmonella* Oslo, *Salmonella* Derby, *Salmonella* Stradford, *Salmonella* Borgon, *Salmonella* Detroit, *Salmonella* Strathcona. The highest number of positive samples was found in patients with age between 0-6 years (70,2%), whereas 29,8% in patients older than 10 years. For *Salmonella* Typhimurium, 26/28 (92,8%) isolates were resistant to ampicillin and amoxicillin-clavulanic, 4 (14,28%) to trimethoprim-sulfamethoxazole, 1 (3,57%) to ceftazidime, the current first line treatment. All isolates were susceptible to carbapenems and fluoroquinolones. For the other *Salmonella* serovars, 33% of isolates were resistant to ampicillin and amoxicillin-clavulanic and all susceptible to trimethoprim-sulfamethoxazole, ceftazidime, carbapenems and fluoroquinolones.

Discussion and Conclusions

Salmonella Typhimurium is the most prevalent serotype responsible for NTS acute paediatric gastroenteritis and the most vulnerable patients are the children with age less than 6 years.

Although multidrug resistance has not been detected in NTS isolates, prudent use of antimicrobials is recommended because the treatment of NTS infections is not always required ensuring the long-term use of available antibiotics.

44 - Pilocarpine interferes with sphingolipids metabolism in *Candida albicans*.

EMERENZIANA OTTAVIANO ⁽¹⁾

UNIVERSITA' DEGLI STUDI DI MILANO, DIP. SCIENZE DELLA SALUTE, MILANO, Italia ⁽¹⁾

Pilocarpine interferes with sphingolipids metabolism in *Candida albicans*.

Emerenziana Ottaviano, Michele Dei Cas, Silvia Ancona, Ornella Xynomilakis, Silvia Bianchi, Elisa Borghi

Department of Health Sciences, Università degli Studi di Milano, Milan (Italy)

Candida albicans is the most common human fungal pathogen with an estimated crude mortality rate of 40%. The ability of the organism to filament and to produce biofilms are important virulence factors, responsible for tissue invasion and antifungal tolerance, respectively. Pilocarpine hydrochloride (PHCl), a muscarinic receptor agonist, has been shown to inhibit *C. albicans* biofilm formation and *in vivo* pathogenicity in the *Galleria mellonella* model, but the mechanism underlying this effect is still unknown.

Due to the sphingolipids' (SLs) role in the yeast cell wall integrity signaling, filamentation and virulence, we investigated the possible effect of PHCl on *C. albicans* sphingolipid content.

Lipids from pellets of planktonic and biofilm-organized cells of *C. albicans* strain SC5314, treated or not with PHCl 25 μ M, were isolated by extraction with methanol/chloroform mixture coupled to alkaline methanolysis for phospholipids removal. The sphingolipids profile was obtained by liquid chromatography tandem mass spectrometry (LC-MS/MS) using electrospray ionization.

Ceramide content was found reduced in both untreated and PHCl-treated biofilm-organized cells, despite no differences in the dihydroceramide precursor. On the contrary, PHCl reduced Cer concentration in planktonic cells. Phytoceramide (PHC) production was increased by PHCl in both planktonic and sessile cells, whereas the alpha-hydroxylated PHC was enriched only in treated sessile cells. Inositol phosphoryl ceramide (IPC), the precursor of mannosylated IPCs (MIPC) reported to be involved in *Candida* morphogenesis, was significantly higher in biofilms and not affected by PHCl treatment.

Biofilm itself causes severe sphingolipid content remodeling. PHCl seems to exert a modulatory effect on SL pathway in both sessile and planktonic cells. Further studies encompassing other sphingolipids, such as MIPC and M(IP)₂C, are necessary to elucidate whether the PHCl-driven reduction in filamentation and biofilm formation could be SL-mediated.

45 - KPC-producing *Klebsiella pneumoniae* spread: genotypic and epidemiological characterization of clinical strains from Marche region

Gloria D'Achille ⁽¹⁾ - Lucia Brescini ⁽¹⁾ - Marina Mingoia ⁽¹⁾ - Antonella Pocognoli ⁽²⁾ - Guido Zeni ⁽¹⁾ - Andrea Brenciani ⁽¹⁾ - Francesco Barchiesi ⁽¹⁾ - Gianluca Morroni ⁽¹⁾

Università Politecnica delle Marche, Dipartimento di Scienze Biomediche e Sanità Pubblica, Ancona, Italia ⁽¹⁾ - Ospedali Riuniti, Laboratorio di Microbiologia, Ancona, Italia ⁽²⁾

KPC-producing *Klebsiella pneumoniae* spread: genotypic and epidemiological characterization of clinical strains from Marche region

GLORIA D'ACHILLE¹, LUCIA BRESCINI^{1,2}, MARINA MINGOIA¹, ANTONELLA POCOGLI³, GUIDO ZENI^{1,3}, ANDREA BRENCIANI¹, FRANCESCO BARCHIESI^{1,4}, GIANLUCA MORRONI¹

¹Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy; ²Infectious Disease Clinic, Azienda Ospedaliero Universitaria "Ospedali Riuniti", Ancona, Italy; ³Microbiology Laboratory, Azienda Ospedaliero Universitaria "Ospedali Riuniti", Ancona, Italy; ⁴Infectious Disease Clinic, Ospedali Riuniti "Marche Nord", Pesaro, Italy

Introduction: The global spread of carbapenem resistant Gram-negative bacteria represents a worrying public health threat as carbapenems were one of the few therapeutic options for extended-spectrum beta-lactamase-producing strains. *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* are the most important one in severe nosocomial infections. We characterized *K.pneumoniae* carbapenemase-producing *K.pneumoniae* (Kp-KPC) from bloodstream infections from Marche region hospitalized patients, Italy, to evaluate the resistance rate to last resort antibiotics, the resistance mechanisms involved in antibiotic resistance beside carbapenems and highlight the presence of already widespread clones.

Materials and methods: A total of 83 Kp-KPC were collected from positive blood cultures from Ancona and Pesaro hospitals between January 2016 and December 2019. The presence of *bla*_{KPC} gene was confirmed by PCR experiments. MICs to colistin and ceftazidime-avibactam (CZA) were performed with the broth microdilution method. *GenElute bacterial genomic DNA* kit was used for total DNA extraction. All strains were typed by XbaI-PFGE: one strain for each pulsotype was subsequently selected and subjected to S1-PFGE and whole genome sequencing (WGS) by the Oxford Nanopore Technology. *Canu* and *Unicycler* were used for reads assembly while *BLAST* and *Center for Genomic Epidemiology* for data analysis.

Results: We found 24 out 83 isolates (28,9%) were colistin resistant (MIC > 2 mg/L). This resistance rate was decreasing in Ancona and Pesaro in the last year of study (2018: 36,4%; 2019: 11,8%). None CZA-resistant clone was detected. PFGE showed 29 pulsotypes with 3 major clusters: among them 2 were common in both hospitals, while the last one was spread only at Pesaro hospital and appeared in 2019. WGS highlighted 7 different sequence types (STs). The most represented were ST512 (71,1%) and ST307 (16,9%) shared by all the areas studied. ST307 showed a significant increase from 9,1% in 2018 to 58,8% in 2019 while ST512 passed from 68,2% to 29,4% respectively. KPC-3 was the most encoded allelic variant: only 4 KPC-2 isolates were detected, belonging to ST307.

Discussion and conclusions: The decreasing trend in colistin resistance in 2019 can be linked to both the administration of new therapeutic agents (CZA) and the success of different STs. Anyway, the shift from ST512 to ST307 should be worryingly since this clone is known for being more virulent and for having a greater number of resistance determinants. It is important to monitor the spread of ST307 to trace its epidemiological evolution and diffusion. Conscious use of CZA is also essential to prevent the appearance of resistant phenotypes.

47 - Re-sensitizing Methicillin-resistant *Staphylococcus aureus* to antimicrobials

Nader Abdelmalek ⁽¹⁾

Università degli studi di Sassari, Dipartimento Scienze biomediche, Sassari, Italia ⁽¹⁾

Re-sensitizing Methicillin-resistant *Staphylococcus aureus* to antimicrobials

NADER ABDELMALEK¹, MOSAED ALOBAIDALLAH², ANA HERRERO-FRESNO², METTE T. CHRISTIANSEN³,
JOHN E. OLSEN², SALVATORE RUBINO¹ AND BIANCA PAGLIETTI¹

¹ Department of Biomedical Sciences, University of Sassari, Sassari, Italy

² Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark

³ National Food Institute, Technical University of Denmark, Kongens Lyngby, Denmark

Introduction: Antimicrobial resistance (AMR) has become a global health concern in livestock and human settings. Methicillin-resistant *Staphylococcus aureus* (MRSA) is one of the most common antibiotic-resistant bacteria, which has been classified as a high-priority pathogen for new antibiotic development. In the battle against AMR, re-sensitizing MRSA to existing antimicrobials might be a promising approach, as the full expression of the resistance phenotype requires helper enzymes that, together with the resistance genes, are essential for displaying resistance. In this study, we seek to identify those helper genes/proteins involved in oxacillin and tetracycline resistance in MRSA, which could serve as targets to restore susceptibility to these antimicrobials.

Materials and Methods: Large-scale transposon mutant library of MRSA ST398 was screened following separate exposure to ½ minimum inhibitory concentration of target drugs using transposon-directed insertion site sequencing technology (TraDis), which allows the identification of metabolic enzymes necessary to express the resistance to oxacillin and tetracycline. Using the Bio::TraDIS pipeline, we measured mutant depletion to compare the insertion density in treated and untreated cultures and assess statistically an eventual under-representation of transposon insertions in non-essential genes. In addition, the identified genes were re-annotated and functionally characterized using the Uniprot database.

Results: The assay revealed 51 and 141 non-essential genes that might contribute to oxacillin and tetracycline resistance, respectively. The statistical analysis of each gene (log2 Fold Change < -2, and p-value < 0.05) and its involvement in biological processes led to selecting a set of genes to be validated by gene knockout.

Conclusion: Transposon mutagenesis can provide an unprecedented insight into bacterial resistance and its secondary resistome. This work presents a preliminary list of secondary resistance genes to oxacillin and tetracycline in *Staphylococcus aureus*. These genes may be potential targets for developing new "helper" compounds that may restore the efficacy of the tested antimicrobials.

49 - Implementation of a selective Chromatic medium for active surveillance of ceftazidime-avibactam resistance during COVID-19 pandemic: outbreaks and diagnostic issues

Gabriele Bianco⁽¹⁾ - Sara Comini⁽¹⁾ - Matteo Boattini⁽¹⁾ - Alessandro Bondi⁽¹⁾ - Alessio Leone⁽¹⁾ - Federica Zullo⁽¹⁾ - Valeria Allizond⁽²⁾ - Rossana Cavallo⁽¹⁾ - Cristina Costa⁽¹⁾

Laboratorio di Microbiologia e Virologia, Città della Salute e della Scienza di Torino, Torino, Italia⁽¹⁾ -
Laboratorio di Batteriologia e Micologia, Dipartimento di Scienze della Sanità Pubbliche e
Pediatrie- UNIVERSITA' DI TORINO, Torino, Italia⁽²⁾

Implementation of a selective Chromatic medium for active surveillance of ceftazidime-avibactam resistance during COVID-19 pandemic: outbreaks and diagnostic issues

GABRIELE BIANCO¹, SARA COMINI^{1,2}, MATTEO BOATTINI^{1,2}, ALESSANDRO BONDI¹, ALESSIO LEONE^{1,2}, FEDERICA ZULLO^{1,2}, VALERIA ALLIZOND², ROSSANA CAVALLO^{1,2}, CRISTINA COSTA^{1,2}

¹Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy.

²Department of Public Health and Paediatrics, University of Torino, Turin, Italy.

Introduction: Acquired resistance towards ceftazidime-avibactam (CAZ-AVI) is increasingly reported. Several mechanisms can be involved, but mutations in the Ω -loop region of β -lactamases are the most described. Herein, we assessed the implementation of Chromatic Super CAZ/AVI[®] medium in rectal swab surveillance cultures in a geographic area with endemic distribution of KPC-producing *Klebsiella pneumoniae* (KPC-Kp).

Methods: Routine rectal swabs collected from Intensive Care Unit (ICU) and non-ICU patients were screened for carbapenemase-producing Enterobacterales (CPE), carbapenems-resistant Gram-negative organisms (CR-GN) and CAZ-AVI-resistant organisms by Chromatic CRE and Super CAZ/AVI[®] media.

Results: Among the 1839 patients screened, 146 (7.9%) were found to be colonized by one or more CPE and/or CR-GN isolates during hospitalization. Overall, among colonized patients the most common bacteria encountered were KPC-producing Enterobacterales (n= 60; 41.1%), meropenem-resistant *Pseudomonas aeruginosa* (n= 41; 28.1%) and meropenem-resistant *A. baumannii* (n= 34; 23.3%). Among patients colonized by KPC-producing Enterobacterales, thirty-five (58.3%) had CAZ-AVI-resistant strains. A 30.5% rate of faecal carriage of CAZ-AVI-resistant KPC-producing *K. pneumoniae*, substantially higher than that of susceptible isolates (2.8%), was observed in the COVID-19 ICU. Twenty-one out of 22 CZA-resistant KPC-Kp strains isolated by COVID-19 patients expressed an ESBL phenotype and showed susceptibility toward carbapenems. All phenotypic carbapenemase detection methods (CarbaNP, Disc Diffusion Synergy test [KPC, MBL and OXA-48 Confirm Kit, Rosco Diagnostica], modified carbapenem inactivation method [mCIM], and lateral flow immunoassay [NG-Test CARBA 5- NG Biotech, France; RESIST-5 O.O.K.N.V- Coris Bioconcept, Belgium] failed to detect KPC carbapenemases conferring CZA resistance. Cluster analysis using Fourier-transform infrared spectroscopy on IR Biotyper system showed that 19 out of the 21 CZA-resistant KPC-Kp isolates belonged to a single outbreak clone.

Prevalence of faecal carriage of metallo- β -lactamases-producing organisms was low (0.5% and 0.2% for Enterobacterales and *P. aeruginosa*, respectively). Chromatic Super CAZ/AVI[®] medium showed 100% sensitivity in detecting CPE or CR-GN isolates resistant to CAZ-AVI regardless of both MIC values and carbapenemases content. Specificity was 86.8%.

Conclusion: The Chromatic Super CAZ/AVI[®] medium might be implemented in rectal swab surveillance cultures for identification of patients carrying CAZ-AVI-resistant organisms to contain the spread of these difficult-to-treat pathogens. Molecular testing are necessary to confirm expression of KPC variants associated with CAZ-AVI resistance.

51 - Cutaneous staphylococcal infection in immunocompromised site during nivolumab treatment for non-small cell lung cancer: a first case report

Terenzio Cosio⁽¹⁾ - Elena Campione⁽²⁾ - Gaetana Costanza⁽³⁾ - Sandro Grelli⁽³⁾ - Eleonora Andreassi⁽³⁾ - Valeria Flammini⁽⁴⁾ - Francesca Pica⁽¹⁾ - Roberta Gaziano⁽¹⁾

Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Roma, Italia⁽¹⁾ - Department of Systems Medicine, Dermatology Unit, Tor Vergata University Hospital, 00133 Rome, Italy;; Department of Systems Medicine, Dermatology Unit, Tor Vergata University Hospital, 00133 Rome, Italy;; Roma, Italia⁽²⁾ - Microbiology and Virology Lab, Tor Vergata University Hospital, V.le Oxford, 81 00133, Rome, Italy., Microbiology and Virology Lab, Tor Vergata University Hospital, V.le Oxford, 81 00133, Rome, Italy., Roma, Italia⁽³⁾ - Department of Systems Medicine, Oncology Unit, Tor Vergata University Hospital Foundation, 00133 Rome, Italy, Department of Systems Medicine, Oncology Unit, Tor Vergata University Hospital Foundation, 00133 Rome, Italy, Roma, Italia⁽⁴⁾

Cutaneous staphylococcal infection in immunocompromised site during nivolumab treatment for non-small cell lung cancer: a first case report

Terenzio COSIO^{1,2}, Elena CAMPIONE², Gaetana COSTANZA³, Sandro GRELLI³, Eleonora ANDREASSI³, Valeria FLAMMINI⁴, Francesca PICA¹, Roberta GAZIANO¹

¹Department of Experimental Medicine, PhD Course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), University of Rome Tor Vergata, 00133 Rome, Italy; ²Department of Systems Medicine, Dermatology Unit, Tor Vergata University Hospital, 00133 Rome, Italy;

³Microbiology and Virology Lab, Tor Vergata University Hospital, V.le Oxford, 81 00133, Rome, Italy.

⁴Department of Systems Medicine, Oncology Unit, Tor Vergata University Hospital Foundation, 00133 Rome, Italy

Introduction Immunotherapy in oncology is supplanting traditional therapies thanks to the specificity of action and the limitation of side effects. Despite its high efficacy, side effect as bacterial infection has been reported, especially pneumonia and urogenital tract infections. Bacterial skin and soft tissue infections (SSTI) represent one of the most important differential diagnoses in patients presenting with reddened and swollen skin and soft tissue. Among these infections, cellulitis (phlegmon) and abscesses are the most frequent. In most cases, they present as localized forms with possible contiguous spread, but in immunocompromised patients multifocal manifestation is frequent. We report a unique case report, of our knowledge, of a diffuse cutaneous infection with a phlegmon, in immunocompromised cutaneous site, in a patient treated with nivolumab for non-small cell lung cancer (NSCLC).

Materials and Methods A 64-year-old, smoker male patient became at our attention for cutaneous lesions at different evolution level in the left arm (three phlegmons), on the left side (erythematous plaque) and on the right wrist (scaly redness papule), all localized on a tattoo. To identify the etiopathologies agents, we performed clinical visit, complete blood test and cutaneous swabs.

Results Blood tests don't underline systemic infection or other concomitant comorbidities, while microbiological cultures and gram stains highlight a gram-positive infection caused by methicillin-susceptible but Erythromycin-resistant (ER-R) clindamycin-resistant CL-R) and gentamicin-resistant (GE-R) *Staphylococcus aureus*. Systemic treatment with clarithromycin 500 mg/day for 15 days and topical fusidic acid twice daily for 30 days was prescribed, with complete resolutions of all cutaneous lesions. No adverse events were reported.

Discussion and Conclusions Despite immunotherapy is being a milestone in oncologic treatment, more than the spectrum of immune-mediated toxicities from these agents need to be investigate. This report highlights the importance of considering lifestyle and cutaneous alteration before starting immunotherapy. Moreover, this case also emphasizes the potential value of dermatological screening in patients treated with Programmed death 1 (PD-1) checkpoint inhibitors and underlines how immunocompromised cutaneous site could be involved during immunotherapies.

54 - Introduction of probiotic-based sanitation in the emergency ward of a children's hospital during the COVID-19 pandemic

Maria D'Accolti⁽¹⁾ - Irene Soffritti⁽¹⁾ - Carolina Cason⁽²⁾ - Giuseppina Campisciano⁽²⁾ - Sante Mazzacane⁽³⁾ - Francesca Bini⁽¹⁾ - Eleonora Mazziga⁽¹⁾ - Manola Comar⁽²⁾ - Elisabetta Caselli⁽¹⁾

Università degli Studi di Ferrara, Dip. Scienze Chimiche, Farmaceutiche ed Agrarie, Ferrara, Italia⁽¹⁾ - I.R.C.C.S materno infantile Burlo Garofolo, Microbiologia avanzata traslazionale, Trieste, Italia⁽²⁾ - Università degli Studi di Ferrara-, CIAS Centro Ricerca, Ferrara, Italia⁽³⁾

Introduction of probiotic-based sanitation in the emergency ward of a children's hospital during the COVID-19 pandemic

MARIA D'ACCOLTI^{1,2}, IRENE SOFFRITTI^{1,2}, CAROLINA CASON³, GIUSEPPINA CAMPISCIANO³, SANTE MAZZACANE², FRANCESCA BINI^{1,2}, ELEONORA MAZZIGA¹, MANOLA COMAR^{3,5}, ELISABETTA CASELLI^{1,2}.

¹ Department of Chemical, Pharmaceutical and Agricultural Sciences, and LTTA, University of Ferrara, Ferrara, Italy;

² CIAS Research Center, University of Ferrara, Ferrara, Italy;

³ Department of Advanced Translational Microbiology, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", Trieste, Italy;

⁵ Department of Medical Sciences, University of Trieste, Trieste, Italy;

Introduction: The massive use of disinfectants to prevent COVID-19 transmission might worsen the antimicrobial resistance (AMR) threat, especially in the hospital environment, possibly leading to future AMR pandemics. However, the control of microbial and viral contamination is crucial in hospitals, since hospital microbiomes can cause the healthcare-associated infections (HAIs), which are particularly frequent and severe in pediatric wards, due to children high susceptibility.

We have previously reported that a probiotic cleaning hygiene system (PCHS) can stably decrease bacterial pathogens and their AMR in the hospital environment, reducing associated HAIs in adult hospitals. Since we recently showed that PCHS can also inactivate enveloped viruses in vitro, here we aimed to test the effect of PCHS in the emergency room (ER) of a children's hospital during the COVID-19 pandemic.

Material and Methods: PCHS was used for routine ER sanitation for 2 months in substitution of the conventional chemical disinfection. The environmental bioburden was characterized before and during PCHS application (at 2, 4, and 9 weeks after PCHS introduction). Microbial contamination was monitored by both conventional culture-based CFU count and molecular assays, including 16S rRNA NGS for bacteriome characterization and microarrays for the assessment of the resistome of the contaminating population. The presence of SARS-CoV-2 was also monitored by PCR.

Results: PCHS usage was associated with a stable 80% decrease in bacterial/fungal pathogens compared to the levels detected with chemical disinfection ($P < 0.01$), accompanied by an up to 99% decrease of AMR genes ($P < 0.01$). Besides, SARS-CoV-2 was stably absent in PCHS-treated environments. The PCHS effects were reversed when reintroducing chemical disinfection, which counteracted the action of the PCHS.

Discussion and Conclusions: Since the control of microbial contamination continues to be a major issue in the management of the pandemic emergency, collected data suggest that PCHS may be successfully used to control virus spread without simultaneous worsening of the AMR concern.

55 - Genomic fingerprinting of a *Mycobacterium bovis* BCG causing a severe vertebral osteomyelitis following BCG instillation in a bladder cancer patient

Giulia Codda ⁽¹⁾ - Edward Willison ⁽²⁾ - Giuliana Carrega ⁽³⁾ - Ramona Barbieri ⁽²⁾ - Anna Marchese ⁽²⁾ - Vincenzo Di Pilato ⁽¹⁾

Università di Genova, Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate, Genova, Italia
⁽¹⁾ - Ospedale Policlinico San Martino-IRCCS, UO Microbiologia, Genova, Italia ⁽²⁾ - ASL2 Pietra Ligure, UO Malattie infettive osteo-articolari, Albenga, Italia ⁽³⁾

Genomic fingerprinting of a *Mycobacterium bovis* BCG causing a severe vertebral osteomyelitis following BCG instillation in a bladder cancer patient

GIULIA CODDA¹, EDWARD WILLISON², GIULIANA CARREGA³, RAMONA BARBIERI², ANNA MARCHESE^{1,2}, VINCENZO DI PILATO^{1*}

¹Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy; ²Microbiology Unit, Ospedale Policlinico San Martino-IRCCS, Genoa, Italy; ³Infectious Diseases and Septic Orthopedics Unit, ASL2 Pietra Ligure, Savona, Italy;

Introduction Bacillus Calmette-Guérin (BCG), an attenuated derivative of the virulent strain of *Mycobacterium tuberculosis* var. *bovis* (*M. bovis*), is globally used for vaccination against tuberculosis or treatment of non-muscle invasive bladder cancer, since it triggers an innate immunological reaction that is protective against tumor recurrence and progression. Nevertheless, adverse reactions (ARs) to BCG immunotherapy can be observed after months or years, especially in immunocompromised patients, including lymphadenitis, osteomyelitis, and disseminated BCG infections. Nosocomially acquired, catheter-related BCG infections have been also documented. At present, genetically diverse BCG sub-strains exist, and their genetic diversity may influence the immunization efficacy and severity of disseminated infections. The limited number of cases, however, prevents a fine assessment of possible genetic variations occurring in BCG strains associated with ARs. Here we report on the genomic characterization of a clinical BCG vaccine strain causing a severe vertebral osteomyelitis following BCG immunotherapy.

Materials and Methods *M. bovis* BCG-GE was isolated (BACTED MGIT, BD, US) in September 2021 from a biopsy sample of a bladder cancer patient admitted to a tertiary-care hospital in Albenga (Savona, Italy), previously subjected to BCG instillation with the OncoTice strain (Merck, US). Initial identification was carried out by MALDI-TOF mass spectrometry (Becton Dickinson, US). Whole-genome sequencing (WGS) was performed using the Oxford Nanopore MinION system (ONT, UK) and raw reads were assembled using Flye. *In silico* identification was performed using the Pathogenwatch webserver, while global genomic comparative analyses were carried out using snippy, iq-tree, and Mauve.

Results Long-reads sequencing resulted in a complete circular genome of BCG-GE (total length: 4,317,915 bp; coverage: 40x; GC%: 65.7). A WGS-based identification as *Mycobacterium tuberculosis* var. *bovis* BCG was achieved. Global phylogenetic analysis, including 143 *M. bovis* genomes, revealed a close clonal relationship with the BCG Tice vaccine strain. A pairwise comparison of BCG-GE and BCG Tice genomes revealed several genetic alterations in gene products likely involved in bacterial growth, host adaptation and virulence processes (e.g. ESX-type secretion systems, MmpL- and MCE-type transport systems, PE/PPE and MCE proteins).

Discussion and Conclusions To the best of our knowledge, we report the first WGS-based comparative analysis of the BCG-Tice vaccine strain and a BCG Tice clinical isolate causing a severe vertebral osteomyelitis. Present results provide a background genomic information that can be exploited to investigate the genetic heterogeneity of BCG strains associated with ARs.

64 - Antimicrobial activity of WMR-K against *Neisseria meningitidis*

Alessia Stornaiuolo⁽¹⁾ - Chiara Pagliuca⁽²⁾ - Elena Scaglione⁽³⁾ - Giuseppe Mantova⁽²⁾ - Valeria Caturano⁽⁴⁾ - Martina Di Rosario⁽²⁾ - Roberta Colicchio⁽⁵⁾ - Annarita Falanga⁽⁶⁾ - Mariateresa Vitiello⁽⁵⁾ - Stefania Galdiero⁽⁷⁾ - Paola Salvatore⁽⁸⁾

University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., University of Naples Federico II, Dpt. of Chem., Mat. and Ind. Prod. Eng., University of Naples Federico II, Naples, Italia⁽¹⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italia⁽²⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Chem., Mat. and Ind. Prod. Eng., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federico II, Naples, Italia⁽³⁾ - University of Naples Federico II, Dpt. of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italia⁽⁴⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federico II, Naples, Italia⁽⁵⁾ - University of Naples Federico II, Department of Agriculture, University of Naples Federico II, Naples, Italia⁽⁶⁾ - University of Naples Federico II, Department of Pharmacy, University of Naples Federico II, Naples, Italia⁽⁷⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federico II, CEINGE, Task Force on Microbiome Studies, Naples, Italia⁽⁸⁾

Antimicrobial activity of WMR-K against *Neisseria meningitidis*

ALESSIA STORNAIUOLO^{1,2}, CHIARA PAGLIUCA¹, ELENA SCAGLIONE^{1,2,3}, GIUSEPPE MANTOVA¹, VALERIA CATURANO³, MARTINA DI ROSARIO¹, ROBERTA COLICCHIO^{1,3}, ANNARITA FALANGA⁴, MARIATERESA VITIELLO^{1,3}, STEFANIA GALDIERO⁵, PAOLA SALVATORE^{1,3,6,7}

¹Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy; ²Department of Chemical, Materials and Industrial Production Engineering, University of Naples Federico II, Naples, Italy; ³Department of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italy; ⁴Department of Agriculture, University of Naples Federico II, Naples, Italy; ⁵Department of Pharmacy, University of Naples Federico II, Naples, Italy; ⁶CEINGE, Advanced Biotechnologies s.c.ar.l., Naples, Italy; ⁷Task Force on Microbiome Studies, University of Naples Federico II, Naples, Italy.

Introduction. Antimicrobial peptides (AMPs) represent an attractive alternative to conventional drugs for the development of new antimicrobials since they have shown to have broad-spectrum activity towards bacteria, fungi and viruses, furthermore, the resistance mechanisms towards them are limited. Although AMPs being highly diverse in sequence, length and structure, they present similar mechanisms of action, which involve the disruption of bacterial membrane integrity. The antimicrobial WMR peptide, which is a modification of the native sequence of myxinidin, a marine peptide isolated from the epidermal mucus of hagfish (*Myxine glutinosa* L.), showed a potent antimicrobial activity against a wide range of bacteria and yeast. A later modification of the WMR sequence, the analogue WMR-K, was developed to enable peptide covalent binding to self-assembled peptide fibers for intracellular delivery. The aim of this study was to investigate the antimicrobial activity of the WMR-K peptide against *Neisseria meningitidis* strains. **Materials and Methods.** In order to identify the antimicrobial activity of the WMR-K peptide against meningococcus, it was evaluated the minimum concentration of molecule capable of inhibiting the growth of the microorganism (MIC) and the minimum concentration of molecule capable of killing the microorganism (MBC) against selected *N. meningitidis* strains (serogroups A and C) testing increasing concentration of analogue (from 1 µM to 100 µM). Time kill kinetics of WMR-K were also evaluated against selected *N. meningitidis* strains: in detail, values corresponding to MBC and 2, 4, 8 -fold the MBC were tested. **Results.** The obtained experimental data highlighted the efficacy of WMR-K analogue against meningococcal strains with MIC and MBC values ranging from 10 µM to 90 µM. Moreover, time kill kinetics assays have defined that the analogue exerts its activity within the first hour of contact. **Discussion and Conclusion.** Although they

are preliminary data, the results of the antimicrobial activities suggest a promising capacity of low concentrations of WMR-K to inhibit *N. meningitidis* strains belonging to widespread serogroups. In the next future, the synergistic effect of the analogue with standard antibiotic therapies will be also evaluated.

65 - Effect of pomegranate peel extracts against ESKAPE

Valeria Caturano⁽¹⁾ - Alessia Stornaiuolo⁽²⁾ - Giuseppe Mantova⁽³⁾ - Elena Scaglione⁽⁴⁾ - Chiara Pagliuca⁽³⁾ - Denise D'Orio⁽¹⁾ - Erika Zarrillo⁽¹⁾ - Antonietta Massaro⁽¹⁾ - Caterina Pagliarulo⁽⁵⁾ - Daniela Sateriale⁽⁵⁾ - Mariateresa Vitiello⁽⁶⁾ - Roberta Colicchio⁽⁶⁾ - Paola Salvatore⁽⁷⁾

University of Naples Federico II, Dpt. of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italia⁽¹⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., University of Naples Federico II, Dpt. of Chem., Mat. and Ind. Prod. Eng., University of Naples Federico II, Naples, Italia⁽²⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italia⁽³⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Chem., Mat. and Ind. Prod. Eng., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federico II, Naples, Italia⁽⁴⁾ - University of Sannio, Benevento, Department of Sciences and Technologies, University of Sannio, Benevento, Italia⁽⁵⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federico II, Naples, Italia⁽⁶⁾ - University of Naples Federico II, Dpt. of Mol. Med. and Med. Biotech., Dpt. of Integ. Activ. of Lab. Med. and Transf. Univ. Hosp. Federico II, CEINGE, Task Force on Microbiome Studies, Naples, Italia⁽⁷⁾

Effect of pomegranate peel extracts against ESKAPE

VALERIA CATURANO¹, ALESSIA STORNAIUOLO^{2,3}, GIUSEPPE MANTOVA², ELENA SCAGLIONE^{1,2,3}, CHIARA PAGLIUCA², DENISE D'ORIO¹, ERIKA ZARRILLO¹, ANTONIETTA MASSARO¹, CATERINA PAGLIARULO⁴, DANIELA SATERIALE⁴, MARIATERESA VITIELLO^{1,2}, ROBERTA COLICCHIO^{1,2}, PAOLA SALVATORE^{1,2,5,6}.

¹Department of Integrated Activity of Laboratory Medicine and Transfusion, Complex Operative Unit of Clinical Microbiology, University Hospital Federico II, Naples, Italy; ² Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy; ³Department of Chemical, Materials and Production Engineering, University of Naples Federico II, Naples, Italy; ⁴Department of Sciences and Technologies, University of Sannio, Benevento, Italy; ⁵Task Force on Microbiome Studies, University of Naples Federico II, Naples, Italy; ⁶CEINGE, Biotechnologie Avanzate s.c.ar.l., Naples, Italy.

Introduction: The improper use and abuse of antibiotics has led to the increase and spread of new mechanisms of multi-drug resistance with a consequent decrease of the effectiveness of standard antibiotic therapies. The multi-drug resistant (MDR) strains entail a greater difficulty of treatment with a strong possibility of therapeutic failure. This phenomenon currently represents a real emergency in the health field which requires alternative routes to fight infections such as the identification of new molecules with antimicrobial activity capable of acting on MDR strains. The aim of the present study was to evaluate the antimicrobial activity of hydroalcoholic pomegranate peel extract thanks to its characterized content of polyphenolic compounds and antioxidant activity strength. **Materials and methods:** The agar diffusion method was conducted to evaluate the inhibitory spectrum of extracts against ESKAPE group: *Staphylococcus aureus* ATCC, *Pseudomonas aeruginosa* ATCC and MDR clinical strains such as Methicillin resistant *S. aureus* (MRSA), *P. aeruginosa* MDR, *Acinetobacter baumannii* MDR and *Klebsiella pneumoniae* carbapenemase producer (KPC). The susceptibility of selected isolates to different concentrations of hydroalcoholic pomegranate peel extracts was determined using microdilution assay. **Results:** The pomegranate peel extracts effectively inhibit the growth and survival of all bacterial strain tested, as demonstrated by the diameters of inhibition zones exerted by low amount of extract (>10mm).

Accordingly, quantitative evaluation of the antimicrobial activity of pomegranate peel extract against selected ESKAPE strains showed high inhibitory activity against *S. aureus* ATCC and MRSA with a minimum bactericidal concentration (MBC) of 16 $\mu\text{g}/\mu\text{l}$; while against *P. aeruginosa* ATCC and relative MDR clinical isolates, the MBC values obtained were ranging from 40 to 80 $\mu\text{g}/\mu\text{l}$. Instead for *A. baumannii* MDR and *K. pneumoniae* KPC the MBC values obtained are respectively 20 $\mu\text{g}/\mu\text{l}$ and 200 $\mu\text{g}/\mu\text{l}$. **Discussion and Conclusion:** The preliminary data obtained by *in vitro* microbiological assay, demonstrate that the hydroalcoholic pomegranate peel extract is able to inhibit the bacterial viability of reference and MDR strains belonging to the ESKAPE group. The promising experimental obtained data suggest to evaluate the synergistic activity with standard antibiotic therapies that could restore the antimicrobial drug efficacy.

66 - Quality assessment of surface and groundwaters in Lombardy, Italy: detection and characterization of ESBLs-producing Enterobacterales

Aurora Piazza ⁽¹⁾ - Aseel AbuAlshaar ⁽¹⁾ - Antonietta Grosso ⁽¹⁾ - Francesca Piscopiello ⁽¹⁾ - Melissa Spalla ⁽¹⁾ - Michela Sturini ⁽²⁾ - Federica Maraschi ⁽²⁾ - Giorgio Pilla ⁽³⁾ - Roberta Migliavacca ⁽¹⁾

Università di Pavia, Dipartimento di Scienze Clinico Chirurgiche Diagnostiche e Pediatriche, Pavia, Italia ⁽¹⁾ - Università di Pavia, Dipartimento di Chimica, Pavia, Italia ⁽²⁾ - Università di Pavia, Dipartimento di Scienze della Terra e dell'Ambiente, Pavia, Italia ⁽³⁾

Quality assessment of surface and groundwaters in Lombardy, Italy: detection and characterization of ESBLs-producing *Enterobacterales*

¹Piazza Aurora, ¹Aseel AbuAlshaar, ¹Antonietta Grosso, ¹Francesca Piscopiello, ¹Spalla Melissa, ²Michela Sturini, ²Federica Maraschi, ³Pilla Giorgio, ¹Migliavacca Roberta

¹Unit of Microbiology and Clinical Microbiology, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Italy.

²Department of Chemistry, University of Pavia

³Department of Earth and Environment Sciences, University of Pavia, Pavia, Italy.

Introduction: This study aimed to screen the presence of Extended-Spectrum beta-Lactamases (ESBLs) and/or carbapenemases-producing *Enterobacterales* in surface/groundwaters in Lombardy, Italy. **Materials and Methods:** On March 2021, n=31 water samples were collected from n=14 natural and n=9 artificial springs, n=6 wastewater treatment plants (WWTPs), and n=2 sites upstream and downstream the Ticino River, within the Vigevano (PV) and Abbiategrasso (MI) areas. 50ml of water were filtered through 0.45µm pore size membranes. The filters were placed on MacConkey Agar (MCA), and selective MCA (cefotaxime 0.5mg/L-2mg/L; meropenem 0.25mg/L-4mg/L). Species identification and antibiotype were obtained by MicroScan autoSCAN-4 System (EUCAST 2020 breakpoints). BL, *aac(6')-Ib-cr* and *qnrB/S* genes were detected by PCR and sequencing. The concentration in the sampling sites of cephalosporines, fluoroquinolones, sulfonamides, macrolides, and tetracycline were also investigated. **Results:** A total of 264 Gram-negative isolates have been identified. The bacterial genera *Acinetobacter* spp. (n=56), *Pseudomonas* spp. (n=34), *Escherichia* (n=28) and *Aeromonas* spp. (n=24) were mostly found. Non-wild type (NWT) species belonging to *Enterobacterales* were further characterized. The 31.1% (n=9) of the NWT *Escherichia coli* isolates were ESBL-producers (6/9 *bla*CTX-M-15, 2/9 *bla*CTX-M-1, and 1/9 *bla*SHV-type positive). Resistance to trimethoprim-sulfamethoxazole occurred in NWT *E. coli* with the same percentage (31.1%); in 14.3% (n=4) of the strains, fluoroquinolones resistance *qnrS* gene related. An aminoglycoside-resistant isolate showed *aac(6')-Ib-cr* gene positivity. Six *E. coli* (5/6 ESBL and 1/6 non-ESBL-producer) were MDR. Among the 16 NWT *Klebsiella* spp. isolates: n=10 were *K. pneumoniae*; n=5 *K. oxytoca* and n=1 *K. ozaenae*. 4/16 of the above isolates (n=3 *K. pneumoniae* and 1 *K. oxytoca*) resulted MDR. These four strains harbored also the *aac(6')-Ib-cr* gene. A total of n=22 NWT strains of *Citrobacter* spp. were identified: 50% *C. freundii*, 4/22 *C. youngae* and *C. braakii*, and 3/22 *C. farmerii*. 31.8% of *Citrobacter* spp. showed acquired resistance to fluoroquinolones (in *C. freundii aac(6')-Ib-cr* gene mediated). Interestingly, trimethoprim was ubiquitously found, while all the other antibiotics showed a detectable presence in the majority of the sampling sites. A high microbial load was found in particular in those sampling sites close to WWTPs. **Discussion and Conclusions:** A low levels antibiotic contamination observed at most sites, together with the *bla*CTX-M-type, *aac(6')-Ib-cr*, and *qnrS* detection in MDR *Enterobacterales* from water compartment in Lombardy highlights the need of undertaking proper remediation measures, as planned in the CE4WE “Hub Research and innovation” project.

69 - The protein HslJ boosts *Acinetobacter baumannii* survival against oxidative stress

Daniela Scribano ⁽¹⁾ - Meysam Sarshar ⁽²⁾ - Carlo Zagaglia ⁽¹⁾ - Anna Teresa Palamara ⁽³⁾ - Cecilia Ambrosi ⁽⁴⁾

Università Sapienza di Roma, Department of Public Health and Infectious Diseases, Roma, Italia ⁽¹⁾ -
2Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, Roma, Italia ⁽²⁾ - Sapienza
University of Rome, Department of Public Health and Infectious Diseases, Laboratory Affiliated to
Institute Pasteur Italia-Cenci Bolognetti, Roma, Italia ⁽³⁾ - San Raffaele Open University, IRCCS, Rome,
Department of Human Sciences and Promotion of the Quality of Life, Roma, Italia ⁽⁴⁾

The protein HslJ boosts *Acinetobacter baumannii* survival against oxidative stress

Daniela Scribano¹, Meysam Sarshar², Carlo Zagaglia¹, Anna Teresa Palamara^{3,4}, and Cecilia Ambrosi⁵

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy; ²Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; ³Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory Affiliated to Institute Pasteur Italia-Cenci Bolognetti Foundation, Rome, Italy; ⁴Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; ⁵Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Open University, IRCCS, Rome, Italy.

1. Introduction: *Acinetobacter baumannii* is a life-threatening opportunistic pathogen that causes different infections, including ventilator-associated pneumonia. Due to its ability to sense and respond to the environmental stresses, *A. baumannii* can survive in hospital settings and persist during host infections. In a previous study, we identified the periplasmic protein encoded by the ABUW_2868 locus (*hslJ* gene) as being upregulated during imipenem exposure and hypothesized that it participates in the protective response against the oxidative stress. 2. Materials and Methods: A *hslJ* mutant was attained from strain AB5075. Hydrogen peroxide assays and macrophage infections were used to determine the survival rates by colony forming units (CFU/ml) of the *hslJ* mutant in comparison with the wild type AB5075 strain. Surface hydrophobicity, biofilm-forming activity and motility in the *hslJ* mutant were also analyzed. *hslJ* transcriptional regulation is under evaluation using trans-activation experiments and electrophoretic motility shift assays (EMSA). 3. Results: In comparison with the wild type strain, the absence of *hslJ* gene caused a significant drop in cell survival rates of the mutant strain both upon exposure to exogenous H₂O₂ and macrophage infection. Moreover, compared to the wild type strain, the *hslJ* mutant displayed a decrease in biofilm formation and motility abilities although had a higher surface hydrophobicity. Furthermore, preliminary results suggest that expression of *hslJ* is under the control of the master regulator in defense against oxidative stress, OxyR. 4. Discussion and Conclusions: The *hslJ* gene could be part of the regulon of OxyR. Being the HslJ protein located into the periplasm, it represents the first line of defense that confers resistance to oxidative stress that *A. baumannii* faces both in disinfectants used in the hospital environments and innate immune cells during infection of the lungs. These findings provide a basis to develop novel therapeutics against this new target.

72 - Antimicrobial resistance during COVID-19 pandemic: microbial surveillance at "Cristo Re" Hospital during 2020-2021

Camilla Bitossi ⁽¹⁾ - Arcangelo Schiattarella ⁽¹⁾ - Letizia Luconi ⁽¹⁾ - Marco Crobeddu ⁽¹⁾ - Elvira Macale ⁽¹⁾ - Gabriella Nasi ⁽²⁾ - Ornella De Pità ⁽¹⁾

Clinical analysis laboratory, "Cristo Re" Hospital, Roma, Italia ⁽¹⁾ - Clinical Management Staff, "Cristo Re" Hospital, Roma, Italia ⁽²⁾

Antimicrobial resistance during COVID-19 pandemic: microbial surveillance at "Cristo Re" Hospital during 2020-2021

Introduction

With the advent of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, an increase in the incidence of antimicrobial resistance (AMR) related to broad-spectrum antibiotics overuse in patients with coronavirus disease-19 (COVID-19) has been documented. On the other hand, new preventive measures against COVID-19 diffusion could have affected microbial infections in healthcare settings. Our aim was to assess AMR incidence among the patients attending "Cristo Re" Hospital, Rome, for routine visit and prolonged hospitalization from January 2020 to December 2021.

Material and Methods

Biological samples were analyzed for common microorganisms by standard methods and procedures for the traditional microbiological investigation. The microorganisms growing on plates were identified and tested for antimicrobial susceptibility by Vitek2 automated system (Biomérieux, France). AMR detection was eased by the use of chromogenic plates for surveillance rectal and pharyngeal swabs (Biomérieux, France). AMR was always confirmed by disk diffusion method (Kirby-Bauer). Statistical analyses were performed with Statistical Package for Social Science (SPSS) version 25.

Results

We registered a total of 316 pathogenic isolates in 2020 and 366 in 2021. A lower number of multidrug resistant (MDR) isolates was registered during 2021 (n=88, 24.0%) compared to 2020 (n=122, 38.6%) ($p<0.001$). Analyzing bacterial isolates individually, a higher incidence emerged for methicillin resistant *Staphylococcus aureus* (MRSA) in 2020 against 2021 (60.0% vs 20.0%, $p=0.002$), while no significant difference emerged for vancomycin resistant *Enterococcus* (VRE) (18.0% vs 9.3%), extended spectrum beta lactamase *Escherichia coli* and *Klebsiella pneumoniae* (ESBL) (36.1% vs 24.2%; 20.7% vs 13.3%), carbapenem resistant *K.pneumoniae* (36.1% vs 20.4%), MDR *Acinetobacter baumannii* cplx (91.3% vs 90.9%), MDR *Pseudomonas aeruginosa* (41.2 vs 33.3) and SXT resistant *Stenotrophomonas maltophilia* (11.1% vs 16.7%) ($p>0.05$).

Conclusion

The retrospective analysis of the microbiological data collected during the first two years of the pandemic suggests a reduction of AMR isolates comparing 2020 to 2021. The adoption of preventive measures against COVID-19 transmission, as the use of adequate personal protective equipment, increased attention to hand sanitation, frequent change of gloves and gowns, segregation of patients with respiratory symptoms and universal masking policies could have had an impact on AMR incidence. In addition, these preliminary results could be partially explained by the recovery of the control practises against MDR isolates diffusion inside hospital units after the emergency of the first year of COVID-19 pandemic. Further investigations are necessary to confirm this trend in our hospital structure.

74 - Antibacterial and antibiofilm activity in artificial sputum medium of Lactobacilli against *Pseudomonas aeruginosa* strains isolated from CF patients

Giuseppantonio Maisetta ⁽¹⁾ - Elisa Catelli ⁽¹⁾ - Esingül Kaja ⁽¹⁾ - Semih Esin ⁽¹⁾ - Giovanna Batoni ⁽¹⁾

Università di Pisa, Dip. di Ricerca Traslationale e delle nuove Tecnologie in Medicina e Chirurgia,
Pisa, Italia ⁽¹⁾

Antibacterial and antibiofilm activity in artificial sputum medium of Lactobacilli against *Pseudomonas aeruginosa* strains isolated from cystic fibrosis patients

Giuseppantonio Maisetta, Elisa Catelli, Esingül Kaya, Semih Esin, Giovanna Batoni

*Department of Translational Research and New Technologies in Medicine and Surgery,
University of Pisa, Pisa, Italy*

Introduction. The therapy of lung infections sustained by *P. aeruginosa* in cystic fibrosis (CF) patients is still problematic due to the presence of a sticky mucus in airways and to the formation of biofilm, which exhibits increased antibiotic tolerance. The use of probiotics has demonstrated efficacy in treating human intestinal disorders, and it is being proposed in a growing number of other than digestive clinical applications including respiratory tract infections. The presence of lactobacilli in the airways of CF patients has been recently demonstrated. In this study we evaluated the ability of probiotic strains to grow in artificial sputum medium (ASM), mimicking the CF lung conditions, and to affect the planktonic and biofilm growth of *P. aeruginosa* in the same conditions.

Materials and methods. Probiotic strains of *Lactobacillus* genus isolated from commercial products and three *P. aeruginosa* strains (CF1: not mucoid; CF4 and CF11: mucoid) isolated from the sputum of CF patients were used in this study. Ability of *Lactobacillus* probiotic strains to grow in ASM and to affect planktonic growth of CF1 and CF4 strains was evaluated by CFU count after 24h of incubation/co-incubation in such medium. The ability of lactobacilli to aggregate with *P. aeruginosa* was tested incubating equal volumes of lactobacilli and CF1 or CF4 strains. Aliquots of coaggregating mixtures were withdrawn at regular intervals to calculate the aggregation index by spectrophotometric measurements at a wavelength of 600nm. The antibiofilm effect of lactobacilli on CF1, CF4 and CF11 in ASM was evaluated by crystal violet staining or by CFU count.

Results. Among six lactobacilli strains tested, *L. plantarum* (Lp) and *L. rhamnosus* (Microbiosis) (Lr) demonstrated the highest ability to grow in ASM. Lp was also able to partially inhibit the growth of CF1 and CF4 strains in ASM and to form aggregates with both *P. aeruginosa* strains. Both Lp and Lr were able to reduce the biomass of mature biofilms of the two *P. aeruginosa* strains tested, whereas they did not inhibit the formation of biofilms by the same strains. Interestingly, when mature biofilms of CF1 and CF11 strains were sequentially exposed to Lp and tobramycin a significant decrease in the number of CFU was observed compared to the biofilms treated with tobramycin only.

Discussion and Conclusions. The ability of Lp to reduce the viable count of *P. aeruginosa* in ASM, either in planktonic or biofilm form of growth, to strongly aggregate with it, and to synergize with tobramycin suggest such probiotic strain as a promising candidate as adjuvant treatment of pulmonary infections in CF patients. *The study received support from the Italian Cystic fibrosis research foundation, Project FFC#13/2021.*

77 - The One-year Comparative study between molecular and cultural cutaneous swab tests during surveillance program of *Candida auris* in ICUs of San Martino Hospital (July 2021-July 2022)

Giulia Codda⁽¹⁾ - Edward Willison⁽²⁾ - Paola Morici⁽²⁾ - Vincenzo Di Pilato⁽¹⁾ - Anna Marchese⁽¹⁾

Università di Genova, Dipartimento di Scienze Chirurgiche Diagnostiche e Integrate (DISC), Genova, Italia⁽¹⁾ - Policlinico San Martino, U.O. Microbiologia, Genova, Italia⁽²⁾

The One-year Comparative study between molecular and cultural cutaneous swab tests during surveillance program of *Candida auris* in ICUs (Intensive Care Units) of San Martino Hospital (July 2021-July 2022)

GIULIA CODDA^A, EDWARD WILLISON^B, PAOLA MORICI^B, VINCENZO DI PILATO^A, ANNA MARCHESE^{A,B}

^ADepartment of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa,

^BU.O. Microbiology, San Martino-IRCCS Hospital, Genoa, Italy

INTRODUCTION *C. auris* is a multi-drug resistant nosocomial fungus emerged as a 'serious threat' worldwide, associated with nosocomial outbreaks and high rate of mortality in critically patients. Since 2019, the San Martino Hospital (HSM, Genoa, Italy) experienced a large *C. auris* outbreak likely fueled by the COVID-19 pandemic. In this , a rapid laboratory response is required for infection prevention and control strategies. We report the one-year data of a preliminary comparative study between cultural and molecular testing for *C. auris* skin colonization, in the context of a surveillance program adopted by HSM to prevent transmission of *C. auris*.

MATERIALS AND METHODS A total of 1124 paired (cultural and molecular) cutaneous swabs were collected from 619 patients admitted to HSM ICUs during the period July 2021–July 2022. Fungal identification was carried out by MALDI-TOF MS (Vitek MS; bioMérieux, France). For cultural analyses (CS), dry cotton swabs (Cliniswab DS, Aptaca Spa) were streaked onto Chromatic Candida agar plates (Liofilchem, Italy), while wet flocked swabs (eSwab®, Copan s.p.a, Italy) were used for molecular analyses (MS). Total DNA was extracted using the MagCore Plus II automatic extractor (RBC Bioscience Corp., Taiwan), and Real-Time PCR testing was performed using the RealCycler *C. auris* PCR Kit (Progenie Molecular SLU, Spain).

RESULTS Overall, 74/1124 (6.6%) swabs from 70 patients tested positive to both CS and MS (CS+/MS+); similarly, all negative CS swabs were also negative to MS (CS-/MS-). Discordant results were observed in 17 cases, testing CS-/MS+. Among these, a second swab pair was available in 6 cases and tested CS+/MS+ after 7-14 days (mean: 10.5±3.5) from the initial sampling, while positive *C. auris* cultures were observed in specimens of other 6 CS-/MS+ cases. In addition, 40/70 (57.1%) patients testing CS+/MS+ had a positive *C. auris* culture from other specimens within a month (mean: 13±9) from the initial sampling (invasive infections in 13/40 cases). A positive and a negative predicting value (PPV, NPV) of 81.3 and 98.4%, respectively, was calculated for the molecular approach.

DISCUSSION AND CONCLUSIONS Present results proved that molecular testing allows for a marked reduction of the turn-around time, lowered to 6-18h vs. 24-72h required from the conventional cultural approach to detect *C. auris* for surveillance purposes. PPV and NPV values were not entirely superimposable, however, consistent results (CS+/MS+ and CS-/MS-) were observed in most cases (98.5%). Further studies are needed to better evaluate the performances of molecular over cultural approaches. The rapid tracking of *C. auris* is of utmost importance to deliver effective responses aimed at containing its spread within the healthcare system.

78 - Development, characterization and antibacterial activity of polyether-co-amide matrix films incorporating choline-calixarene nanoassembly

Loredana Ferreri ⁽¹⁾ - Grazia M.L. Consoli ⁽¹⁾ - Paola Bernardo ⁽²⁾ - Gabriele Clarizia ⁽²⁾ - Giovanna Ginestra ⁽³⁾ - Maria L. Giuffrida ⁽⁴⁾ - Giuseppe Granata ⁽¹⁾ - Daniela Zampino ⁽⁵⁾ - Stefania Zimbone ⁽⁴⁾ - Antonia Nostro ⁽³⁾

CNR, Institute of Biomolecular Chemistry, Catania, Italia ⁽¹⁾ - CNR, Institute on Membrane Technology, Rende (CS), Italia ⁽²⁾ - University of Messina, Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, Messina, Italia ⁽³⁾ - CNR, Institute of Crystallography, Catania, Italia ⁽⁴⁾ - CNR, Institute of Polymers, Composites and Biomaterials, Catania, Italia ⁽⁵⁾

Development, characterization and antibacterial activity of polyether-co-amide matrix films incorporating choline-calixarene nanoassembly

LOREDANA FERRERI¹, GRAZIA M.L. CONSOLI¹, PAOLA BERNARDO², GABRIELE CLARIZIA², GIOVANNA GINESTRA³, MARIA L. GIUFFRIDA⁴, GIUSEPPE GRANATA¹, DANIELA ZAMPINO⁵, STEFANIA ZIMBONE⁴, ANTONIA NOSTRO³

Institute of Biomolecular Chemistry (ICB-CNR) Catania, Italy¹; Institute on Membrane Technology (ITM-CNR), Rende (CS), Italy²; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Italy³; Institute of Crystallography (IC-CNR) Catania, Italy⁴; Institute of Polymers, Composites and Biomaterials (IPCB-CNR), Catania, Italy⁵

Introduction Calix[n]arenes are a family of phenolic-based macrocycles of great interest for their synthetic versatility and ability to self-assemble in nanostructured systems. In the search for novel antibacterial agents, we previously demonstrated that the micellar calix[4]arene amphiphile (Chol-Calix), bearing hydrophilic choline moieties and long hydrophobic aliphatic chains, is a nanocarrier for antibiotics (ofloxacin, tetracycline and chloramphenicol) and possesses intrinsic antibacterial properties also against antibiotic-resistant bacteria. To extend the research, here we develop a novel material by incorporating the Chol-Calix into a polyether-co-amide matrix (Pebax®2533) and study its physico-chemical and antibacterial properties.

Materials and Methods Flexible films based on Pebax®2533 loaded with Chol-Calix were prepared by solution casting method. The films were characterized for morphology, phase miscibility, thermal stability, gas transport, spectral properties, and Chol-Calix release. The antibacterial activity of the films, neat Pebax® and Pebax® blends loaded with Chol-Calix (0.5, 1, 5 wt%), was evaluated against *Escherichia coli* ATCC 10536 and *Staphylococcus aureus* ATCC 6538 at different time intervals (2, 4, 6, 8, 10, 24 h) by cell number evaluation and time kill plots construction. The effect on biofilm formation was estimated by biomass measurements. MTT assay was employed to investigate the interference on vitality of mouse embryonic fibroblast cells (NIH-3T3).

Results The thermal stability of the copolymer was not affected by the Chol-Calix incorporation, nevertheless it was detected an increase of crystallinity, gas permeability and wettability of the blend films according to the additive concentration. Leaching of Chol-Calix was tracked by release tests. Neat Pebax® and Pebax®-0.5 wt% Chol-Calix showed no significant antibacterial activity against both *E. coli* and *S. aureus*. Pebax®-1 wt% Chol-Calix displayed good antibacterial activity against *S. aureus*, with a reduction of 1.8 and 2.1 log CFU/mL observed at 10 and 24 h, respectively. A clear effect was observed with Pebax®-5 wt % Chol-Calix that reduced the number of viable *E. coli* cells of 2.57 and 2.66 log CFU/mL at 10 and 24 h, respectively. A similar trend was observed for *S. aureus* with a reduction of 2 log CFU/mL at 10 h that increased to 2.49 log CFU/mL at 24 h. Pebax®-5 wt % Chol-Calix showed biofilm biomass reduced (~30%) as compared to the neat polymer. The films were non-cytotoxic as revealed by MTT assay.

Discussion and Conclusions The results indicate the Pebax®/Chol-Calix combination as a promising approach for the development of novel biocompatible flexible antibacterial thin-films upgradable by loading antibacterial drugs in the Chol-Calix nanocarrier.

79 - Antimicrobial effectiveness of ozonated olive and sunflower seeds oils

Silvia Puxeddu ⁽¹⁾ - Sarah Vascellari ⁽¹⁾ - Ilenia Delogu ⁽¹⁾ - Giuseppe Pala ⁽²⁾ - Alessandra Scanu ⁽³⁾ - Guido Ennas ⁽³⁾ - Aldo Manzin ⁽¹⁾ - Fabrizio Angius ⁽¹⁾

Università degli studi di Cagliari, Dipartimento di Scienze Biomediche, Cagliari, Italia ⁽¹⁾ - AOU Policlinico "D. Casula", Applied Microbiology Lab, Monserrato, Italia ⁽²⁾ - Università degli studi di Cagliari, Dipartimento di scienze chimiche e geologiche, Cagliari, Italia ⁽³⁾

Antimicrobial effectiveness of ozonated olive and sunflower seeds oils

SILVIA PUXEDDU ¹, SARAH VASCELLARI ¹, ILENIA DELOGU ¹, GIUSEPPE PALA ^{1,2}, ALESSANDRA SCANO ^{3,4}, GUIDO ENNAS ^{3,4}, ALDO MANZIN ^{1,2}, FABRIZIO ANGIUS ¹

¹ Department of Biomedical Sciences, Unit of Microbiology and Virology, University of Cagliari, Cagliari, Italy;

² AOU Policlinico "D. Casula", Applied Microbiology Lab, Monserrato (CA), Italy;

³ Department of Chemical and Geological Sciences, University of Cagliari, Cagliari, Italy;

⁴ Cagliari Research Unit of the National Consortium of Materials Science and Technology (INSTM), Cagliari, Italy;

Introduction

Drug-resistance represents one of the great plagues of our time, largely limiting the treatment of common infections and accounting for the urge in the development of new antibiotics or other alternatives. Noteworthy, the indiscriminate use of antibiotics is mostly responsible for the emergence of mutations that confer drug-resistance to microbes. Recently, beyond synthetic and green molecules studied to tackle microbial infections, ozone is raising interest for its unique biological properties in particular when dissolved in natural oils, which stabilize it. In fact, ozonated oils have been reported to act in a non-specific way on microorganisms hindering the acquisition of advantageous mutations resulting in resistance. Here, we focused on comparing the antimicrobial effect of two different types of ozonated oils over a panel of opportunistic and pathogenic microbes.

Materials and methods

Ozonated olive (OOO) and sunflower seeds (OSO) oils were preliminarily characterized by chemico-physical investigation and used in *in vitro* experiments. A panel of microorganism that usually cause common infections (i.e., *Candida albicans*, *Enterococcus faecalis*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Escherichia coli*) have been challenged with different ozonated oils concentrations to evaluate the antimicrobial resistance/susceptibility by agar diffusion and broth dilution tests. Cytotoxicity was also evaluated in keratinocytes and endothelial cells.

Results

In our experimental conditions, OOO and OSO showed a potent microbicidal effect especially against *C. albicans* and *E. faecalis*, with the intermediate concentrations showing the highest efficacy unexpectedly. However, further investigations are required to clarify the effect on the other microbes. Both OOO and OSO do not exert any cytotoxic effect at the active concentrations in both cell lines.

Discussion and conclusion

Our results indicate that these ozonated oils are not toxic for mammalian cells and exert potent antimicrobial effects on specific microorganisms. Therefore, they may be considered to integrate standard therapies in the treatment of common infections, likely overcoming drug resistance issues.

82 - Epidemiology of bloodstream infections and mortality rates in patients admitted to the Intensive Care Unit in the pandemic era

Nadia Marascio ⁽¹⁾ - Angela Quirino ⁽¹⁾ - Luigia Gallo ⁽¹⁾ - Giuseppe Guido Maria Scarlata ⁽¹⁾ - Claudia Cicino ⁽¹⁾ - Giorgio Settimo Barreca ⁽¹⁾ - Aida Gancotti ⁽¹⁾ - Giovanni Matera ⁽¹⁾

Università degli Studi Magna Graecia di Catanzaro, Dipartimento di Scienze della Salute, Catanzaro, Italia ⁽¹⁾

Epidemiology of bloodstream infections and mortality rates in patients admitted to the Intensive Care Unit in the pandemic era

Authors: *NADIA MARASCIO¹, ANGELA QUIRINO¹, LUIGIA GALLO¹, GIUSEPPE G.M. SCARLATA¹, CLAUDIA CICINO¹, GIORGIO S. BARRECA¹, AIDA GIANCOTTI¹, GIOVANNI MATERA¹*

Affiliations:

¹Department of Health Sciences, Institute of Clinical Microbiology, "Magna Graecia" University of Catanzaro, Italy.

Introduction: Bloodstream infections (BSIs) are defined by the presence of bacterial or fungal microorganisms in the bloodstream, which is demonstrated by positive blood cultures. Recent studies show that 20% of BSIs occur in the Intensive Care Unit (ICU) where SARS-CoV-2 infection has exacerbated this problem, regarding prognosis and mortality. The aim of this study was to assess the burden of BSI in ICU patients in terms of prevalence and mortality rates in our Teaching Hospital during the pandemic era.

Materials and Methods: A total of 82 SARS-CoV-2 positive and 229 SARS-CoV-2 negative patients with at least one positive blood culture, admitted to the ICU, were enrolled, in a period between 1st January 2020 and 31st December 2021. The diagnosis of COVID-19 was confirmed by rRT-PCR. Blood culturing was performed for 7 days using the BacT/ALERT VIRTUO system (bioMérieux) according to routine laboratory practice. Identification was carried out using MALDI-TOF (bioMérieux) and Vitek®2 System (bioMérieux). Antibiotic susceptibility testing was performed by conventional methods. Statistical analysis was conducted using the chi-square test ($p\text{-value} \leq 0.05$).

Results: Out of 311 patients enrolled, 75% (235/311) were male, while 25% (76/311) were female, with a median age of 69 years (age range 16-93). SARS-CoV-2 positive patients showed a higher prevalence of BSIs with *A. baumannii cplx* (16% vs. 8%; $p = 0.03$), *Enterococcus spp.* (12% vs. 7%), *K. pneumoniae* (8% vs. 6%), *E. coli* (2% vs. 1%) and *Streptococcus spp* (2% vs. 1%). SARS-CoV-2 negative patients showed a higher prevalence of BSIs with coagulase-negative staphylococci (CoNS) (52%) versus 44% among SARS-CoV-2 positive patients, *S. aureus* (4% vs. 0%, $p = 0.01$) and *Pseudomonas spp.* (3% vs. 2%). In SARS-CoV-2 positive and negative patients *Candida spp.* isolated strains were similar. We estimated the mortality rate in ICUs for patients with BSIs to be 38%. Regarding the causes of death, pulmonary complications were associated with SARS-CoV-2 positive patients (98% vs. 52%; $p = 0.04$), while cardiac and other complications were associated with SARS-CoV-2 negative patients (28% vs. 2%; $p = 0.0006$ and 20% vs. 0%; $p = 0.002$, respectively). 18 patients with BSIs were subjected to Extracorporeal Membrane Oxygenation (ECMO).

Discussion and Conclusions: Our study shows a mortality rate in accordance with the data in the literature (between 20% and 40%). Furthermore, the most frequently isolated microorganisms were CoNS, associated with SARS-CoV-2 negative patients. However, the burden of deaths from pulmonary complications is associated with SARS-CoV-2 positive patients.

83 - Humoral Response to Microbial Biomarkers in Parkinson's disease Patients

Seyedesomaye Jasemi (1) - Kai Paulus (2) - Davide Cossu (1) - Elena Rita Simula (1) - Marta Noli (1) - Stefano Ruberto (1)

Dipartimento di Scienze Biomediche, Università di Sassari, Università di Sassari, Sassari, Italia (1) - ATS Sardegna, Departement, Sassari, Italia (2)

Title: Humoral Response to Microbial Biomarkers in Parkinson's disease Patients

Seyedesomaye Jasemi¹, Kai Paulus², Davide Cossu¹, Elena Rita Simula¹, Marta Noli¹, Stefano Ruberto¹ and Leonardo A. Sechi¹

¹Dipartimento di Scienze Biomediche, Università di Sassari

²ATS Sardegna

Introduction:

Parkinson's disease (PD) is a neurodegenerative disorder with the accumulation of alpha-synuclein (α -syn)/Lewy bodies in the brain and enteric nervous system. The etiology of the disease is not well understood but bacterial and viral infections may contribute to the etiopathogenesis of PD. It has been suggested that Gastrointestinal (GI) complications observed in PD patients may rise from bacterial dysbiosis and curly/ α -syn deposits in the enteric nervous system. Enteric bacteria such as *E. coli*, and *Salmonella* secrete curli, a functional amyloid peptide that is involved in adhesion to surfaces, cell invasion, and biofilm formation. However, these bacterial amyloids can initiate additional α -syn deposits through a different mechanism. In this study, we investigated the humoral response against α -syn, curli peptides, and various bacterial and viral immunogen peptides in PD patients and compared them with healthy controls (HCs) sera.

Materials and Methods: Polyclonal IgG antibodies (Abs) specific were detected against peptides derived from alpha-synuclein (α -syn₁₀₀₋₁₁₄), curli (csgA₁₃₃₋₁₄₁), *Porphyromonas gingivalis*; Pg (RgpA₈₀₀₋₈₁₂, Kpg₃₂₈₋₃₃₉), *Aggregatibacter actinomycetemcomitans* (LtxA1₄₂₉₋₄₄₅, LtxA2₆₄₋₈₀), *Mycobacterium avium* subsp. *paratuberculosis* (MAP 3865c₁₂₅₋₁₃₃, MAP 1,4-a-gbp₁₅₇₋₁₇₃ and MAP_4027₁₈₋₃₂), Epstein-Barr virus (EBNA1₄₀₀₋₄₁₃, BOLF₁₃₀₅₋₃₂₀), and Herpes Simplex virus 1 (UI42₂₂₋₃₆) investigated by indirect ELISA in 51 serum samples from PD and 58 sex and age-matched HCs.

Results: Significant differences in antibody titers and positivity were observed for Kpg (82.3% vs. 10.3%) followed by RgpA (60.7% vs. 24.1%), CsgA (51% vs. 22.4%) and UI42 (43.1% vs. 25.8%) in PD compared HCs sera ($p < 0.001$). No significant difference was found in the antibody's titers to other tested peptides in patients with PD compared to HCs. A significant positive correlation between OD values obtained by ELISA was observed for UI42 and CsgA ($r = 0.811$, $p < 0.0001$), Kpg and RgpA ($r = 0.659$, $p < 0.0001$) followed by LtxA1 and LtxA2 ($r = 0.653$, $p < 0.0001$). The correlation analysis between the HY scale (Hoehn and Yahr Scale) and LtxA1 ($r = 0.306$, $p < 0.028$) and HY and Kpg ($r = 0.290$, $p < 0.038$) was significantly positive.

Discussion and Conclusion: This study reports a significantly increased humoral response against Curli, Pg, and HSV1 in PD patients implying that they could be an important factor in the pathogenesis of the disease. In addition, a high positive correlation between UI42 and CsgA may suggest the hypothesis of the involvement of HSV1 in GI dysbiosis and biofilm formation. Therefore, the role of each individual pathogen and curli in PD needs to be further investigated.

Keywords: Parkinson's disease; humoral response; Curli; *P. gingivalis*; *A. actinomycetemcomitans*; Epstein-Barr virus; *M. avium* subspecies *paratuberculosis*; *Herpes simplex virus*.

84 - Active surveillance for MDR bacteria and correlation with HCAI in patients attending to a University Hospital: a 5-year retrospective study

Angela Quirino⁽¹⁾ - Nadia Marascio⁽¹⁾ - Luigia Gallo⁽¹⁾ - Claudia Cicino⁽¹⁾ - Giuseppe Guido Maria Scarlata⁽¹⁾ - Maria Giuseppina Stillitano⁽¹⁾ - Elettra Mancuso⁽¹⁾ - Neill James Adams⁽¹⁾ - Giovanni Matera⁽¹⁾

Università degli Studi Magna Graecia, Dipartimento di Scienze della Salute, Catanzaro, Italia⁽¹⁾

Active surveillance for MDR bacteria and correlation with HCAI in patients attending to a University Hospital: a 5-year retrospective study

Authors: *ANGELA QUIRINO*¹, *NADIA MARASCIO*¹, *LUIGIA GALLO*¹, *CLAUDIA CICINO*¹, *GIUSEPPE G.M. SCARLATA*¹, *MARIA G. STILLITANO*¹, *ELETTRA MANCUSO*¹, *NEILL J. ADAMS*¹, *GIOVANNI MATERA*¹

Affiliations:

¹Department of Health Sciences, Institute of Clinical Microbiology, "Magna Graecia" University of Catanzaro, Italy.

Introduction: Healthcare associated infections (HCAI) are infections occurring in a patient undergoing medical treatment in a hospital or other healthcare facility which were absent at the time of admission. They are a serious burden on public health in terms of costs and patient management. MDR bacteria are main causes of HCAI and are associated with high mortality in critical wards. We aim to assess the prevalence of MDR bacteria isolated from nasal, pharyngeal and rectal surveillance swabs and their correlation with HCAI in the University Hospital, Catanzaro, Southern Italy.

Materials and Methods: In this retrospective study, from 1st January 2017 to 31st December 2021, a total of 2621 patients attending our Teaching Hospital were enrolled. MDR bacteria were isolated by conventional culture media from rectal and pharyngeal swabs, while MRSA was isolated from nasal swabs. Identification and antibiotic resistance testing were performed by Vitek®2 and Sensititre systems. Positive patients were stratified into two different groups: positive patients on hospital admission (group 1) and positive patients after 48 hours of hospitalisation (group 2). Statistical analysis was conducted using chi-square test (p-value ≤ 0.05).

Results: Over the course of five years, a total of 15.122 screening swabs were performed, with an increasing trend over the years (from 2648 in 2017 to 4630 in 2021). Among 2621 patients, 83% (2177/2621) were negative to MDR bacteria, 12% (240/2621) belonged to group 1, while 8% (204/2621) belonged to group 2. In the first three years, we observed a linear increase of patients who were positive both on admission to our hospital and with HCAI (from 7% and 5% in 2017 to 13% and 9% in 2019, respectively). In the last two years the trend is strongly decreasing: 11% and 10% in 2020, 7.2% and 6.5% in 2021, respectively. MDR strains isolated from rectal (7.7%) and pharyngeal (3.8%) swabs were *K. pneumoniae*, *A. baumannii* (1.5% and 3.7%), *Enterobacter spp.* (0.5% and 0.4%) and *E. coli* (0.2% and 0.4%); while from nasal swabs 2% were MRSA. Finally, differences between group 1 and group 2 were assessed by isolated microorganisms, showing statistically significant differences for *Enterobacter spp.* (6% group 1 vs. 3% group 2; p = 0.03) and MRSA (13% group 1 vs. 5% group 2; p = 0.0001).

Discussion and Conclusions: Our data show an increase in screening swabs over the years. The trend, limited to the period of the pandemic, is different: there is an increase in MDR pathogens in COVID-19 patients assessed on all biological samples, with *A. baumannii* responsible for 68.7% of deaths from bloodstream infections. We demonstrated the importance of these swabs in the active surveillance of MDR bacteria and in improving infection control in hospital wards.

85 - Class-IIc bacteriocins produced by *S. salivarius* 24SMBc involved in antibacterial activity

Gaia Vertillo Aluisio ⁽¹⁾ - Ambra Spitale ⁽¹⁾ - Luca Bonifacio ⁽¹⁾ - Aldo Stivala ⁽¹⁾ - Giuseppe Baglieri ⁽¹⁾ - Renata Scuderi ⁽¹⁾ - Stefania Stefani ⁽¹⁾ - Maria Santagati ⁽¹⁾

Università di Catania, Dipartimento di Scienze Biomediche e Biotecnologiche, Catania, Italia ⁽¹⁾

Categoria: Batteriologia, micologia e parassitologia

Titolo:

Class-IIc bacteriocins produced by *S. salivarius* 24SMBc involved in antibacterial activity

GAIA VERTILLO ALUISIO¹, AMBRA SPITALE¹, LUCA BONIFACIO¹, ALDO STIVALA¹, GIUSEPPE BAGLIERI¹, RENATA SCUDERI¹, STEFANIA STEFANI¹, MARIA SANTAGATI¹

¹ Department of Biomedical and Biotechnological Sciences (BIOMETEC), Section of Microbiology, University of Catania, Catania, Italy

Introduction: *Streptococcus salivarius* 24SMBc is an oral probiotic strain characterized by strong antimicrobial activity against potential pathogens that colonize the upper respiratory tract, like *Streptococcus pyogenes* and *Streptococcus pneumoniae*, and for this 24SMBc can be used in local bacteriotherapy to prevent *upper respiratory tract infections* (URTIs). Several clinical studies have reinforced the role of 24SMBc in reducing the recurrence of infection and rebalancing the nasal microbiota to a healthy status after antibiotic treatment. The aim of this work was to determine the presence of potential bacteriocins that could be responsible for the antimicrobial effect of this strain.

Materials and Methods: The genome of *S. salivarius* 24SMBc was sequenced with Illumina Miseq and de-novo assembled by SPAdes v3.14.0. Bioinformatic analysis with BAGEL4 and antiSMASH v 6.1.1. was performed to find bacteriocin genes carried by the 24SMBc genome.

Results: Genomic analysis of *S. salivarius* 24SMBc identified multiple genes involved in bacteriocin production and transport. BAGEL analysis found two genes encoding *Blp*-like class-IIc bacteriocins, *blpU* and *blpK*, in a cluster on contig 24. Moreover, antiSMASH confirmed the two bacteriocins genes in the same position and identified a peptidase_C39 encoding a putative ABC-type bacteriocin transport.

Discussion and Conclusions: These findings validate the presence of genes encoding for two different bacteriocins in 24SMBc genome, which could contribute to the antimicrobial activity exerted by this oral probiotic against other pathogenic streptococci, namely *S. pyogenes* and *S. pneumoniae*. Bacteriocin production is also important for the intra- and inter-species balance within microbial communities, and these results could further corroborate the efficacy of *S. salivarius* 24SMBc in rebalancing a healthy microbiota after local bacteriotherapy. In conclusion, the genome analysis confirmed the potential of this strain for its probiotic usage in clinical settings.

89 - Four-Year Environmental Surveillance Program of *Legionella* spp. in One of Palermo's Largest Hospitals

IGNAZIO ARRIGO⁽¹⁾ - ELENA GALIA⁽¹⁾ - TERESA FASCIANA⁽²⁾ - MARIA RITA TRICOLI⁽²⁾ - MARIO PALERMO⁽³⁾ - ANNA GIAMMANCO⁽²⁾

LABORATORIO DI RIFERIMENTO REGIONALE PER LA LEGIONELLOSI DI PALERMO, A.O.U.P.
P.GIACCONE, PALERMO, Italia⁽¹⁾ - DIPARTIMENTO PROMISE, A.O.U.P PAOLO GIACCONE, PALERMO,
Italia⁽²⁾ - ASSESSORATO DELLA SALUTE, UNIVERSITA DEGLI STUDI DI PALERMO, PALERMO, Italia⁽³⁾

Four-Year Environmental Surveillance Program of *Legionella* spp. in One of Palermo's Largest Hospitals

IGNAZIO ARRIGO¹, ELENA GALIA¹, TERESA FASCIANA², MARIA RITA TRICOLI², MARIO PALERMO³, ANNA GIAMMANCO²

¹ Regional Reference Laboratory for Clinical Environmental Surveillance and Control of Legionellosis, Palermo, Italy;

² Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy;

³ Sicilian Health Department, Public Health and Environmental Risks Service, University of Palermo, Italy.

Introduction: *Legionella* is a ubiquitous bacterium that lives in freshwater environments and colonizes human-made water systems. *Legionella pneumophila* is the most virulent species that may cause an atypical pneumonia after an incubation period of 2-10 days. Risk factors for disease include increasing age, smoking, chronic diseases and immunodeficiency. Because of this consideration, it is very important to monitor hospital water systems to prevent disease. Our laboratory, recognized as Regional Reference Center for Legionellosis in Western Sicily, according to ministerial guidelines, carries out surveillance in hospital buildings. We report the data achieved from the analysis of a four-year surveillance in a hospital of Palermo.

Materials and Methods: According to the standards of the Italian ministerial guidelines, we used the culture method, which is considered the gold standard for *Legionella* detection. The principal sites of sampling were, storage tanks, boilers (hot water), sinks and showers. Briefly, the samples were collected in sterile 1-liter containers, after filtration through a 0.2 µm cellulose membrane, 100 µL of the heat-treated sample and untreated sample was inoculated on two BCYE plate and incubated for 10 days at 37 °C in a incubator with 5% CO₂. The suspected colonies were confirmed using a latex agglutination test. The other species were identified by MALDI-TOF.

Results: Five areas were monitored over four years of time - Underground facility, Medicine, Surgery, Oncohematology, Others. A total of 251 samples were collected, 49% of which were *Legionella* spp. positive and 51% were negative. The percentages of positive samples for *Legionella* spp. collected during the period of study were very similar in all areas, with the exception of the Underground area. Positive samples with *L. pneumophila* sgr 2-15 were most frequent in the Medicine area. In addition, we identified 6/123 samples positive for *Legionella anisa*. Our data also shows how different strains coexist in the same sample.

Discussion and Conclusions: Legionnaires' disease could be a health risk for hospitalized patients, especially in immunocompromised patients. During these years of surveillance, it has been possible to detect a high bacterial load in the various areas that tends to be rather constant over time. Our data, based on the annual trend, show that the *L. pneumophila* sgr 2-15 strains are particularly resistant to water disinfection processes. The complete eradication of the germ is complicated for its ability to resist disinfection treatments, especially where it forms biofilms. In addition, the emergence of *L. anisa* increases the possibility of infection in hospitalized patients. Thus it is important to continue monitoring the water system to prevent legionellosis in patients.

94 - Occurrence of a KPC-3-producing *Klebsiella michiganensis* strain in clams

SERENA SIMONI⁽¹⁾ - FRANCESCA LEONI⁽²⁾ - LAURA VESCHETTI⁽³⁾ - MARIA CARELLI⁽⁴⁾ - GIOVANNI MALERBA⁽³⁾ - MARIA DEL MAR FERNANDEZ LLEO⁽⁵⁾ - ANDREA BRENCIANI⁽⁶⁾ - GIANLUCA MORRONI⁽⁶⁾ - ELEONORA GIOVANETTI⁽⁶⁾ - CARLA VIGNAROLI⁽¹⁾

UNIVERSITA POLITECNICA DELLE MARCHE, Department of Life and Environmental Sciences, ANCONA, Italia⁽¹⁾ - Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, Laboratorio Nazionale di Riferimento (LNR) per il Controllo delle Contaminazioni Batteriche dei Molluschi Bivalvi Vivi, ANCONA, Italia⁽²⁾ - UNIVERSITA DI VERONA, Department of Neurosciences, Biomedicine and Movement Sciences, VERONA, Italia⁽³⁾ - UNIVERSITA DI VERONA, Department of Diagnostics and Public Health, VERONA, Italia⁽⁴⁾ - UNIVERSITA DI VERONA, Department of Diagnostics and Public Health, VERONA, Italia⁽⁵⁾ - UNIVERSITA POLITECNICA DELLE MARCHE, Department of Biomedical Sciences and Public Health, ANCONA, Italia⁽⁶⁾

Occurrence of a KPC-3-producing *Klebsiella michiganensis* strain in clams

SERENA SIMONI¹, FRANCESCA LEONI², LAURA VESCHETTI³, MARIA CARELLI⁴, GIOVANNI MALERBA³, MARIA DEL MAR FERNANDEZ LLEO⁴, ANDREA BRENCIANI⁵, GIANLUCA MORRONI⁵, ELEONORA GIOVANETTI¹, CARLA VIGNAROLI¹

*1*Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy; *2*Istituto Zooprofilattico Sperimentale dell'Umbria e delle Marche, Sezione di Ancona, Laboratorio Nazionale di Riferimento (LNR) per il Controllo delle Contaminazioni Batteriche dei Molluschi Bivalvi Vivi, Ancona, Italy; *3* Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; *4* Department of Diagnostics and Public Health, University of Verona, Verona, Italy; *5* Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy

Introduction. Nosocomial infections caused by carbapenem resistant *Klebsiella michiganensis* have frequently been reported. Recently, *K. michiganensis* has also been isolated from wastewaters suggesting that faecal polluted coastal area may represent a potential source of human infections. This study describes the first recovery of a multidrug resistant (MDR) and KPC-3-producing *K. michiganensis* from Venus clams collected along the Adriatic Sea coast.

Materials and Methods. The *K. michiganensis* 23999A2 was selected from a clam sample plated on MacConkey agar supplemented with ertapenem. Carbapenem resistance was confirmed by the modified Hodge test, multiplex PCR for *bla_{KPC}*, *bla_{VIM}*, *bla_{NDM}*, *bla_{OXA-48}* and MIC determination. Plasmid profile and typing was determined by S1-nuclease pulsed field gel electrophoresis and PBRT 2.0 kit, respectively. The transferability of carbapenem resistance was investigated by conjugation experiments. Whole genome sequencing and a comparison with NCBI complete genomes was carried out. *K. michiganensis* pan-genome was also investigated.

Results. *K. michiganensis* 23999A2 was ertapenem resistant (MIC 256 µg/ml) and positive to the modified Hodge test. Carbapenem resistance was confirmed by the presence of KPC-3 encoding gene. The strain belonged to the new ST382 and carried seven plasmid replicon sequences including four IncF type plasmids (FII, FIIV, FIIV, FIB), one IncHI1 and two Col plasmids. FIB and FIIV replicons were found on plasmid contigs of ~49 kb and ~140 kb. The strain was positive for: *bla_{OXA-9}*, *bla_{TEM-1A}*, *bla_{KPC-3}* and *bla_{SHV-12}*, all plasmid-associated. The *bla_{OXA-9}* and *bla_{TEM-1A}* were carried by the FIB contig whereas *bla_{KPC-3}*, inserted in a Tn4401a, was carried by the FIIV contig. The *bla_{SHV-12}* was found on the FIIV plasmid. Conjugal transfer of both *bla_{TEM-1A}* and *bla_{KPC-3}* occurred at a frequency of 5×10^{-7} . The closest genome sequences to *K. michiganensis* 23999A2 were an environmental isolate collected from soil in South Korea and a clinical isolate sampled from human sputum in Japan. Of interest, *K. michiganensis* 23999A2 did not carry any *bla_{OXY}* gene. Pan-genome analysis revealed the presence of a large accessory genome.

Discussion and Conclusions. The report of an MDR KPC-producing *K. michiganensis* from Venus clam samples, and more globally from seafood product, pose a direct threat to public health. Filter-feeding molluscs can accumulate pathogenic bacteria and have a role in their transmission back to humans through the food chain and in the spread of antibiotic resistance in the environment. The great genomic plasticity of this strain highlights the capability of *K. michiganensis* species to adapt to new environments and underlines the risk of multidrug-resistant or hypervirulent clones emergence.

96 - In silico identification of novel inhibitors targeting the superoxide dismutase from the dental pathogen *Streptococcus mutans* and counteracting the biofilm formation.

Chiara Varriale⁽¹⁾ - Umberto Galdiero⁽¹⁾ - Emanuela Roscetto⁽¹⁾ - Camilla Esposito⁽¹⁾ - Maria Rosaria Catania⁽¹⁾ - Carmen Cerchia⁽²⁾ - Rosarita Nasso⁽³⁾ - Rosario Rullo⁽¹⁾ - Antonio Lavecchia⁽²⁾

Università Federico II di Napoli, Dip. di Medicina Molecolare e Biotecnologie Mediche, Napoli, Italia
(¹) - Università Federico II di Napoli, Dip di Farmacia, Napoli, Italia (²) - Università Parthenope di Napoli, Dip. di Scienze Motorie e del Benessere, napoli, Italia (³)

In silico identification of novel inhibitors targeting the superoxide dismutase from the dental pathogen *Streptococcus mutans* and counteracting the biofilm formation.

EMANUELA ROSCETTO¹, CARMEN CERCHIA², ROSARITA NASSO³, CHIARA VARRIALE¹, UMBERTO GALDIERO¹, CAMILLA ESPOSITO¹, ANTONIO LAVECCHIA², ROSARIO RULLO^{1,4}, MARIA R. CATANIA¹.

¹ Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.

² "Drug Discovery" Laboratory, Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy.

³ Department of Human Movement Sciences and Wellness, University of Naples "Parthenope", 80133 Naples, Italy.

⁴ Institute for the Animal Production Systems in the Mediterranean Environment, 80147 Naples, Italy.

INTRODUCTION - The microaerophile *Streptococcus mutans*, the main responsible for the development of dental plaque, has a single cambialistic superoxide dismutase (*SmSOD*) for its protection against reactive oxygen species. In order to discover novel inhibitors of *SmSOD*, possibly interfering with the biofilm formation by this pathogen, a virtual screening study was realised using the available 3D-structure of *SmSOD*.

MATERIALS AND METHODS - Measurements of residual activity of *SmSOD* in the presence of the putative novel inhibitors were performed through an indirect assay method. The oligomerization status of *SmSOD* was analyzed by gel-filtration.

The possible toxic effect of selected molecules was investigated using the human fibroblast cell line BJ-5ta; total protein extracts obtained from BJ5-ta cells were used for Western blotting analysis.

The antibacterial activity of selected compounds against *S. mutans* was assayed by a standard broth micro-dilution method and the crystal violet staining method was used to measure biofilm biomass formed in the presence of the compounds.

RESULTS - Among the 36 molecules, compound ALS-31 was capable of inhibiting *SmSOD* with an IC₅₀ value of 159 μ M. Its inhibition power was affected by the Fe/Mn ratio in the active site of *SmSOD*. Furthermore, ALS-31 also inhibited the activity of other SODs. Gel-filtration of *SmSOD* in the presence of ALS-31 showed that the compound provoked the dissociation of the *SmSOD* homodimer in two monomers, thus compromising the catalytic activity of the enzyme. Cell viability of the cell line BJ5-ta was not affected up to 100 μ M ALS-31. A preliminary lead optimization program allowed the identification of one derivative, ALS-31-9, endowed with an improved inhibition power. Interestingly, below toxic threshold, planktonic growth and biofilm formation of *S. mutans* were inhibited by ALS-31, and even more by its derivative ALS-31-9.

DISCUSSION AND CONCLUSIONS - A deeper examination of the 3D-structure of *SmSOD* highlighted the possibility of targeting the dimer interface and disrupting the quaternary structure of this enzyme. Our results open the perspective of future drug design studies to fight dental caries, based on the identification of molecules acting on a crucial antioxidant enzyme target of *S. mutans*. Concerning the possible application of the identified novel molecules for treatment of dental caries, we can envisage their usage as a local topical medication, as the compounds have a direct antibiofilm activity on dental plaque formation by *S. mutans*.

98 - HPLC-MS-MS quantification of short-chain fatty acids secreted by probiotic strains

Marco Calvigioni ⁽¹⁾ - Andrea Bertolini ⁽²⁾ - Simone Codini ⁽²⁾ - Diletta Mazzantini ⁽¹⁾ - Francesco Celandroni ⁽¹⁾ - Adelaide Panattoni ⁽¹⁾ - Alessandro Saba ⁽²⁾ - Emilia Ghelardi ⁽¹⁾

Università di Pisa, Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Pisa, Italia ⁽¹⁾ - Università di Pisa, Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Pisa, Italia ⁽²⁾

HPLC-MS-MS quantification of short-chain fatty acids secreted by probiotic strains

MARCO CALVIGIONI¹, ANDREA BERTOLINI², SIMONE CODINI², DILETTA MAZZANTINI¹, FRANCESCO CELANDRONI¹, ADELAIDE PANATTONI¹, ALESSANDRO SABA², EMILIA GHELARDI^{1,3}

¹ Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy;

² Department of Surgical, Medical, and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy;

³ Research Center Nutraceuticals and Food for Health – Nutrafood, University of Pisa, Pisa, Italy.

Introduction. Short-chain fatty acids (SCFAs) are the main by-products of microbial fermentations occurring in the human intestine and are directly involved in the host's physiological balance. As impaired gut concentrations of acetic, propionic, and butyric acids are often associated with systemic disorders in humans, the administration of SCFAs-producing microorganisms has been suggested as attractive approach to solve symptoms related to SCFAs deficiencies.

Materials and Methods. In this research, nine probiotic strains (*Bacillus clausii* NR, OC, SIN, and T, *Bacillus coagulans* ATCC 7050, *Bifidobacterium breve* DSM 16604, *Limosilactobacillus reuteri* DSM 17938, *Lactiseibacillus rhamnosus* ATCC 53103, and *Saccharomyces boulardii* CNCM I-745) commonly included in commercial formulations were tested for their ability to secrete SCFAs by using an improved and sensitive protocol in high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS-MS).

Results. All tested microorganisms were shown to secrete acetic acid, with only *B. clausii* and *S. boulardii* additionally able to produce propionate and butyrate. Quantitative differences in the secretion of SCFAs were evidenced, thus demonstrating some strains being able to produce more acetic, propionic, and butyric acids than others.

Discussion and Conclusions. The application of a novel HPLC-MS-MS protocol for the detection and quantification of SCFAs allowed us to highlight species- and strain-specific behaviors for the *in vitro* synthesis and active secretion of SCFAs by probiotics. These data represent an innovation in the microbial characterization of strains commercialized in probiotic formulations, remarking the ability of only a few probiotic microorganisms present on the market to directly produce SCFAs. The direct production of SCFAs should be taken into consideration as a key beneficial feature when probiotic strains are evaluated for their clinical effectiveness, thus contributing to the spread of more targeted and personalized strategies to promote human health and manage diseases.

99 - IQOS vapours decrease *Klebsiella pneumoniae* growth without compromising lung cells compared to cigarette smoke

Virginia Fuochi ⁽¹⁾ - Rosalia Emma ⁽¹⁾ - Massimo Caruso ⁽¹⁾ - Pio Maria Furneri ⁽¹⁾

Università degli Studi di Catania, BIOMETEC, Catania, Italia ⁽¹⁾

IQOS vapours decrease *Klebsiella pneumoniae* growth without compromising lung cells compared to cigarette smoke

VIRGINIA FUOCHI¹, ROSALIA EMMA¹, MASSIMO CARUSO¹ AND PIO MARIA FURNERI^{1,2}

¹Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Catania, Italy; ²Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University of Catania, Catania, Italy

Introduction: The use of Reduced-Risk Products (RRPs) is expanding rapidly around the world so an assessment of the biological activities of the vapors produced by RRP is needed to delineate their properties after aerosolization. Nowadays, smoke reduction devices such as IQOS should be used instead of tobacco cigarettes with the commitment to reduce consumption over time until complete smoking and vape cessation. However, the question that most often grips is the possible increase in susceptibility to infections that these devices could cause. Anyway, to date few analyses have been carried out to get a precise representation of the effects of vapors on bacteria. Our study aimed to evaluate the antibacterial activity of aerosols produced by IQOS device. **Materials and Methods:** In order to evaluate the possible inhibitory activity against bacterial pathogens the IQOS Duo device equipped with Heets "Siena Selection" was chosen, the formula most requested by consumers. Moreover, the pathogen chosen for the test was the ATCC strain of *Klebsiella pneumoniae*, a known cause of pneumonia and chronic obstructive pulmonary disease exacerbations, which are also smoking related diseases. Besides, the bacterial reverse mutation test (Ames test), the primary component of the chemical safety assessment data required by regulatory agencies worldwide, was performed after exposure smoke/vapors generated from 1R6F cigarettes and IQOS, respectively, in order to detect mutagenic activities. Finally, human fibroblast lung diploid cells (MRC5) were exposed to cigarette smoke and aerosol from IQOS, to evaluate possible cytotoxic effects on lung tissue. **Results:** A very intense inhibitory activity was showed against *K. pneumoniae* by the vapors produced by Heets. Instead, no cytotoxic activity on lung cells or mutagenesis effects on TA98 - *S. typhimurium* tester strain was shown. In contrast, cigarette smoking caused evident damage to lung cells and showed a high rate of mutagenic capacity. **Discussion:** Our study proposed a standardized method for the evaluation of antimicrobial activity to be followed in this type of studies. Additionally, evidence of RRP vapors effects on bacterial growth without compromising lung cells was demonstrated for the first time.

101 - Transcriptomics of VISA Emerging in a genomic context of CA-MRSA Under Teicoplanin Therapy

[rossella salemi](#)⁽¹⁾ - Elvira Aguglia⁽¹⁾ - Alessandra Zega⁽¹⁾ - Flavia Loverde⁽¹⁾ - Stefania Stefani⁽¹⁾ - Viviana Cafiso⁽¹⁾

Università degli studi di Catania, BIOMETEC, Catania, Italia⁽¹⁾

Transcriptomics of VISA Emerging in a genomic context of CA-MRSA Under Teicoplanin Therapy

Rossella Salemi¹, Elvira Aguglia¹, Alessandra Zega¹, Flavia Loverde¹, Stefania Stefani¹, Viviana Cafiso¹

¹*Department of Biomedical and Biotechnological Sciences, Section of Microbiology, University of Catania, Catania, Italy*

* Corresponding author e-mail: v.cafiso@unict.it

Background

Outbreaks of Community-Acquired *Staphylococcus aureus* (CA- MRSA) infections have been reported worldwide supporting the increasing antimicrobial resistance trend also among the community circulating *S.aureus*. However, Vancomycin-Intermediate *S.aureus* (VISA) have been frequently reported among the health care-associated Methicillin Resistant *S.aureus* (HA-MRSA), whereas only few cases were recorded among CA-MRSA.

Methods

Our study aims to investigate the transcriptomic adaptations of a VISA strains clustering and genomically characterized as ST1-spatypet127-agrIII-SCCmecIVa-PVL-positive CA-MRSA, carrying the ant(6)-Ia and aph(3')-III (aminoglycoside-R), blaZ (β-lactam-R), mecA (β-lactam-R), ermC (macrolide-R) and tetK (tetracycline-R) acquired resistance genes, emerged in a patient under teicoplanin therapy. Comparative transcriptomics of the clinical VISA CA-MRSA versus its VSSA parent strain was investigated during the exponential growth-phase by RNA-Seq. Computational analysis was carried out by Rockhopper, bioinformatic, Enrichment and Gene-Ontology (GO) and KEGG.

Results

Transcriptomics provided insights into the complex nature of the transcriptomic adaptation traits of CA-MRSA strain versus its VSSA parent. Gene-Set Enrichment (GSE), Gene-Ontology and KEGG-pathway analysis evidenced a statistically significant dysregulation in sets of genes associated to different pathways. In particular, the over- and under-expressed gene clusters highlighted dysregulations in GO-term transcripts and pathway implicated in two-component regulatory systems, cell membrane structure, response to antimicrobials, oxidation and reduction processes, polysaccharide biosynthesis, protein/purine/amino sugar/nucleotide sugar metabolism, DNA-replication, transcription regulation and transport.

Conclusions

Our findings showed the complex nature of the VISA transcriptomic adaptations in the genomic context of a CA-MRSA superbug.

104 - Evaluation of the anti-biofilm activity of four different antibiotics against *Staphylococcus aureus* strains from ocular infections

Aseel AbuAlshaar ⁽¹⁾ - Aurora Piazza ⁽¹⁾ - Francesca Piscopiello ⁽¹⁾ - Marta Corbella ⁽²⁾ - Patrizia Cambieri ⁽²⁾ - Carola Mauri ⁽³⁾ - Alessandra Consonni ⁽³⁾ - Sara Rimoldi ⁽⁴⁾ - Chiara Motta ⁽⁵⁾ - Giampiero Pietrocola ⁽⁵⁾ - [Roberta Migliavacca](#) ⁽¹⁾

University of Pavia, Unit of Microbiology and Clinical Microbiology, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, Pavia, Italy ⁽¹⁾ - Fondazione IRCCS Policlinico San Matteo, U.O.C. Microbiology and Virology, Pavia, Italy ⁽²⁾ - A. Manzoni Hospital ASST Lecco, Microbiology and Virology Unit, Lecco, Italy ⁽³⁾ - ASST Fatebenefratelli Sacco, Laboratory of Clinical microbiology, Virology and Bioemergency diagnostics, Milano, Italy ⁽⁴⁾ - University of Pavia, Unit of Biochemistry, Department of Molecular Medicine, Pavia, Italy ⁽⁵⁾

Evaluation of the anti-biofilm activity of four different antibiotics against *Staphylococcus aureus* strains from ocular infections

¹Aseel AbuAlshaar, ¹Aurora Piazza, ¹Francesca Piscopiello, ²Marta Corbella, ²Patrizia Cambieri, ³Carola Mauri, ³Alessandra Consonni, ⁴Sara Rimoldi, ⁵Chiara Motta, ⁵Giampiero Pietrocola, ¹Roberta Migliavacca

¹Unit of Microbiology and Clinical Microbiology, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Italy

²U.O.C. Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

³Microbiology and Virology Unit, A. Manzoni Hospital ASST Lecco, Lecco, Italy

⁴Laboratory of Clinical microbiology, Virology and Bioemergency diagnostics, ASST Fatebenefratelli Sacco, Milano, Italy

⁵Unit of Biochemistry, Department of Molecular Medicine, University of Pavia, Italy

Introduction: We investigated the biofilm forming ability of n=45 *Staphylococcus aureus* (14/45 MRSA; 31/45 MSSA) of the period 2017-2021 and involved in ocular infections, in Lombardy. We evaluated MICs/MBCs and Minimal Biofilm Eradication Concentration (MBEC) and the ability of levofloxacin (LEV), chloramphenicol (CAF), netilmicin (NET), and tobramycin (TOB) in avoiding cells adhesion and biofilm eradication. **Materials and Methods:** MICs/MBCs and a quantitative biofilm production were assessed for all the *S. aureus* isolates by broth microdilution (EUCAST breakpoints) and crystal violet assay, respectively. The biofilm inhibitory activity of the four antibiotics was tested on six strong biofilm producers selected as not clonally related by RAPD: 5/6 MSSA and the ATCC *S. aureus* 25923 strain using the crystal violet staining method. Biofilm biomass was quantified by staining with crystal violet and absorbance measurements at OD600nm. MBEC was performed by Calgary biofilm device. **Results:** 43/45 (95.6%) were CAF susceptible (93.5% MSSA vs 100% MRSA); 33/45 (73.3%) LEV susceptible (100% MSSA vs 14.3% MRSA); 28/45 (62.2%) resulted Wild Type (71% MSSA vs 42.9% MRSA); 32/45 (71.1%) TOB susceptible (100% MSSA vs 14.3% MRSA). All the *S. aureus* strains resulted strong biofilm producers. Regarding CAF, LEV, NET and TOB all the MSSA strains tested showed an CAF MIC=8mg/L and 0.125-0.25mg/L for LEV/NET/TOB (MBC= >32mg/L for CAF; 0.125-0.5mg/L for LEV; 0.125-0.25mg/L for NET and TOB); an enhancement in biofilm formation at the sub MIC values equal to 0.5mg/L (CAF); 0.03mg/L (LEV); 0.125mg/L (NET); 0.03 mg/L (TOB). The complete biofilm formation inhibition was near/at the MIC values of 8mg/L; 0.125mg/L; 0.25mg/L and 0.06, respectively. The MBEC results on cells organized in a 24h biofilm are: 512mg/L (CAF), 128-2048 mg/L (LEV), 256mg/L (NET); 32-64mg/L (TOB). **Discussion and Conclusions:** CAF/LEV/NET/TOB resulted effective in preventing bacterial adhesion and biofilm formation when used at concentrations equal to or higher than the MICs of the sensitive strains. Based on the dosages commonly reachable for CAF/LEV (with only one exception)/NET/TOB ophthalmic use, the results showed a clear efficacy in the eradication of newly formed biofilms of sensitive *S. aureus* strains. The efficacy of each drug against biofilm forming *S. aureus* strains is however subjected to the local epidemiology in terms of susceptible strains presence.

105 - Prevalence and virulence potential of *Aeromonas* spp. isolated from patients suffering from diarrhea

Giulia Bernabè⁽¹⁾ - Paola Brun⁽¹⁾ - Giuseppe Di Pietra⁽²⁾ - Silvia Meneghello⁽²⁾ - Maria Antonello⁽²⁾ - Elisabetta Valente⁽²⁾ - Giampaolo Cordioli⁽²⁾ - Valeria Besutti⁽²⁾ - Ignazio Castagliuolo⁽¹⁾

Università degli studi di Padova, Dipartimento di medicina molecolare, Padova, Italia⁽¹⁾ - Azienda Ospedaliera di Padova, Microbiologia, Padova, Italia⁽²⁾

Prevalence and virulence potential of *Aeromonas* spp. isolated from patients suffering from diarrhea

GIULIA BERNABÈ¹, PAOLA BRUN¹, GIUSEPPE DI PIETRA^{1,2}, SILVIA MENEGHELLO^{1,2}, MARIA ANTONELLO^{1,2}, ELISABETTA VALENTE^{1,2}, GIAMPAOLO CORDIOLI^{1,2}, VALERIA BESUTTI², IGNAZIO CASTAGLIUOLO¹

¹Department of Molecular Medicine, University of Padua

²Microbiology Unit, Azienda Ospedaliera of Padua

Background - aim: *Aeromonas* spp are considered emerging human pathogens causing intestinal and extra-intestinal infections. In this study, we aimed to investigate the epidemiology of *Aeromonas* spp in patients with diarrhoea and characterize virulence mechanisms of human isolates.

Methods: During 14 months (5/2020 – 6/2021), 10856 diarrhoeic fecal samples were analyzed at the Microbiology Unit of Padua University Hospital using standard culture methods. *Aeromonas* spp were identified by sequencing the housekeeping gene *rpoB*. Antibiotic susceptibility was assessed by the VITEK-2 automated system, according to EUCAST criteria. The presence of genes involved in toxins coding such as *ela*, *ast*, *alt*, and *aer* was searched by polymerase chain reaction (PCR). Biofilms were grown in microtitre plates, stained with Crystal Violet, and the mean optical density (OD) quantified. Interaction of *Aeromonas* strains with Caco2 human intestinal epithelial cells (IEC) was assessed by quantifying adhesion, interleukin (IL)-8 secretion, integrity of epithelial barrier.

Results: 66 faecal samples were positive for *Aeromonas* spp (second most common enteropathogen identified): *A. caviae* (56,82%), *A. dhakensis* and *A. aquatica* (11,36) and *A. taiwanensis* (9%) were the most common specie. Infection was more common in subjects <10 years or >50 years old (32% and 59%, respectively). Forty-seven of *Aeromonas* isolates were resistant to amikacin whereas only 2.8% and 11,1% were resistant to ciprofloxacin or trimetoprim-sulfamethoxazole, respectively. Multiple drug resistance was detected in 2 isolates, instead 30.5% strains were susceptible to all antibiotics. PCR analysis showed that all strains were *ela* (elastase) positive, whereas *ast*, *alt*, *aer* toxins were present in 57%, 66% and 45% of strains, respectively. Moreover, 25% of isolates reported the simultaneous expression of the three genes tested. Tested strains produced moderate biofilm (22,7% of strains had weak biofilm producing ability). *Aeromonas* isolates showed an excellent ability to interact with human IEC since: 43% of strains showed adhesion ability ≥ 1 CFU/cell; *Aer*+ strains, as opposed to *aer*-, significantly reduced trans-epithelial resistance; 27% of isolates significantly enhanced release of interleukin-8, particularly *A. taiwanensis* strongly stimulate its production.

Conclusions: *Aeromonas* spp are relevant cause of diarrhea in humans, representing the second most common enteropathogen isolated, affecting mainly young children and subjects older than 50 years. To date, human strains are still largely sensible to antibiotics. *Aeromonas* spp possesses a heterogeneous armamentarium of pathogenicity factors to efficiently interact with IEC, suggesting that *Aeromonas* spp induce diarrhea through different mechanisms.

106 - Spread of Metallo-Beta Lactamase genes: characteristics and diffusion of broad-host range and highly conjugative plasmids

Gaia Menichincheri⁽¹⁾ - Valerio Capitani⁽¹⁾ - Gabriele Arcari⁽¹⁾ - Federica Sacco⁽²⁾ - Riccardo Polani⁽¹⁾ - Francesco Bruno⁽¹⁾ - Maria Trancassini⁽³⁾ - Monica Coletti⁽⁴⁾ - Gianmarco Raponi⁽³⁾ - Alessandra Carattoli⁽¹⁾

Università La Sapienza, Medicina Molecolare, Roma, Italia⁽¹⁾ - Università La Sapienza, Policlinico Umberto I (UOC di Microbiologia e Virologia), Roma, Italia⁽²⁾ - Università La Sapienza, Sanità Pubblica e Malattie Infettive, Roma, Italia⁽³⁾ - Università La Sapienza, Policlinico Umberto I (laboratorio di microbiologia), Roma, Italia⁽⁴⁾

Spread of Metallo-Beta Lactamase genes: characteristics and diffusion of broad-host range and highly conjugative plasmids

Gaia Menichincheri¹, Valerio Capitani¹, Gabriele Arcari¹, Federica Sacco^{1,2}, Riccardo Polani¹, Francesco Bruno¹, Maria Trancassini³, Monica Coletti⁴, Gianmarco Raponi³, Alessandra, Carattoli¹

¹Dept. Molecular Medicine, Sapienza University of Rome, Rome, Italy

²Complex Operating Unit of Microbiology and Virology, Policlinico Umberto I, Rome, Italy

³Dept. of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

⁴Microbiology Laboratory, Policlinico Umberto I, Rome, Italy

Introduction: The rapid spread of carbapenem resistant Enterobacterales is currently a worldwide growing public health threat. At the Policlinico Umberto I (PUI) of Rome, the surveillance performed in 2019–2021 on invasive infections showed that on 797 *K. pneumoniae* (*Kp*) isolates, 32% were carbapenem resistant. Most of these strains were KPC-producing strains. The high incidence of KPC-*Kp* is favouring the use of ceftazidime-avibactam (CZA), a novel beta-lactam/beta-lactamase inhibitor combination, as the first drug of choice for treatment of KPC-*Kp* infections. Metallo-Beta-Lactamases (MBL: New Delhi MBL, NDM; Verona integron-encoded MBL, VIM; imipenemase, IMP), confer resistance to both CZA and meropenem (MEM) and will increase their prevalence under selective pressure exerted by the intensive use of CZA treatment in the hospital. NDM in the last years reported an increment of its detection in Italy, due to the large outbreak occurred in Tuscany, while VIM was diffused at PUI accounting for 75.6% of all MBL-producing Enterobacterales in 2018.

Materials and Methods. Whole Genome Sequencing (Illumina and Nanopore technologies) was performed on VIM and NDM-producing strains from PUI hospital. VIM and NDM-carrying plasmids were compared with plasmids downloaded from a collection of 34,513 plasmids from GenBank (PLSDB database). We characterized the plasmids retrieved from VIM and NDM-positive strains by transformation in chemically competent *Escherichia coli* DH5 alpha cells.

Results: Analysis of data available at PUI on severe infections occurred in 2020-2021, showed that resistance to CZA combination is increasing in *Kp* strains from 4,0% to 6,2%. Among them the percentage of strains showing CZA and MEM co-resistance is also increasing going from 1% in 2020 to 2% in 2021. In 2020-2022, 18 strains were identified at PUI as NDM-producers (*Kp*, *Escherichia coli*, *Enterobacter cloacae*, *Providencia stuartii*), and 8 strains were positive for VIM (*Kp*, *E. coli*, *Klebsiella oxytoca*, *E. cloacae*, *Enterobacter aerogenes*). The *bla*_{NDM} genes were carried on different plasmid types, but the most frequent at PUI was the broad-host range IncC plasmid, identified in 83% of the NDM-positive strains in which *bla*_{NDM} was associated with the 16S rRNA methylase *rmtC*. The *bla*_{VIM} genes were carried on two major plasmid types of the IncN and IncA groups. The *bla*_{VIM}-gene cassette was typically inserted into integron platforms.

Discussion and conclusions: IncC and IncA are plasmids showing extremely wide host range and show high-efficient conjugation properties. By comparison of plasmids identified in different bacterial species throughout the years at PUI well demonstrated the ability of spreading. A multi-species bunch of VIM-1 and NDM-1 producing strains was identified in the hospital.

108 - Anatomy of pKpQIL, the bla_{KPC} plasmid, and its role in ceftazidime-avibactam resistance

Gabriele Arcari⁽¹⁾ - Riccardo Polani⁽¹⁾ - Francesco Bruno⁽¹⁾ - Valerio Capitani⁽¹⁾ - Gaia Menichincheri⁽¹⁾ - Alessandra Carattoli⁽¹⁾

Sapienza Università di Roma, Dipartimento di Medicina Molecolare, Roma, Italia⁽¹⁾

Anatomy of pKpQIL, the bla_{KPC} plasmid, and its role in ceftazidime-avibactam resistance

GABRIELE ARCARI¹, RICCARDO POLANI¹, FRANCESCO BRUNO¹, VALERIO CAPITANI¹, GAIA MENICHINCHERI¹ and ALESSANDRA CARATTOLI¹

¹ Dept. of Molecular Medicine, Sapienza University of Rome, Rome, Italy

Introduction. *Klebsiella pneumoniae* plays a crucial role in the global emergence of carbapenem resistance. In Italy this phenomenon is led by the spread of the plasmid-located bla_{KPC} genes. The combination of ceftazidime-avibactam (CZA) has been introduced in clinical settings in 2018 for the treatment of serine-beta-lactamases producing bacteria. Yet, KPC-producing, CZA resistant *K. pneumoniae* isolates are emerging.

Materials and Methods. Whole Genome Sequencing (Illumina and Nanopore technologies) was performed on 23 KPC-producing CZA-resistant strains from the Policlinico Umberto I (PUI) hospital. Most of them (18) carried bla_{KPC} on a pKpQIL plasmid. These plasmids were compared with 104 plasmids carrying the FIB(pQIL) and FII(K) replicons downloaded from a collection of 34,513 plasmids (PLSDB database). Statistical (chi-squared, Pearson's and Spearman's R) and bioinformatic (pangenome definition, phylogenesis, detection of associating genes, estimation of average nucleotide identity) analyses were carried out on data from the 122 genomes. Furthermore, we characterized the activity against CZA of the KPC-producing *K. pneumoniae* isolates retrieved from PUI by transformation of the respective pKpQIL plasmids in chemically competent *Escherichia coli* DH5-alpha cells.

Results. pKpQIL plasmids have a length ranging from 85,040 to 307,743 bp (median 116,381, IQR 21,363 bp) and a GC content ranging from 50.705 to 54.783% (median 53.663, IQR 1.209). The typical pKpQIL plasmid carries few resistance genes (mode and median = 2 genes), in most cases KPC (83/122, p< 0.00001) or other beta-lactamases (NDM-1 in 8 cases and CTX-M-15 in 14 cases) but they can harbor up to 16 different resistance genes. As these plasmids grow in length, their GC content decreases (R=-0.509, p=0.00002) and they have more resistance genes (R=0.653, p<0.00001). The pangenome of pKpQIL plasmids is made up of 1,739 genes, 24 of which are present in more than 90% of the genomes (i.e. the plasmid core genome).

CZA-resistant isolates harboring bla_{KPC} on a pKpQIL-like plasmid from PUI belonged to three high-risk clones: ST512, ST37 and ST307. MICs for CZA ranged from 8,0 mg/L to >256 mg/L and were mediated by 8 different KPC-variants. In 5 cases co-resistance to meropenem was observed. *E. coli* transformed with pKpQIL displayed comparable characteristics.

Discussion and Conclusions. While KPC-31 (D179Y variant of KPC-3) has been described as one of the major causes of CZA resistance in KPC-producing *K. pneumoniae* worldwide, KPC-66, -67, -69, -70 and -110 have been isolated for the first time in PUI. These data suggest that the spread of bla_{KPC} is related to pKpQIL and that, in high endemicity settings, CZA-resistance is driven by the pliability of the bla_{KPC} gene in a subset of high-risk clones.

109 - A new core-genome based typing method for *Providencia stuartii*: characterization of New Delhi Metallo-Beta-Lactamase-producing strains causing an outbreak

Valerio capitani⁽¹⁾ - gabriele arcari⁽¹⁾ - federica sacco⁽²⁾ - riccardo polani⁽¹⁾ - francesco bruno⁽¹⁾ - federico cecilia⁽¹⁾ - gaia menichincheri⁽¹⁾ - giammarco raponi⁽³⁾ - alessandra carattoli⁽¹⁾

la sapienza, dipartimento di medicina molecolare, roma, Italia⁽¹⁾ - Complex Operating Unit of Microbiology and Virology, Policlinico Umberto I, roma, Italia⁽²⁾ - Sapienza University of Rome, , Sapienza University of Rome, Rome, Italy Dept. of Public Health and Infectious Diseases, roma, Italia⁽³⁾

A new core-genome based typing method for *Providencia stuartii*: characterization of New Delhi Metallo-Beta-Lactamase-producing strains causing an outbreak

Valerio Capitani¹, Gabriele Arcari¹, Federica Sacco^{1,2}, Riccardo Polani¹, Francesco Bruno¹, Federico Cecilia¹, Gaia Menichincheri¹, Giammarco Raponi³, Alessandra, Carattoli¹

1 Dept. Molecular Medicine, Sapienza University of Rome, Rome, Italy

2 Complex Operating Unit of Microbiology and Virology, Policlinico Umberto I, Rome, Italy

3 Dept. of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

INTRODUCTION:

Providencia stuartii is a gram negative, highly mobile, opportunistic pathogen member of Enterobacterales. *P. stuartii* causes urinary and respiratory infections in nosocomial context. It shows intrinsic resistances to the polymyxin and carries intrinsic genes like *tet(B)*, *catA3* and *aac(2')-Ia*. *P. stuartii* typing has not yet been implemented and it doesn't exist a multi locus sequences typing (MLST) scheme for this opportunistic pathogen. Here, we describe a 4-patient outbreak occurred in two intensive care units (ICUs) of the Policlinico Umberto I (PUI) caused by NDM-producing *P. stuartii*. To trace *P. stuartii* of this outbreak and compare them with those circulating worldwide, we established a new MLST scheme based on seven genes and a core genome based MLST

MATERIALS AND METHODS:

Seven NDM-producing *P. stuartii* strains from four patients were identified in three months at the PUI hospital. Complete genomes were obtained for 3 prototypic strains by Illumina MiSeq and Oxford Nanopore Technologies. Genomes were assembled by Unicycler and analysed by Prokka for gene assignment and Staramr for identification of antibiotic resistance and plasmid content. IncC complete plasmid sequences were compared with related plasmids previously identified at the PUI. CHubbaca and other tools were utilized for identification of *P. stuartii* core genome to build up effective MLST and core genome MLST. The novel MLST method was applied to PUI isolates compared with 54 *P. stuartii* genomes downloaded from Genbank.

RESULTS:

Analysis on the *P. stuartii* genomics from PUI showed high phylogenetic similarity of strains causing the outbreak, with a range of 0-2 SNPs on the core genome. We identified two plasmids carried by *P. stuartii* strains: one ColpVC present only in 1/3 strains and an IncC plasmid detected in the 3 isolates analysed. The IncC plasmid carried numerous resistance genes, including *bla*_{NDM}, *bla*_{CMY-6} and the 16S rRNA methyltransferase *rmtC* and conferred resistance to all beta-lactams and aminoglycosides. It was indistinguishable from the IncC causing an outbreak in NDM-producing *Klebsiella pneumoniae* ST15 clone occurred in 2020 at PUI.

DISCUSSION AND CONCLUSION:

The IncC plasmid previously observed in ST15 *K. pneumoniae* causing an outbreak in same hospital, was unseen for approximately 2 years and then recurred in *P. stuartii*. Low differences between these plasmids were identified: K.

pneumoniae IncC showed one IS3 that was lost in the IncC from *P.stuartii* that acquired one IS1 and a *K. pneumoniae* genome fragment. This acquisition traced the origin of the plasmid from *K. pneumoniae*. We used genomic data to build up pangenome and coregenome, establishing a global typing method for the *P. stuartii* species, currently divided in 21 different phylogenetic groups.

112 - Study of *Acinetobacter* species resistance patterns and virulence in a multidisciplinary hospital

Carmen-Sarah Costinas⁽¹⁾ - Mihaela Elena Idomir⁽¹⁾ - Orietta Massidda⁽²⁾

Faculty of Medicine, Transilvania University of Brasov, Microbiology department, Brasov, Romania

⁽¹⁾ - University of Trento, Italy, Department of Cellular Computational and Integrative Biology, Center of Medical Sciences (CISMed), Trento, Italia ⁽²⁾

Study of *Acinetobacter* species resistance patterns and virulence in a multidisciplinary hospital

Carmen S. Costinas^{1,2}, *Mihaela E. Idomir*^{1,2}, *Orietta Massidda*³

¹Microbiology Department, Clinical Laboratory, Clinical County Emergency Hospital, Brasov, Romania; ²Microbiology Department, Faculty of Medicine, Transilvania University of Brasov, Romania; ³Department of Cellular Computational and Integrative Biology, Center of Medical Sciences (CISMed), University of Trento, Italy

1. Introduction: *Acinetobacter* genus includes aerobic, non-fermenting, gram negative coccoid rods. Their extensive survival on various surface of medical equipment in hospital units is alarming. Each year, the number of human infections caused by these conditional pathogens is rapidly increasing, therefore WHO labeled *Acinetobacter spp.* as "critical level or priority". They can hold responsibility of serious infections especially in debilitated patients that undergo invasive medical procedures. Antibiotic resistance profile shows a multi-drug-resistance pattern. The aim of the study is to evaluate the dynamics of *Acinetobacter* infections spectrum and to assess the resistance patterns of *Acinetobacter spp.* identified from hospitalized patients' samples in a multidisciplinary hospital. **2: Materials and Methods:** This is a retrospective descriptive study that includes 1164 *Acinetobacter* strains isolated from patient samples from Clinical County Emergency Hospital of Brasov during 1st of January 2018-31st of December 2021. Data was collected from MEDIS system and WHO-NET database provided by Clinical County Emergency Hospital of Brasov. Data was processed in Microsoft Excel Worksheet. Bacterial identification was performed based on biochemical testing. Antimicrobial susceptibility of microorganisms was evaluated by means of disk diffusion method and confirmed by automated VITEK 2 COMPACT. **3. Results:** *Acinetobacter spp.* have been frequently identified in patient samples from intensive care units (53.4%) and plastic surgery department (11%). Most samples were respiratory secretions (38%), wound secretions (26%) and pus (18.5%). More than 80% of tested strains were resistance to both Imipenem and Meropenem. **4. Discussions and Conclusions:** This study underlines the importance of constantly monitoring the antibiotic resistance pattern of *Acinetobacter spp.* pathogens with the aim of optimizing the treatment prescription, especially regarding the empirical antimicrobial therapy.

117 - Activity of cell-free supernatants from probiotic *Lactobacillus* strains against *Pseudomonas aeruginosa* from cystic fibrosis patients

Esingül Kaya⁽¹⁾ - Arianna Pompilio⁽²⁾ - Elisa Catelli⁽¹⁾ - Giuseppantonio Maisetta⁽¹⁾ - Veronica Lupetti⁽²⁾ - Giovanni Di Bonaventura⁽²⁾ - Semih Esin⁽¹⁾ - Giovanna Batoni⁽¹⁾

University of Pisa, Translational Research and New Technologies in Medicine and Surgery, Pisa, Italia⁽¹⁾ - "G. d'Annunzio" University of Chieti-Pescara, Medical, Oral and Biotechnological Sciences, and Center of Advanced Studies and Technologies (CAST), Chieti, Italia⁽²⁾

Activity of cell-free supernatants from probiotic *Lactobacillus* strains against *Pseudomonas aeruginosa* from cystic fibrosis patients

Esingül Kaya¹, Arianna Pompilio², Elisa Catelli¹, Giuseppantonio Maisetta¹, Veronica Lupetti², Giovanni Di Bonaventura², Semih Esin¹, Giovanna Batoni¹

¹Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy;

²Department of Medical, Oral and Biotechnological Sciences, and Center of Advanced Studies and Technologies (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy

Introduction: The potential application of probiotics is continuously widening, although the therapeutic use of live bacterial cells may pose safety concerns, especially in vulnerable subjects. New evidence points to postbiotics as a step forward in the use of pre- and probiotics. Roughly defined as a complex mixture of metabolic products secreted by probiotics in cell-free supernatants (CFS), postbiotics may have several advantages over probiotics, including safety, ease of production and storage, and multiple mechanisms of action. As part of a project funded by the Italian cystic fibrosis (CF) foundation, in this study we evaluated the antibacterial, antibiofilm, and anti-virulence properties of CFS from *Lactobacillus* strains against *Pseudomonas aeruginosa* isolated from CF patients.

Materials and Methods: CFS were prepared by growing *Lactobacillus* strains in MRS broth for 48 h at 37°C in agitation, followed by centrifugation of the cultures and filtering of the supernatants. Growth inhibitory activity was assessed against mucoid and non-mucoid strains via the agar-well diffusion method and by monitoring the optical density over 24 h of incubation. To mimic the CF lung environment, killing kinetics against planktonic bacteria and mature biofilms were performed by exposing *P. aeruginosa* strains to CSF in an artificial sputum medium (ASM) and evaluating CFU counts at different time intervals.

Results: CFS (pH approximately 4.0) from multiple *Lactobacillus* strains exerted marked growth inhibitory and killing capacity towards several *P. aeruginosa* strains, with CFS from *L. rhamnosus* and *L. plantarum* being the most active. Such capacity was abolished when the pH was adjusted to 6.0 with NaOH. Nevertheless, CFS exerted higher inhibitory capacity and killing activity than sterile MRS broth adjusted at pH 4.0 with HCl, suggesting that the inhibitory capacity was not merely due to the acidity. CSF also exerted a fast and strong antibacterial and antibiofilm activity in ASM. The evaluation of the anti-virulence properties of CFS is ongoing.

Discussion and conclusions: The use of postbiotics, a term recently revised to include both metabolites and fragments derived from microorganisms, seems an attractive therapeutic/preventive strategy in the era of antibiotic resistance. Herein we demonstrated their activity towards clinical strains of *P. aeruginosa* in conditions mimicking CF lung. Future studies are warranted to identify the full spectrum of such metabolites' activities and unveil innovative postbiotics' uses in anti-infective therapy. *The study received support from the Italian Cystic fibrosis research foundation, Project FFC#13/2021.*

120 - Antibiofilm activity of *Moringa oleifera* Lam. leaf extracts by Scanned Electron Microscopy visualization against *Xanthomonas campestris* pv. *campestris*

Riccardo Fontana⁽¹⁾ - Anna Caproni⁽¹⁾ - Chiara Nordi⁽¹⁾ - Marco Marzola⁽¹⁾ - Mattia Buratto⁽¹⁾ - Francesca Salvatori⁽¹⁾ - Mariangela Pappadà⁽¹⁾ - Mariaconcetta Sicurella⁽²⁾ - Peggy Marconi⁽¹⁾

Università degli Studi di Ferrara, Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie, Ferrara, Italia⁽¹⁾ - Università degli Studi di Ferrara, Dipartimento di Scienze dell'Ambiente e della Prevenzione, Ferrara, Italia⁽²⁾

Antibiofilm activity of *Moringa oleifera* Lam. leaf extracts by Scanned Electron Microscopy visualization against *Xanthomonas campestris* pv. *campestris*

RICCARDO FONTANA¹, ANNA CAPRONI¹, CHIARA NORDI¹, MARCO MARZOLA¹, MATTIA BURATTO¹, FRANCESCA SALVATORI¹, MARIANGELA PAPPADÀ¹, MARIACONCETTA SICURELLA², PEGGY MARCONI¹

¹ Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy

² Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy

Introduction *Xanthomonas campestris* pv. *campestris* (XCC) is the causal agent of black rot in crucifers, a plant disease with high economic impact. Xanthomonadaceae are a large genus of Gram-negative bacteria that cause their symptoms by blocking plants water flow by invading the xylem. To accomplish that, biofilm formation is the main mechanism that XCC uses to adapt to environmental changes and to colonize tissues. In recent years, the growing interest in natural antimicrobial compounds led to the study of different phytocomplexes derived from different plants. In our project, *Moringa oleifera* Lam. (MOL), was selected, as MOL leaves are rich in phenols, essential oils, and vitamins that exert antibacterial properties. Biofilms are often studied with scanned electron microscopy (SEM), and therefore XCC biofilm formation and removal were analyzed on abiotic and biotic surfaces, with and without the influence of different MOL leaf extracts.

Materials and methods Biofilm formation and removal assay: XCC strains, isolated from the Emilia-Romagna phytosanitary department, were inoculated in LB broth with MOLs at non-lethal concentration in a 6-well plate containing a cell strainer for 120 h at 25 °C. For biofilm removal, after incubation and after visually assessing biofilm formation, MOLs at non-lethal concentration were added and incubated for 48 hours.

In planta biofilm formation: XCC suspensions, containing 10⁶ CFU/mL, were inoculated in LB broth in a 4 weeks old cabbage, and then incubated for 7 days at RT. Once the infection started, MOLs at their MIC were added.

Biofilm SEM visualization: samples were fixed in 2.5% glutaraldehyde in 0.1M KPO₄ buffer, dehydrated in alcohol and dried with critical point dryer. Samples were mounted on metal stubs and gold-coated. Samples were examined with SEM Zeiss Evo40.

Results The assay showed a complete colonization by XCC on abiotic and biotic surfaces if not under the effects of MOLs: the control, in fact, showed that the fibers of the cell-strainer were coated with EPS, as well as cabbage xylem was completely invaded; furthermore, the production of xanthan gum (one of the main components of XCC EPS and virulence factors) laminae was observed. The fact that HAMD-MOL and MeOH-MOL can exert antibiofilm properties is proven and confirmed by the presence of just few solitary planktonic bacteria, and no complex or organized structures were observed.

Conclusions In conclusion, XCC can adhere to both abiotic and biotic surfaces developing its biofilm on them, while, when under the effects of MOLs, XCC changes its cell shape and interrupts that ultrastructural organization that characterize a developed biofilm, in particular in the adhesion part of the process, and this may have important applications in disease control.

121 - Effects on *Xanthomonas campestris* pv. *campestris* by *Moringa oleifera* Lam. leaf fermented extracts

Anna Caproni ⁽¹⁾ - Riccardo Fontana ⁽¹⁾ - Chiara Nordi ⁽¹⁾ - Marco Marzola ⁽¹⁾ - Mattia Buratto ⁽¹⁾ - Francesca Salvatori ⁽¹⁾ - Mariangela Pappadà ⁽¹⁾ - Anna Baldisserotto ⁽²⁾ - Stefano Manfredini ⁽²⁾ - Raissa Buzzi ⁽²⁾ - Peggy Marconi ⁽¹⁾

Università degli Studi di Ferrara, Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie, Ferrara, Italia ⁽¹⁾ - Università degli Studi di Ferrara, Dipartimento di Scienze della Vita e Biotecnologie, Ferrara, Italia ⁽²⁾

Effects on *Xanthomonas campestris* pv. *campestris* by *Moringa oleifera* Lam. leaf fermented extracts

ANNA CAPRONI¹, RICCARDO FONTANA¹, MARCO MARZOLA¹, CHIARA NORDI¹, MATTIA BURATTO¹, FRANCESCA SALVATORI¹, MARIANGELA PAPPADÀ¹, ANNA BALDISSEROTTO², STEFANO MANFREDINI², RAISSA BUZZI², PEGGY MARCONI¹

¹ Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy

² Department of Life Sciences and Biotechnologies, University of Ferrara, 44121 Ferrara, Italy

Introduction *Xanthomonas campestris* pv. *campestris* (Xcc) is the causal agent of black rot in crucifers, a plant disease with high economic impact. Biofilm formation is the main mechanism that Xcc uses to adapt to environmental changes and to colonize tissues. In recent years, the growing interest in natural antimicrobial compounds led to the study of different phytocomplexes with antimicrobial properties derived from the vegetable world. For this reason, *Moringa oleifera* Lam. leaves (MOL) were selected and studied by our group. After the extraction processes, waste material can still be rich in active substances: in this project we focused on an Herbal Medicines By-product generated from the extraction processing of MOL leaves (MHMB) and on its antimicrobial effects.

Materials and methods MHMB have been suitably diluted and submerged fermentations with 5 different species of fungi have been carried out for 35 days under optimal stirring and temperature conditions. Minimal Inhibitory Concentration (MIC) was assessed. Biofilm formation and removal assay: XCC strains, isolated from the Emilia-Romagna phytosanitary department, were inoculated in LB broth with MOLs at non-lethal concentration in a 96-well plate 72 h at 25 °C. For biofilm removal, MHMB at non-lethal concentration were added after incubation and after visually assessing biofilm formation and incubated for 48 hours. The crystal violet (CV) method was then used. Membrane permeability (MP) was assessed by the propidium iodide assay. MP was examined after 30, 60, 120, 180 minutes of contact with the different MHMB.

Results and conclusions From all the different MHMB tested, only one of the fermented extracts could significantly alter membrane permeability and biofilm formation processes in a *in field*-usable concentration. In fact, MHMB-PC could alter XCC membrane permeability already after 10 minutes of contact at a [V/V] concentration of 12.5%. Regarding its antibiofilm activity, the removal results appear to be promising, leading to the removal of 87% of a mature biofilm when used at a sub-lethal concentration.

122 - A fast microbiology experience in a Southern Italy hospital: a diagnostic stewardship approach.

Maria Teresa Della Rocca ⁽¹⁾ - Vittorio Panetta ⁽¹⁾ - Adriana Durante ⁽¹⁾ - Stefano Labella ⁽¹⁾ - Giuseppe Carfora Lettieri ⁽¹⁾ - Filomena Merola ⁽¹⁾ - Rita Greco ⁽¹⁾

UOSD Microbiologia, AORN Sant'Anna e San Sebastiano, Caserta, Italia ⁽¹⁾

A fast microbiology experience in a Southern Italy hospital: a diagnostic stewardship approach.

MARIA T. DELLA ROCCA¹, VITTORIO PANETTA¹, ADRIANA DURANTE¹, STEFANO LABELLA¹, GIUSEPPE CARFORA LETTIERI¹, FILOMENA MEROLA¹, RITA GRECO¹

¹UOSD Microbiology – AORN Sant 'Anna and San Sebastiano, Caserta, Italy.

Introduction

Diagnostic microbiology has remained relatively unchanged for decades, but recent years have witnessed a remarkable effort to develop novel technologies for faster microbiological diagnosis of sepsis. Faster identification of blood culture pathogens was associated with a shorter time for adequate therapy and decreased mortality in combination with antibiotic stewardship programs (ASP). The diagnostic stewardship is part of a unified stewardship strategy and means: right patients, appropriate test, right interpretation of the results at the right time. We proposed in laboratory routines one of rapid diagnostic test to improve BSI management. The study aims to emphasize advantages in using this fast panel to perform a BSI diagnosis with a complete rapid susceptibility profile.

Materials and Methods

The study involved 11 positive blood cultures from septic patients at Sant 'Anna and San Sebastiano Hospital of Caserta. None of patients underwent empiric treatment. Blood samples were collected and flagged positive within a 7-hour medium incubation time in a continuously monitored system. Identification and antimicrobial susceptibility tests were performed according to the manufacturer's instructions within 8 hours in Accelerate *Pheno*, with a medium time length of respectively 1 hour and 30 minutes and 6 hours and 30 minutes.

Result

5 *Acinetobacter baumannii* and 4 *Klebsiella pneumoniae*, 1 *Proteus mirabilis* and 1 *Serratia marcescens* were isolated. For all the gram negative identified MIC value for the principal antibiotic were obtained.

Particularly colistin MIC for *A. baumannii*; 3dg cephalosporins and carbapenem for *Klebsiella spp.* and MIC values for amikacin, trimethoprim/sulfamethoxazole, piperacillin/tazobactam were obtained for *Serratia* and *Proteus*. The test also performed for all the strains the antimicrobial drug for Multidrug Resistance Organism like Ceftazidime/Avibactam and Ceftolozane/Tazobactam. Thanks to the availability of a fast susceptibility profile a definitive therapy was prescribed to the patients. BSI had different courses: all the *A. baumannii* were resistant to all the tested antibiotic except for colistin. The *Klebsiella pneumoniae* showed carbapenem resistant profile (1 OXA-48 and 4 KPC) and were treatment with ceftazidime/avibactam. *Serratia* had susceptibility for all the tested antibiotics.

Discussion and conclusion

The future of sepsis therapy has led to many attempts to personalize the management of sepsis patients involving fast microbiology diagnostic technologies like Accelerate *Pheno* test. Rapid identification of the infection and its antibiotics sensitivity is of primary importance for improving the turnaround time in BSI but also in the infection control program. In this way a unified strategy integrated the diagnostic stewardship improve the management of sepsis and the clinical outcome.

125 - A case report of oral candidiasis in an immunocompetent patient

Case report: Disseminated cryptococcus neoformans in an immunocompetent patient.

GIUSEPPE GRECO^{1,2}, FRANCESCO FOGLIA^{1,2}, ENRICA SERRETIELLO^{1,2}, FRANCESCA BORRELLI^{1,2}, ROSADEA ZIMBARDI^{1,2}, RAFFAELE VISCARDI^{1,2}, DANIELA FONTANELLA^{1,2}, CONCETTA BENTIVOGLIO¹, MONTELLA FORTUNATO¹, VALERIA CRUDELE¹, EMILIANA FINAMORE¹, MASSIMILIANO GALDIERO^{1,2}

¹Microbiology and Virology Unit, University Hospital of Campania "Luigi Vanvitelli", Naples, Italy

²Department of Experimental Medicine, section of Microbiology and Clinical Microbiological, University of Campania "Luigi Vanvitelli", Naples, Italy

Introduction: Cryptococcosis is an opportunistic fungal disease, caused by *Cryptococcus grubii*, *Cryptococcus neoformans* (*C. neoformans*), and *Cryptococcus gattii*. These species mainly lead to lung infections and central nervous system infections, such as meningoencephalitis and cranial neuropathies. Other types of infections include skin, prostate, eyes, bone marrow and joints. Infection occurs more easily in patients with immunosuppression or with other infections. A very high mortality rate was reported for cryptococcal meningitis ranging from 27% to nearly 50%. We describe one case of meningoencephalitis from *Cryptococcus neoformans* that occurred in an apparently immunocompetent patient.

Materials and Methods: A 38-year-old Ukrainian woman was reported to be in excellent health up to 2 weeks before hospitalization, when she developed fever and confusion. After 48 hours, progressed to visual hallucinations along with urinary incontinence. The differential diagnosis included pulmonary tuberculosis, bacterial or fungal pneumonia, and lung cancer. The patient was subsequently diagnosed with disseminated *C. neoformans*, which remains very rare.

Results: A diagnosis of bacterial meningitis was made, and ceftriaxone and corticosteroids were given to reduce inflammation and edema of the brain and cranial nerves. Two days later, due to lack of clinical improvement, an aliquot of the cerebrospinal fluid (CSF) was tested, and it was found that she had a cryptococcal antigen titre of 1: 320. Within 72 hours of culture, the laboratory notified doctors that *C. neoformans* was isolated from CSF. Using mass spectrometry (MALDI-TOF MS), the isolate was identified as subspecies *C. neoformans*. Therapy was changed to amphotericin B and her mental status improved significantly over the next 1 week and her cerebrospinal fluid culture had a decreased CSF cryptococcal antigen titre to 1: 160.

Discussion and Conclusions: *C. neoformans* have a complex polysaccharide capsule with antiphagocytic properties. Low concentrations of anticryptococcal antibodies are normally found in immunocompetent people due to daily exposure. Although exposure is almost omnipresent in some regions of the world, this organism rarely causes clinically important infections in immunocompetent hosts. Conversely, it has become a notable opportunistic infection in those possessing a compromised cell-mediated immune response. Our case highlights the importance of collecting an accurate travel history in all patients, as the differential diagnosis should include atypical pathogens that may be endemic to the travel area. It also highlights the significant morbidity associated with cryptococcosis and drug-related toxicities and methods of preventing complications.

126 - Comparison of Loop Mediated Amplification (LAMP) and quantitative Real Time PCR (qRT-PCR) methods for the routine detection of *Pneumocystis jirovecii*.

Neill Adams ⁽¹⁾ - Nadia Marascio ⁽¹⁾ - Aida Giancotti ⁽¹⁾ - Marta Pantanella ⁽¹⁾ - Giuseppe De Angelis ⁽¹⁾ - Mariangela Cassadonte ⁽¹⁾ - Michele Manno ⁽¹⁾ - Grazia Pavia ⁽¹⁾ - Francesca Divenuto ⁽¹⁾ - Angela Quirino ⁽¹⁾ - Giovanni Matera ⁽¹⁾

Università degli Studi Magna Graecia, Dip di Scienza della Salute, U.O.C. Microbiologia, Catanzaro, Italia ⁽¹⁾

Comparison of Loop Mediated Amplification (LAMP) and quantitative Real Time PCR (qRT-PCR) methods for the routine detection of *Pneumocystis jirovecii*.

NEILL J ADAMS¹, NADIA MARASCIO¹, AIDA GIANCOTTI¹, MARTA PANTANELLA¹, GIUSEPPE DE ANGELIS¹, MARIANGELA CASSADONTE¹, MICHELE MANNO¹, GRAZIA PAVIA¹, FRANCESCA DIVENUTO¹, ANGELA QUIRINO¹, GIOVANNI MATERA¹

¹Clinical Microbiology Unit, Department of Health Sciences, “Magna Graecia” University, Catanzaro, Italy

Introduction

Pneumocystis jirovecii is the causative agent of Pneumocystis Pneumonia (PCP) in immunocompromised hosts. HIV positive patients demonstrate higher fungal loads and less severe clinical course than non-HIV patients. *Pneumocystis* is species specific and healthy humans represent an important reservoir. Routine diagnosis requires identification of *Pneumocystis* forms in respiratory samples by microscopy or nucleic acid detection by molecular assays. The measurement of 1,3-beta-D-glucan (BDG), is not specific for *Pneumocystis*, but has a high negative predictive value for PCP. This study aimed to compare traditional microscopy with commercial Loop-mediated isothermal Amplification (LAMP) and quantitative Real Time-PCR (qRT-PCR) methods.

Materials and Methods

Between January 2019 and June 2022, 180 respiratory samples from 132 patients were analyzed by microscopy during routine screening for *Pneumocystis*. Retrospectively, microscopy positive or microscopy negative/BDG positive samples were analyzed using molecular methods. Microscopy was performed by Giemsa staining (RAL 555, RAL Diagnostics) and direct Immunofluorescence, (Mono-fluo *P. jirovecii* IFA test kit, Biorad). BDG was tested using kinetic turbidometry (ALIFAX). LAMP and qRT-PCR were performed with EASYplex® (Amplex Diagnostics GmbH) and Realstar® *Pneumocystis jirovecii* kit 1.0 (Altona Diagnostics GmbH), respectively.

Results

We selected thirty-six patients based on positivity with microscopy (n=9, male 88%, age 32-88, mean 59.6) or microscopy negative but BDG positive (n=27, male 74%, age 19-83, mean 59.9). Utilizing the LAMP method, 4/36 (11.1%) patients were found positive, whilst 7/36 (19.4%) were positive with qRT-PCR, with fungal loads varying from 1 to 1.24 x 10⁶ copies/ml. All LAMP positive results were confirmed by qRT-PCR. In 4/9 (44%) microscopy positive patients, results were not confirmed by either molecular method. In 4 patients with negative microscopy but positive BDG, LAMP was negative. However, the qRT-PCR was positive, but with low fungal loads (10.2 – 110 copies/ml). In particular, 25/27 microscopy negative/BDG positive patients were co-infected with other fungi (*Candida spp* or *Aspergillus spp*).

Discussion and Conclusion

Microscopy is susceptible to false positive and negative results and may require other confirmatory tests. The Easyplex LAMP assay (limit of detection around 3000 copies/ml) is time-saving, easy to perform and a positive result may be associated with PCP diagnosis. The qRT-PCR is a highly sensitive method, but a positive result requires careful interpretation in parallel with clinical data to separate PCP patients from colonized patients.

130 - INCREASE OF KPC-PRODUCING *KLEBSIELLA PNEUMONIAE* IN A NEONATAL INTENSIVE CARE UNIT: A THREE- YEARS EVALUATION

VALENTINA COSTANZO⁽¹⁾ - FEDERICA OCCHIPINTI⁽¹⁾ - GIUSEPPE PEPE⁽¹⁾ - FABRIZIO PUGLISI⁽¹⁾ - NICOLETTA SEVERINO⁽¹⁾ - CRISTIAN LEMBO⁽¹⁾ - ADRIANA DI MAURO⁽¹⁾

AZIENDA OSPEDALIERA, AZIENDA OSPEDALIERA POLICLINICO-SAN MARCO, CATANIA, Italia⁽¹⁾

INCREASE OF KPC-PRODUCING *KLEBSIELLA PNEUMONIAE* IN A NEONATAL INTENSIVE CARE UNIT: A THREE- YEARS EVALUATION

VALENTINA COSTANZO¹, FEDERICA OCCHIPINTI^{1,2}, GIUSEPPE PEPE^{1,2}, NICOLETTA SEVERINO^{1,2}, FABRIZIO PUGLISI^{1,2}, CRISTIAN LEMBO^{1,2}, ADRIANA DI MAURO^{1,2}

¹ U.O.C. Laboratory Analysis, University Hospital Policlinico-San Marco, Catania, Italy

² Department of Biomedical and biotechnological Sciences, University of Catania, Catania, Italy.

INTRODUCTION: Carbapenem-resistant *Klebsiella pneumoniae* (KPC) infections represent a critical issue worldwide and also a challenge in medicine, due to therapeutic difficulties and high mortality rates. Italy is KPC endemic and a significant KPC increase strains has been reported since 2010. Nowadays, KPC is considered the most common cause of hospital-acquired pneumonia, especially in ICUs, including NICUs. Active surveillance protocols are considered the most effective strategy to prevent invasive infections, especially in the case of patients actively colonized by multidrug-resistant (MDR) Gram-negative. A three-year (2019-2021) statistical evaluation was performed considering NICU from University Hospital Policlinico of Catania.

MATERIALS AND METHODS: We analyzed microbiological data from NICU samples collected between 2019 and 2021, considering potential changes in microbial colonization or infection. Collected samples were related to surveillance controls, performed through oro-pharyngeal, nasal and rectal swabs, and also respiratory and urinary samples. Gram-negatives percentages were compared along the three years, with particular regard to KPC isolates.

RESULTS: Among 2019 isolates, only 6.25% were positive for KPC, while 37.50% showed complete antimicrobial susceptibility and 56.25% produced extended-spectrum beta-lactamases (ESBL). Considering *K. pneumoniae* positive cultures, 2020 revealed a KPC isolation rate of 34.14%. ESBL isolates were equal to 9.70%, while 56.01% were completely susceptible to antibiotics. 2021 KPC isolates hold a percentage of 63.90%. In the same year, 2.8% were ESBL producers, while 33.40% showed completely antimicrobial susceptibility.

DISCUSSION AND CONCLUSION: *K. pneumoniae* can be considered one of the most common aetiological agents of nosocomial infections. Critically ill patients are significantly exposed to its colonization. Among this type of patient, newborns seem to be particularly prone to develop invasive infections, due to a possible preterm birth and an incomplete structuring of the immunological system. According to our data, KPC percentages progressively increased from 2019 to 2020, with a significantly high spread during 2021. These results highlight the importance to intensify sanitizing and surveillance protocols in intensive care units, with particular regard to NICUs. Protocols should implement hygiene education programs and eventual patient isolation, due to reduce bacterial transmission and diffusion.

131 - Human infection by *Trichostrongylus* spp. in an immigrant patient living in an asylum seekers center in Southern Italy

Marianna Marangi⁽¹⁾ - Fabio Arena⁽¹⁾ - Maurizio Margaglione⁽¹⁾ - Rossella De Nittis⁽²⁾

Università di Foggia, Dipartimento di Medicina Clinica e Sperimentale, Foggia, Italia⁽¹⁾ - Azienda Ospedaliero-Universitaria "Policlinico Riuniti", Foggia, SSVD Microbiologia e Virologia, Foggia, Italia⁽²⁾

Human infection by *Trichostrongylus* spp. in an immigrant patient living in an asylum seekers center in Southern Italy

MARIANNA MARANGI¹, FABIO ARENA¹, MAURIZIO MARGAGLIONE¹, ROSSELLA DE NITTIS²

¹Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy; ²Microbiology and Virology Unit, Ospedali Riuniti, Foggia, Italy

Introduction: Nematodes of the genus *Trichostrongylus* are ubiquitous parasites found in the digestive tract or respiratory system of several animals (widely spread among the herbivores), with a global distribution. Sheep and goats are important reservoirs of these parasites, but chickens also can be infected. The life cycle takes place when eggs are passed in the feces of infected animals. Subsequently, first-stage larvae (L1) hatch from mature eggs and develop into the second stage (L2) and then into the third stage (L3) infective larvae. The transmission of the parasite to humans is often related to the ingestion of water or unwashed vegetables contaminated with infective larvae. Although the prevalence of infections is low and usually asymptomatic, in the most severe cases, the hematophagism of the infective larvae can cause inflammation of the bowel mucosa and tissue damage with clinical symptoms as cramping, abdominal pain, flatulence, nausea and diarrhea.

Materials and Methods: From February 2022, n. 50 patients coming from different region of Sub-Saharan Africa and temporarily hospitalized in an asylum seekers center (Borgo Mezzanone, Foggia, Apulia Region) were screened for the presence of gastrointestinal parasites. From each individual, a fecal sample was collected and subjected to microscopic investigation by using the Mini-FLOTAC® technique. Data referencing age, gender, nationality, physical complaints and other microbiological analysis were collected from enrolled patient laboratory records.

Results: Out of 50 fecal samples subjected to coprological screening, n. 1 (1/50, 2%) was positive to gastrointestinal parasites and eggs of *Trichostrongylus* were detected by microscopic examination. No other eggs/cysts/oocysts related to other parasites were found in the sample. The infected patient was a man of 21 years old coming from Burkina Faso.

Discussion and Conclusions: This is the first report of a case of *Trichostrongylus* infection in an immigrant patient coming from Africa and temporarily living in Italy. Incidence and prevalence of *Trichostrongylus* spp. infections change significantly depending on population and geographical region studied, with rates of prevalence higher in rural areas. The direct contact with animals, the water reservoirs for human consumption contaminated with feces of ruminants, rodents or even humans, water used for irrigation contaminated with infective larvae and the poor socioeconomic conditions and hygiene may represent risk factors for the infection. The source of *Trichostrongylus* infection in this patient is uncertain. Further studies on the *Trichostrongylus* spp. prevalence in human hosts should be carried out in order to adopt specific measures to control widespread parasitic infections.

136 - Bacteria from the vaginal microbiota cause suppurative hysteritis/pelvic inflammation in mice treated with estrogens

Elisa Lazzeri ⁽¹⁾ - Elena Pettini ⁽¹⁾ - Lorenzo Leoncini ⁽¹⁾ - Francesco Iannelli ⁽¹⁾ - Gianni Pozzi ⁽¹⁾

Università degli Studi di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia ⁽¹⁾

Bacteria from the vaginal microbiota cause suppurative hysteritis/pelvic inflammation in mice treated with estrogens

LAZZERI E.¹, PETTINI E.¹, LEONCINI L.¹, IANNELLI F.¹, POZZI G.¹

1 Department of Medical Biotechnologies, Laboratory of Molecular Microbiology and Biotechnology (LA.M.M.B.), University of Siena, Siena, Italy

Introduction: The health status of the female genital tract is largely related to the presence of a normal vaginal microbiota. It is known that estrogens influence the vaginal environment, affecting the quality and quantity of resident microorganisms. The vaginal microbiota is indeed modified by hormonal and physiological changes that occur during the menstrual cycle, pregnancy and in menopause, leading to microbial ‘dysbiosis’, including bacterial vaginosis and aerobic vaginitis. In both diseased the normal vaginal microbiota shifts to a population dominated by enterobacteria, staphylococci, streptococci, enterococci or anaerobic microorganisms. In the present work we report the setup of a mouse model of genital tract infection by bacteria of the indigenous microbiota following estrogen treatment.

Materials and Methods: C57BL/6 mice were subcutaneously treated with 100 µg of 17-*beta*-estradiol and the changes in the normal vaginal flora were characterized 7, 14, 21 and 28 days following hormone treatment by standard microbiological and molecular techniques. The establishment of the upper genital tract infection was confirmed by cultural analysis of suppurative material collected in the uterus and by histological examination of samples collected at the sacrifice.

Results: In this study, a pelvic inflammation was observed in mice after estrogen treatment, with bacteria such as *Staphylococcus aureus*, *Proteus mirabilis*, *Klebsiella aerogenes* and *Enterococcus faecalis* isolated in vaginal swabs and from the suppurative material collected in the uterus of the same mice. The genital tract infection caused by indigenous microbiota was confirmed by histological examination that showed the uterine cavity completely filled with suppurative material (pyometra).

Discussion and Conclusions: This murine model of infection is an optimal tool in the study the complexity of the genital tract infections, to discover biomarkers of health/inflammation and furthermore to evaluate new antimicrobial agents aimed at guaranteeing the well-being of women and reducing the risks associated with any obstetric complications.

138 - Antibiofilm activity of Ciprofloxacin-loaded niosomes.

Linda Maurizi⁽¹⁾ - Maria Grazia Ammendolia⁽²⁾ - Jacopo Forte⁽³⁾ - Maria Gioia Fabiano⁽³⁾ - Carlo Zagaglia⁽¹⁾ - Maria Pia Conte⁽¹⁾ - Antonietta Lucia Conte⁽¹⁾ - Catia Longhi⁽¹⁾

"Sapienza" Università di Roma, Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia⁽¹⁾ - Istituto Superiore di Sanità, Centro Nazionale Tecnologie Innovative in Sanità Pubblica, Roma, Italia⁽²⁾ - "Sapienza" Università di Roma, Dipartimento di Chimica e Tecnologie del Farmaco, Roma, Italia⁽³⁾

Antibiofilm activity of Ciprofloxacin-loaded niosomes

LINDA MAURIZI¹, MARIA G. AMMENDOLIA², JACOPO FORTE³, MARIA G. FABIANO³, CARLO ZAGAGLIA¹, MARIA P. CONTE¹, ANTONIETTA L. CONTE,¹ CATIA LONGHI¹.

¹Department of Public Health and Infectious Diseases, Microbiology Section, "Sapienza" University of Rome, Rome, Italy; ²National Center of Innovative Technologies in Public Health, Italian National Institute of Health, Rome, Italy; ³Department of Drug Chemistry and Technologies, "Sapienza" University of Rome, Rome, Italy.

Introduction. Antimicrobial resistance is one of the main problems of Public Health with important clinical and economic implications. A phenomenon that leads to an increase in antibiotic resistance is linked to the ability of bacteria to form biofilm, a microbial community immersed in an exopolysaccharide matrix in which bacterial cells are protected from the action of the immune system, disinfectants, and antibiotics. Ciprofloxacin (CIP), that belongs to the class of fluoroquinolones, has been used extensively against various bacterial infections; however, an increasing proportion of clinical isolates have proven resistant. To improve the bioavailability and the effectiveness of antibiotics, even against bacterial strains producing biofilm, the use of nanotechnology could play a fundamental role. CIP transport studies with nanocarriers have shown reduce side effects, increase stability, release control and decrease antibiotic resistance. In this work, the activity of niosome preparations, loaded with CIP, were tested against Gram-positive and Gram-negative bacterial strains.

Materials and Methods. A deep physical-chemical characterization in term of stability over time/biological media and drug entrapment efficiency was carried out on niosome preparations. Minimum Inhibitory Concentration and Minimum Bactericidal Concentration of these sample was estimated by the broth micro-dilution method against Gram-negative and Gram-positive strains. To measure the biofilm inhibition induced by CIP-loaded niosomes, the growth medium was supplemented with sub-MIC concentrations of nanocarriers. To evaluate the uptake of niosome formulations into epithelial cultured cells, CIP and Nile Red were loaded inside the nanocarriers. The cytotoxicity was determined on cells monolayers by MTT assay.

Results. All the samples presented nanometric dimensions and a good stability profile. The CIP-loaded niosomes exhibited an antibacterial activity against all tested strains, in a dose dependent manner, but lower respect to free CIP. Furthermore, when delivered in niosomes, CIP showed a greater ability to inhibit biofilm formation against strong biofilm producer strains, compared to free CIP. The internalization of niosomes occurred in cells monolayers already after 7 hs of contact. The cytotoxic effect of these preparations was detectable only at the highest concentrations.

Discussion and Conclusions. It has been reported that niosomal vesicles, due to their cationicity, interact electrostatically with the negatively charged biofilms; the drug can be released into the biofilm structure. Our preliminary results confirmed that the delivery of CIP by nanocarriers may be very promising to inhibit biofilm formation by both Gram positive and Gram negative bacteria.

144 - Cryptococcal Meningitis

ALESSIA FILOSA ⁽¹⁾ - DE ROSA PAOLA ⁽¹⁾ - IMMACOLATA ABAGNALE ⁽¹⁾ - ANTONIO PACIOLLA ⁽¹⁾ - ITALO GRIMALDI ⁽¹⁾ - FRANCESCA FEROCE ⁽¹⁾ - ENRICO PUNZO ⁽¹⁾

ASL NAPOLI 3 SUD, U.O.C Patologia clinica OO.RR. Area Stabiese, CASTELLAMMARE DI STABIA, Italia
(1)

Cryptococcal Meningitis

ALESSIA FILOSA¹, PAOLA DE ROSA¹, IMMACOLATA ABAGNALE¹, FRANCESCA FEROCE¹, ANTONIO PACIOLLA¹, ENRICO PUNZO¹, ITALO GRIMALDI¹

¹ U.O.C. Patologia Clinica O.O. R.R. Area Stabiese, Castellammare di Stabia, Italia

Introduction: Cryptococcosis is an opportunistic infection, caused by *Cryptococcus spp.*, that lives in the environment throughout the world. Even though the infection is usually HIV-related, most of the non-HIV-related cases include patients under immunosuppressive treatments or with organic failure syndromes. The organism is acquired by inhalation. While all organs can be involved, *Cryptococcus spp.* have a strong affinity for the central nervous system. Cryptococcal meningitis usually presents as a subacute meningoencephalitis.

Materials and Methods: The company operating procedures provide for the execution of at least 2 portions of CSF, each of at least 1ml. The first rate is used for the physical and chemical examination. The second rate is used for microbiological tests: crops before and after enrichment are sown on selective, enriched and differential medium. Gram staining slide is set up and syndromic panel for meningitis/encephalitis in nested multiplex PCR is started for the rapid identification of the most common etiological agents. The volume of CFS used in each reaction is 200 µL and the run time is about 1 h.

Results: 40-year-old cancer patient, myasthenics following thymoma, immunosuppressive therapy, comes to the E.R. in 13.07.2022 with neurological symptoms such as a headache, altered mental status, lethargy. Neurological consultation is required. Blood chemistry tests are normal. The chemical-physical examination of CSF is suggestive for meningitis: opalescent appearance, hypoglycorrhachia (7 mg/dl), hyperprotidorrhachia (192 mg/dl) and elevated cell count (>50 cell/mm³, mainly PMNs). At Gram staining slide are visible capsulated sporulating yeasts. Syndromic panel in PCR is positive for *Cryptococcus neoformans/gattii*. From the cultural examination on Sabouraud Dextrose Agar, incubated at 37°C for 24-48 h, the colonies are creamy, glossy, roundish, white. The microorganism, identified by automatic system as *C. neoformans*, was found to be sensitive to amphotericin B, fluconazole, itraconazole, and voriconazole, resistant to caspofungin, tested using microdilution in broth.

Discussion and Conclusions: In non-immunocompromised people, spontaneous healing occurs in about a week, while in immunocompromised patients Cryptococcal meningitis is a serious disorder with high mortality and thus best managed by an interprofessional team that includes a emergency doctor, microbiologist, disease specialist, neurologist and a pharmacist. Early diagnosis has enabled timely intervention with targeted therapy. The patient is treated in combination therapy with antifungal agents (amphotericin B + fluconazole). The patient was subsequently transferred to a centre specialised in infectious diseases.

147 - Effect of Vitamin C on dormant states of *Helicobacter pylori*

Paola Di Fermo ⁽¹⁾ - Silvia Di Lodovico ⁽¹⁾ - Emanuela Di Campi ⁽¹⁾ - Sara D'Arcangelo ⁽¹⁾ - Luigina Cellini ⁽¹⁾ - [Mara Di Giulio](#) ⁽¹⁾

Università "G.d'Annunzio" Chieti-Pescara, Dipartimento di Farmacia, Chieti, Italia ⁽¹⁾

Effect of Vitamin C on dormant states of *Helicobacter pylori*

PAOLA DI FERMO, SILVIA DI LODOVICO, EMANUELA DI CAMPLI, SARA D'ARCANGELO, LUIGINA CELLINI, MARA DI GIULIO

¹Department of Pharmacy, University of "G. d'Annunzio" Chieti-Pescara, Chieti, Italy

Introduction. *Helicobacter pylori* shows capability to colonize human gastric mucosa, producing biofilm and entering in dormant state that permit a long self-preservation, overcoming stressful conditions such as antibiotic administration. Recently, Vitamin C (VitC) has showed the capability to reactivate dormant bacteria by stimulation of cell respiration and, in *H. pylori*, the combination of VitC with antibiotic seems to interfere the eradication rate. The first aim of this work was to evaluate, in *H. pylori*, the progression of physiological changes from active state to Viable But Non-Cultivable (VBNC) and Persister (AP) states, establishing times and conditions to enter dormant state. Finally, Vit C ability to interfere with dormancy generation and to resuscitate dormant *H. pylori* were investigated.

Materials and Methods. The clinical MDR *H. pylori* 10A/13 coming from our lab collection was used in this study (ID Number RICH9RTLH). The antibacterial effect (MIC/MBC) of VitC was evaluated and the dormant states of *H. pylori* were induced by: nutrient starvation (for VBNC generation) incubating in: i) unenriched medium (BB without 2%FCS); (ii) sterile saline solution (SS-0.9%NaCl) and (for AP generation) antibiotic treatment at high concentration 10xMIC amoxicillin (AMX). The samples were monitored after 24-48-72h, 8 and 14 days by OD₆₀₀, CFUs determination, LIVE/DEAD staining under fluorescent microscopy and MTT viability test. In order to determine the VitC ability to interfere with the VBNC and AP generation, ¼ MIC of VitC was added to *H. pylori* suspension before the generation time (t= 0) or after dormant states generation and monitored after 24, 48, 72h.

Results. In *H. pylori*, the most suitable conditions to induce the VBNC state were in SS for 8 days and for the AP state at 10xMIC AMX for 48h, with a morphological transition from bacillary to viable coccoid form. VitC was able to affect the entry in VBNC state reducing the viable coccoid formation also associated to death of bacillary forms. In AP cells, VitC delayed the entry with a decrease of viable coccal cells and more bacillary and U-shaped bacteria. On induced dormant states, VitC acted in a different way: on VBNC state, it was capable to induce resuscitation (60% more than the control); whereas on AP state, VitC did not resuscitate dormant bacteria but it acted reducing the large aggregates typical of AP state.

Discussion and Conclusions. *H. pylori* shows wide dynamic physiological states which are significantly modified in presence of VitC. VitC acts reducing the entry in dormant states enhancing the resuscitation rate. The pretreatment with VitC in the *H. pylori* therapeutical schemes could favour the selection of microbial vegetative forms more susceptible to treatments.

This work was funded by Research Grant PRIN 2017 SFBFER (Prof. S. Stefani) MIUR, Italy.

148 - Mechanisms involved in the reversal of antimicrobial resistance in *Acinetobacter baumannii* by albumin nanoparticles

SARA SCUTERA⁽¹⁾ - ROSARIA SPARTI⁽¹⁾ - FRANCESCA MENOTTI⁽¹⁾ - MONICA ARGENZIANO⁽²⁾ - STEFANIA RAIMONDO⁽³⁾ - ILARIO FERROCINO⁽⁴⁾ - GABRIELE BIANCO⁽⁵⁾ - ROBERTA CAVALLI⁽²⁾ - TIZIANA MUSSO⁽¹⁾

UNIVERSITA' DI TORINO, DIPARTIMENTO DI SCIENZE DELLA SANITA' PUBBLICA E PEDIATRICHE, TORINO, Italia⁽¹⁾ - UNIVERSITA' DI TORINO, DIPARTIMENTO DI SCIENZA E TECNOLOGIA DEL FARMACO, TORINO, Italia⁽²⁾ - UNIVERSITA' DI TORINO, DIPARTIMENTO DI SCIENZE CLINICHE E BIOLOGICHE, TORINO, Italia⁽³⁾ - UNIVERSITA' DI TORINO, Dipartimento di Scienze Agrarie, Forestali e Alimentari, GRUGLIASCO (TO), Italia⁽⁴⁾ - AUO CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO, UNITA' DI MICROBIOLOGIA E VIROLOGIA, TORINO, Italia⁽⁵⁾

Mechanisms involved in the reversal of antimicrobial resistance in *Acinetobacter baumannii* by albumin nanoparticles

SARA SCUTERA¹, ROSARIA SPARTI¹, FRANCESCA MENOTTI¹, MONICA ARGENZIANO², STEFANIA RAIMONDO³, ILARIO FERROCINO⁴, GABRIELE BIANCO⁵, ROBERTA CAVALLI² AND TIZIANA MUSSO¹

¹Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy; ² Department of Drug Science and Technology, University of Turin, Turin, Italy; ³Department of Clinical and Biological Sciences, University of Turin, Turin, Italy; ⁴Department of Agricultural, Forest and Food Sciences, University of Turin, Turin, Italy; ⁵Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy

Introduction Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) are a global problem in healthcare settings. The narrow range of treatments has forced the use of colistin (Col) as last-resort antibiotic, and increasing development of Col resistance has been reported. Nanotechnology is a promising strategy to counteract resistant bacterial infections. We developed a new formulation of human albumin nanoparticles for Col delivery (Col / haNPs), effective on Col-resistant (Col R) bacteria, in particular *Acinetobacter baumannii* (*Ab*). The aim of this study focused on the relationships between Col / haNPs modes of action and bacterial resistance mechanisms. **Materials and methods:** Five clinical MDR-Col R strains of *Ab* sensitive to Col/haNPs were phenotypically characterized for Col resistance mechanisms. *Ab* ATCC 19606 was used as a Col-sensitive (Col S) control. The susceptibility profile for free Col and Col/haNPs was determined using the broth microdilution method according to the breakpoint defined EUCAST. LPS amount was quantified by sensitivity to vancomycin and pattern of growth in the presence/absence of Col by E-test. The *mcr-1*- mediated resistance was identified by a Col prediffusion assay and EDTA incubation (CPD-E test). Phenotypic detection of efflux pump was performed using the efflux inhibitor carbonyl cyanide 3-chlorophenylhydrazone (CCCP) and the EtBr-agar cartwheel assay. For genomic characterization, Whole Genome Sequence analysis (WGS) of Col R strains was performed. To investigate the antibacterial mechanisms of Col/haNPs, we followed the interaction haNPs-*Ab* by TEM imaging and evaluated the release of reactive oxygen species (ROS) (DCFH-DA assay) and outer membrane permeabilization (NPN assay). Efflux studies were performed using EtBr as substrate. **Results:** Col/haNPs exhibited a higher antibacterial activity when compared to free Col. A significant decrease in the MIC values was observed for *Ab* Col R strains (>40 to 2.5/1.25 µg/mL Col vs. Col/haNPs). Phenotypic and genomic characterization of *Ab* Col R strains indicate that all strains were negative for the presence of *mcr-1* gene and were not LPS-deficient. WGS analysis identified in all strains genes related to drug efflux system (AcrAB, Emr, TolC) and lipid A (*lpx*, *pmrAB*, *phoP*), with SNPs implicated in Col R. All strains displayed high frequency of ARGs genes. Accordingly phenotypic tests highlight a role of efflux pump in our Col R strains and indicate that haNPs restore Col sensitivity inhibiting efflux pumps. Moreover, results of TEM analysis indicate localization of the NPs on both bacterial surface but also inside cells, which further leads to cell breakage. Outer membrane permeability assay showed no permeabilization by Col/haNPs while confirmed the effect of free Col. Instead, both free Col and Col/haNPs induce an increase in ROS production. **Discussion and Conclusions:** Col/haNPs combat microbes via multiple mechanisms

that are simultaneously active. NPs can adhere to the surface of bacterial cells to produce ROS and damage the composition and structure of the bacterial cell. Moreover, efflux pumps are indeed inhibited by haNPs. Further studies will be needed to demonstrate the nanoparticle entry mechanism and the possible action of NPs on gene expression and metabolism of bacterial cells.

152 - Complete Genome Sequence of *Lactobacillus crispatus* Type Strain ATCC 33820

Elisa Lazzeri ⁽¹⁾ - Lucia Teodori ⁽¹⁾ - Lorenzo Colombini ⁽¹⁾ - AnnaMaria Cuppone ⁽¹⁾ - David Pinzauti ⁽¹⁾ - Francesco Santoro ⁽¹⁾ - Gianni Pozzi ⁽¹⁾ - Francesco Iannelli ⁽¹⁾

Università degli Studi di Siena, Dipartimento di Biotechnologie Mediche, Siena, Italia ⁽¹⁾

Complete Genome Sequence of *Lactobacillus crispatus* Type Strain ATCC 33820

LAZZERI E¹., TEODORI L¹., COLOMBINI L¹., CUPPONE AM¹., PINZAUTI D.¹, SANTORO F.¹, POZZI G¹., IANNELLI F¹.

¹ Department of Medical Biotechnologies, Laboratory of Molecular Microbiology and Biotechnology (LA.M.M.B.), University of Siena, Siena, Italy; Bacteriology Unit, Siena University Hospital, Siena, Italy

Introduction: *Lactobacillus crispatus* is the most frequently isolated species among the vaginal lactobacilli of the human microbiota of healthy women; its presence is associated with reduced risk of preterm delivery, viral sexually transmitted infections, and bacterial vaginosis. To date (June 2021), only eight *L. crispatus* complete genomes are available in the NCBI database (<https://www.ncbi.nlm.nih.gov/genome/browse#!/prokaryotes/1815/>). Here, we contribute to the genomic characterization of this species by publicly releasing the genome of strain ATCC 33820, the type strain of *Lactobacillus crispatus*.

Materials and Methods: The complete genome sequence of *Lactobacillus crispatus* type strain ATCC 33820 was obtained by combining Nanopore and Illumina sequencing technologies. Nanopore and Illumina sequencing generated 136,000 long reads (630,559,194 bp; N_{50} , 8.7 kb) and 762,936 read pairs (2×250 bp), respectively. Nanopore reads were filtered using Filtlong v0.2.0 with the parameter-target_bases to retain a total of 230 Mbp (<https://github.com/rrwick/Filtlong>) (N_{50} , 19,822 bp) and assembled using Unicycler v0.4.7. The resulting circular contig was polished using Medakav 0.7.1 (<https://github.com/nanoporetech/medaka>) with all Nanopore reads, followed by two polishing rounds with Pilon v1.22 using the Illumina reads. Assembly quality was evaluated using Ideel (<https://github.com/mw55309/ideel>). Annotation was performed with the NCBI Prokaryotic Genome Annotation Pipeline (PGAP) v5.1. Default parameters were used for all software unless otherwise specified.

Results: The genome of *L. crispatus* ATCC 33820 consists of a single circular chromosome (2,239,089 bp) with an overall GC content of 37.0%. The assembly contains 2,194 open reading frames, 78.8% with putative biological function, 64 tRNA genes, 3 rRNA operons, and 3 structural RNAs.

Discussion and Conclusions: The characterization of genomes is of fundamental importance for the taxonomy and in the context of comparative genomics. A complete genome represents a finished product in which the order and accuracy of each base has been verified, constituting an important resource for the understanding of biochemical diversity, virulence and pathogenetic and evolutionary mechanisms of microorganisms

156 - Antimicrobial and antivirulence effects of Hop extract against multi-drug resistant Staphylococci strains and Cutibacterium acnes

Silvia Di Lodovico⁽¹⁾ - Simonetta D'Ercole⁽²⁾ - Firas Diban⁽¹⁾ - Sara D'Arcangelo⁽¹⁾ - Emanuela Di Campli⁽¹⁾ - Lucinda Bessa⁽³⁾ - Luigina Cellini⁽¹⁾ - Mara Di Giulio⁽¹⁾

University "G. d'Annunzio" Chieti-Pescara, Department of Pharmacy, Chieti, Italia⁽¹⁾ - University "G. d'Annunzio" Chieti-Pescara, Department of Medical, Oral and Biotechnological Sciences, Chieti, Italia⁽²⁾ - Centro de Investigação Interdisciplinar Egas Moniz, IUEM/CiiEM, Almada, Portugal⁽³⁾

Antimicrobial and antivirulence effects of Hop extract against multi-drug resistant Staphylococci strains and Cutibacterium acnes

*SILVIA DI LODOVICO*¹, *SIMONETTA D'ERCOLE*², *FIRAS DIBAN*¹, *SARA D'ARCANGELO*¹, *EMANUELA DI CAMPLI*¹, *LUCINDA J. BESSA*³, *LUIGINA CELLINI*¹, *MARA DI GIULIO*¹

¹Department of Pharmacy, University "G. d'Annunzio" Chieti-Pescara, 66100, Chieti, Italy. ²Department of Medical, Oral and Biotechnological Sciences, University of "G. d'Annunzio" Chieti-Pescara, 66100, Chieti, Italy. ³Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Portugal.

Abstract

Introduction: The increase of multi-drug resistant (MDR) and tolerant bacteria represents a global challenge that strongly underlines the need to search non-antibiotic strategies. In particular, significant is the number of MDR Gram-positive microorganisms coming from skin infections with a high percentage of methicillin-resistant *Staphylococcus aureus* (MRSA) and MDR *S. epidermidis*. These bacteria are also often found with *Cutibacterium acnes* in different skin diseases. The worrying resistance/tolerance phenomenon has raised the attention on the antimicrobial and antivirulence effects of plant extract such as Hop extract. The aim of this work was to evaluate the antimicrobial and antivirulence effects of the hydroalcoholic Hop extract of *Humulus lupulus* L. variety *cascade*, grown in Abruzzo region (Italy), against *S. aureus* and *S. epidermidis* MDR strains, and against *C. acnes*. **Materials and methods:** The Hop extract was phytochemical characterized by reversed phase HPLC-fluorimetric method and its biocompatibility and cytotoxicity were studied by using *Artemia salina* L. and two cell lines through MTT assay. Docking analysis was used to identify the mechanism of action. The antimicrobial effect was studied by the detection of inhibition zones and MICs against six clinical strains (four MRSA and two MDR *S. epidermidis* strains) and *S. aureus* ATCC 29213, *S. epidermidis* ATCC 12228, *C. acnes* ATCC 11827. The antivirulence action was determined by: membrane fluidity change by Laurdan Generalized Polarization (GPexc); anti-biofilm activity by biomass quantification and cell viability. **Results:** The main components of Hop extract, biocompatible and non-cytotoxic at all tested concentrations, were: gallic acid, resveratrol and rutin. The docking analysis showed high affinity of rutin against PBP2a and KAS III with Ki values in the submicromolar range. The tested Hop extract displayed good antimicrobial action with remarkable inhibition zones with all tested strains and MIC values ranging from 1 to 16 µg/ml with a not significant action in membrane fluidity. The extract also showed a remarkable anti-biofilm effect with percentages of reduction up to 99.34%±0.26 at MIC value. The Live/Dead images showed a relevant inhibition effect in the biofilm formation with a weak killing action. **Discussion and Conclusions:** Hop extract exhibited an interesting antibacterial and antivirulence action against the tested MDR strains suggesting it's a possible role in the prevention of infection caused by MDR Gram-positive pathogens.

159 - The administration of *Enterococcus faecium* SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice

Adelaide Panattoni ⁽¹⁾ - Marco Calvigioni ⁽¹⁾ - Laura Benvenuti ⁽²⁾ - Vanessa D'Antongiovanni ⁽²⁾ - Carolina Pellegrini ⁽²⁾ - Clelia Di Salvo ⁽²⁾ - Diletta Mazzantini ⁽¹⁾ - Francesco Celandroni ⁽¹⁾ - Matteo Fornai ⁽²⁾ - Luca Antonioli ⁽²⁾ - Emilia Ghelardi ⁽¹⁾

Università di Pisa, Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Pisa, Italia ⁽¹⁾ - Università di Pisa, Dipartimento di Medicina Clinica e Sperimentale, Pisa, Italia ⁽²⁾

The administration of *Enterococcus faecium* SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice

ADELAIDE PANATTONI^a, MARCO CALVIGIONI^a, LAURA BENVENUTI^b, VANESSA D'ANTONGIOVANNI^b, CAROLINA PELLEGRINI^b, CLELIA DI SALVO^b, DILETTA MAZZANTINI^a, FRANCESCO CELANDRONI^a, MATTEO FORNAI^b, LUCA ANTONIOLI^b, EMILIA GHELARDI^a

^a Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy

^b Department of Clinical and Experimental Medicine, University of Pisa, Italy

Introduction. Microorganisms with probiotic properties are eliciting an increasing interest as adjuvants in the prevention and treatment of obesity through modulation of the gut microbiota. In this study, a probiotic formulation based on *Enterococcus faecium* SF68 was administered to mice fed with a high-fat diet (HFD) to evaluate its efficacy in reducing body mass gain and in modulating the intestinal bacterial composition.

Materials and methods. Both stool and ileal samples were collected from untreated and SF68-administered HFD-fed mice. Bacterial genomic DNAs were extracted from samples and absolute abundances of specific *taxa* constituting the gut microbial *consortium* evaluated through 16S rDNA-targeting Real-Time qPCRs.

Results. SF68 administration significantly reduced the HFD-induced weight gain. In these animals, the microbial gut composition shifted towards an enrichment in microbes positively correlated with mucus thickness, lower inflammation, lower glycemia levels, and SCFA production (*i.e.*, *Bifidobacterium*, *Akkermansia*, *Faecalibacterium*), as well as a depletion in bacterial phyla having a key role in obesity (*i.e.*, *Firmicutes*, *Proteobacteria*).

Discussion and conclusion. Our results demonstrate the efficacy of *E. faecium* SF68 in adjusting the composition of the dysbiotic microbiota of HFD-fed animals, thus ameliorating clinical conditions and exerting anti-obesity effects.

161 - *Klebsiella pneumoniae* ST37: a never-ending story

Riccardo Polani⁽¹⁾

Università di Roma, "La Sapienza", Policlinico Umberto I, Università di Roma, "La Sapienza", Roma, Italia⁽¹⁾

Klebsiella pneumoniae ST37: a never-ending story

Riccardo Polani¹, Francesco Bruno¹, Valerio Capitani¹, Gabriele Arcari¹, Federico Cecilia¹, Gaia Menichincheri¹, Federica Sacco^{1,2}, Giammarco Raponi³, Alessandra, Carattoli¹

¹Dept. Molecular Medicine, Sapienza University of Rome, Rome, Italy

²Complex Operating Unit of Microbiology and Virology, Policlinico Umberto I, Rome, Italy

³Dept. of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

Introduction: The first reports of carbapenem resistant Enterobacterales in the Policlinico Umberto I (PUI) hospital date back to 2006. In that period, few *K. pneumoniae* ertapenem-resistant and meropenem-susceptible strains were identified and assigned to sequence type (ST) 37. These produced CTX-M-15, *OmpK35* was depleted due to a nonsense mutation, and a novel *OmpK36* variant was identified. From 2010, KPC-producing ST512 isolates started prevailing and ST37 apparently vanished from PUI. Since 2018 the clinical use of ceftazidime-avibactam (CZA) has been implemented for the treatment of bacteria producing serine- beta-lactamases.

Yet KPC-producing, CZA resistant *K. pneumoniae* are emerging. We report about an outbreak caused by four CZA-resistant and KPC-producing ST37 *K. pneumoniae*.

Materials and methods: Seven *K. pneumoniae* ST37 isolates (three sampled in 2011 and four in 2021) were subjected to Whole Genome Sequencing (Illumina and Oxford Nanopore Technologies) and to genomic analyses. Furthermore, *bla*_{KPC} gene cloning in *Escherichia coli* and transformation of the *bla*_{KPC} carrying pKpQIL plasmid were performed to assess the role of KPC variants in the CZA-resistant phenotype.

Results: The seven ST37 strains were highly related, clustering together in a SNP-based phylogenetic tree. Contemporary and historical isolates shared the same outer antigens (O3b and KL38), and only few major genomic differences were detected in the chromosome (two different prophages and the ICEKp mediated acquisition of the virulence locus *ybt* in the current isolates). Contemporary ST37 isolates acquired *bla*_{KPC} on identical pKpQIL plasmids, distinguishable only for the *bla*_{KPC} gene. Specifically, 3 variants of the KPC enzyme have been identified: KPC-31 in isolates 1016 and 1021, KPC-70 in isolate 1015 and a novel KPC variant, KPC-110, in isolate 1020. The KPC variants showed a D179Y mutation in the omega loop compared to KPC-3, coupled with a T268A substitution in KPC-70 and a R43G substitution in KPC-110. In *E. coli* KPC-70 and KPC-110 displayed higher MICs for CZA than KPC-31, yet all these variants did not confer resistance to carbapenems

Discussion and Conclusions: The analysis of the evolution of CZA resistance in the once-dominant clone ST37 demonstrates that this clone is very flexible, proposing 3 different KPC variants in four isolates. Contemporary and historical ST37 isolates were highly related, hinting that ST37 survived unnoticed in our hospital for 10 years, waiting for the selection of mutant *bla*_{KPC} to re-emerge as a CZA-resistant *K. pneumoniae* clone. The genomic dissection of this clone highlighted its evolutionary pathways (the acquisition of the pKpQIL plasmid and of the *ybt* locus) and its development (with the KPC-70 and KPC-110 variants) to high CZA MICs.

166 - Antibacterial efficacy of glycine airflow and hyaluronic acid-vehicled antibiotic mixture on contaminated titanium surfaces of dental osseointegrated implants

Janira Roana⁽¹⁾ - Lorenza Cavallo⁽¹⁾ - Mario Alovise⁽²⁾ - Massimo Carossa⁽²⁾ - Enrico Pira⁽¹⁾ - Maria Grazia Putzu⁽³⁾ - Davide Bosio⁽³⁾ - Ilaria Roato⁽²⁾ - Federico Mussano⁽²⁾ - Nicola Scotti⁽²⁾ - Narcisa Mandras⁽¹⁾

Università degli Studi di Torino, Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Torino, Italia⁽¹⁾ - Università degli Studi di Torino, Dipartimento di Scienze Chirurgiche-CIR Dental School, Torino, Italia⁽²⁾ - Unità di Medicina Occupazionale, A.O.U. Città della Salute e della Scienza, Torino, Italia⁽³⁾

Antibacterial efficacy of glycine airflow and hyaluronic acid-vehicled antibiotic mixture on contaminated titanium surfaces of dental osseointegrated implants

JANIRA ROANA¹, LORENZA CAVALLO¹, MARIO ALOVISI², MASSIMO CAROSSA², ENRICO PIRA³¹, MARIA GRAZIA PUTZU³, DAVIDE BOSIO³, ILARIA ROATO², FEDERICO MUSSANO², NICOLA SCOTTI², NARCISA MANDRAS¹

¹ Department of Public Health and Pediatrics, University of Turin, Turin, Italy;

² Department of Surgical Sciences, CIR Dental School, University of Turin, Turin, Italy;

³ Occupational Medicine Unit, University Hospital A.O.U Città della Salute e della Scienza di Torino, Turin, Italy.

Introduction. Dental implants are exposed to numerous oral bacteria, which can colonize the titanium (Ti) surface leading to peri-implantitis: a chronic inflammatory process therefore, due to a polymicrobial infection that involves the soft and hard tissues around the osseointegrated implants. The inflammatory process leads to the formation of a peri-implant pocket with bone loss. Therefore, complications of biofilm formation are prolific in implantology, accounting for a quarter of all infections each year. The decontamination of the implant surface and the consequently resolution of the inflammation represent the main goal that has to be achieved in the treatment of peri-implantitis. Different methods have been reported to minimize or even completely remove biofilms from contaminated surfaces. Implantoplasty remains a preferred way to remove infected contaminants and the surface quality of the implant after decontamination is considered an important predictor of future outcome. Despite some positive effects, a complete resolution of the pathology is not usually achieved. The treatment of peri-implantitis is still a challenge and a final therapy remains a matter of discussion. The purpose of this *in vitro* study was to compare the effect of different decontamination protocols on the disinfection of treated acid (MAC) and etched acid (SLA) Ti disks contaminated and assess the biocompatibility of MAC/SLA disks with adhesion and grow of Adipose derived Mesenchymal Stem cells (ASCs). **Materials and Methods.** Samples were infected with a polymicrobial biofilm to simulate *in vitro* a peri-implantitis. 17 MAC and 20 SLA Ti disks were randomly assigned to three different decontamination protocols: Glycine powder air-flow (GYPAP), a local delivered triple paste antibiotic composed by ciprofloxacin, metronidazole and clarithromycin (3MIX) and a combination of GYPAP + 3MIX. Biocompatibility of the Ti disks after each protocols was assessed by measurement of adhesion and grow of ASCs after 24 and 72 h. Confocal laser scanning microscope (CLSM) was used to evaluate the antibacterial effectiveness of treatment regimens. Ti disks were analyzed with Scanning electron microscopy (SEM) to visualize the presence of biofilm on the surface after 3 different decontamination treatments. **Results.** The best viability data were achieved by the 3MIX and GYPAP combination on the SLA surfaces after 72 h. CLSM analysis showed a mean ratio of dead bacteria statistically higher in 3MIX+GYPAP group compared with GYPAP and 3MIX subgroups. In SEM images 3MIX+GYPAP disinfection protocol appeared more efficient in removing bacteria. **Discussion and Conclusions.** Data showed that the combination of GYPAP and 3MIX should may be preferred to the other protocols, especially in presence of SLA titanium surface.

172 - Comparative evaluation of antimicrobial, antiamebic, and antiviral efficacy of ophthalmic formulations

Martina Pannetta⁽¹⁾ - Daniela Eletto⁽¹⁾ - Ciro Caruso⁽²⁾ - Alessandra Tosco⁽¹⁾ - Amalia Porta⁽¹⁾

Università degli studi di Salerno, Dipartimento di Farmacia, Fisciano, Italia⁽¹⁾ - Ospedale, Ospedale "Pellegrini", Napoli, Italia⁽²⁾

Comparative evaluation of antimicrobial, antiamebic, and antiviral efficacy of ophthalmic formulations

Martina Pannetta^{1,2}, Daniela Eletto¹, Ciro Caruso³, Alessandra Tosco¹, Amalia Porta¹

¹ Department of Pharmacy, University of Salerno, 84084 Fisciano (SA), Italy;

² PhD Program in Drug Discovery and Development, University of Salerno, 84084 Fisciano (SA), Italy;

³ Corneal Transplant Centre, Pellegrini Hospital, 80134 Naples, Italy.

1. Introduction. Ocular infections are becoming increasingly challenging to treat due to limited drug penetrability through corneal stroma and the appearance of resistant bacterial strains. In addition to the emerging drug resistance, antibiotics are also ineffective against parasites and viruses, making urgent a valid alternative for ophthalmic treatment. In this context, antiseptics are gaining more attention because they have a non-selective mechanism of action preventing bacterial resistance, moreover they combine parasite-killing and virucidal effects. The most used antiseptics in ophthalmology are povidone-iodine (PVP-I) and chlorhexidine (CHX), which we tested along with a natural antiseptic molecule, thymol. In the present study, we compared the *in vitro* antibacterial, antiamebic, and antiviral activities of six ophthalmic formulations containing the abovementioned antiseptics. **2. Materials and methods.** To assess their activities, Gram-positive and Gram-negative bacteria, the amoeba *Acanthamoeba castellanii*, and two respiratory viruses were enrolled. In particular, we evaluated the antibacterial activity of the ophthalmic solutions by broth microdilutions assay, disk diffusion assay and challenge test. The amoebicidal effect was assessed by determining the minimum concentration required to inhibit 50% of *A. castellanii* trophozoites replication. A plaque assay was finally used to evaluate their activity against the human adenovirus 2 (HAdV-2) and the human coronavirus OC43 (HCoV-OC43). **3. Results.** Among the tested formulations, Dropsept, consisting of Vitamin E TPGS-based (tocopheryl polyethylene glycol succinate) in combination with chlorhexidine, showed the highest range of activities, as it works efficiently against bacteria, amoeba, and viruses. On the other hand, the solution containing PVA (polyvinyl alcohol) and thymol showed an antimicrobial wide spectrum with a promising inhibitory effect on *Pseudomonas aeruginosa*. Also, thymol-based formulations were shown to be effective against *A. castellanii*. Regarding the antiviral activity, also Iodim exerted inhibition of viral replication for both respiratory viruses. **4. Discussion and conclusions.** Altogether our data suggest that, given its multiple activities, Dropsept might be a valuable alternative to treat ocular infections. Promising results were also shown by thymol, which deserves deeper investigations.

173 - Nocardia infections in a University Hospital in NorthEast Italy

Giampaolo Cordioli ⁽¹⁾ - Giuseppe Di Pietra ⁽¹⁾ - Shirin Asa'ad ⁽¹⁾ - Silvia Meneghello ⁽¹⁾ - [Ignazio Castagliuolo](#) ⁽¹⁾ - Claudia Del Vecchio ⁽¹⁾ - Ettore De Canale ⁽²⁾ - Antonella Zorzi ⁽²⁾

Università degli studi di Padova, Università degli studi di Padova, Dipartimento di Medicina Molecolare, Padova, Italia ⁽¹⁾ - Azienda Ospedale Università Padova, Azienda Ospedale Università Padova, UOC Microbiologia e Virologia, Padova, Italia ⁽²⁾

Nocardia infections in a University Hospital in NorthEast Italy

Giampaolo Cordioli¹, Giuseppe Di Pietra¹, Shirin Asa'ad¹, Silvia Meneghello¹, Claudia Del Vecchio^{1,2}, Ettore De Canale², Antonella Zorzi², and [Ignazio Castagliuolo](#)^{1,2}

¹Department of Microbiology and Virology, University of Padova, Padova, Italy

² UOC Microbiology Unit of Padua University Hospital, Padova, Italy

Introduction

Nocardiosis is a rare infection that can have severe morbidity and mortality, in particular among patients with compromised immunity. Since the route of infections can vary, involving soft tissue injuries and inhalation of contaminated aerosol, primarily affected organs are the lungs, the skin, and soft tissues; From the first site Nocardia can invade the bloodstream and disseminate to any organ. In Italy, nocardiosis has not a high prevalence, but most of the reported cases have an elevated morbidity. Furthermore, like other age and immunosuppression related diseases, it is bound to increase its relevance in the near future.

In this study, we analysed cases of nocardiosis that were diagnosed at the Microbiology Unit of Azienda Ospedale Università Padova (AOPD) between 1/2017 and 5/2022.

Materials and Methods

We retrospectively analysed the cases of nocardiosis that occurred in AOPD, interrogating our data base and noting the sex, age, clinical conditions, antibiotic susceptibility of the strains. The susceptibility was determined using both microdilution in broth method and E-TEST strips.

Results and Conclusions

Table 1 Cases occurred in AOPD 2017-2022

Case	Sex	Age	Site of Infection	Nocardia spp.
1	F	87	lungs	<i>N. farcinica</i>
2	M	59	skin	<i>N. farcinica</i>
3	M	54	brain	<i>N. abscessus</i>
4	M	79	lungs	<i>N.spp</i>
5	M	70	lungs	<i>N.spp</i>
6	M	69	lungs	<i>N. abscessus</i>
7	M	80	brain	<i>N. farcinica</i>
8	F	60	lungs	<i>N.spp</i>
9	F	68	lungs	<i>N.spp</i>
10	F	80	lungs and skin	<i>N. farcinica</i>
11	M	50	lungs	<i>N.spp</i>

Nocardiosis showed to be slightly more frequent in men (M/F : 7/4), and a compromised immune state appears to be a major risk factor. This seems more related to clinical conditions and immunosuppressant drugs, while the age seems to play a minor role (median age 69 +/- 12 years). Regarding the site of the infection, 70% involved the lungs and 20% the brain. *N. farcinica* was the most common specie identified in our series, followed by *N. abscessus*. *N. farcinica* showed a general resistance to beta-lactams as opposed to *N. abscessus* strains displaying a higher sensitivity to these antibiotics. Towards Imipenem the sensibility of both species was variable, Ciprofloxacin too seemed to be not very effective. Linezolid, Cotrimoxazole, and Amikacin were the most effective molecules. MICs determined with ETEST strips had a tendency to underestimate the MIC values, in particular of beta-lactams.

In conclusion, in AOPD lungs and brain are the most common site of nocardiosis and *N. farcinica* is the most common isolate. *N. farcinica* strains showed a general resistance to beta-lactams and variable susceptibility to carbapenems, thus empirical therapy for nocardiosis should take into account Linezolid, Cotrimoxazole, and Amikacin that resulted the most effective antibiotics.

177 - Characterization of multidrug-resistant *Escherichia coli* strains isolated from mares with fertility problems

Francesca Paola Nocera ⁽¹⁾ - Carlo Zagaglia ⁽²⁾ - Linda Maurizi ⁽²⁾ - Antonietta L. Conte ⁽²⁾ - Monica Ambrosio ⁽¹⁾ - Luisa De Martino ⁽³⁾ - Catia Longhi ⁽²⁾

Università degli Studi di Napoli "Federico II", Dipartimento di Medicina Veterinaria e Produzioni Animali, Napoli, Italia ⁽¹⁾ - Università degli Studi di Roma "La Sapienza", Dipartimento di Sanità Pubblica e Malattie Infettive, Roma, Italia ⁽²⁾ - Università degli Studi di Napoli "Federico II", Dipartimento di Medicina Veterinaria e Produzioni Animali, Task Force on Microbiome Studies, Napoli, Italia ⁽³⁾

Characterization of multidrug-resistant *Escherichia coli* strains isolated from mares with fertility problems

FRANCESCA PAOLA NOCERA¹, CARLO ZAGAGLIA², LINDA MAURIZI², ANTONIETTA LUCIA CONTE², MONICA AMBROSIO¹, LUISA DE MARTINO^{1,3} AND CATIA LONGHI²

¹Department of Veterinary Medicine and Animal Production, University of Naples "Federico II", Naples, Italy;

²Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy; ³Task Force on Microbiome Studies, University of Naples "Federico II", Naples, Italy.

Introduction: Bacterial infections, mainly caused by opportunistic or commensal microorganisms, are frequently associated with equine fertility problems, and *Escherichia coli* (*E. coli*) has been described as the main pathogen. Mares are prone to developing chronic infections due to bacteria capability to produce biofilm, which confers the ability to microorganisms to evade the immune system and to resist to antimicrobial therapy. Furthermore, the pathogens need essential pathogenicity traits, including adhesion and invasion to host cells, motility mediated by flagella and toxins, to manifest the disease. This study aimed to define the phenotypic and genotypic characterization of *E. coli* strains isolated from mares suffering from fertility problems.

Materials and Methods: *E. coli* strains were isolated from routine bacteriological examinations of uterine swabs collected from mares diagnosed with reproductive disorders. A total of 24 *E. coli* strains were collected in 2018. The isolates were characterized for antibiotic resistant profile using the simple disk diffusion technique as recommended by the Clinical and Laboratory Standards Institute guidelines for veterinary isolates (CLSI 2015). Biofilm formation ability was established by crystal violet staining. The presence of some virulence factor genes was assessed according to multiplex PCR assay.

Results: The antimicrobial resistance profiles showed high resistance to penicillin (95.8%), ampicillin (95.5%), imipenem (91.7%), amoxycillin/clavulanic acid and tetracycline (41.7%). Whereas the most efficient antimicrobial was amikacin (100% of cultures), followed by enrofloxacin (95.8%), ofloxacin (91.7%) ceftiofur (86.9%) and gentamicin (75.0%). In addition, 54% (13/24) of the isolated *E. coli* resulted to be multidrug-resistant strains. Only two out of the total of 24 *E. coli* isolates showed haemolysis on blood agar. The majority of *E. coli* strains 71% (17/24), were strong or moderate biofilm producers; among them 65% (11/17) were MDR strains. Furthermore, PCR analysis showed the presence of bacterial virulence factor genes such as *kpsMTII*.

Discussion and Conclusions: This study characterized *E. coli* strains from mares diagnosed with reproductive disorders. Some of them showed a multidrug-resistant profiles, carried virulence genes and were strong and moderate biofilm producers. The high resistance revealed by almost all strains to imipenem underline the need to expand this

investigation to a larger number of isolates and to deepen the characteristics of virulence of these strains. A better understanding of bacteria can guide the adoption of more effective management practices and treatment strategies.

181 - Omic-insights of Ceftazidime-Avibactam resistant *Klebsiella pneumoniae* clinical isolates

Dalida A Bivona⁽¹⁾ - Claudia Cicino⁽²⁾ - Enrico M Trecarichi⁽³⁾ - Alessandro Russo⁽³⁾ - Dafne Bongiorno⁽¹⁾ - Nadia Marascio⁽²⁾ - Marilina Mezzatesta⁽¹⁾ - Nicolò Musso⁽¹⁾ - Grete Privitera⁽¹⁾ - Angela Quirino⁽²⁾ - Giuseppe G.M Scarlata⁽²⁾ - Giovanni Matera⁽²⁾ - Carlo Torti⁽³⁾ - Stefania Stefani⁽¹⁾

Università di Catania, Department of Biomedical and Biotechnological Science, Catania, Italia⁽¹⁾ - Unit of Clinical Microbiology, Department of Health Sciences, “Magna Graecia” University, Catanzaro, Italia⁽²⁾ - Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, “Magna Graecia” University, Catanzaro, Italia⁽³⁾

Omic-insights of Ceftazidime-Avibactam resistant *Klebsiella pneumoniae* clinical isolates

Dalida Bivona^{*1}, Claudia Cicino^{*2}, Enrico M. Trecarichi³, Alessandro Russo³, Dafne Bongiorno¹, Nadia Marascio², Marilina Mezzatesta¹, Nicolò Musso¹, Grete Privitera¹, Angela Quirino², Giuseppe G.M. Scarlata², Giovanni Matera², Carlo Torti³ and Stefania Stefani¹.

*both AA contributed equally to this work

¹ Microbiology section, Dept of Biomedical and Biotechnological Science, University of Catania, Catania, Italy;

² Unit of Clinical Microbiology, Department of Health Sciences, “Magna Graecia” University, Catanzaro, Italy;

³ Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, “Magna Graecia” University, Catanzaro, Italy.

Introduction

In the last decade, multiple-drug-resistant *Klebsiella pneumoniae* strains emerged as an important cause of healthcare-associated infections worldwide. In particular, *K.pneumoniae* carbapenem resistant (KPC) strains complicate the treatment of infections. In 2018, ceftazidime/avibactam (CZA) was approved by the Italian authorities to cure infections sustained by KPC. Unfortunately, CZA exposure rapidly increased the emergency of CZA-resistant strains. Herein, we characterize resistome and virulome of the KPC-producing CZA-resistant strains selected under CZA treatment in three hospitals of Southern Italy, by molecular approach.

Materials and Methods

Sixteen isolates were collected from three hospital located in Catania and Catanzaro between May 2020 to October 2021. Isolates were collected from 13 patients who developed CAZ resistance during treatment. Antimicrobial susceptibility was determined by broth microdilution method against a panel of antibiotics. The samples included in the study were analyzed for Resistome, Virulome and to determine Sequence Type (ST) by Whole Genome Sequencing (WGS).

Results

Molecular analysis showed circulation of three major clones ST101, ST307 and ST512. In ten of sixteen strains we found *bla*_{KPC-3} gene; in the remaining samples we detected four different KPC variants (28, 31, 34 and 50). A plethora of Beta-lactams genes (*bla*_{SHV28-45-55-100-106-187-205-212}, *bla*_{OXA1-9-48}-*bla*_{TEM-181} and *bla*_{CTX-M-15}) were found variably associated with the different genetic profile while *bla*_{OXA-9} was found in ST307 and 512. With regards to membrane permeability, we investigated *ompK35* and *ompK36* that present frameshift mutations in 15 out of 16 strains; *ompK37*, all strains harbored a non-functional protein. Our isolates possessed wild-type PBP3.

Discussion and Conclusion

In this study, we reported the occurrence of CZA-resistance in a group of KPC isolates, serially collected during the pandemic period in two regions of Southern Italy. All isolates belonged to different genotypes and all of them were further analyzed to characterize their virulome and resistome. In all CZA-R isolates, MER/VAP and cefiderocol remained in the range of susceptibility, demonstrating to maintain reliable *in vitro* activity against these difficult to treat isolates. The enhanced use of CZA, would cause an emergence of concerning resistance. The results of this study provide further evidence for the plasticity and the evolutionary potential of clone of *K.pneumoniae*. In conclusion our data would prompt a further characterization of carbapenem resistance and the intrinsic bacterial factors that facilitate the rapid emergence of resistance, together with improving the timely detection of these KPC variants, contributing differently to the resistance phenotype.

183 - Oral hygiene, dietary habits, dental caries experience, and quantitative determination of microbial species with high cariogenic potential in children with autism spectrum disorder

Esingül Kaya⁽¹⁾ - Semih Esin⁽¹⁾ - Francesca Pardossi⁽²⁾ - Irene Tonacci⁽²⁾ - Giuseppantonio Maisetta⁽¹⁾ - Maria Rita Giuca⁽³⁾ - Giovanna Batoni⁽¹⁾

University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italia⁽¹⁾ - University of Pisa, Unit of Dentistry and Oral Surgery, University Hospital of Pisa, Pisa, Italia⁽²⁾ - University of Pisa, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, Pisa, Italia⁽³⁾

Oral hygiene, dietary habits, dental caries experience, and quantitative determination of microbial species with high cariogenic potential in children with autism spectrum disorder

Esingül Kaya^a, Semih Esin^a, Francesca Pardossi^b, Irene Tonacci^b, Giuseppantonio Maisetta^a, Maria Rita Giuca^{b,c}, and Giovanna Batoni^a

^aDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy;

^bUnit of Dentistry and Oral Surgery, University Hospital of Pisa, Pisa, Italy ^cDepartment of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy

Introduction: Communication deficits, poor social interactions, repetitive unusual behaviors and high sensitivity to external stimuli render extremely challenging the dental care of children with Autism Spectrum Disorder (ASD), demanding for early identification of subjects at high risk of caries development in order to implement timely preventive measures. The aim of the present study was to evaluate the oral hygiene and dietary habits, the caries status, the occurrence in saliva and the salivary count of microbial species with cariogenic potential in a group of Italian children with ASD attending the Pediatric Dentistry Outpatient Clinic, reserved for patients with ASD, "Sharing to cure" path, of Pisa's University Hospital.

Materials and Methods: 52 patients with diagnosis of ASD and of 29 age-matched neurotypical subjects, mainly represented by patient's siblings were recruited. Questionnaires were administered to mothers to inquire about the eating and oral hygiene habits of their children. Each subject underwent a careful intra-oral examination by a dentist specifically trained to deal with ASD subjects in order to take record of the oral health status. A commercial saliva-check buffer kit was used for determination of saliva pH and buffering capacity. *Mitis salivarius* bacitracin agar and *Candida* ident. agar medium supplemented with gentamicin were used for the selective recovery of *Streptococcus mutans* and *Candida spp* respectively. The study is under approval by the local Ethics Committee and was in accordance with the Declaration of Helsinki.

Results: Among the variables assessed, a statistical significant difference was recorded between ASD and control group in the use of aids other than toothbrush (e.g. floss, brush, and mouthwash), frequency of intake of sugary drinks and probiotics, salivary pH, oral hygiene index and fraction of decayed teeth on the total number of teeth. In a sub-group of 22 ASD and 13 controls tested so far, the occurrence of *Streptococcus mutans* and *Candida spp* was higher in ASD children than healthy controls, although the difference did not reach statistical significance. Overall, the salivary counts of *S. mutans* were low with only few subjects exhibiting levels of the bacterium higher than 10⁵ colony-forming unit (CFU)/ml, considered predictive of high caries-risk.

Discussion and conclusions: The results obtained support the view that ASD children are at higher risk of caries development than healthy controls, although dedicated pathways aimed at improving oral hygiene and cooperation during dental treatments may contribute to keep low the oral colonization by cariogenic species.

186 - Ceftobiprole non-susceptibility in *Enterococcus faecalis* is influenced by PBP4 alterations

LORENZO M. LAZZARO ⁽¹⁾ - Marta Cassisi ⁽²⁾ - Fabio Longo ⁽¹⁾ - Stefania Stefani ⁽¹⁾ - [Floriana Campanile](#) ⁽¹⁾

Università di Catania, Dipartimento di Scienze Biomediche e Biotechnologiche, Catania, Italia ⁽¹⁾ - Casa di cura, Casa di cura Regina Pacis, Sto arrivando!n Cataldo (CL), Italia ⁽²⁾

Ceftobiprole non-susceptibility in *Enterococcus faecalis* is influenced by PBP4 alterations

LORENZO M. LAZZARO, MARTA CASSISI, FABIO LONGO, STEFANIA STEFANI, [FLORIANA CAMPANILE](#)
Department of Biomedical and Biotechnological Sciences (BIOMETEC). University of Catania, Italy.

Introduction

We previously demonstrated that elevated ceftobiprole (BPR) MICs were attributable to increased *pbp4* transcription, associated with a single upstream adenine deletion (*delA*). PBP4 substitutions in the catalytic-site *motifs* alter the protein folding and stability and may account for the (already low) PBP4 affinity to BPR, and MIC increase. Here we aim to correlate how these aminoacidic substitutions, especially those falling near the catalytic site, interfere with the formation of the BPR/PBP4 complex.

Materials and Methods

Two already characterized *Enterococcus faecalis* clinical isolates were selected for their β -lactam resistance profile, *pbp4* gene sequence and key mutations influencing the BPR antibacterial activity. *pbp4* gene expression was performed by RT qPCR and the relative gene expression levels were calculated using the $2^{-\Delta\Delta C_t}$ method. BPR/PBP4 binding affinity was analyzed in a competition assay with increasing concentrations of BPR (sub-MIC; 1X, 2X and 4X MIC). PBPs were labelled using the fluorescent reporter molecule BOCILLIN™ FL.

Results

The comprehensive analysis of *pbp4* gene sequence, expression levels of transcription, and competition assays revealed that the coexistence of the *delA* upstream the promoter region and aminoacidic substitutions near the catalytic-site significantly affect the formation of the BPR/PBP4 complex. The Penicillin-Resistant-Ampicillin-Susceptible/BPR-Non-Susceptible (PRAS/BPR-NS) strain exhibited the adenine deletion (*del A*) in the promoter region and 4 different aminoacidic substitutions, among which 2 felt next to the PBP4 catalytic-site *motifs*. *delA* leads to a 3 log₁₀ increase such that the *pbp4* expression levels of transcription were upregulated, consistently to its higher BPR MICs (MIC 16 mg/L). Aminoacidic substitutions next to the PBP4 catalytic-site *motifs* clearly interferes with the BPR/PBP4 affinity, leading to a saturation of PBP4 at lower MIC concentrations. The Penicillin-Susceptible-Ampicillin-Susceptible/BPR Susceptible (PSAS/BPRS) did not show *delA* and showed only one aminoacidic substitution, far from the catalytic site. This strain maintains lower *pbp4* expression levels ($\leq 10^2$ fold-change increase) and full BPR susceptibility (0.25 mg/L). Its PBP profile is not altered, showing an increasing saturation of PBP4, proportionally dependent to BPR concentrations.

Discussion and Conclusions

Our data suggest that diverse factors converge in determining reduced susceptibility to ceftobiprole, in specific *E. faecalis* strains: increased expression of low-affinity PBP4, as a result of *delA* in the promotor region, and over-reduced BPR/PBP4 binding, due to aminoacidic substitutions next to the catalytic-site *motifs*.

Keywords: *Enterococcus faecalis*; PBP4 substitutions; competition assay; RT-qPCR.

188 - *Blastocystis* sp. prevalence and subtypes in autochthonous and immigrant patients in a Southern Italy hospital

Marianna Marangi⁽¹⁾ - Daniela Pisanelli⁽²⁾ - Maurizio Margaglione⁽¹⁾ - Rossella De Nittis⁽³⁾

Università di Foggia, Dipartimento di Medicina Clinica e Sperimentale, Foggia, Italia⁽¹⁾ - Azienda Ospedaliero-Universitaria "Policlinico Riuniti", SSVD Microbiologia e Virologia, Foggia, Italia⁽²⁾ - Azienda Ospedaliero-Universitaria "Policlinico Riuniti", Foggia, SSVD Microbiologia e Virologia, Foggia, Italia⁽³⁾

***Blastocystis* sp. prevalence and subtypes in autochthonous and immigrant patients in a Southern Italy hospital**

MARIANNA MARANGI¹, DANIELA PISANELLI², MAURIZIO MARGAGLIONE¹, ROSSELLA DE NITTIS²

¹Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy; ²Microbiology and Virology Unit, Ospedali Riuniti, Foggia, Italy.

Introduction: *Blastocystis* (Stramenopiles) is a common enteric protist transmitted by fecal-oral direct contact or waterborne transmission with a worldwide distribution. Although several publications suggest an association with gastrointestinal symptoms (i.e. diarrhea, abdominal pain, nausea, vomiting, fatigue, flatulence, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD)), the clinical significance of *Blastocystis* and of its subtypes (STs) still remains a controversial issue. Since the pathogenicity has not been fully elucidated, testing for *Blastocystis* is not routinely pursued by most laboratories and clinicians. Thus, the *Blastocystis* prevalence is underestimated. The aim of the study is to explore the prevalence of *Blastocystis* and characterize the genetic diversity in autochthonous and immigrant patients, evaluating: *i*) the influence of the geographical origin, *ii*) the dynamic of different STs and *iii*) the association with other parasite coinfections.

Material and methods: From February 2022, an individual stool sample of autochthonous and immigrant patients with gastrointestinal symptoms admitted to the Microbiology and Virology Unit was screened for the presence of *Blastocystis* sp. by using Allplex™ GI-Parasite Assay Real Time. The samples found positive were subjected to traditional PCRs targeting a partial fragment of the SSU rRNA gene and then subjected to the BygDye Terminator sequencing in order to identify and characterize *Blastocystis* subtypes.

Results: Until now, out of 60 screened samples, n. 13 (21.6%) have been found positive to *Blastocystis* sp. The prevalence was higher in male (n. 9, 69.2%) compared to female (n. 4, 30.7%) and in Italian (n. 10, 77%) compared to African (n. 3, 23%) patients. Moreover, out of 13, 1 (7.7%) has found also positive to *Dientamoeba fragilis*. Two *Blastocystis* subtypes were identified with the following distribution: ST3 in 11 samples and ST1 in 2 samples.

Discussion and conclusions: *Blastocystis* was detected in both the Italian and African group patients. Our data confirmed previous studies performed in Italy, in which ST3 proved to be the most prevalent subtype, but we highlight also the detection of ST1 subtype, which was probably underestimated in former analyses. We found an association between *Blastocystis* and *D. fragilis* that might indicate a potential cooperative interaction between these two enteric protozoa. In order to explore the potential clinical relevance of *Blastocystis* and its subtypes, the association with other protozoa and also the possible changes of gut microbiota associated to *Blastocystis* infection further prospective studies with a higher number of samples will be performed.

190 - In vivo antibacterial activity of disposable gauzes for periocular antisepsis

Mariacristina Massimino ⁽¹⁾ - Francesco Celandroni ⁽¹⁾ - Vincenzo Scorcìa ⁽²⁾ - Marco Calvigioni ⁽¹⁾ - Diletta Mazzantini ⁽¹⁾ - Adelaide Panattoni ⁽¹⁾ - Sabrina Vaccaro ⁽²⁾ - Giuseppe Giannaccare ⁽²⁾ - Emilia Ghelardi ⁽¹⁾

Università di Pisa, Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Pisa, Italia ⁽¹⁾ - Università di Catanzaro, Dipartimento di Oftalmologia, Catanzaro, Italia ⁽²⁾

***In vivo* antibacterial activity of disposable gauzes for periocular antisepsis**

MARIACRISTINA MASSIMINO¹, FRANCESCO CELANDRONI¹, VINCENZO SCORCIA², MARCO CALVIGIONI¹, DILETTA MAZZANTINI¹, ADELAIDE PANATTONI¹, SABRINA VACCARO², GIUSEPPE GIANNACCARE², EMILIA GHELARDI¹

¹Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

²Department of Ophthalmology, Magna Graecia University of Catanzaro, Catanzaro, Italy

Introduction. Disposable gauzes for periocular antisepsis can be useful for removing debris of eyelid desquamation or secretions due to inflammatory events or allergies or as adjuvant in the treatment of eye pathologies such as conjunctivitis, blepharitis, and blepharoconjunctivitis. Herein we evaluated the effect of gauzes containing natural extracts from *Citrus limon* (Biosecur), *Aloe vera*, and *Ruscus aculeatus* in reducing the bacterial load of the conjunctiva and eyelids of patients undergoing intravitreal injections for maculopathies.

Materials and Methods. Swabs from conjunctiva and eyelids of both right and left eyes of patients were collected before the treatment to assess differences in the microbial colonization. The eye that needed to receive the intravitreal injection was treated 4 times a day for 4 days with the gauzes and sampling was repeated for both eyes at the end of the treatment. The eye not receiving the treatment was used as control. Bacterial counts were performed by plating. Bacterial genomic DNAs were extracted from the samples and Real-Time qPCRs performed to analyze the composition of the microbial community in terms of total bacterial load and major taxa.

Results. Before treatment, no differences between right and left eyes were evidenced in any patient and both samples from eyelids and conjunctiva displayed *Staphylococcus* spp. as predominant bacteria. A significant reduction in bacterial counts was evidenced after the use of the antiseptic gauzes both on eyelids and conjunctival samples, with *Staphylococcus* spp. almost undetectable after treatment. Molecular analyses are still in progress.

Discussion and Conclusions. In the present study, the application of the antiseptic gauzes was shown to be effective in reducing the bacterial load of the eyelids and the conjunctiva. While effects on the eyelid may be due to direct contact of the active principles contained in the gauzes with bacteria as well as to mechanical removal, we hypothesized that the reduction of bacterial load on conjunctiva may be a result of the spread of the active principles from the eyelid and the periocular area to the conjunctiva itself, thus conferring to the antiseptic device a wider and more effective antimicrobial effect. Although the *in vivo* antibacterial effect of the tested gauzes and the usefulness of this kind of treatment for periocular antisepsis have been clearly demonstrated, the results of Real-Time qPCRs will be useful to better comprehend the effect of the treatment on different bacterial populations.

192 - Cyano-pyrimidines and enamines as promising scaffolds for antibacterial activity

Floriana Campanile ⁽¹⁾ - Fabio Longo ⁽¹⁾ - Lorenzo M. Lazzaro ⁽¹⁾ - Matteo Pappalardo ⁽²⁾ - Vincenzo G. Nicoletti ⁽¹⁾ - Salvatore Guccione ⁽²⁾

Università di Catania, Dipartimento di Scienze Biomediche e Biotechnologiche, Catania, Italia ⁽¹⁾ -

Università di Catania, Dipartimento di Scienze del Farmaco, Catania, Italia ⁽²⁾

Cyano-pyrimidines and enamines as promising scaffolds for antibacterial activity

FLORIANA CAMPANILE¹, FABIO LONGO¹, LORENZO M. LAZZARO¹, MATTEO PAPPALARDO², VINCENZO G. NICOLETTI¹ AND SALVATORE GUCCIONE².

¹Department of Biomedical and Biotechnological Sciences; ²Department of Drug Sciences. University of Catania, Italy.

Introduction

The combination of virtual screening and chemoinformatic with biology has finally led to practical applications in workflows for prioritizing narrow subsets from large chemical spaces. Pyrimidine- imidazole- and enamine-based derivatives are privileged scaffolds that attracted considerable attention in designing of molecules, with DNA replication or bacterial cell division inhibitory properties. A series of cyano-pyrimidines, cyano-imidazoles and enamines was previously selected by virtual and experimental screening (Research Centre for Natural Sciences, Budapest) and Enamine Ltd. covalent fragment libraries, resulted in several hits with potential antibacterial activity. In this study, we show a preliminary evaluation of these compounds as suitable starting points for developing new antibiotics.

Materials and Methods

27 compounds (N. 10 cyano-pyrimidine, N. 5 cyano-imidazole and N. 12 enamine derivatives) selected from a covalent docking-based virtual screening workflow, using different *state of art* softwares, were explored for their antibacterial properties against eight microbial reference strains from ATCC (American Type Culture Collection). Three independent experiments were performed to calculate Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC).

Results

n. 5 cyano-pyrimidine and n. 7 enamine derivatives showed promising antibacterial activity against some standard bacteria. No activity was achieved for cyano-imidazoles. We found that overall, almost all candidates (11/12) exhibited potential antibacterial activity against *A. baumannii* species, inhibiting the growth at 64 µg mL⁻¹ concentration, and being bactericidal at the same concentration or one concentration above the MIC (125 µg mL⁻¹). Three cyano-pyrimidines showed specific activity against *E. faecalis* (16, 32 and 64 µg mL⁻¹). One compound (4-chloropyrimidine-2-carbonitrile) showed a broad-spectrum activity also against *P. aeruginosa* and *C. albicans* strains (MIC 64 µg mL⁻¹). Enamine derivatives were specifically active against Gram-negative bacteria, killing *A. baumannii* at 64 µg mL⁻¹ and inhibiting also *P. aeruginosa*, *K. pneumoniae*, *E. coli*, and *C. albicans* (5/7). No antimicrobial activity was found at relevant concentrations against *S. aureus* and *B. subtilis* species (MIC ≥256 µg mL⁻¹).

Conclusions

Given the rise in antibiotic resistance, our promising results, particularly against *A. baumannii*, open the way to further development of cyano-pyrimidine and enamine derivatives as optimal candidates for the treatment of Multidrug Resistant (MDR) clinical isolates.

Keywords: Virtual screening; Covalent Docking; antibacterial activity.

196 - Lytic activity of four bacteriophages against planktonic and biofilm *Staphylococcus aureus* clinical isolates

Claudia Campobasso⁽¹⁾ - Jeroen Wagemans⁽²⁾ - Daria Bottai⁽¹⁾ - Arianna Tavanti⁽¹⁾ - Rob Lavigne⁽²⁾ - Mariagrazia Di Luca⁽¹⁾

Università di Pisa, Dipartimento di Biologia, Pisa, Italia⁽¹⁾ - KU Leuven, Department of Biosystems, Leuven, Belgio⁽²⁾

Lytic activity of four bacteriophages against planktonic and biofilm *Staphylococcus aureus* clinical isolates

CLAUDIA CAMPOBASSO^{1,2}, JEROEN WAGEMANS², DARIA BOTTAI¹, ARIANNA TAVANTI¹, ROB LAVIGNE², MARIAGRAZIA DI LUCA¹.

¹Department of Biology, University of Pisa, Pisa, Italy; ²Department of Biosystems, Laboratory of Gene Technology, KU Leuven, Leuven, Belgium.

Introduction: Phage therapy represents a promising approach to cure difficult-to-treat infections. In 2019, *Staphylococcus aureus* became the second most commonly found pathogen causing lethal antibiotic-resistant infections worldwide. This is primarily due to its capacity to either develop multidrug-resistance or to form biofilm, in which bacterial cells are more tolerant to antibiotics in comparison to their planktonic counterparts. The aim of the study was to evaluate the host range and the lytic activity of 4 established staphylococcal bacteriophages against a panel of *S. aureus* strains.

Material and methods: 4 phages, ISP, Sb-1 (Eliava Phage Therapy Center), Romulus and Remus (KU Leuven), all belonging to the *Twortvirinae* subfamily, were employed in this study. A 20 *S. aureus* strains dataset, including 2 strains from type culture collections and 18 clinical isolates from 4 countries (Belgium, Germany, Italy, and Switzerland), was used. The phage host range was evaluated by performing a spot assay of each phage against all strains at 3 titers (10^8 - 10^6 - 10^4 PFU/ml) and assessing their susceptibility by the presence of lysis plaques. A 24h growth kinetic was performed to determine the activity of each single phage and a combination (cocktail) of all of them (10^8 - 10^6 PFU/ml) against planktonic cells by measuring culture optical density (OD). Finally, antibiofilm activity of ISP was assessed against 2 strains, treating their biofilms (preformed on porous glass beads) with 3 titers (10^8 - 10^7 - 10^6 PFU/ml) for 24h.

Results: The spot assay revealed that all bacterial strains were sensitive at least to 2 phages and 15 out of 20 strains were susceptible to the highest tested titer of all 4 phages. ISP and Sb-1 had the broadest host range, being active against all 20 strains. Growth kinetic assays showed that the OD value of 9 strains incubated with at least one phage did not increase within 24h, suggesting that phages were able to kill planktonic bacteria. Moreover, the phage cocktail, when provided at both titers, had a bactericidal effect against all strains tested. ISP showed an antibiofilm activity against both tested strains, resulting in complete biofilm eradication for one strain and a 3-log reduction for the other, relative to the untreated control.

Discussion and Conclusions: Our results provide evidence that the tested phages have rather wide host ranges and exhibit lytic activity against the *S. aureus* strains tested. Moreover, the ability of phage cocktail to inhibit cell growth in all cases suggests a synergistic effect of the phages, which may differ in their mechanism of interaction with the target bacteria, increasing the probability of infection. Further experiments to evaluate the antibiofilm activity of staphylococcal bacteriophages are ongoing.

201 - *Klebsiella pneumoniae* strains resistant to ceftazidime/avibactam and meropenem/vaborbactam: molecular characterization.

Maddalena Calvo⁽¹⁾ - Giuseppe Migliorisi⁽¹⁾ - Dalida Angela Bivona⁽²⁾ - Francesca Di Bernardo⁽³⁾ - Alessia Mirabile⁽¹⁾ - Nicolò Musso⁽²⁾ - Grete Privitera⁽²⁾ - Laura Saporito⁽³⁾ - Laura Sessa⁽¹⁾ - Dafne Bongiorno⁽²⁾ - Stefania Stefani⁽²⁾

Università di Catania, U.O.C. Laboratory Analysis, University Hospital Policlinico-San Marco,, Catania, Italia⁽¹⁾ - Università di Catania, Dipartimento di Scienze Biomediche e Biotecnologiche, Catania, Italia⁽²⁾ - ARNAS Civico-Di Cristina-Benfratelli, Unit of Clinical Microbiology, Palermo, Italy, Palermo, Italia⁽³⁾

***Klebsiella pneumoniae* strains resistant to ceftazidime/avibactam and meropenem/vaborbactam: molecular characterization.**

MADDALENA CALVO^{*1}, GIUSEPPE MIGLIORISI^{*1}, DALIDA A. BIVONA², FRANCESCA DI BERNARDO³, ALESSIA MIRABILE¹, NICOLÒ MUSSO², GRETE PRIVITERA², LAURA SAPORITO³, LAURA SESSA¹, DAFNE BONGIORNO² AND STEFANIA STEFANI².

**Both AA equally contributed to this work*

¹U.O.C. Laboratory Analysis, University Hospital Policlinico-San Marco, Catania, Italy.

²Microbiology section, Dept of Biomedical and Biotechnological Science, University of Catania, Catania, Italy.

³U.O.C. of Clinical Microbiology, ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy.

INTRODUCTION

In the last decades, multidrug-resistant (MDR) Gram-negative bacteria recorded high distribution rates among clinical isolates. Beta-lactamases and carbapenemases production slightly decreased the effectiveness of beta-lactams and carbapenems. Specifically, *Klebsiella pneumoniae* carbapenemases (KPC) became a global public health concern. Several studies showed excellent activity of ceftazidime/avibactam and meropenem/vaborbactam against KPC-producers with low resistance percentages. The isolation of two MDR hypervirulent *K. pneumoniae* resistant to ceftazidime/avibactam (CZA) and meropenem/vaborbactam (MER/VAB) attracted our attention. Here we report their first molecular characterization.

MATERIALS AND METHODS

Two isolates of *K. pneumoniae* were collected from patients recovered respectively in the Internal Medicine Unit in Civico Hospital (Palermo) and in the Hematology ward in University Hospital Policlinico (Catania). Clinical specimens were respectively a blood sample and a rectal swab. *In vitro* susceptibility testing and NGS sequencing were performed. Illumina DNA Prep was used for sequencing analysis, and the pooled libraries were sequenced on Illumina MiSeq. Data were analyzed using QIAGEN CLC Genomics Workbench software, Microbial Module.

RESULTS

Original *in vitro* susceptibility tests performed in the hospital clinical laboratories revealed multi-drug resistance extended to novel beta-lactam/beta-lactamase inhibitor combinations. The strains were resistant to 3d generation cephalosporins, meropenem, CZA and MER/VAB. Molecular analysis revealed the following similar characteristics: isolates belong to ST101 clone, featured with capsular locus KL-17 and O-antigen locus O1/O2v1. We found carbapenem genes *bla*_{KPC3} and *bla*_{OXA-48} and beta-lactams gene

bla_{SHV1}. Moreover, membrane permeability was investigated with attention to *ompK35*, *ompK36*, *ompK37* and frameshift mutations were detected. Otherwise, the absence of mutation was confirmed on PBP3 sequences.

DISCUSSION AND CONCLUSION

The clinical impact of new molecules' resistance leads to significant difficulties in the therapeutical management of infections. Although low prevalence rates have been currently recorded, our data implement evidence already reported in the literature. We detected resistance mechanisms related to the presence of carbapenems genes *bla_{kpc3}* and *bla_{OXA48}* and beta-lactams gene *bla_{SHV1}*. Furthermore, frameshift mutations on *ompK35*, *ompK36*, and *ompK37* genes were found. This study highlights how the presence of multiple resistance mechanisms on bacterial strains should be always investigated. Whole genome sequencing could represent an additional step analysis to perform anytime an unusual susceptibility pattern is clinically revealed.

208 - *Pleurotus eryngii* var. *thapsiae* a new potential culinary-medicinal mushroom from Sicily with antibiofilm potentiality.

Teresa Maria Fasciana⁽¹⁾ - Valeria Ferraro⁽²⁾ - Fortunato Cirilincione⁽²⁾ - Gaetano Balenzano⁽³⁾ - Maria R. Tricoli⁽¹⁾ - Ignazio Arrigo⁽¹⁾ - Elena Galia⁽¹⁾ - Laura Di Paola⁽¹⁾ - Giuseppe Venturella⁽¹⁾ - Anna Giammanco⁽¹⁾

University of Palermo, Department of Health Promotion, Maternal-Childhood, Internal Medicine of Excellence "G. D'Alessandro", Palermo, Italia⁽¹⁾ - University of Palermo, Department of Agricultural, Food and Forest Sciences, Palermo, Italia⁽²⁾ - University of Bari, University of Bari, Bari, Italia⁽³⁾

***Pleurotus eryngii* var. *thapsiae* a new potential culinary-medicinal mushroom from Sicily with antibiofilm potentiality.**

Teresa Fasciana¹, Valeria Ferraro², Fortunato Cirilincione², Gaetano Balenzano³, Maria R. Tricoli¹, Ignazio Arrigo¹, Elena Galia¹, Laura di Paola¹, Giuseppe Venturella², Anna Giammanco¹.

¹ Department of Health Promotion, Maternal-Childhood, Internal Medicine of Excellence "G. D'Alessandro", University of Palermo, Via Del Vespro 133, 90127, Palermo, Italy.

² Department of Agricultural, Food and Forest Sciences, University of Palermo, Viale delle Scienze, Bldg. 5, 90128 Palermo (Italy).

³ University of Bari, Piazza Umberto I - 70121 Bari (Italy).

Introduction: Mushroom extracts are a rich source of natural compounds with antimicrobial properties. In recent years, there has been an increased interest in natural antimicrobials, especially those obtained from medicinal and culinary mushrooms. The genus *Pleurotus* (Fr.) P. Kumm. includes economically important mushrooms, cultivated around the world, widely used in human nutrition and recognized as medicinal mushrooms. Within this genus, the *P. eryngii* species-complex is undoubtedly worth mentioning. Among the members of the *P. eryngii* species-complex, our attention focused on *P. eryngii* (DC.) Quél. var. *thapsiae* Venturella, Zervakis & Saitta, this mushroom has been reported so far only in Sicily (Italy), where it has a rather limited geographical distribution, at altitude ranging from 0 to 1500 m. The aim of this study was to investigate the potential of extracts from *P. eryngii* var. *thapsiae*, against ATCC Gram-positive and Gram-negative strains.

Materials and Methods: The cultivation was carried out on two different substrates, one based on wheat straw and another consisting of a mix of wheat straw and *Aegilops geniculata* Roth., a wheat weed. *P. eryngii* var. *thapsiae* exhibited good production performance, with yields above 15% on both substrates. Besides, the collected basidiomes were subjected to drying, then reduced to powder and a chemical analysis was then performed on this powder. One share of the mushroom powder was used to obtain aqueous extracts using two different techniques, traditional and ultrasound-assisted extraction, in order to evaluate and compare their activity against ATCC Gram-positive (*S. aureus*, *E. faecalis*), and Gram-negative (*K. pneumoniae*, *E. coli* and *P. aeruginosa*) strains.

Crystal violet assay (CVA) was executed to quantify biofilm formation by all ATCC isolates

Results: The best activity was obtained against *S. aureus*, with a reduction of about 60% of biofilm biomass, by means of both ultrasonic extracts.

Conclusions: Extract of mushroom or their purified antimicrobial constituents are alternative biocides that have recently gained attention as possible cleansing agents, because the chances of resistance development in bacterial cells could be minimal. This study, therefore, highlights the potential application of this mushroom for large-scale cultivation, aimed at the marketing of a local, quality product with high nutritional and organoleptic properties.

210 - Profile of antibacterial activity of *Moringa oleifera* Lam. single phenols against the phytopathogen *Xanthomonas campestris* pv. *campestris*

Anna Caproni ⁽¹⁾ - Riccardo Fontana ⁽¹⁾ - Chiara Nordi ⁽¹⁾ - Marco Marzola ⁽¹⁾ - Giulia Trioschi ⁽¹⁾ - Ottavia Bonucelli ⁽¹⁾ - Mariaconcetta Sicurella ⁽²⁾ - Stefano Manfredini ⁽³⁾ - Anna Baldisserotto ⁽³⁾ - Peggy Marconi ⁽¹⁾

Università degli Studi di Ferrara, Dipartimento di Scienze Chimiche, Farmaceutiche e Agrarie, Ferrara, Italia ⁽¹⁾ - Università degli Studi di Ferrara, Dipartimento di Scienze dell'Ambiente e della Prevenzione, Ferrara, Italia ⁽²⁾ - Università degli Studi di Ferrara, Dipartimento di Scienze della Vita e Biotecnologie, Ferrara, Italia ⁽³⁾

Profile of antibacterial activity of *Moringa oleifera* Lam. single phenols against the phytopathogen *Xanthomonas campestris* pv. *campestris*

ANNA CAPRONI¹, RICCARDO FONTANA^{1,2}, CHIARA NORDI¹, MARCO MARZOLA¹, GIULIA TRIOSCHI¹, OTTAVIA BONUCELLI¹, MARIACONCETTA SICURELLA³, STEFANO MANFREDINI², ANNA BALDISSEROTTO², PEGGY MARCONI¹

1 Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy

2 Department of Biotechnology and Life Sciences, University of Ferrara, Ferrara, Italy

3 Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy

Introduction: *Xanthomonas campestris* pv. *campestris* (XCC) is the phytopathogenic agent causing black rot in crucifers; once reached the target site in the plant, it damages the plant cells causing maceration of tissues and obstruction of the xylematic vessels. The research of alternative to pesticides/antibiotics has led to the study of plant extracts with antibacterial properties, and with this optic, the effects of extracts of *Moringa oleifera* Lam. (MO) against XCC have been studied. Knowing which phenolic compounds are mostly present in our MO extracts, i.e., chlorogenic acid, ellagic acid, rutin and quercetin, in the project we investigated the effects of the single phenols constituting the phytocomplex on bacterial cells.

Materials and methods: The potential antimicrobial effects on biofilm and membrane permeability on XCC of several phytochemical phenolic compounds have been evaluated: chlorogenic acid (CA), ellagic acid (EA), rutin (RU) and quercetin (QU) have been studied.

Result and Conclusions: The four different phenolics compounds have both bacteriostatic and bactericidal effects at the concentrations of 10 µg/ml for RU, 50 µg/ml for QU and CA and 100 µg/ml for EA. All of the compounds detected in MOs show effects on inhibition in biofilm formation processes and lead to a significant alteration of the bacterial membrane. It is assumed that the effect is carried out at several levels: these phenolic compounds are in fact capable of altering the permeability of the membrane leading to a halt in the ATP-synthesis, resulting in slowing down of all ATP-dependent functions. The modification of membrane integrity and permeability results in a considerable energy dissipation as it involves the dissipation of the action potential and the alteration of the electrochemical gradient, necessary conditions for the synthesis of ATP. This alters various ATP-dependent mechanisms, such as biofilm formation: XCC, subjected to these energy shortages, retains a capacity to form biofilms reduced by 87% (RU), 71% (CA), 60% (QU) and 54% (EA).

212 - *Blastocystis* sp. subtypes detected from 2016 to 2018 and correlation to intestinal disease.

Adriana Calderaro ⁽¹⁾ - [Maria Cristina Angelici](#) ⁽²⁾ - Sara Montecchini ⁽¹⁾ - Giovanna Piccolo ⁽¹⁾ - Sabina Rossi ⁽¹⁾ - Mirko Buttrini ⁽¹⁾ - Benedetta Farina ⁽¹⁾ - Maria Cristina Arcangeletti ⁽¹⁾ - Carlo Chezzi ⁽¹⁾ - Flora De Conto ⁽¹⁾

Università di Parma, Dipartimento di Medicina e Chirurgia, Parma, Italia ⁽¹⁾ - Istituto Superiore di Sanità, Dipartimento Ambiente e Salute, Roma, Italia ⁽²⁾

***Blastocystis* sp. subtypes detected from 2016 to 2018 and correlation to intestinal disease.**

ADRIANA CALDERARO, MARIA CRISTINA ANGELICI, SARA MONTECCHINI, GIOVANNA PICCOLO, SABINA ROSSI, MIRKO BUTTRINI, BENEDETTA FARINA, MARIA CRISTINA ARCANGELETTI, CARLO CHEZZI, FLORA DE CONTO.

Department of Medicine and Surgery, Unit of Clinical Microbiology and Virology, University of Parma, Parma, Italy

Department of Environment and Health, Istituto Superiore di Sanità, Rome, Italy.

Introduction. *Blastocystis* sp. is often reported as the most commonly detected intestinal protozoa in humans and animals, despite pathogenicity continues to be debated and investigated.

Among the 17 known subtypes (STs), 9 were found in humans, with ST1-ST4 the most prevalent and ST5-ST9 isolated sporadically and likely related to zoonotic transmission. The aim of this study was to carry out the analysis of subtypes of *Blastocystis* sp. detected in human faecal samples.

Materials and Methods. DNA extracted from 104 *Blastocystis* sp. positive faecal samples (about the half of *Blastocystis* sp. positive specimens collected in a 2-year period) was submitted to subtyping by sequencing the 600 bp fragment of the small subunit rDNA gene. The samples belonged to 102 patients suspected of having an intestinal parasitosis (75 males, 27 females; 94 adults, 8 children; 41 born in Italy, 61 born in developing countries, 35 of them attending to an immigrant health service, 5 with a documented recent arrival in Italy) and submitted to conventional methods for the diagnosis of intestinal parasitoses. Some of those revealed also coinfections by other parasites (45 cases).

Results. The subtypes found in 103 of the 104 sequences obtained belonged to ST1-ST4. Among the analysed cases, ST3 was the most frequent (41.7%), followed by ST1 (30.2%), ST4 (17.7%), and ST2 (15.6%). In 1 case a ST14 was revealed in an Italian 33-year-old woman. ST3 was the prevalent strain among males, foreigners, and adults; ST4 was the prevalent ones among females and Italians, and ST2 in children. Each subtype seems not to be related to the presence of a co-infecting parasites; however, subtype 4 was mainly detected in absence of parasites other than *Blastocystis*. Among the people attending the immigrant health service and/or recently arrived in Italy, 62.8% was infected by ST3 (55% of all the ST3 infected patients). There seems to be no correlation between ST and clinical signs and symptoms among the cases analysed in this study.

Discussion and Conclusions. The frequency rate of the STs found in this study is similar to that previously reported in Italy and, except in 1 case where a zoonotic strain (ST14) was revealed, only the STs most common in humans were encountered (ST1-ST4). However, among the different subpopulations (sex, origin, age) of this study the STs ratio was different. This study responds to the need to increase the data and consequently the knowledge about the subtypes circulating in Italy, where still few studies in the field have been undertaken.

215 - Characterization of fosfomycin-resistance mechanisms in clinical isolates of methicillin-resistant *Staphylococcus aureus*

Noemi Aiezza ⁽¹⁾ - Alberto Antonelli ⁽¹⁾ - Marco Coppi ⁽¹⁾ - Vincenzo Di Pilato ⁽²⁾ - Tommaso Giani ⁽¹⁾ - Gian Maria Rossolini ⁽¹⁾

University of Florence, Department of Experimental and Clinical Medicine, Florence, Italia ⁽¹⁾ -

University of Genoa, Department of Surgical Sciences and Integrated Diagnostics, Genoa, Italia ⁽²⁾

Abstract

Characterization of fosfomycin-resistance mechanisms in clinical isolates of methicillin-resistant *Staphylococcus aureus*

NOEMI AIEZZA¹, ALBERTO ANTONELLI^{1,3}, MARCO COPPI^{1,3}, VINCENZO DI PILATO^{2,3}, TOMMASO GIANI^{1,3}, GIAN MARIA ROSSOLINI^{1,3}

¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; ²Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy; ³Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy

Introduction. Methicillin-resistant *Staphylococcus aureus* (MRSA) was among the first problematic multi-resistant pathogens emerged in the clinical setting, causing infections associated with high morbidity and mortality rates. Intravenous fosfomycin, due to its notable anti-staphylococcal activity and favorable safety and pharmacokinetic profiles, is an interesting agent for combination antimicrobial chemotherapy against some MRSA infections. In this work we investigated fosfomycin susceptibility and resistance mechanisms in a multicenter collection of MRSA from Italy. **Materials and Methods.** A total of 64 non-replicate clinical isolates of MRSA *Staphylococcus aureus* collected from Hospital-acquired pneumonia cases from different Italian hospitals in 2016 were studied. Fosfomycin susceptibility testing was performed by reference agar dilution according to the ISO-20776-1:2019 guidelines and interpreted according to EUCAST clinical breakpoints (12.0). Bioinformatic analysis was carried out on genome assemblies of the 64 isolates that had previously been generated by WGS analysis. Gene expression experiments were carried out by RT-Real Time PCR. Selection of fosfomycin-resistant mutants was carried out using an overnight culture plated on fosfomycin selective agar plates. **Results.** Overall, 22% (14/64) of the MRSA isolates resulted resistant to fosfomycin. Bioinformatics analysis on resident *uhpT*, *glpT*, *murA*, *tet38*, and *fosB* genes, detected 6 distinct alterations putatively associated with resistance in the *uhpT* and *tet38* genes. Of these, three alterations introduced a premature stop codon in the *uhpT* gene, one was characterized by a deletion of part of *uhpT* gene and two caused aminoacidic substitutions in the Tet38 efflux pump. Overexpression of *tet38* was detected in two isolates. The resident *fosB* gene was detected only among isolates belonging to CC8, CC5 and ST30 (in total 29 of the 64 MRSA isolates), of which only six were resistant to fosfomycin. Interestingly, in two of them a *fosB* overexpression was mediated by an IS1182 insertion upstream of the *fosB* gene, which provided an additional promoter. Mutant-selection experiments were able to obtain fosfomycin-resistant mutants by the same mechanisms from two susceptible strains. **Discussion and Conclusion.** In conclusion, in this work a high fosfomycin resistance-rate in MRSA from Italy was detected. Multiple fosfomycin-resistance mechanisms were identified, including *uhpT* gene alterations, *tet38* gene alterations and overexpression, and upregulation of the *fosB* gene mediated by an IS1182 transposition upstream of the gene.

219 - Cupferron, a new promising metal chelator against *Candida albicans*

Francesca Palma⁽¹⁾ - Veronica Folliero⁽¹⁾ - Annalisa Ambrosino⁽¹⁾ - Roberta Della Marca⁽¹⁾ - Rosa Giugliano⁽¹⁾ - Mariavittoria Morone⁽¹⁾ - Sara Borrelli⁽¹⁾ - Anna De Filippis⁽¹⁾ - Gianluigi Franci⁽²⁾ - Massimiliano Galdiero⁽¹⁾

Università degli Studi della Campania "Luigi Vanvitelli", Dipartimento di Medicina Sperimentale, Napoli, Italia⁽¹⁾ - Università degli Studi di Salerno, Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana", Salerno, Italia⁽²⁾

Cupferron, a new promising metal chelator against *Candida albicans*

FRANCESCA PALMA¹, VERONICA FOLLIERO¹, ANNALISA AMBROSINO¹, ROBERTA DELLA MARCA¹, ROSA GIUGLIANO¹, MARIAVITTORIA MORONE¹, SARA BORRELLI¹, ANNA DE FILIPPIS¹, GIANLUIGI FRANCI², MASSIMILIANO GALDIERO¹

¹ Department of Experimental Medicine; University of Campania "Luigi Vanvitelli"; 80138 Naples; Italy.

² Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana"; University of Salerno; 84081 Baronissi; Italy.

Introduction: *Candida albicans* (*C. albicans*) represents a life-threatening opportunistic fungal pathogen with a high mortality and morbidity rate, particularly among immunocompromised patients. The high multidrug resistance combined with the limited drugs available calls for the urgent need for new therapeutic strategies. As part of the ongoing search for new antifungal drugs, we focused on metal chelators, whose activity has already been documented. In this context, the antifungal activity of N-nitroso-N-phenylhydroxylamine (Cupferron) and its effect on fungal virulence were assessed against *C. albicans* strains. The obtained data suggested that Cupferron could represent a promising drug for the treatment of *C. albicans* infections.

Materials and Methods: The cytotoxicity of Cupferron was evaluated via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) on VERO cells and hemolysis assays on human erythrocytes (400 – 1.56 µg/mL). The antifungal potential was assessed via disk diffusion test, broth microdilution method, time-killing assay and live-dead evaluation. Cupferron effect on phospholipase and catalase activity, as well as on yeast-to-hyphal transition was estimated.

Results: Cupferron exhibited cytotoxicity and hemolysis rates below 18% at concentrations below 200 µg/mL. The minimum inhibitory concentration (MIC) of the compound was 50 µg/mL, exerting fungistatic action. MIC and sub-MIC concentrations of Cupferron significantly reduced the activity of phospholipase and catalase and hyphae formation.

Discussion and Conclusions: Cupferron impairs fungal growth and some virulence factors involved in the invasiveness of *C. albicans*. Given the low rates of cytotoxicity at active concentrations and the growing interest in the search for new antifungal drugs, Cupferron could represent a promising candidate for *C. albicans* infections.

220 - Fourier Transform Infrared (FT-IR) Spectroscopy as new approach to analyze the clonal relationship of *Citrobacter koseri* and real time outbreak tracing

Mattia Scarazzai ⁽¹⁾ - Anna Bertoncelli ⁽¹⁾ - Davide Gibellini ⁽¹⁾ - Annarita Mazzariol ⁽¹⁾

Università di Verona, Dipartimento di Diagnostica e Sanità Pubblica, Verona, Italia ⁽¹⁾

Fourier Transform Infrared (FT-IR) Spectroscopy as new approach to analyze the clonal relationship of *Citrobacter koseri* and real time outbreak tracing.

MATTIA SCARAZZAI, ANNA BERTONCELLI, DAVIDE GIBELLINI, ANNARITA MAZZARIOL

Department of Diagnostics and Public Health, University of Verona, Verona Italy

Introduction. *Citrobacter* are opportunistic pathogens, we can identify different groups of patients that suffered for *Citrobacter* associated infection and almost everyone present immunocompromised situation. *C. koseri* is an opportunistic pathogen that shows the highest tropism for Central Nervous System among *Citrobacter* species. Nowadays the rapid identification of possible hospital or community outbreak is important to take preventive measure in order to contain the spread of specific strain. The study aims of evaluate the Fourier Transform Infra-Red (FT-IR) approach for the detection of clonal relationship of *C. koseri* strains.

Material and methods. 107 *C. koseri* strains were included in the study and they were isolated from different specimen. The 107 *C. koseri* were divided into 2 groups: 56 strains were clonally related with different DNA typing technique, 51 were not genotypically related with the first group.

To investigate the clonal relationship among the isolated strains was performed three different genetic approaches: Pulsed Field Gel Electrophoresis (PFGE), core genome Multi Locus Sequence Typing (cgMLST) and PCR that target a region that belong only to a particular clonal strain. To keep preanalytical variable as standardized as possible, spectra acquisition with FT-IR (IR Biotyper, Bruker) was performed from strains grown on Tryptic Soy Agar medium at 37°C for 24h±1h. Data analysis of acquired spectra were performed with different statistical tools that are already included in the software: Euclidian single linkage (dendrogram), Principal Component Analysis (2D or 3D scatter plot and deviation plot) and Linear Discriminant Analysis (LDA). To evaluate the concordance among the FT-IR and the genetic typing methods (PFGE and cgMLST) we calculate the Adjusted Random coefficient (AR), Adjusted Wallace coefficient (AW) with corresponding Confidence Interval (CI) and Simpson's Index (SI).

Results

We start from known genetic data, in order to set up an epidemiological analysis using a new proteomic approach named FT-IR spectroscopy

Among the 56 clonal strains, 52 were grouped in a cluster and four of them form a new cluster. This event may occur due to biochemical modification in the microorganism, which were not detected by genetic typing, but further analysis may clarify this theory. During the analysis of non-clonal strains, we also discovered the presence of another cluster composed by 12 isolates. The clonality of the new cluster was confirmed with PFGE, except for an isolate. We found out also two cluster composed each by two isolates that were confirmed related by PFGE analysis.

Conclusions. FT-IR may represent a valid alternative to classical genetic typing method, especially for the saving of time, which allow performing a real-time epidemiological analysis. This study implement the few data available nowadays about the concordance between DNA based typing method and FT-IR biotyping. This rapid typing analysis produce a real time epidemiological surveillance, which may be an important factor in prevention of large spread of strains that may be highly pathogenic or that may carry Multi Drug Resistance

221 - Prevalence and antimicrobial profile of *Pseudomonas aeruginosa* in clinical isolates collected at Ruggi d'Aragona Hospital in 2015-2019 period

ENRICA SERRETIELLO⁽¹⁾ - VERONICA FOLLIERO⁽¹⁾ - DOMENICO IERVOLINO⁽²⁾ - ADELE SANTANGELO⁽¹⁾ - ALESSANDRO PERRELLA⁽³⁾ - EMANUELA SANTORO⁽⁴⁾ - VINCENZO CASOLARO⁽⁴⁾ - MASSIMILIANO GALDIERO⁽¹⁾ - MARIO CAPUNZO⁽⁴⁾ - GIANLUIGI FRANCI⁽⁴⁾ - GIOVANNI BOCCIA⁽⁴⁾

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", NAPOLI, Italia⁽¹⁾ - Department of Public Health and Infectious Diseases, Sapienza University of Rome, ROMA, Italia⁽²⁾ - Division Emerging Infectious Disease and High Contagiousness, OSPEDALE D. COTUGNO, NAPOLI, Italia⁽³⁾ - Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, BARONISSI, SALERNO, Italia⁽⁴⁾

Prevalence and antimicrobial profile of *Pseudomonas aeruginosa* in clinical isolates collected at Ruggi d'Aragona Hospital in 2015-2019 period.

ENRICA SERRETIELLO¹, VERONICA FOLLIERO¹, DOMENICO IERVOLINO², ADELE SANTANGELO¹, ALESSANDRO PERRELLA³, EMANUELA SANTORO⁴, VINCENZO CASOLARO⁴, MASSIMILIANO GALDIERO¹, MARIO CAPUNZO⁴, GIANLUIGI FRANCI^{4,5}, GIOVANNI BOCCIA^{4,5}

1. Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy;
2. Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy;
3. Division Emerging Infectious Disease and High Contagiousness, Hospital D Cotugno, Naples, Italy;
4. Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy;
5. Dai Department of "Igiene Sanitaria e Medicina Valutativa U.O.C. Patologia Clinica E Microbiologica, Azienda Ospedaliero-Universitaria S. Giovanni di Dio e Ruggi D'Aragona, Scuola Medica Salernitana", Largo Città di Ippocrate, Salerno, Italy.

Introduction: *Pseudomonas aeruginosa* (*P. aeruginosa*) is a Gram-negative, ubiquitous environmental and opportunistic pathogenic bacteria. Able to infect several human districts, especially, the respiratory and the urinary tract, and skin, in immunocompromised patients it can provoke persistent infections. Being a biofilms producer bacterium, *P. aeruginosa* is involved in clinical field and nosocomial infections. Its aggressiveness is also due to its inherent antibiotic resistance and to a large repertoire of virulence factors. The present retrospective study focusses the *P. aeruginosa* presence among samples collected at Ruggi d'Aragona hospital in Salerno, its resistance profile with the relative variations during the five years analyzed.

Material and Methods: samples collected from patients by 0-98 years in the 2015-2019, resulted positive for PA growth, were analyzed. Bacterial identification and antibiotic susceptibility tests were carried out by VITEK® 2. Database and statistical analysis were performed by Excel and R software, respectively.

Results: In the 2015-2019 time frame, 1621 isolates of *P. aeruginosa* resulted from respiratory samples (33.6%), wound swabs (21.3%), urine culture (16.9%), cultural swab (12.4%), blood and liquor culture (7.5%), catheters (3.9%), vaginal swabs (2.7%), and others (1.5%). Male resulted more susceptible, with an incidence of 58.7%, in respect to the female (41.3%). The isolated strains resulted low resistant versus amikacin (17.4%), gentamicin (25.4%), and cefepime (28.2%), moderately resistant versus ceftazidime (34.3%), imipenem (35%), and piperacillin/tazobactam (37.6%), highly resistant versus ciprofloxacin (42.5%) and levofloxacin (49.7%).

Discussion and Conclusion: Albeit picks recorded during the five years, a decreasing trend was observed for ceftazidime, imipenem, gentamicin, and amikacin. Several new alternative strategies for ESKAPE treatment are underway. Monitor the sentinel germs in own reality, their frequency, distribution and antibiotic resistance trend variations over time is useful to optimize their antibiotic treatment, avoiding the antibiotic resistance phenomena spread

222 - Biofilm formation, genetic signatures, and antimicrobial resistance profile of *Neisseria gonorrhoeae* strains

Anna Carannante⁽¹⁾ - Enea Di Domenico⁽²⁾ - Paola Vacca⁽¹⁾ - Ilaria Cavallo⁽³⁾ - Francesca Sivori⁽³⁾ - Luigina Ambrosio⁽¹⁾ - Paola Stefanelli⁽¹⁾

Istituto Superiore di Sanità, Department Infectious Diseases, Rome, Italia⁽¹⁾ - Sapienza University, Department of Biology and Biotechnology "C. Darwin", Rome, Italia⁽²⁾ - IRCCS San Gallicano Institute, Microbiology and Virology, Rome, Italia⁽³⁾

Biofilm formation, genetic signatures, and antimicrobial resistance profile of *Neisseria gonorrhoeae* strains

ANNA CARANNANTE¹, ENEA GINO DI DOMENICO², PAOLA VACCA¹, ILARIA CAVALLO³, FRANCESCA SIVORI³, LUIGINA AMBROSIO¹, PAOLA STEFANELLI¹

¹Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; ²Department of Biology and Biotechnology

"C. Darwin", Sapienza University, Rome, Italy; ³Microbiology and Virology, IRCCS San Gallicano Institute, Rome, Italy.

***Gruppo di Studio per l'antibiotico-resistenza in *Neisseria gonorrhoeae*:** Elisabetta Pagani, Richard Ashbacher, Patrizia Innocenti: Ospedale di Bolzano, Laboratorio Aziendale di Microbiologia e Virologia, Bolzano; Stefano Grandesso, Rita Baradello: Ospedali di San Donà di Piave, Azienda ULSS4 Veneto Orientale-Laboratorio Analisi-Microbiologia, Portogruaro; Eliana Modolo: Ospedale di Belluno-Laboratorio di Microbiologia, AULSS1 Dolomiti, Belluno; Giuseppa Fornaro: Ospedale di San Bortolo-Servizio di Microbiologia, Vicenza; Davide Gibellini, Maria M Lleo Fernandez: Università di Verona-Settore Genito-urinario e infezioni a trasmissione sessuale (AOUI verona), Verona; Ivano Dal Conte: Clinica SoS Infezioni Sessualmente Trasmesse, Dipartimento di Malattie Infettive, Ospedale Amedeo di Savoia, Torino; Anna Lucchini, Valeria Ghesetti, Simonetta Del Re, Gabriella Gregori: Laboratorio di Microbiologia e Virologia, Dipartimento di Malattie Infettive, Ospedale Amedeo di Savoia, Torino; Federica Poletti, Giuseppina Caffiero, Loredana Pangaro: Ospedale Sant'Andrea, Laboratorio di Microbiologia, Vercelli; Maria Agnese Latino, Ester Gaido: Dipartimento di Medicina di Laboratorio, P. O. Sant'Anna, Città della Salute e della Scienza di Torino, Torino; Anna M Barbui: Laboratorio di Microbiologia e Virologia, Ospedale Molinette, Torino; Sergio Del Monte: Clinica MST di Ospedale Dermatologico San Lazzaro, 'A. O. U. Città della Salute e della Scienza di Torino; Rosanna Cavallo, Alessandro Bondi: SC Microbiologia e Virologia, Città della Salute e della Scienza di Torino, Torino; Marco Cusini, Patrizia Bono, Stefano Ramoni: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano; Alberto Matteelli, Maurizio Gulletta: Istituto di Malattie Infettive e Tropicali, Università di Brescia, Brescia; Maria A De Francesco: Dipartimento di Medicina Molecolare e Traslazionale, Sezione di Microbiologia, Università di Brescia, Brescia; Gian Maria Rossolini: Università di Firenze, Dipartimento di Medicina Clinica e Sperimentale, Firenze; Alessandra Fontanelli, Eleonora Riccobono, Andrea Bartolini: Ospedale Careggi, Unità di Microbiologia e Virologia, Firenze; Maria C Re, Antonietta D'Antuono, Caterina Vocale: Azienda Ospedaliero-Universitaria di Bologna, Laboratorio CRREM, Policlinico S. Orsola-Malpighi, Bologna; Antonella Mencacci, Arduino Melelli Roia: Sezione di Microbiologia, Dipartimento di Medicina Sperimentale, Università di Perugia, Perugia; Antonella Pocognoli, Annamaria Masucci: Azienda Ospedaliero Universitaria- Ospedali Riuniti di Ancona; Ancona; Aldo Di Carlo, Fulvia Pimpinelli, Antonio Cristaudo, Grazia Prignano, Massimo Giuliani, Alessandra Latini, Mirko Frasca: IFO-IRCCS S. Gallicano, Roma; Carmen Luciana Bonanno, Maria Carmela Cava: UO di Microbiologia e Virologia, Ospedale Sandro Pertini, Roma, Raffaele Antonetti, Rossella De Nittis: Dipartimento di Patologia Clinica, Azienda Ospedaliero-Universitaria OORR, Ospedali Riuniti, Foggia.

Introduction *Neisseria gonorrhoeae* is able to produce biofilms thus might be considered as a factor leading both to persistent of gonorrhea infections as well as influence the antimicrobial resistance profile. This study aims to evaluate the relationship between biofilm-forming capacity, the presence of some specific genetic signature by whole-genome sequencing (WGS), and the antimicrobials resistance profiles in *N. gonorrhoeae*. **Materials and Methods** A sample of 22 gonococci was analysed together with 5 World Health Organization (WHO) reference strains. The Biofilm Ring Test (BRT) method was used to quantify the biofilm production of *N. gonorrhoeae in vitro*, the attachment and initial biofilm formation in the presence of DNase, and to assess the kinetic of early biofilm formation. The phenotypic characterization

of gonococci was assessed by gradient diffusion methods (E-Test and MIC Test Strip) to define the antimicrobial susceptibility profiles. The genome sequencing was performed by Illumina NextSeq 500 platform, and the genomes were analyzed on <https://pubmlst.org/organisms/neisseria-spp/>. **Results** Strong biofilm producers (SBPs) were 71.4%, while 28.6% were classified as weak biofilm producers (WBPs). The cut-off for SBP classification was defined as three standard deviations above the mean BRT values obtained for the *N. gonorrhoeae* ATCC 49226 reference strain. In addition, DNase I treatment caused a significant ($P < 0.001$) reduction compared with proteinase K in the initial microbial attachment and biofilm formation. This suggests that biofilm formation in *N. gonorrhoeae* depends more on extracellular DNA (eDNA) than on protein production. Among SBP, four gonococci showed a decreased susceptibility to cefixime and resistance to ciprofloxacin. The majority of them belong to genogroup (G)1407 and to the *N. gonorrhoeae* sequence typing for antimicrobial resistance (NG-STAR) ST90 and Multi Locus Sequence Type (MLST) ST1901. The core genome MLST (cgMLST) scheme, which utilizes a set of 1649 loci, highlighted a high genetic diversity of gonococci. By genomic analysis of the target genes involved in biofilm production, we observed that the allele type 12 of the *nagZ* gene, which is involved in gonococcal biofilm disassembly, was predominant among the WBP producers. **Discussion and Conclusions** The results represent a first step beyond the state-of-art of antimicrobial resistance providing a novelty in the evaluation of *N. gonorrhoeae* resistant isolates.

223 - In vivo evolution of ceftazidime-avibactam and meropenem-vaborbactam resistance in a KPC-producing *Klebsiella pneumoniae* from meningoencephalitis complicated with brain abscess

Marco Coppi⁽¹⁾ - EMMA PRUNERI⁽²⁾ - DILETTA BASAGNI⁽²⁾ - ALBERTO ANTONELLI⁽¹⁾ - VINCENZO DI PILATO⁽³⁾ - TOMMASO GIANI⁽¹⁾ - BRUNO VIAGGI⁽⁴⁾ - GIAN MARIA ROSSOLINI⁽¹⁾

University of Florence, Department of Experimental and Clinical Medicine, Florence, Italia⁽¹⁾ - University of Florence, Department of Health Sciences, Florence, Italia⁽²⁾ - University of Genoa, Department of Surgical Sciences and Integrated Diagnostics, Genoa, Italia⁽³⁾ - Florence Careggi University Hospital, Department of Anaesthesiology, Neuro Intensive Care Unit, Florence, Italia⁽⁴⁾

***In vivo* evolution of ceftazidime-avibactam and meropenem-vaborbactam resistance in a KPC-producing *Klebsiella pneumoniae* from meningoencephalitis complicated with brain abscess**

MARCO COPPI^{1,2}, EMMA PRUNERI^{3,4}, DILETTA BASAGNI^{3,4}, ALBERTO ANTONELLI^{1,2}, VINCENZO DI PILATO^{2,5}, TOMMASO GIANI^{1,2}, BRUNO VIAGGI⁴, GIAN MARIA ROSSOLINI^{1,2}

1 Department of Experimental and Clinical Medicine, University of Florence, Italy; 2 Microbiology and Virology Unit, Florence Careggi University Hospital, Italy; 3 Department of Health Sciences, University of Florence, Florence, Italy; 4 Department of Anaesthesiology, Neuro Intensive Care Unit, Florence Careggi University Hospital, Florence, Italy, 5 Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Italy.

Introduction The worldwide spread of carbapenemase-producing *Klebsiella pneumoniae* (Kp), steered by several high-risk clones, has been recognized as a worrisome public health challenge. Although the beta-lactam/beta-lactamase inhibitor combinations as ceftazidime-avibactam (CZA) and meropenem-vaborbactam (MVB) were recently introduced as novel therapeutic options against Class A beta-lactamases (e.g., KPC-type), resistance to CZA and/or MVB cases have been already reported, mostly associated with enzyme mutations (only for CZA resistance), or with porin alterations and increased *bla*_{KPC} expression (cross-resistance). This work reports on the characterization of a CZA-MVB resistant KPC-producing *K. pneumoniae*, selected *in vivo* during CZA therapy. **Materials and Methods** Kp KP16340 and KP16600 were sequentially isolated from rectal swabs, before and after therapy with CZA, respectively, in a patient with a KPC-producing Kp (KP16537) meningoencephalitis with brain abscess. Species identification and antimicrobial susceptibility testing were performed using MALDI-TOF MS and reference broth microdilution, respectively. Results were interpreted according to the EUCAST clinical breakpoints v.12. Meropenem (MEM) hydrolyzing specific activity was determined for KP16340, KP16357, KP16600 and Kp FIPP-1 as comparator strain. The *bla*_{KPC} copy number was evaluated by a relative qPCR quantification. Whole-Genome Sequencing (WGS) was performed on KP-16340 and KP16600 to verify the presence of mutations in KPC and porins and clonal relatedness, using tools of Center for Genomic Epidemiology (www.genomicepidemiology.org). Gene transfer experiments were carried out with *Escherichia coli* DH10B on Mueller-Hinton agar supplemented with ceftazidime 4 mg/L. **Results** KP16340, KP16357 and KP16600 showed CZA MICs of 4, 8 and 32 mg/L, respectively. KP16600 also presented a MVB MIC of 32 mg/L. Moreover, KP16600 showed an increased MEM hydrolysing activity (2.25-fold vs KP16340), due to an increased number of copies of the *bla*_{KPC} gene (7.7-fold vs KP16340). WGA analysis revealed that both KP16340 and KP16600 belonged to ST2502, a single locus variant of the high-risk clone ST101 and were almost identical in the core genome (1 SNP), with the same porin status and KPC allelic variant. The *bla*_{KPC}-harbouring plasmids of KP16600 were successfully transferred to *E. coli* DH10B, which, after the transfer, showed an increased MIC to CAZ/AVI (from ≤1/4 to 2/4). **Discussion and Conclusions** The increased expression of *bla*_{KPC-3} in KP16600, putatively due to a rearrangement of the *bla*_{KPC} harbouring plasmid, with the addition of a truncated OmpK35 and a GD (134-135) duplication in OmpK36, could be associated with the rapid *in vivo* development of resistance to both CZA and MVB.

228 - Niclosamide as a Repurposing Drug against *Corynebacterium striatum* Multidrug-Resistant Infections

Federica Dell'Annunziata⁽¹⁾ - Veronica Folliero⁽¹⁾ - Emanuela Roscetto⁽²⁾ - Marcella Cammarota⁽¹⁾ - Federica Carillo⁽¹⁾ - Anna De Filippis⁽¹⁾ - Chiara Schiraldi⁽¹⁾ - Maria Rosaria Catania⁽²⁾ - Vincenzo Casolaro⁽³⁾ - Alessandro Perrella⁽⁴⁾ - Massimiliano Galdiero⁽¹⁾ - Gianluigi Franci⁽³⁾

University of Campania "Luigi Vanvitelli", Department of Experimental Medicine, Napoli, Italia⁽¹⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, Napoli, Italia⁽²⁾ - University of Salerno, Baronissi, Department of Medicine Surgery and Dentistry, Salerno, Italia⁽³⁾ - Hospital D Cotugno, Division Emerging Infectious Disease and High Contagiousness, Napoli, Italia⁽⁴⁾

Niclosamide as a Repurposing Drug against *Corynebacterium striatum* Multidrug-Resistant Infections

FEDERICA DELL'ANNUNZIATA¹, VERONICA FOLLIERO¹, EMANUELA ROSCETTO², MARCELLA CAMMAROTA¹, FEDERICA CARRILLO¹, ANNA DE FILIPPIS¹, CHIARA SCHIRALDI¹, MARIA ROSARIA CATANIA², VINCENZO CASOLARO³, ALESSANDRO PERRELLA⁴, MASSIMILIANO GALDIERO¹, GIANLUIGI FRANCI^{3,5}

1. Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy;
2. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy;
3. Department of Medicine Surgery and Dentistry, University of Salerno, Baronissi, Salerno, Italy;
4. Division Emerging Infectious Disease and High Contagiousness, Hospital D Cotugno, Naples, Italy;
5. Clinical Pathology and Microbiology Unit, San Giovanni di Dio e Ruggi D'Aragona University Hospital, Salerno, Italy.

Introduction: *Corynebacterium striatum* (*C. striatum*) is an emerging multidrug-resistant (MDR) pathogen associated with nosocomial infections. Due to the depletion of effective antibiotics, drug-repurposing as an alternative approach to discovering new potential antibiotics is attracting considerable interest. Since these drugs are approved by the Food and Drug Administration (FDA), information on their pharmacological characteristics (chemical stability, toxicity, dosage, action kinetics, etc.) is readily available. This reduces the time and economic costs required to evaluate new therapeutic applications. In this scenario, we screened the antimicrobial activity of the anthelmintic drugs doramectin, moxidectin, selamectin and niclosamide against 20 *C. striatum* MDR clinical isolates. Among these, niclosamide was the best performing drug against *C. striatum*.

Material and Methods: The antibacterial efficacy was determined via disc diffusion, broth microdilution, time-killing assays and Scanning Electron Microscopy. The biofilm biomass eradicating action was investigated through crystal violet (CV), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and confocal laser scanning microscopy (CLSM). Niclosamide cytotoxicity was evaluated by MTT assay on immortalized human keratinocyte cells (HaCaT). The intracellular action of niclosamide was evaluated by gentamicin protection assay, in HaCaT cells.

Results: Among the anthelmintic drugs, doramectin and moxidectin did not exhibit effective antibacterial activity in the concentration range tested, while selamectin showed a MIC₉₀ value of 6.25 µg/mL. Niclosamide represented the pharmacological agent with the best performing antibacterial activity, recording a MIC₉₀ value of 0.39 µg/mL. Moreover, the drug-induced a growth inhibitory area of 22 mm in agar plates and exhibited bactericidal action after 20 hours of treatment. Niclosamide affected the biofilm viability in a dose-dependent manner and degraded biomass by 55 and 49% at 0.39 µg/mL and 0.19 µg/mL. CLSM images confirmed the biofilm biomass degradation, showing a drastic reduction in cell viability. The MTT assay after 20 h of treatment on HaCaT cells recorded a 50% cytotoxic concentration (CC₅₀) at 2.56 µg/mL. The dose of 1.56 µg/mL was sufficient to inhibit the replication of *C. striatum* into HaCaT cells by

approximately 400 times, resulting in an intracellular load of 1.5×10^4 CFU / mL relative to 7×10^6 CFU / mL in untreated cells.

Discussion and Conclusions: Our findings demonstrate that niclosamide represents a safe therapeutic agent with strong antibacterial and antibiofilm activity. This study could promote the drug-repurposing of the anthelmintic FDA-approved niclosamide as a therapeutic agent to counteract the *C. striatum* MDR infections.

229 - Giving drugs a second chance: identification of drugs active against *Pseudomonas aeruginosa* from cystic fibrosis patients using a drug repurposing strategy

ARIANNA POMPILIO⁽¹⁾ - VERONICA LUPETTI⁽¹⁾ - LISA CARIANI⁽²⁾ - GIOVANNI DI BONAVENTURA⁽¹⁾

Università, Università degli Studi "G. d'Annunzio" di Chieti-Pescara / Dipartimento di Scienze Mediche, Orali e Biotecnologiche, CHIETI, Italia⁽¹⁾ - Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico/ Fondazione IRCCS Ca' Granda, MILANO, Italia⁽²⁾

Giving drugs a second chance: identification of drugs active against *Pseudomonas aeruginosa* from cystic fibrosis patients using a drug repurposing strategy

ARIANNA POMPILIO,¹ VERONICA LUPETTI,¹ LISA CARIANI,² GIOVANNI DI BONAVENTURA¹

¹Department of Medical, Oral and Biomedical Sciences; and Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Microbiology Unit, Chieti, Italy; ² Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Microbiology Unit, Milan, Italy

Introduction. *Pseudomonas aeruginosa* causes chronic airway infections in cystic fibrosis (CF) patients. The multidrug resistance this pathogen shows does the search for novel antibiotics urgent. In the present study, a drug repurposing approach was used to find drugs active against *P. aeruginosa* under experimental conditions relevant to CF. **Materials and Methods.** A total of 3386 approved and clinical drugs (Drug Repurposing Compound Library; HY-L035; MedChemExpress, Sollentuna, Sweden) were screened, each at 0.1 mM, against *P. aeruginosa* RP73 under "CF-like" conditions - i.e., artificial sputum medium, pH 6.8, and 5% CO₂. After 24 h-incubation at 37°C, the antibacterial activity was assessed by spectrophotometric reading (OD₆₂₀) and tetrazolium-based assay (OD₄₉₂; CellTiter AQueous One Solution, Promega Italia, Milan, Italy). A potential "antibacterial hit" was identified for OD₆₂₀ or OD₄₉₂ reduction of ≥ 90%. The antibacterial potential of the hits was then furtherly explored against 10 *P. aeruginosa* CF strains, selected for their virulence and antibiotic-resistance traits: MIC and MBC values were measured by broth microdilution assay, whereas time-kill assay was performed against RP73 strain. The potential for cytotoxicity was assessed towards IB3-1 CF bronchial epithelial cells by CellTiter AQueous One Solution (Promega). **Results.** The initial screening towards RP73 strain identified a total of 14 (14 out of 3386, 0.4%) hits, namely drugs that have been developed for therapeutic indications other than antibacterial. Hits were classified according to their therapeutic indications (cancer, n=12; anti-infection - i.e., antiparasitic, antifungal or antiviral - n=2) and clinical information (launched, n=9; phase 3, n=5). Using a set of *P. aeruginosa* CF strains, we found that antibacterial activity was highly preserved by auranofin (MIC₅₀: 0.025 mM; MIC₉₀: 0.1 mM), followed by 5-fluorouracil (MIC₅₀: 0.025 mM; MIC₉₀: 0.2 mM), and tirapazamine (MIC₅₀: 0.05 mM; MIC₉₀: 0.2 mM). MBC₅₀ values were less changeable, ranging from 0.2 to >0.2 mM, while MBC₉₀ was always higher than 0.2 mM. Time-kill results showed bacteriostatic activity of most hits, except for ebselen that at 4xMIC caused 100% killing already after 2 h-exposure. Cytotoxicity tests revealed the best profile for tavaborole, L-SelenoMethionine, and 5-fluorouracil being not toxic until 8 uM. Generally, hits were not toxic at the antibacterial concentrations, except for auranofin (already toxic at 0.0126 uM).

Discussion and Conclusions. Our results defined some drugs that have the potential to be repurposed as antibacterial agents toward *P. aeruginosa* and, therefore, may represent progenitor scaffolds for new classes of anti-*P. aeruginosa* agents. *In vitro* and *in vivo* efficacy/toxicity studies are ongoing for further screening.

230 - T2Bacteria® Panel sensitivity in bone marrow transplanted neutropenic febrile patients

Fabio Buffoli ⁽¹⁾ - Pierfrancesco Rizzi ⁽¹⁾ - Enzo Scifo ⁽¹⁾ - Silvia Carletti ⁽²⁾ - Floriana Gona ⁽²⁾ - Davide Carcione ⁽²⁾ - Nicola Clementi ⁽¹⁾ - Nicasio Mancini ⁽¹⁾ - Andrea Acerbis ⁽³⁾ - Edoardo Campodonico ⁽³⁾ - Raffaella Greco ⁽⁴⁾ - Daniela Clerici ⁽⁴⁾ - Massimo Clementi ⁽²⁾ - Fabio Ciceri ⁽³⁾

Università Vita-Salute San Raffaele, Università Vita-Salute San Raffaele Laboratorio di Microbiologia e Virologia, Milano, Italia ⁽¹⁾ - IRCCS Ospedale San Raffaele, IRCCS Ospedale San Raffaele Laboratorio di Microbiologia e Virologia, Milano, Italia ⁽²⁾ - Università Vita Salute San Raffaele, Università Vita Salute San Raffaele Unità di Ematologia e Trapianto di Midollo Osseo, Milano, Italia ⁽³⁾ - IRCCS Ospedale San Raffaele, IRCCS Ospedale San Raffaele Unità di Ematologia e Trapianto di Midollo Osseo, Milano, Italia ⁽⁴⁾

T2Bacteria® Panel sensitivity in bone marrow transplanted neutropenic febrile patients

FABIO BUFFOLI¹, PIERFRANCESCO RIZZI¹ ENZO SCIFO,¹ SILVIA CARLETTI², FLORIANA GONA², DAVIDE CARCIONE², NICOLA CLEMENTI¹⁻², NICASIO MANCINI¹⁻², ACERBIS ANDREA³, EDOARDO CAMPODONICO³, GRECO RAFFAELLA⁴ CLERICI DANIELA⁴, MASSIMO CLEMENTI¹⁻², CICERI FABIO³⁻⁴

¹Laboratory of Microbiology and Virology Vita-Salute San Raffaele University, Milan Italy

²Laboratory of Microbiology and Virology IRCCS San Raffaele Scientific Institute, Milan Italy

³Hematology and Bone Marrow Transplantation Unit, Vita-Salute San Raffaele University, Milan Italy

⁴Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan Italy

Despite a general drop in mortality rate, sepsis is still one of the major causes of death urging for new tools that could help shortening the diagnostic turnaround time. Blood culture is still the gold standard, but many diagnostic algorithms have included molecular techniques from positive blood cultures, thus reducing average time to identify relevant pathogens and to detect genes of resistance. Other molecular diagnostics were developed to be used directly on blood samples, such as the T2Dx system.

In this study, we evaluated the T2Bacteria® panel in our diagnostic routine of neutropenic bone marrow transplanted patients.

We collected samples from patients in bone marrow transplant unit and hematology day hospital in IRCCS San Raffaele hospital. We included samples associated with first fever for each septic event. Blood samples were processed from 9.00 to 19.00 and results were referred to clinicians. No antimicrobial therapy was changed or modified according to T2Dx results. Positive blood cultures were processed during the same time shift.

Seventy-seven samples were collected, but seven were excluded due to technical issues. Comparing the results of T2Dx system with blood culture results, most were matched negative tests (49). Nine positive T2Bacteria®panels included matched positive blood culture (5) and positive tests with no matched blood culture (4). We found twelve negative tests associated with positive blood cultures with nine out of twelve species included in the panel. According to our results overall sensitivity was 50%, considering ESKAPE group only, lowering to 42% considering other bacteria. Considering off-hours (19.00 - 9.00) we esteemed an average time of blood culture positivity of 15 hours with longer times needed to process blood cultures if positivity occurred during nightshifts.

Despite other studies showed high sensitivity and considerable reduction in starting appropriate antimicrobial therapy according to T2Bacteria®results, no studies were available on bone marrow transplanted patients yet. We have not definitive explanations on the factors contributing to the low sensitivity observed, but they may include kinetics of Gram-negative bacteria during the septic event in these patients or possible drug interactions. Further studies are certainly needed. Moreover, our study highlights the importance of a 24/7 microbiology lab is crucial to fully benefit the impact of new molecular techniques. Many positive tests were in fact referred to clinicians the morning after when the matched blood culture was positive and processable for further testing

231 - Preliminary data of the prevalence of *Capnocytophaga* spp in kennel dogs and feline colonies of North-East Italy: emergent zoonotic bacteria?

Elena Spagnolo ⁽¹⁾ - Michela Corrà ⁽¹⁾ - Mery Campalto ⁽¹⁾ - Flavio Sbardellati ⁽²⁾ - Marilena Carrino ⁽¹⁾ - Elisa Mazzotta ⁽¹⁾ - Alda Natale ⁽¹⁾

Istituto Zooprofilattico delle Venezie, SCT3 - Diagnostica in sanità animale, Legnaro (PD), Italia ⁽¹⁾ - Azienda Ulss 9 Scaligera, Azienda Ulss 9 Scaligera, Verona (VR), Italia ⁽²⁾

TITOLO: Preliminary data of the prevalence of *Capnocytophaga* spp in kennel dogs and feline colonies of North-East Italy: emergent zoonotic bacteria?

Authors: Elena Spagnolo ⁽¹⁾, *Michela Corrà* ⁽¹⁾, *Mery Campalto* ⁽¹⁾, *Flavio Sbardellati* ⁽²⁾, *Marilena Carrino* ⁽¹⁾, *Elisa Mazzotta* ⁽¹⁾, *Alda Natale* ⁽¹⁾

(1) Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe), Padua, Italy

(2) Azienda Ulss 9 Scaligera, Verona, Italy

1. Introduction: *Capnocytophaga* spp. (*C. spp*) is recently isolated a commensal microorganism of human and animals, some species are common in human (*C. ochracea*, *C. sputigena*, *C. gingivalis*), other in animals (*C. cynodegmi*, *C. canimorsus*, *C. canis*). This microorganism could cause infection in humans, especially in subjects with precarious health condition. Infection occurs via cat or dog bite or after a close contact with the animal's saliva. According to the literature, infection in humans could have serious complication (e.g. sepsis, endocarditis, death) which are mainly caused by *C. canimorsus* (*C. ca*), while other species could cause minor infection like *C. cynodegmi* (*C. cy*). As *Capnocytophaga* is considered as an emergent zoonosis is necessary to develop a method to specifically isolate and identify it. In this work are reported preliminary data of a study conducted in kennels dogs and feline colonies of North-East Italy, evaluating the prevalence of this microorganism in dogs and cats and to identify the present species by both molecular and culture methods.
2. Materials and methods: Oral swabs obtained from dogs and cats were analysed in IZSVe laboratory: Swabs was subjected to bacteriological examination, suspected *C. spp* colonies were identified by biochemical methods and species identification was performed by MALDI-TOF mass-spectrometry (MTMS). Moreover, the presence of *Capnocytophaga* was investigated by Real Time PCR using the method developed by Dam et al. (2009) based on two different species-specific PCRs for *C. ca* and *C. cy*.
3. Results: In 2021 was sampled 346 animals (44% dogs, 56% cats). By bacterial culture *C. spp* was isolated in 13% of dogs and 6% of cats. Among the positive samples, 43% are *C. cy* and remaining results to be "not identifiable". Real Time PCRs reported an overall positivity of 66% for *C. spp*: 27% result to be positive for *C. cy*, 25% as *C. ca* and remaining shown a double positivity for both species.
4. Discussion and conclusion: This work reports preliminary data of a research conducted on the prevalence of *C. spp* in kennels dogs and feline colony in North-East area. Identification and isolation was performed with both microbiological and molecular methods. In Oral swabs by culture method *C. spp* was isolated in 13% of cases whereas by Real Time PCRs 66% of cases results as positive. Species identification by MTMS was not very efficient since only a 43% of isolates was identified as *C. cy*. Also, Real time PCR in a lot of cases shows a positivity to both *C. cy* and *C. ca*. These preliminary data highlight that *C. spp* is present in oral flora of dogs and cats, hence the improvement of both bacterial culture and molecular methods to isolate/detect this bacterium is crucial in a One-Health vision. The Italian Ministry of Health [IZSVE 12/19 RC] supported this work.

234 - Antimicrobial applications of bimetallic nanoparticles by heterogenous green synthesis

Pragati Rajendra More⁽¹⁾ - BIANCA MARIA Nastri⁽¹⁾ - Annalisa Ambrosino⁽¹⁾ - Rosa Giuglino⁽¹⁾ - MARCO MANFREDINI⁽¹⁾ - ANTONETTA SCHETTINO⁽¹⁾ - MARIANNA ASCIERTO⁽¹⁾ - FRANCESCO FOGLIA⁽¹⁾ - ANNA DE FILIPPIS⁽¹⁾ - Massimiliano Galderio⁽¹⁾

Department of experimental medicine, University of Campania Luigi Vanvitelli, Naples, Italia⁽¹⁾

Antimicrobial applications of bimetallic nanoparticles by heterogenous green synthesis

PRAGATI R. MORE¹, BIANCA M. NASTRI¹, ANNALISA AMBROSINO¹, ROSA GIUGLIANO¹, MARCO MANFREDINI¹, ANTONETTA SCHETTINO¹, MARIANNA ASCIERTO¹, FRANCESCO FOGLIA¹, ANNA DE FILIPPIS¹, MASSIMILIANO GALDIERO¹

¹ Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 80138 Naples, Italy.

Introduction: The increase of high resistant bacterial strains to antibacterial drugs seriously impacts public health. In recent years, bimetallic nanoparticles, formed through the integration of two different metals, such as silver, gold, and platinum, have shown improved antibacterial efficacy compared to monometallic ones due to the synergistic effects, the wide range of physicochemical properties, and the different mechanism of action. They have shown numerous applications in different fields from the medical to the physical one. To satisfy the increasing demand for commercial NPs, a new eco-friendly “green” method of synthesis has been evolved and it avoids environmental build-up. The aim of this study was focused on the synthesis of bimetallic silver and platinum nanoparticles (AgPtNPs) by a biological source, i.e. *Ocimum basilicum*, and the evaluation of their antimicrobial potential. **Materials and Methods:** *Ocimum basilicum* leaf extract was prepared following the protocol of Saba Pirtarighat et al. In brief, dried samples were ground to a fine powder, double-distilled water was added and the mixture was boiled for 5 min. The aqueous extracts were filtered through Whatman No.1 filter paper after cooling. To synthesize AgPtNPs in the presence of plant extract, *O. basilicum* was mixed with 1 mM AgNO₃ and 1 mM K₂PtCl₄ solution and stirred at 85° C for 60 minutes. The reaction was monitored with UV-Vis spectroscopy. The obtained NPs were centrifuged and washed several times with H₂O to remove any untreated salts and extracts. The pellet was then oven-dried at 40 ° C to obtain the NPs powder. FTIR spectra of extract-reduced AgPtNPs were obtained using a FTIR fitted with an ATR detector in the range of 4000-500 cm⁻¹. The NPs morphology and particle size were determined by using transmission electron microscopy (TEM) at 200kV voltage, meanwhile NPs stability was checked by using the Dynamic light scattering (DLS) technique. The antimicrobial activity of AgPt was tested by using the serial microdilution method against Gram-positive and Gram-negative bacterial pathogens. **Results:** The reduction of noble metal can be confirmed by observing the color change in the reaction. Initially, the color of *O.basilicum* was yellow, although after the addition of AgNO₃ and K₂PtCl₄ under constant shaking at 80° C the color change of reaction was observed turning from dark yellow to an orangish green color indicating the formation of AgPtNPs. After 1 hr of reaction time, UV-Vis spectra of extract of *O.basilicum* capped AgPtNPs showed the peak around 320-450nm. Further, TEM analysis confirmed AgPtNPs size ranged from 20 to 80nm. The NPs were stable with different and formatted spherical shape nanoclusters. The minimum inhibitory concentration (MIC) was analyzed against Gram-positive and Gram-negative bacteria, namely *Escherichia coli*, *Klebsiella pneumonia*, *Enterococcus faecalis*, and *Staphylococcus aureus*, by testing different NPs concentrations from 0.75 to 100 µg/ml. MIC values were around 3.15 µg/ml for all bacteria. **Discussion and Conclusions:** The study has highlighted the potential of bimetallic nanoparticles synthesized by *O. basilicum* extract. Therefore, the combinational activity of AgPtNP can be used for the treatment of multidrug-resistant bacteria as a novel antimicrobial strategy.

235 - Repurposing Selamectin as antimicrobial drug against Hospital-Acquired *Staphylococcus aureus* infections

Veronica Folliero⁽¹⁾ - Federica Dell'Annunziata⁽¹⁾ - Emanuela Roscetto⁽²⁾ - Umberto Galdiero⁽²⁾ - Anna De Filippis⁽¹⁾ - Gianluigi Franci⁽³⁾ - Mariarosaria Catania⁽²⁾ - Massimiliano Galdiero⁽¹⁾

University of Campania "Luigi Vanvitelli", Department of Experimental Medicine, Napoli, Italia⁽¹⁾ - University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, Napoli, Italia⁽²⁾ - University of Salerno, Department of Medicine Surgery and Dentistry, Napoli, Italia⁽³⁾

Repurposing Selamectin as antimicrobial drug against Hospital-Acquired *Staphylococcus aureus* infections

VERONICA FOLLIERO¹, FEDERICA DELL'ANNUNZIATA¹, EMANUELA ROSCETTO², UMBERTO GALDIERO², ANNA DE FILIPPIS¹, GIANLUIGI FRANCI³, MARIAROSARIA CATANIA², MASSIMILIANO GALDIERO¹

1. Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy;
2. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy;
3. Department of Medicine Surgery and Dentistry, University of Salerno, Baronissi, Salerno, Italy

Introduction: *Staphylococcus aureus* (*S. aureus*) represents a clinically relevant pathogen in both the nosocomial and community settings. The emergence of multidrug-resistant strains requires the urgent discovery of new antibacterial drugs. Drug reuse reduces development costs and drug approval time. In this context, an antibacterial screening of anthelmintic avermectins doramectin, moxidectin and selamectin against *S. aureus* was performed.

Material and methods: The antibacterial screening of anthelmintic drugs was performed via broth microdilution method against *S. aureus* ATCC 6538 (50 - 0.4 µg/mL). Among the drugs tested, selamectin had a strong antibacterial action. Therefore, its antibacterial activity was thorough on clinical isolates via time-killing assays and Scanning Electron Microscopy. The potential target of Selamectin was detected through PatchDock and FireDock software. The synergistic effect with Ampicillin was assessed via checkerboard test. The intracellular action of Selamectin was evaluated by gentamicin protection assay in HaCaT cells. The biofilm biomass eradicating activity was assessed via crystal violet (CV) and confocal laser scanning microscopy (CLSM).

Results: Selamectin represents a high-performance drug. Its minimum inhibitory concentration (MIC) was 6.25 µg/mL against all *S. aureus* strains, except for the macrolide resistant isolate (MIC 12.5 µg/mL), exhibiting bactericidal action. This result defined its involvement in the protein synthesis process, confirmed *in silico* through interaction studies with 23S rRNA. As a result, selamectin drug exposure caused cell wall alterations, probably due to changes of the surface protein structures. A synergistic effect was observed between the drug and selamectin, dictated by an FIC value of 0.5 against methicillin-resistant *S. aureus*. We assessed the role of selamectin in the *S. aureus* invasion of human keratinocytes via gentamicin protection assays. Drug administration at 1× MIC reduced the intracellular bacterial load by 81.3%. The biofilm degradation was investigated via crystal violet (CV) and confocal laser scanning microscopy (CLSM). Selamectin degraded the biomass biofilm in a dose-dependent manner with minimal biofilm eradication concentrations inducing 50% (MBEC₅₀) eradication 10.33 µg/mL. The cytotoxic tests proved that selamectin exhibited no relevant hemolytic and cytotoxic activity at concentrations below 12.5 µg/mL.

Discussion and Conclusions: These data, together with the already available *in vivo* toxicity studies, strongly state that selamectin represents the most promising macrocyclic lactone for the treatment of *S. aureus* infections.

237 - In vitro antibacterial and anti-inflammatory activity of *Arctostaphylos uva-ursi* leaf extract against *Propionibacterium acnes*

Roberta Della Marca⁽¹⁾ - Federica Dell'Annunziata⁽¹⁾ - Serena A. Maiella⁽¹⁾ - Stefania Cometa⁽²⁾ - Francesco Busto⁽²⁾ - Elvira De Giglio⁽²⁾ - Gianluigi Franci⁽³⁾ - Anna De Filippis⁽¹⁾ - Massimiliano Galdiero⁽¹⁾

University of Campania "Luigi Vanvitelli", Department of Experimental Medicine, Napoli, Italia⁽¹⁾ - University of Bari, Department of Chemistry, Bari, Italia⁽²⁾ - University of Salerno, Baronissi, Department of Medicine Surgery and Dentistry, Salerno, Italia⁽³⁾

In vitro antibacterial and anti-inflammatory activity of *Arctostaphylos uva-ursi* leaf extract against *Propionibacterium acnes*

ROBERTA DELLA MARCA¹, FEDERICA DELL'ANNUNZIATA¹, SERENA A. MAIELLA¹, STEFANIA COMETA², FRANCESCO BUSTO², ELVIRA DE GIGLIO^{2,3}, GIANLUIGI FRANCI⁴, ANNA DE FILIPPIS¹, MASSIMILIANO GALDIERO¹

1. Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy;
2. Department of Chemistry, University of Bari, Bari, Italy;
3. INSTM, National Consortium of Materials Science and Technology, Florence, Italy;
4. Department of Medicine Surgery and Dentistry, University of Salerno, Baronissi, Salerno, Italy.

Introduction: *Propionibacterium acnes* (*P. acnes*) is the main causative agent of acne vulgaris. Although acne vulgaris is not a life-threatening disease, it has a great social and psychological impact on the patient's life. Today therapeutic options for this disease include the use of antibiotics with some disadvantages as dryness, redness, skin irritation and hyperpigmentation and the improper use of antibiotics for a long time leads to the development of multi-drug resistance. Contextually, the use of natural substrates as a source of bioactive compounds is arousing considerable interest nowadays. The advantages associated with the use of plant extracts concern minimal side effects in the patient, use of renewable compounds and a high degree of safety with low production costs compared to synthetic drugs. For this reason, the study aims to evaluate the antimicrobial activity of a natural product, *Arctostaphylos uva-ursi* leaf extract, against *P. acnes*.

Materials and Methods: *Arctostaphylos uva-ursi* leaf extract antimicrobial activity was evaluated via disk diffusion, microdilution broth, time-killing and live/dead assays. The influence of natural compound on biofilm matrix inhibition and degradation was investigated by the crystal violet (CV) method. The 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide (MTT) test determined the viability of immortalized human keratinocytes (HaCaT) after exposure to *Arctostaphylos uva-ursi* leaf extract, for 24 and 48 hours. Levels of interleukin (IL)-1 β , IL-6, IL-8, and tumour necrosis factor (TNF)- α were quantified after heat-killed *P. acnes* HaCaT cells infection and *Arctostaphylos uva-ursi* leaf extract treatment.

Results: The minimum inhibitory concentration (MIC)-value of *Arctostaphylos uva-ursi* leaf extract against *P. acnes* was 0.6 mg/mL, showing bacteriostatic action and an inhibition zone on agar-plates of 24 ± 1.2 mm. Furthermore, the compound influenced the biofilm formation phases, recording a percentage of inhibition that exceeded 50 and 40% at 0.6 and 0.3 mg/mL, respectively. *Arctostaphylos uva-ursi* leaf extract disrupted biofilm biomass of 57 and 45% at the same concentrations mentioned above. Active *Arctostaphylos uva-ursi* leaf extract doses did not affect the viability of HaCaT cells. On the other hand, at 1.25 and 0.6 mg/mL, complete inhibition of the secretion of pro-inflammatory cytokines was recorded.

Discussion and conclusions: Taken together, these findings indicate that *Arctostaphylos uva-ursi* leaf extract could represent a natural product to counter the virulence of *P. acnes*, representing a new alternative therapeutic option for the treatment of acne vulgaris.

239 - Rapid identification of clinically relevant *Candida* spp. by Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopy

Roberta Fais⁽¹⁾ - Cesira Giordano⁽²⁾ - Maria Rita Calabrese⁽¹⁾ - Arianna Tavanti⁽³⁾ - Simona Barnini⁽²⁾ - Antonella Lupetti⁽¹⁾

Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Università di Pisa, Pisa, Italia⁽¹⁾ - SD Microbiologia Batteriologica, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italia⁽²⁾ - Dipartimento di Biologia, Università di Pisa, Pisa, Italia⁽³⁾

Rapid identification of clinically relevant *Candida* spp. by Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopy

Roberta Fais¹, Cesira Giordano², Maria R. Calabrese¹, Arianna Tavanti³, Simona Barnini², Antonella Lupetti¹

¹Dipartimento di Ricerca Traslationale e delle Nuove Tecnologie in Medicina e Chirurgia, Università di Pisa, Pisa, Italia;

²SD Microbiologia Batteriologica, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italia. ³Dipartimento di Biologia, Università di Pisa, Pisa, Italia.

1. Introduction. Currently Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-ToF MS) and molecular techniques are used in the routine diagnosis of clinically relevant bacteria and yeast. Attenuated Total Reflectance (ATR) Fourier Transform InfraRed (FT-IR) spectroscopy is a spectrum-based technique that quantifies the absorption of infrared light by molecules present in the microbial cell. The IR spectrum provides a specific fingerprint that reflects the cell composition of nucleic acids, proteins, lipids, and carbohydrates. The aim of the present study was to evaluate the performance of the ATR-FTIR spectroscopic technique (I-dOne 2.0 Alifax) compared with the MALDI-TOF MS (Bruker Daltonics) in identifying *Candida* spp. isolated at the Micology Unit of Pisa University Hospital.
2. Materials and Methods. A yeast colony isolated from Sabouraud agar was deposited onto the ATR crystal sampling surface of the ATR-FTIR spectrometer for identification. Spectral acquisition time was approximately 60 s (30 s for the background and 30 s for the sample) and the automated spectral processing and yeast identification required additional 30 s. Yeast identification was performed in triplicate. Each Infrared Spectrum was compared with spectra stored in the software database.
3. Results. Identification performed by I-dOne software of 133 yeast clinical isolates yielded 125 (93,9 %) concordant identification results with MALDI-TOF MS. Two isolates (2.2%) were identified as *Candida* spp. (1 *C. albicans*, 1 *C. parapsilosis*) and six isolates (4.5%) were misidentified at the species level (2 *C. albicans* as *C. psilosis* complex, 2 *C. glabrata* as *C. krusei*, 2 *C. tropicalis* as *C. albicans*).

Discussion and Conclusions. A reliable database for the identification of clinical yeast species has been built. Additional strains belonging to species rarely found in clinical samples and not easily available from laboratory collections should be included to expand the database. The database has several valuable potentials that should be further studied in the next future.

242 - Molecular characterization of linezolid resistance determinants in *Staphylococcus epidermidis* from invasive infections

Ilaria Baccani⁽¹⁾ - Marco Coppi⁽¹⁾ - Lorenzo Paci⁽²⁾ - Alberto Antonelli⁽¹⁾ - Tommaso Giani⁽¹⁾ - Orietta Massidda⁽²⁾ - Gian Maria Rossolini⁽¹⁾

University of Florence, Department of Experimental and Clinical Medicine, Florence, Italia⁽¹⁾ -
University of Trento, Department of Cellular, Computational and Integrative Biology (CIBIO), Trento, Italia⁽²⁾

Molecular characterization of linezolid resistance determinants in *Staphylococcus epidermidis* from invasive infections

ILARIA BACCANI^{1,2}, MARCO COPPI^{1,2}, LORENZO PACI³, ALBERTO ANTONELLI^{1,2}, TOMMASO GIANI^{1,2}, ORietta MASSIDDA³, GIAN MARIA ROSSOLINI^{1,2}

*1*Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; *2* Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy; *3* Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy

Introduction. *Staphylococcus epidermidis* is a common skin and mucosal membranes commensal, able to induce opportunistic infections mainly associated to medical devices. The recent spread of isolates resistant to several classes of antimicrobial compounds, including last resort antibiotics such as linezolid is of concern. Since now, linezolid resistance in *S. epidermidis* has been associated to 23S rRNA, L3, L4 and L22 mutations or the acquisition of transferrable resistance determinants (mainly the methyltransferase Cfr). Therefore, the aim of this work was to characterize the mechanisms of linezolid-resistance of *S. epidermidis* isolated from invasive infections. **Materials and Methods.** Samples collection included *S. epidermidis* strains isolated from clinical specimens collected from June 2014 to July 2021 in the AOU-Careggi Hospital showing a linezolid-resistant phenotype tested with automated devices. Linezolid resistance was confirmed by reference broth microdilution assays and interpreted according to EUCAST clinical breakpoints. The most common Gram-positive acquired oxazolidinone resistance genes were searched by Real-time PCR (*optrA*, *poxTA*, *cfr* and *cfr(B)*). A subgroup of isolates was subjected to Whole Genome Sequencing (WGS) using an Illumina platform and raw reads were assembled using SPAdes-software. Bioinformatics analysis for the detection of resistance mechanisms was performed by BLAST, MLST, RESfinder and LREfinder tools. **Results.** A total of 77 *S. epidermidis* isolates were included in the study. All the strains showed high level of resistance to linezolid (MIC >8mg/L), but only 12 of them tested positive for the presence of *cfr* gene. WGS was performed on 15 isolates. All strains belonged to ST-2 and the presence of the *cfr* gene was confirmed in 4 isolates, while the other strains did not show any acquired resistance gene. G2603T mutation of the 23S rRNA gene were detected in 13/15 isolates, while only few strains showed additional mutations in the L3 and L4 proteins (8 and one, respectively). No mutations in the L22 ribosomal protein were detected. **Discussion and Conclusions.** These data highlight a high prevalence of previously reported chromosomal mutations and few Cfr-producing isolates (15.6%) leading to linezolid resistance. Novel chromosomal mutations were also identified in most of the isolates underlying the impact of the selective pressure induced by linezolid usage. Epidemiological surveys should be performed to limit the spread of acquired resistance mechanisms and monitor the raise of novel mutations. WGS analysis on the remaining isolates will be necessary in order to investigate the molecular origin of linezolid resistance and their clonality.

245 - Prevalence and Antimicrobial Resistance Profile of Enterococcus Species: A Retrospective Cohort Study in Italy

Biagio Santella ⁽¹⁾ - Mariarosaria Boccella ⁽²⁾ - Roberta Manente ⁽¹⁾ - Domenico Iervolino ⁽³⁾ - Andrea Cirino ⁽¹⁾ - Mariagrazia Di Cristo ⁽¹⁾ - Pasquale Pagliano ⁽⁴⁾ - Riccardo Giorgio ⁽⁴⁾ - Luigi Fortino ⁽⁴⁾ - Domenico Pecora ⁽⁴⁾ - Anna Borrelli ⁽⁵⁾ - Massimiliano Galdiero ⁽¹⁾ - Mario Capunzo ⁽⁴⁾ - Gianluigi Franci ⁽⁴⁾ - Giovanni Boccia ⁽⁴⁾

University of Campania "Luigi Vanvitelli", Section of Microbiology and Virology, University Hospital "Luigi Vanvitelli", Napoli, Italia ⁽¹⁾ - Agostino Gemelli University Hospital IRCCS, Department of Laboratory and Infectious Disease Sciences, Agostino Gemelli University Hospital IRCCS, Rome, Italia ⁽²⁾ - Sapienza University of Rome, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italia ⁽³⁾ - University of Salerno, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italia ⁽⁴⁾ - Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D'Aragona, Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italia ⁽⁵⁾

Prevalence and Antimicrobial Resistance Profile of Enterococcus Species: A Retrospective Cohort Study in Italy

Biagio Santella, Mariarosaria Boccella, Roberta Manente, Domenico Iervolino, Andrea Cirino, Mariagrazia Di Cristo, Pasquale Pagliano, Riccardo Giorgio, Luigi Fortino, Domenico Pecora, Anna Borrelli, Massimiliano Galdiero, Mario Capunzo, Gianluigi Franci, Giovanni Boccia.

1 Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy

2 Dai Dipartimento di Igiene Sanitaria e Medicina Valutativa U.O.C. Patologia Clinica E Microbiologica, Azienda Ospedaliero-Universitaria S. Giovanni di Dio e Ruggi D'Aragona Scuola Medica Salernitana, Largo Città di Ippocrate, 84131 Salerno, Italy

3 Section of Microbiology and Virology, University Hospital "Luigi Vanvitelli", Naples, Italy

4 Department of Laboratory and Infectious Disease Sciences, Agostino Gemelli University Hospital IRCCS, 00168 Rome, Italy

5 Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D'Aragona, 84131 Salerno, Italy

Background

Antimicrobial resistance represents one of the main threats to healthy ecosystems. In recent years, among the multidrug-resistant microorganisms responsible for nosocomial infections, the *Enterococcus* species have received much attention. Indeed, *Enterococcus* have peculiar skills in their ability to acquire resistance genes and to cause severe diseases, such as endocarditis. This study showed the prevalence and antimicrobial resistance rate of *Enterococcus* spp. isolated from clinical samples, from January 2015 to December 2019 at the University Hospital "San Giovanni di Dio e Ruggi d'Aragona" in Salerno, Italy.

Methods

Bacterial identification and antibiotic susceptibility were performed with VITEK 2. Statistical analysis was done using SPSS (IBM Corp, Armonk, NY). A chi-square test was used to compare the differences antibiotic sensitivities over the range of years considered in the study.

Results

A total of 3236 isolates of *Enterococcus faecalis* (82.2%) and *Enterococcus faecium* (17.8%) were collected from urine cultures, blood cultures, catheters, respiratory tract, and other samples. *E. faecium* showed a high resistance rate against ampicillin (84.5%), ampicillin/sulbactam (82.7%), and imipenem (86.7%), while *E. faecalis* showed the highest resistance rate against gentamicin and streptomycin high level, but both were highly sensitive to such antibiotics as tigecycline and vancomycin.

Conclusions

Studies of surveillance are an important tool to detect changes in the resistance profiles of the main pathogens. These antimicrobial susceptibility patterns are necessary to improve the empirical treatment guideline of infections.

246 - Bacterial Coinfection and Antibiotic Resistance Profiles among COVID-19 Patients

Biagio Santella ⁽¹⁾ - Domenico Iervolino ⁽²⁾ - Massimiliano Galdiero ⁽¹⁾ - Mario Capunzo ⁽³⁾ - Gianluigi Franci ⁽³⁾ - Giovanni Boccia ⁽³⁾

University of Campania "Luigi Vanvitelli", Section of Microbiology and Virology, University Hospital "Luigi Vanvitelli", Napoli, Italia ⁽¹⁾ - Agostino Gemelli University Hospital IRCCS, Department of Laboratory and Infectious Disease Sciences, Agostino Gemelli University Hospital IRCCS, Rome, Italia ⁽²⁾ - Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italia ⁽³⁾

Bacterial Coinfection and Antibiotic Resistance Profiles among COVID-19 Patients

Biagio Santella, Domenico Iervolino, Massimiliano Galdiero, Mario Capunzo, Gianluigi Franci, Giovanni Boccia.

1 Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy

2 Dai Dipartimento di Igiene Sanitaria e Medicina Valutativa U.O.C. Patologia Clinica E Microbiologica, Azienda Ospedaliero-Universitaria S. Giovanni di Dio e Ruggi D'Aragona Scuola Medica Salernitana, Largo Città di Ippocrate, 84131 Salerno, Italy

3 Section of Microbiology and Virology, University Hospital "Luigi Vanvitelli", Naples, Italy

4 Department of Laboratory and Infectious Disease Sciences, Agostino Gemelli University Hospital IRCCS, 00168 Rome, Italy

5 Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D'Aragona, 84131 Salerno, Italy

INTRODUCTION: Many studies showed that microbial co-infections in COVID-19 patients can aggravate the symptomatology and clinical course of the disease. The purpose of this retrospective study is to evaluate the prevalence of bacterial coinfections and associated antibiotic resistance profiles among COVID-19 patients admitted to the University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy between April 2020 and June 2021.

MATERIALS AND METHODS: Age, gender, bacterial identities, and antibiotic sensitivity profiles were collected retrospectively for 358 hospitalized COVID-19 patients. Identification of microorganisms and antibiotic sensitivity tests were performed with Vitek 2. The IBM Statistical Package for Social Sciences Version 22.00 (SPSS Inc., Chicago, IL, USA) was used for data analysis.

RESULTS: The co-infection rate was higher in male patients (64.5%) aged 60 to 80 years (62.5%). Among them, microbial co-infection events are distributed as follows: bacteremia (33.9%), pneumonia (28.5%), bacteriuria (28.2%), skin and soft tissue infections (5.4%) and others (4%). Out of 806 isolated species, 431 (53.5%) were Gram-positive bacteria, 359 (44.5%) were Gram-negative bacteria and 16 (2.0%) were mycetes. The microorganisms most frequently isolated from the lower respiratory tract and blood cultures are *Staphylococcus aureus* and Staphylococci coagulase negative (CoNS), while *Escherichia coli* and *Enterococcus faecalis*, have been more isolated from urine cultures. Antimicrobial sensitivity tests showed high rates of resistance to erythromycin (88.3%) and oxacillin (70.8%) by *Staphylococcus aureus* isolates and excellent sensitivity to linezolid (100%) and vancomycin (97.1%). In addition,

Escherichia coli isolates showed highest sensitivity to Fosfomycin (100%), and a high rate of resistance to piperacillin (81.3%) and cefuroxime (73.9%).

CONCLUSIONS: The data showed increased rates of antibiotic resistance compared to the values reported in studies prior to the pandemic period; in particular, an increase of prevalence of methicillin-resistant *Staphylococcus aureus* and extended-spectrum β -lactamase producing *Enterobacteriaceae* were reported. In conclusion, these data could be used to improve empirical antimicrobial therapy and co-infection management strategies in COVID-19 patients, and finally, prevent the spread of multi-resistant bacteria.

248 - Carbapenem-resistant and extended-spectrum β -lactamase producing *Klebsiella pneumoniae*: Prevalence and Antimicrobial Resistance trends in Strains Isolated from Hospital in Italy.

Biagio Santella ⁽¹⁾ - Mariarosaria Boccella ⁽²⁾ - Roberta Manente ⁽¹⁾ - Massimiliano Galdiero ⁽¹⁾ - Mario Capunzo ⁽³⁾ - Gianluigi Franci ⁽³⁾ - Giovanni Boccia ⁽³⁾

University of Campania "Luigi Vanvitelli", Section of Microbiology and Virology, University Hospital "Luigi Vanvitelli", Napoli, Italia ⁽¹⁾ - Agostino Gemelli University Hospital IRCCS, Department of Laboratory and Infectious Disease Sciences, Agostino Gemelli University Hospital IRCCS, Rome, Italia ⁽²⁾ - Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italia ⁽³⁾

Carbapenem-resistant and extended-spectrum β -lactamase producing *Klebsiella pneumoniae*: Prevalence and Antimicrobial Resistance trends in Strains Isolated from Hospital in Italy.

Biagio Santella, Mariarosaria Boccella, Roberta Manente, Massimiliano Galdiero, Mario Capunzo, Gianluigi Franci, Giovanni Boccia.

1 Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy

2 Dai Dipartimento di Igiene Sanitaria e Medicina Valutativa U.O.C. Patologia Clinica E Microbiologica, Azienda Ospedaliero-Universitaria S. Giovanni di Dio e Ruggi D'Aragona Scuola Medica Salernitana, Largo Città di Ippocrate, 84131 Salerno, Italy

3 Section of Microbiology and Virology, University Hospital "Luigi Vanvitelli", Naples, Italy

4 Department of Laboratory and Infectious Disease Sciences, Agostino Gemelli University Hospital IRCCS, 00168 Rome, Italy

5 Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D'Aragona, 84131 Salerno, Italy

Background

Antibiotic resistance has become a main public health concern worldwide. Among the species with greater clinical interest, *Klebsiella pneumoniae* is a major opportunistic pathogen cause of urinary tract infections, pneumonia, and septicemia. An increased incidence of multi-drug resistant and extremely drug-resistant organisms of *K. pneumoniae* has been observed during the last decades in clinical practice. Therefore, the aim of the study was to identify the prevalence and trends of *Klebsiella pneumoniae* antibiotic resistance from January 2015 to December 2019 at the University Hospital "San Giovanni di Dio e Ruggi d'Aragona" in Salerno, Italy.

Methods

Bacterial identification and antibiotic susceptibility were performed with VITEK 2. Statistical analysis was done using SPSS (IBM Corp, Armonk, NY). A chi-square test was used to compare the differences antibiotic sensitivities over the range of years considered in the study.

Results

A total of 3,157 isolates were collected from urine cultures, blood cultures, respiratory tract, and other samples. *K. pneumoniae* isolates showed the highest resistance rate to penicillin and cephalosporin antibiotic class, and lower resistance to fosfomycin and gentamicin. Extended spectrum beta-lactamase isolates were between 20-22%. Moreover, a low rate of resistance was shown for carbapenems class as imipenem (28%), meropenem (42%) and ertapenem (44%).

Conclusions

In recent years, *K. pneumoniae* infections have found worldwide importance, mainly due to multiple antibiotic resistances. Mainly the production of ESBLs and resistance to carbapenems is now a major public health problem. Constant monitoring of drug-resistant isolates is useful to find practical approaches to implementing antimicrobial therapy and reducing the spread of *K. pneumoniae* in nosocomial environments.

249 - Identification of new antivirulence compounds active against cystic fibrosis *Pseudomonas aeruginosa*

Arianna Pompilio ⁽¹⁾ - Veronica Lupetti ⁽¹⁾ - Gabriele Carullo ⁽²⁾ - Giuseppe Campiani ⁽²⁾ - Sandra Gemma ⁽²⁾ - Giovanni Di Bonaventura ⁽¹⁾

University of Chieti-Pescara "G. d'Annunzio", Department of Medical, Oral and Biotechnological Sciences, Chieti, Italia ⁽¹⁾ - University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Siena, Italia ⁽²⁾

Identification of new antivirulence compounds active against cystic fibrosis *Pseudomonas aeruginosa*
ARIANNA POMPILIO,¹ VERONICA LUPETTI,¹ GABRIELE CARULLO,² GIUSEPPE CAMPIANI,² SANDRA GEMMA,² GIOVANNI DI BONAVENTURA¹

¹Department of Medical, Oral and Biotechnological Sciences; and Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy; ²Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy

Introduction. Current treatments for *Pseudomonas aeruginosa* infections are becoming less effective due to the increasing rates of multi-antibiotic resistance, especially in cystic fibrosis (CF) patients. Pharmacological targeting of virulence through inhibiting quorum sensing (QS)-dependent virulence gene regulation has considerable therapeutic potential. In *P. aeruginosa*, the QS system regulates the production of multiple virulence factors and biofilm formation and, therefore, is a promising approach for developing antimicrobial adjuvants for combatting drug resistance. Here we report the hit discovery/optimization of quinazoline-based antivirulence compounds designed and synthesized based on the structure of endogenous modulators of PqsR, a key regulator of the QS system.

Materials and methods. Target quinazolines were synthesized by condensation of appropriately substituted anthranilic acids with acetic anhydride followed by treatment with hydrazine or with formamide to furnish the core bicyclic rings. The latter have been decorated through alkylation with a variety of heterocyclic and aromatic benzyl-derivatives. *P. aeruginosa* RP73, a prototype strain used for studying CF chronic pulmonary illness, was tested under conditions like those observed in the CF airways (artificial sputum medium, pH 6.8, 5% CO₂ atmosphere). MIC and MBC were measured by broth microdilution. Biofilm formation was evaluated in terms of biomass (extracellular matrix and cells, as assessed by crystal violet assay) and cell viability (viable cell count). Pyocyanin and pyoverdine formation was measured spectrophotometrically. The cytotoxic potential of each compound was evaluated toward IB3-1 bronchial epithelial CF cells by an MTS tetrazolium-based colorimetric assay.

Results. At 50 µM, some of the tested compounds affected biofilm formation, particularly NF3034 which reduced cell viability and extracellular matrix. Partial activity was shown by NF3017 and NF3033 (decreased cell viability), NF3077, and NF3081 (biofilm dispersion, although increased cellularity). More pronounced was the inhibition of pigments production. NF3072, NF3075, NF3069, and NF3088, affected both pyocyanin and pyoverdine formation. NF3033 and NF3086 affected pyocyanin only, while NF3077 and NF3081 were active against pyoverdine. Interestingly, none of the compounds showed antibacterial activity when tested in MIC assays or toxicity to IB3-1 cells at the same concentration used for the above assays.

Discussion and Conclusions. Through a panel of phenotypical assays, we highlighted some interesting antivirulence properties of quinazoline-based compounds against *P. aeruginosa* CF strain. The results so far obtained are of interest in the field of antibacterial drug discovery. Further studies to clarify the putative mode of action of the synthesized compounds are currently ongoing.

250 - Prevalence and Antimicrobial Profile of Causative Agents to Ocular Infections

Roberta Manente ⁽¹⁾ - Biagio Santella ⁽¹⁾ - Pasquale Pagliano ⁽²⁾ - Enrica Serretiello ⁽¹⁾ - Valentina Volpicelli ⁽¹⁾ - Anna Borrelli ⁽³⁾ - Massimiliano Galdiero ⁽¹⁾ - Mario Capunzo ⁽²⁾ - Gianluigi Franci ⁽²⁾ - Giovanni Boccia ⁽²⁾

University of Campania "Luigi Vanvitelli", Section of Microbiology and Virology, University Hospital "Luigi Vanvitelli", Napoli, Italia ⁽¹⁾ - Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italia ⁽²⁾ - Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D'Aragona, Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italia ⁽³⁾

Prevalence and Antimicrobial Profile of Causative Agents to Ocular Infections

Roberta Manente, Biagio Santella, Pasquale Pagliano, Enrica Serretiello, Valentina Volpicelli, Anna Borrelli, Massimiliano Galdiero, Mario Capunzo, Gianluigi Franci, Giovanni Boccia.

1 Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy

2 Dai Dipartimento di Igiene Sanitaria e Medicina Valutativa U.O.C. Patologia Clinica E Microbiologica, Azienda Ospedaliero-Universitaria S. Giovanni di Dio e Ruggi D'Aragona Scuola Medica Salernitana, Largo Città di Ippocrate, 84131 Salerno, Italy

3 Section of Microbiology and Virology, University Hospital "Luigi Vanvitelli", Naples, Italy

4 Department of Laboratory and Infectious Disease Sciences, Agostino Gemelli University Hospital IRCCS, 00168 Rome, Italy

5 Azienda Ospedaliero Universitaria San Giovanni di Dio e Ruggi D'Aragona, 84131 Salerno, Italy

Background

Bacterial ocular infections are a worldwide health problem and, if untreated, can damage the structure of the eye and contribute to permanent disability. Knowledge of the prevalence and antimicrobial susceptibility patterns of the main causative agents involved in ocular infections is necessary for defining an optimal antibiotic therapy. The aim of this study was to analyse bacterial species involved in ocular infections and the antimicrobial susceptibility patterns. Conjunctival swab samples were collected from patients with bacterial conjunctivitis at the University Hospital San Giovanni di Dio e Ruggi d'Aragona between January 2015 and December 2019.

Methods

Bacterial identification and antibiotic susceptibility were performed with VITEK 2. Statistical analysis was done using SPSS (IBM Corp, Armonk, NY). A chi-square test was used to compare the differences antibiotic sensitivities over the range of years considered in the study.

Results

A total of 281 causative agents of ocular infections were isolated, 81.8% of which were Gram-positive bacteria. Coagulase negative staphylococci (CoNS) were the most isolated species among Gram-positive bacteria, followed by *Staphylococcus aureus*. In contrast, *Pseudomonas* spp. and *Escherichia coli* were the main species isolated among Gram-negative bacteria (18.2%). Overall, linezolid, teicoplanin, tigecycline and vancomycin were the most effective antimicrobials. Analysis of resistance rates over time highlighted increasing resistance for azithromycin, clarithromycin and erythromycin among CoNS, and clindamycin and erythromycin among *Staphylococcus aureus*.

Conclusions

This study has identified the profiles of the major pathogens involved in ocular infection and their susceptibility patterns, which will help improve the treatments and the choice of antibiotics in ocular infections.

.

253 - Antibiotic resistance profiles of microplastics associated microbial communities in the Adriatic Sea

Anna-Rita Attili ⁽¹⁾ - **Angela Piersanti** ⁽¹⁾ - **Martina Linardi** ⁽¹⁾ - **Vincenzo Cuteri** ⁽¹⁾ - **Francesco Alessandro Palermo** ⁽¹⁾ - **Paolo Cocci** ⁽¹⁾ - **Cristina Miceli** ⁽¹⁾

Università di Camerino, Scuola di Bioscienze e Medicina Veterinaria, Camerino, Italia ⁽¹⁾

Antibiotic resistance profiles of microplastics associated microbial communities in the Adriatic Sea

ANNA-RITA ATTILI ¹, **ANGELA PIERSANTI** ², **MARTINA LINARDI** ¹, **VINCENZO CUTERI** ¹, **FRANCESCO ALESSANDRO PALERMO** ², **PAOLO COCCI** ², **CRISTINA MICELI** ²

¹ School of Biosciences and Veterinary Medicine, Microbiology and Infectious Diseases, University of Camerino, Matelica, Italy; ² School of Biosciences and Veterinary Medicine, Cell biology and Biotechnology, University of Camerino, Camerino, Italy.

Introduction. Plastics have gradually become a global environmental pollution problem with a significant impact on human and animal health. Their large dispersion in the marine environment generates microplastics (MPs) which also release nanoplastics with effects on living organisms. The aim of this study was: i) to identify MPs and their associated microorganisms in the sea sediments of the Regional Natural Reserve Sentina (Adriatic Sea) and ii) to evaluate the antibiotic susceptibility patterns of the microbial communities.

Materials and Methods. Beach transects, parallel to the shoreline where the waves break, has been identified for the samplings. Each sample was in three replicas at three different positions of the transect (0, 15, and 30 meters). A protocol to perform microplastics isolation from sand sediments, suitable for biological samples and based on plastic floating in high salinity water, has been optimized. On floating microplastics, DNA isolation was performed with DNeasy PowerSoil Pro Kit (QIAGEN) for the shotgun metagenomic analysis. Isolated aerobic and anaerobic cultivable microorganisms have been identified by MALDI-TOF MS (Bruker). Susceptibility to a panel of 14 human and veterinary antibiotics, belonging to 12 different categories, was assessed by Kirby-Bauer and E-test methods.

Results. From sea sediments, the increased seawater density allowed plastics floating and through filtration, different kind of plastic materials, such as polyethylene, polypropylene, poly-methyl acrylate and poly-vinyl chloride were found. The metagenomics results are currently under processing and analysis. By microbial cultivation and MALDI-TOF MS identification, different bacterial species (n=29), both Gram -ve (55.2%) and Gram +ve (44.8%), have been isolated from the samples enriched in microplastics. Some bacteria are promising for the involvement in plastic degradation, such as *Lysinobacillus fusiformis*, *Exiguobacterium* sp., *Pseudomonas oleovorans*. Other bacteria are potentially pathogens, like *Clostridium septicum*, *Clostridium novyi*, *Shewanella putrefaciens*. Only the 17.2% of bacteria, *Exiguobacterium* sp., *Halomonas aquamarina*, *Paenibacillus brevicompactum*, *Lactobacillus fuchuensis*, *Providencia rettgeri*, resulted susceptible to all human and veterinary antibiotics. Higher percentages of resistance were observed for penicillins (85.7%) and monobactams (80.9%), in Gram +ve and Gram -ve, respectively. Although not significant, a resistant pattern was recorded for carbapenems in Gram +ve (28.6%) and Gram -ve bacteria (61.9%, $P=0.0532$). Significant higher resistances for tetracyclines (64.3%, $P=0.0166$) were observed for Gram +ve microorganisms.

Discussion and Conclusions. The MPs may work as a vehicle of phenotypic resistant microorganisms in the Adriatic Sea environment.

255 - A high-resolution melting PCR assay for rapid detection of linezolid-resistance-associated new mutations in *Mycobacterium avium* complex

Rosario Musumeci⁽¹⁾ - Stefania Torri⁽²⁾ - Marianna Martinelli⁽¹⁾ - Chiara Giubbi⁽¹⁾ - Federica Perdoni⁽¹⁾ - Chiara Vismara⁽²⁾ - Francesco Scaglione⁽²⁾ - Clementina E. Cocuzza⁽¹⁾

University of Milano-Bicocca, Department of Medicine and Surgery, Monza (MB), Italia⁽¹⁾ - ASST Grande Ospedale Metropolitano Niguarda, Unit of Microbiology, Department of Chemical-Clinical and Microbiology Analyses, Milan, Italia⁽²⁾

A high-resolution melting PCR assay for rapid detection of linezolid-resistance-associated new mutations in *Mycobacterium avium* complex

ROSARIO MUSUMECI^{*1}, *STEFANIA TORRI*², *MARIANNA MARTINELLI*¹, *CHIARA GIUBBI*¹, *FEDERICA PERDONI*¹, *CHIARA VISMARA*², *FRANCESCO SCAGLIONE*², *CLEMENTINA E. COCUZZA*¹

¹Laboratory of Clinical Microbiology and Virology, Department of Medicine and Surgery, University of Milano-Bicocca, Monza (MB), Italy

²Unit of Microbiology, Department of Chemical-Clinical Analysis and Microbiology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

Background: *Mycobacterium avium* complex (MAC) is a group of slowly growing non-tuberculous mycobacteria that is emerging as major infectious threat in developing countries. The most frequent are *M. avium* and *M. intracellulare*, for which the conventional treatment is a macrolide-based multidrug regimen. However, due to the increased macrolide-resistance, alternative treatments are needed.

Linezolid, the only FDA-approved oxazolidinone for mycobacterial diseases representing 2nd line treatment for *M. tuberculosis*, has been shown to have a good activity against Non-Tuberculous *Mycobacteria* (NTM) [Winthrop et al. 2015]. However, the long-term treatment, typical for mycobacterial infections, promotes the acquisition of linezolid-resistance due to mutations in *rrl*, *rplC* and *rplD*.

In this study we developed a High-Resolution Melting (HRM) PCR assay to detect linezolid-resistance-associated mutations in MAC.

Materials/methods: An HRM PCR assay was performed on 60 linezolid-resistant MAC clinical isolates (55 *M. avium* and 5 *M. intracellulare*) provided by ASST Grande Ospedale Metropolitano Niguarda (selected following American Thoracic Society Criteria) to detect linezolid-resistance-associated mutations in *rrl*, *rplC* and *rplD* genes.

The results were analysed using Precision Melt AnalysisTM software (BioRad) obtaining different clusters based on mutations presence and then verified through Sanger sequencing.

Results: Preliminary results, based on 10 MAC (5 *M. avium* and 5 *M. intracellulare*), showed in 20% of isolates mutations in *rplD* gene: G443A (Arg148Lys) in *M. intracellulare* and A439G (Thr147Ala) in *M. avium*, respectively, already identified in a recent study [Kim et al 2018]. We have also found new mutations, never reported before (data not shown) and under confirmation.

Conclusions: In recent years, in the Milan macroarea, MAC clinical isolates have shown low resistance to first line drugs (1.2% for clarithromycin and 4,7% for intravenously-administered amikacin), but high level of resistance for second line drugs (40.2% for moxifloxacin and 91% for linezolid). Linezolid-resistance is higher in our strains compared to that described in other parts of the world.

The HRM PCR assay is a rapid screening method to discriminate wild type from mutated sequences thanks to creation of different clusters. This can be useful to detect new and known linezolid-resistance-associated mutations both before and during treatment to monitoring the resistance onset.

258 - Biofilm formation, genetic signatures, and antimicrobial resistance profile of *Neisseria gonorrhoeae* strains

Anna Carannante⁽¹⁾ - Enea Gino Di Domenico⁽²⁾ - Paola Vacca⁽¹⁾ - Ilaria Cavallo⁽³⁾ - Francesca Sivori⁽³⁾ - Luigina Ambrosio⁽¹⁾ - Silvia Fillo⁽⁴⁾ - Florigio Lista⁽⁴⁾ - Paola Stefanelli⁽¹⁾

Istituto Superiore di Sanità, Department Infectious Diseases, Rome, Italia⁽¹⁾ - Sapienza University, Department of Biology and Biotechnology "C. Darwin", Rome, Italia⁽²⁾ - IRCCS San Gallicano Institute, Microbiology and Virology, Rome, Italia⁽³⁾ - Army Medical Center, Scientific Department, Rome, Italia⁽⁴⁾

Biofilm formation, genetic signatures, and antimicrobial resistance profile of *Neisseria gonorrhoeae* strains

ANNA CARANNANTE¹, ENEA GINO DI DOMENICO², PAOLA VACCA¹, ILARIA CAVALLO³, FRANCESCA SIVORI³, LUIGINA AMBROSIO¹, SILVIA FILLO⁴, FLORIGIO LISTA⁴, PAOLA STEFANELLI¹

¹Department Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; ²Department of Biology and Biotechnology

"C. Darwin", Sapienza University, Rome, Italy; ³Microbiology and Virology, IRCCS San Gallicano Institute, Rome, Italy;

⁴Scientific Department, Army Medical Center, Rome, Italy

* ***Neisseria gonorrhoeae* Italian Study Group:** Elisabetta Pagani, Richard Ashbacher, Patrizia Innocenti: Ospedale di Bolzano, Laboratorio Aziendale di Microbiologia e Virologia, Bolzano; Stefano Grandesso, Rita Baradello: Ospedali di San Donà di Piave, Azienda ULSS4 Veneto Orientale-Laboratorio Analisi-Microbiologia, Portogruaro; Eliana Modolo: Ospedale di Belluno-Laboratorio di Microbiologia, AULSS1 Dolomiti, Belluno; Giuseppa Fornaro: Ospedale di San Bortolo-Servizio di Microbiologia, Vicenza; Davide Gibellini, Maria M Lleo Fernandez: Università di Verona-Settore Genito-urinario e infezioni a trasmissione sessuale (AOUI verona), Verona; Ivano Dal Conte: Clinica SoS Infezioni Sessualmente Trasmesse, Dipartimento di Malattie Infettive, Ospedale Amedeo di Savoia, Torino; Anna Lucchini, Valeria Ghisetti, Simonetta Del Re, Gabriella Gregori: Laboratorio di Microbiologia e Virologia, Dipartimento di Malattie Infettive, Ospedale Amedeo di Savoia, Torino; Federica Poletti, Giuseppina Caffiero, Loredana Pangaro: Ospedale Sant'Andrea, Laboratorio di Microbiologia, Vercelli; Maria Agnese Latino, Ester Gaido: Dipartimento di Medicina di Laboratorio, P. O. Sant'Anna, Città della Salute e della Scienza di Torino, Torino; Anna M Barbui: Laboratorio di Microbiologia e Virologia, Ospedale Molinette, Torino; Sergio Del Monte: Clinica MST di Ospedale Dermatologico San Lazzaro, 'A. O. U. Città della Salute e della Scienza di Torino; Rosanna Cavallo, Alessandro Bondi: SC Microbiologia e Virologia, Città della Salute e della Scienza di Torino, Torino; Marco Cusini, Patrizia Bono, Stefano Ramoni: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano; Alberto Matteelli, Maurizio Gulletta: Istituto di Malattie Infettive e Tropicali, Università di Brescia, Brescia; Maria A De Francesco: Dipartimento di Medicina Molecolare e Traslazionale, Sezione di Microbiologia, Università di Brescia, Brescia; Gian Maria Rossolini: Università di Firenze, Dipartimento di Medicina Clinica e Sperimentale, Firenze; Alessandra Fontanelli, Eleonora Riccobono, Andrea Bartolini: Ospedale Careggi, Unità di Microbiologia e Virologia, Firenze; Maria C Re, Antonietta D'Antuono, Caterina Vocale: Azienda Ospedaliero-Universitaria di Bologna, Laboratorio CRREM, Policlinico S. Orsola-Malpighi, Bologna; Antonella Mencacci, Arduino Melelli Roia: Sezione di Microbiologia, Dipartimento di Medicina Sperimentale, Università di Perugia, Perugia; Antonella Pocognoli, Annamaria Masucci: Azienda Ospedaliero Universitaria- Ospedali Riuniti di Ancona; Ancona; Aldo Di Carlo, Fulvia Pimpinelli, Antonio Cristaudo, Grazia Prignano, Massimo Giuliani, Alessandra Latini, Mirko Frasca: IFO-IRCCS S. Gallicano, Roma; Carmen Luciana Bonanno, Maria Carmela Cava: UO di Microbiologia e Virologia, Ospedale Sandro Pertini, Roma, Raffaele Antonetti, Rossella De Nittis: Dipartimento di Patologia Clinica, Azienda Ospedaliero-Universitaria OORR, Ospedali Riuniti, Foggia.

Introduction *Neisseria gonorrhoeae* is able to produce biofilms thus might be considered as a factor leading both to persistent of gonorrhea infections as well as influence the antimicrobial resistance profile. This study aims to evaluate the relationship between biofilm-forming capacity, the presence of some specific genetic signature by whole-genome sequencing (WGS), and the antimicrobials resistance profiles in *N. gonorrhoeae*. **Materials and Methods** A sample of 22 gonococci was analysed together with 5 World Health Organization (WHO) reference strains. The Biofilm Ring Test (BRT) method was used to quantify the biofilm production of *N. gonorrhoeae* *in vitro*, the attachment and initial biofilm

formation in the presence of DNase, and to assess the kinetic of early biofilm formation. The phenotypic characterization of gonococci was assessed by gradient diffusion methods (E-Test and MIC Test Strip) to define the antimicrobial susceptibility profiles. The genome sequencing was performed by Illumina NextSeq 500 platform, and the genomes were analyzed on <https://pubmlst.org/organisms/neisseria-spp/>. **Results** Strong biofilm producers (SBPs) were 71.4%, while 28.6% were classified as weak biofilm producers (WBPs). The cut-off for SBP classification was defined as three standard deviations above the mean BRT values obtained for the *N. gonorrhoeae* ATCC 49226 reference strain. In addition, DNase I treatment caused a significant ($P < 0.001$) reduction compared with proteinase K in the initial microbial attachment and biofilm formation. This suggests that biofilm formation in *N. gonorrhoeae* depends more on extracellular DNA (eDNA) than on protein production. Among SBP, four gonococci showed a decreased susceptibility to cefixime and resistance to ciprofloxacin. The majority of them belong to genogroup (G)1407 and to the *N. gonorrhoeae* sequence typing for antimicrobial resistance (NG-STAR) ST90 and Multi Locus Sequence Type (MLST) ST1901. The core genome MLST (cgMLST) scheme, which utilizes a set of 1649 loci, highlighted a high genetic diversity of gonococci. By genomic analysis of the target genes involved in biofilm production, we observed that the allele type 12 of the *nagZ* gene, which is involved in gonococcal biofilm disassembly, was predominant among the WBP producers. **Discussion and Conclusions** The results represent a first step beyond the state-of-art of antimicrobial resistance providing a novelty in the evaluation of *N. gonorrhoeae* resistant isolates.

260 - Dissection of the enigmatic role of Everolimus during *Mycobacterium tuberculosis* infections.

Flavio De Maio⁽¹⁾ - Delia Mercedes Bianco⁽²⁾ - Ivana Palucci⁽²⁾ - Giada Bianchetti⁽³⁾ - Alessandro Salustri⁽²⁾ - Giulia Santarelli⁽²⁾ - Enrica Tamburrini⁽⁴⁾ - Giuseppe Maulucci⁽³⁾ - Michela Sali⁽²⁾ - Giovanni Delogu⁽⁵⁾

Istituto di Microbiologia, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS/ Dipartimento di Scienze di Laboratorio e Infettivologiche, Roma, Italia⁽¹⁾ - Istituto di Microbiologia, Università Cattolica del Sacro Cuore/Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie, Roma, Italia⁽²⁾ - Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore/Dipartimento di Neuroscienze, Roma, Italia⁽³⁾ - Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS/ Dipartimento di Scienze di Laboratorio e Infettivologiche, Roma, Italia⁽⁴⁾ - Mater Olbia Hospital, Mater Olbia Hospital/ Istituto di Microbiologia, Olbia, Italia⁽⁵⁾

Dissection of the enigmatic role of Everolimus during *Mycobacterium tuberculosis* infections.

Flavio De Maio¹, Delia Mercedes Bianco², Ivana Palucci^{1,2}, Giada Bianchetti³, Alessandro Salustri², Giulia Santarelli², Enrica Tamburrini^{1,4}, Giuseppe Maulucci³, Michela Sali^{1,2}, Giovanni Delogu^{2,5}

¹ Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Rome, Italy

² Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie – Sezione di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy

³ Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Roma, Italy

⁴ Dipartimento di Sicurezza e Bioetica, Sez. Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy

⁵ Mater Olbia Hospital, Olbia, Italy

Introduction: Tuberculosis (TB) remains one of the most alarming infectious diseases worldwide. Although anti-TB treatment has a high efficacy in susceptible TB, the emergence and spread of resistant *Mycobacterium tuberculosis* (*Mtb*) strains is drawing attention to the development of new drugs and therapeutic strategies.

The search for new solutions includes the investigation of both novel agents and repurposing of approved drugs with potential anti-mycobacterial effects. A common trend is to consider host factors essential for pathogen survival or emergence of disease, focusing on both host metabolism and immunomodulation. All drugs that act mainly on the host are identified as host directed therapies (HDTs). Among the proposed molecules is everolimus, a compound that exerts an immunosuppressant activity by inhibiting the mTOR pathway and blocking growth-factor driven T-cell proliferation that has been described to exert both anti-mycobacterial and immunomodulatory activities

Even though everolimus has been investigated in a phase II randomized trial as a host directed therapy to treat TB, an oncological patient treated with everolimus for a neuroendocrine pancreatic neoplasia developed active TB twice and a non-tuberculous mycobacterial (NTM) infection in a time span of a year and a half.

Materials and Methods: To investigate this interesting case, we isolated and genotypically characterized the *Mycobacterium tuberculosis* (*Mtb*) clinical strain and tested the effect of everolimus on its viability in an axenic culture and in a human Peripheral Blood Mononuclear Cells (PBMCs) infection model. To exclude strain-specific resistance, we tested the activity of everolimus against *Mtb* H37Rv reference strain and clinical strains of ancient (EAI Manila) and modern lineages (H3). Furthermore, we investigated the proposed biological antimycobacterial mechanisms of everolimus, by studying its effect on ROS and autophagy induction during *Mtb* infection.

Results: Everolimus, and its analogues, did not show a direct effect on mycobacteria viability compared to isoniazid treated cultures. In PBMCs infection model, everolimus induced a negligible effect during *Mtb* infection in host cells only against *Mtb* H37Rv reference strain, but not against clinical isolates despite stimulating autophagy and a non-significant increase in ROS production was observed.

Discussion and Conclusions: With this case we want to underline that despite the need for therapeutical advances in TB treatment, a careful approach for testing, in relevant models, host directed therapies is necessary, as biological plausibility does not always translate to a pharmacological effect.

266 - The mobilome of probiotic *Lactobacillus crispatus* M247 includes Tn7088 a novel integrative and mobilizable element (IME) carrying a biosynthetic gene cluster for a class I bacteriocin

Lorenzo Colombini⁽¹⁾ - Francesco Santoro⁽¹⁾ - Nagaia Ciacchi⁽¹⁾ - Elisa Lazzeri⁽¹⁾ - Lorenzo Morelli⁽²⁾ - Francesco Iannelli⁽¹⁾ - Gianni Pozzi⁽¹⁾

Università di Siena, Dipartimento di Biotecnologie Mediche, Siena, Italia⁽¹⁾ - Università Cattolica del Sacro Cuore, Dipartimento di Scienze e Tecnologie Alimentari per una filiera agro-alimentare Sostenibile, Piacenza, Italia⁽²⁾

The mobilome of probiotic *Lactobacillus crispatus* M247 includes Tn7088 a novel integrative and mobilizable element (IME) carrying a biosynthetic gene cluster for a class I bacteriocin

LORENZO COLOMBINI¹, FRANCESCO SANTORO¹, NAGAIA CIACCHI¹, ELISA LAZZERI¹, LORENZO MORELLI², FRANCESCO IANNELLI¹, GIANNI POZZI¹

¹Department of Medical Biotechnologies, Laboratory of Molecular Microbiology and Biotechnology (LA.M.M.B.), University of Siena, Siena, Italy;

²Università Cattolica del Sacro Cuore, Department of Food Science and Technologies for a Sustainable Agri-food Supply Chain (DiSTAS), University of Piacenza, Piacenza, Italy

Introduction: *Lactobacillus crispatus* is the most frequently isolated species among the lactobacilli of a healthy human vaginal microbiome, however, not much is known about the *L. crispatus* mobilome. Here we report the complete genome sequence and the mobilome of the *L. crispatus* M247, a probiotic strain originally isolated from the stools of a newborn.

Materials and Methods: M247 genome was determined combining Nanopore and Illumina sequencing technologies and analyzed with bioinformatic tools. Mobile genetic elements were manually annotated using the NCBI and pfam databases and a functional analysis was carried out by quantitative real-time PCR.

Results: M247 genome consists of a single circular contig of 2,336,109 bp. M247 mobilome accounts for 14% of the whole genome and includes i) Tn7088, a novel 14,184-bp long integrative and mobilizable element (IME), ii) phiM247, a novel 42,649-bp long *Siphovirus* prophage, iii) 3 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) loci, iv) 226 Insertion Sequences (ISs) belonging to 15 families. Tn7088 contains 16 ORFs and is organized in a mobilization module with relaxosome encoding genes, an integration/excision module and an adaptation module homologous to the listeriolysin S locus of *Listeria monocytogenes* encoding a class I bacteriocin. Comparison with Tn7088-like elements integrated in the genome of other *L. crispatus* strains available in the NCBI database, indicated that the adaptation module is subject to insertions and deletions mediated by ISs elements. PCR experiments showed that Tn7088 element excises from M247 chromosome and produces a circular form, where the left and right ends are joined by *attTn*, at a concentration of 3.92×10^{-5} copies/chromosome, restoring the *attB* insertion site (1.03×10^{-4} copies/chromosome). The prophage contains 52 ORFs, including genes for phage structural proteins, DNA replication and packaging, lysogenic and lytic cycle related proteins. Circular forms of phiM247 were present at a concentration of 3.40×10^{-5} copies/chromosome, whereas reconstituted *attB* sites were at 2.52×10^{-5} copies/chromosome.

Discussion and Conclusions: In this study, the mobilome of the probiotic *L. crispatus* strain M247 was defined by whole genome sequencing. M247 mobilome accounts for 14% of the genome and includes i) the novel IME Tn7088 which contains the genes for relaxosome and encodes a functional integration/excision system as demonstrated by the formation of circular intermediates and ii) the novel prophage phiM247 encoding for a putative *Siphovirus* phage, which is able to excise from bacterial chromosome producing circular forms. Tn7088 represents the first example of an IME carrying a bacteriocin biosynthetic gene cluster in *L. crispatus*.

267 - Epidemiological trends in Nontuberculous Mycobacteria isolation in the period 2018-2021 in a large tertiary care hospital

IVANA PALUCCI ⁽¹⁾ - MARIA DEL CARMEN Pereyra Boza ⁽²⁾ - FRANCESCO PAGLIONE ⁽²⁾ - ENRICA INTINI ⁽³⁾ - ALESSANDRO SALUSTRI ⁽¹⁾ - FLAVIO DE MAIO ⁽¹⁾ - GIULIA SANTARELLI ⁽¹⁾ - MAURIZIO SANGUINETTI ⁽¹⁾ - GIOVANNI DELOGU ⁽¹⁾ - MICHELA SALI ⁽¹⁾

Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie- Istituto di Microbiologia, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Roma, ROMA, Italia
⁽¹⁾ - Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie- Istituto di Microbiologia, Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Roma, roma, Italia ⁽²⁾ - IRCCS - Policlinico Universitario A. Gemelli, - Roma, UOC Pneumologia, ROMA, Italia ⁽³⁾

Epidemiological trends in Nontuberculous Mycobacteria isolation in the period 2018-2021 in a large tertiary care hospital.

Palucci I.¹, Pereyra Boza MC.¹, Paglione F.¹, Intini E.², Salustri A.¹, De Maio F.¹, Santarelli G.¹, Sanguinetti M.¹, Delogu G.³, Sali M.¹.

¹ Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie- Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Roma

² UOC Pneumologia, IRCCS - Policlinico Universitario A. Gemelli, - Roma

³ Mater Olbia, Olbia

Background: Despite decreasing prevalence in tuberculosis, the incidence of the diseases associated with non-tuberculosis mycobacteria (NTM) has been on the rise in Italy and around the world. The present retrospective study was conducted to determine longitudinal changes in the epidemiology and distribution of NTM over 3 years at tertiary care hospital Agostino Gemelli University Policlinic.

Materials and Methods: We retrospectively analysed data on *Mycobacterium* species over 4 years (January 2018 to December 2021) by utilizing the laboratory information system. *Mycobacterium* species were identified using molecular tests and sequencing of hsp65 gene.

Results: We have detected a total 1100 samples positive for mycobacteria and, of these, we isolated in culture 112 NTM. The proportion of NTM continuously increased over these 4 –year period, from 3.77% in 2018 to 21,47% in 2021. Among the most common species were *Mycobacterium avium* complex (33.6 %), *Mycobacterium chimaera* (27,7%), *Mycobacterium intracellulare* (19,8 %), *Mycobacterium fortuitum* Complex (5,9%), *Mycobacterium xenopi* (3,96%), *Mycobacterium gordonae* (2,97%), *Mycobacterium kansasii* (2,97%), *Mycobacterium abscessus* (1,98%), and *Mycobacterium chelonae* (0,98%). In patients over 60 years, the proportion of NTM among the isolated increased from 10,89 % in 2018 to 36,63 % in 2021. Particularly the case *M. chimaera*, the isolation is 4 times more in 2021 than in 2018. The frequency and specie identification of these NTM have been associated with the clinical features of the patients, to assess the role of these mycobacteria in pulmonary and non-pulmonary diseases.

Conclusion: The number of NTM isolated continuously increased over study period. The role of *M. avium subsp. hominissuis* as a cause of pulmonary disease is a cause of concerns in the adult immunocompetent population.

268 - Shaping the subway microbiome by a probiotic-based sanitation during the COVID-19 emergency

Maria D'Accolti⁽¹⁾ - Irene Soffritti⁽¹⁾ - Francesca Bini⁽¹⁾ - Eleonora Mazziga⁽¹⁾ - Antonella Volta⁽²⁾ - Matteo Bisi⁽³⁾ - Sante Mazzacane⁽³⁾ - Elisabetta Caselli⁽¹⁾

Università degli Studi di Ferrara, Dip. Scienze Chimiche, Farmaceutiche ed Agrarie e LTTA, Ferrara, Italia⁽¹⁾ - Università degli Studi di Ferrara, CIAS Centro Ricerca, Ferrara, Italia⁽²⁾ - Università degli Studi di Ferrara-, CIAS Centro Ricerca, Ferrara, Italia⁽³⁾

Shaping the subway microbiome by a probiotic-based sanitation during the COVID-19 emergency

MARIA D'ACCOLTI^{1,2}, IRENE SOFFRITTI^{1,2}, FRANCESCA BINI^{1,2}, ELEONORA MAZZIGA¹, ANTONELLA VOLTA², MATTEO BISI², SANTE MAZZACANE², ELISABETTA CASELLI^{1,2}.

¹ Department of Chemical, Pharmaceutical and Agricultural Sciences, and LTTA, University of Ferrara, Ferrara, Italy;

² CIAS Research Center, University of Ferrara, Ferrara, Italy;

Introduction: The COVID-19 pandemics has highlighted how much the public transportation environment, such as subways, may be important for transmission of potential pathogenic microbes among humans. For these reasons, sanitation procedures including massive use of chemical disinfection were mandatorily introduced during the SARS-CoV-2 emergency, which however might worsen the antimicrobial resistance (AMR) threat, due to the reported favouring action of chemical disinfectants. By contrast, a probiotic-based sanitation (PBS) was recently shown to provide effective and long-term anti-SARS-CoV-2 activity and control of pathogens and AMR spread. Based on these observations, our aim was to assess its applicability and impact on the surface microbiome of the subway environment in comparison with chemical disinfectants during the COVID-19 pandemics.

Material and Methods: Two underground trains were enrolled in the study: one train served as control and continued to receive a conventional chemical sanitation, whereas the second train received the PBS in substitution of chemical disinfection. The presence of SARS-CoV-2 was monitored by droplet digital PCR (ddPCR), and the microbial contamination was evaluated simultaneously by conventional culture-based CFU count and molecular assays, including 16S rRNA NGS for bacteriome characterization and microarrays for the assessment of the microbial resistome.

Results: PCHS usage was associated with a stable >80% reduction in bacterial/fungal pathogens compared to the levels detected with chemical disinfection ($P < 0.01$), accompanied by a strong decrease of AMR genes ($P_c < 0.01$), as well as of SARS-CoV-2 presence ($P < 0.01$).

Discussion and Conclusions: The data presented here provide the first direct assessment of the impact of different sanitation procedures on the subway surface microbiome, allowing a better understanding of its composition and dynamics, and showing that a biological ecosustainable sanitation approach may be highly effective in counteracting pathogens' spread in our increasingly urbanized and interconnected environment without impacting on environmental pollution and further AMR diffusion.

269 - Peptidoglycan analysis of *Streptococcus pneumoniae* serotype 19A isolates belonging to the same clonal complex with different susceptibility to beta-lactams in the presence or absence of cefotaxime

Dalia Denapaite⁽¹⁾ - Berenice Furlan⁽¹⁾ - Jacob Biboy⁽²⁾ - Joe Gray⁽²⁾ - Waldemar Vollmer⁽²⁾ - Orietta Massidda⁽¹⁾

Dipartimento di Biologia Computazionale, Cellulare e Integrata, Università di Trento, Trento, Italia⁽¹⁾
- Centre for Bacterial Cell Biology, Biosciences Institute, Newcastle University, Newcastle upon Tyne, Regno Unito⁽²⁾

Peptidoglycan analysis of *Streptococcus pneumoniae* serotype 19A isolates belonging to the same clonal complex with different susceptibility to beta-lactams in the presence or absence of cefotaxime

Dalia Denapaite¹, Berenice Furlan¹, Jacob Biboy², Joe Gray², Waldemar Vollmer², Orietta Massidda¹

¹Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy; ²Centre for Bacterial Cell Biology, Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

1. Introduction: *Streptococcus pneumoniae*, the pneumococcus, is a clinically relevant human respiratory pathogen responsible for more than a million deaths per year worldwide. Beta-lactam antibiotics have been employed to treat infections caused by *S. pneumoniae* for decades. However, beta-lactam resistant *S. pneumoniae* strains, frequently expressing multiple antibiotic resistance phenotypes, have increased dramatically since the 1980s and pose serious problems in the treatment of infections. The Hungary^{19A}-6 clone, a multiple antibiotic-resistant strain with unusually high-levels of beta-lactam resistance was prevalent in Hungary during the 1990s. This clone spread also in the Czech Republic and Slovakia but not significantly to other areas. In this work, we analyzed the peptidoglycan (PG) composition of two serotype 19A strains from Hungary, strains Hu15 and Hu17 as well as of two Hu15 derivatives in which the mosaic *pbp2x* and *pbp2x* together with *pbp1a* were introduced. Both Hu15 and Hu17 isolates are members of the same clonal complex, ST226, a single-locus variant of the representative strain HUN663 of the Hungary^{19A}-6 clone. Hu17 exhibits high-level penicillin resistance, whereas Hu15 is penicillin sensitive. This unique situation allows to study the development of beta-lactam resistance and to understand the impact of the main resistance determinants on the PG composition and, ultimately, on the resistant phenotype. 2. Materials and Methods: The PG of four *S. pneumoniae* isolates was extracted from culture grown in the presence or the absence of the beta-lactam cefotaxime and its composition was analyzed by high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Growth and viability under the same conditions were also determined. 3. Results: Compared to the laboratory strain R6, the Hu strains had a PG profile showing an enrichment in branched vs linear peptides, consistent with the presence of a mosaic *murM* allele that is responsible for the synthesis of branched muropeptides and complex dimers, mostly bound through Ala-Ala crosslinks. These indirect cross-links are necessary for beta-lactam resistance but not sufficient for beta-lactam resistance in the absence of the mosaic PBP determinants. Moreover, as expected, the fraction of pentapeptides increased in all strains upon cefotaxime treatment in comparison to the condition of growth in absence of antibiotic. Finally, a bacteriostatic effect was observed upon treatment of the Hu strains with 1× MIC of cefotaxime with different behaviour depending on the specific strain. 4. Discussion and conclusion: The results support that the Hu strains change their PG composition upon cefotaxime treatment, including increasing their cross-linked muropeptides and increasing fraction of pentapeptides, supporting the notion that cefotaxime selectively binds PBP2x and PBP3. Our results also show that beta-lactam resistance in the pneumococcus is a complex event that involve modifications in factors other than PBPs and they highlight that a specific genetic background is required to express full resistance.

270 - Antibiotic resistance pattern of *Staphylococcus* spp isolated from blood culture of hospitalized patients during the first and second wave of SARS-Cov2 infection: a single center retrospective analysis

Elena Di Prima ⁽¹⁾ - Paola Di Carlo ⁽¹⁾ - Nicola Serra ⁽²⁾ - Maria Andriolo ⁽³⁾ - Vincenza Maria Carelli ⁽³⁾ - Giovanni Mazzola ⁽⁴⁾ - Teresa Rea ⁽²⁾ - Maria R. Tricoli ⁽¹⁾ - Ignazio Arrigo ⁽¹⁾ - Anna Giammanco ⁽¹⁾

University of Palermo, Department of Health Promotion, Maternal-Childhood, Internal Medicine of Excellence "G. D'Alessandro", Palermo, Italia ⁽¹⁾ - University Federico II of Naples, Department of Public Health, Napoli, Italia ⁽²⁾ - Microbiology Unit, Sant'Elia Hospital, Caltanissetta, Italia ⁽³⁾ - Infectious diseases Unit, Sant'Elia Hospital, Caltanissetta, Italia ⁽⁴⁾

Antibiotic resistance pattern of *Staphylococcus* spp isolated from blood culture of hospitalized patients during the first and second wave of SARS-Cov2 infection: a single center retrospective analysis from Southern Italy.

Elena Di Prima¹, Paola Di Carlo², Nicola Serra³, Andriolo Maria⁴, Vincenza Carelli⁴, Giovanni Mazzola⁵, Teresa Rea⁶, Teresa Fasciana², Maria R. Tricoli², Ignazio Arrigo², Anna Giammanco².

¹ University of Palermo. Piazza Marina Piazza Marina, 61, 90133, Palermo, Italy.

² Department of Health Promotion, Maternal-Childhood, Internal Medicine of Excellence "G. D'Alessandro", University of Palermo, Via Del Vespro 133, 90127, Palermo, Italy.

³ Department of Public Health, University Federico II of Naples, 80131 Napoli, Italy.

⁴ Microbiology Unit, Sant'Elia Hospital, 93100 Caltanissetta, Italy.

⁵ Infectious diseases Unit, Sant'Elia Hospital, 93100 Caltanissetta, Italy.

⁶ Department of Public Health, University Federico II of Naples, 80131 Napoli, Italy.

Introduction: The Sars Cov-2 pandemic infection has showed up old and new issue in health care system. Recent studies reported an increasing of blood stream infection (BSI) incidence in community as well as in hospital healthcare system. Moreover, due to abuse of antibiotics during the Sars Cov-2 pandemia, the increase of phenomena of antimicrobial resistance was also observed. In our geographical area the impact of Sars Cov-2 infection in hospital setting has showed a difference of management between the first and second wave of infection with low incidence during the period June - October 2020. Therefore, to study Gram positive pattern of BSI in patients with and without Sars Cov-2 infection we retrospectively analyzed *Staphylococcus* spp isolation during the first and second Sars Cov-2 wave.

Materials and Methods: This study was a retrospective investigation of blood culture (BC) positive samples for *Staphylococcus* spp detected in 177 adult patients hospitalized for more than 48 hours at the Sant'Elia hospital in Caltanissetta from January 2018 to October 2020, of which 46 infected with Sars Cov-2. The samples for the blood cultures were collected aseptically by peripheral venipuncture from patients with a suspected bloodstream infection according to the guidelines.

Bacterial identification and antimicrobial susceptibility testing were carried out using the Vitek-2 System (BioMérieux, Marcy l'Etoile, France). According to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, the antimicrobial sensitivity test of the strains was determined.

Results: Our results showed a significant most frequent infection correlated to *Staphylococcus aureus* in both group (Sars Cov-2 positive and negative), respectively 69,6% and 64,9%. Among the *Staphylococcus* spp the most significant presence was associated to *Staphylococcus capitis*, and *Staphylococcus hominis* for both two groups. In addition by comparison between two groups, we observed a significant presence of male gender in no Sars Cov-2 patients, while in Sars Cov-2 infected patients the mortality rate for BSI was more relevant.

Conclusions: The current study results showed the increasing of *Staphylococcus* spp, resistance, which may become a severe health-related issue in the future. Therefore, strict compliance of antibiotic use and employment of antibiotic stewardship programs at the public or private institutional level are recommended.

271 - Novel strategy against Chlamydiae: EVOO-based extracts.

Simone Filardo⁽¹⁾ - Marisa Di Pietro⁽¹⁾ - Roberto Mattioli⁽²⁾ - Luciana Mosca⁽²⁾ - Rosa Sessa⁽¹⁾

Dipartimento di Sanità Pubblica e Malattie Infettive, Università di Roma "Sapienza", Roma, Italia⁽¹⁾ -
Dipartimento di Scienze Biochimiche, Università di Roma "Sapienza", Roma, Italia⁽²⁾

Novel strategy against *Chlamydiae*: EVOO-based extracts.

Simone Filardo¹, Marisa Di Pietro¹, Roberto Mattioli², Luciana Mosca², Rosa Sessa¹

¹Department of Public Health and Infectious Diseases, Section of Microbiology; ²Department of Biochemical Sciences, Faculty of Pharmacy and Medicine, "Sapienza" University, Rome, Italy.

1. Introduction

Extra virgin olive oil (EVOO), a cornerstone in the Mediterranean diet, is well-known for its nutritional and health properties, and, recently, has been increasingly studied for its anti-bacterial properties. To date, no studies have been performed on its activity against obligate intracellular bacteria, like *Chlamydia trachomatis*, leading cause of bacterial sexually transmitted diseases, and *C. pneumoniae*, responsible for respiratory infections, like pneumonia. In the last decades, clinical treatment failures to antibiotics have been reported, and, hence, novel therapeutic approaches need to be investigated. Therefore, here we evaluated, for the first time, the anti-chlamydial activity of a green EVOO-based extract in natural deep eutectic solvent (NaDES), as well as of its main polyphenol components, namely purified oleocanthal and oleacein in NaDES.

2. Materials and Methods

Different concentrations of EVOO extract (170 µg/mL, 17 µg/mL and 1.7 µg/mL), oleacein and oleocanthal in NaDES (55 µg/mL, 5.5 µg/mL and 0.55 µg/mL) were tested against *C. trachomatis* serovar D strain UW3 and *C. pneumoniae* strain IOL-207, in different phases of their growth cycle: i. pre-treatment of chlamydial Elementary Bodies (EBs); ii. pre-incubation of host cells; iii. treatment of chlamydial infected cells.

3. Results

EVOO extract in NaDES (170 µg/mL) showed the highest anti-chlamydial activity against *C. trachomatis* and *C. pneumoniae* EBs (decrease of the number of IFU/field 93.5% and 91.1%, respectively, $p < 0.01$). Oleacein and oleocanthal (55 µg/mL) also showed efficacy ($p < 0.05$) during the pre-treatment of chlamydial EBs. No anti-chlamydial activity was observed following pre-incubation or treatment phases.

4. Discussion and Conclusions

The effect of EVOO extract, as well as of oleacein and oleocanthal, in NaDES, against *C. trachomatis* or *C. pneumoniae* EBs, suggests EVOO as potential preventive strategy for reducing *Chlamydiae* infections.

272 - A new indole derivative dry powder for inhalation inhibits *Staphylococcus aureus* biofilm formation in vitro

Samuele Sabbatini⁽¹⁾ - Styliani Xiroudaki⁽²⁾ - Camilla Pecoraro⁽³⁾ - Stella Cascioferro⁽³⁾ - Patrizia Diana⁽³⁾ - Nathalie Wauthoz⁽⁴⁾ - Cinzia Antognelli⁽⁵⁾ - Stefano Giovagnoli⁽²⁾ - Aurélie Schoubben⁽²⁾ - Claudia Monari⁽¹⁾

Università degli Studi di Perugia, Dipartimento di Medicina e Chirurgia, Sezione di Microbiologia Medica, Perugia, Italia⁽¹⁾ - Università degli Studi di Perugia, Dipartimento di Scienze Farmaceutiche, Perugia, Italia⁽²⁾ - Università degli Studi di Palermo, Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Palermo, Italia⁽³⁾ - Université libre de Bruxelles, Unit of Pharmaceutics and Biopharmaceutics, Brussels, Belgio⁽⁴⁾ - Università degli Studi di Perugia, Dipartimento di Medicina e Chirurgia, Sezione di Bioscienze ed Embriologia Medica, Perugia, Italia⁽⁵⁾

A new indole derivative dry powder for inhalation inhibits *Staphylococcus aureus* biofilm formation in vitro

SAMUELE SABBATINI¹, STYLIANI XIROUDAKI², CAMILLA PECORARO³, STELLA CASCIOFERRO³, PATRIZIA DIANA³, NATHALIE WAUTHOZ⁴, CINZIA ANTONELLI⁵, STEFANO GIOVAGNOLI², AURÉLIE SCHOUBBEN², CLAUDIA MONARI¹

¹Department of Medicine and Surgery, Medical Microbiology Section, University of Perugia, Perugia, Italy;

²Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy;

³Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Palermo, Italy;

⁴Unit of Pharmaceutics and Biopharmaceutics, Université libre de Bruxelles (ULB), Brussels, Belgium;

⁵Department of Medicine and Surgery, Biosciences and Medical Embryology Section, University of Perugia, Perugia, Italy;

Introduction: Recent estimates suggest that biofilms account for over 80% of microbial infections. Biofilms can lead to life-threatening lung infections especially in patients with chronic respiratory diseases, including cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). In particular, *Staphylococcus aureus* and *Pseudomonas aeruginosa* are the two most common pathogens associated with chronic lung infections in CF patients. Effective treatment of biofilm-associated lung infections is hindered by the required high local drug concentrations. In this regard, inhalation is gaining attention as a valid strategy to increase lung drug concentration, reducing the potential side-effects associated with high doses and long-term administration regimens delivered by systemic routes. The aim of this work was to assess the effect of a new indole derivative dry powder on *S. aureus* biofilm formation and disgregation. **Materials and methods:** The compound 1-methyl-3-[6-(4-nitrophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl]-1H-indole (SC38) was encapsulated into previously optimized chitosan microparticles (CS MP). The effects of SC38 and SC38-loaded CS MP was assessed on methicillin-sensitive *S. aureus* (MSSA) ATCC 6538 and methicillin-resistant *S. aureus* (MRSA) ATCC 43300 biofilm formation and disruption. Biofilm biomass and metabolic activity were determined through the crystal violet staining method and the XTT reduction assay, respectively. **Results:** The SC38-loaded chitosan microparticles exhibited favorable aerodynamic properties. SC38 was able to inhibit both the MSSA and MRSA biofilm formation in a dose-dependent manner, eliciting BIC₅₀ of 3.7 and 8.0 µg/mL, respectively. The optimized formulation significantly reduced both MSSA and MRSA biofilm formation at all (for MSSA) and the highest (for MRSA) tested concentrations. No effect on preformed biofilm was observed. SC38-loaded CS MP showed a relatively safe profile in lung cells after 72 h exposure. **Discussion and Conclusions:** In this study, an inhalable dry powder formulation of the novel anti-biofilm compound SC38 was developed by spray-drying involving CS as a polymeric carrier. Our results

showed how this new indole derivative dry powder could be useful against biofilm-associated lung infections caused by *S. aureus*. Particularly, the proven efficacy in preventing biofilm formation is of great interest for the development of preventive therapies that aim to avoid the establishment of infections or to limit their progress. Future *in vivo* tolerability and efficacy studies are needed to confirm pre-clinical *in vitro* results and unravel the potential of this novel formulation for the treatment of difficult-to-treat biofilm-mediated lung infections.

279 - Uncomplicated UTIs and old antimicrobials: a retrospective study on southern Sardinian population

giuseppe pala ⁽¹⁾ - Silvia Puxeddu ⁽¹⁾ - Fabrizio Angius ⁽²⁾ - Aldo Manzin ⁽¹⁾

Università degli Studi di Cagliari, AOU "D.Casula", Monserrato, Cagliari/Università degli studi di Cagliari/Dipartimento di scienze biomediche, Cagliari, Italia ⁽¹⁾ - Università degli studi di Cagliari, Università degli studi di Cagliari/Dipartimento di scienze biomediche, Cagliari, Italia ⁽²⁾

Uncomplicated UTIs and old antimicrobials: a retrospective study on southern Sardinian population

GIUSEPPE PALA ^{1,2}, **SILVIA PUXEDDU** ¹, **FABRIZIO ANGIUS** ¹, **ALDO MANZIN** ^{1,2}

¹ Department of Biomedical Sciences, Unit of Microbiology and Virology, University of Cagliari, Cagliari, Italy

² AOU Policlinico "D. Casula", Applied Microbiology Lab, Monserrato (CA), Italy

Introduction

Urinary tract infections (UTIs) are the most common among out-patient cases referred to microbiology labs. Therapy relies on a wide spectrum of available antimicrobials hence the most appropriate must be prescribed considering the species and their frequencies in the community, as well as possible emerging drug-resistant strains. In this regard, a broad panel of drugs, even dated, is still valid in terms of susceptibility scale such as nitrofurantoin, fosfomicin, cefepime and amoxicillin in combination with clavulanic acid. In addition, these drugs are cost-effective compared to the modern one; however are not free from side effects nor from contraindications, though limited by a careful anamnesis, physical examination and deep knowledge of the species mostly isolated in the reference community. Here, we focus on the species that are frequently isolated from UTI cases in the southern Sardinian region and their susceptibility to old antibiotics.

Materials and method

We performed a retrospective study by analyzing the reports from out-patient urine samples received and processed by our laboratory at the "Duilio Casula" University Hospital of Monserrato (Cagliari) between June 2021 and June 2022. Samples were seeded in linearcount and suspicious colonies isolated. Susceptibility data to nitrofurantoin and other common drugs such as fosfomicin, cefepime and amoxicillin/clavulanic acid were obtained by VITEK 2 compact for the different microbes, recorded and compared.

Results

Over a total of 574 samples, 455 tested positive to *E. coli* (79% of UTIs), *K. pneumoniae* (63), *E. faecalis* (25), *P. aeruginosa* (12), *C. koseri* (9), *P. mirabilis* (5), *E. aerogenes* (3), *P. stuartii* and *R. planticola* (1), respectively. The VITEK data regarding the most represented *E.coli*, showed it to be susceptible to nitrofurantoin (100%), cefepime (87%), fosfomicin (89%) and amoxicillin/clavulanic acid (71%).

Discussion and Conclusions

Beyond its affordability, nitrofurantoin seems to be the best choice for uncomplicated UTIs as suggested by the highest sensitivity of *E. coli* and *E. faecalis* although the high incidence of G6PD deficiency among Sardinians may represent a contraindication for its use. Fosfomicin still remains very advantageous for its bacteriostatic activity in single-dose. Amoxicillin/clavulanic acid shows a good percentage of susceptibility, however it is more expensive and may cause post-treatment dysbiosis. Finally, the more percentage cefepime is effective as fosfomicin but needs parenteral administration. Overall, these data suggest that the very cheap nitrofurantoin may be more convenient than other much more commonly used antimicrobials to treat most uncomplicated UTIs.

281 - Case report: Disseminated *Cryptococcus neoformans* in an immunocompetent patient.

Giuseppe Greco⁽¹⁾ - FRANCESCO FOGLIA⁽¹⁾ - ENRICA SERRETIELLO⁽¹⁾ - FRANCESCA BORRELLI⁽¹⁾ - ROSADEA ZIMBARDI⁽¹⁾ - RAFFAELE VISCARDI⁽¹⁾ - DANIELA FONTANELLA⁽¹⁾ - CONCETTA BENTIVOGLIO⁽¹⁾ - MONTELLA FORTUNATO⁽¹⁾ - VALERIA CRUDELE⁽¹⁾ - EMILIANA FINAMORE⁽¹⁾ - MASSIMILIANO GALDIERO⁽¹⁾

Department of Experimental Medicine, University of Campania, Department of Experimental Medicine, University of Campania, Napoli, Italia⁽¹⁾

Case report: Disseminated *Cryptococcus neoformans* in an immunocompetent patient.

GIUSEPPE GRECO^{1,2}, FRANCESCO FOGLIA^{1,2}, ENRICA SERRETIELLO^{1,2}, FRANCESCA BORRELLI^{1,2}, ROSADEA ZIMBARDI^{1,2}, RAFFAELE VISCARDI^{1,2}, DANIELA FONTANELLA^{1,2}, CONCETTA BENTIVOGLIO¹, MONTELLA FORTUNATO¹, VALERIA CRUDELE¹, EMILIANA FINAMORE¹, MASSIMILIANO GALDIERO^{1,2}

¹Microbiology and Virology Unit, University Hospital of Campania "Luigi Vanvitelli", Naples, Italy

²Department of Experimental Medicine, section of Microbiology and Clinical Microbiology, University of Campania "Luigi Vanvitelli", Naples, Italy

Introduction: Cryptococcosis is an opportunistic fungal disease, caused by *Cryptococcus grubii*, *Cryptococcus neoformans* (*C. neoformans*), and *Cryptococcus gattii*. These species mainly lead to lung infections and central nervous system infections, such as meningoencephalitis and cranial neuropathies. Other types of infections include skin, prostate, eyes, bone marrow and joints. Infection occurs more easily in patients with immunosuppression or with other infections. A very high mortality rate was reported for cryptococcal meningitis ranging from 27% to nearly 50%. We describe one case of meningoencephalitis from *Cryptococcus neoformans* that occurred in an apparently immunocompetent patient.

Materials and Methods: A 38-year-old Ukrainian woman was reported to be healthy up to 2 weeks before hospitalization, when she developed fever and confusion. After 48 hours, progressed to visual hallucinations along with urinary incontinence. The differential diagnosis included pulmonary tuberculosis, bacterial or fungal pneumonia, and lung cancer. The patient was subsequently diagnosed with disseminated *C. neoformans*, which remains very rare.

Results: A diagnosis of bacterial meningitis was made, and ceftriaxone and corticosteroids were given to reduce inflammation and edema of the brain and cranial nerves. Two days later, due to lack of clinical improvement, an aliquot of the cerebrospinal fluid (CSF) was tested, and it was found that she had a cryptococcal antigen titre of 1: 320. Within 72 hours of culture, the laboratory notified doctors that *C. neoformans* was isolated from CSF. Using mass spectrometry (MALDI-TOF MS), the isolate was identified as subspecies *C. neoformans*. Therapy was changed to amphotericin B and her mental status improved significantly over the next 1 week and her cerebrospinal fluid culture had a decreased CSF cryptococcal antigen titre to 1: 160.

Discussion and Conclusions: *C. neoformans* has a complex polysaccharide capsule with antiphagocytic properties. Low concentrations of anticryptococcal antibodies are normally found in immunocompetent people due to daily exposure. Although exposure is almost omnipresent in some regions of the world, this organism rarely causes clinically important infections in immunocompetent hosts. Conversely, it has become a notable opportunistic infection in those possessing a compromised cell-mediated immune response. Our case highlights the importance of collecting an accurate travel history in all patients, as the differential diagnosis should include atypical pathogens that may be endemic to the travel area. It also highlights the significant morbidity associated with cryptococcosis and drug-related toxicities and methods of preventing complications.

283 - Co-infection of *Pseudomonas aeruginosa* and *Achromobacter xylosoxidans* in green nail syndrome treated with ozenoxacin: a case report.

Terenzio Cosio⁽¹⁾ - Rosalba Petruccelli⁽²⁾ - Roberta Gaziano⁽¹⁾ - Carla Fontana⁽³⁾ - Marco Favaro⁽¹⁾ - Paola Zampini⁽¹⁾ - Enrico Salvatore Pistoia⁽¹⁾ - Flavia Lozzi⁽⁴⁾ - Luca Bianchi⁽⁴⁾ - Elena Campione⁽⁴⁾

Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;;
Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy;; Roma, Italia⁽¹⁾ - Microbiology and Virology Lab, Tor Vergata University Hospital, V.le Oxford, 81 00133, Rome, Italy., Microbiology and Virology Lab, Tor Vergata University Hospital, V.le Oxford, 81 00133, Rome, Italy., Roma, Italia⁽²⁾ - National Institute for Infectious Diseases (INMI) L. Spallanzani, IRCCS, Rome, Italy, National Institute for Infectious Diseases (INMI) L. Spallanzani, IRCCS, Rome, Italy, Roma, Italia⁽³⁾ - Department of Systems Medicine, Dermatologic Unit, University of Rome Tor Vergata, Viale Oxford, Rome, Italy;; Department of Systems Medicine, Dermatologic Unit, University of Rome Tor Vergata, Viale Oxford, Rome, Italy;; Roma, Italia⁽⁴⁾

Co-infection of *Pseudomonas aeruginosa* and *Achromobacter xylosoxidans* in green nail syndrome treated with ozenoxacin: a case report.

Terenzio COSIO^{1,2}, Rosalba PETRUCCELLI³, Roberta GAZIANO⁴, Carla FONTANA⁵, Marco FAVARO⁴, Paola ZAMPETTI², Enrico PISTOIA⁴, Flavia LOZZI¹, Oreste CENNAMO³, Luca BIANCHI¹ and Elena CAMPIONE¹

¹ Department of Systems Medicine, Dermatologic Unit, University of Rome Tor Vergata, Viale Oxford, Rome, Italy;

² Department of Experimental Medicine, PhD course in Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), Microbiology Section, University of Rome "Tor Vergata", Rome, 00133, Italy;

³ Laboratory of Microbiology, Polyclinic of "Tor Vergata", 00133 Rome, Italy;

⁴ Department of Experimental Medicine, Microbiology Chair, "Tor Vergata" University, 00133 Rome, Italy;

⁵ National Institute for Infectious Diseases (INMI) L. Spallanzani, IRCCS, Rome, Italy

Introduction Green nail syndrome (GNS) is a persistent greenish pigmentation of the nail plate, originally described in 1944 by Goldman and Fox, due to *Pseudomonas aeruginosa* infection. Recently, co-infection of *P. aeruginosa* and *Achromobacter* spp. have been described in patient with fibrosis cystic. *Achromobacter xylosoxidans* is an emerging, multidrug-resistant (MDR) pathogen involved in lung and soft tissue skin infection, widespread in nature, inhabiting mainly in water as *P. aeruginosa*. To data, no there are no recognized co-infection due to *P. aeruginosa* and *A. xylosoxidans* in skin and skin appendages. In this case report, we describe the first documented GNS due to *P. aeruginosa* and *A. xylosoxidans* co-infection.

Material and method A 65-year-old healthy retired woman become to our attention for a symptomatic greenish discoloration of the nail plate of the right and left fingernails over a period of 10 months. Dermatologic examination showed greenish-yellow bilateral discoloration of the first fingernail, in the proximal area, mild onychodystrophy of the entire nail plate, onychomadesis and distal onycholysis. Nail clipping was performed to confirm the clinical hypothesis of GNS.

Results Bacteriologic culture of nail clipping was positive for multidrug resistance (MDR) *A. xylosoxidans* and for quinolones intermediate resistance *P. aeruginosa*. Fungal coinfection was excluded by potassium hydroxide preparation and culture. Due to the co-infection of *P. aeruginosa* and *A. xylosoxidans*, topical therapy with ozenoxacin 1% daily for 12 weeks was prescribed. After the first 4 weeks of application, the patient presents clinical resolution, regrowth of the right nail and disappearance of the chloronychia of the left nail.

Discussion and conclusion The clinical management of the syndrome can be confusing, especially when the bacterial culture result is inconsistent or when non-*Pseudomona* bacteria are isolated with *P. aeruginosa*. In our case, due to the nail co-infection of *P. aeruginosa* and *Achromobacter spp.* no guidelines or previously reports have been published and antibiotic stewardship is crucial to act on both pathogens and reducing adverse events. However, for *A. xylosoxidans* there are no solid data regarding optimal topical antibiotic treatment. Ozenoxacin, the first nonfluorinated quinolone, could be a safe, topical treatment in case of MDR nail infections. This case highlights the complexity of the microbiological milieu in GNS and provide a possible treatment option in case of MDR co-infection of the nail unit. Further studies are required to evaluate clinical isolate from nail infections and the co-presence of *P. aeruginosa* and *A. xylosoxidans* as culprit bacteria in skin and skin appendage infection.

284 - Molecular characterization of *Listeria monocytogenes* strains isolated from food and human sources

ANTONELLA COSTA ⁽¹⁾ - ANTONIETTA GATTUSO ⁽²⁾ - TERESA FASCIANA ⁽³⁾ - MARINA TORRESI ⁽⁴⁾ - VINCENZINA ALIO ⁽¹⁾ - MARIA RITA TRICOLI ⁽³⁾ - GASPARE BUTERA ⁽¹⁾ - ANNAMARIA CASTELLO ⁽¹⁾ - FRANCESCO POMILIO ⁽⁴⁾ - ANNA GIAMMANCO ⁽³⁾

Istituto Zooprofilattico Sperimentale della Sicilia, Istituto Zooprofilattico Sperimentale della Sicilia, Palermo, Italia ⁽¹⁾ - Istituto Superiore di Sanità, Dipartimento di Sicurezza Alimentare, Nutrizione, Sanità Veterinaria, Istituto Superiore di Sanità, Roma, Roma, Italia ⁽²⁾ - Pro.Mi.Se/Azienda Ospedaliera Universitaria Policlinico P.Giaccone, Palermo, Pro.Mi.Se/Azienda Ospedaliera Universitaria Policlinico P.Giaccone, Palermo, Palermo, Italia ⁽³⁾ - Istituto Zooprofilattico Sperimentale Abruzzo e Molise, LNR per *Listeria monocytogenes* Istituto Zooprofilattico Sperimentale Abruzzo e Molise, Teramo, Italia ⁽⁴⁾

Molecular characterization of *Listeria monocytogenes* strains isolated from food and human sources

ANTONELLA COSTA¹, ANTONIETTA GATTUSO², TERESA FASCIANA³, MARINA TORRESI⁴, VINCENZINA ALIO¹, MARIA RITA TRICOLI³, GASPARE BUTERA¹, ANNAMARIA CASTELLO¹, FRANCESCO POMILIO⁴, ANNA GIAMMANCO³

¹Istituto Zooprofilattico Sperimentale della Sicilia, Palermo, Italy; ²Dipartimento di Sicurezza Alimentare, Nutrizione, Sanità Veterinaria, Istituto Superiore di Sanità, Roma, Italy; ³Pro.Mi.Se/Azienda Ospedaliera Universitaria Policlinico P.Giaccone, Palermo, Italy; ⁴LNR per *Listeria monocytogenes* Istituto Zooprofilattico Sperimentale Abruzzo e Molise, Teramo, Italy

Introduction: The aim of the work was the molecular characterization of *L. monocytogenes* (*L.m.*) isolated from food and humans in the period 2019-2021.

Materials and methods: A total of 67 *L.m.* isolates have been collected (UNI EN ISO 11290-1: 2017) at the Food Microbiology laboratories of the IZS Palermo from different food matrices with a prevalence of ready-to-eat food products such as dairy, fresh cheese, meat, fish sampled by Veterinary Services. The bacterial isolates were stored at -20 °C in Microbank and sent to the LNR of Teramo for the determination of the serogroup (PCR-Multiplex) and molecular investigation (MLST and Whole Genome Sequencing -WGS). The sequencing was carried out on the Illumina NextSeq 500 platform and the data analysis was performed on a bioinformatics and data collection platform of the LNR *L.m.*, called GenPat. N. 39 clinical strains of *L.m.* were collected at Palermo hospital laboratories (Regional Reference Laboratory for listeriosis). The strains, together with the sheets for the collection of epidemiological data, were sent to the Istituto Superiore di Sanità (ISS-Operational Microbiological Contact Point for *L.m.*) for molecular characterization by WGS. The sequencing was carried out on an IonTorrent S5 platform and the analysis was performed automatically on a bioinformatics and data collection platform, called IRIDA-ARIES.

Results: The results on the molecular characterization of the strains isolated from food showed a prevalence of serogroup IVb (70%), followed by IIa (24%), IIb (4.5%) and IIc (1.5%). The 46.3% of the strains, all belonging to serogroup IVb, have been isolated from milk products (mozzarella and string cheese) taken from the same producer during official controls, in the period August-September 2020, following a positivity detected in self-control. The results of the sequencing carried out by the LNR highlighted the existence of clusters of strains belonging to Clonal Complex (CC) 2, CC199 and CC1. In particular, all the strains isolated in the same cheese factory, both in the period considered and in a subsequent sampling in January 2022, belonged to CC2 and Sequence Type 2 (ST2). Regarding the 39 clinical *L.m.* strains, the phylogenetic analysis of the genomes allowed the identification of a Cluster_90 composed of 25 strains of which 6 were isolated in 2019, 16 in 2020, 1 in 2021 and 2 of which the year of isolation is unknown. The 25 strains were found to belong to serogroup IVb, ST2 and CC2, presenting between them an allelic difference in

the MLST core genome between 0 and 12. It has been noted the presence of 8 strains, isolated between October 2019 and August 2021, associated with maternal and neonatal cases. The genomic sequences of the 39 clinical strains of *L.m.* were compared with the sequences deposited in the IRIDA-ARIES database. From the analysis, it emerged that the Cluster_90, ST2 also included 3 isolated strains in Lombardy (2 in 2019, 1 in 2020), 2 in Piedmont, 1 in Lazio, 1 in Tuscany in 2020 and 2 isolated strains in Sicily (1 in 2019 from Syracuse and 1 in 2020 from the province of Palermo). Conclusion: This study allowed to start the construction of an integrated medical/veterinary network between laboratories to enhance the listeriosis surveillance system in the Sicily region.

Indice degli autori

A

ABAGNALE IMMACOLATA	353
Abbatecola Angela Marie	212
Abbondio Marcello	12; 14; 89
Abdelmalek Nader	288
AbuAlshaar Aseel	300; 327
Acerbis Andrea	404
Adams Neill	345
Adams Neill James	314
Agliata Gloria	190
Aguglia Elvira	325
Aiezza Noemi	389
Albano Camilla	2; 57
ALBANO CAMILLA	151
Albiges Laurence	120
Albini Elisa	272
Alfano Alberto	47
Alfè Saveria	94
Alifano Pietro	136
ALIO VINCENZINA	449
Allizond Valeria	266; 268; 289
Alovisi Mario	363
Altucci Lucia	220
Amato ALESSANDRA	101
Amatore Donatella	21
Ambrosi Cecilia	19; 69; 302
Ambrosino Annalisa	246; 391; 407
Ambrosio Luigina	397; 429
Ambrosio Monica	278; 368
Amitrano Sergio	220
Ammendolia Maria Grazia	351
Amodio Federica	94
Amoroso Maria Grazia	216
Andolfi Anna	214
André Fabrice	120
Andreassi eleonora	179
Andreassi Eleonora	291
Andreoni Massimo	77; 90; 155
Andriolo Maria	439
Angelici Maria Cristina	387
Angelo Carfi	118
Angius Fabrizio	134; 226; 308; 444
Antinori Andrea	186
Antognelli Cinzia	442
Antonelli Alberto	389; 415
ANTONELLI ALBERTO	399
Antonelli Guido	63; 73; 114
Antonelli Incalzi Raffaele	212
Antonello Maria	328
Antonioli Luca	360
Aprèa Giuseppe	236
Arbyn Marc	224
Arcangeletti Cristina	153

Arcangeletti Maria Cristina	6; 7; 128; 161; 162; 275; 277; 387
arcari gabriele	334
Arcari Gabriele	330; 332
Ardizzoni Andrea	81
Arduino Irene	169
Arena Fabio	349
ARGENZIANO MONICA	355
Arrigo Ignazio	384; 439
ARRIGO IGNAZIO	316
Artini Marco	130
Asa'ad Shirin	366
ASCIERTO MARIANNA	407
Attili Anna Rita	216
Attili Anna-Rita	426
Audigier-Valette Clarisse	120
Avagliano Carmen	87

B

Baccani Ilaria	415
Bagattini Maria	132
Baglieri Giuseppe	315
Bagnoli Pietro	194
Bailey Nicholas P.	71
Baj Andreina	185; 199; 240
Bajetto Greta	2; 57
BAJETTO GRETA	151
BALDELLI SARA	174
Baldini Francesco	186
Baldisserotto Anna	340; 385
Balenzano Gaetano	384
balestrieri emanuela	107
Balestrieri Emanuela	77; 83; 85; 90; 96
Banche Giuliana	266; 270
Baratè Claudia	103
Barbieri Ramona	295
Barchiesi Francesco	286
Barile Nadia	236
Barlesi Fabrice	120
Barnini Simona	413
Baroni Marcello	3
Barreca Davide	167
Barreca Giorgio Settimo	310
Barros Lucas	120
Barski Piotr	210
BASAGNI DILETTA	399
Basile Anna	97
Batoni Giovanna	40; 304; 337; 372
Bavagnoli Laura	188
Beikpour Farzad	236
Belkacem Ines Ait	77
Bellato Massimo	140
Bellini Pierantonio	138
Beltrami Silvia	3
Beninati Concetta	5; 13; 125

BENINATI CONCETTA	1
BENTIVOGLIO CONCETTA	445
Benvenuti Laura	360
Berisio Rita	132; 147
Bernabè Giulia	140; 328
Bernardini Sergio	159
Bernardo Paola	306
Bertea Cinzia Margherita	266
Bertelli Anna	149
Bertoli Ada	179
Bertolini Andrea	322
Bertoncelli Anna	145; 393
Bessa Lucinda	358
Besse Benjamin	120
Besutti Valeria	328
Bettini Aurora	186
Bianchetti Giada	431
Bianchi Luca	447
Bianco Delia Mercedes	431
Bianco Gabriele	268; 289
BIANCO GABRIELE	355
Biba Camilla	188
Biboy Jacob	438
Bini Francesca	153; 293; 437
Biolatti Matteo	2; 57; 270
BIOLATTI MATTEO	151
Bisaglia Carlo	236
Bisi Matteo	437
Bitossi Camilla	73; 114; 303
Bivona Dalida	264
Bivona Dalida A	370
Bivona Dalida Angela	79; 382
Bjork Johannes	120
Blasi Elisabetta	81; 138
Boatti Lara	248
Boattini Matteo	268; 289
Boccella Mariarosaria	417; 421
Bocchia Monica	103
Boccia Giovanni	417; 419; 421; 424
BOCCIA GIOVANNI	395
Bolte Laura	120
Bona Elisa	248; 250
Bonacci Paolo	264
Bonacci Paolo G	79
Bonadonna Lucia	242
Bonanno Ferraro Giusy	235; 236; 242
Bondi Alessandro	289
Bongiorno Dafne	79; 264; 370; 382
Bonifacio Luca	315
Bonifazi Francesca	244
Bonomo Carmelo	79; 264
Bonucelli Ottavia	385
Bonura Floriana	172; 184; 197
Bonvicini Francesca	164
Borgatti Eva Caterina	244
Borgogna Cinzia	51; 53
Borrelli Anna	417; 424
BORRELLI FRANCESCA	445
Borrelli Sara	391
Bortolotti Daria	3; 149
Bosio Davide	363

Bosisio Daniela	23
Bottai Daria	380
Bouchard Nicole	120
BOUTAHAR SARA	185; 199
Brai Annalaura	168; 195
Brambilla Massimo	236
Brandtner David	235; 242
Brazzini Gabriele	159
Brenciani Andrea	272; 273; 286
BRENCIANI ANDREA	318
Brescini Lucia	286
Brogi Simone	188
Brun Paola	140; 328
Bruna Riccardo	51
Brunati Cristina	256
Brunetti Francesca	144
Bruni Roberto	73
bruno francesco	334
Bruno Francesco	330; 332
Btugneti Marta	179
Bua Gloria	164
Bucalossi Alessandro	113
Buffoli Fabio	404
Bugatti Antonella	149
Buommino Elisabetta	87; 126
Buonocore Carmine	222
Buoncuore Giovanna	190
Buonomo Antonio R.	94
Buratto Mattia	338; 340
Busto Francesco	411
BUTERA GASPARE	449
Buttà Michela	231
Buttrini Mirko	6; 7; 128; 161; 162; 275; 277; 387
Buzzatti Elisa	83
Buzzi Raissa	340

C

Cacace Angela	47; 49
Caccuri Francesca	149
Cacioppo Federica	172
Cafariello Carmine	212
Cafiso Viviana	325
Calà Cinzia	197
Calabrese Maria Rita	413
CALANTONI VALERIA	205
Calati Federica	23
Caldara Federica	90
Calderaro Adriana	6; 7; 128; 161; 162; 275; 277; 387
Caleca Domenico	280
CALECA DOMENICO	262
Calvigioni Marco	31; 322; 360; 377
Calvo Maddalena	252; 258; 382
CALVO MADDALENA	254
Cambieri Patrizia	327
Camici Marta	186
Cammarota Marcella	401
Campagna Marcello	75
Campalto Mery	405
Campanile Floriana	374; 378
Campiani Giuseppe	423
Campione Elena	159; 291; 447

Campisciano Giuseppina	25; 26; 32; 293
Campisi Giovanni	149
Campisi Giuseppina	231
Campobasso Claudia	380
Campodonico Edoardo	404
Caneparo Valeria	38
CANTALUPPI VINCENZO	38
CAPASSO CLEMENTE	105
capitani Valerio	334
Capitani Valerio	330; 332
Capra Giuseppina	197
CAPRIA ANNA-LISA	230
Caproni Anna	338; 340; 385
Capunzo Mario	417; 419; 421; 424
CAPUNZO MARIO	395
cara alice	233
Cara Alice	195; 202; 230
Caraci Filippo	79
Caramaschi Alice	250
Carannante Anna	397; 429
carattoli alessandra	334
Carattoli Alessandra	330; 332
Carcione Davide	404
CARELLI MARIA	318
Carelli Vincenza Maria	439
Carfora Lettieri Giuseppe	341
CARIANI LISA	403
Carillo Federica	401
Carletti Fabrizio	186
Carletti Silvia	404
Carli Petra	36
CAROLEO MARIA CRISTINA	205
Carossa Massimo	363
CARRADORI SIMONE	105; 111
Carraro Monica	41
Carrega Giuliana	295
Carreras Pier Paolo	226
Carrino Marilena	405
Carsetti Rita	65
Carta Antonio	170
Carubbi Cecilia	128
Carullo Gabriele	423
Caruso Arnaldo	149
Caruso Ciro	365
Caruso Gabriella	182
Caruso Giuseppe	79
Caruso Massimo	218; 323
Casagrande Proietti Patrizia	45
Casale Roberto	268
Cascianelli Chiara	165
Cascioferro Stella	442
Caselli Desiree	283
Caselli Elisabetta	153; 293; 437
Casolaro Vincenzo	101; 401
CASOLARO VINCENZO	395
Cason Carolina	25; 26; 32; 293
Cassadonte Mariangela	345
Cassisi Marta	374
Castagliuolo Ignazio	140; 328; 366
CASTELLO ANNAMARIA	449
CASTILLO PACHECO SERGIO F.	151
Castronovo Lara Mitia	117
Cat Genova Elena	2
Catania Maria Rosaria	101; 320; 401
Catania Mariarosaria	409
Catelli Elisa	40; 304; 337
Cattaneo Chiara	149
Caturano Valeria	15; 17; 136; 296; 298
Caughey Byron	226
Cavallari Eugenio Nelson	63
Cavalli Roberta	173; 270
CAVALLI ROBERTA	355
Cavallo Ilaria	143; 397; 429
Cavallo Lorenza	266; 270; 363
Cavallo Rossana	268; 289
Ceccarelli Giancarlo	63
cecilia federico	334
Celandroni Francesco	31; 322; 360; 377
Cellini Luigina	60; 354; 358
Cennamo Oreste	179
Cerboni Cristina	23
Cerchia Carmen	320
Cermelli Claudio	190
Cerracchio Claudia	214; 216; 278
Cerroni Mario	242
Cesaro Patrizia	248
Chandel Shika	53
Chandel Shikha	38
checconi paola	174
Checoni Paola	67
Chessa Luchino	75
Chezzi Carlo	6; 7; 128; 161; 162; 275; 277; 387
Chianese Annalisa	116; 220; 228
Chiaradia Elisabetta	45
Chiarelli Massimo Giuseppe	182
Chiaromonte Adriana	47; 49
Chilin Adriana	140
Chiricio Rossella	77
Chirico Rossella	85; 90; 96
Ciabattini Annalisa	29; 92; 103; 113; 176
Ciacchi Nagaia	433
Cicalini Stefania	186
Ciccaglione Anna R.	73
Ciccozzi Massimo	149
Ciceri Fabio	404
Cicino Claudia	310; 314; 370
Cimini Donatella	49
Cimino Giuseppe	114
Cinthy Marzia	272; 273
Cinti Lilia	63
Ciociola Tecla	60
CIONE ERIKA	205
Ciotti Marco	155; 159; 179
Cipriani Chiara	83; 85
Cirino Andrea	417
ciriolo maria rosa	174
Cirlincione Fortunato	384
Civra Andrea	173
Clarizia Gabriele	306
Clementi Massimo	404
Clementi Nicola	404
Clerici Daniela	404

Cocchia Natascia	260
Cocci Paolo.....	426
Coccitto Sonia Nina	272; 273
Cocuzza Clementina E.....	428
Cocuzza Clementina Elvezia	224
Codda Giulia.....	295; 305
Codini Simone	322
Colavita Francesca.....	186
Coletti Monica	330
Colicchio Roberta	15; 17; 94; 136; 296; 298
Colli Claudia.....	36
Collura Antonina	184
Colombari Bruna	138
Colombini Lorenzo.....	357; 433
COLOSIMO MANUELA	205
Comai Giorgia	244
Comar Manola	25; 26; 32; 36; 293
Comella Federica.....	87
Cometa Stefania.....	411
Comini Sara	266; 268; 270; 289
Consoli Grazia M.L.	306
Consonni Alessandra	327
Contaldo Maria	343
Conte Antonietta L.	368
Conte Antonietta Lucia.....	144; 351
Conte Maria Pia	144; 351
Conte Marisa.....	142
Conti Maria Giulia.....	65
Conti Stefania	60
Continisio Leonardo	136
Coppi Marco.....	389; 399; 415
Coppola Bartolomeo.....	266
Coppola Luigi.....	155
Coppolino Francesco	5; 13; 125
COPPOLINO FRANCESCO	1
Corà Davide	38; 250
Corbella Marta	327
CORDINE CLAUDIA.....	262
Cordini Claudia.....	280
Cordioli Giampaolo	328; 366
Coretti Lorena.....	87
Corotti Anna	168
Corrò Michela.....	405
Cosio Terenzio.....	159; 291; 447
Cossu Davide	43; 59; 123; 312
Cossu Giovanni.....	226
COSTA ANTONELLA	449
Costa Cristina	268; 289
Costa Silva Carolina A.	120
Costantino Matteo.....	173
Costanza Gaetana.....	179; 181; 291
Costanzo Valentina	258
COSTANZO VALENTINA	347
Costinas Carmen-Sarah	336
Covan Silvia	7; 275
Cozzi Loredana.....	236
Crespan Emmanuele	188
Crinelli Rita	21
Crobeddu Marco	303
Crocamo Federica.....	275; 277
CRUDELE VALERIA	445

Cuffini Anna Maria.....	266; 270
Cuppone Anna Maria.....	117
Cuppone AnnaMaria.....	357
Curtovic Ida	238
Cusi Maria Grazia	21
Cuteri Vincenzo	426

D

D'Angelantonio Daniela	236
D'Abrasca Brigida.....	126
D'Accolti Maria.....	153; 293; 437
D'Achille Gloria.....	273; 286
D'Acunto Mario	202
D'AGOSTINO ILARIA	105
Daillère Romain	120
Dal Piaz Fabrizio.....	220
Dall'Acqua Stefano	140
D'Amati Giulia.....	157
D'Ambrosio Sergio	49
Damiano Cecilia.....	212
D'Antongiovanni Vanessa.....	360
D'Arcangelo Sara	354; 358
Darik Ines.....	120
D'Auria Alessandra	63; 65; 73; 114
D'Avenio Giuseppe	242
D'Avorio Erica	85
De Andrea Marco.....	2; 51; 53; 57
DE ANDREA MARCO	38
De Angelis Giuseppe	345
De Angelis Marta.....	21; 34; 67
De Canale Ettore.....	366
De Carli Alessandro.....	210
De Caro Carmen	87
De Chiara Giovanna.....	99; 109; 238
De Conto Flora.....	6; 7; 128; 161; 162; 275; 277; 387
De Diego Laura.....	89
DE FAZIO MARCO	205
De filippis Anna.....	101
De Filippis Anna.....	116; 222; 228; 246; 391; 401; 409; 411
De Gaetano Giuseppe Valerio.....	5; 13; 125
DE GAETANO GIUSEPPE VALERIO	1
De Giglio Elvira.....	411
De Grazia Simona.....	172; 182; 184; 197
De Gregorio Eliana	132
De Maio Flavio	431
DE MAIO FLAVIO	435
De Marco Margot.....	97
De Martino Luisa	214; 260; 278; 368
De Nittis Rossella	349; 376
De Palma Antonella	149
de Pascale Donatella	222
De Pità Ornella.....	303
De Santis Riccardo.....	21
De Seta Francesco.....	25; 26; 36; 81
Deidda Graziano	188
Del Giacco Stefano	75
Del Giudice Claudia.....	236; 242
Del Matto Ilaria.....	236
Del Poeta Giovanni	83
Del Prete Chiara.....	260

Del Prete Raffaele.....	282; 283
Del Principe Maria Ilaria	83
Del Vecchio Claudia.....	366
Delbue Serena.....	53; 57; 192; 194
Della Marca Roberta.....	391; 411
Della Rocca Maria Teresa.....	341
Dell'Annunziata Federica.....	401; 409; 411
Dell'Oste Valentina.....	2; 57
DELL'OSTE VALENTINA	151
Delogu Giovanni.....	118; 147; 431
DELOGU GIOVANNI	435
Delogu Ilenia	308
Denapaite Dalia	438
Denicolo' Sofia	283
Denti Luca	194
D'Ercole Simonetta	60; 358
Derosa Lisa	120
Dessi' Daniele	71
d'Ettorre Gabriella.....	63
Deutsch Eric	120
Di Bernardo Francesca	184; 382
Di Bonaventura Giovanni	337; 423
DI BONAVENTURA GIOVANNI	403
Di Campi Emanuela.....	354; 358
Di Carlo Paola	439
Di Cristo Mariagrazia	417
Di Domenico Enea.....	397
Di Domenico Enea Gino.....	143; 429
Di Fabio Carlotta	159
Di Fermo Paola.....	60; 354
DI GIOVANNI PAMELA	105
Di Giulio Mara.....	60; 354; 358
Di Lodovico Silvia.....	354; 358
Di Lonardo Anna	212
DI Lorenzo Flaviana	15
Di Luca Mariagrazia	380
Di Maio Alan	7; 275
Di Maio Valeria	157
DI MAURO ADRIANA	347
Di Nardo Giovanni	55
Di Paola Laura	384
Di Pasquale Simona	236
Di Pietra Giuseppe.....	140; 328; 366
Di Pietro Marisa.....	441
Di Pilato Vincenzo.....	295; 305; 389
DI PILATO VINCENZO	399
Di Prima Elena.....	439
Di Primio Cristina.....	201
Di Rosario Martina	136; 296
DI Rosario Martina	15
Di Salvo Clelia.....	360
Di Sante Gabriele.....	118
Di Silvestre Dario	149
DI SOTTO ANTONELLA	111
Di Stefano Sharon.....	6; 161
Diana Patrizia	442
Diani Erica	165
Diaz Nicia	71
Diban Firas	60; 358
Divenuto Francesca	345
DOLCE VINCENZA.....	205

Dolci Maria	57; 192; 194
Dolfa Camilla.....	202
Donadio Giuliana	220
Donadio Stefano.....	256
Donalisio Manuela	169
Donnarumma Giovanna	42; 47; 49; 343
Dore Maria Pina	89
D'Orio Denise	298
Doti Nunzianna	116
Drago Filippo	218
Dragoferrante Francesca	185; 199
Dreassi Elena	168; 195
Drubay Damien.....	120
Durante Adriana.....	341
Durante Miriam.....	176
D'Ursi Pasqualina.....	149

E

Eletto Daniela	142; 365
Emma Rosalia	218; 323
Enea Marco	197
Ennas Guido.....	134; 308
Epifani Anna Chiara	155
Escudier Bernard.....	120
Esin Semih	40; 304; 337; 372
Esposito Camilla	320
Esposito Emanuela.....	61
Esposito Francesca.....	134

F

Fabbiani Massimiliano	29; 92; 176
Fabiano Maria Gioia	351
Fabrizio Giorgia.....	143
Fais Roberta	413
Falanga Annarita.....	296
Falcone Giorgia.....	246
falcone marco.....	233
FAMA' AGATA	1; 13
Famà Agata	5; 125
Fanasca Luca.....	94
Fanelli Marialaura.....	77; 83; 85; 90; 96; 179
Farina Benedetta	7; 162; 275; 277; 387
Farotto Marianna.....	250
fasano erika	152
Fasano Erika	164
FASCIANA TERESA	316; 449
Fasciana Teresa Maria	384
Favaro Domenico.....	210
Favaro Marco	447
Favero Francesco	38; 250
Fedele Giorgio	212
Felici Enrico.....	55
FERLITO GRAZIELLA	258
FERNANDEZ LLEO MARIA DEL MAR.....	318
FEROCE FRANCESCA.....	353
Ferrante Daniela.....	51
Ferrante Francesca D.	240
Ferrante Pasquale	192; 194
Ferrara Gianmarco	10
Ferrara Lidia	250
Ferraro Donatella	172; 197
Ferraro Valeria.....	384

Ferreri Loredana	306
Ferretti Francesca.....	69
FERROCINO ILARIO	355
FETTWAIS Jennifer.....	71
Fiaschi Lia	188
Filardo Simone	441
Filippini Fabio	240
Filippini Federica.....	149
FILIPPIS ANNA DE	407
Filipponi Carolina.....	204
Filisetti Alex	236
Filizzolo Chiara	182; 184
Fillo Silvia	429
FILOSA ALESSIA	353
FINAMORE EMILIANA.....	445
Fiore Valentina	246
Fiorentini Simona	149
Fiorentino Antonio.....	126
Fioretti Anna.....	94
Fiori Pier Luigi	71
FIORILLO MARIA TERESA.....	205
Fiorino fabio	29
Fiorino Fabio	4; 41; 92; 103; 113; 176
Fiorito Filomena	214; 216; 278
Firinu Davide	75
Firon Arnaud.....	5
Flammini Valeria	291
Focosi Daniele	199
Foffa Ilenia	202
Foglia Francesco	101
FOGLIA FRANCESCO	407; 445
Folliero Veronica.....	391; 401; 409
FOLLIERO VERONICA	395
Fonnesu Rossella	170; 202; 204; 210
Fontana Carla.....	447
Fontana Riccardo.....	338; 340; 385
FONTANELLA DANIELA	445
Fornai Matteo	360
forniti arianna	233
Forte Jacopo.....	351
Fortino Luigi.....	417
FORTUNATO MONTELLA	445
Fracella Matteo	63; 65; 73; 114
FRAGALA' ELISABETTA.....	258
Francalancia Massimo	186
Francesco Iannelli.....	4
Francese Rachele	169
Franci Gianluigi 97; 101; 116; 220; 222; 228; 391; 401; 409; 411; 417; 419; 421; 424	
FRANCI GIANLUIGI.....	395
Franciosini Maria Pia.....	45
franconi iacopo	233
Frasca Federica	63; 65; 73; 114
Fraternale Alessandra	21
Fraumene Cristina.....	12; 14
freer giulia.....	233
Freer Giulia.....	168; 170; 201; 204
Friard Sylvie	120
Fuochi Virginia.....	218; 323
Furlan Berenice.....	438
Furneri Pio Maria.....	218; 323

Fusco Alessandra	42; 343
G	
Gabriele Lucia.....	73
Gabrielli Liliana	244
Gaeta Aurelia	63
Gagliardini Roberta.....	186
Gaidano Gianluca.....	51
Gaidano Valentina	51
Galderio Massimiliano.....	407
Galdiero Massimiliano.... 101; 116; 220; 222; 228; 246; 391; 401; 409; 411; 417; 419; 421; 424	
GALDIERO MASSIMILIANO.....	395; 445
Galdiero Stefania	296
Galdiero Umberto	101
Galdiero Umberto	320; 409
Galia Elena.....	384
GALIA ELENA	316
Galimberti Sara	103
Gallinella Giorgio	164
Gallo Luigia	310; 314
Gamalero Elisa.....	248
Garaci Enrico	90
Garbuglia Anna Rosa.....	186
Gariglio Marisa	2; 23; 51; 53
GARIGLIO MARISA.....	38
Garlisi Emanuela.....	172
Garzone Stefania.....	282
Gasparro ROBERTA	101
GATTUSO ANTONIETTA	449
Gaziano Roberta.....	291; 447
Gemma Sandra.....	188; 423
Gennaioli Emma	117
Genoni Angelo	240
Genoni Angelo Paolo.....	185; 199
Gentile Andrea	256
Gentile Ivan.....	94
Gentili Valentina.....	149
Gerlini Alice	41
Germoni Chiara.....	41
Ghelardi Emilia.....	31; 322; 360; 377
Ghiringhelli Francois	120
Gholami Samaneh.....	41
Giammanco Anna	384; 439
GIAMMANCO ANNA	316; 449
Giammanco Giovanni M.....	172; 197
Giammanco Giovanni Maurizio.....	182; 184
Giancotti Aida.....	310; 345
Giani Tommaso.....	389; 415
GIANI TOMMASO	399
Giannaccare Giuseppe	377
Giannì Maria Lorella.....	192
Gibellini Davide.....	145; 165; 393
Gigante Paolo.....	280
GIGANTE PAOLO	262
Ginestra Giovanna	306
Giordano Cesira	413
Giorgio Riccardo.....	417
Giovagnoli Stefano	442
Giovanetti Eleonora	272; 273
GIOVANETTI ELEONORA.....	318

Giovanetti Marta.....	149
Giovinazzo Alessandro.....	83
Girardi Enrico.....	186
Girone Carlo.....	23
Giubbi Chiara.....	224; 428
Giuca Maria Rita.....	372
Giudice Martina.....	77; 85; 90; 96
Giuffrida Iolanda.....	258
Giuffrida Maria L.....	306
Giugliano Rosa.....	391
Glugliano Rosa.....	222
Giuglino Rosa.....	407
Gobbi Marco.....	272
Goldwasser Francois.....	120
Gona Floriana.....	404
Gori Savellini Gianni.....	21
Gorrini Chiara.....	280
GORRINI CHIARA.....	262
Granata Giuseppe.....	306
GRANDE ROSSELLA.....	105; 111
Grandi Guido.....	8
Grassi Claudio.....	109
Grassi Fabio.....	19
Grassi Sara.....	144
Gray Joe.....	438
Graziano Onder.....	118
Grazioso Rinaldo.....	228
Greco Giuseppe.....	220; 228; 343; 445
Greco Raffaella.....	404
Greco Rita.....	341
Grelli Sandro.....	77; 83; 85; 90; 96; 179; 291
Griffante Gloria.....	2; 38; 51; 53; 57
GRIFFANTE GLORIA.....	151
Grigioni Mauro.....	242
GRIMALDI ITALO.....	353
Grosso Antonietta.....	300
Guccione Salvatore.....	378
Gugliesi Francesca.....	2; 57
GUGLIESI FRANCESCA.....	151
Guiot Caterina.....	270
GUZZO FRANCESCA.....	126

H

Hattori Nobutaka.....	43; 123
HEWELT-BELKA WERONIKA.....	151
Hirt Robert P.....	71
Hiscott John.....	23
Hohenegger Martin.....	278
Horvat Branka.....	90

I

Iaconelli Marcello.....	235; 236; 242
Iacono Elena.....	204
Iacono Giorgio.....	182
Iannelli Francesco.....	41; 117; 350; 357; 433
Iannetta Marco.....	77; 90
Iannucci Andrea.....	38
Iannuzzi Filomena.....	99; 109
iapoce riccardo.....	233
Ibba Roberta.....	170
Idomir Mihaela Elena.....	336
Iebba Valerio.....	120

Iervolino Domenico.....	417; 419
IERVOLINO DOMENICO.....	395
Improda Elvira.....	10
Indraccolo Francesca.....	283
INTINI ENRICA.....	435
Iorio Marianna.....	256
Iovane Giuseppe.....	228
Iovane Valentina.....	10; 216
Isaksen Morten.....	120
Isernia Carla.....	228

J

JAKOBSEN MARTIN R.....	151
Jasemi Seyedesomaye.....	59; 312

K

Kaja Esingül.....	304
Kasper Dennis L.....	28
Kaya Esingül.....	40; 337; 372
Kittakoop Prasat.....	169
KRAPP CHRISTIAN.....	151
Kroemer Guido.....	120

L

La Campora Mariagrazia.....	136
La Frazia Simone.....	178
La Rocca Veronica.....	204
La Rosa Giuseppina.....	235; 236; 242
La Vergata Lorena.....	280
Labella Stefano.....	341
Lacarbonara Davide.....	38
Laconi Ezio.....	12; 14
Ladetto Marco.....	51
Lagni Anna.....	165
Lai Michele.....	51; 168; 170; 201; 204; 210
Lama Adriano.....	87
Lama Giuseppe.....	190
Landolfo Santo.....	2; 57
LANDOLFO SANTO.....	38; 151
LANDRUM LESLIE.....	126
Lapa Daniele.....	186
Latsuzbaia Ardashel.....	224
Laureana Roberta.....	83
Lavecchia Antonio.....	320
LAVERGATA LORENA.....	262
Lavigne Rob.....	380
Lazzaro Lorenzo M.....	378
LAZZARO LORENZO M.....	374
Lazzarotto Tiziana.....	244
Lazzeri Elisa.....	350; 357; 433
Lee Karla.....	120
Leli Cristian.....	250
LEMBO CRISTIAN.....	347
Lembo David.....	169; 173
Lembo Francesca.....	87; 126
Lentini Germana.....	5; 13; 125
LENTINI GERMANA.....	1
Leoncini Lorenzo.....	350
Leone Alessio.....	289
Leone Pasqualina.....	212
LEONI FRANCESCA.....	318
Lepera Valentina.....	280

LEPERA VALENTINA	262
Li Puma Domenica Donatella.....	109
limongi dolores	174
Limongi Dolores	67
Linardi Martina.....	426
Lingua Guido	248
Liotti Federica.....	17
Lippi Arianna.....	92
Lista Florigio	429
Lista Florigio Romano	21
Lo Cascio Giuliana	280
LO CASCIO GIULIANA.....	262
Lo Cigno Irene.....	2; 23; 38
Lodi Alessandra.....	155
LOMBARDO FRANCESCO	254
Longhi Catia	144; 351; 368
Longo Fabio.....	374; 378
Lordello Leonardo	120
Losi Paola	202
Lotti Virginia	165
Lottini Giulia	168; 170; 201
Loverde Flavia.....	325
Lozzi Flavia	447
Lucchesi Simone.....	29; 92; 113; 176
Lucentini Luca	242
Luconi Letizia.....	303
Lupetti Antonella.....	413
Lupetti Veronica.....	337; 423
LUPETTI VERONICA	403
Ly Pierre	120

M

Macale Elvira.....	303
Maccari Clara	128; 153
Maddaloni Luca.....	63
Maffioli Sonia I.	256
Maffongelli Gaetano.....	186
Maga Giovanni	188
Maggi Fabrizio	185; 186; 199; 240
Maggiore Maria Elena	283
Magistrali Chiara Francesca	272
Magnani Mauro	21
Magni Elena.....	36
Mahmoud Abdurraouf	51
Maiella Serena A.	411
Maisetta Giuseppantonio	40; 304; 337; 372
Malara Alba	212
MALERBA GIOVANNI.....	318
Malergue Fabrice.....	77
Manaresi Elisabetta.....	164
Manca Valeria.....	75
Mancini Nicasio.....	404
Mancini Pamela	235; 236; 242
Mancini Roberto	260
Mancino Enrica.....	73
Mancuso Elettra.....	314
Mandalari Giuseppina.....	167
Mandorino Manuela.....	282
Mandras Narcisa	270; 363
Manente Roberta.....	246; 417; 421; 424
MANFREDINI MARCO.....	407
Manfredini Stefano	340; 385
Mangiaracina Leonardo	184
Mangoni Maria Luisa.....	238
Manno Michele	345
Mansi Antonella.....	190
Mantova Giuseppe	15; 17; 136; 296; 298
Manzin Aldo	75; 134; 226; 308; 444
Maracchioni Christian.....	77
Marangi Marianna.....	349; 376
Maraschi Federica.....	300
Marascio Nadia	310; 314; 345; 370
Marazzato Massimiliano	55; 144
Marchese Anna	295; 305
Marchesi Isabella	190
Marchetti Monia.....	51
Marcocci Maria Elena.....	99; 109; 238
Marconi Peggy	338; 340; 385
Marcuccilli Fabbio	179
Margaglione Maurizio	349; 376
Margarita Valentina	71
MARINACCI BEATRICE	105; 111
marinelli anna maria	174
Marinelli Anna Maria	67
Marino Andrea	264
Marino Andreana	61
Marongiu ALESSANDRA	75
Marongiu Fabio.....	12; 14
Marotta Giuseppe.....	113
Marotta Maria	17
Marracchioni Christian	85; 90; 96
Martinelli Marianna	224; 428
Martinelli Monica	7; 275
Martines Stephanie.....	120
Martuscelli Licia	51
Marzaro Giovanni	140
Marzola Marco.....	338; 340; 385
Marzullo Liberato	97
Mascarella Chiara	197
Masella Alessia	117
Maso Gianpaolo	25
Masotti Andrea	69
Massa Nadia.....	248
Massacci Francesca Romana	272
Massaia Massimo.....	51
Massaro Antonietta	298
Massidda Orietta	336; 415; 438
Massimino Mariacristina	31; 377
Mastria Michele	282; 283
Mastroianni Claudio Maria	63
Masullo Angelo.....	260
Matera Giovanni	310; 314; 345; 370
Mattace Raso Giuseppina.....	87
Matteucci Claudia	77; 83; 85; 90; 96; 179
Mattioli Roberto.....	441
Matusali Giulia	186
MAUGERI GAETANO.....	254
Maulucci Giuseppe	431
Mauri Carola	327
Mauri Pierluigi.....	149
Maurizi Linda	144; 351; 368
Mazibrada Jasenka	2

Mazieres Julien	120
Mazzacane Sante	293; 437
Mazzantini Diletta	31; 322; 360; 377
Mazzariol Annarita	145; 393
mazzetti paola	233
Mazzetti Paola	202; 230
Mazziga Eleonora	153; 293; 437
Mazzola Giovanni	439
Mazzotta Elisa	405
Mazzotta Valentina	186
Medaglini Donata	29; 41; 92; 103; 113; 176
Meini Simone	230
Melillo Rosa Marina	17
Mellai Marta	250
Meloni Gian Franco	59
Meneghello Silvia	328; 366
menichincheri gaia	334
Menichincheri Gaia	330; 332
Menotti Francesca	266; 270
MENOTTI FRANCESCA	355
Merola Filomena	341
Meschi Silvia	186
Messali Serena	149
Messaoudene Meriem	120
Meto Aida	138
Mezzatesta Marilina	370
Miceli Cristina	426
Midulla Fabio	65; 73
Migliaccio Antonella	132
Migliavacca Roberta	300; 327
Migliorisi Giuseppe	252; 382
MIGLIORISI GIUSEPPE	254
Mignanelli Marianna	201
Mignone Flavio	248
Milanesi Maria	149
MINA ERICA	151
Minchella Pasquale	212
MINCHELLA PASQUALE	205
Mingoia Marina	286
Mini Giuseppe	197
Minosse Claudia	186
Minutolo Antonella	77; 83; 85; 90; 96; 179
Mirabile Alessia	264; 382
Mirabile Domenico	182
Miteva Mariya T.	238
Miteva Mariya Timotey	99; 109
Mizzoni Klizia	186
Moens Ugo	155; 157; 159
Molfetta Nicola	126
Molinari Jessica	61
Molinaro Antonio	15
Monari Claudia	442
Monasta Lorenzo	36
Monciardini Paolo	256
Mondi Annalisa	186
Montagnani Francesca	29; 92; 103; 113; 176
Montagnaro Serena	10; 228
Montanari Giulia	6; 161
Montanile Giuseppina	94
Montecchini Sara	6; 7; 128; 161; 162; 275; 277; 387
Monti Alessandra	116

More Pragati R.	246
More Pragati Rajendra	407
Morelli Enrico	176
Morelli Lorenzo	433
Morelli Maria Cristina	244
Morici Paola	305
Mornioli Daniela	192
Moro Tiziano	275
Morone Maria Vittoria	116; 220
Morone Mariavittoria	391
Moro-Sibilot Denis	120
Morroie Aldo	143
Morroni Gianluca	273; 286
MORRONI GIANLUCA	318
Mosca Adriana	282; 283
Mosca Fabio	192
Mosca Luciana	441
Moscardini Isabelle	41
moscato giovanna	233
Motta Chiara	125; 327
Motta Federica	277
Munir Zunaira	270
Musa Laura	45
Mussano Federico	363
Musso Nicolò	79; 370; 382
MUSSO TIZIANA	355
Musumeci Rosario	428
N	

Napoli Anna	63
Nasi Gabriella	303
Nasso Rosarita	320
Nastri Bianca Maria	246
Nastri BIANCA MARIA	407
Natale Alda	405
Nebbioso Angela	220
Nencioni Lucia	21; 34; 67; 238
Nenna Raffaella	65; 73
Nerone Eliana	236
Neroni Bruna	55
NETWORK SARI	242
Nicastri Emanuele	186
Nicoletti Mauro	19
Nicoletti Rosario	214
Nicoletti Vincenzo G.	378
NICOLOSI ALICE	254
Nocera Francesca Paola	10; 214; 260; 278; 368
Noli Marta	59; 123; 312
Nordi Chiara	338; 340; 385
Nostro Antonia	61; 306
Novazzi Federica	185; 199; 240
Novello Giorgia	248
O	

OCCHIPINTI FEDERICA	347
Odorici Alessandra	138
Oliveri Salvatore	252
Oliveto Giuseppe	65; 73; 114
Olivetta Eleonora	212
Ombres domenico	179
Onder Graziano	212
Orlandi Lidia	236; 242

Orrù Christina	226
OTERI ROSARIA	205
OTTAVIANO EMERENZIANA	285

P

Paba Pierpaolo	179
Paci Lorenzo	415
Pacifico Severina	246
PACIOLLA ANTONIO	353
Paduano Stefania	190
Paganoni Silvia	224
Pagliano Pasquale	417; 424
Pagliarulo Caterina	298
PAGLIONE FRANCESCO	435
Pagliuca Chiara	15; 17; 136; 296; 298
Pagnini Ugo	10; 228
Pagnozzi Daniela	12; 14
pala giuseppe	444
Pala Giuseppe	308
palamara anna teresa	174
Palamara Anna Teresa 19; 21; 34; 67; 69; 99; 109; 144; 212; 238; 302	
Palazzotto Emilia	182; 197
Palermo Francesco Alessandro	426
Palermo Mario	182
PALERMO MARIO	316
Palma Esposito Fortunato	222
Palma Francesca	246; 391
Palmas Vanessa	75
Palmero Paola	266
Palmieri Annapina	212
Palomba Antonio	12; 14
Palucci Ivana	431
PALUCCI IVANA	435
Panattoni Adelaide	31; 322; 360; 377
PANDURI GIUSEPPINA	205
Panetta Vittorio	341
Pannetta Martina	142; 365
Pantanella Fabrizio	55
Pantanella Marta	345
Panzarella Vera	231
PAOLA DE ROSA	353
Papa Rosanna	130
Pappadà Mariangela	338; 340
Pappalardo Matteo	378
Parapini Silvia	57
Pardossi Francesca	372
Pariani Elena	192
Park Joon S.	28
PASCERI FEDERICA	205
Pascucci Luisa	45
Pasolini Maria Pia	260
Pasquali Flavia	99; 109
Pasquero Selina	2; 57
PASQUERO SELINA	151
Passerini Sara	155; 157; 159; 238
Pastore Gabiria	29; 92; 103; 113; 176
PATAMIA ILDEBRANDO	254
Paterniti Irene	61
Paterno Giovangiacinto	83
Patriarca Andrea	51

Pauciullo Silvia	178
Pauletto Anthony	140
Paulus Kai	312
Pavia Grazia	345
Pavone Silvia	272
Pecora Domenico	417
Pecoraro Camilla	442
Pedata Valeria	94
Pegliasco Hervé	120
Pellegrinelli Laura	192
Pellegrini Carolina	360
Pennisi Rosamaria	167
PEPE GIUSEPPE	347
Peppoloni Samuele	138
Perdoni Federica	428
Perego Federica	192; 194
Pereyra Boza Maria del Carmen	118
Pereyra Boza MARIA DEL CARMEN	435
Perfetto Brunella	47; 49
Pericolini Eva	81
Pernazza Angelina	157
PERONACE CINZIA	205
Peroni Irene	280
PERONI IRENE	262
Perra Andrea	75
Perrella Alessandro	401
PERRELLA ALESSANDRO	395
Perron Hervé	90
Perruzza Lisa	19
Pertusio Raffaele	270
Pes Giovanni Mario	89
Petix Vincenzo	36
Petrarca Laura	65; 73
Petrini Morena	60
Petrone Vita	77; 83; 85; 90; 96; 179
Petrucelli Rosalba	447
Pettini Elena	4; 29; 41; 92; 113; 176; 350
Philosof Bar	4
Piacentini Sara	178
Piano Mortari Eva	65
Piazza Aurora	300; 327
Piazza Carmen	195
Piazza Carmen Rita	168; 201
Pica Francesca	291
Piccaluga Pier Paolo	165
Piccirilli Giulia	244
Piccolella Simona	246
Piccolo Giovanna	162; 387
Piel Jorn	169
Pierangeli Alessandra	65; 73; 114
Piersanti Angela	426
Pietrasanta Carlo	192
Pietrocola Giampiero	125; 327
pietropaolo valeria	174
Pietropaolo Valeria	114; 155; 157; 159; 238
Pilla Giorgio	300
Pimpinelli Fulvia	143
Pinnetti Carmela	186
PINTOMALLI LETIZIA	205
Pinzauti David	357
Pira Enrico	363

Piras Cristina.....	75
Piras Sandra	170
Pisanelli Daniela	376
Pisanti, P.	55
Piscopiello Francesca.....	300; 327
pistello mauro	233
Pistello Mauro...51; 168; 170; 195; 201; 202; 204; 210; 230; 240	
Pistoia Daniela	197; 231
Pistoia Enrico Salvatore.....	447
Pither Molly D.	15
Pizzo Mariangela	182
Planchard David	120
Plicanti Erika	170; 204
Pocognoli Antonella	286
polani riccardo	334
Polani Riccardo.....	330; 332; 361
Poli Giuseppe.....	173
Polvere Jacopo.....	29; 92; 103; 113; 176
Polverino Maria Grazia.....	216
POMILIO FRANCESCO	449
Pompilio Arianna.....	337; 423
POMPILO ARIANNA	403
Pongolini Stefano	149
Porotto Matteo	228
PORPORATO PAOLO E.	151
Porta Amalia	142; 365
Potena Luciano	244
Pozzi Gianni	4; 41; 117; 350; 357; 433
Prandini Elizabeth.....	275
Prevete Nella.....	17
Prezioso Carla.....	67; 155; 157; 159; 238
PREZIOSO CARLA.....	174
Privitera Grete.....	79; 264; 370; 382
Prota Annalisa.....	155
Protto Virginia	99; 109; 238
PRUNERI EMMA.....	399
PUCA VALENTINA.....	105; 111
PUGLISI FABRIZIO.....	347
PUNZO ENRICO	353
PURDY JOHN	151
Putzu Maria Grazia	363
Puxeddu Silvia.....	308; 444

Q

Quadrifoglio Mariachiara	26
Quaranta Paola.....	168; 170; 195; 201; 202
Quirino Angela	310; 314; 345; 370

R

Radocchia Giulia	55
Raffa Vittoria	210
RAIMONDO STEFANIA	355
Rancan Ilaria.....	92; 176
Ranieri Enrica M.....	282
Rapezzi Davide.....	51
raponi giammarco	334
Raponi Gianmarco	330
Rappelli Paola.....	71
Rauch Ciro.....	94
Raviola Stefano.....	38
Rea Teresa	439

Recubito Federica	190
Reni Anna	120
Ricceri Laura.....	85
Ricchi Francesco.....	190; 208
Ricciardelli Guido.....	268
Rimoldi Sara	327
Rittà Massimo	169
Rizzi Pierfrancesco	404
Rizzo Roberta	3; 149
Rizzo Sabrina.....	3
Roana Janira.....	270; 363
Roato Ilaria	363
Roberto Piergiorgio.....	63
Rocchetti Andrea	250
Rogala Oliwia Sara	130
Romano Greta	162
Ronchi Andrea	192
Ronchi Celestino.....	218
Ronchi Federica	218
Ronga Luigi	282; 283
Rosati Alessandra.....	97
Roschetto Emanuela.....	101; 320; 401; 409
Rosellini Afredo.....	202
rosellini alfredo	233
Rosellini Alfredo.....	230
Rossetti Barbara	176
Rossi Mirko.....	242
Rossi Sabina.....	277; 387
Rossi Stefania	73
Rossolini Gian Maria	389; 415
ROSSOLINI GIAN MARIA	399
Routy Bertrand.....	120
Ruberto Stefano	59; 312
Ruffi Maria C.	75
Rullo Rosario	320
Russo Alessandro.....	370
Russo Matteo Antonio	109

S

Saba Alessandro.....	322
Sabbatini Samuele.....	442
sacco federica.....	334
Sacco Federica	330
salemi rossella.....	325
Salfa Maria Cristina	36
Sali Michela	118; 431
SALI MICHELA	435
Salustri Alessandro	431
SALUSTRI ALESSANDRO	435
Salvatore Maria Michela.....	214
Salvatore Paola	15; 17; 94; 136; 296; 298
Salvatori Francesca	338; 340
Salvemme Aurora	238
Salvi Valentina.....	23
Sammartano Vincenzo	103
Sanfilippo Giuseppa.....	172
Sanfilippo Giuseppa Luisa.....	182; 184
Sanguinetti Maurizio.....	118
SANGUINETTI MAURIZIO	435
sani spartaco.....	233
Sanna Giuseppina.....	75; 220

Sansone Luigi	109	Serra Nicola	439
Santacroce Luigi	282	Serrelli Marta	75
Santagati Maria	315	Serretello Enrica	424
Santangelo Adele	246	SERRETIELLO ENRICA	395; 445
SANTANGELO ADELE	395	Sessa Laura	382
Santarelli Giulia	431	SESSA LAURA	258
SANTARELLI GIULIA	435	Sessa Rosa	441
Santella Biagio	228; 417; 419; 421; 424	SEVERINO NICOLETTA	347
Santinelli Letizia	63	Sian Veronica	220
Santoni Adele	103	Sicuranza Anna	103
SANTORO EMANUELA	395	Sicurella Mariaconcetta	338; 385
Santoro Francesco	4; 41; 357; 433	sidoti maria	233
Santorio Maria Gabriella	178	Sidoti Maria	170; 204
Saporito Laura	382	Signorini Lucia	53; 192; 194
Sarmati Loredana	77; 90; 155	Silipo Alba	15
Sarshar Meysam	19; 69; 302	Simoncelli Martina	103
Sateriale Daniela	298	Simonetti Federica	242
Sau Rosangela	12; 14; 89	SIMONI SERENA	318
Savio Vittoria	42; 47; 343	Simula Elena Rita	59; 312
Sbardellati Flavio	405	Sinibaldi-Vallebona Paola	85
Scaglione Elena	15; 17; 94; 136; 296; 298	Sivori Francesca	143; 397; 429
Scaglione Francesco	428	Skvortsova Ira-Ida	96
Scagnolari Carolina	63; 65; 73; 114	Soffritti Irene	153; 293; 437
Scaltriti Erika	149	Soldani Giorgio	202
Scano Alessandra	134	Sorace Chiara	90
Scanu Alessandra	308	Sorbo Lucia	136
Scarazzai Mattia	393	Soriani Alessandra	23
Scarlata Giuseppe G.M.	370	Sorio Claudio	165
Scarlata Giuseppe Guido Maria	310; 314	Sorrentino Leonardo	63; 65; 73; 114
Scarpa Melania	140	Sorriento Daniela	17
Scattini Gabriele	45	Sorz Alice	25
Scattolini Silvia	236	Sosio Margherita	256
Scherpereel Arnaud	120	Sossi Karin	36
SCHETTINO ANTONETTA	407	Sow Cissé	120
Schiattarella Arcangelo	303	Spaggiari Luca	81
Schiavo Roberta	280	Spagnolo Elena	405
SCHIAVO ROBERTA	262	Spalla Melissa	300
Schiavoni Ilaria	212	Sparti Rosaria	266
Schioppa Tiziana	23	SPARTI ROSARIA	355
Schippa Serena	55	Specchiarello Eliana	186
Schiraldi Chiara	401	Spezia Pier Giorgio	185
Schiuma Giovanna	3	Spezia Pietro Giorgio	168; 201; 230; 240
Schoubben Aurélie	442	Speziale Pietro	125
Scifo Enzo	404	Spitale Ambra	315
Sciortino Maria Teresa	167	Squartini Gianfranco	81
Scorcia Vincenzo	377	Stabile Maria	132
Scordio Mirko	63; 65; 73; 114	Stampalija Tamara	26
Scorzolini Laura	186	Stanzione Mariamelia	190
Scotti Nicola	363	Stefanelli Paola	212; 397; 429
Scribano Daniela	19; 69; 302	Stefanetti Giuseppe	28
Scuderi Renata	315	Stefani Stefania	79; 264; 315; 325; 370; 374; 382
Scuderi Sarah Adriana	61	STEFANI STEFANIA	258
Scutera Sara	266	Stillitano Maria Giuseppina	314
SCUTERA SARA	355	Stivala Aldo	315
Sechi Leonardo Antonio	43; 59; 123	Stornaiuolo Alessia	15; 136; 296; 298
Segata Nicola	120	Stracquadanio Stefano	264
Selan Laura	130	Strati Francesco	19
Selvaggi Carla	63	Stura Ilaria	270
Sen Sudeshna	57	Sturini Michela	300
Serpico Rosario	343	suardi lorenzo	233
Serra Monica	12; 14	Suffredini Elisabetta	235; 236; 242

Suligoi Barbara	36
Sun Ximei	28
SUPURAN CLAUDIU TRANDAFIR	105
Sut Stefania	140

T

tagliaferri entrico	233
TALLERICO ROSSANA	205
TALOTTA ILENIA	205
Tamburello Maria Pia	167
Tamburrini Enrica	431
Tanca Alessandro	12; 14; 89
Tartaglione Anna Maria	85
Tassinari Valentina	23
Tavanti Arianna	380; 413
Tedesco Pietro	222
Teodori Lucia	357
Teti Elisabetta	90
Teti Giuseppe	5; 13; 125
TETI GIUSEPPE	1
Thelemaque Cassandra	120
Thomas Andrew	120
Thompson Paul R	57
Tocchetti Arianna	256
Tocci Gabriella	280
TOCCI GABRIELLA	262
Todeschini Valeria	248
Tognoloni Alessia	45
Tonacci Irene	372
Toppi Valeria	45
Torresani Alessandra	26
TORRESI MARINA	449
Torri Stefania	428
Torti Carlo	370
Toscanelli Walter	34
Tosco Alessandra	142; 365
Toumatia Omrane	248
Tozzi Monica	113
Tramontozzi Caterina	178
Trancassini Maria	114; 330
Trapella Claudio	3
Trecarichi Enrico M.	370
Tredicine Maria	118
Trevisan Caterina	212
Triassi Maria	132
Tricoli Maria R.	384; 439
TRICOLI MARIA RITA	316; 449
TRIFIRO' LINDA	151
Trioschi Giulia	385
Trovato Laura	252
Tucci Alessandra	149
Tullio Vivian	270
Tumbarello Mario	29; 92; 176
Turco Luigia	87
Turco Maria Ctaerina	97
Turello Gabriele	244
Turrin Giulia	3

U

Ucciero Maghalie	51
Ueoka Reiko	169
Uliana Francesca	36

Uzzau Sergio	12; 14; 89
--------------------	------------

V

Vacca Paola	397; 429
Vaccaro Sabrina	377
Vaia Francesco	186
Valente Elisabetta	328
Vallini Ivan	224
VALLINO MARTA	151
Varasi Ilenia	188
Varriale Chiara	320
Vascellari Sarah	226; 308
Vassallo Francesca	55
Veneri Carolina	235; 236; 242
Ventura Anna	145
Venturella Giuseppe	384
Venturelli Irene	138
Venuti Aldo	23
Verdolotti Letizia	190
Vertillo Aluisio Gaia	315
VESCHETTI LAURA	318
VIAGGI BRUNO	399
Viceconte Giulio	94
Vicenti Ilaria	188
Vicenza Teresa	236
Vidmar Martina	32
VIGNAROLI CARLA	318
Villa Pietro	230
Vind Kristiina	256
VISCARDI RAFFAELE	445
Viscido Agnese	73; 114
Vismara Chiara	428
VITALE IRENE	111
Vitale Pietro	77
Vitiello Mariateresa	94; 136; 296; 298
Volante Marco	173
Vollmer Waldemar	438
Volpicelli Valentina	424
Volta Antonella	437
VON EINEM JENS	151
Vrenna Gianluca	130
Vuolo Francesco	248

W

Wagemans Jeroen	380
Wauthoz Nathalie	442
Weersma Rinse	120
Willison Edward	295; 305
Wu Meng	28

X

Xiroudaki Styliani	442
--------------------------	-----

Z

Zadini Antonella	32
Zagaglia Carlo	19; 302; 351; 368
Zalcman Gerard	120
Zampini Paola	447
Zampino Daniela	306
Zani Alberto	149
Zannella Carla	97; 101; 116; 222; 228
Zanotta Nunzia	25; 26; 32; 36

Zappavigna Andrea.....	280
ZAPPAVIGNA ANDREA	262
Zarrilli Raffaele	132
Zarrillo Erika	298
Zazzi Maurizio.....	188
Zdouc Mitja M.....	256
Zega Alessandra	325
Zeni Guido.....	286
Zenzeri Letizia	55

ZIMBARDI ROSADEA	445
Zimbone Stefania	306
Zirpoli Sara	29; 92; 176
Zitvogel Laurence	120
Zoppi Silvia.....	120
Zordan Marta	77
Zorzi Antonella	366
Zullo Federica	289

Sommario

5 - Formyl peptide receptors 1 and 2 are essential vita-PAMP sensors of bacterial pathogens	1
7 - PAD-mediated citrullination provides a new biomarker and an effective target to counteract human papillomavirus transformation	475
13 - Effect of SARS-CoV-2 on the coagulation cascade in COVID-19 associated coagulopathies	3
15 - Vaginal immunization by the human microbiota bacterium <i>Streptococcus gordonii</i> expressing a <i>Chlamydia trachomatis</i> antigen efficiently primes the immune system in mice	4
30 - The two-component SaeRS system controls the interactions of group B streptococci with host cells by modulating PbsP expression	5
31 - Prevalence of hepatitis B virus infection among pregnant women: results from a hospital-based survey in Northern Italy.	6
34 - Classification of <i>Clostridioides difficile</i> strains using a MALDI-TOF MS typing method.	7
37 - "Bacterial Outer Membrane Vesicles: from biology to vaccines and cancer immunity".	475
43 - Insight into the apoptosis mediated by feline herpesvirus (FeHV-1) on permissive cells	10
46 - Time-restricted feeding induces <i>Lactobacillus</i> - and <i>Akkermansia</i> -specific functional changes in the rat fecal microbiota	12
57 - Interferon beta augments the in vitro and in vivo microbicidal responses of neutrophils leading to clearance of staphylococcal infection.	475
59 - Consumption of traditional Sardinian fresh cheese casu axedu promotes changes in the rat gut microbiota composition and functions	14
61 - The immunological activity of <i>Bacteroides thetaiotaomicron</i> rough-type lipopolysaccharide	15
67 - The probiotic <i>Lactobacillus rhamnosus</i> LGG restrains the angiogenic potential of colorectal carcinoma cells by activating a pro-resolving program via Formyl Peptide Receptor 1	17
68 - The <i>Shigella flexneri</i> virulence factor apyrase is released inside eukaryotic cells to manipulate host cell fate	19
71 - Exploring the Nrf2-mediated antioxidant pathway and the potential use of redox-modulating compounds during respiratory virus infections	21
80 - Drug-targeted activation of the RIG-I pathway to develop novel combinatorial therapeutic approaches against human papillomavirus-associated cancers	23
87 - Pro inflammatory status and bacterial gut-vagina translocation in pregnant women affected by COVID-19	25
88 - The fetal environment can harbor bacterial DNA overlapping the microbiome of vaginal, rectal and oral maternal body sites	26
90 - Specific microbiota compositions regulate humoral and cellular responses to vaccines in outbred mice	28
91 - Persistence of spike-specific memory B cells and antibodies nine months after two doses of BNT162b2 mRNA vaccine	29
95 - Depletion of the MS-ring protein FliF impacts motility, mucin-adhesion, and virulence in <i>Bacillus cereus</i>	31

97 - Role of gut and oral microbiota in pediatric autism spectrum disorder	32
102 - Influenza virus-induced APE1 downregulation: implications for NRF2 pathway and host immune response	34
103 - Results from a large cross-sectional Italian study assessing <i>Ureaplasma</i> spp. and <i>Mycoplasma</i> spp urogenital infections among STI clinic attendees and couples with primary infertility.	36
114 - Human cytomegalovirus infection drives a cellular senescence-like phenotype in kidney epithelial cells	38
115 - Three-label host-cell adhesion assay to assess the exclusion effect exerted by <i>Lactobacillus acidophilus</i> on adhesion of <i>Pseudomonas aeruginosa</i> to A549 alveolar epithelial cells	40
118 - Recall immune responses after murine respiratory pneumococcal infection are detected by in vitro restimulation of splenocytes with <i>Streptococcus pneumoniae</i> inactivated whole cells	41
119 - Antimicrobial peptide human beta-defensin-2 reduces the gut inflammation induced by enteroinvasive <i>Escherichia coli</i> by inhibiting invasion and virulence factors expression	42
123 - Epstein-Barr virus and <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> homologues peptides elicit a strong humoral response in patients with neuroinflammatory disorders, and exacerbate EAE	43
129 - <i>Salmonella</i> <i>Infantis</i> releases Outer Membrane Vesicles (OMVs) including beta-lactamases enzymes during their biogenesis	45
133 - Creation of an in vitro model for the screening of different probiotic strains able to prevent to inflammatory diseases of the gastrointestinal system	47
135 - <i>Limosilactobacillus fermentum</i> from buffalo milk inhibits <i>Helicobacter pylori</i> in a gastric epithelial cell model	49
137 - Induction of robust humoral immunity against SARS-CoV-2 both at post-infection and post-vaccine administration in a cohort of haematological cancer patients	51
146 - THE VIRAL SENSOR IFI16 AT THE CROSSROADS BETWEEN DAMAGE AND TOLERANCE DURING HUMAN CORONAVIRUS INFECTION	53
149 - Correlations between chronic intestinal pseudo-obstruction (CIPO), gut microbiota and intestinal serotonin-related genes expression.	55
150 - Characterization of citrullination during infection with DNA and RNA viruses: a new strategy for host-targeting antivirals drugs	57
151 - News Microbiological Marker in type 1 diabetes	477
The possible role of MAP And HERVs in the type 1 diabetes onset.	
153 - Peptide L18R plays an antimicrobial modulating action against polymicrobial biofilm in LCWB model	60
154 - Potential preventive role of probiotics against <i>Pseudomonas aeruginosa</i> corneal infection	61
157 - Prospective monitoring of HIV-1 infected patients after SARS-CoV-2 mRNA vaccination: characterization of IFN gene expression signature and humoral immune response	63
158 - Characterization of mucosal immune response against SARS-CoV-2 in vaccinated children.	65
160 - Evaluation of redox state alterations in influenza A virus-infected neuronal cells: involvement in neurotropism.	67

163 - Fecal-associated Enterobacteriaceae isolates from Celiac disease patients: could dietary sugars drive changes in bacterial composition?	69
164 - Discovering the role of <i>Mycoplasma girerdii</i> in <i>Trichomonas vaginalis</i> pathobiology: just a parasite or a new friend for the protist?	71
165 - Study of immunological parameters associated with Long COVID in children/adolescents	73
167 - Neutralization titers and Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2 in a Sardinian cohort group.	75
168 - CD169 IN BLOOD & CIRCULATING MICROVESICLES AS AN EARLY BIOMARKER OF COVID-19 DISEASE PROGRESSION	77
169 - Preliminary evaluation of genomic and transcriptomic changes in the evolution from a USA300 wild-type isolate to SCV, able to perform phagosomal escape.	79
171 - In vitro analysis of epithelial tolerability and anti-Candida effect of a new lactic acid-based vaginal gel formulation	81
174 - Human endogenous retroviruses as markers of disease and prognosis of chronic lymphocytic leukemia	83
178 - Maternal immune activation induces abnormal expression of endogenous retroviruses and immune effectors in a sex-dependent manner in a mouse model of Autism Spectrum Disorders	85
182 - Effects of dysbiosis on 6-OHDA mouse model of Parkinson's disease: insights from core microbiota and co-occurrence network analyses	477
187 - Effects of antimicrobial protocols for <i>Helicobacter pylori</i> eradication on structure and functions of the human gut microbiota	89
191 - HERVs IMPLICATION IN DEVELOPMENT, PROGRESSION AND LONG-TERM COMPLIANCE OF COVID-19	478
199 - Third Sars-CoV-2 vaccine dose: B cell and antibody responses following heterologous and homologous vaccination strategies	92
200 - Prediction of <i>Pneumocystis jirovecii</i> pneumonia in COVID-19 patients through quantitative PCR on oral washings	94
202 - Human endogenous retroviruses as potential therapeutic targets for the treatment of head and neck squamous cell carcinoma resistant to radiotherapy	96
205 - A specific anti-IFITM2 antibody bars the way to SARS-CoV-2 entry into host cells.	97
209 - HSV-1 INDUCED COMPLEMENT ACTIVATION IN BRAIN CELLS: POSSIBLE TRIGGER OF SYNAPTIC DEFICITS	99
211 - Antibacterial activity of Rhein against <i>Streptococcus mutans</i>	101
213 - Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines	478
214 - Antimicrobial and Antibiofilm Activities of Carvacrol, Amoxicillin and Salicylhydroxamic acid Alone and in Combination versus <i>Helicobacter pylori</i>	105

216 - Expression profile of Human Endogenous Retroviruses, their receptors, inflammatory and regulatory cytokines in children with Kawasaki disease and Multisystem inflammatory syndrome	107
217 - HSV-1-induced tau spreading in the brain: neurodegenerative damage or protective effect?	109
218 - Antimicrobial and Antibiofilm Activities of Cell Free Supernatant of <i>Limosilactobacillus reuteri</i> DSM 17938	111
233 - Longitudinal profiling of spike-specific antibody and B cell responses following mRNA-1273 SARS-CoV-2 vaccination in hematopoietic cell transplantation recipients	113
243 - <i>Aspergillus</i> infection and differential expression of TLRs and type I-III IFNs in the respiratory tract of a large cohort of CF patients from the Italian (Lazio) Reference Center for Cystic Fibrosis	114
254 - Evaluation of amphibian antimicrobial peptides as new therapeutic treatments against infectious diseases	116
264 - In vitro characterization of an mRNA vaccine model.	117
275 - SARS-CoV-2 vaccine immune response in adults with Down syndrome	118
277 - A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota	120
285 - Epstein-Barr virus and <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> homologues peptides elicit a strong humoral response in patients with neuroinflammatory disorders, and exacerbate EAE	123
11 - Streptococcal Surface Repeat (SSURE) domains from <i>Streptococcus pneumoniae</i> bind to different types of collagens	479
17 - Bio-guided approach in the search of novel antibacterial compounds from three Myrtaceae plants	126
33 - Life cycle peculiarities of enteric Adenovirus 41	128
52 - Serratiopeptidase affects adhesive features of <i>Pseudomonas aeruginosa</i> isolates from cystic fibrosis patients on biotic and abiotic substrates	130
60 - Resveratrol Restores Susceptibility to Chlorhexidine and Benzalkonium in Microorganisms Causing Health-Care Associated Infection	132
63 - RiV4PoC: A high effective microbicidal coating for high-touch surfaces	134
70 - Characterization of stringent response phenotype in <i>Neisseria meningitidis</i>	136
86 - Novel Options to Counteract Oral Biofilm Formation: in Vitro Evidence	138
143 - A novel phenolic derivative inhibits AHL-dependent Quorum Sensing signaling in <i>Pseudomonas aeruginosa</i>	140
170 - Role of the histone deacetylase Hst3p in <i>Candida albicans</i> biology	142
176 - Skin dysbiosis in inflammatory acne lesions and the role of <i>Cutibacterium acnes</i> biofilm	143
179 - Genotypic and phenotypic characterization of <i>Staphylococcus aureus</i> strains isolated in patients with atopic dermatitis	144
197 - Molecular characterization of hypermucoviscous and hypervirulent strains of <i>Klebsiella pneumoniae</i> : an emergent health care threat	145

274 - PGRS domain structures: doomed to sail the mycomembrane	147
4 - Competition for dominance within replicating quasi-species during prolonged SARS-CoV-2 infection in an immunocompromised host	149
6 - IFI16 impacts metabolic reprogramming during human cytomegalovirus infection	151
19 - Mesenchymal stem cells are susceptible but non-permissive to B19V replication	152
21 - Coinfection by Human Cytomegalovirus and Herpesvirus type 6 can trigger cell fibrosis: possible impact on scleroderma.	153
27 - Prevalence analysis of urinary and plasma JCPyV, BKPyV, MCPyV, HPyV6, HPyV7 and QPyV in patients infected with HIV-1.	155
28 - CLINICAL AND PROGNOSTIC SIGNIFICANCE OF MERKEL CELL POLYOMAVIRUS (MCPyV) IN NON-SMALL CELL LUNG CANCER (NSCLC)	157
29 - Prevalence of Merkel cell polyomaviruses, human polyomaviruses 6, 7 and Trichodysplasia Spinulosa-associated polyomaviruses in Actinic Keratosis Biopsy Specimens	159
32 - Epidemiology of viral agents causing acute gastroenteritis in children in Northern Italy (2019-2021): focus on Norovirus circulation.	161
39 - Genomic sequence analysis of 8 SARS-CoV-2 strains circulating in Parma (Northern Italy) during the first and the second wave of COVID-19 pandemic.	162
48 - Study of Parvovirus B19 translocation across the placenta using the BeWo model	164
53 - Transcriptional analysis of human bronchial epithelial cells with and without CFTR modification after SARS-CoV-2 infection	165
56 - Anti-HSV-1 Activity of natural raw and roasted unsalted pistachio kernels in human monocytic THP-1 and Vero cells.	167
58 - Broad range antiviral properties of small molecules against enveloped viruses	168
62 - The peptide A-3302-B isolated from a marine bacterium Micromonospora sp. inhibits HSV-2 infection by preventing the viral egress from host cells	169
73 - Evaluation of the effect of time of addition of several compounds against SARS-CoV-2 and other RNA viruses	170
75 - Evaluation of neutralizing antibodies against Sars-Cov-2 in patients with Inflammatory bowel disease	172
76 - CHARACTERIZATION OF THE ANTI-RHINOVIRUS ACTIVITY OF 25-HYDROXYCHOLESTEROL AND 27-HYDROXYCHOLESTEROL, AND VALIDATION ON NASAL AND BRONCHIAL HISTOCULTURES.	173
81 - Characterization of Human Polyomavirus JC (JCPyV) infection in Human Neuroblastoma SH-SY5Y cells and evaluation of redox state during viral replication.	174
92 - B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy	176
100 - Indomethacin inhibits human seasonal coronavirus replication at post-entry level	178
107 - Infection rate of respiratory viruses in the pandemic SARS-CoV-2 period considering symptomatic patients: comparison between 2020 and 2021.	179
110 - ARE III-GENERATION ANTIGENIC TEST SENSITIVE AS MOLECULAR TEST FOR DETECTION OF SARS-CoV-2?	181

111 - Wastewater-based surveillance for the monitoring of SARS-CoV-2 circulation in Sicily	182
116 - Emergence of novel Rotavirus G1P[8] strains in Sicily in 2021	184
127 - PREVALENCE AND LOAD OF THE RECENTLY DISCOVERED REDONDOVIRUS IN SALIVA SAMPLES FROM HEALTHY AND COVID-19 SUBJECTS	185
128 - Prolonged viral shedding and monkeypox virus isolation from seminal fluid	186
132 - Development of SARS-CoV-2 Mpro inhibitors retaining in vitro activity against circulating SARS-CoV-2 variants of concern	188
134 - In vitro evaluation of the virucide activity of nanostructured antimicrobial coatings for personal protective equipments	190
139 - Anti-SARS-CoV-2 Neutralizing activity of human breast milk from COVID-19 positive and negative lactating mothers	192
140 - Expression of Human Endogenous Retroviruses (HERVs) in clinical specimens of colon cancer patients	194
141 - Study of the effects of new small molecules as antiviral agents against SARS-CoV-2	195
155 - SEROPREVALENCE OF TORCH INFECTIONS IN WOMEN OF CHILDBEARING AGE OVER THE 2012-2022 DECADE IN SICILY	197
162 - SARS-CoV-2 OMICRON recombinant epidemiology in Northwest of Italy.	480
175 - The role of human DDX3 helicase in HSV-2 infection.	201
184 - Antiviral activity of natural compounds and composite polymeric matrix against SARS-CoV-2.	202
185 - Palmitoylethanolamide (PEA) inhibits SARS-CoV-2 entry by interacting with S protein and ACE-2 receptor.	204
193 - First identification of SARS-CoV-2 Omicron BA.4 sub-variant in Italy: genomic comparison with omicron sub-variants	205
195 - In vitro virucidal activity of active food packaging based on monoglycerides against a Human Coronavirus and other viruses	208
204 - Gold-Nanoparticle delivery of CRISPR/Cas13 as antiviral strategy against emerging RNA viruses	210
207 - Humoral and cell-mediated immune response in COVID-19 vaccinees according to history of prior SARS-CoV-2 infection.	212
226 - Antiviral activity of fungal secondary metabolites against Canine coronavirus infection	214
227 - Canine coronavirus activates the aryl hydrocarbon receptor during infection	216
236 - In vitro study of the interaction of enoxaparin sodium or heparan sulfate with not SARS-CoV strains	218
238 - Identification of interactions between human nuclear proteins and HPV16 genome	220
240 - Antiviral Activity of the Rhamnolipids from the Antarctic Bacterium Pseudomonas gessardii against Herpesviridae and Coronaviridae family	222
241 - Evaluation of HPV genotype-specific viral loads in clinician-collected cervical samples as compared to vaginal self-collected samples in women with cervical dysplasia	224
247 - Prion-like alpha-synuclein detection in ante-mortem intestinal biopsies from Parkinson's disease patients by RT-QuIC assay	481

252 - Inhibition of viral entry by peptides designed on the glycoproteins Gn and Gc of Schmallenberg virus	228
256 - A Cluster of SARS-CoV-2 omicron variant of concern harbouring a rare mutation in the spike gene	481
257 - Distribution and prevalence of Human papillomavirus (HPV) in oral samples collected from 2001 to 2020 in Sicily	231
259 - Isolation of SARS-CoV-2 in viral cell culture and immunologic characterization in immunocompromised patients	233
262 - Genetic diversity of norovirus Genogroups I and II in untreated wastewater in Rome Italy: a five-year monitoring study	235
263 - Hepatitis E in urban wastewater, pig slurry, food products, and wild boars: a One Health approach for the study of virus occurrence and diversity in the region of Abruzzo	236
265 - Antiviral effect of bombinin H2/H4 against enveloped and naked viruses	238
273 - Comparative assessment of molecular methods for studying TTV-virome species composition and prevalence estimates	240
276 - Wastewater surveillance of SARS-CoV-2 in Italy: outcomes of nine months of nationwide monitoring	242
278 - Utility of genotypic CMV-drug resistance testing in immunocompromised patients	244
280 - Antiviral potential of <i>Galdieria sulphuraria</i> , an extremophilic red alga	246
2 - Climatic zone and soil properties determine the biodiversity of the soil bacterial communities associated to native plants from desert areas of North-Central Algeria	248
3 - Sequencing of the whole genome of <i>Acinetobacter baumannii</i> : monitoring of antibiotic resistance in hospital during the Sars-CoV-2 pandemic.	250
9 - Monitoring of fungal biodiversity in sea beaches of Sicily: a one-year environmental study	252
10 - A case of rhino-pharyngeal myiasis from Eastern Sicily: rare infectious diseases have their time for revenge	254
12 - Increasing the odds of discovering novel metabolites from a large microbial library	256
14 - Changes in microbial aetiology of Prosthetic Joint Infections: a three years evaluation.	258
16 - Interference on uterine bacterial population in hypofertile mares of intrauterine infusion of equine fresh platelets-rich plasma.	260
18 - The spread of fluconazole-resistant <i>Candida parapsilosis</i> strains during the global COVID-19 pandemic in a Northern Italy hospital.	262
20 - <i>Acinetobacter baumannii</i> and cefiderocol between virulence and adaptability	264
22 - Combination of essential oils to poly(ϵ -caprolactone)-based biomaterial to achieve anti-bacterial and osteoblast proliferative properties for regenerative medicine scaffolds.	266
23 - New drugs, new diagnostic techniques and new algorithms in fast track workflow of Gram-negative bloodstream infections: a three-year single-centre study	268
24 - Antimicrobial activity of Curcumin and Curcumin/Chitosan loaded nanobubbles with photodynamic light	270

25 - <i>optrA</i> -mediated linezolid resistance in an <i>Enterococcus faecalis</i> isolate recovered from a wild raptor (<i>Falco peregrinus peregrinus</i>), central Italy	272
26 - Detection of an <i>Enterococcus faecium</i> carrying the phenicol-oxazolidinone resistance gene <i>poxtA</i> recovered from a freshwater river, central Italy	273
35 - Evaluation of the MALDI-TOF mass spectrometry workflow for the identification of microorganisms involved in monomicrobial and polymicrobial bloodstream infections.	275
36 - <i>Schistosoma haematobium</i> , an imported parasite: a 5-year epidemiological study.	277
38 - In vitro effect of innovative light with photodynamic microbicidal activity in bacteria	278
40 - Temporal correlation between SARS-CoV-2 infection and <i>Candida parapsilosis</i> bloodstream infections.	280
41 - Sexually transmitted pathogens in a selected population: a preliminary study	282
42 - Nontyphoidal <i>Salmonella</i> gastroenteritis in children: a preliminary study on antibiotic resistance.	283
44 - Pilocarpine interferes with sphingolipids metabolism in <i>Candida albicans</i> .	285
45 - KPC-producing <i>Klebsiella pneumoniae</i> spread: genotypic and epidemiological characterization of clinical strains from Marche region	286
47 - Re-sensitizing Methicillin-resistant <i>Staphylococcus aureus</i> to antimicrobials	288
49 - Implementation of a selective Chromatic medium for active surveillance of ceftazidime-avibactam resistance during COVID-19 pandemic: outbreaks and diagnostic issues	289
51 - Cutaneous staphylococcal infection in immunocompromised site during nivolumab treatment for non-small cell lung cancer: a first case report	291
54 - Introduction of probiotic-based sanitation in the emergency ward of a children's hospital during the COVID-19 pandemic	293
55 - Genomic fingerprinting of a <i>Mycobacterium bovis</i> BCG causing a severe vertebral osteomyelitis following BCG instillation in a bladder cancer patient	295
64 - Antimicrobial activity of WMR-K against <i>Neisseria meningitidis</i>	296
65 - Effect of pomegranate peel extracts against ESKAPE	298
66 - Quality assessment of surface and groundwaters in Lombardy, Italy: detection and characterization of ESBLs-producing Enterobacterales	300
69 - The protein HslJ boosts <i>Acinetobacter baumannii</i> survival against oxidative stress	302
72 - Antimicrobial resistance during COVID-19 pandemic: microbial surveillance at "Cristo Re" Hospital during 2020-2021	303
74 - Antibacterial and antibiofilm activity in artificial sputum medium of <i>Lactobacilli</i> against <i>Pseudomonas aeruginosa</i> strains isolated from CF patients	483
77 - The One-year Comparative study between molecular and cultural cutaneous swab tests during surveillance program of <i>Candida auris</i> in ICUs of San Martino Hospital (July 2021-July 2022)	305
78 - Development, characterization and antibacterial activity of polyether-co-amide matrix films incorporating choline-calixarene nanoassembly	306
79 - Antimicrobial effectiveness of ozonated olive and sunflower seeds oils	308

82 - Epidemiology of bloodstream infections and mortality rates in patients admitted to the Intensive Care Unit in the pandemic era	310
83 - Humoral Response to Microbial Biomarkers in Parkinson's disease Patients	312
84 - Active surveillance for MDR bacteria and correlation with HCAI in patients attending to a University Hospital: a 5-year retrospective study	314
85 - Class-IIc bacteriocins produced by <i>S. salivarius</i> 24SMBc involved in antibacterial activity	483
89 - Four-Year Environmental Surveillance Program of <i>Legionella</i> spp. in One of Palermo's Largest Hospitals	316
94 - Occurrence of a KPC-3-producing <i>Klebsiella michiganensis</i> strain in clams	318
96 - In silico identification of novel inhibitors targeting the superoxide dismutase from the dental pathogen <i>Streptococcus mutans</i> and counteracting the biofilm formation.	320
98 - HPLC-MS-MS quantification of short-chain fatty acids secreted by probiotic strains	322
99 - IQOS vapours decrease <i>Klebsiella pneumoniae</i> growth without compromising lung cells compared to cigarette smoke	323
101 - Transcriptomics of VISA Emerging in a genomic context of CA-MRSA Under Teicoplanin Therapy	483
104 - Evaluation of the anti-biofilm activity of four different antibiotics against <i>Staphylococcus aureus</i> strains from ocular infections	327
105 - Prevalence and virulence potential of <i>Aeromonas</i> spp. isolated from patients suffering from diarrhea	328
106 - Spread of Metallo-Beta Lactamase genes: characteristics and diffusion of broad-host range and highly conjugative plasmids	483
108 - Anatomy of pKpQIL, the blaKPC plasmid, and its role in ceftazidime-avibactam resistance	332
109 - A new core-genome based typing method for <i>Providencia stuartii</i> : characterization of New Delhi Metallo-Beta-Lactamase-producing strains causing an outbreak	334
112 - Study of <i>Acinetobacter</i> species resistance patterns and virulence in a multidisciplinary hospital	484
117 - Activity of cell-free supernatants from probiotic <i>Lactobacillus</i> strains against <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients	337
120 - Antibiofilm activity of <i>Moringa oleifera</i> Lam. leaf extracts by Scanned Electron Microscopy visualization against <i>Xanthomonas campestris</i> pv. <i>campestris</i>	338
121 - Effects on <i>Xanthomonas campestris</i> pv. <i>campestris</i> by <i>Moringa oleifera</i> Lam. leaf fermented extracts	340
122 - A fast microbiology experience in a Southern Italy hospital: a diagnostic stewardship approach.	341
125 - A case report of oral candidiasis in an immunocompetent patient	343

126 - Comparison of Loop Mediated Amplification (LAMP) and quantitative Real Time PCR (qRT-PCR) methods for the routine detection of <i>Pneumocystis jirovecii</i> .	345
130 - INCREASE OF KPC-PRODUCING <i>KLEBSIELLA PNEUMONIAE</i> IN A NEONATAL INTENSIVE CARE UNIT: A THREE- YEARS EVALUATION	347
131 - Human infection by <i>Trichostrongylus</i> spp. in an immigrant patient living in an asylum seekers center in Southern Italy	349
136 - Bacteria from the vaginal microbiota cause suppurative hysteritis/pelvic inflammation in mice treated with estrogens	350
138 - Antibiofilm activity of Ciprofloxacin-loaded niosomes.	351
144 - Cryptococcal Meningitis	353
147 - Effect of Vitamin C on dormant states of <i>Helicobacter pylori</i>	354
148 - Mechanisms involved in the reversal of antimicrobial resistance in <i>Acinetobacter baumannii</i> by albumin nanoparticles	355
152 - Complete Genome Sequence of <i>Lactobacillus crispatus</i> Type Strain ATCC 33820	357
156 - Antimicrobial and antivirulence effects of Hop extract against multi-drug resistant <i>Staphylococci</i> strains and <i>Cutibacterium acnes</i>	358
159 - The administration of <i>Enterococcus faecium</i> SF68 counteracts compositional shifts in the gut microbiota of diet-induced obese mice	360
161 - <i>Klebsiella pneumoniae</i> ST37: a never-ending story	361
166 - Antibacterial efficacy of glycine airflow and hyaluronic acid-vehicled antibiotic mixture on contaminated titanium surfaces of dental osseointegrated implants	363
172 - Comparative evaluation of antimicrobial, antiamebic, and antiviral efficacy of ophthalmic formulations	365
173 - <i>Nocardia</i> infections in a University Hospital in NorthEast Italy	366
177 - Characterization of multidrug-resistant <i>Escherichia coli</i> strains isolated from mares with fertility problems	368
181 - Omic-insights of Ceftazidime-Avibactam resistant <i>Klebsiella pneumoniae</i> clinical isolates	370
183 - Oral hygiene, dietary habits, dental caries experience, and quantitative determination of microbial species with high cariogenic potential in children with autism spectrum disorder	372
186 - Ceftobiprole non-susceptibility in <i>Enterococcus faecalis</i> is influenced by PBP4 alterations	374
188 - <i>Blastocystis</i> sp. prevalence and subtypes in autochthonous and immigrant patients in a Southern Italy hospital	376
190 - In vivo antibacterial activity of disposable gauzes for periocular antisepsis	377
192 - Cyano-pyrimidines and enamines as promising scaffolds for antibacterial activity	378
196 - Lytic activity of four bacteriophages against planktonic and biofilm <i>Staphylococcus aureus</i> clinical isolates	380
201 - <i>Klebsiella pneumoniae</i> strains resistant to ceftazidime/avibactam and meropenem/vaborbactam: molecular characterization.	382
208 - <i>Pleurotus eryngii</i> var. <i>thapsiae</i> a new potential culinary-medicinal mushroom from Sicily with antibiofilm potentiality.	384

210 - Profile of antibacterial activity of <i>Moringa oleifera</i> Lam. single phenols against the phytopathogen <i>Xanthomonas campestris</i> pv. <i>campestris</i>	385
212 - <i>Blastocystis</i> sp. subtypes detected from 2016 to 2018 and correlation to intestinal disease.	387
215 - Characterization of fosfomycin-resistance mechanisms in clinical isolates of methicillin-resistant <i>Staphylococcus aureus</i>	389
219 - Cupferron, a new promising metal chelator against <i>Candida albicans</i>	391
220 - Fourier Transform Infrared (FT-IR) Spectroscopy as new approach to analyze the clonal relationship of <i>Citrobacter koseri</i> and real time outbreak tracing	393
221 - Prevalence and antimicrobial profile of <i>Pseudomonas aeruginosa</i> in clinical isolates collected at Ruggi d' Aragona Hospital in 2015-2019 period	395
222 - Biofilm formation, genetic signatures, and antimicrobial resistance profile of <i>Neisseria gonorrhoeae</i> strains	397
223 - In vivo evolution of ceftazidime-avibactam and meropenem-vaborbactam resistance in a KPC-producing <i>Klebsiella pneumoniae</i> from meningoencephalitis complicated with brain abscess	399
228 - Niclosamide as a Repurposing Drug against <i>Corynebacterium striatum</i> Multidrug-Resistant Infections	401
229 - Giving drugs a second chance: identification of drugs active against <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients using a drug repurposing strategy	403
230 - T2Bacteria® Panel sensitivity in bone marrow transplanted neutropenic febrile patients	404
231 - Preliminary data of the prevalence of <i>Capnocytophaga</i> spp in kennel dogs and feline colonies of North-East Italy: emergent zoonotic bacteria?	405
234 - Antimicrobial applications of bimetallic nanoparticles by heterogenous green synthesis	485
235 - Repurposing Selamectin as antimicrobial drug against Hospital-Acquired <i>Staphylococcus aureus</i> infections	485
237 - In vitro antibacterial and anti-inflammatory activity of <i>Arctostaphylos uva-ursi</i> leaf extract against <i>Propionibacterium acnes</i>	485
239 - Rapid identification of clinically relevant <i>Candida</i> spp. by Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopy	413
242 - Molecular characterization of linezolid resistance determinants in <i>Staphylococcus epidermidis</i> from invasive infections	415
245 - Prevalence and Antimicrobial Resistance Profile of <i>Enterococcus</i> Species: A Retrospective Cohort Study in Italy	417
246 - Bacterial Coinfection and Antibiotic Resistance Profiles among COVID-19 Patients	419
248 - Carbapenem-resistant and extended-spectrum β -lactamase producing <i>Klebsiella pneumoniae</i> : Prevalence and Antimicrobial Resistance trends in Strains Isolated from Hospital in Italy.	421

249 - Identification of new antivirulence compounds active against cystic fibrosis <i>Pseudomonas aeruginosa</i>	423
250 - Prevalence and Antimicrobial Profile of Causative Agents to Ocular Infections	424
253 - Antibiotic resistance profiles of microplastics associated microbial communities in the Adriatic Sea	426
255 - A high-resolution melting PCR assay for rapid detection of linezolid-resistance-associated new mutations in <i>Mycobacterium avium</i> complex	428
258 - Biofilm formation, genetic signatures, and antimicrobial resistance profile of <i>Neisseria gonorrhoeae</i> strains	429
260 - Dissection of the enigmatic role of Everolimus during <i>Mycobacterium tuberculosis</i> infections.	486
266 - The mobilome of probiotic <i>Lactobacillus crispatus</i> M247 includes Tn7088 a novel integrative and mobilizable element (IME) carrying a biosynthetic gene cluster for a class I bacteriocin	433
267 - Epidemiological trends in Nontuberculous <i>Mycobacteria</i> isolation in the period 2018-2021 in a large tertiary care hospital	435
268 - Shaping the subway microbiome by a probiotic-based sanitation during the COVID-19 emergency	437
269 - Peptidoglycan analysis of <i>Streptococcus pneumoniae</i> serotype 19A isolates belonging to the same clonal complex with different susceptibility to beta-lactams in the presence or absence of cefotaxime	438
270 - Antibiotic resistance pattern of <i>Staphylococcus</i> spp isolated from blood culture of hospitalized patients during the first and second wave of SARS-Cov2 infection: a single center retrospective analysis	439
271 - Novel strategy against <i>Chlamydiae</i> : EVOO-based extracts.	441
272 - A new indole derivative dry powder for inhalation inhibits <i>Staphylococcus aureus</i> biofilm formation in vitro	442
279 - Uncomplicated UTIs and old antimicrobials: a retrospective study on southern Sardinian population	444
281 - Case report: Disseminated <i>Cryptococcus neoformans</i> in an immunocompetent patient.	445
283 - Co-infection of <i>Pseudomonas aeruginosa</i> and <i>Achromobacter xylosoxidans</i> in green nail syndrome treated with ozenoxacin: a case report.	447
284 - Molecular characterization of <i>Listeria monocytogenes</i> strains isolated from food and human sources	486